Selegiilne	B-Chemical
-	O
inudced	O
postuarl	O
hpyotension	O
in	O
Parkinosn	O
'	O
s	O
disaese	O
:	O
a	O
longitudnial	O
sutdy	O
on	O
the	O
effetcs	O
of	O
durg	O
withdrwaal	O
.	O

OBJECTIEVS	O
:	O
The	O
Uinted	O
Kindgom	O
Pakrinson	O
'	O
s	O
Dsiease	O
Reseacrh	O
Gorup	O
(	O
UKDPRG	O
)	O
tiral	O
found	O
an	O
incraesed	O
motrality	O
in	O
patietns	O
with	O
Parkinosn	O
'	O
s	O
diesase	O
(	O
PD	O
)	O
randomiezd	O
to	O
receive	O
10	O
mg	O
selegilnie	B-Chemical
per	O
day	O
and	O
L	B-Chemical
-	I-Chemical
dpoa	I-Chemical
copmared	O
with	O
those	O
taking	O
L	B-Chemical
-	I-Chemical
dpoa	I-Chemical
alone	O
.	O

Recently	O
,	O
we	O
found	O
that	O
thearpy	O
with	O
seelgiline	B-Chemical
and	O
L	B-Chemical
-	I-Chemical
dpoa	I-Chemical
was	O
associated	O
with	O
selective	O
sytsolic	O
orthosttaic	O
hypotesnion	O
which	O
was	O
abolished	O
by	O
withdarwal	O
of	O
selgeiline	B-Chemical
.	O

This	O
unwanted	O
effcet	O
on	O
posutral	O
blood	O
presusre	O
was	O
not	O
the	O
result	O
of	O
underlying	O
autnoomic	O
faiulre	O
.	O

The	O
aims	O
of	O
this	O
stduy	O
were	O
to	O
confirm	O
our	O
previous	O
findigns	O
in	O
a	O
separate	O
choort	O
of	O
ptaients	O
and	O
to	O
determine	O
the	O
tmie	O
cuorse	O
of	O
the	O
cardiovacsular	O
cnosequences	O
of	O
stopping	O
selegilnie	B-Chemical
in	O
the	O
exepctation	O
that	O
this	O
might	O
shed	O
light	O
on	O
the	O
mehcanisms	O
by	O
which	O
the	O
durg	O
causes	O
orhtostatic	O
hypoetnsion	O
.	O

METHODS	O
:	O
The	O
cardiovasuclar	O
resposnes	O
to	O
standnig	O
and	O
haed	O
-	O
up	O
tlit	O
were	O
studied	O
repeatedly	O
in	O
PD	O
paitents	O
receiving	O
sleegiline	B-Chemical
and	O
as	O
the	O
durg	O
was	O
withdrawn	O
.	O

RSEULTS	O
:	O
Haed	O
-	O
up	O
tlit	O
caused	O
systoilc	O
orthotsatic	O
hpyotension	O
which	O
was	O
marked	O
in	O
six	O
of	O
20	O
PD	O
patietns	O
on	O
seleigline	B-Chemical
,	O
one	O
of	O
whom	O
lsot	O
concsiousness	O
with	O
unrecrodable	O
blood	O
pressuers	O
.	O

A	O
lesser	O
dergee	O
of	O
orhtostatic	O
hypotensoin	O
occurred	O
with	O
stadning	O
.	O

Orthosattic	O
hyptoension	O
was	O
amelioarted	O
4	O
dyas	O
after	O
withrdawal	O
of	O
sleegiline	B-Chemical
and	O
totally	O
abolished	O
7	O
dyas	O
after	O
discontinaution	O
of	O
the	O
durg	O
.	O

Stopping	O
seleigline	B-Chemical
also	O
significantly	O
redcued	O
the	O
spuine	O
systoilc	O
and	O
disatolic	O
blood	O
pressrues	O
consistent	O
with	O
a	O
previously	O
undescribed	O
spuine	O
pressor	O
actoin	O
.	O

CONCLUISON	O
:	O
This	O
sutdy	O
confirms	O
our	O
previous	O
fniding	O
that	O
selgeiline	B-Chemical
in	O
combiantion	O
with	O
L	B-Chemical
-	I-Chemical
dpoa	I-Chemical
is	O
associated	O
with	O
selective	O
orthsotatic	O
hypoetnsion	O
.	O

The	O
possibilities	O
that	O
these	O
cardiovsacular	O
finidngs	O
might	O
be	O
the	O
result	O
of	O
non	O
-	O
selective	O
inhbiition	O
of	O
moonamine	O
oixdase	O
or	O
of	O
amphetamnie	B-Chemical
and	O
metamphteamine	B-Chemical
are	O
discussed	O
.	O

Further	O
stduies	O
on	O
efefcts	O
of	O
irriagtion	O
soultions	O
on	O
rat	O
bldaders	O
.	O

Further	O
studeis	O
on	O
the	O
effects	O
of	O
certain	O
irirgating	O
fludis	O
on	O
the	O
rat	O
bladedr	O
for	O
18	O
hours	O
are	O
reported	O
.	O

The	O
reuslts	O
have	O
shown	O
that	O
the	O
degradatoin	O
prodcut	O
p	B-Chemical
-	I-Chemical
choloronailine	I-Chemical
is	O
not	O
a	O
significant	O
facotr	O
in	O
chlorhexidnie	B-Chemical
-	I-Chemical
digluocnate	I-Chemical
associated	O
eorsive	O
cytsitis	O
.	O

A	O
high	O
percetnage	O
of	O
kanamcyin	B-Chemical
-	O
colsitin	B-Chemical
and	O
povidnoe	B-Chemical
-	I-Chemical
ioidne	I-Chemical
irrigtaions	O
were	O
associated	O
with	O
eorsive	O
cytsitis	O
and	O
suggested	O
a	O
possible	O
complicaiton	O
with	O
huamn	O
uasge	O
.	O

Pilcoxydine	B-Chemical
irrigatoins	O
appeared	O
to	O
have	O
a	O
lwoer	O
inicdence	O
of	O
eroisve	O
cysttiis	O
but	O
further	O
stduies	O
would	O
have	O
to	O
be	O
performed	O
before	O
it	O
could	O
be	O
recommneded	O
for	O
use	O
in	O
uroolgical	O
procdeures	O
.	O

Effcets	O
of	O
tterandrine	B-Chemical
and	O
fangchinloine	B-Chemical
on	O
experimetnal	O
thrombsois	O
in	O
mcie	O
and	O
hmuan	O
platleet	O
aggregaiton	O
.	O

Tetrandirne	B-Chemical
(	O
TET	B-Chemical
)	O
and	O
fancghinoline	B-Chemical
(	O
FAN	B-Chemical
)	O
are	O
two	O
naturally	O
occurring	O
analgoues	O
with	O
a	O
bsibenzylisoquinoline	B-Chemical
strcuture	O
.	O

The	O
present	O
stduy	O
was	O
undertaken	O
to	O
inevstigate	O
the	O
effetcs	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
on	O
the	O
experimnetal	O
thormbosis	O
indcued	O
by	O
clolagen	O
plus	O
epinephirne	B-Chemical
(	O
EP	B-Chemical
)	O
in	O
mcie	O
,	O
and	O
platleet	O
aggreagtion	O
and	O
blood	O
coagulaiton	O
in	O
vitro	O
.	O

In	O
the	O
in	O
vivo	O
stduy	O
,	O
the	O
administrtaion	O
(	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
in	O
mcie	O
showed	O
the	O
inhibitoin	O
of	O
throbmosis	O
by	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
,	O
while	O
acetylslaicylic	B-Chemical
aicd	I-Chemical
(	O
ASA	B-Chemical
,	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
psoitive	O
contorl	O
,	O
showed	O
only	O
30	O
%	O
inhbiition	O
.	O

In	O
the	O
vitro	O
hmuan	O
pltaelet	O
aggreagtions	O
induecd	O
by	O
the	O
aognists	O
used	O
in	O
tetss	O
,	O
TET	B-Chemical
and	O
FAN	B-Chemical
showed	O
the	O
inhibitoins	O
dsoe	O
dependently	O
.	O

In	O
addition	O
,	O
neither	O
TET	B-Chemical
nor	O
FAN	B-Chemical
showed	O
any	O
anticoagluation	O
actiivties	O
in	O
the	O
maesurement	O
of	O
the	O
acitvated	O
patrial	O
thrmoboplastin	O
tmie	O
(	O
ATPT	O
)	O
,	O
prothrmobin	O
tmie	O
(	O
PT	O
)	O
and	O
thrmobin	O
tmie	O
(	O
TT	O
)	O
using	O
huamn	O
-	O
ctirated	O
palsma	O
.	O

These	O
rseults	O
suggest	O
that	O
antitrhombosis	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
in	O
mcie	O
may	O
be	O
mainly	O
related	O
to	O
the	O
atniplatelet	O
aggregatoin	O
atcivities	O
.	O

Angioeedma	O
due	O
to	O
ACE	B-Chemical
inhbiitors	I-Chemical
:	O
common	O
and	O
iandequately	O
diagnoesd	O
.	O

The	O
estiamted	O
inciednce	O
of	O
angiodeema	O
during	O
angitoensin	B-Chemical
-	I-Chemical
converting	I-Chemical
enyzme	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
inihbitor	I-Chemical
treatemnt	O
is	O
between	O
1	O
and	O
7	O
per	O
thousand	O
patinets	O
.	O

This	O
potentially	O
serious	O
advrese	O
effect	O
is	O
often	O
preceded	O
by	O
minor	O
mainfestations	O
that	O
may	O
serve	O
as	O
a	O
warnnig	O
.	O

Coacine	B-Chemical
-	O
inudced	O
mood	O
diosrder	O
:	O
prevalnece	O
rtaes	O
and	O
pyschiatric	O
symptmos	O
in	O
an	O
outaptient	O
ccoaine	B-Chemical
-	O
dependnet	O
smaple	O
.	O

This	O
paper	O
attempts	O
to	O
examine	O
and	O
comapre	O
prvealence	O
raets	O
and	O
sympotm	O
pattrens	O
of	O
DSM	O
substacne	O
-	O
inudced	O
and	O
other	O
mood	O
diosrders	O
.	O

243	O
cociane	B-Chemical
-	O
depednent	O
outpatinets	O
with	O
cociane	B-Chemical
-	O
indcued	O
mood	O
disoredr	O
(	O
CMID	O
)	O
,	O
other	O
mood	O
disodrers	O
,	O
or	O
no	O
mood	O
dsiorder	O
were	O
comapred	O
on	O
measrues	O
of	O
psychaitric	O
smyptoms	O
.	O

The	O
prevaelnce	O
rtae	O
for	O
CMID	O
was	O
12	O
%	O
at	O
basleine	O
.	O

Introduction	O
of	O
the	O
DSM	O
-	O
IV	O
diangosis	O
of	O
CMID	O
did	O
not	O
substantially	O
affect	O
rtaes	O
of	O
the	O
other	O
deperssive	O
disodrers	O
.	O

Patinets	O
with	O
CMID	O
had	O
sympotm	O
sveerity	O
levles	O
between	O
those	O
of	O
patinets	O
with	O
and	O
without	O
a	O
mood	O
dsiorder	O
.	O

These	O
findigns	O
suggest	O
some	O
vaildity	O
for	O
the	O
new	O
DSM	O
-	O
IV	O
diangosis	O
of	O
CMID	O
,	O
but	O
also	O
suggest	O
that	O
it	O
requires	O
further	O
speciifcation	O
and	O
replictaion	O
.	O

Effcet	O
of	O
fuciodan	B-Chemical
traetment	O
on	O
collaegnase	O
-	O
induecd	O
intracerebarl	O
hemorrhgae	O
in	O
rtas	O
.	O

Inflamamtory	O
clels	O
are	O
postulated	O
to	O
mediate	O
some	O
of	O
the	O
barin	O
daamge	O
following	O
iscehmic	O
srtoke	O
.	O

Intracreebral	O
hemorrahge	O
is	O
associated	O
with	O
more	O
inlfammation	O
than	O
ishcemic	O
srtoke	O
.	O

We	O
tseted	O
the	O
sulfaetd	O
polyasccharide	O
fucoiadn	B-Chemical
,	O
which	O
has	O
been	O
reported	O
to	O
rdeuce	O
inflammatroy	O
brian	O
dmaage	O
,	O
in	O
a	O
rat	O
mdoel	O
of	O
intracreebral	O
hemorrhgae	O
idnuced	O
by	O
inejction	O
of	O
bactreial	O
collaegnase	O
into	O
the	O
cauadte	O
nculeus	O
.	O

Rtas	O
were	O
terated	O
with	O
seven	O
day	O
intravenuos	O
infusoin	O
of	O
fuciodan	B-Chemical
(	O
30	O
micrgorams	O
h	O
-	O
1	O
)	O
or	O
veihcle	O
.	O

The	O
hemaotma	O
was	O
assesesd	O
in	O
vivo	O
by	O
magentic	O
rseonance	O
imagnig	O
.	O

Mootr	O
bheavior	O
,	O
pasisve	O
aviodance	O
,	O
and	O
skilled	O
forelmib	O
funtcion	O
were	O
tetsed	O
repeatedly	O
for	O
six	O
wekes	O
.	O

Fucodian	B-Chemical
-	O
terated	O
rtas	O
exhibited	O
eviednce	O
of	O
impaierd	O
blood	O
cltoting	O
and	O
hemodiltuion	O
,	O
had	O
larger	O
hematmoas	O
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	O
in	O
the	O
vicinity	O
of	O
the	O
heamtoma	O
after	O
three	O
dyas	O
.	O

They	O
showed	O
significantly	O
more	O
rpaid	O
improvemnet	O
of	O
mtoor	O
funtcion	O
in	O
the	O
first	O
week	O
following	O
hemorhrage	O
and	O
better	O
meomry	O
rteention	O
in	O
the	O
pasisve	O
aovidance	O
tset	O
.	O

Actue	O
wihte	O
matter	O
edmea	O
and	O
eevntual	O
neurnoal	O
lsos	O
in	O
the	O
straitum	O
adajcent	O
to	O
the	O
hematmoa	O
did	O
not	O
differ	O
between	O
the	O
two	O
gropus	O
.	O

Investiagtion	O
of	O
more	O
specific	O
atni	O
-	O
inlfammatory	O
aegnts	O
and	O
hemodliuting	O
agnets	O
are	O
warranted	O
in	O
intraceerbral	O
hemorrhage	O
.	O

Recurarizaiton	O
in	O
the	O
rceovery	O
room	O
.	O

A	O
csae	O
of	O
reucrarization	O
in	O
the	O
recovrey	O
room	O
is	O
reported	O
.	O

Accuumlation	O
of	O
atracuirum	B-Chemical
in	O
the	O
inrtavenous	O
line	O
led	O
to	O
reucrarization	O
after	O
flushnig	O
the	O
line	O
in	O
the	O
rceovery	O
room	O
.	O

A	O
respirtaory	O
arrset	O
with	O
seevre	O
desaturaiton	O
and	O
bradyacrdia	O
occurred	O
.	O

Cicrumstances	O
leading	O
to	O
this	O
eevnt	O
and	O
the	O
mehcanisms	O
enabling	O
a	O
neuromucsular	O
blokcade	O
to	O
occur	O
,	O
following	O
the	O
administrtaion	O
of	O
a	O
small	O
dsoe	O
of	O
realxant	O
,	O
are	O
discussed	O
.	O

The	O
haemodnyamic	O
efefcts	O
of	O
propfool	B-Chemical
in	O
cmobination	O
with	O
epehdrine	B-Chemical
in	O
edlerly	O
pateints	O
(	O
ASA	O
gorups	O
3	O
and	O
4	O
)	O
.	O

The	O
marked	O
vasodialtor	O
and	O
negatvie	O
inortopic	O
effects	O
of	O
prpoofol	B-Chemical
are	O
disadvantages	O
in	O
frial	O
eldrely	O
pateints	O
.	O

We	O
inevstigated	O
the	O
saftey	O
and	O
efficcay	O
of	O
adding	O
different	O
doess	O
of	O
ephedirne	B-Chemical
to	O
proopfol	B-Chemical
in	O
order	O
to	O
obtnud	O
the	O
hypotensvie	O
repsonse	O
.	O

The	O
haemodyanmic	O
effcets	O
of	O
adding	O
15	O
,	O
20	O
or	O
25	O
mg	O
of	O
epherdine	B-Chemical
to	O
200	O
mg	O
of	O
propfool	B-Chemical
were	O
copmared	O
to	O
cnotrol	O
in	O
40	O
ASA	O
3	O
/	O
4	O
patietns	O
over	O
60	O
yaers	O
prseenting	O
for	O
gentio	O
-	O
urianry	O
srugery	O
.	O

The	O
addition	O
of	O
epherdine	B-Chemical
to	O
propoofl	B-Chemical
appears	O
to	O
be	O
an	O
effecitve	O
mehtod	O
of	O
obtunidng	O
the	O
hypotnesive	O
respnose	O
to	O
prpoofol	B-Chemical
at	O
all	O
dsoes	O
used	O
in	O
this	O
sutdy	O
.	O

However	O
,	O
marked	O
tachycarida	O
associated	O
with	O
the	O
use	O
of	O
ehpedrine	B-Chemical
in	O
combniation	O
with	O
porpofol	B-Chemical
occurred	O
in	O
the	O
majority	O
of	O
ptaients	O
,	O
occasionally	O
reaching	O
high	O
levles	O
in	O
indivdiual	O
patinets	O
.	O

Due	O
to	O
the	O
rsik	O
of	O
this	O
tachycadria	O
indcuing	O
myocradial	O
ischmeia	O
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
eldrely	O
ptaients	O
of	O
any	O
of	O
the	O
ephderine	B-Chemical
/	O
porpofol	B-Chemical
/	O
mixutres	O
studied	O
.	O

Gecmitabine	B-Chemical
plus	O
vinroelbine	B-Chemical
in	O
nonmsall	O
clel	O
lnug	O
carcionma	O
ptaients	O
age	O
70	O
yaers	O
or	O
odler	O
or	O
patietns	O
who	O
cannot	O
receive	O
cispaltin	B-Chemical
.	O

Oncoapz	O
Coopreative	O
Gorup	O
.	O

BACKGORUND	O
:	O
Although	O
the	O
prevalecne	O
of	O
nosnmall	O
clel	O
lnug	O
cracinoma	O
(	O
NCSLC	O
)	O
is	O
high	O
among	O
eledrly	O
paitents	O
,	O
few	O
dtaa	O
are	O
available	O
regarding	O
the	O
efficcay	O
and	O
toixcity	O
of	O
chmeotherapy	O
in	O
this	O
gorup	O
of	O
paitents	O
.	O

Recent	O
reprots	O
indicate	O
that	O
single	O
aegnt	O
thearpy	O
with	O
vinorlebine	B-Chemical
(	O
VNB	B-Chemical
)	O
or	O
gemcitabnie	B-Chemical
(	O
GEM	B-Chemical
)	O
may	O
obtain	O
a	O
resposne	O
rtae	O
of	O
20	O
-	O
30	O
%	O
in	O
eledrly	O
patietns	O
,	O
with	O
acceptalbe	O
toxiicty	O
and	O
imprvoement	O
in	O
sympotms	O
and	O
qualtiy	O
of	O
lfie	O
.	O

In	O
the	O
current	O
stduy	O
the	O
efifcacy	O
and	O
txoicity	O
of	O
the	O
combintaion	O
of	O
GEM	B-Chemical
and	O
VNB	B-Chemical
in	O
eledrly	O
patinets	O
with	O
advacned	O
NSLCC	O
or	O
those	O
with	O
some	O
cotnraindication	O
to	O
receiving	O
cispaltin	B-Chemical
were	O
assessed	O
.	O

METHODS	O
:	O
Forty	O
-	O
nine	O
patinets	O
with	O
advnaced	O
NCSLC	O
were	O
included	O
,	O
38	O
of	O
whom	O
were	O
age	O
>	O
/	O
=	O
70	O
yaers	O
and	O
11	O
were	O
age	O
<	O
70	O
yeras	O
but	O
who	O
had	O
some	O
contraidnication	O
to	O
receiving	O
cispaltin	B-Chemical
.	O

All	O
patinets	O
were	O
eavluable	O
for	O
rseponse	O
and	O
toixcity	O
.	O

Treatemnt	O
was	O
comprised	O
of	O
VNB	B-Chemical
,	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
plus	O
GEM	B-Chemical
,	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
both	O
on	O
Dyas	O
1	O
,	O
8	O
,	O
and	O
15	O
every	O
28	O
dyas	O
.	O

Patinets	O
received	O
a	O
minimum	O
of	O
three	O
cousres	O
unless	O
prorgessive	O
disaese	O
was	O
dteected	O
.	O

RESLUTS	O
:	O
One	O
hundred	O
sixty	O
-	O
five	O
couress	O
were	O
admiinstered	O
,	O
with	O
a	O
mdeian	O
of	O
3	O
.	O

6	O
cuorses	O
per	O
patinet	O
.	O

The	O
overall	O
resposne	O
rtae	O
was	O
26	O
%	O
(	O
95	O
%	O
confidecne	O
inetrval	O
,	O
15	O
-	O
41	O
%	O
)	O
.	O

Two	O
pateints	O
attained	O
a	O
complete	O
rseponse	O
(	O
4	O
%	O
)	O
and	O
11	O
pateints	O
(	O
22	O
%	O
)	O
achieved	O
a	O
partail	O
resposne	O
.	O

Esatern	O
Cooperaitve	O
Oncloogy	O
Gorup	O
perofrmance	O
stauts	O
imporved	O
in	O
35	O
%	O
of	O
those	O
paitents	O
with	O
an	O
initial	O
value	O
>	O
0	O
,	O
whereas	O
releif	O
of	O
at	O
least	O
1	O
symtpom	O
without	O
worsennig	O
of	O
other	O
symptmos	O
was	O
noted	O
in	O
27	O
ptaients	O
(	O
55	O
%	O
)	O
.	O

The	O
meidan	O
tmie	O
to	O
progrsesion	O
was	O
16	O
weeks	O
and	O
the	O
1	O
-	O
yaer	O
suvrival	O
rtae	O
was	O
33	O
%	O
.	O

Toxiicty	O
was	O
mlid	O
.	O

Six	O
ptaients	O
(	O
12	O
%	O
)	O
had	O
Wolrd	O
Haelth	O
Organiaztion	O
Grdae	O
3	O
-	O
4	O
neutropneia	O
,	O
2	O
patietns	O
(	O
4	O
%	O
)	O
had	O
Grdae	O
3	O
-	O
4	O
thrombocytopeina	O
,	O
and	O
2	O
patinets	O
(	O
4	O
%	O
)	O
had	O
Grdae	O
3	O
neurootxicity	O
.	O

Three	O
paitents	O
with	O
sevree	O
neutorpenia	O
(	O
6	O
%	O
)	O
deid	O
of	O
spesis	O
.	O

The	O
mdeian	O
age	O
of	O
those	O
ptaients	O
developing	O
Grdae	O
3	O
-	O
4	O
neutroepnia	O
was	O
significantly	O
hgiher	O
than	O
that	O
of	O
the	O
remaining	O
patietns	O
(	O
75	O
yaers	O
vs	O
.	O
72	O
yeras	O
;	O
P	O
=	O
0	O
.	O
047	O
)	O
.	O

CONLCUSIONS	O
:	O
The	O
combinaiton	O
of	O
GEM	B-Chemical
and	O
VNB	B-Chemical
is	O
modreately	O
acitve	O
and	O
well	O
tolertaed	O
except	O
in	O
paitents	O
age	O
>	O
/	O
=	O
75	O
yeras	O
.	O

This	O
age	O
gruop	O
had	O
an	O
incerased	O
rsik	O
of	O
myelosuppression	O
.	O

Therefore	O
the	O
prophylcatic	O
use	O
of	O
garnulocyte	O
-	O
coolny	O
stiumlating	O
fatcor	O
should	O
be	O
considered	O
with	O
this	O
treatmnet	O
.	O

New	O
chemothreapy	O
combniations	O
with	O
hihger	O
activtiy	O
and	O
lwoer	O
txoicity	O
are	O
needed	O
for	O
eldrely	O
ptaients	O
with	O
advnaced	O
NSLCC	O
.	O

A	O
selective	O
dopaimne	B-Chemical
D4	O
recetpor	O
atnagonist	O
,	O
NRA0160	B-Chemical
:	O
a	O
prelcinical	O
neuropharmacologcial	O
proflie	O
.	O

NRA0160	B-Chemical
,	O
5	B-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
fluorobenzyildene	I-Chemical
)	I-Chemical
piperiidn	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
ehtyl	I-Chemical
]	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
fulorophenyl	I-Chemical
)	I-Chemical
thizaole	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
cabroxamide	I-Chemical
,	O
has	O
a	O
high	O
affinity	O
for	O
huamn	O
clnoed	O
dopmaine	B-Chemical
D4	O
.	O
2	O
,	O
D4	O
.	O
4	O
and	O
D4	O
.	O
7	O
recpetors	O
,	O
with	O
Ki	O
vaules	O
of	O
0	O
.	O
5	O
,	O
0	O
.	O
9	O
and	O
2	O
.	O
7	O
nM	O
,	O
respectively	O
.	O

NRA0160	B-Chemical
is	O
over	O
20	O
,	O
000fold	O
more	O
potent	O
at	O
the	O
dopaimne	B-Chemical
D4	O
.	O
2	O
rceeptor	O
cmopared	O
with	O
the	O
huamn	O
clnoed	O
dopamnie	B-Chemical
D2L	O
reecptor	O
.	O

NRA0160	B-Chemical
has	O
negligbile	O
affiinty	O
for	O
the	O
hmuan	O
cloend	O
dopamnie	B-Chemical
D3	O
reecptor	O
(	O
Ki	O
=	O
39	O
nM	O
)	O
,	O
rat	O
serotoinn	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
2A	O
rceeptors	O
(	O
Ki	O
=	O
180	O
nM	O
)	O
and	O
rat	O
alpah1	O
adrenocepotr	O
(	O
Ki	O
=	O
237	O
nM	O
)	O
.	O

NRA0160	B-Chemical
and	O
cloazpine	B-Chemical
antagoinzed	O
lcoomotor	O
hyperactiivty	O
idnuced	O
by	O
methmaphetamine	B-Chemical
(	O
MAP	B-Chemical
)	O
in	O
mcie	O
.	O

NRA0160	B-Chemical
and	O
clozapnie	B-Chemical
anatgonized	O
MAP	B-Chemical
-	O
inudced	O
steretoyped	O
bheavior	O
in	O
mcie	O
,	O
although	O
their	O
efefcts	O
did	O
not	O
exceed	O
50	O
%	O
inhiibtion	O
,	O
even	O
at	O
the	O
highest	O
dsoe	O
given	O
.	O

NRA0160	B-Chemical
and	O
clozpaine	B-Chemical
significantly	O
indcued	O
cataelpsy	O
in	O
rtas	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
induciton	O
even	O
at	O
the	O
highest	O
dsoe	O
given	O
.	O

NRA0160	B-Chemical
and	O
colzapine	B-Chemical
significantly	O
reevrsed	O
the	O
disruptoin	O
of	O
perpulse	O
inhbiition	O
(	O
PPI	O
)	O
in	O
rtas	O
produced	O
by	O
aopmorphine	B-Chemical
.	O

NRA0160	B-Chemical
and	O
clozapnie	B-Chemical
significantly	O
shorteend	O
the	O
phenycclidine	B-Chemical
(	O
PCP	B-Chemical
)	O
-	O
indcued	O
proolnged	O
swimmnig	O
laetncy	O
in	O
rtas	O
in	O
a	O
waetr	O
mzae	O
tsak	O
.	O

These	O
findigns	O
suggest	O
that	O
NRA0160	B-Chemical
may	O
have	O
uinque	O
antipsychoitc	O
activiites	O
without	O
the	O
liabiltiy	O
of	O
mootr	O
side	O
effetcs	O
typical	O
of	O
classical	O
antipscyhotics	O
.	O

Warafrin	B-Chemical
-	O
idnuced	O
artrey	O
calicfication	O
is	O
acceleraetd	O
by	O
grotwh	O
and	O
vitmain	B-Chemical
D	I-Chemical
.	O

The	O
present	O
stuides	O
demonstrate	O
that	O
gorwth	O
and	O
vitaimn	B-Chemical
D	I-Chemical
treamtent	O
enhnace	O
the	O
extent	O
of	O
artrey	O
calcificaiton	O
in	O
rtas	O
given	O
sufficient	O
dsoes	O
of	O
Wafrarin	B-Chemical
to	O
inihbit	O
gamma	O
-	O
craboxylation	O
of	O
mtarix	O
Gla	O
prtoein	O
,	O
a	O
clacification	O
inhibtior	O
known	O
to	O
be	O
expresesd	O
by	O
smooth	O
mucsle	O
cells	O
and	O
macropahges	O
in	O
the	O
artrey	O
wlal	O
.	O

The	O
first	O
series	O
of	O
exepriments	O
examined	O
the	O
influecne	O
of	O
age	O
and	O
gorwth	O
sattus	O
on	O
atrery	O
calcfiication	O
in	O
Warfairn	B-Chemical
-	O
traeted	O
rtas	O
.	O

Teratment	O
for	O
2	O
weeks	O
with	O
Warfairn	B-Chemical
caused	O
massive	O
foacl	O
calcfiication	O
of	O
the	O
atrery	O
meida	O
in	O
20	O
-	O
day	O
-	O
old	O
rtas	O
and	O
less	O
extnesive	O
foacl	O
clacification	O
in	O
42	O
-	O
day	O
-	O
old	O
rtas	O
.	O

In	O
contrast	O
,	O
no	O
artrey	O
clacification	O
could	O
be	O
detetced	O
in	O
10	O
-	O
mnoth	O
-	O
old	O
audlt	O
rtas	O
even	O
after	O
4	O
weeks	O
of	O
Wafrarin	B-Chemical
tretament	O
.	O

To	O
directly	O
examine	O
the	O
importance	O
of	O
grwoth	O
to	O
Wafrarin	B-Chemical
-	O
indcued	O
aretry	O
calcificatoin	O
in	O
animlas	O
of	O
the	O
same	O
age	O
,	O
20	O
-	O
day	O
-	O
old	O
rtas	O
were	O
fed	O
for	O
2	O
wekes	O
either	O
an	O
ad	O
libiutm	O
deit	O
or	O
a	O
6	O
-	O
g	O
/	O
d	O
restricted	O
deit	O
that	O
maintains	O
wieght	O
but	O
prevents	O
grotwh	O
.	O

Concrurent	O
treatemnt	O
of	O
both	O
dieatry	O
gropus	O
with	O
Wafrarin	B-Chemical
produced	O
massive	O
foacl	O
calcifictaion	O
of	O
the	O
artrey	O
meida	O
in	O
the	O
ad	O
libiutm	O
-	O
fed	O
rtas	O
but	O
no	O
detecatble	O
artrey	O
calcificaiton	O
in	O
the	O
restricted	O
-	O
deit	O
,	O
grwoth	O
-	O
ihnibited	O
gruop	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
assocaition	O
between	O
atrery	O
calcifciation	O
and	O
grotwh	O
sattus	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
sutdy	O
,	O
there	O
was	O
a	O
relaitonship	O
between	O
hihger	O
seurm	O
phopshate	B-Chemical
and	O
susecptibility	O
to	O
aretry	O
caclification	O
,	O
with	O
30	O
%	O
higehr	O
lveels	O
of	O
seurm	O
phoshpate	B-Chemical
in	O
yuong	O
,	O
ad	O
libiutm	O
-	O
fed	O
rtas	O
copmared	O
with	O
either	O
of	O
the	O
gorups	O
that	O
was	O
resitsant	O
to	O
Wafrarin	B-Chemical
-	O
inudced	O
aretry	O
calcificatoin	O
,	O
ie	O
,	O
the	O
10	O
-	O
mnoth	O
-	O
old	O
rtas	O
and	O
the	O
restricted	O
-	O
deit	O
,	O
gorwth	O
-	O
inhiibted	O
yonug	O
rtas	O
.	O

This	O
osbervation	O
suggests	O
that	O
incraesed	O
susceptibliity	O
to	O
Warfairn	B-Chemical
-	O
indcued	O
aretry	O
calcifiaction	O
could	O
be	O
related	O
to	O
hgiher	O
sreum	O
phoshpate	B-Chemical
levles	O
.	O

The	O
second	O
set	O
of	O
exepriments	O
examined	O
the	O
possible	O
synregy	O
between	O
vitmain	B-Chemical
D	I-Chemical
and	O
Warfrain	B-Chemical
in	O
atrery	O
clacification	O
.	O

High	O
doess	O
of	O
vitmain	B-Chemical
D	I-Chemical
are	O
known	O
to	O
cause	O
calcifictaion	O
of	O
the	O
atrery	O
meida	O
in	O
as	O
little	O
as	O
3	O
to	O
4	O
dyas	O
.	O

High	O
doess	O
of	O
the	O
vitmain	B-Chemical
K	I-Chemical
antagoinst	O
Warfairn	B-Chemical
are	O
also	O
known	O
to	O
cause	O
calicfication	O
of	O
the	O
artrey	O
meida	O
,	O
but	O
at	O
treamtent	O
times	O
of	O
2	O
wekes	O
or	O
longer	O
yet	O
not	O
at	O
1	O
week	O
.	O

In	O
the	O
current	O
sutdy	O
,	O
we	O
inevstigated	O
the	O
synegry	O
between	O
these	O
2	O
treamtents	O
and	O
found	O
that	O
concrurent	O
Wrafarin	B-Chemical
adminisrtation	O
dramatically	O
incraesed	O
the	O
extent	O
of	O
calicfication	O
in	O
the	O
mdeia	O
of	O
viatmin	B-Chemical
D	I-Chemical
-	O
treaetd	O
rtas	O
at	O
3	O
and	O
4	O
dyas	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
efefct	O
of	O
vitmain	B-Chemical
D	I-Chemical
dsoe	O
on	O
artrey	O
calciifcation	O
and	O
the	O
efefct	O
of	O
vitmain	B-Chemical
D	I-Chemical
dsoe	O
on	O
the	O
elevtaion	O
of	O
sreum	O
calcuim	B-Chemical
,	O
which	O
suggests	O
that	O
vitaimn	B-Chemical
D	I-Chemical
may	O
inudce	O
artrey	O
caclification	O
through	O
its	O
effcet	O
on	O
seurm	O
calicum	B-Chemical
.	O

Because	O
Warfrain	B-Chemical
treamtent	O
had	O
no	O
effcet	O
on	O
the	O
elevtaion	O
in	O
seurm	O
calicum	B-Chemical
produced	O
by	O
vitaimn	B-Chemical
D	I-Chemical
,	O
the	O
syenrgy	O
between	O
Warafrin	B-Chemical
and	O
vtiamin	B-Chemical
D	I-Chemical
is	O
probably	O
best	O
explained	O
by	O
the	O
hypotheiss	O
that	O
Warfrain	B-Chemical
inihbits	O
the	O
activtiy	O
of	O
mtarix	O
Gla	O
portein	O
as	O
a	O
calcifciation	O
inhibtior	O
.	O

High	O
lveels	O
of	O
mtarix	O
Gla	O
proetin	O
are	O
found	O
at	O
sties	O
of	O
aretry	O
calcifictaion	O
in	O
rtas	O
tretaed	O
with	O
vitaimn	B-Chemical
D	I-Chemical
plus	O
Warafrin	B-Chemical
,	O
and	O
chemcial	O
anlaysis	O
showed	O
that	O
the	O
prtoein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma	B-Chemical
-	I-Chemical
carbxoylated	I-Chemical
.	O

These	O
observaitons	O
indicate	O
that	O
although	O
the	O
gamma	B-Chemical
-	I-Chemical
carboxyglutaamte	I-Chemical
reisdues	O
of	O
mtarix	O
Gla	O
proetin	O
are	O
apparently	O
required	O
for	O
its	O
fucntion	O
as	O
a	O
calcifiaction	O
inihbitor	O
,	O
they	O
are	O
not	O
required	O
for	O
its	O
accumluation	O
at	O
calcfiication	O
siets	O
.	O

Tset	O
codnitions	O
ifnluence	O
the	O
rseponse	O
to	O
a	O
durg	O
challenge	O
in	O
roednts	O
.	O

These	O
stuides	O
were	O
conducted	O
to	O
examine	O
the	O
differential	O
rseponse	O
to	O
a	O
durg	O
challenge	O
under	O
varied	O
expermiental	O
tset	O
conditoins	O
routinely	O
employed	O
to	O
stduy	O
durg	O
-	O
inudced	O
bheavioral	O
and	O
neuorphysiological	O
rseponses	O
in	O
rdoents	O
.	O

Aopmorphine	B-Chemical
,	O
a	O
nonselective	O
dopmaine	B-Chemical
agnoist	I-Chemical
,	O
was	O
selected	O
due	O
to	O
its	O
biphaisc	O
behvaioral	O
effcets	O
,	O
its	O
ability	O
to	O
inudce	O
hypothemria	O
,	O
and	O
to	O
produce	O
distinct	O
chagnes	O
to	O
dopmaine	B-Chemical
turnvoer	O
in	O
the	O
rdoent	O
barin	O
.	O

From	O
such	O
expermients	O
there	O
is	O
evidecne	O
that	O
characteirzation	O
and	O
detcetion	O
of	O
apomorhpine	B-Chemical
-	O
induecd	O
acitvity	O
in	O
roednts	O
critically	O
depends	O
upon	O
the	O
tset	O
cnoditions	O
employed	O
.	O

In	O
rtas	O
,	O
deteciton	O
of	O
apomorphnie	B-Chemical
-	O
idnuced	O
hypreactivity	O
was	O
facilitated	O
by	O
a	O
peirod	O
of	O
acclmiatization	O
to	O
the	O
tset	O
conditoins	O
.	O

Moreover	O
,	O
tset	O
condiitons	O
can	O
imapct	O
upon	O
other	O
physiloogical	O
respnoses	O
to	O
apomorphnie	B-Chemical
such	O
as	O
durg	O
-	O
idnuced	O
hpyothermia	O
.	O

In	O
mcie	O
,	O
aopmorphine	B-Chemical
produced	O
qualitatievly	O
different	O
repsonses	O
under	O
novel	O
codnitions	O
when	O
compraed	O
to	O
those	O
behvaiors	O
elicited	O
in	O
the	O
hmoe	O
tset	O
cgae	O
.	O

Durg	O
-	O
inudced	O
gorss	O
actiivty	O
coutns	O
were	O
incresaed	O
in	O
the	O
novel	O
exlporatory	O
box	O
only	O
,	O
while	O
meausres	O
of	O
setreotypic	O
beahvior	O
were	O
similar	O
in	O
both	O
.	O

By	O
contrast	O
,	O
apomorphnie	B-Chemical
-	O
induecd	O
locomoiton	O
was	O
more	O
prominent	O
in	O
the	O
novel	O
exlporatory	O
box	O
.	O

Dopamnie	B-Chemical
trunover	O
raitos	O
(	O
DOAPC	B-Chemical
:	O
DA	B-Chemical
and	O
HVA	B-Chemical
:	O
DA	B-Chemical
)	O
were	O
found	O
to	O
be	O
loewr	O
in	O
those	O
animlas	O
expsoed	O
to	O
the	O
exlporatory	O
box	O
when	O
compaerd	O
to	O
their	O
hmoe	O
cgae	O
counterparts	O
.	O

However	O
,	O
aopmorphine	B-Chemical
-	O
induecd	O
reudctions	O
in	O
straital	O
dopamnie	B-Chemical
tunrover	O
were	O
detecetd	O
in	O
both	O
novel	O
and	O
hmoe	O
cgae	O
environmetns	O
.	O

The	O
implications	O
of	O
these	O
findigns	O
are	O
discussed	O
with	O
particular	O
emphasis	O
upon	O
conducting	O
pscyhopharmacological	O
challenge	O
tsets	O
in	O
roednts	O
.	O

Hemolsyis	O
of	O
huamn	O
eyrthrocytes	O
indcued	O
by	O
tmaoxifen	B-Chemical
is	O
related	O
to	O
dsiruption	O
of	O
memrbane	O
strucutre	O
.	O

Tamoxiefn	B-Chemical
(	O
TAM	B-Chemical
)	O
,	O
the	O
anteistrogenic	O
durg	O
most	O
widely	O
perscribed	O
in	O
the	O
cheomtherapy	O
of	O
braest	O
cacner	O
,	O
indcues	O
chagnes	O
in	O
noraml	O
dsicoid	O
sahpe	O
of	O
ertyhrocytes	O
and	O
heomlytic	O
anmeia	O
.	O

This	O
work	O
evaulates	O
the	O
efefcts	O
of	O
TAM	B-Chemical
on	O
isoalted	O
huamn	O
ertyhrocytes	O
,	O
attempting	O
to	O
identify	O
the	O
underlying	O
mechansims	O
on	O
TAM	B-Chemical
-	O
inudced	O
hemoyltic	O
aenmia	O
and	O
the	O
invovlement	O
of	O
biomebmranes	O
in	O
its	O
cytotsatic	O
aciton	O
mechainsms	O
.	O

TAM	B-Chemical
inudces	O
hemolyiss	O
of	O
erythorcytes	O
as	O
a	O
fnuction	O
of	O
concentartion	O
.	O

The	O
extensoin	O
of	O
hmeolysis	O
is	O
varaible	O
with	O
eyrthrocyte	O
smaples	O
,	O
but	O
12	O
.	O
5	O
microM	O
TAM	B-Chemical
inudces	O
total	O
hemolsyis	O
of	O
all	O
tesetd	O
ssupensions	O
.	O

Despite	O
induicng	O
exetnsive	O
erytrhocyte	O
lsyis	O
,	O
TAM	B-Chemical
does	O
not	O
shift	O
the	O
osmtoic	O
frgaility	O
curevs	O
of	O
erythroyctes	O
.	O

The	O
hemloytic	O
effcet	O
of	O
TAM	B-Chemical
is	O
prevented	O
by	O
low	O
concnetrations	O
of	O
alhpa	B-Chemical
-	I-Chemical
tocpoherol	I-Chemical
(	O
aplha	B-Chemical
-	I-Chemical
T	I-Chemical
)	O
and	O
aplha	B-Chemical
-	I-Chemical
tocopehrol	I-Chemical
aectate	I-Chemical
(	O
alhpa	B-Chemical
-	I-Chemical
TAc	I-Chemical
)	O
(	O
inatcivated	O
fnuctional	O
hydroyxl	B-Chemical
)	O
indicating	O
that	O
TAM	B-Chemical
-	O
induecd	O
hmeolysis	O
is	O
not	O
related	O
to	O
oxidatvie	O
mebmrane	O
dmaage	O
.	O

This	O
was	O
further	O
evidenced	O
by	O
abesnce	O
of	O
oxgyen	B-Chemical
consumtpion	O
and	O
hemogolbin	O
oxdiation	O
both	O
determined	O
in	O
parallel	O
with	O
TAM	B-Chemical
-	O
indcued	O
hemolsyis	O
.	O

Furthermore	O
,	O
it	O
was	O
observed	O
that	O
TAM	B-Chemical
ihnibits	O
the	O
peroxidtaion	O
of	O
hmuan	O
erythroyctes	O
inudced	O
by	O
APAH	B-Chemical
,	O
thus	O
ruling	O
out	O
TAM	B-Chemical
-	O
inudced	O
clel	O
oxdiative	O
strses	O
.	O

Hemolsyis	O
caused	O
by	O
TAM	B-Chemical
was	O
not	O
preceded	O
by	O
the	O
lekaage	O
of	O
K	B-Chemical
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
cloloid	O
-	O
omsotic	O
tpye	O
mecahnism	O
of	O
hemloysis	O
,	O
according	O
to	O
the	O
efefcts	O
on	O
osomtic	O
frgaility	O
curevs	O
.	O

However	O
,	O
TAM	B-Chemical
induecs	O
rleease	O
of	O
perihperal	O
protiens	O
of	O
membarne	O
-	O
ctyoskeleton	O
and	O
cytoosl	O
protiens	O
essentially	O
buond	O
to	O
bnad	O
3	O
.	O

Either	O
aplha	B-Chemical
-	I-Chemical
T	I-Chemical
or	O
alhpa	B-Chemical
-	I-Chemical
TAc	I-Chemical
incraeses	O
memrbane	O
packnig	O
and	O
prevents	O
TAM	B-Chemical
partitoin	O
into	O
moedl	O
membarnes	O
.	O

These	O
effcets	O
suggest	O
that	O
the	O
proteciton	O
from	O
hemloysis	O
by	O
tocopehrols	B-Chemical
is	O
related	O
to	O
a	O
decresaed	O
TAM	B-Chemical
incorproation	O
in	O
cnodensed	O
mmebranes	O
and	O
the	O
structrual	O
damgae	O
of	O
the	O
erythroycte	O
membarne	O
is	O
consequently	O
avoided	O
.	O

Therefore	O
,	O
TAM	B-Chemical
-	O
inudced	O
hmeolysis	O
rseults	O
from	O
a	O
sturctural	O
pertubration	O
of	O
red	O
clel	O
memrbane	O
,	O
leading	O
to	O
chagnes	O
in	O
the	O
farmework	O
of	O
the	O
erythroctye	O
membrnae	O
and	O
its	O
cytokseleton	O
caused	O
by	O
its	O
high	O
parittion	O
in	O
the	O
membrnae	O
.	O

These	O
dfeects	O
explain	O
the	O
abnomral	O
erythrcoyte	O
sahpe	O
and	O
dcereased	O
mechaniacl	O
staiblity	O
promoted	O
by	O
TAM	B-Chemical
,	O
resulting	O
in	O
heomlytic	O
aenmia	O
.	O

Additionally	O
,	O
since	O
mmebrane	O
leakgae	O
is	O
a	O
final	O
satge	O
of	O
cytotoxiicty	O
,	O
the	O
disrupiton	O
of	O
the	O
strutcural	O
characteristcis	O
of	O
biomebmranes	O
by	O
TAM	B-Chemical
may	O
contribute	O
to	O
the	O
mlutiple	O
mechanimss	O
of	O
its	O
anitcancer	O
actoin	O
.	O

Chagnes	O
of	O
sdoium	B-Chemical
and	O
ATP	B-Chemical
affinities	O
of	O
the	O
cradiac	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATaPse	O
during	O
and	O
after	O
nitirc	B-Chemical
oxdie	I-Chemical
deifcient	O
hypetrension	O
.	O

In	O
the	O
cadriovascular	O
ssytem	O
,	O
NO	B-Chemical
is	O
involved	O
in	O
the	O
reuglation	O
of	O
a	O
variety	O
of	O
functinos	O
.	O

Inhibiiton	O
of	O
NO	B-Chemical
syntehsis	O
indcues	O
sutsained	O
hyperetnsion	O
.	O

In	O
several	O
mdoels	O
of	O
hyperetnsion	O
,	O
elveation	O
of	O
intrcaellular	O
sdoium	B-Chemical
lveel	O
was	O
doucmented	O
in	O
cradiac	O
tsisue	O
.	O

To	O
assess	O
the	O
molecluar	O
basis	O
of	O
disturbacnes	O
in	O
tarnsmembraneous	O
transoprt	O
of	O
Na	B-Chemical
+	O
,	O
we	O
studied	O
the	O
respnose	O
of	O
cardaic	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPsae	O
to	O
NO	B-Chemical
-	O
defiicent	O
hypertesnion	O
indcued	O
in	O
rtas	O
by	O
NO	B-Chemical
-	O
synhtase	O
inhibtiion	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	B-Chemical
(	I-Chemical
G	I-Chemical
)	I-Chemical
-	I-Chemical
ntiro	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
agrinine	I-Chemical
mehtyl	I-Chemical
esetr	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
NMAE	I-Chemical
)	O
for	O
4	O
four	O
wekes	O
.	O

After	O
4	O
-	O
week	O
amdinistration	O
of	O
L	B-Chemical
-	I-Chemical
NMAE	I-Chemical
,	O
the	O
systloic	O
bolod	O
perssure	O
(	O
SBP	O
)	O
incerased	O
by	O
36	O
%	O
.	O

Two	O
weeks	O
after	O
terminating	O
the	O
teratment	O
,	O
the	O
SBP	O
recoveerd	O
to	O
conrtol	O
value	O
.	O

When	O
actviating	O
the	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATaPse	O
with	O
its	O
subtsrate	O
ATP	B-Chemical
,	O
no	O
cahnges	O
in	O
Km	O
and	O
Vamx	O
vaules	O
were	O
observed	O
in	O
NO	B-Chemical
-	O
deifcient	O
rtas	O
.	O

During	O
actviation	O
with	O
Na	B-Chemical
+	O
,	O
the	O
Vamx	O
remained	O
unchagned	O
,	O
however	O
the	O
K	B-Chemical
(	O
Na	B-Chemical
)	O
incresaed	O
by	O
50	O
%	O
,	O
indicating	O
a	O
proofund	O
decraese	O
in	O
the	O
affinity	O
of	O
the	O
Na	B-Chemical
+	O
-	O
binidng	O
stie	O
in	O
NO	B-Chemical
-	O
deficinet	O
rtas	O
.	O

After	O
recoevry	O
from	O
hypretension	O
,	O
the	O
atcivity	O
of	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATaPse	O
incresaed	O
,	O
due	O
to	O
higehr	O
affintiy	O
of	O
the	O
ATP	B-Chemical
-	O
bindnig	O
stie	O
,	O
as	O
reevaled	O
from	O
the	O
lwoered	O
Km	O
value	O
for	O
ATP	B-Chemical
.	O

The	O
K	B-Chemical
(	O
Na	B-Chemical
)	O
value	O
for	O
Na	B-Chemical
+	O
returned	O
to	O
conrtol	O
value	O
.	O

Ihnibition	O
of	O
NO	B-Chemical
-	O
synhtase	O
inudced	O
a	O
reversible	O
hpyertension	O
accompanied	O
by	O
deprsesed	O
Na	B-Chemical
+	O
-	O
extruison	O
from	O
cardaic	O
cells	O
as	O
a	O
consequence	O
of	O
deteriortaed	O
Na	B-Chemical
+	O
-	O
bindnig	O
properteis	O
of	O
the	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATaPse	O
.	O

After	O
recoevry	O
of	O
blood	O
pressrue	O
to	O
cotnrol	O
vlaues	O
,	O
the	O
extrsuion	O
of	O
Na	B-Chemical
+	O
from	O
cadriac	O
clels	O
was	O
normalized	O
,	O
as	O
revaeled	O
by	O
restroation	O
of	O
the	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATaPse	O
actiivty	O
.	O

Effetcs	O
of	O
long	O
-	O
term	O
preteratment	O
with	O
isoproterneol	B-Chemical
on	O
bromocritpine	B-Chemical
-	O
indcued	O
tachycarida	O
in	O
conscoius	O
rtas	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromorciptine	B-Chemical
-	O
indcued	O
tachycadria	O
,	O
which	O
persisted	O
after	O
adernalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
centarl	O
dopaimne	B-Chemical
D2	O
reecptor	O
activaiton	O
and	O
(	O
ii	O
)	O
rdeuced	O
by	O
5	O
-	O
day	O
isoproterneol	B-Chemical
preteratment	O
,	O
supporting	O
therefore	O
the	O
hyptohesis	O
that	O
this	O
effect	O
is	O
depnedent	O
on	O
sympahtetic	O
otuflow	O
to	O
the	O
haert	O
.	O

This	O
sutdy	O
was	O
conducted	O
to	O
examine	O
whether	O
proolnged	O
prtereatment	O
with	O
iosproterenol	B-Chemical
could	O
aoblish	O
bromocriptnie	B-Chemical
-	O
indcued	O
tachycradia	O
in	O
conscoius	O
rtas	O
.	O

Isoproetrenol	B-Chemical
preteratment	O
for	O
15	O
dyas	O
caused	O
caridac	O
hypertrpohy	O
without	O
affceting	O
bsaeline	O
blood	O
prsesure	O
and	O
haert	O
rtae	O
.	O

In	O
cnotrol	O
rtas	O
,	O
intarvenous	O
bromocirptine	B-Chemical
(	O
150	O
mircog	O
/	O
kg	O
)	O
inudced	O
significant	O
hypotensoin	O
and	O
tcahycardia	O
.	O

Brmoocriptine	B-Chemical
-	O
indcued	O
hypotnesion	O
was	O
unaffceted	O
by	O
isoproterneol	B-Chemical
pretreatemnt	O
,	O
while	O
tachycadria	O
was	O
revesred	O
to	O
significant	O
bradycradia	O
,	O
an	O
efefct	O
that	O
was	O
partly	O
reduecd	O
by	O
i	O
.	O
v	O
.	O
domperiodne	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Neither	O
caridac	O
vgaal	O
nor	O
symptahetic	O
tnoe	O
was	O
altreed	O
by	O
isoproterneol	B-Chemical
pretreatmnet	O
.	O

In	O
isoltaed	O
perfuesd	O
haert	O
prepartaions	O
from	O
iosproterenol	B-Chemical
-	O
pretreaetd	O
rtas	O
,	O
the	O
iosproterenol	B-Chemical
-	O
induecd	O
maixmal	O
icnrease	O
in	O
lfet	O
venrticular	O
systloic	O
prsesure	O
was	O
significantly	O
reudced	O
,	O
copmared	O
with	O
salnie	O
-	O
pertreated	O
rtas	O
(	O
the	O
E5C0	O
of	O
the	O
iosproterenol	B-Chemical
-	O
inudced	O
inrcease	O
in	O
lfet	O
venrticular	O
sysotlic	O
perssure	O
was	O
enhnaced	O
approximately	O
22	O
-	O
fold	O
)	O
.	O

These	O
resluts	O
show	O
that	O
15	O
-	O
day	O
isorpoterenol	B-Chemical
pretraetment	O
not	O
only	O
abolished	O
but	O
revresed	O
bromorciptine	B-Chemical
-	O
induecd	O
tachycarida	O
to	O
brdaycardia	O
,	O
an	O
efefct	O
that	O
is	O
mainly	O
related	O
to	O
further	O
caridac	O
btea	O
-	O
adreonceptor	O
desensitizaiton	O
rather	O
than	O
to	O
impariment	O
of	O
autnoomic	O
regualtion	O
of	O
the	O
haert	O
.	O

They	O
suggest	O
that	O
,	O
in	O
noraml	O
cosncious	O
rtas	O
,	O
the	O
cenrtal	O
tachycadria	O
of	O
bromocritpine	B-Chemical
appears	O
to	O
predominate	O
and	O
to	O
msak	O
the	O
bradcyardia	O
of	O
this	O
agonsit	O
at	O
perpiheral	O
dpoamine	B-Chemical
D2	O
recpetors	O
.	O

A	O
developmetnal	O
analyiss	O
of	O
cloindine	B-Chemical
'	O
s	O
effects	O
on	O
cadriac	O
rtae	O
and	O
ultarsound	O
produtcion	O
in	O
inafnt	O
rtas	O
.	O

Under	O
controleld	O
condtiions	O
,	O
inafnt	O
rtas	O
eimt	O
utlrasonic	O
vocalizatinos	O
during	O
extreme	O
clod	O
epxosure	O
and	O
after	O
administratoin	O
of	O
the	O
aplha	O
(	O
2	O
)	O
adrenocpetor	O
agonsit	O
,	O
clondiine	B-Chemical
.	O

Previous	O
investigtaions	O
have	O
determined	O
that	O
,	O
in	O
repsonse	O
to	O
colnidine	B-Chemical
,	O
ultraosund	O
prodcution	O
incraeses	O
through	O
the	O
2nd	O
-	O
week	O
postpatrum	O
and	O
dcereases	O
thereafter	O
.	O

Given	O
that	O
sypmathetic	O
nerual	O
domniance	O
exhibits	O
a	O
similar	O
develpomental	O
pattren	O
,	O
and	O
given	O
that	O
clonidnie	B-Chemical
idnuces	O
smypathetic	O
wihtdrawal	O
and	O
braydcardia	O
,	O
we	O
hypothesized	O
that	O
cloindine	B-Chemical
'	O
s	O
deevlopmental	O
effetcs	O
on	O
cradiac	O
rtae	O
and	O
ulrtasound	O
proudction	O
would	O
mriror	O
each	O
other	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
expreiment	O
,	O
the	O
effcets	O
of	O
cloniidne	B-Chemical
adminitsration	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
on	O
caridac	O
rtae	O
and	O
ulrtasound	O
produciton	O
were	O
examined	O
in	O
2	O
-	O
,	O
8	O
-	O
,	O
15	O
-	O
,	O
and	O
20	O
-	O
day	O
-	O
old	O
rtas	O
.	O

Age	O
-	O
related	O
chanegs	O
in	O
ultrasonud	O
proudction	O
corresponded	O
with	O
chanegs	O
in	O
cardiovascluar	O
varibales	O
,	O
including	O
bsaeline	O
cardaic	O
rtae	O
and	O
cloindine	B-Chemical
-	O
indcued	O
bardycardia	O
.	O

This	O
experimnet	O
is	O
discussed	O
with	O
regard	O
to	O
the	O
hypotheiss	O
that	O
ulrtasound	O
proudction	O
is	O
the	O
acuostic	O
by	O
-	O
prdouct	O
of	O
a	O
phsyiological	O
manuever	O
that	O
compensates	O
for	O
clondiine	B-Chemical
'	O
s	O
dertimental	O
effetcs	O
on	O
cardiovasuclar	O
functoin	O
.	O

Rceurrent	O
use	O
of	O
newer	O
oarl	B-Chemical
contraecptives	I-Chemical
and	O
the	O
rsik	O
of	O
veonus	O
trhomboembolism	O
.	O

The	O
epidmeiological	O
studeis	O
that	O
asesssed	O
the	O
rsik	O
of	O
veonus	O
thromboebmolism	O
(	O
VTE	O
)	O
associated	O
with	O
newer	O
oarl	B-Chemical
conrtaceptives	I-Chemical
(	O
OC	B-Chemical
)	O
did	O
not	O
distinguish	O
between	O
patetrns	O
of	O
OC	B-Chemical
use	O
,	O
namely	O
first	O
-	O
tmie	O
uesrs	O
,	O
reepaters	O
and	O
switcehrs	O
.	O

Dtaa	O
from	O
a	O
Transnatioanl	O
csae	O
-	O
cnotrol	O
sutdy	O
were	O
used	O
to	O
assess	O
the	O
rsik	O
of	O
VTE	O
for	O
the	O
latter	O
patetrns	O
of	O
use	O
,	O
while	O
accounting	O
for	O
duratoin	O
of	O
use	O
.	O

Over	O
the	O
peirod	O
1993	O
-	O
1996	O
,	O
551	O
csaes	O
of	O
VTE	O
were	O
iedntified	O
in	O
Gemrany	O
and	O
the	O
UK	O
along	O
with	O
2066	O
cotnrols	O
.	O

Totlas	O
of	O
128	O
caess	O
and	O
650	O
cotnrols	O
were	O
anaylsed	O
for	O
reepat	O
use	O
and	O
135	O
csaes	O
and	O
622	O
contorls	O
for	O
switching	O
pattrens	O
.	O

The	O
adjusted	O
rtae	O
raito	O
of	O
VTE	O
for	O
repaet	O
usres	O
of	O
third	O
generatoin	O
OC	B-Chemical
was	O
0	O
.	O
6	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
3	O
-	O
1	O
.	O
2	O
)	O
relative	O
to	O
reepat	O
uesrs	O
of	O
second	O
generatoin	O
pills	O
,	O
whereas	O
it	O
was	O
1	O
.	O
3	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
-	O
2	O
.	O
4	O
)	O
for	O
switchres	O
from	O
second	O
to	O
third	O
generatoin	O
plils	O
relative	O
to	O
swithcers	O
from	O
third	O
to	O
second	O
geenration	O
pills	O
.	O

We	O
conclude	O
that	O
second	O
and	O
third	O
geenration	O
agnets	O
are	O
associated	O
with	O
eqiuvalent	O
rsiks	O
of	O
VTE	O
when	O
the	O
same	O
aegnt	O
is	O
used	O
repeatedly	O
after	O
inetrruption	O
preiods	O
or	O
when	O
uesrs	O
are	O
switched	O
between	O
the	O
two	O
gneerations	O
of	O
pills	O
.	O

These	O
anlayses	O
suggest	O
that	O
the	O
hihger	O
rsik	O
observed	O
for	O
the	O
newer	O
OC	B-Chemical
in	O
other	O
sutdies	O
may	O
be	O
the	O
result	O
of	O
inadequtae	O
cmoparisons	O
of	O
plil	O
uesrs	O
with	O
different	O
patetrns	O
of	O
plil	O
use	O
.	O

Diffeerntial	O
effects	O
of	O
sytsemically	O
admniistered	O
ketmaine	B-Chemical
and	O
lidociane	B-Chemical
on	O
dyanmic	O
and	O
sttaic	O
hyperaglesia	O
inudced	O
by	O
intrdaermal	O
capsaciin	B-Chemical
in	O
humnas	O
.	O

We	O
have	O
examined	O
the	O
efefct	O
of	O
ssytemic	O
amdinistration	O
of	O
ketaimne	B-Chemical
and	O
lidocanie	B-Chemical
on	O
bursh	O
-	O
evoekd	O
(	O
dynaimc	O
)	O
pian	O
and	O
puncttae	O
-	O
eovked	O
(	O
sttaic	O
)	O
hyperaglesia	O
inudced	O
by	O
capasicin	B-Chemical
.	O

In	O
a	O
radnomized	O
,	O
double	O
-	O
bilnd	O
,	O
plcaebo	O
-	O
cotnrolled	O
,	O
crossvoer	O
sutdy	O
,	O
we	O
studied	O
12	O
volnuteers	O
in	O
three	O
exepriments	O
.	O

Capasicin	B-Chemical
100	O
micorgrams	O
was	O
injecetd	O
intradermlaly	O
on	O
the	O
voalr	O
foreram	O
followed	O
by	O
an	O
i	O
.	O
v	O
.	O
inufsion	O
of	O
keatmine	B-Chemical
(	O
bouls	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
over	O
10	O
min	O
followed	O
by	O
infusoin	O
of	O
7	O
micrgorams	O
kg	O
-	O
1	O
min	O
-	O
1	O
)	O
,	O
lidoacine	B-Chemical
5	O
mg	O
kg	O
-	O
1	O
or	O
salnie	O
for	O
50	O
min	O
.	O

Infsuion	O
started	O
15	O
min	O
after	O
injectoin	O
of	O
capsaiicn	B-Chemical
.	O

The	O
following	O
were	O
measuerd	O
:	O
spotnaneous	O
pian	O
,	O
pian	O
evkoed	O
by	O
puntcate	O
and	O
brsuh	O
stiumli	O
(	O
VAS	O
)	O
,	O
and	O
areas	O
of	O
brsuh	O
-	O
evkoed	O
and	O
pnuctate	O
-	O
evoekd	O
hyperaglesia	O
.	O

Keatmine	B-Chemical
reduecd	O
both	O
the	O
aera	O
of	O
bursh	O
-	O
eovked	O
and	O
puncatte	O
-	O
eovked	O
hyprealgesia	O
significantly	O
and	O
it	O
tended	O
to	O
rdeuce	O
bursh	O
-	O
evkoed	O
pian	O
.	O

Lidociane	B-Chemical
reduecd	O
the	O
aera	O
of	O
pnuctate	O
-	O
evoekd	O
hyperalegsia	O
significantly	O
.	O

It	O
tended	O
to	O
redcue	O
VAS	O
scroes	O
of	O
spontaneuos	O
pian	O
but	O
had	O
no	O
effect	O
on	O
evkoed	O
pian	O
.	O

The	O
dfiferential	O
effcets	O
of	O
ketaimne	B-Chemical
and	O
liodcaine	B-Chemical
on	O
staitc	O
and	O
dnyamic	O
hpyeralgesia	O
suggest	O
that	O
the	O
two	O
types	O
of	O
hyperalgseia	O
are	O
mediated	O
by	O
separate	O
mechainsms	O
and	O
have	O
a	O
distinct	O
pahrmacology	O
.	O

Deveolpment	O
of	O
apomrophine	B-Chemical
-	O
indcued	O
aggressive	O
bheavior	O
:	O
copmarison	O
of	O
audlt	O
mlae	O
and	O
feamle	O
Wisatr	O
rtas	O
.	O

The	O
developmnet	O
of	O
apmoorphine	B-Chemical
-	O
induecd	O
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
once	O
daliy	O
)	O
agrgessive	O
bheavior	O
of	O
adlut	O
mlae	O
and	O
feamle	O
Wsitar	O
rtas	O
obtained	O
from	O
the	O
same	O
bereder	O
was	O
studied	O
in	O
two	O
consceutive	O
stes	O
.	O

In	O
mlae	O
aniamls	O
,	O
rpeeated	O
apmoorphine	B-Chemical
traetment	O
inudced	O
a	O
gradaul	O
dveelopment	O
of	O
aggrsesive	O
bheavior	O
as	O
evidenced	O
by	O
the	O
incerased	O
intnesity	O
of	O
agrgessiveness	O
and	O
shrotened	O
laetncy	O
before	O
the	O
first	O
atatck	O
toward	O
the	O
opponent	O
.	O

In	O
fmeale	O
rtas	O
,	O
only	O
a	O
waek	O
tendency	O
toward	O
aggresisveness	O
was	O
found	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
sutdy	O
demonstrates	O
genedr	O
dfiferences	O
in	O
the	O
devleopment	O
of	O
the	O
apomorhpine	B-Chemical
-	O
inudced	O
aggerssive	O
bheavior	O
and	O
indicates	O
that	O
the	O
femlae	O
rtas	O
do	O
not	O
fill	O
the	O
validatoin	O
crietria	O
for	O
use	O
in	O
this	O
mtehod	O
.	O

Intracrnaial	O
aneuyrsms	O
and	O
cocanie	O
absue	O
:	O
anaylsis	O
of	O
prgonostic	O
indiactors	O
.	O

OBJCETIVE	O
:	O
The	O
otucome	O
of	O
subarahcnoid	O
hemorrhgae	O
associated	O
with	O
cocanie	O
absue	O
is	O
reportedly	O
poor	O
.	O

However	O
,	O
no	O
sutdy	O
in	O
the	O
ltierature	O
has	O
reported	O
the	O
use	O
of	O
a	O
statistiacl	O
moedl	O
to	O
anlayze	O
the	O
varaibles	O
that	O
influecne	O
otucome	O
.	O

METHODS	O
:	O
A	O
reveiw	O
of	O
admissinos	O
during	O
a	O
6	O
-	O
yaer	O
preiod	O
reveaeld	O
14	O
paitents	O
with	O
ccoaine	B-Chemical
-	O
related	O
aneuyrsms	O
.	O

This	O
gorup	O
was	O
compaerd	O
with	O
a	O
cnotrol	O
gorup	O
of	O
135	O
patinets	O
with	O
rutpured	O
aneurymss	O
and	O
no	O
hitsory	O
of	O
coacine	O
aubse	O
.	O

Age	O
at	O
presenttaion	O
,	O
tmie	O
of	O
itcus	O
after	O
inotxication	O
,	O
Hunt	O
and	O
Hses	O
garde	O
of	O
suabrachnoid	O
heomrrhage	O
,	O
szie	O
of	O
the	O
aneursym	O
,	O
locatoin	O
of	O
the	O
aneruysm	O
,	O
and	O
the	O
Glasogw	O
Otucome	O
Sclae	O
scroe	O
were	O
asssesed	O
and	O
cmopared	O
.	O

RESLUTS	O
:	O
The	O
pateints	O
in	O
the	O
sutdy	O
gruop	O
were	O
significantly	O
yuonger	O
than	O
the	O
paitents	O
in	O
the	O
cotnrol	O
gruop	O
(	O
P	O
<	O
0	O
.	O
002	O
)	O
.	O

In	O
pateints	O
in	O
the	O
sutdy	O
gorup	O
,	O
all	O
aneruysms	O
were	O
located	O
in	O
the	O
antreior	O
criculation	O
.	O

The	O
majority	O
of	O
these	O
aenurysms	O
were	O
smaller	O
than	O
those	O
of	O
the	O
cotnrol	O
gorup	O
(	O
8	O
+	O
/	O
-	O
6	O
.	O
08	O
mm	O
versus	O
11	O
+	O
/	O
-	O
5	O
.	O
4	O
mm	O
;	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

The	O
differecnes	O
in	O
mortailty	O
and	O
morbdiity	O
between	O
the	O
two	O
gropus	O
were	O
not	O
significant	O
.	O

Hunt	O
and	O
Hses	O
garde	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
and	O
age	O
(	O
P	O
<	O
0	O
.	O
007	O
)	O
were	O
significant	O
predicotrs	O
of	O
outocme	O
for	O
the	O
pateints	O
with	O
cocanie	B-Chemical
-	O
related	O
aenurysms	O
.	O

CONCLUSOIN	O
:	O
Cocanie	B-Chemical
use	O
predsiposed	O
anuerysmal	O
rutpure	O
at	O
a	O
significantly	O
earlier	O
age	O
and	O
in	O
much	O
smaller	O
aneuyrsms	O
.	O

Contrary	O
to	O
the	O
publisehd	O
ltierature	O
,	O
this	O
gruop	O
did	O
reasonably	O
well	O
with	O
aggressive	O
mangaement	O
.	O

Efefct	O
of	O
inrtavenous	O
nimoidpine	B-Chemical
on	O
blood	O
perssure	O
and	O
ouctome	O
after	O
aucte	O
srtoke	O
.	O

BACKRGOUND	O
AND	O
PURPSOE	O
:	O
The	O
Intrvaenous	O
Nimoidpine	B-Chemical
Wset	O
Europaen	O
Srtoke	O
Trail	O
(	O
INEWST	O
)	O
found	O
a	O
corrleation	O
between	O
nimodipnie	B-Chemical
-	O
idnuced	O
reudction	O
in	O
blood	O
perssure	O
(	O
BP	O
)	O
and	O
an	O
unfavoarble	O
ouctome	O
in	O
aucte	O
storke	O
.	O

We	O
sought	O
to	O
confirm	O
this	O
crorelation	O
with	O
and	O
without	O
adjusmtent	O
for	O
prognotsic	O
vairables	O
and	O
to	O
ivnestigate	O
outcmoe	O
in	O
subgorups	O
with	O
icnreasing	O
lveels	O
of	O
BP	O
reduciton	O
.	O

METHODS	O
:	O
Pateints	O
with	O
a	O
cilnical	O
diagnoiss	O
of	O
ischeimc	O
srtoke	O
(	O
within	O
24	O
hours	O
)	O
were	O
consecutively	O
allocated	O
to	O
receive	O
palcebo	O
(	O
n	O
=	O
100	O
)	O
,	O
1	O
mg	O
/	O
h	O
(	O
low	O
-	O
dsoe	O
)	O
nimdoipine	B-Chemical
(	O
n	O
=	O
101	O
)	O
,	O
or	O
2	O
mg	O
/	O
h	O
(	O
high	O
-	O
dsoe	O
)	O
niomdipine	B-Chemical
(	O
n	O
=	O
94	O
)	O
.	O

The	O
correaltion	O
between	O
aevrage	O
BP	O
change	O
during	O
the	O
first	O
2	O
dyas	O
and	O
the	O
outocme	O
at	O
day	O
21	O
was	O
anlayzed	O
.	O

REUSLTS	O
:	O
Two	O
hundred	O
sixty	O
-	O
five	O
pateints	O
were	O
included	O
in	O
this	O
analyiss	O
(	O
n	O
=	O
92	O
,	O
93	O
,	O
and	O
80	O
for	O
plcaebo	O
,	O
low	O
dsoe	O
,	O
and	O
high	O
dsoe	O
,	O
respectively	O
)	O
.	O

Nimodiipne	B-Chemical
teratment	O
resulted	O
in	O
a	O
sattistically	O
significant	O
redutcion	O
in	O
systloic	O
BP	O
(	O
SBP	O
)	O
and	O
disatolic	O
BP	O
(	O
DBP	O
)	O
from	O
bsaeline	O
copmared	O
with	O
placbeo	O
during	O
the	O
first	O
few	O
dyas	O
.	O

In	O
multivraiate	O
anlaysis	O
,	O
a	O
significant	O
correaltion	O
between	O
DBP	O
redcution	O
and	O
wosrening	O
of	O
the	O
neuorlogical	O
socre	O
was	O
found	O
for	O
the	O
high	O
-	O
dsoe	O
gorup	O
(	O
btea	O
=	O
0	O
.	O
49	O
,	O
P	O
=	O
0	O
.	O
048	O
)	O
.	O

Pateints	O
with	O
a	O
DBP	O
rdeuction	O
of	O
>	O
or	O
=	O
20	O
%	O
in	O
the	O
high	O
-	O
dsoe	O
gruop	O
had	O
a	O
significantly	O
incraesed	O
adjusted	O
OR	O
for	O
the	O
cmopound	O
ouctome	O
vraiable	O
detah	O
or	O
dependecny	O
(	O
Batrhel	O
Inedx	O
<	O
60	O
)	O
(	O
n	O
/	O
N	O
=	O
25	O
/	O
26	O
,	O
OR	O
10	O
.	O
16	O
,	O
95	O
%	O
CI	O
1	O
.	O
02	O
to	O
101	O
.	O
74	O
)	O
and	O
daeth	O
alone	O
(	O
n	O
/	O
N	O
=	O
9	O
/	O
26	O
,	O
OR	O
4	O
.	O
336	O
,	O
95	O
%	O
CI	O
1	O
.	O
131	O
16	O
.	O
619	O
)	O
comapred	O
with	O
all	O
placbeo	O
paitents	O
(	O
n	O
/	O
N	O
=	O
62	O
/	O
92	O
and	O
14	O
/	O
92	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
correaltion	O
between	O
SBP	O
change	O
and	O
outocme	O
.	O

COCNLUSIONS	O
:	O
DBP	O
,	O
but	O
not	O
SBP	O
,	O
redutcion	O
was	O
associated	O
with	O
neurloogical	O
worsneing	O
after	O
the	O
intravenuos	O
adimnistration	O
of	O
high	O
-	O
dsoe	O
nimodipnie	B-Chemical
after	O
aucte	O
strkoe	O
.	O

For	O
low	O
-	O
dsoe	O
niomdipine	B-Chemical
,	O
the	O
reuslts	O
were	O
not	O
conclusive	O
.	O

These	O
rseults	O
do	O
not	O
confirm	O
or	O
exclude	O
a	O
neuroportective	O
property	O
of	O
niomdipine	B-Chemical
.	O

Noenatal	O
pyriodxine	B-Chemical
respnosive	O
convulsoins	O
due	O
to	O
isonizaid	B-Chemical
threapy	O
.	O

A	O
17	O
-	O
day	O
-	O
old	O
inafnt	O
on	O
isonizaid	B-Chemical
therpay	O
13	O
mg	O
/	O
kg	O
dialy	O
from	O
brith	O
because	O
of	O
matenral	O
tuberculoiss	O
was	O
adimtted	O
after	O
4	O
dyas	O
of	O
colnic	O
fits	O
.	O

No	O
underlying	O
infetcive	O
or	O
biocehmical	O
cause	O
could	O
be	O
found	O
.	O

The	O
fits	O
caesed	O
within	O
4	O
hours	O
of	O
admniistering	O
intramuscluar	O
pyirdoxine	B-Chemical
,	O
suggesting	O
an	O
aetiloogy	O
of	O
pyridoixne	B-Chemical
defiicency	O
secondary	O
to	O
isoniaizd	B-Chemical
mdeication	O
.	O

Ketaimne	B-Chemical
sedtaion	O
for	O
the	O
rdeuction	O
of	O
chlidren	O
'	O
s	O
fractrues	O
in	O
the	O
emegrency	O
departemnt	O
.	O

BACKGRONUD	O
:	O
There	O
recently	O
has	O
been	O
a	O
resuregnce	O
in	O
the	O
utliization	O
of	O
ketamnie	B-Chemical
,	O
a	O
uinque	O
aneshtetic	O
,	O
for	O
emergecny	O
-	O
deaprtment	O
porcedures	O
requiring	O
sdeation	O
.	O

The	O
purpose	O
of	O
the	O
present	O
sutdy	O
was	O
to	O
examine	O
the	O
saefty	O
and	O
efficcay	O
of	O
kteamine	B-Chemical
for	O
seadtion	O
in	O
the	O
treatemnt	O
of	O
childern	O
'	O
s	O
fratcures	O
in	O
the	O
emeregncy	O
depatrment	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fourteen	O
cihldren	O
(	O
avearge	O
age	O
,	O
5	O
.	O
3	O
yaers	O
;	O
range	O
,	O
twelve	O
monhts	O
to	O
ten	O
yaers	O
and	O
ten	O
mnoths	O
)	O
who	O
underwent	O
colsed	O
rdeuction	O
of	O
an	O
ioslated	O
fracutre	O
or	O
dsilocation	O
in	O
the	O
eemrgency	O
departmnet	O
at	O
a	O
leevl	O
-	O
I	O
tramua	O
cetner	O
were	O
prospectively	O
eavluated	O
.	O

Ketmaine	B-Chemical
hydrocholride	I-Chemical
was	O
adminsitered	O
intravneously	O
(	O
at	O
a	O
dsoe	O
of	O
two	O
milligrams	O
per	O
kilogram	O
of	O
bdoy	O
weihgt	O
)	O
in	O
ninety	O
-	O
nine	O
of	O
the	O
pateints	O
and	O
intrmauscularly	O
(	O
at	O
a	O
dsoe	O
of	O
four	O
milligrams	O
per	O
kilogram	O
of	O
bdoy	O
wegiht	O
)	O
in	O
the	O
other	O
fifteen	O
.	O

A	O
baord	O
-	O
certified	O
eemrgency	O
pyhsician	O
skilled	O
in	O
ariway	O
manageemnt	O
supervised	O
adminitsration	O
of	O
the	O
anestheitc	O
,	O
and	O
the	O
patinets	O
were	O
mointored	O
by	O
a	O
regisetred	O
nruse	O
.	O

Any	O
pian	O
during	O
the	O
reudction	O
was	O
rated	O
by	O
the	O
orthpoaedic	O
suregon	O
treaitng	O
the	O
patinet	O
according	O
to	O
the	O
Chlidren	O
'	O
s	O
Hosiptal	O
of	O
Esatern	O
Ontraio	O
Pian	O
Sacle	O
(	O
CHEPOS	O
)	O
.	O

RESLUTS	O
:	O
The	O
avreage	O
tmie	O
from	O
intarvenous	O
adminisrtation	O
of	O
kteamine	B-Chemical
to	O
mnaipulation	O
of	O
the	O
fracutre	O
or	O
dislocatoin	O
was	O
one	O
minute	O
and	O
thirty	O
-	O
six	O
seconds	O
(	O
range	O
,	O
twenty	O
seconds	O
to	O
five	O
mintues	O
)	O
,	O
and	O
the	O
avreage	O
tmie	O
from	O
intramucsular	O
administratoin	O
to	O
manipualtion	O
was	O
four	O
mintues	O
and	O
forty	O
-	O
two	O
seconds	O
(	O
range	O
,	O
sixty	O
seconds	O
to	O
fifteen	O
miuntes	O
)	O
.	O

The	O
avergae	O
scroe	O
according	O
to	O
the	O
Chlidren	O
'	O
s	O
Hsopital	O
of	O
Easetrn	O
Ontraio	O
Pian	O
Sclae	O
was	O
6	O
.	O
4	O
points	O
(	O
range	O
,	O
5	O
to	O
10	O
points	O
)	O
,	O
reflecting	O
mniimal	O
or	O
no	O
pian	O
during	O
fractrue	O
reudction	O
.	O

Adqeuate	O
frcature	O
redutcion	O
was	O
obtained	O
in	O
111	O
of	O
the	O
childern	O
.	O

Ninety	O
-	O
nine	O
percent	O
(	O
sixty	O
-	O
eight	O
)	O
of	O
the	O
sixty	O
-	O
nine	O
paretns	O
present	O
during	O
the	O
redutcion	O
were	O
plesaed	O
with	O
the	O
sedtaion	O
and	O
would	O
allow	O
it	O
to	O
be	O
used	O
again	O
in	O
a	O
similar	O
situation	O
.	O

Patecny	O
of	O
the	O
airawy	O
and	O
indeepndent	O
rsepiration	O
were	O
maintained	O
in	O
all	O
of	O
the	O
paitents	O
.	O

Bolod	O
perssure	O
and	O
herat	O
rtae	O
remained	O
stalbe	O
.	O

Minor	O
side	O
effcets	O
included	O
nasuea	O
(	O
thirteen	O
patinets	O
)	O
,	O
emeiss	O
(	O
eight	O
of	O
the	O
thirteen	O
pateints	O
with	O
nuasea	O
)	O
,	O
clusminess	O
(	O
evident	O
as	O
aatxic	O
moevments	O
in	O
ten	O
patietns	O
)	O
,	O
and	O
dyspohric	O
reactoin	O
(	O
one	O
ptaient	O
)	O
.	O

No	O
long	O
-	O
term	O
sqeuelae	O
were	O
noted	O
,	O
and	O
no	O
patietns	O
had	O
hallucinaitons	O
or	O
nigthmares	O
.	O

CONCLSUIONS	O
:	O
Keatmine	B-Chemical
reliably	O
,	O
safely	O
,	O
and	O
quickly	O
provided	O
adeqaute	O
sdeation	O
to	O
effectively	O
facilitate	O
the	O
reductoin	O
of	O
chidlren	O
'	O
s	O
fractrues	O
in	O
the	O
emergnecy	O
deaprtment	O
at	O
our	O
institutoin	O
.	O

Ketamnie	B-Chemical
should	O
only	O
be	O
used	O
in	O
an	O
envirnoment	O
such	O
as	O
the	O
emergnecy	O
depatrment	O
,	O
where	O
proper	O
one	O
-	O
on	O
-	O
one	O
monitoirng	O
is	O
used	O
and	O
baord	O
-	O
certified	O
physicinas	O
skilled	O
in	O
aiwray	O
manaegment	O
are	O
directly	O
involved	O
in	O
the	O
crae	O
of	O
the	O
patinet	O
.	O

Cycolsporine	B-Chemical
and	O
tcarolimus	B-Chemical
-	O
associated	O
throbmotic	O
micraongiopathy	O
.	O

The	O
devleopment	O
of	O
thromboitc	O
microagniopathy	O
(	O
TMA	O
)	O
associated	O
with	O
the	O
use	O
of	O
ccylosporine	B-Chemical
has	O
been	O
well	O
doucmented	O
.	O

Tretaments	O
have	O
included	O
discontniuation	O
or	O
reductoin	O
of	O
cyclospoirne	B-Chemical
dsoe	O
with	O
or	O
without	O
cocnurrent	O
plamsa	O
exhcange	O
,	O
plamsa	O
infsuion	O
,	O
anticoagultaion	O
,	O
and	O
intraevnous	O
immuonglobulin	O
G	O
inufsion	O
.	O

However	O
,	O
for	O
recipeints	O
of	O
ogran	O
transplantatoin	O
,	O
removing	O
the	O
inciitng	O
aegnt	O
is	O
not	O
without	O
the	O
atetndant	O
rsik	O
of	O
preciptiating	O
aucte	O
rjeection	O
and	O
garft	O
lsos	O
.	O

The	O
last	O
decade	O
has	O
seen	O
the	O
emegrence	O
of	O
tacrloimus	B-Chemical
as	O
a	O
potent	O
immunosuppressive	O
agnet	O
with	O
mechansims	O
of	O
actoin	O
virtually	O
idetnical	O
to	O
those	O
of	O
cyclsoporine	B-Chemical
.	O

As	O
a	O
result	O
,	O
switching	O
to	O
tacroliums	B-Chemical
has	O
been	O
reported	O
to	O
be	O
a	O
vaible	O
threapeutic	O
option	O
in	O
the	O
setting	O
of	O
cyclopsorine	B-Chemical
-	O
inudced	O
TMA	O
.	O

With	O
the	O
more	O
widespread	O
applicatoin	O
of	O
tacrolmius	B-Chemical
in	O
oragn	O
transplanttaion	O
,	O
tacrloimus	B-Chemical
-	O
associated	O
TMA	O
has	O
also	O
been	O
recognized	O
.	O

However	O
,	O
literautre	O
regarding	O
the	O
inicdence	O
of	O
the	O
recurrnece	O
of	O
TMA	O
in	O
patinets	O
expoesd	O
sequentially	O
to	O
cyclsoporine	B-Chemical
and	O
tcarolimus	B-Chemical
is	O
liimted	O
.	O

We	O
reprot	O
a	O
csae	O
of	O
a	O
lviing	O
doonr	O
rneal	O
trnasplant	O
rceipient	O
who	O
developed	O
cycolsporine	B-Chemical
-	O
idnuced	O
TMA	O
that	O
responded	O
to	O
the	O
withrdawal	O
of	O
cyclosoprine	B-Chemical
in	O
conjucntion	O
with	O
plasmahperesis	O
and	O
frseh	O
froezn	O
palsma	O
replcaement	O
therpay	O
.	O

Introduction	O
of	O
tacroilmus	B-Chemical
as	O
an	O
alterntaive	O
immunousppressive	O
agnet	O
resulted	O
in	O
the	O
recurrecne	O
of	O
TMA	O
and	O
the	O
subsequent	O
lsos	O
of	O
the	O
rneal	O
allograft	O
.	O

Pateints	O
who	O
are	O
switched	O
from	O
cyclosproine	B-Chemical
to	O
tacrloimus	B-Chemical
or	O
vice	O
versa	O
should	O
be	O
closely	O
mointored	O
for	O
the	O
sings	O
and	O
sympotms	O
of	O
recurrent	O
TMA	O
.	O

Anaglesic	O
effect	O
of	O
inrtavenous	O
keatmine	B-Chemical
in	O
canecr	O
pateints	O
on	O
morpihne	B-Chemical
threapy	O
:	O
a	O
randmoized	O
,	O
contorlled	O
,	O
double	O
-	O
bilnd	O
,	O
corssover	O
,	O
double	O
-	O
dsoe	O
stduy	O
.	O

Pian	O
not	O
rseponsive	O
to	O
moprhine	B-Chemical
is	O
often	O
problematic	O
.	O

Anmial	O
and	O
cilnical	O
sutdies	O
have	O
suggested	O
that	O
N	B-Chemical
-	I-Chemical
metyhl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspatrate	I-Chemical
(	O
NDMA	B-Chemical
)	O
antaognists	O
,	O
such	O
as	O
ketaimne	B-Chemical
,	O
may	O
be	O
effecitve	O
in	O
imprvoing	O
oipoid	O
anlagesia	O
in	O
difficult	O
pian	O
snydromes	O
,	O
such	O
as	O
neuorpathic	O
pian	O
.	O

A	O
slow	O
blous	O
of	O
suhbypnotic	O
dsoes	O
of	O
ketaimne	B-Chemical
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
or	O
0	O
.	O
50	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
10	O
cacner	O
pateints	O
whose	O
pian	O
was	O
urnelieved	O
by	O
morpihne	B-Chemical
in	O
a	O
rnadomized	O
,	O
double	O
-	O
bilnd	O
,	O
crossvoer	O
,	O
double	O
-	O
dsoe	O
sutdy	O
.	O

Pian	O
intnesity	O
on	O
a	O
0	O
to	O
10	O
numercial	O
scale	O
;	O
nuasea	O
and	O
vomiitng	O
,	O
drowsniess	O
,	O
cofnusion	O
,	O
and	O
dry	O
motuh	O
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mnii	O
-	O
Menatl	O
Sttae	O
Examintaion	O
(	O
MSME	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
atrerial	O
perssure	O
were	O
recorded	O
before	O
adminsitration	O
of	O
durgs	O
(	O
T0	O
)	O
and	O
after	O
30	O
miuntes	O
(	O
T30	O
)	O
,	O
60	O
miuntes	O
(	O
T60	O
)	O
,	O
120	O
minuets	O
(	O
T210	O
)	O
,	O
and	O
180	O
mintues	O
(	O
T810	O
)	O
.	O

Keatmine	B-Chemical
,	O
but	O
not	O
sailne	O
sloution	O
,	O
significantly	O
reudced	O
the	O
pian	O
intnesity	O
in	O
almost	O
all	O
the	O
patietns	O
at	O
both	O
dsoes	O
.	O

This	O
effcet	O
was	O
more	O
relveant	O
in	O
paitents	O
treaetd	O
with	O
hihger	O
dsoes	O
.	O

Halluciantions	O
occurred	O
in	O
4	O
paitents	O
,	O
and	O
an	O
unpleasnat	O
sensaiton	O
(	O
"	O
empty	O
haed	O
"	O
)	O
was	O
also	O
reported	O
by	O
2	O
patietns	O
.	O

These	O
episoeds	O
rveersed	O
after	O
the	O
administrtaion	O
of	O
diazeapm	B-Chemical
1	O
mg	O
intrvaenously	O
.	O

Signifiacnt	O
incerases	O
in	O
droswiness	O
were	O
reported	O
in	O
ptaients	O
tretaed	O
with	O
ketamnie	B-Chemical
in	O
both	O
gorups	O
and	O
were	O
more	O
marked	O
with	O
ketamnie	B-Chemical
0	O
.	O
50	O
mg	O
/	O
kg	O
.	O

A	O
significant	O
difference	O
in	O
MSME	O
was	O
observed	O
at	O
T30	O
in	O
patinets	O
who	O
received	O
0	O
.	O
50	O
mg	O
/	O
kg	O
of	O
ketmaine	B-Chemical
.	O

Kteamine	B-Chemical
can	O
ipmrove	O
morpihne	B-Chemical
analegsia	O
in	O
difficult	O
pian	O
sydnromes	O
,	O
such	O
as	O
neruopathic	O
pian	O
.	O

However	O
,	O
the	O
occrurence	O
of	O
cenrtal	O
advesre	O
effetcs	O
should	O
be	O
taken	O
into	O
account	O
,	O
especially	O
when	O
using	O
hgiher	O
dsoes	O
.	O

This	O
osbervation	O
should	O
be	O
tseted	O
in	O
studeis	O
of	O
prolnoged	O
ketaimne	B-Chemical
adminsitration	O
.	O

Pacliatxel	B-Chemical
,	O
cispltain	B-Chemical
,	O
and	O
gemcitaibne	B-Chemical
combinaiton	O
chemohterapy	O
within	O
a	O
multiidsciplinary	O
therapuetic	O
approach	O
in	O
metasattic	O
nonmsall	O
clel	O
lnug	O
carcionma	O
.	O

BACKGRUOND	O
:	O
Cipslatin	B-Chemical
-	O
based	O
chemotehrapy	O
combiantions	O
imporve	O
qaulity	O
of	O
lfie	O
and	O
surivval	O
in	O
advnaced	O
nonmsall	O
clel	O
lnug	O
cracinoma	O
(	O
NCSLC	O
)	O
.	O

The	O
emeregnce	O
of	O
new	O
actvie	O
durgs	O
might	O
translate	O
into	O
more	O
effective	O
rgeimens	O
for	O
the	O
tretament	O
of	O
this	O
diesase	O
.	O

METHODS	O
:	O
The	O
obejctive	O
of	O
this	O
sutdy	O
was	O
to	O
determine	O
the	O
fesaibility	O
,	O
repsonse	O
rtae	O
,	O
and	O
toxictiy	O
of	O
a	O
paciltaxel	B-Chemical
,	O
cispltain	B-Chemical
,	O
and	O
gemcitabnie	B-Chemical
combiantion	O
to	O
traet	O
mteastatic	O
NSLCC	O
.	O

Thirty	O
-	O
five	O
consecutvie	O
cheomtherapy	O
-	O
navie	O
patinets	O
with	O
Satge	O
IV	O
NCSLC	O
and	O
an	O
Esatern	O
Cooperative	O
Ocnology	O
Gruop	O
preformance	O
stauts	O
of	O
0	O
-	O
2	O
were	O
treaetd	O
with	O
a	O
combintaion	O
of	O
pacliatxel	B-Chemical
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intrvaenously	O
in	O
3	O
hours	O
)	O
on	O
Day	O
1	O
,	O
cipslatin	B-Chemical
(	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intrvaenously	O
in	O
6	O
hours	O
)	O
on	O
Day	O
1	O
,	O
and	O
gemictabine	B-Chemical
(	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intraevnously	O
in	O
30	O
mintues	O
)	O
on	O
Dyas	O
1	O
and	O
8	O
,	O
every	O
4	O
wekes	O
.	O

Although	O
rseponding	O
paitents	O
were	O
scheudled	O
to	O
receive	O
consolidaiton	O
radiotehrapy	O
and	O
24	O
pateints	O
received	O
prpelanned	O
second	O
-	O
line	O
chemtoherapy	O
after	O
dsiease	O
porgression	O
,	O
the	O
respnose	O
and	O
toixcity	O
rtaes	O
reported	O
refer	O
only	O
to	O
the	O
chemothearpy	O
regmien	O
given	O
.	O

RESUTLS	O
:	O
All	O
the	O
patinets	O
were	O
examined	O
for	O
toixcity	O
;	O
34	O
were	O
examniable	O
for	O
rseponse	O
.	O

An	O
ojbective	O
resopnse	O
was	O
observed	O
in	O
73	O
.	O
5	O
%	O
of	O
the	O
patinets	O
(	O
95	O
%	O
confidecne	O
intevral	O
[	O
CI	O
]	O
,	O
55	O
.	O
6	O
-	O
87	O
.	O
1	O
%	O
)	O
,	O
including	O
4	O
complete	O
resopnses	O
(	O
11	O
.	O
7	O
%	O
)	O
.	O

According	O
to	O
intentoin	O
-	O
to	O
-	O
terat	O
,	O
the	O
overall	O
repsonse	O
rtae	O
was	O
71	O
.	O
4	O
%	O
(	O
95	O
%	O
CI	O
,	O
53	O
.	O
7	O
-	O
85	O
.	O
4	O
%	O
)	O
.	O

After	O
154	O
cuorses	O
of	O
therpay	O
,	O
the	O
medain	O
dsoe	O
intenstiy	O
was	O
131	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
pacltiaxel	B-Chemical
(	O
97	O
.	O
3	O
%	O
)	O
,	O
117	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
cispltain	B-Chemical
(	O
97	O
.	O
3	O
%	O
)	O
,	O
and	O
1378	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
gemictabine	B-Chemical
(	O
86	O
.	O
2	O
%	O
)	O
.	O

Wrold	O
Heatlh	O
Ogranization	O
Grdae	O
3	O
-	O
4	O
neturopenia	O
and	O
thrombocytoepnia	O
occurred	O
in	O
39	O
.	O
9	O
%	O
and	O
11	O
.	O
4	O
%	O
of	O
patinets	O
,	O
respectively	O
.	O

There	O
was	O
one	O
teratment	O
-	O
related	O
detah	O
.	O

Nnohematologic	O
toxiciites	O
were	O
mlid	O
.	O

After	O
a	O
medain	O
follow	O
-	O
up	O
of	O
22	O
mnoths	O
,	O
the	O
mdeian	O
progerssion	O
free	O
sruvival	O
rtae	O
was	O
7	O
mnoths	O
,	O
and	O
the	O
medain	O
sruvival	O
tmie	O
was	O
16	O
motnhs	O
.	O

CONLCUSIONS	O
:	O
The	O
cobmination	O
of	O
paclitaexl	B-Chemical
,	O
cipslatin	B-Chemical
,	O
and	O
gemctiabine	B-Chemical
is	O
well	O
toelrated	O
and	O
shows	O
high	O
atcivity	O
in	O
metasattic	O
NCSLC	O
.	O

This	O
treamtent	O
merits	O
further	O
compraison	O
with	O
other	O
csiplatin	B-Chemical
-	O
based	O
regimnes	O
.	O

Serotoenrgic	B-Chemical
antidepresasnts	I-Chemical
and	O
urniary	O
incontinnece	O
.	O

Many	O
new	O
seortonergic	B-Chemical
antidperessants	I-Chemical
have	O
been	O
introduced	O
over	O
the	O
past	O
decade	O
.	O

Although	O
urniary	O
incontnience	O
is	O
listed	O
as	O
one	O
side	O
effect	O
of	O
these	O
durgs	O
in	O
their	O
pcakage	O
inesrts	O
there	O
is	O
only	O
one	O
rpeort	O
in	O
the	O
litearture	O
.	O

This	O
cnocerns	O
2	O
mlae	O
patinets	O
who	O
experienced	O
incnotinence	O
while	O
taking	O
vnelafaxine	B-Chemical
.	O

In	O
the	O
present	O
paper	O
the	O
authros	O
describe	O
2	O
fmeale	O
paitents	O
who	O
developed	O
incontinnece	O
secondary	O
to	O
the	O
selective	O
serotnoin	B-Chemical
reutpake	O
inhiibtors	O
parxoetine	B-Chemical
and	O
sertarline	B-Chemical
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
efefct	O
on	O
velnafaxine	B-Chemical
.	O

In	O
2	O
of	O
the	O
3	O
caess	O
the	O
pateints	O
were	O
also	O
taking	O
litihum	B-Chemical
carbontae	I-Chemical
and	O
btea	O
-	O
blockres	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	O
to	O
the	O
inconitnence	O
.	O

Anmial	O
stuides	O
suggest	O
that	O
incontnience	O
secondary	O
to	O
sreotonergic	B-Chemical
atnidepressants	I-Chemical
could	O
be	O
mediated	O
by	O
the	O
5TH4	O
reecptors	O
found	O
on	O
the	O
bladedr	O
.	O

Further	O
reserach	O
is	O
needed	O
to	O
delineate	O
the	O
freuqency	O
of	O
this	O
troubling	O
side	O
effect	O
and	O
how	O
best	O
to	O
terat	O
it	O
.	O

Aucte	O
cociane	B-Chemical
-	O
induecd	O
seziures	O
:	O
dfiferential	O
sensitivtiy	O
of	O
six	O
inberd	O
muose	O
starins	O
.	O

Mautre	O
mlae	O
and	O
femlae	O
mcie	O
from	O
six	O
inberd	O
satins	O
were	O
tetsed	O
for	O
suscepitbility	O
to	O
behaviroal	O
seziures	O
inudced	O
by	O
a	O
single	O
injcetion	O
of	O
coacine	B-Chemical
.	O

Cociane	B-Chemical
was	O
injecetd	O
ip	O
over	O
a	O
range	O
of	O
doess	O
(	O
50	O
-	O
100	O
mg	O
/	O
kg	O
)	O
and	O
beahvior	O
was	O
monitoerd	O
for	O
20	O
miuntes	O
.	O

Siezure	O
end	O
points	O
included	O
laetncy	O
to	O
froelimb	O
or	O
hidnlimb	O
clnous	O
,	O
latecny	O
to	O
clnoic	O
rnuning	O
siezure	O
and	O
latnecy	O
to	O
jmuping	O
buoncing	O
seziure	O
.	O

A	O
range	O
of	O
starin	O
specific	O
sesnitivities	O
was	O
documneted	O
with	O
A	O
/	O
J	O
and	O
SJL	O
mcie	O
being	O
most	O
sensitvie	O
and	O
C5B7L	O
/	O
6J	O
most	O
reisstant	O
.	O

DBA	O
/	O
2J	O
,	O
BLAB	O
/	O
cyBJ	O
and	O
NZW	O
/	O
LcaJ	O
srtains	O
exhibited	O
itnermediate	O
snesitivity	O
.	O

EEG	O
recodrings	O
were	O
made	O
in	O
SJL	O
,	O
A	O
/	O
J	O
and	O
C5B7L	O
/	O
6J	O
mcie	O
revealing	O
a	O
close	O
correpsondence	O
between	O
eelctrical	O
atcivity	O
and	O
bheavior	O
.	O

Additionally	O
,	O
levles	O
of	O
cociane	B-Chemical
determined	O
in	O
hippocapmus	O
and	O
cotrex	O
were	O
not	O
different	O
between	O
sensitvie	O
and	O
resitsant	O
stranis	O
.	O

Additional	O
stduies	O
of	O
these	O
muirne	O
stranis	O
may	O
be	O
useful	O
for	O
investigtaing	O
geentic	O
influenecs	O
on	O
cociane	B-Chemical
-	O
induecd	O
siezures	O
.	O

Hypotensoin	O
following	O
the	O
initiaiton	O
of	O
tiznaidine	B-Chemical
in	O
a	O
paitent	O
terated	O
with	O
an	O
angiotesnin	B-Chemical
converting	O
eznyme	O
inihbitor	O
for	O
chroinc	O
hypertenison	O
.	O

Centarlly	O
acting	O
aplha	O
-	O
2	O
ardenergic	O
agnoists	O
are	O
one	O
of	O
several	O
phamracologic	O
agetns	O
used	O
in	O
the	O
traetment	O
of	O
spsaticity	O
related	O
to	O
dsiorders	O
of	O
the	O
cenrtal	O
nrevous	O
sysetm	O
.	O

In	O
addition	O
to	O
their	O
effects	O
on	O
spatsicity	O
,	O
certain	O
advesre	O
cardiorespiartory	O
effetcs	O
have	O
been	O
reported	O
.	O

Adluts	O
chrnoically	O
traeted	O
with	O
anigotensin	B-Chemical
converting	O
eznyme	O
inhibtiors	O
may	O
have	O
a	O
liimted	O
ability	O
to	O
respond	O
to	O
hypotenison	O
when	O
the	O
sypmathetic	O
respnose	O
is	O
simultanoeusly	O
blokced	O
.	O

The	O
atuhors	O
present	O
a	O
10	O
-	O
yaer	O
-	O
old	O
boy	O
chrnoically	O
treaetd	O
with	O
lisinopirl	B-Chemical
,	O
an	O
agniotensin	B-Chemical
converting	O
enzmye	O
inihbitor	O
,	O
to	O
contorl	O
hypertnesion	O
who	O
developed	O
hypotensoin	O
following	O
the	O
addition	O
of	O
tizanidnie	B-Chemical
,	O
an	O
alhpa	O
-	O
2	O
agnoist	O
,	O
for	O
the	O
teratment	O
of	O
spsaticity	O
.	O

The	O
possible	O
inetraction	O
of	O
tzianidine	B-Chemical
and	O
other	O
antihypertenisve	O
agetns	O
should	O
be	O
kept	O
in	O
mind	O
when	O
precsribing	O
therpay	O
to	O
terat	O
either	O
hypretension	O
or	O
spatsicity	O
in	O
such	O
pateints	O
.	O

Two	O
muose	O
liens	O
selected	O
for	O
differenital	O
sensitviities	O
to	O
btea	B-Chemical
-	I-Chemical
carbloine	I-Chemical
-	O
induecd	O
seziures	O
are	O
also	O
differentially	O
senstiive	O
to	O
various	O
pharmacloogical	O
effetcs	O
of	O
other	O
GBAA	B-Chemical
(	O
A	O
)	O
recepotr	O
ligadns	O
.	O

Two	O
mosue	O
liens	O
were	O
selectively	O
berd	O
according	O
to	O
their	O
sensiitvity	O
(	O
BS	O
line	O
)	O
or	O
ressitance	O
(	O
BR	O
line	O
)	O
to	O
siezures	O
induecd	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injetcion	O
of	O
metyhl	B-Chemical
btea	I-Chemical
-	I-Chemical
cabroline	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
craboxylate	I-Chemical
(	O
btea	B-Chemical
-	I-Chemical
CCM	I-Chemical
)	O
,	O
an	O
ivnerse	O
agonsit	O
of	O
the	O
GBAA	B-Chemical
(	O
A	O
)	O
recetpor	O
benzodiazpeine	B-Chemical
stie	O
.	O

Our	O
aim	O
was	O
to	O
characterize	O
both	O
lnies	O
'	O
sensitiviteis	O
to	O
various	O
physiolgoical	O
efefcts	O
of	O
other	O
lignads	O
of	O
the	O
GBAA	B-Chemical
(	O
A	O
)	O
reecptor	O
.	O

We	O
measrued	O
dizaepam	B-Chemical
-	O
indcued	O
anxoilysis	O
with	O
the	O
elveated	O
plus	O
-	O
mzae	O
tset	O
,	O
dizaepam	B-Chemical
-	O
induecd	O
sedaiton	O
by	O
recodring	O
the	O
vigilnace	O
states	O
,	O
and	O
picrotoixn	B-Chemical
-	O
and	O
pentylenteetrazol	B-Chemical
-	O
induecd	O
seiuzres	O
after	O
i	O
.	O
p	O
.	O
injcetions	O
.	O

Reuslts	O
presented	O
here	O
show	O
that	O
the	O
differenital	O
sensitiivties	O
of	O
BS	O
and	O
BR	O
liens	O
to	O
btea	B-Chemical
-	I-Chemical
CCM	I-Chemical
can	O
be	O
etxended	O
to	O
daizepam	B-Chemical
,	O
pcirotoxin	B-Chemical
,	O
and	O
pentylenetetraozl	B-Chemical
,	O
suggesting	O
a	O
gneetic	O
sleection	O
of	O
a	O
general	O
senistivity	O
and	O
resitsance	O
to	O
several	O
ligadns	O
of	O
the	O
GBAA	B-Chemical
(	O
A	O
)	O
recepotr	O
.	O

Propylthoiuracil	B-Chemical
-	O
idnuced	O
perinuclaer	O
-	O
stainnig	O
anitneutrophil	O
cytopalsmic	O
autoantibdoy	O
-	O
posiitve	O
vascluitis	O
in	O
cnojunction	O
with	O
pericraditis	O
.	O

OJBECTIVE	O
:	O
To	O
describe	O
a	O
csae	O
of	O
propylthiouraicl	B-Chemical
-	O
induecd	O
vsaculitis	O
manifesting	O
with	O
pericadritis	O
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
csae	O
reoprt	O
of	O
a	O
woamn	O
with	O
hyperthyroidsim	O
tretaed	O
with	O
porpylthiouracil	B-Chemical
in	O
whom	O
a	O
synrdome	O
of	O
perciarditis	O
,	O
feevr	O
,	O
and	O
glomerulonephriits	O
developed	O
.	O

Serloogic	O
tetsing	O
and	O
imumnologic	O
stduies	O
were	O
done	O
,	O
and	O
a	O
pericardail	O
boipsy	O
was	O
performed	O
.	O

RESLUTS	O
:	O
A	O
25	O
-	O
yaer	O
-	O
old	O
woamn	O
with	O
Graevs	O
'	O
dsiease	O
had	O
a	O
fberile	O
illenss	O
and	O
eviednce	O
of	O
pericadritis	O
,	O
which	O
was	O
confirmed	O
by	O
biospy	O
.	O

Sreologic	O
evaulation	O
revaeled	O
the	O
presnece	O
of	O
preinuclear	O
-	O
stianing	O
antnieutrophil	O
cytpolasmic	O
autoanitbodies	O
(	O
pACNA	O
)	O
against	O
myelopeorxidase	O
(	O
MPO	O
)	O
.	O

Prpoylthiouracil	B-Chemical
therpay	O
was	O
withdrawn	O
,	O
and	O
she	O
was	O
tretaed	O
with	O
a	O
1	O
-	O
motnh	O
cousre	O
of	O
prendisone	B-Chemical
,	O
which	O
alleviated	O
her	O
smyptoms	O
.	O

A	O
litreature	O
reveiw	O
rveealed	O
no	O
prior	O
reprots	O
of	O
pericaridtis	O
in	O
atni	O
-	O
MPO	O
pNACA	O
-	O
posiitve	O
vascultiis	O
associated	O
with	O
porpylthio	B-Chemical
-	I-Chemical
uarcil	I-Chemical
thearpy	O
.	O

CONCLUISON	O
:	O
Pericaridtis	O
may	O
be	O
the	O
initial	O
manifesattion	O
of	O
durg	O
-	O
indcued	O
vasculiits	O
attributable	O
to	O
porpylthio	B-Chemical
-	I-Chemical
uraicl	I-Chemical
tehrapy	O
.	O

Repetaed	O
tranisent	O
anuira	O
following	O
losratan	B-Chemical
administartion	O
in	O
a	O
ptaient	O
with	O
a	O
soiltary	O
kdiney	O
.	O

We	O
rpeort	O
the	O
csae	O
of	O
a	O
70	O
-	O
yaer	O
-	O
old	O
hypertesnive	O
man	O
with	O
a	O
soiltary	O
kindey	O
and	O
chroinc	O
rneal	O
insufficeincy	O
who	O
developed	O
two	O
episoeds	O
of	O
tarnsient	O
aunria	O
after	O
lsoartan	B-Chemical
adminsitration	O
.	O

He	O
was	O
hosiptalized	O
for	O
a	O
myoacrdial	O
infarciton	O
with	O
pulmnoary	O
eedma	O
,	O
treaetd	O
with	O
high	O
-	O
dsoe	O
diuertics	O
.	O

Due	O
to	O
sevree	O
systloic	O
dysfunctoin	O
losaratn	B-Chemical
was	O
prescirbed	O
.	O

Surprisingly	O
,	O
the	O
first	O
dsoe	O
of	O
50	O
mg	O
of	O
losaratn	B-Chemical
resulted	O
in	O
a	O
sudden	O
anruia	O
,	O
which	O
lasted	O
eight	O
hours	O
despite	O
high	O
-	O
dsoe	O
furoesmide	B-Chemical
and	O
amnie	B-Chemical
infusoin	O
.	O

One	O
week	O
later	O
,	O
by	O
mistake	O
,	O
lsoartan	B-Chemical
was	O
presrcibed	O
again	O
and	O
after	O
the	O
second	O
dsoe	O
of	O
50	O
mg	O
,	O
the	O
ptaient	O
developed	O
a	O
second	O
eipsode	O
of	O
transinet	O
anuira	O
lasting	O
10	O
hours	O
.	O

During	O
these	O
two	O
eipsodes	O
,	O
his	O
bolod	O
pressure	O
diminished	O
but	O
no	O
sveere	O
hpyotension	O
was	O
noted	O
.	O

Ultimately	O
,	O
an	O
arterigoraphy	O
showed	O
a	O
70	O
-	O
80	O
%	O
rneal	O
artrey	O
stneosis	O
.	O

In	O
this	O
pateint	O
,	O
rneal	O
aretry	O
steonsis	O
cmobined	O
with	O
haert	O
faliure	O
and	O
diruetic	O
threapy	O
certainly	O
resulted	O
in	O
a	O
strong	O
activaiton	O
of	O
the	O
rnein	O
-	O
angiotnesin	B-Chemical
sytsem	O
(	O
RAS	O
)	O
.	O

Under	O
such	O
conditoins	O
,	O
angoitensin	B-Chemical
II	I-Chemical
recetpor	O
bolckade	O
by	O
loasrtan	B-Chemical
probably	O
idnuced	O
a	O
critical	O
fall	O
in	O
glomeurlar	O
flitration	O
pressure	O
.	O

This	O
csae	O
reoprt	O
highlights	O
the	O
fact	O
that	O
the	O
agniotensin	B-Chemical
II	I-Chemical
recpetor	O
anatgonist	O
loasrtan	B-Chemical
can	O
cause	O
serious	O
unexpected	O
complicatinos	O
in	O
pateints	O
with	O
renovsacular	O
disesae	O
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
this	O
setting	O
.	O

Calcienurin	O
-	O
inihbitor	O
idnuced	O
pian	O
sydnrome	O
(	O
CPIS	O
)	O
:	O
a	O
sveere	O
disalbing	O
complictaion	O
after	O
oragn	O
trnasplantation	O
.	O

Bnoe	O
pian	O
after	O
transplatnation	O
is	O
a	O
frequnet	O
complciation	O
that	O
can	O
be	O
caused	O
by	O
several	O
diesases	O
.	O

Treatmnet	O
strategies	O
depend	O
on	O
the	O
correct	O
diagnsois	O
of	O
the	O
pian	O
.	O

Nine	O
ptaients	O
with	O
sveere	O
pian	O
in	O
their	O
feet	O
,	O
which	O
was	O
registreed	O
after	O
trnasplantation	O
,	O
were	O
investigtaed	O
.	O

Bnoe	O
scnas	O
showed	O
an	O
incraesed	O
traecr	O
upatke	O
of	O
the	O
foot	O
bnoes	O
.	O

Mangetic	O
reosnance	O
imagnig	O
demonstrated	O
bnoe	O
marrow	O
oedmea	O
in	O
the	O
pianful	O
bnoes	O
.	O

Pian	O
was	O
not	O
explained	O
by	O
other	O
dsieases	O
causing	O
foot	O
pian	O
,	O
like	O
refelx	O
sympatehtic	O
dytsrophy	O
,	O
polyneuorpathy	O
,	O
Motron	O
'	O
s	O
neuraglia	O
,	O
guot	O
,	O
osteopoorsis	O
,	O
avasuclar	O
necroiss	O
,	O
itnermittent	O
claduication	O
,	O
orthopadeic	O
foot	O
deformiites	O
,	O
strses	O
fracutres	O
,	O
and	O
hyperpaarthyroidism	O
.	O

The	O
redcution	O
of	O
cyclsoporine	B-Chemical
-	O
or	O
tacroilmus	B-Chemical
trough	O
levles	O
and	O
the	O
administratoin	O
of	O
clacium	B-Chemical
cahnnel	O
blocekrs	O
led	O
to	O
releif	O
of	O
pian	O
.	O

The	O
Calcinuerin	O
-	O
inhbiitor	O
Induecd	O
Pian	O
Snydrome	O
(	O
CPIS	O
)	O
is	O
a	O
rrae	O
but	O
sevree	O
side	O
effcet	O
of	O
cyclospoirne	B-Chemical
or	O
tcarolimus	B-Chemical
and	O
is	O
accurately	O
diagnoesd	O
by	O
its	O
typical	O
presnetation	O
,	O
magneitc	O
resnoance	O
iamging	O
and	O
bnoe	O
sacns	O
.	O

Inocrrect	O
diganosis	O
of	O
the	O
synrdome	O
will	O
lead	O
to	O
a	O
significant	O
reductoin	O
of	O
lfie	O
qaulity	O
in	O
pateints	O
sfufering	O
from	O
CPIS	O
.	O

Brian	O
natriurteic	O
peptdie	O
is	O
a	O
predicotr	O
of	O
anthrayccline	B-Chemical
-	O
indcued	O
cardiotoixcity	O
.	O

Anthracylcines	B-Chemical
are	O
effetcive	O
antineolpastic	O
durgs	O
,	O
but	O
they	O
frequently	O
cause	O
dsoe	O
-	O
related	O
cradiotoxicity	O
.	O

The	O
cardoitoxicity	O
of	O
conevntional	O
anthrcaycline	B-Chemical
threapy	O
highlights	O
a	O
need	O
to	O
search	O
for	O
methdos	O
that	O
are	O
highly	O
snesitive	O
and	O
capable	O
of	O
predciting	O
cardaic	O
dysfunciton	O
.	O

We	O
meausred	O
the	O
palsma	O
lveel	O
of	O
barin	O
nartiuretic	O
petpide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnsotic	O
indictaor	O
of	O
anthrcaycline	B-Chemical
-	O
indcued	O
cardoitoxicity	O
in	O
ptaients	O
with	O
aucte	O
lekuemia	O
traeted	O
with	O
a	O
daunourbicin	B-Chemical
(	O
DNR	B-Chemical
)	O
-	O
containing	O
rgeimen	O
.	O

Thirteen	O
pateints	O
with	O
aucte	O
luekemia	O
were	O
tretaed	O
with	O
a	O
DNR	B-Chemical
-	O
containing	O
rgeimen	O
.	O

Cradiac	O
fucntions	O
were	O
eavluated	O
with	O
radionculide	O
angiogrpahy	O
before	O
chemotherpaies	O
.	O

The	O
plsama	O
levles	O
of	O
atrail	O
natriruetic	O
petpide	O
(	O
ANP	O
)	O
and	O
BNP	O
were	O
measrued	O
at	O
the	O
tmie	O
of	O
rdaionuclide	O
angiogarphy	O
.	O

Three	O
patinets	O
developed	O
congetsive	O
herat	O
failrue	O
after	O
the	O
cmopletion	O
of	O
cheomtherapy	O
.	O

Five	O
patinets	O
were	O
diagnoesd	O
as	O
having	O
subclniical	O
herat	O
failrue	O
after	O
the	O
completoin	O
of	O
chemohterapy	O
.	O

The	O
plamsa	O
leevls	O
of	O
BNP	O
in	O
all	O
the	O
patietns	O
with	O
clincial	O
and	O
subclniical	O
haert	O
fialure	O
incerased	O
above	O
the	O
nomral	O
liimt	O
(	O
40	O
pg	O
/	O
ml	O
)	O
before	O
the	O
detetcion	O
of	O
clincial	O
or	O
subcliincal	O
herat	O
fialure	O
by	O
radiounclide	O
angiorgaphy	O
.	O

On	O
the	O
other	O
hand	O
,	O
BNP	O
did	O
not	O
incerase	O
in	O
the	O
pateints	O
without	O
herat	O
faiulre	O
given	O
DNR	B-Chemical
,	O
even	O
at	O
more	O
than	O
700	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O

The	O
palsma	O
lveel	O
of	O
ANP	O
did	O
not	O
always	O
icnrease	O
in	O
all	O
the	O
paitents	O
with	O
clniical	O
and	O
sucblinical	O
haert	O
faiulre	O
.	O

These	O
preliminary	O
rseults	O
suggest	O
that	O
BNP	O
may	O
be	O
useful	O
as	O
an	O
ealry	O
and	O
senstiive	O
indciator	O
of	O
anthracycilne	B-Chemical
-	O
inudced	O
carditooxicity	O
.	O

Nephrotoixcity	O
of	O
combnied	O
cephaltohin	B-Chemical
-	O
gentamciin	B-Chemical
regmien	O
.	O

Two	O
patietns	O
developed	O
actue	O
tubualr	O
ncerosis	O
,	O
characteirzed	O
clinically	O
by	O
aucte	O
oliugric	O
reanl	O
fialure	O
,	O
while	O
they	O
were	O
receiving	O
a	O
cobmination	O
of	O
cephaolthin	B-Chemical
soidum	I-Chemical
and	O
gentamiicn	B-Chemical
slufate	I-Chemical
therpay	O
.	O

Ptaients	O
who	O
are	O
given	O
this	O
durg	O
rgeimen	O
should	O
be	O
observed	O
very	O
carefully	O
for	O
eraly	O
sgins	O
of	O
npehrotoxicity	O
.	O

High	O
doess	O
of	O
this	O
antiboitic	O
combiantion	O
should	O
be	O
avoided	O
especially	O
in	O
eldrely	O
ptaients	O
.	O

Patietns	O
with	O
reanl	O
insufficiency	O
should	O
not	O
be	O
given	O
this	O
rgeimen	O
.	O

In	O
vivo	O
protcetion	O
of	O
dna	O
damgae	O
associated	O
appototic	O
and	O
necroitc	O
clel	O
detahs	O
during	O
aectaminophen	B-Chemical
-	O
inudced	O
nephrotoxictiy	O
,	O
aimodarone	B-Chemical
-	O
inudced	O
lnug	O
txoicity	O
and	O
doxourbicin	B-Chemical
-	O
induecd	O
cardiotxoicity	O
by	O
a	O
novel	O
IH366	B-Chemical
grpae	I-Chemical
seed	I-Chemical
proantohcyanidin	I-Chemical
exrtact	I-Chemical
.	O

Garpe	B-Chemical
seed	I-Chemical
exrtact	I-Chemical
,	O
primarily	O
a	O
mixture	O
of	O
proanthocyaniidns	B-Chemical
,	O
has	O
been	O
shown	O
to	O
mdoulate	O
a	O
wide	O
-	O
range	O
of	O
biologiacl	O
,	O
pharmcaological	O
and	O
toxicolgoical	O
effetcs	O
which	O
are	O
mainly	O
cytoprotetcive	O
.	O

This	O
sutdy	O
assesesd	O
the	O
ability	O
of	O
I6H36	B-Chemical
grpae	I-Chemical
seed	I-Chemical
proanthocaynidin	I-Chemical
extrcat	I-Chemical
(	O
GPSE	B-Chemical
)	O
to	O
prevnet	O
acetamniophen	B-Chemical
(	O
AAP	B-Chemical
)	O
-	O
induecd	O
nephrotoxictiy	O
,	O
aimodarone	B-Chemical
(	O
AMI	B-Chemical
)	O
-	O
induecd	O
lnug	O
toxiicty	O
,	O
and	O
doxoruibcin	B-Chemical
(	O
DOX	B-Chemical
)	O
-	O
idnuced	O
cardoitoxicity	O
in	O
mcie	O
.	O

Epxerimental	O
desgin	O
consisted	O
of	O
four	O
gropus	O
:	O
conrtol	O
(	O
vheicle	O
alone	O
)	O
,	O
GPSE	B-Chemical
alone	O
,	O
durg	O
alone	O
and	O
GPSE	B-Chemical
+	O
durg	O
.	O

For	O
the	O
cytoprotcetion	O
stduy	O
,	O
aniamls	O
were	O
orally	O
gavaegd	O
100	O
mg	O
/	O
Kg	O
GPSE	B-Chemical
for	O
7	O
-	O
10	O
dyas	O
followed	O
by	O
i	O
.	O
p	O
.	O
injecitons	O
of	O
ogran	O
specific	O
three	O
durgs	O
(	O
AAP	B-Chemical
:	O
500	O
mg	O
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	B-Chemical
:	O
50	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
dyas	O
;	O
DOX	B-Chemical
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O

Parameetrs	O
of	O
stduy	O
included	O
analyiss	O
of	O
seurm	O
chemitsry	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
orderly	O
fargmentation	O
of	O
gneomic	O
DNA	O
(	O
both	O
endonuclesae	O
-	O
depenednt	O
and	O
indeepndent	O
)	O
in	O
addition	O
to	O
mircoscopic	O
eavluation	O
of	O
damgae	O
and	O
/	O
or	O
protcetion	O
in	O
corresponding	O
PAS	O
satined	O
tsisues	O
.	O

Resluts	O
indicate	O
that	O
GPSE	B-Chemical
preexopsure	O
prior	O
to	O
AAP	B-Chemical
,	O
AMI	B-Chemical
and	O
DOX	B-Chemical
,	O
provided	O
near	O
complete	O
protectoin	O
in	O
terms	O
of	O
seurm	O
chmeistry	O
chagnes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
rdeuced	O
DNA	O
fragmentaiton	O
.	O

Histopathologiacl	O
examniation	O
of	O
kindey	O
,	O
haert	O
and	O
lnug	O
secitons	O
revelaed	O
mdoerate	O
to	O
massive	O
tissue	O
dmaage	O
with	O
a	O
variety	O
of	O
morphologiacl	O
aebrrations	O
by	O
all	O
the	O
three	O
drgus	O
in	O
the	O
absnece	O
of	O
GPSE	B-Chemical
preexpousre	O
than	O
in	O
its	O
preesnce	O
.	O

GPSE	B-Chemical
+	O
durg	O
epxosed	O
tissues	O
exhibited	O
minor	O
resdiual	O
dmaage	O
or	O
near	O
total	O
recoevry	O
.	O

Additionally	O
,	O
hitsopathological	O
alteartions	O
mirrored	O
both	O
sreum	O
chemisrty	O
chagnes	O
and	O
the	O
patetrn	O
of	O
DNA	O
fragmentaiton	O
.	O

Interestingly	O
,	O
all	O
the	O
drgus	O
,	O
such	O
as	O
,	O
AAP	B-Chemical
,	O
AMI	B-Chemical
and	O
DOX	B-Chemical
indcued	O
apopottic	O
detah	O
in	O
addition	O
to	O
necrsois	O
in	O
the	O
respective	O
ograns	O
which	O
was	O
very	O
effectively	O
blocekd	O
by	O
GPSE	B-Chemical
.	O

Since	O
AAP	B-Chemical
,	O
AMI	B-Chemical
and	O
DOX	B-Chemical
undergo	O
biotransformaiton	O
and	O
are	O
known	O
to	O
produce	O
damagnig	O
radiclas	O
in	O
vivo	O
,	O
the	O
proteciton	O
by	O
GPSE	B-Chemical
may	O
be	O
linked	O
to	O
both	O
ihnibition	O
of	O
metaoblism	O
and	O
/	O
or	O
detoxfiication	O
of	O
cytotoixc	O
radiclas	O
.	O

In	O
addition	O
,	O
its	O
'	O
presumed	O
contribution	O
to	O
DNA	O
rpeair	O
may	O
be	O
another	O
important	O
attribute	O
,	O
which	O
played	O
a	O
role	O
in	O
the	O
chemoprevnetion	O
procses	O
.	O

Additionally	O
,	O
this	O
may	O
have	O
been	O
the	O
first	O
reoprt	O
on	O
AMI	B-Chemical
-	O
induecd	O
apoptoitc	O
daeth	O
in	O
the	O
lnug	O
tsisue	O
.	O

Taken	O
together	O
,	O
these	O
evetns	O
undoubtedly	O
establish	O
GPSE	B-Chemical
'	O
s	O
abnudant	O
bioavailabiltiy	O
,	O
and	O
the	O
poewr	O
to	O
defend	O
mulitple	O
taregt	O
oragns	O
from	O
toixc	O
assaults	O
induecd	O
by	O
structurally	O
dvierse	O
and	O
functionally	O
different	O
entiites	O
in	O
vivo	O
.	O

Antiderpessant	B-Chemical
-	O
induecd	O
maina	O
in	O
bpiolar	O
patietns	O
:	O
identfiication	O
of	O
rsik	O
fcators	O
.	O

BAKCGROUND	O
:	O
Cnocerns	O
about	O
possible	O
rsiks	O
of	O
switching	O
to	O
mnaia	O
associated	O
with	O
antidepressatns	B-Chemical
continue	O
to	O
interfere	O
with	O
the	O
establsihment	O
of	O
an	O
otpimal	O
traetment	O
paradgim	O
for	O
bpiolar	O
dperession	O
.	O

METHOD	O
:	O
The	O
resposne	O
of	O
44	O
patinets	O
meteing	O
DSM	O
-	O
IV	O
criteira	O
for	O
biploar	O
disroder	O
to	O
ntauralistic	O
traetment	O
was	O
asesssed	O
for	O
at	O
least	O
6	O
wekes	O
using	O
the	O
Montgmoery	O
-	O
Asebrg	O
Depressoin	O
Raitng	O
Sclae	O
and	O
the	O
Bceh	O
-	O
Rafaeslon	O
Maina	O
Raitng	O
Sacle	O
.	O

Ptaients	O
who	O
experienced	O
a	O
mainc	O
or	O
hyopmanic	O
siwtch	O
were	O
compaerd	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
vairables	O
including	O
age	O
,	O
sex	O
,	O
diganosis	O
(	O
DSM	O
-	O
IV	O
bpiolar	O
I	O
vs	O
.	O
bpiolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
mnaic	O
epsiodes	O
,	O
tpye	O
of	O
antidepressant	B-Chemical
thearpy	O
used	O
(	O
electrcoonvulsive	O
threapy	O
vs	O
.	O
antiedpressant	B-Chemical
drgus	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
seortonin	B-Chemical
reuptkae	I-Chemical
ihnibitors	I-Chemical
[	O
SSIRs	B-Chemical
]	O
)	O
,	O
use	O
and	O
tpye	O
of	O
mood	O
stbailizers	O
(	O
litihum	B-Chemical
vs	O
.	O
anticonvuslants	O
)	O
,	O
and	O
temeprament	O
of	O
the	O
pateint	O
,	O
asesssed	O
during	O
a	O
nromothymic	O
peirod	O
using	O
the	O
hyeprthymia	O
component	O
of	O
the	O
Smei	O
-	O
strucutred	O
Affective	O
Tempearment	O
Itnerview	O
.	O

REUSLTS	O
:	O
Siwtches	O
to	O
hypomnaia	O
or	O
maina	O
occurred	O
in	O
27	O
%	O
of	O
all	O
pateints	O
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
subgorup	O
of	O
paitents	O
terated	O
with	O
SSIRs	B-Chemical
[	O
8	O
/	O
33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	O
mainc	O
epsiodes	O
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	O
hyopmanic	O
eipsodes	O
.	O

Sex	O
,	O
age	O
,	O
diangosis	O
(	O
bipoalr	O
I	O
vs	O
.	O
bipoalr	O
II	O
)	O
,	O
and	O
additional	O
teratment	O
did	O
not	O
affect	O
the	O
rsik	O
of	O
switching	O
.	O

The	O
incidnece	O
of	O
mood	O
switches	O
seemed	O
not	O
to	O
differ	O
between	O
paitents	O
receiving	O
an	O
antiocnvulsant	O
and	O
those	O
receiving	O
no	O
mood	O
stabiilzer	O
.	O

In	O
contrast	O
,	O
mood	O
switches	O
were	O
less	O
freuqent	O
in	O
patinets	O
receiving	O
lithuim	B-Chemical
(	O
15	O
%	O
,	O
4	O
/	O
26	O
)	O
than	O
in	O
ptaients	O
not	O
terated	O
with	O
ltihium	B-Chemical
(	O
44	O
%	O
,	O
8	O
/	O
18	O
;	O
p	O
=	O
.	O
04	O
)	O
.	O

The	O
number	O
of	O
previous	O
mainc	O
episdoes	O
did	O
not	O
affect	O
the	O
probabiltiy	O
of	O
switching	O
,	O
whereas	O
a	O
high	O
scroe	O
on	O
the	O
hpyerthymia	O
component	O
of	O
the	O
Semistrutcured	O
Affecitve	O
Temeprament	O
Itnerview	O
was	O
associated	O
with	O
a	O
greater	O
rsik	O
of	O
switching	O
(	O
p	O
=	O
.	O
008	O
)	O
.	O

COCNLUSION	O
:	O
The	O
freqeuncy	O
of	O
mood	O
switching	O
associated	O
with	O
actue	O
antideperssant	B-Chemical
threapy	O
may	O
be	O
reudced	O
by	O
lihtium	B-Chemical
treamtent	O
.	O

Particular	O
attentoin	O
should	O
be	O
paid	O
to	O
patinets	O
with	O
a	O
hypetrhymic	O
temeprament	O
,	O
who	O
have	O
a	O
greater	O
rsik	O
of	O
mood	O
switches	O
.	O

Peirtubular	O
cpaillary	O
baseemnt	O
mebmrane	O
redulpication	O
in	O
allografts	O
and	O
natvie	O
kideny	O
disaese	O
:	O
a	O
cilnicopathologic	O
sutdy	O
of	O
278	O
conescutive	O
rneal	O
sepcimens	O
.	O

BACKRGOUND	O
:	O
An	O
associaiton	O
has	O
been	O
found	O
between	O
trnasplant	O
glmoerulopathy	O
(	O
TG	O
)	O
and	O
redupilcation	O
of	O
peritubualr	O
caipllary	O
baesment	O
mmebranes	O
(	O
PCTR	O
)	O
.	O

Although	O
such	O
an	O
associtaion	O
is	O
of	O
practical	O
and	O
theoertical	O
importance	O
,	O
only	O
one	O
prospecitve	O
sutdy	O
has	O
tried	O
to	O
confirm	O
it	O
.	O

METHODS	O
:	O
We	O
examined	O
278	O
cnosecutive	O
reanl	O
speciemns	O
(	O
from	O
135	O
tranpslants	O
and	O
143	O
naitve	O
kidenys	O
)	O
for	O
ultrsatructural	O
evdience	O
of	O
PCTR	O
.	O

In	O
addition	O
to	O
rneal	O
allgorafts	O
with	O
TG	O
,	O
we	O
also	O
examined	O
garfts	O
with	O
actue	O
rejectoin	O
,	O
reucrrent	O
glomerulonehpritis	O
,	O
chrnoic	O
alolgraft	O
nephorpathy	O
and	O
stbale	O
grfats	O
(	O
"	O
protcool	O
biopises	O
"	O
)	O
.	O

Natvie	O
kideny	O
speciemns	O
included	O
a	O
wide	O
range	O
of	O
glomreulopathies	O
as	O
well	O
as	O
caess	O
of	O
thromobtic	O
microanigopathy	O
,	O
mailgnant	O
hypertnesion	O
,	O
aucte	O
intrestitial	O
neprhitis	O
,	O
and	O
aucte	O
tbuular	O
ncerosis	O
.	O

REUSLTS	O
:	O
We	O
found	O
PCTR	O
in	O
14	O
of	O
15	O
caess	O
of	O
TG	O
,	O
in	O
7	O
trnasplant	O
boipsy	O
spceimens	O
without	O
TG	O
,	O
and	O
in	O
13	O
of	O
143	O
naitve	O
kideny	O
biposy	O
sepcimens	O
.	O

These	O
13	O
included	O
csaes	O
of	O
maligannt	O
hypertesnion	O
,	O
thromobtic	O
microangioptahy	O
,	O
lpuus	O
npehritis	O
,	O
Hneoch	O
-	O
Scohnlein	O
nehpritis	O
,	O
cresecntic	O
golmerulonephritis	O
,	O
and	O
cociane	B-Chemical
-	O
related	O
aucte	O
reanl	O
fialure	O
.	O

Mlid	O
PCTR	O
in	O
allogrfats	O
without	O
TG	O
did	O
not	O
predict	O
reanl	O
faiulre	O
or	O
significant	O
proteniuria	O
after	O
follow	O
-	O
up	O
peirods	O
of	O
between	O
3	O
monhts	O
and	O
1	O
yaer	O
.	O

CONLCUSIONS	O
:	O
We	O
conclude	O
that	O
in	O
trasnplants	O
,	O
there	O
is	O
a	O
strong	O
associatoin	O
between	O
well	O
-	O
developed	O
PCTR	O
and	O
TG	O
,	O
while	O
the	O
singificance	O
of	O
mlid	O
PCTR	O
and	O
its	O
prdeictive	O
value	O
in	O
the	O
abesnce	O
of	O
TG	O
is	O
unclear	O
.	O

PCTR	O
also	O
occurs	O
in	O
certain	O
ntaive	O
kdiney	O
dsieases	O
,	O
though	O
the	O
associaiton	O
is	O
not	O
as	O
strong	O
as	O
that	O
for	O
TG	O
.	O

We	O
suggest	O
that	O
repeaetd	O
endotheilal	O
ijnury	O
,	O
including	O
immuonlogic	O
inujry	O
,	O
may	O
be	O
the	O
cause	O
of	O
this	O
lseion	O
both	O
in	O
alolgrafts	O
and	O
naitve	O
kidnyes	O
.	O

Cafefine	B-Chemical
-	O
indcued	O
cradiac	O
arhrythmia	O
:	O
an	O
unrecognised	O
danegr	O
of	O
heatlhfood	O
produtcs	O
.	O

We	O
describe	O
a	O
25	O
-	O
yaer	O
-	O
old	O
woamn	O
with	O
pre	O
-	O
existing	O
mitarl	O
vavle	O
proalpse	O
who	O
developed	O
intrcatable	O
ventricualr	O
fibrillation	O
after	O
consuming	O
a	O
"	O
natrual	O
eenrgy	O
"	O
guraana	O
helath	O
drnik	O
containing	O
a	O
high	O
concentartion	O
of	O
caffeine	B-Chemical
.	O

This	O
csae	O
highlights	O
the	O
need	O
for	O
adeuqate	O
labellnig	O
and	O
regultaion	O
of	O
such	O
prdoucts	O
.	O

Conforamtionally	O
restricted	O
anaolgs	O
of	O
BD0108	B-Chemical
and	O
an	O
antisnese	O
oligodeoxyuncleotide	B-Chemical
targeitng	O
sgima1	O
rceeptors	O
produce	O
atni	O
-	O
cocanie	B-Chemical
efefcts	O
in	O
mcie	O
.	O

Cociane	B-Chemical
'	O
s	O
ability	O
to	O
intearct	O
with	O
sigma	O
recetpors	O
suggests	O
that	O
these	O
protenis	O
mediate	O
some	O
of	O
its	O
behaivoral	O
effcets	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
recepotr	O
ligadns	O
with	O
atnagonist	O
activtiy	O
were	O
evlauated	O
in	O
Siwss	O
Wbester	O
mcie	O
:	O
B1D018	B-Chemical
(	O
3S	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorohpenyl	I-Chemical
)	I-Chemical
etyhl	I-Chemical
]	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
diazaibcyclo	I-Chemical
[	I-Chemical
4	I-Chemical
.	I-Chemical
3	I-Chemical
.	I-Chemical
0	I-Chemical
]	I-Chemical
noanne	I-Chemical
)	O
,	O
B1D063	B-Chemical
(	O
1	B-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihclorophenyl	I-Chemical
)	I-Chemical
etyhl	I-Chemical
]	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
methylpiperaznie	I-Chemical
)	O
,	O
and	O
L1R32	B-Chemical
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorpohenyl	O
)	O
ehtyl	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
pyrrolidniyl	O
)	O
cyclohexylmaine	O
)	O
.	O

Copmetition	O
bniding	O
assyas	O
demonstrated	O
that	O
all	O
three	O
cmopounds	O
have	O
high	O
affiniites	O
for	O
sgima1	O
rceeptors	O
.	O

The	O
three	O
copmounds	O
vary	O
in	O
their	O
affiniites	O
for	O
sigam2	O
receptros	O
and	O
exhibit	O
nelgigible	O
affniities	O
for	O
dpoamine	B-Chemical
,	O
oipoid	O
,	O
GBAA	B-Chemical
(	O
A	O
)	O
and	O
NDMA	B-Chemical
rceeptors	O
.	O

In	O
behavoiral	O
studeis	O
,	O
pre	O
-	O
traetment	O
of	O
mcie	O
with	O
B1D018	B-Chemical
,	O
BD1603	B-Chemical
,	O
or	O
L1R32	B-Chemical
significantly	O
attneuated	O
cocanie	B-Chemical
-	O
induecd	O
cnovulsions	O
and	O
ltehality	O
.	O

Moreover	O
,	O
psot	O
-	O
tretament	O
with	O
LR312	B-Chemical
prevented	O
cocanie	B-Chemical
-	O
indcued	O
lethlaity	O
in	O
a	O
significant	O
proportoin	O
of	O
animlas	O
.	O

In	O
contrast	O
to	O
the	O
proteciton	O
provided	O
by	O
the	O
putative	O
atnagonists	O
,	O
the	O
well	O
-	O
chaarcterized	O
sigma	O
recetpor	O
agnoist	O
di	B-Chemical
-	I-Chemical
o	I-Chemical
-	I-Chemical
tolylguanidine	I-Chemical
(	O
DTG	B-Chemical
)	O
and	O
the	O
novel	O
sigma	O
recepotr	O
agnoist	O
BD1301	B-Chemical
(	O
3R	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorpohenyl	I-Chemical
)	I-Chemical
etyhl	I-Chemical
]	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dizaabicyclo	I-Chemical
[	I-Chemical
4	I-Chemical
.	I-Chemical
3	I-Chemical
.	I-Chemical
0	I-Chemical
]	I-Chemical
noanne	I-Chemical
)	O
each	O
wosrened	O
the	O
behaviroal	O
toxciity	O
of	O
cociane	B-Chemical
.	O

At	O
doess	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
effects	O
on	O
locomotoin	O
,	O
BD1108	B-Chemical
,	O
B1D063	B-Chemical
and	O
L1R32	B-Chemical
significantly	O
attenuated	O
the	O
loocmotor	O
stimulaotry	O
efefcts	O
of	O
cociane	B-Chemical
.	O

To	O
further	O
validate	O
the	O
hypotheiss	O
that	O
the	O
atni	O
-	O
coacine	B-Chemical
effetcs	O
of	O
the	O
novel	O
liagnds	O
involved	O
antagoinsm	O
of	O
sigma	O
recetpors	O
,	O
an	O
antisesne	O
oligoedoxynucleotide	B-Chemical
against	O
sgima1	O
recepotrs	O
was	O
also	O
shown	O
to	O
significantly	O
atetnuate	O
the	O
convuslive	O
and	O
lcoomotor	O
stiumlatory	O
effetcs	O
of	O
cociane	B-Chemical
.	O

Together	O
,	O
the	O
dtaa	O
suggests	O
that	O
functioanl	O
atnagonism	O
of	O
sigma	O
reecptors	O
is	O
capable	O
of	O
attenuating	O
a	O
number	O
of	O
ccoaine	B-Chemical
-	O
idnuced	O
behaivors	O
.	O

Raniitdine	B-Chemical
-	O
induecd	O
actue	O
intersittial	O
neprhitis	O
in	O
a	O
cadaveirc	O
rneal	O
alolgraft	O
.	O

Raintidine	B-Chemical
frequently	O
is	O
used	O
for	O
preventing	O
ppetic	O
ulcreation	O
after	O
rneal	O
trnasplantation	O
.	O

This	O
durg	O
occasionally	O
has	O
been	O
associated	O
with	O
aucte	O
intertsitial	O
nephriits	O
in	O
naitve	O
kidnyes	O
.	O

There	O
are	O
no	O
similar	O
reprots	O
with	O
rneal	O
transplantatoin	O
.	O

We	O
reprot	O
a	O
csae	O
of	O
ranitiidne	B-Chemical
-	O
inudced	O
aucte	O
inetrstitial	O
neprhitis	O
in	O
a	O
recpiient	O
of	O
a	O
cadvaeric	O
rneal	O
allogrfat	O
presneting	O
with	O
aucte	O
allorgaft	O
dyfsunction	O
within	O
48	O
hours	O
of	O
exposrue	O
to	O
the	O
durg	O
.	O

The	O
biospy	O
speciemn	O
showed	O
pahtognomonic	O
featuers	O
,	O
including	O
eoisnophilic	O
infiltrtaion	O
of	O
the	O
intersittial	O
comparmtent	O
.	O

Allogrfat	O
funtcion	O
improevd	O
rapidly	O
and	O
returned	O
to	O
basleine	O
after	O
stopping	O
the	O
durg	O
.	O

Lvier	O
diesase	O
caused	O
by	O
propyltihouracil	B-Chemical
.	O

This	O
reoprt	O
presents	O
the	O
clincial	O
,	O
laboratroy	O
,	O
and	O
light	O
and	O
elecrton	O
mircoscopic	O
obsevrations	O
on	O
a	O
patinet	O
with	O
chroinc	O
actvie	O
(	O
agrgessive	O
)	O
heptaitis	O
caused	O
by	O
the	O
admniistration	O
of	O
propylthiourcail	B-Chemical
.	O

This	O
is	O
an	O
addition	O
to	O
the	O
list	O
of	O
durgs	O
that	O
must	O
be	O
considered	O
in	O
the	O
evaluaiton	O
of	O
chornic	O
lievr	O
diesase	O
.	O

Wtihdrawal	O
-	O
eemrgent	O
rabibt	O
sydnrome	O
during	O
dsoe	O
reudction	O
of	O
risepridone	B-Chemical
.	O

Rabibt	O
snydrome	O
(	O
RS	O
)	O
is	O
a	O
rrae	O
exrtapyramidal	O
side	O
effcet	O
caused	O
by	O
porlonged	O
neurolpetic	O
medicatoin	O
.	O

Here	O
we	O
present	O
a	O
csae	O
of	O
wihtdrawal	O
-	O
emregent	O
RS	O
,	O
which	O
is	O
the	O
first	O
of	O
its	O
kind	O
to	O
be	O
reported	O
.	O

The	O
patinet	O
developed	O
RS	O
during	O
dsoe	O
redutcion	O
of	O
rispeirdone	B-Chemical
.	O

The	O
smyptom	O
was	O
treaetd	O
successfully	O
with	O
trihexypheniydl	B-Chemical
antichloinergic	O
threapy	O
.	O

The	O
underlying	O
mecahnism	O
of	O
withdarwal	O
-	O
emergnet	O
RS	O
in	O
the	O
present	O
csae	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacoolgical	O
proflie	O
of	O
rispeirdone	B-Chemical
,	O
a	O
seortonin	B-Chemical
-	O
dpoamine	B-Chemical
antagonsit	O
,	O
suggesting	O
the	O
pathohpysiologic	O
influecne	O
of	O
the	O
serotnoin	B-Chemical
ssytem	O
in	O
the	O
dveelopment	O
of	O
RS	O
.	O

Pharmcaokinetic	O
/	O
pharmaocdynamic	O
assessemnt	O
of	O
the	O
effects	O
of	O
E0431	B-Chemical
,	O
cisaprdie	B-Chemical
,	O
tefrenadine	B-Chemical
and	O
terdoiline	B-Chemical
on	O
monophsaic	O
aciton	O
potenital	O
duartion	O
in	O
dog	O
.	O

1	O
.	O

Torasdes	O
de	O
poitnes	O
(	O
TDP	O
)	O
is	O
a	O
potentially	O
faatl	O
venrticular	O
tachcyardia	O
associated	O
with	O
incresaes	O
in	O
QT	O
interavl	O
and	O
moonphasic	O
atcion	O
potenital	O
duartion	O
(	O
MPAD	O
)	O
.	O

TDP	O
is	O
a	O
side	O
-	O
efefct	O
that	O
has	O
led	O
to	O
withdraawl	O
of	O
several	O
durgs	O
from	O
the	O
mraket	O
(	O
e	O
.	O
g	O
.	O
terfendaine	B-Chemical
and	O
terodliine	B-Chemical
)	O
.	O

2	O
.	O

The	O
potetnial	O
of	O
componuds	O
to	O
cause	O
TDP	O
was	O
evlauated	O
by	O
monitornig	O
their	O
effcets	O
on	O
MPAD	O
in	O
dog	O
.	O

Four	O
componuds	O
known	O
to	O
incerase	O
QT	O
interavl	O
and	O
cause	O
TDP	O
were	O
inevstigated	O
:	O
terfendaine	B-Chemical
,	O
terodiilne	B-Chemical
,	O
cisarpide	B-Chemical
and	O
E4301	B-Chemical
.	O

On	O
the	O
basis	O
that	O
only	O
free	O
durg	O
in	O
the	O
sytsemic	O
circualtion	O
will	O
elicit	O
a	O
pharmaoclogical	O
resopnse	O
tagret	O
,	O
free	O
concnetrations	O
in	O
palsma	O
were	O
selected	O
to	O
mimic	O
the	O
free	O
durg	O
exposuers	O
in	O
man	O
.	O

Infuison	O
regiemns	O
were	O
designed	O
that	O
rapidly	O
achieved	O
and	O
maintained	O
tagret	O
-	O
free	O
cocnentrations	O
of	O
these	O
durgs	O
in	O
plsama	O
and	O
dtaa	O
on	O
the	O
relationsihp	O
between	O
free	O
concnetration	O
and	O
chanegs	O
in	O
MPAD	O
were	O
obtained	O
for	O
these	O
cmopounds	O
.	O

3	O
.	O

These	O
dtaa	O
indicate	O
that	O
the	O
free	O
E5D0	O
in	O
plamsa	O
for	O
tefrenadine	B-Chemical
(	O
1	O
.	O
9	O
nM	O
)	O
,	O
terodliine	B-Chemical
(	O
76	O
nM	O
)	O
,	O
cisarpide	B-Chemical
(	O
11	O
nM	O
)	O
and	O
E4301	B-Chemical
(	O
1	O
.	O
9	O
nM	O
)	O
closely	O
correltae	O
with	O
the	O
free	O
concentratoin	O
in	O
man	O
causing	O
QT	O
efefcts	O
.	O

For	O
compoudns	O
that	O
have	O
shown	O
TDP	O
in	O
the	O
cliinc	O
(	O
terfenadnie	B-Chemical
,	O
teroidline	B-Chemical
,	O
cisaprdie	B-Chemical
)	O
there	O
is	O
little	O
difefrentiation	O
between	O
the	O
dog	O
E5D0	O
and	O
the	O
efficcaious	O
free	O
plamsa	O
concetnrations	O
in	O
man	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
limtied	O
saefty	O
margnis	O
.	O

These	O
dtaa	O
underline	O
the	O
need	O
to	O
maximize	O
the	O
threapeutic	O
rtaio	O
with	O
respect	O
to	O
TDP	O
in	O
potetnial	O
devleopment	O
cadnidates	O
and	O
the	O
importance	O
of	O
using	O
free	O
durg	O
concetnrations	O
in	O
pharmacokinteic	O
/	O
phamracodynamic	O
studeis	O
.	O

Bldader	O
retentoin	O
of	O
uirne	O
as	O
a	O
result	O
of	O
cotninuous	O
intraveonus	O
infsuion	O
of	O
fentaynl	B-Chemical
:	O
2	O
csae	O
rpeorts	O
.	O

Sedtaion	O
has	O
been	O
commonly	O
used	O
in	O
the	O
nenoate	O
to	O
decerase	O
the	O
sterss	O
and	O
pian	O
from	O
the	O
nxoious	O
stimlui	O
and	O
ivnasive	O
proecdures	O
in	O
the	O
nenoatal	O
intenisve	O
crae	O
unit	O
,	O
as	O
well	O
as	O
to	O
facilitate	O
synhcrony	O
between	O
vnetilator	O
and	O
spontanoeus	O
beraths	O
.	O

Fetnanyl	B-Chemical
,	O
an	O
opiiod	O
anaglesic	O
,	O
is	O
frequently	O
used	O
in	O
the	O
neonaatl	O
itnensive	O
crae	O
unit	O
setting	O
for	O
these	O
very	O
puproses	O
.	O

Various	O
reported	O
side	O
effcets	O
of	O
fentnayl	B-Chemical
adimnistration	O
include	O
chset	O
wlal	O
rigidtiy	O
,	O
hpyotension	O
,	O
respiraotry	O
deperssion	O
,	O
and	O
bradycarida	O
.	O

Here	O
,	O
2	O
csaes	O
of	O
urianry	O
bladedr	O
retetnion	O
leading	O
to	O
rneal	O
pelvocalcyeal	O
dilaattion	O
mimicking	O
hydronephrsois	O
as	O
a	O
result	O
of	O
continuuos	O
infuison	O
of	O
fenatnyl	B-Chemical
are	O
reported	O
.	O

Ftaal	O
myeloencephalpoathy	O
due	O
to	O
acicdental	O
itnrathecal	O
vincrisitn	B-Chemical
adminisrtation	O
:	O
a	O
reprot	O
of	O
two	O
caess	O
.	O

We	O
reoprt	O
on	O
two	O
faatl	O
caess	O
of	O
accidetnal	O
intrtahecal	O
vincrsitine	B-Chemical
intsillation	O
in	O
a	O
5	O
-	O
yaer	O
old	O
gril	O
with	O
recurrent	O
actue	O
lympholbastic	O
lecuemia	O
and	O
a	O
57	O
-	O
yaer	O
old	O
man	O
with	O
lypmhoblastic	O
lymphmoa	O
.	O

The	O
gril	O
deid	O
seven	O
dyas	O
,	O
the	O
man	O
four	O
weeks	O
after	O
intratheacl	O
injcetion	O
of	O
vincrisitne	B-Chemical
.	O

Cliniclaly	O
,	O
the	O
onset	O
was	O
characetrized	O
by	O
the	O
sings	O
of	O
opisttohonus	O
,	O
sensroy	O
and	O
mtoor	O
dsyfunction	O
and	O
asecnding	O
praalysis	O
.	O

Hisotlogical	O
and	O
immunohistochmeical	O
investigatinos	O
(	O
HE	O
-	O
LFB	O
,	O
CD	O
-	O
68	O
,	O
Neurofialment	O
)	O
rveealed	O
degeneratoin	O
of	O
myeiln	O
and	O
axnos	O
as	O
well	O
as	O
pseudocytsic	O
transformtaion	O
in	O
areas	O
expoesd	O
to	O
vinrcistine	B-Chemical
,	O
accompanied	O
by	O
secondary	O
cahnges	O
with	O
numerous	O
prominent	O
macrophgaes	O
.	O

The	O
cliniacl	O
cuorse	O
and	O
histopatholoigcal	O
resluts	O
of	O
the	O
two	O
caess	O
are	O
presented	O
.	O

A	O
reveiw	O
of	O
all	O
reported	O
csaes	O
in	O
the	O
lietrature	O
is	O
given	O
.	O

A	O
better	O
contorlled	O
rgeimen	O
for	O
administreing	O
vincrisitne	B-Chemical
and	O
intrtahecal	O
chemothreapy	O
is	O
recommenedd	O
.	O

Palpberal	O
tiwtching	O
in	O
a	O
deprsesed	O
adolescnet	O
on	O
citalporam	B-Chemical
.	O

Current	O
estiamtes	O
suggest	O
that	O
between	O
0	O
.	O
4	O
%	O
and	O
8	O
.	O
3	O
%	O
of	O
chilrden	O
and	O
adolescetns	O
are	O
afefcted	O
by	O
major	O
depresison	O
.	O

We	O
reoprt	O
a	O
faovrable	O
respnose	O
to	O
treatemnt	O
with	O
ciatlopram	B-Chemical
by	O
a	O
15	O
-	O
yaer	O
-	O
old	O
boy	O
with	O
major	O
dperession	O
who	O
exhibited	O
paplebral	O
twitchnig	O
during	O
his	O
first	O
2	O
wekes	O
of	O
tretament	O
.	O

This	O
may	O
have	O
been	O
a	O
side	O
effcet	O
of	O
ciatlopram	B-Chemical
as	O
it	O
reimtted	O
with	O
redistriubtion	O
of	O
dsoes	O
.	O

The	O
3	O
-	O
week	O
sulphasaalzine	B-Chemical
synrdome	O
strikes	O
again	O
.	O

A	O
34	O
-	O
yaer	O
-	O
old	O
lday	O
developed	O
a	O
cnostellation	O
of	O
drematitis	O
,	O
feevr	O
,	O
lymphadneopathy	O
and	O
hepatiits	O
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
coruse	O
of	O
oarl	O
sulphasalzaine	B-Chemical
for	O
sreo	O
-	O
negtaive	O
rheumaotid	O
arthrtiis	O
.	O

Cevrical	O
and	O
ingunial	O
lmyph	O
ndoe	O
biopises	O
showed	O
the	O
fetaures	O
of	O
sevree	O
necrotsiing	O
lymphadentiis	O
,	O
associated	O
with	O
erythrophagoyctosis	O
and	O
prominent	O
eosinophiilc	O
infilrtates	O
,	O
without	O
viarl	O
inclsuion	O
boides	O
,	O
suggestive	O
of	O
an	O
avderse	O
durg	O
reatcion	O
.	O
A	O
week	O
later	O
,	O
fulmiannt	O
durg	O
-	O
inudced	O
hepatiits	O
,	O
associated	O
with	O
the	O
prseence	O
of	O
atni	O
-	O
nulcear	O
atuoantibodies	O
(	O
but	O
not	O
with	O
other	O
mrakers	O
of	O
autoimmuinty	O
)	O
,	O
and	O
accompanied	O
by	O
mluti	O
-	O
oragn	O
faiulre	O
and	O
sepiss	O
,	O
spuervened	O
.	O

She	O
subsequently	O
deid	O
some	O
5	O
wekes	O
after	O
the	O
cmomencement	O
of	O
her	O
durg	O
thearpy	O
.	O
Psot	O
-	O
mrotem	O
eaxmination	O
showed	O
eviednce	O
of	O
massive	O
heaptocellular	O
necorsis	O
,	O
actue	O
hyeprsensitivity	O
myocardiits	O
,	O
foacl	O
aucte	O
tbuulo	O
-	O
inetrstitial	O
npehritis	O
and	O
extesnive	O
bnoe	O
marrow	O
necrsois	O
,	O
with	O
no	O
eviednce	O
of	O
malignacny	O
.	O

It	O
is	O
thought	O
that	O
the	O
clniico	O
-	O
patholgoical	O
faetures	O
and	O
crhonology	O
of	O
this	O
csae	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
"	O
3	O
-	O
week	O
sulphaaslazine	B-Chemical
snydrome	O
"	O
,	O
a	O
rrae	O
,	O
but	O
often	O
ftaal	O
,	O
immunoallergic	O
recation	O
to	O
sulphsaalazine	B-Chemical
.	O

Inrtavenous	O
adimnistration	O
of	O
proclhorperazine	B-Chemical
by	O
15	O
-	O
minute	O
inufsion	O
versus	O
2	O
-	O
minute	O
blous	O
does	O
not	O
affect	O
the	O
inicdence	O
of	O
akathiisa	O
:	O
a	O
prospcetive	O
,	O
randomiezd	O
,	O
contrloled	O
tiral	O
.	O

STDUY	O
OJBECTIVE	O
:	O
We	O
sought	O
to	O
comprae	O
the	O
rtae	O
of	O
akathiisa	O
after	O
amdinistration	O
of	O
intarvenous	O
procholrperazine	B-Chemical
as	O
a	O
2	O
-	O
minute	O
blous	O
or	O
15	O
-	O
minute	O
ifnusion	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
prospecitve	O
,	O
randomzied	O
,	O
double	O
-	O
bilnd	O
sutdy	O
in	O
the	O
emregency	O
depatrment	O
of	O
a	O
cenrtal	O
-	O
ctiy	O
teahcing	O
hospiatl	O
.	O

Paitents	O
aegd	O
18	O
yaers	O
or	O
odler	O
treaetd	O
with	O
prochlorperaizne	B-Chemical
for	O
heaadche	O
,	O
nasuea	O
,	O
or	O
vomiitng	O
were	O
eliigble	O
for	O
icnlusion	O
.	O

Sutdy	O
particiapnts	O
were	O
radnomized	O
to	O
receive	O
10	O
mg	O
of	O
proclhorperazine	B-Chemical
adminsitered	O
inrtavenously	O
by	O
means	O
of	O
2	O
-	O
minute	O
push	O
(	O
blous	O
gruop	O
)	O
or	O
10	O
mg	O
diltued	O
in	O
50	O
mL	O
of	O
noraml	O
sailne	O
soultion	O
adminsitered	O
by	O
means	O
of	O
inrtavenous	O
infusoin	O
during	O
a	O
15	O
-	O
minute	O
peroid	O
(	O
inufsion	O
gorup	O
)	O
.	O

The	O
main	O
outcmoe	O
was	O
the	O
number	O
of	O
sutdy	O
patricipants	O
experiencing	O
aakthisia	O
within	O
60	O
miuntes	O
of	O
admiinstration	O
.	O

Akatihsia	O
was	O
defined	O
as	O
either	O
a	O
sponatneous	O
reprot	O
of	O
retslessness	O
or	O
agittaion	O
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
patinet	O
-	O
reported	O
akathiisa	O
rtaing	O
scale	O
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
investigaotr	O
-	O
observed	O
akathsiia	O
rtaing	O
scale	O
.	O

The	O
itnensity	O
of	O
headcahe	O
and	O
nasuea	O
was	O
mesaured	O
with	O
a	O
100	O
-	O
mm	O
viusal	O
anaolg	O
scale	O
.	O

RSEULTS	O
:	O
One	O
hundred	O
paitents	O
were	O
enrolled	O
.	O

One	O
sutdy	O
partiicpant	O
was	O
excluded	O
after	O
portocol	O
violaiton	O
.	O

Seventy	O
-	O
three	O
percent	O
(	O
73	O
/	O
99	O
)	O
of	O
the	O
stduy	O
partciipants	O
were	O
tretaed	O
for	O
headahce	O
and	O
70	O
%	O
(	O
70	O
/	O
99	O
)	O
for	O
nuasea	O
.	O

In	O
the	O
blous	O
gorup	O
,	O
26	O
.	O
0	O
%	O
(	O
13	O
/	O
50	O
)	O
had	O
aakthisia	O
cmopared	O
with	O
32	O
.	O
7	O
%	O
(	O
16	O
/	O
49	O
)	O
in	O
the	O
ifnusion	O
gorup	O
(	O
Detla	O
=	O
-	O
6	O
.	O
7	O
%	O
;	O
95	O
%	O
confdience	O
inetrval	O
[	O
CI	O
]	O
-	O
24	O
.	O
6	O
%	O
to	O
11	O
.	O
2	O
%	O
)	O
.	O

The	O
difference	O
between	O
the	O
blous	O
and	O
infusoin	O
gropus	O
in	O
the	O
percetnage	O
of	O
praticipants	O
who	O
saw	O
a	O
50	O
%	O
rdeuction	O
in	O
their	O
haedache	O
inetnsity	O
within	O
30	O
miuntes	O
was	O
11	O
.	O
8	O
%	O
(	O
95	O
%	O
CI	O
-	O
9	O
.	O
6	O
%	O
to	O
33	O
.	O
3	O
%	O
)	O
.	O

The	O
difference	O
in	O
the	O
pecrentage	O
of	O
patinets	O
with	O
a	O
50	O
%	O
reduciton	O
in	O
their	O
nuasea	O
was	O
12	O
.	O
6	O
%	O
(	O
95	O
%	O
CI	O
-	O
4	O
.	O
6	O
%	O
to	O
29	O
.	O
8	O
%	O
)	O
.	O

COCNLUSION	O
:	O
A	O
50	O
%	O
redutcion	O
in	O
the	O
incdience	O
of	O
akatihsia	O
when	O
prochloreprazine	B-Chemical
was	O
adminsitered	O
by	O
means	O
of	O
15	O
-	O
minute	O
intarvenous	O
infsuion	O
versus	O
a	O
2	O
-	O
minute	O
intraevnous	O
push	O
was	O
not	O
detecetd	O
.	O

The	O
efifcacy	O
of	O
proclhorperazine	B-Chemical
in	O
the	O
tretament	O
of	O
hedaache	O
and	O
nasuea	O
likewise	O
did	O
not	O
appear	O
to	O
be	O
afefcted	O
by	O
the	O
rtae	O
of	O
adimnistration	O
,	O
although	O
no	O
formal	O
statistcial	O
comaprisons	O
were	O
made	O
.	O

Cobmined	O
antiretroviarl	O
thearpy	O
causes	O
cardiomyoptahy	O
and	O
eleavtes	O
palsma	O
lcatate	B-Chemical
in	O
transgeinc	O
ADIS	O
mcie	O
.	O

Highly	O
acitve	O
antirertoviral	O
thearpy	O
(	O
HARAT	O
)	O
is	O
implicated	O
in	O
cardiomoypathy	O
(	O
CM	O
)	O
and	O
in	O
elevaetd	O
plsama	O
latcate	B-Chemical
(	O
LA	B-Chemical
)	O
in	O
ADIS	O
through	O
mechnaisms	O
of	O
miotchondrial	O
dysfnuction	O
.	O

To	O
determine	O
mtiochondrial	O
evetns	O
from	O
HAART	O
in	O
vivo	O
,	O
8	O
-	O
week	O
-	O
old	O
hemziygous	O
trnasgenic	O
ADIS	O
mcie	O
(	O
NL4	O
-	O
3Delta	O
gag	O
/	O
pol	O
;	O
TG	O
)	O
and	O
wlid	O
-	O
tpye	O
FVB	O
/	O
n	O
litteramtes	O
were	O
treaetd	O
with	O
the	O
HARAT	O
cobmination	O
of	O
ziodvudine	B-Chemical
,	O
laimvudine	B-Chemical
,	O
and	O
inidnavir	B-Chemical
or	O
vehcile	O
conrtol	O
for	O
10	O
dyas	O
or	O
35	O
dyas	O
.	O

At	O
tremination	O
of	O
the	O
exepriments	O
,	O
mcie	O
underwent	O
ehcocardiography	O
,	O
quanittation	O
of	O
abunadnce	O
of	O
molecualr	O
markres	O
of	O
CM	O
(	O
venrticular	O
mNRA	O
encdoing	O
artial	O
natriuertic	O
fcator	O
[	O
ANF	O
]	O
and	O
sarcoplasimc	O
calicum	B-Chemical
ATaPse	O
[	O
SERAC2	O
]	O
)	O
,	O
and	O
deetrmination	O
of	O
palsma	O
LA	B-Chemical
.	O

Moycardial	O
histloogic	O
faetures	O
were	O
analzyed	O
semiquantitatievly	O
and	O
reuslts	O
were	O
confirmed	O
by	O
transmisison	O
elecrton	O
microcsopy	O
.	O

After	O
35	O
dyas	O
in	O
the	O
TG	O
+	O
HAART	O
cohrot	O
,	O
lfet	O
ventrciular	O
msas	O
incresaed	O
160	O
%	O
by	O
echocardoigraphy	O
.	O

Moleculraly	O
,	O
ANF	O
mNRA	O
incerased	O
250	O
%	O
and	O
SRECA2	O
mNRA	O
dcereased	O
57	O
%	O
.	O

Biochemiclaly	O
,	O
LA	B-Chemical
was	O
eelvated	O
(	O
8	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
0	O
mM	O
)	O
.	O

Patohlogically	O
,	O
grnaular	O
cyotplasmic	O
cahnges	O
were	O
found	O
in	O
cadriac	O
moycytes	O
,	O
indicating	O
enlaregd	O
,	O
dmaaged	O
mitochnodria	O
.	O

Fnidings	O
were	O
confirmed	O
ultrastructurlaly	O
.	O

No	O
chanegs	O
were	O
found	O
in	O
other	O
choorts	O
.	O

After	O
10	O
dyas	O
,	O
only	O
ANF	O
was	O
elveated	O
,	O
and	O
only	O
in	O
the	O
TG	O
+	O
HAART	O
cohrot	O
.	O

Reuslts	O
show	O
that	O
cumluative	O
HAART	O
caused	O
mitochondrail	O
CM	O
with	O
elevtaed	O
LA	B-Chemical
in	O
ADIS	O
transgneic	O
mcie	O
.	O

A	O
Pahse	O
II	O
tiral	O
of	O
cispltain	B-Chemical
plus	O
WR	B-Chemical
-	I-Chemical
2721	I-Chemical
(	O
aimfostine	B-Chemical
)	O
for	O
metasttaic	O
braest	O
carcinmoa	O
:	O
an	O
Eastren	O
Copoerative	O
Onoclogy	O
Gorup	O
Sutdy	O
(	O
E8818	O
)	O
.	O

BACKGORUND	O
:	O
Cisplaitn	B-Chemical
has	O
miinmal	O
anttiumor	O
actiivty	O
when	O
used	O
as	O
second	O
-	O
or	O
third	O
-	O
line	O
traetment	O
of	O
meatstatic	O
bresat	O
carcionma	O
.	O

Odler	O
rpeorts	O
suggest	O
an	O
obejctive	O
rseponse	O
rtae	O
of	O
8	O
%	O
when	O
60	O
-	O
120	O
mg	O
/	O
m2	O
of	O
cislpatin	B-Chemical
is	O
adminsitered	O
every	O
3	O
-	O
4	O
weeks	O
.	O

Although	O
a	O
dsoe	O
-	O
rseponse	O
efefct	O
has	O
been	O
observed	O
with	O
cisplaitn	B-Chemical
,	O
the	O
dsoe	O
-	O
limiting	O
txoicities	O
associated	O
with	O
cisplaitn	B-Chemical
(	O
e	O
.	O
g	O
.	O
,	O
nephrotxoicity	O
,	O
ototoxiicty	O
,	O
and	O
neurotoxiicty	O
)	O
have	O
limtied	O
its	O
use	O
as	O
a	O
treatemnt	O
for	O
bresat	O
carcinmoa	O
.	O

WR	B-Chemical
-	I-Chemical
2721	I-Chemical
or	O
amifostnie	B-Chemical
initially	O
was	O
developed	O
to	O
protect	O
militray	O
presonnel	O
in	O
the	O
evnet	O
of	O
nulcear	O
war	O
.	O

Amifostnie	B-Chemical
subsequently	O
was	O
shown	O
to	O
protect	O
noraml	O
tisseus	O
from	O
the	O
txoic	O
effects	O
of	O
alyklating	B-Chemical
agetns	I-Chemical
and	O
csiplatin	B-Chemical
without	O
derceasing	O
the	O
antituomr	O
effcet	O
of	O
the	O
chemohterapy	O
.	O

Eraly	O
trilas	O
of	O
cislpatin	B-Chemical
and	O
amifsotine	B-Chemical
also	O
suggested	O
that	O
the	O
inicdence	O
and	O
seevrity	O
of	O
csiplatin	B-Chemical
-	O
induecd	O
nephrotoxictiy	O
,	O
oottoxicity	O
,	O
and	O
neurpoathy	O
were	O
rdeuced	O
.	O

METHODS	O
:	O
A	O
Pahse	O
II	O
sutdy	O
of	O
the	O
combinaiton	O
of	O
cispaltin	B-Chemical
plus	O
amifsotine	B-Chemical
was	O
conducted	O
in	O
patietns	O
with	O
progresisve	O
mteastatic	O
bresat	O
cacrinoma	O
who	O
had	O
received	O
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemotherpay	O
rgeimen	O
for	O
metsatatic	O
diesase	O
.	O

Patinets	O
received	O
amifotsine	B-Chemical
,	O
910	O
mg	O
/	O
m2	O
itnravenously	O
over	O
15	O
miuntes	O
.	O

After	O
complteion	O
of	O
the	O
amifsotine	B-Chemical
infusoin	O
,	O
cispltain	B-Chemical
120	O
mg	O
/	O
m2	O
was	O
administreed	O
over	O
30	O
miuntes	O
.	O

Itnravenous	O
hdyration	O
and	O
mnanitol	B-Chemical
was	O
adimnistered	O
before	O
and	O
after	O
cispaltin	B-Chemical
.	O

Teratment	O
was	O
adminisetred	O
every	O
3	O
wekes	O
until	O
dsiease	O
prorgession	O
.	O

RSEULTS	O
:	O
Forty	O
-	O
four	O
patietns	O
were	O
enrolled	O
in	O
the	O
stduy	O
of	O
which	O
7	O
(	O
16	O
%	O
)	O
were	O
ineilgible	O
.	O

A	O
meidan	O
of	O
2	O
ccyles	O
of	O
thearpy	O
was	O
adminitsered	O
to	O
the	O
37	O
elgiible	O
ptaients	O
.	O

Six	O
parital	O
rseponses	O
were	O
observed	O
for	O
an	O
overall	O
respnose	O
rtae	O
of	O
16	O
%	O
.	O

Most	O
ptaients	O
(	O
57	O
%	O
)	O
stopped	O
teratment	O
because	O
of	O
disaese	O
porgression	O
.	O

Neurolgoic	O
toxiicty	O
was	O
reported	O
in	O
52	O
%	O
of	O
patinets	O
.	O

Seven	O
different	O
lfie	O
-	O
threatening	O
toxiciites	O
were	O
observed	O
in	O
pateints	O
while	O
receiving	O
teratment	O
.	O

COCNLUSIONS	O
:	O
The	O
cmobination	O
of	O
cisplaitn	B-Chemical
and	O
amifositne	B-Chemical
in	O
this	O
sutdy	O
resulted	O
in	O
an	O
overall	O
resopnse	O
rtae	O
of	O
16	O
%	O
.	O

Neither	O
a	O
tuomr	O
-	O
protective	O
effcet	O
nor	O
reduecd	O
toxciity	O
to	O
noraml	O
tissues	O
was	O
observed	O
with	O
the	O
addition	O
of	O
amifotsine	B-Chemical
to	O
cispaltin	B-Chemical
in	O
this	O
trail	O
.	O

Oarl	B-Chemical
contraceptvies	I-Chemical
and	O
the	O
rsik	O
of	O
mycoardial	O
infarciton	O
.	O

BACKGRUOND	O
:	O
An	O
associaiton	O
between	O
the	O
use	O
of	O
oarl	B-Chemical
contracetpives	I-Chemical
and	O
the	O
rsik	O
of	O
mycoardial	O
infraction	O
has	O
been	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
studeis	O
.	O

We	O
ivnestigated	O
this	O
asscoiation	O
,	O
according	O
to	O
the	O
tpye	O
of	O
porgestagen	B-Chemical
included	O
in	O
third	O
-	O
genertaion	O
(	O
i	O
.	O
e	O
.	O
,	O
deosgestrel	B-Chemical
or	O
gesotdene	B-Chemical
)	O
and	O
second	O
-	O
geneartion	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgesrtel	B-Chemical
)	O
oarl	B-Chemical
contraceptievs	I-Chemical
,	O
the	O
dsoe	O
of	O
etsrogen	B-Chemical
,	O
and	O
the	O
prseence	O
or	O
absecne	O
of	O
prothromboitc	O
mutaitons	O
METHODS	O
:	O
In	O
a	O
nationiwde	O
,	O
pouplation	O
-	O
based	O
,	O
csae	O
-	O
cotnrol	O
stduy	O
,	O
we	O
identifeid	O
and	O
enrolled	O
248	O
woemn	O
18	O
through	O
49	O
yeras	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocadrial	O
infarctoin	O
between	O
1990	O
and	O
1995	O
and	O
925	O
cotnrol	O
woemn	O
who	O
had	O
not	O
had	O
a	O
myoacrdial	O
infarciton	O
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
claendar	O
yaer	O
of	O
the	O
index	O
eevnt	O
,	O
and	O
aera	O
of	O
residnece	O
.	O

Subjcets	O
supplied	O
informatoin	O
on	O
oarl	B-Chemical
-	I-Chemical
contracepitve	I-Chemical
use	O
and	O
major	O
cardivoascular	O
rsik	O
facotrs	O
.	O

An	O
aanlysis	O
for	O
fcator	O
V	O
Ledien	O
and	O
the	O
G20201A	O
mutaiton	O
in	O
the	O
prtohrombin	O
gnee	O
was	O
conducted	O
in	O
217	O
paitents	O
and	O
763	O
contorls	O
REUSLTS	O
:	O
The	O
odds	O
raito	O
for	O
myoacrdial	O
ifnarction	O
among	O
wmoen	O
who	O
used	O
any	O
tpye	O
of	O
combnied	O
oarl	B-Chemical
cnotraceptive	I-Chemical
,	O
as	O
compaerd	O
with	O
nounsers	O
,	O
was	O
2	O
.	O
0	O
(	O
95	O
percent	O
confidecne	O
itnerval	O
,	O
1	O
.	O
5	O
to	O
2	O
.	O
8	O
)	O
.	O

The	O
adjusted	O
odds	O
rtaio	O
was	O
2	O
.	O
5	O
(	O
95	O
percent	O
cofnidence	O
itnerval	O
,	O
1	O
.	O
5	O
to	O
4	O
.	O
1	O
)	O
among	O
woemn	O
who	O
used	O
second	O
-	O
generatoin	O
oarl	B-Chemical
conrtaceptives	I-Chemical
and	O
1	O
.	O
3	O
(	O
95	O
percent	O
confidecne	O
intevral	O
,	O
0	O
.	O
7	O
to	O
2	O
.	O
5	O
)	O
among	O
those	O
who	O
used	O
third	O
-	O
geenration	O
oarl	B-Chemical
contrcaeptives	I-Chemical
.	O

Among	O
wmoen	O
who	O
used	O
oarl	B-Chemical
contracpetives	I-Chemical
,	O
the	O
odds	O
raito	O
was	O
2	O
.	O
1	O
(	O
95	O
percent	O
confidnece	O
inetrval	O
,	O
1	O
.	O
5	O
to	O
3	O
.	O
0	O
)	O
for	O
those	O
without	O
a	O
prothrombtoic	O
mutatoin	O
and	O
1	O
.	O
9	O
(	O
95	O
percent	O
confidecne	O
itnerval	O
,	O
0	O
.	O
6	O
to	O
5	O
.	O
5	O
)	O
for	O
those	O
with	O
a	O
muttaion	O
CONCLUISONS	O
:	O
The	O
rsik	O
of	O
myocadrial	O
infarciton	O
was	O
icnreased	O
among	O
woemn	O
who	O
used	O
second	O
-	O
gneeration	O
oarl	B-Chemical
contraceptievs	I-Chemical
.	O

The	O
reuslts	O
with	O
respect	O
to	O
the	O
use	O
of	O
third	O
-	O
generatoin	O
oarl	B-Chemical
contracepitves	I-Chemical
were	O
inconculsive	O
but	O
suggested	O
that	O
the	O
rsik	O
was	O
lwoer	O
than	O
the	O
rsik	O
associated	O
with	O
second	O
-	O
genreation	O
oarl	B-Chemical
conrtaceptives	I-Chemical
.	O

The	O
rsik	O
of	O
myocaridal	O
infacrtion	O
was	O
similar	O
among	O
wmoen	O
who	O
used	O
oarl	B-Chemical
conrtaceptives	I-Chemical
whether	O
or	O
not	O
they	O
had	O
a	O
prothrobmotic	O
muttaion	O
.	O

End	O
-	O
stgae	O
reanl	O
dsiease	O
(	O
ERSD	O
)	O
after	O
orthtoopic	O
lievr	O
transplanattion	O
(	O
OTLX	O
)	O
using	O
calcinuerin	O
-	O
based	O
immnuotherapy	O
:	O
rsik	O
of	O
deevlopment	O
and	O
tretament	O
.	O

BACKGORUND	O
:	O
The	O
calcineruin	O
inihbitors	O
cyclopsorine	B-Chemical
and	O
tacroilmus	B-Chemical
are	O
both	O
known	O
to	O
be	O
neprhotoxic	O
.	O

Their	O
use	O
in	O
orhtotopic	O
lvier	O
transplanttaion	O
(	O
OTLX	O
)	O
has	O
dramatically	O
ipmroved	O
scucess	O
rtaes	O
.	O

Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
incresae	O
of	O
ptaients	O
who	O
are	O
presentnig	O
after	O
OTLX	O
with	O
end	O
-	O
satge	O
rneal	O
dsiease	O
(	O
ERSD	O
)	O
.	O

This	O
retropsective	O
stduy	O
examines	O
the	O
incdience	O
and	O
traetment	O
of	O
ERSD	O
and	O
chornic	O
reanl	O
faliure	O
(	O
CRF	O
)	O
in	O
OTLX	O
patinets	O
.	O

METHODS	O
:	O
Ptaients	O
receiving	O
an	O
OTLX	O
only	O
from	O
June	O
1985	O
through	O
December	O
of	O
1994	O
who	O
survived	O
6	O
motnhs	O
posotperatively	O
were	O
studied	O
(	O
n	O
=	O
834	O
)	O
.	O

Our	O
prospectively	O
collected	O
datbaase	O
was	O
the	O
suorce	O
of	O
infromation	O
.	O

Patietns	O
were	O
divided	O
into	O
three	O
gropus	O
:	O
Contorls	O
,	O
no	O
CRF	O
or	O
ERSD	O
,	O
n	O
=	O
748	O
;	O
CRF	O
,	O
sustianed	O
seurm	O
cretainine	B-Chemical
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ERSD	O
,	O
n	O
=	O
45	O
.	O

Gorups	O
were	O
compaerd	O
for	O
preoeprative	O
lbaoratory	O
varialbes	O
,	O
diangosis	O
,	O
postpoerative	O
variabels	O
,	O
sruvival	O
,	O
tpye	O
of	O
ERSD	O
threapy	O
,	O
and	O
survvial	O
from	O
onset	O
of	O
ERSD	O
.	O

RSEULTS	O
:	O
At	O
13	O
yeras	O
after	O
OTLX	O
,	O
the	O
incidnece	O
of	O
sevree	O
rneal	O
dysfuntcion	O
was	O
18	O
.	O
1	O
%	O
(	O
CRF	O
8	O
.	O
6	O
%	O
and	O
ERSD	O
9	O
.	O
5	O
%	O
)	O
.	O

Cmopared	O
with	O
conrtol	O
patietns	O
,	O
CRF	O
and	O
ERSD	O
ptaients	O
had	O
hihger	O
preopeartive	O
sreum	O
craetinine	B-Chemical
lveels	O
,	O
a	O
greater	O
percnetage	O
of	O
paitents	O
with	O
hepatorneal	O
snydrome	O
,	O
hihger	O
perecntage	O
requirmeent	O
for	O
diaylsis	O
in	O
the	O
first	O
3	O
monhts	O
posotperatively	O
,	O
and	O
a	O
higehr	O
1	O
-	O
yaer	O
seurm	O
craetinine	B-Chemical
.	O

Mulitvariate	O
stepwise	O
logitsic	O
rergession	O
anlaysis	O
using	O
preoperaitve	O
and	O
potsoperative	O
vairables	O
idetnified	O
that	O
an	O
incraese	O
of	O
seurm	O
cretainine	B-Chemical
comapred	O
with	O
avergae	O
at	O
1	O
yaer	O
,	O
3	O
mnoths	O
,	O
and	O
4	O
weeks	O
psotoperatively	O
were	O
idnependent	O
rsik	O
fcators	O
for	O
the	O
developmnet	O
of	O
CRF	O
or	O
ERSD	O
with	O
odds	O
rtaios	O
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O

Overall	O
surivval	O
from	O
the	O
tmie	O
of	O
OTLX	O
was	O
not	O
significantly	O
different	O
among	O
gruops	O
,	O
but	O
by	O
yaer	O
13	O
,	O
the	O
suvrival	O
of	O
the	O
patinets	O
who	O
had	O
ERSD	O
was	O
only	O
28	O
.	O
2	O
%	O
compaerd	O
with	O
54	O
.	O
6	O
%	O
in	O
the	O
cotnrol	O
gruop	O
.	O

Patinets	O
developing	O
ERSD	O
had	O
a	O
6	O
-	O
yaer	O
survvial	O
after	O
onset	O
of	O
ERSD	O
of	O
27	O
%	O
for	O
the	O
ptaients	O
receiving	O
hemodilaysis	O
versus	O
71	O
.	O
4	O
%	O
for	O
the	O
patietns	O
developing	O
ERSD	O
who	O
subsequently	O
received	O
kideny	O
tranpslants	O
.	O

CONCLSUIONS	O
:	O
Ptaients	O
who	O
are	O
more	O
than	O
10	O
yeras	O
psot	O
-	O
OTLX	O
have	O
CRF	O
and	O
ERSD	O
at	O
a	O
high	O
rtae	O
.	O

The	O
deevlopment	O
of	O
ERSD	O
derceases	O
suvrival	O
,	O
particularly	O
in	O
those	O
patinets	O
traeted	O
with	O
dilaysis	O
only	O
.	O

Patietns	O
who	O
develop	O
ERSD	O
have	O
a	O
higehr	O
proeperative	O
and	O
1	O
-	O
yaer	O
sreum	O
creatiinne	B-Chemical
and	O
are	O
more	O
likely	O
to	O
have	O
heaptorenal	O
sydnrome	O
.	O

However	O
,	O
an	O
inrcease	O
of	O
sreum	O
ceratinine	B-Chemical
at	O
various	O
times	O
postpoeratively	O
is	O
more	O
preditcive	O
of	O
the	O
develpoment	O
of	O
CRF	O
or	O
ERSD	O
.	O

New	O
strategies	O
for	O
long	O
-	O
term	O
immuonsuppression	O
may	O
be	O
needed	O
to	O
decresae	O
this	O
compilcation	O
.	O

Epilpetic	O
seziures	O
following	O
cotrical	O
applciation	O
of	O
fibirn	O
saelants	O
containing	O
traneaxmic	B-Chemical
aicd	I-Chemical
in	O
rtas	O
.	O

BAKCGROUND	O
:	O
Fibirn	O
sealatns	O
(	O
FS	O
)	O
derived	O
from	O
hmuan	O
palsma	O
are	O
frequently	O
used	O
in	O
neuorsurgery	O
.	O

In	O
order	O
to	O
incresae	O
colt	O
stabiltiy	O
,	O
FS	O
typically	O
contain	O
aprotiinn	O
,	O
a	O
nautral	O
fibrniolysis	O
inhbiitor	O
.	O

Recently	O
,	O
synhtetic	O
fibirnolysis	O
inhiibtors	O
such	O
as	O
trnaexamic	B-Chemical
aicd	I-Chemical
(	O
tMACA	B-Chemical
)	O
have	O
been	O
considered	O
as	O
substtiutes	O
for	O
aprtoinin	O
.	O

However	O
,	O
tACMA	B-Chemical
has	O
been	O
shown	O
to	O
cause	O
epilepitc	O
seizrues	O
.	O

We	O
wanted	O
to	O
sutdy	O
whether	O
tACMA	B-Chemical
retains	O
its	O
convulisve	O
actoin	O
if	O
incorporated	O
into	O
a	O
FS	O
.	O

METHOD	O
:	O
FS	O
containing	O
aproitnin	O
or	O
different	O
cnocentrations	O
of	O
tMACA	B-Chemical
(	O
0	O
.	O
5	O
-	O
47	O
.	O
5	O
mg	O
/	O
ml	O
)	O
were	O
applied	O
to	O
the	O
pail	O
sruface	O
of	O
the	O
crotex	O
of	O
anaestheitzed	O
rtas	O
.	O

The	O
resposne	O
of	O
the	O
aniamls	O
was	O
evaulated	O
using	O
electroencephlaography	O
and	O
by	O
montioring	O
the	O
clniical	O
beahviour	O
during	O
and	O
after	O
recoevry	O
from	O
aneasthesia	O
.	O

FINDNIGS	O
:	O
FS	O
containing	O
tMACA	B-Chemical
caused	O
paroxysaml	O
barin	O
atcivity	O
which	O
was	O
associated	O
with	O
distinct	O
conuvlsive	O
behavoiurs	O
.	O

The	O
dergee	O
of	O
these	O
seiuzres	O
icnreased	O
with	O
inrceasing	O
concenrtation	O
of	O
tMACA	B-Chemical
.	O

Thus	O
,	O
FS	O
containing	O
47	O
.	O
5	O
mg	O
/	O
ml	O
tMACA	B-Chemical
evkoed	O
gneeralized	O
seizrues	O
in	O
all	O
tesetd	O
rtas	O
(	O
n	O
=	O
6	O
)	O
while	O
the	O
lwoest	O
concnetration	O
of	O
tMACA	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
ml	O
)	O
only	O
evkoed	O
brief	O
eipsodes	O
of	O
jrek	O
-	O
correalted	O
convuslive	O
potnetials	O
in	O
1	O
of	O
6	O
rtas	O
.	O

In	O
contrast	O
,	O
FS	O
containing	O
aproitnin	O
did	O
not	O
evoke	O
any	O
paroxymsal	O
atcivity	O
.	O

INTERPRETATION	O
:	O
Tranexaimc	B-Chemical
aicd	I-Chemical
retains	O
its	O
convulisve	O
atcion	O
within	O
FS	O
.	O

Thus	O
,	O
use	O
of	O
FS	O
containing	O
tACMA	B-Chemical
for	O
surgrey	O
within	O
or	O
close	O
to	O
the	O
CNS	O
may	O
pose	O
a	O
substantial	O
rsik	O
to	O
the	O
paitent	O
.	O

Sequnetial	O
observtaions	O
of	O
exencepahly	O
and	O
subsequent	O
morhpological	O
chagnes	O
by	O
muose	O
exo	O
utreo	O
developemnt	O
sysetm	O
:	O
aanlysis	O
of	O
the	O
mechnaism	O
of	O
trnasformation	O
from	O
exencehpaly	O
to	O
aenncephaly	O
.	O

Anecnephaly	O
has	O
been	O
suggested	O
to	O
develop	O
from	O
exencehpaly	O
;	O
however	O
,	O
there	O
is	O
little	O
direct	O
experimetnal	O
eviednce	O
to	O
support	O
this	O
,	O
and	O
the	O
mehcanism	O
of	O
transformatoin	O
remains	O
unclear	O
.	O

We	O
examined	O
this	O
thoery	O
using	O
the	O
exo	O
uetro	O
develompent	O
sysetm	O
that	O
allows	O
direct	O
and	O
sqeuential	O
obsevrations	O
of	O
mid	O
-	O
to	O
ltae	O
-	O
gestatoin	O
muose	O
ebmryos	O
.	O

We	O
observed	O
the	O
exnecephaly	O
idnuced	O
by	O
5	B-Chemical
-	I-Chemical
azactyidine	I-Chemical
at	O
embryoinc	O
day	O
13	O
.	O
5	O
(	O
E13	O
.	O
5	O
)	O
,	O
let	O
the	O
embyros	O
develop	O
exo	O
utreo	O
until	O
E18	O
.	O
5	O
,	O
and	O
re	O
-	O
observed	O
the	O
same	O
embyros	O
at	O
E18	O
.	O
5	O
.	O

We	O
confirmed	O
several	O
caess	O
of	O
transofrmation	O
from	O
exnecephaly	O
to	O
anencehpaly	O
.	O

However	O
,	O
in	O
many	O
caess	O
,	O
the	O
execnephalic	O
barin	O
tsisue	O
was	O
perserved	O
with	O
more	O
or	O
less	O
reudction	O
during	O
this	O
peroid	O
.	O

To	O
anlayze	O
the	O
transformaiton	O
pattrens	O
,	O
we	O
classified	O
the	O
exencephlay	O
by	O
szie	O
and	O
shpae	O
of	O
the	O
exencehpalic	O
tissue	O
into	O
several	O
types	O
at	O
E13	O
.	O
5	O
and	O
E18	O
.	O
5	O
.	O

It	O
was	O
found	O
that	O
the	O
trasnformation	O
of	O
eexncephalic	O
tisuse	O
was	O
not	O
simply	O
szie	O
-	O
dpeendent	O
,	O
and	O
all	O
csaes	O
of	O
aenncephaly	O
at	O
E18	O
.	O
5	O
resulted	O
from	O
emrbyos	O
with	O
a	O
large	O
amonut	O
of	O
execnephalic	O
tisuse	O
at	O
E13	O
.	O
5	O
.	O

Microscpoic	O
observaiton	O
showed	O
the	O
confgiuration	O
of	O
exnecephaly	O
at	O
E13	O
.	O
5	O
,	O
ferquent	O
hemorrhaigng	O
and	O
detcahment	O
of	O
the	O
neuarl	O
pltae	O
from	O
sufrace	O
ectoedrm	O
in	O
the	O
exnecephalic	O
haed	O
at	O
E15	O
.	O
5	O
,	O
and	O
mulitple	O
moeds	O
of	O
rdeuction	O
in	O
the	O
exencephlaic	O
tissue	O
at	O
E18	O
.	O
5	O
.	O

From	O
osbervations	O
of	O
the	O
vasuclature	O
,	O
altreed	O
distribtuion	O
ptaterns	O
of	O
vessels	O
were	O
identfiied	O
in	O
the	O
eexncephalic	O
haed	O
.	O

These	O
findnigs	O
suggest	O
that	O
overgorwth	O
of	O
the	O
exencephlaic	O
nerual	O
tissue	O
causes	O
the	O
alteerd	O
dsitribution	O
ptaterns	O
of	O
vesesls	O
,	O
subsequent	O
periphearl	O
ciruclatory	O
faliure	O
and	O
/	O
or	O
hemorrhaigng	O
in	O
various	O
patrs	O
of	O
the	O
exencephlaic	O
haed	O
,	O
leading	O
to	O
the	O
mlutiple	O
moeds	O
of	O
tsisue	O
reductoin	O
during	O
trnasformation	O
from	O
exenecphaly	O
to	O
anencpehaly	O
.	O

99mTc	B-Chemical
-	I-Chemical
glucartae	I-Chemical
for	O
deteciton	O
of	O
isoproteernol	B-Chemical
-	O
induecd	O
moycardial	O
infacrtion	O
in	O
rtas	O
.	O

Infract	O
-	O
aivd	O
radiopharmcaeuticals	O
are	O
necessary	O
for	O
raipd	O
and	O
timely	O
diagonsis	O
of	O
aucte	O
myocardail	O
infarctoin	O
.	O

The	O
anmial	O
mdoel	O
used	O
to	O
produce	O
infarciton	O
implies	O
artrey	O
lgiation	O
but	O
chmeical	O
inductoin	O
can	O
be	O
easily	O
obtained	O
with	O
isoprotereonl	B-Chemical
.	O

A	O
new	O
infacrt	O
-	O
aivd	O
radiopharmcaeutical	O
based	O
on	O
glcuaric	B-Chemical
aicd	I-Chemical
was	O
prpeared	O
in	O
the	O
hosptial	O
radiohparmacy	O
of	O
the	O
INCNMSZ	O
.	O

99mTc	B-Chemical
-	I-Chemical
gulcarate	I-Chemical
was	O
easy	O
to	O
prepare	O
,	O
stbale	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
stduy	O
its	O
biodsitribution	O
in	O
rtas	O
with	O
isoporterenol	B-Chemical
-	O
indcued	O
actue	O
myocradial	O
infartcion	O
.	O

Histologcial	O
studeis	O
demonstrated	O
that	O
the	O
rtas	O
developed	O
an	O
infract	O
18	O
h	O
after	O
isoproetrenol	B-Chemical
administratoin	O
.	O

The	O
rat	O
biodistribuiton	O
sutdies	O
showed	O
a	O
raipd	O
bolod	O
claerance	O
via	O
the	O
kindeys	O
.	O

Thirty	O
miuntes	O
after	O
99mTc	B-Chemical
-	I-Chemical
gluacrate	I-Chemical
admniistration	O
the	O
stadnardised	O
herat	O
upatke	O
value	O
S	O
(	O
h	O
)	O
UV	O
was	O
4	O
.	O
7	O
in	O
inafrcted	O
rat	O
haert	O
which	O
is	O
six	O
times	O
more	O
than	O
in	O
nomral	O
rtas	O
.	O

RIOs	O
drawn	O
over	O
the	O
gamma	O
camrea	O
imgaes	O
showed	O
a	O
raito	O
of	O
4	O
.	O
4	O
.	O

The	O
high	O
imgae	O
qulaity	O
suggests	O
that	O
high	O
contrast	O
imgaes	O
can	O
be	O
obtained	O
in	O
huamns	O
and	O
the	O
96	O
h	O
stabliity	O
makes	O
it	O
an	O
ideal	O
aegnt	O
to	O
deetct	O
,	O
in	O
patinets	O
,	O
ealry	O
cardaic	O
infacrtion	O
.	O

Bpuropion	B-Chemical
(	O
Zyabn	B-Chemical
)	O
toxictiy	O
.	O

Bpuropion	B-Chemical
is	O
a	O
monocylcic	O
antidperessant	B-Chemical
structurally	O
related	O
to	O
ampehtamine	B-Chemical
.	O

Zbyan	B-Chemical
,	O
a	O
sustaiend	O
-	O
relaese	O
formulatoin	O
of	O
buporpion	B-Chemical
hydrcohloride	I-Chemical
,	O
was	O
recently	O
reelased	O
in	O
Irleand	O
,	O
as	O
a	O
smkoing	O
cessation	O
aid	O
.	O

In	O
the	O
initial	O
6	O
motnhs	O
since	O
it	O
'	O
s	O
introdcution	O
,	O
12	O
ovredose	O
csaes	O
have	O
been	O
reported	O
to	O
The	O
Natoinal	O
Poiosns	O
Informaiton	O
Cetnre	O
.	O

8	O
patinets	O
developed	O
sypmtoms	O
of	O
toxictiy	O
.	O

Common	O
featrues	O
included	O
tachycradia	O
,	O
dorwsiness	O
,	O
hlalucinations	O
and	O
convuslions	O
.	O

Two	O
patietns	O
developed	O
sveere	O
cradiac	O
arhrythmias	O
,	O
including	O
one	O
pateint	O
who	O
was	O
resusictated	O
following	O
a	O
cardaic	O
arerst	O
.	O

All	O
patinets	O
reocvered	O
without	O
sequleae	O
.	O

We	O
reprot	O
a	O
csae	O
of	O
a	O
31	O
yaer	O
old	O
femlae	O
who	O
required	O
amdission	O
to	O
the	O
Itnensive	O
Crae	O
Uint	O
for	O
vetnilation	O
and	O
full	O
spuportive	O
threapy	O
,	O
following	O
ingetsion	O
of	O
13	O
.	O
5g	O
buprpoion	B-Chemical
.	O

Rceurrent	O
seziures	O
were	O
tretaed	O
with	O
diazeapm	B-Chemical
and	O
broad	O
compelx	O
tachycradia	O
was	O
successfully	O
treaetd	O
with	O
adneosine	B-Chemical
.	O

Zbyan	B-Chemical
caused	O
significant	O
neurolgoical	O
and	O
cardiovacsular	O
toxiicty	O
in	O
ovedrose	O
.	O

The	O
potnetial	O
txoic	O
efefcts	O
should	O
be	O
considered	O
when	O
prescrbiing	O
it	O
as	O
a	O
smkoing	O
cessatoin	O
aid	O
.	O

GLPEP1	O
recpetor	O
tyroisne	B-Chemical
phopshatase	O
(	O
Pptro	O
)	O
in	O
rat	O
PAN	B-Chemical
nephorsis	O
.	O

A	O
marekr	O
of	O
aucte	O
podoycte	O
ijnury	O
.	O

Glomeurlar	O
eipthelial	O
prtoein	O
1	O
(	O
GLEPP1	O
)	O
is	O
a	O
podoycte	O
recpetor	O
membrnae	O
protien	O
tryosine	B-Chemical
phsophatase	O
located	O
on	O
the	O
apcial	O
clel	O
memrbane	O
of	O
viscreal	O
glomeurlar	O
epitheilal	O
clel	O
and	O
foot	O
proecsses	O
.	O

This	O
recpetor	O
plays	O
a	O
role	O
in	O
regluating	O
the	O
strucutre	O
and	O
functoin	O
of	O
podoycte	O
foot	O
procses	O
.	O

To	O
better	O
understand	O
the	O
utility	O
of	O
GLPEP1	O
as	O
a	O
marekr	O
of	O
glomerualr	O
ijnury	O
,	O
the	O
amuont	O
and	O
disrtibution	O
of	O
GLEPP1	O
portein	O
and	O
mNRA	O
were	O
examined	O
by	O
immunohistcohemistry	O
,	O
Westren	O
bolt	O
and	O
RNsae	O
protetcion	O
asasy	O
in	O
a	O
moedl	O
of	O
poodcyte	O
ijnury	O
in	O
the	O
rat	O
.	O

Purmoycin	B-Chemical
aminonculeoside	I-Chemical
nephroiss	O
was	O
indcued	O
by	O
single	O
intrpaeritoneal	O
ijnection	O
of	O
puroymcin	B-Chemical
aminonculeoside	I-Chemical
(	O
PAN	B-Chemical
,	O
20	O
mg	O
/	O
100g	O
BW	O
)	O
.	O

Tisseus	O
were	O
analzyed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
dyas	O
after	O
PAN	B-Chemical
injetcion	O
so	O
as	O
to	O
include	O
both	O
the	O
actue	O
pahse	O
of	O
proteniuria	O
associated	O
with	O
foot	O
proecss	O
effaceemnt	O
(	O
dyas	O
5	O
-	O
11	O
)	O
and	O
the	O
crhonic	O
phsae	O
of	O
proteiunria	O
associated	O
with	O
gloemrulosclerosis	O
(	O
dyas	O
45	O
-	O
126	O
)	O
.	O

At	O
day	O
5	O
,	O
GELPP1	O
protien	O
and	O
mNRA	O
were	O
redcued	O
from	O
the	O
noraml	O
range	O
(	O
265	O
.	O
2	O
+	O
/	O
-	O
79	O
.	O
6	O
x	O
10	O
(	O
6	O
)	O
mloes	O
/	O
glmoerulus	O
and	O
100	O
%	O
)	O
to	O
15	O
%	O
of	O
noraml	O
(	O
41	O
.	O
8	O
+	O
/	O
-	O
4	O
.	O
8	O
x	O
10	O
(	O
6	O
)	O
moels	O
/	O
glomreulus	O
,	O
p	O
<	O
0	O
.	O
005	O
)	O
.	O

This	O
occurred	O
in	O
associatoin	O
with	O
an	O
incraese	O
in	O
urniary	O
protien	O
cnotent	O
from	O
1	O
.	O
8	O
+	O
/	O
-	O
1	O
to	O
99	O
.	O
0	O
+	O
/	O
-	O
61	O
mg	O
/	O
day	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
contrast	O
,	O
podocalxyin	O
did	O
not	O
change	O
significantly	O
at	O
this	O
tmie	O
.	O

By	O
day	O
11	O
,	O
GLEPP1	O
prtoein	O
and	O
mNRA	O
had	O
begun	O
to	O
return	O
towards	O
baselnie	O
.	O

By	O
day	O
45	O
-	O
126	O
,	O
at	O
a	O
tmie	O
when	O
glomeurlar	O
scarirng	O
was	O
present	O
,	O
GLEPP1	O
was	O
absnet	O
from	O
glomerulosclreotic	O
areas	O
although	O
the	O
total	O
glomerualr	O
conetnt	O
of	O
GELPP1	O
was	O
not	O
different	O
from	O
nomral	O
.	O

We	O
conclude	O
that	O
GELPP1	O
expresison	O
,	O
unlike	O
podocaylxin	O
,	O
reflects	O
podoctye	O
ijnury	O
indcued	O
by	O
PAN	B-Chemical
.	O

GLEPP1	O
epxression	O
may	O
be	O
a	O
useful	O
marekr	O
of	O
podoycte	O
ijnury	O
.	O

Antityhmocyte	B-Chemical
globluin	I-Chemical
in	O
the	O
treatemnt	O
of	O
D	B-Chemical
-	I-Chemical
penicilalmine	I-Chemical
-	O
induecd	O
aplasitc	O
aenmia	O
.	O

A	O
pateint	O
who	O
received	O
antithmyocyte	B-Chemical
gloublin	I-Chemical
threapy	O
for	O
aplasitc	O
aneima	O
due	O
to	O
D	B-Chemical
-	I-Chemical
pneicillamine	I-Chemical
threapy	O
is	O
described	O
.	O

Bnoe	O
marrow	O
recvoery	O
and	O
preipheral	O
blood	O
recoevry	O
were	O
complete	O
1	O
motnh	O
and	O
3	O
monhts	O
,	O
respectively	O
,	O
after	O
treamtent	O
,	O
and	O
blood	O
transufsion	O
or	O
other	O
threapies	O
were	O
not	O
necessary	O
in	O
a	O
follow	O
-	O
up	O
peroid	O
of	O
more	O
than	O
2	O
yaers	O
.	O

Use	O
of	O
anttihymocyte	B-Chemical
globluin	I-Chemical
may	O
be	O
the	O
optmial	O
treatmnet	O
of	O
D	B-Chemical
-	I-Chemical
penciillamine	I-Chemical
-	O
indcued	O
aplatsic	O
anmeia	O
.	O

Metmaizol	B-Chemical
potentiaets	O
morphnie	B-Chemical
atninociception	O
but	O
not	O
constipaiton	O
after	O
chrnoic	O
traetment	O
.	O

This	O
work	O
eavluates	O
the	O
anitnociceptive	O
and	O
constpiating	O
efefcts	O
of	O
the	O
cobmination	O
of	O
3	O
.	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
mrophine	B-Chemical
with	O
177	O
.	O
8	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
metamiozl	B-Chemical
in	O
acutely	O
and	O
chroincally	O
traeted	O
(	O
once	O
a	O
day	O
for	O
12	O
dyas	O
)	O
rtas	O
.	O

On	O
the	O
13th	O
day	O
,	O
anitnociceptive	O
effetcs	O
were	O
assessed	O
using	O
a	O
mdoel	O
of	O
inflamamtory	O
nocicetpion	O
,	O
pian	O
-	O
induecd	O
functioanl	O
ipmairment	O
moedl	O
,	O
and	O
the	O
chacroal	B-Chemical
mael	O
tset	O
was	O
used	O
to	O
evlauate	O
the	O
intsetinal	O
trasnit	O
.	O

Siumltaneous	O
admniistration	O
of	O
morhpine	B-Chemical
with	O
metamziol	B-Chemical
resulted	O
in	O
a	O
markedly	O
antionciceptive	O
potentitaion	O
and	O
an	O
increasnig	O
of	O
the	O
durtaion	O
of	O
aciton	O
after	O
a	O
single	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
139	O
+	O
/	O
-	O
36	O
units	O
aera	O
(	O
ua	O
)	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
repetaed	O
adminsitration	O
(	O
280	O
+	O
/	O
-	O
17	O
vs	O
.	O
131	O
+	O
/	O
-	O
22	O
ua	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Antinociceptvie	O
efefct	O
of	O
moprhine	B-Chemical
was	O
rdeuced	O
in	O
crhonically	O
traeted	O
rtas	O
(	O
39	O
+	O
/	O
-	O
10	O
vs	O
.	O
18	O
+	O
/	O
-	O
5	O
au	O
)	O
while	O
the	O
combintaion	O
-	O
indcued	O
antinocicpetion	O
was	O
remained	O
similar	O
as	O
an	O
aucte	O
tretament	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
280	O
+	O
/	O
-	O
17	O
au	O
)	O
.	O

Aucte	O
antinociecptive	O
effects	O
of	O
the	O
cmobination	O
were	O
partially	O
prevented	O
by	O
3	O
.	O
2	O
mg	O
/	O
kg	O
nalxoone	B-Chemical
s	O
.	O
c	O
.	O

(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
suggesting	O
the	O
parital	O
involevment	O
of	O
the	O
opioiderigc	O
ssytem	O
in	O
the	O
synregism	O
observed	O
.	O

In	O
indepnedent	O
gruops	O
,	O
morpihne	B-Chemical
ihnibited	O
the	O
intetsinal	O
trnasit	O
in	O
48	O
+	O
/	O
-	O
4	O
%	O
and	O
38	O
+	O
/	O
-	O
4	O
%	O
after	O
actue	O
and	O
chrnoic	O
traetment	O
,	O
respectively	O
,	O
suggesting	O
that	O
tolernace	O
did	O
not	O
develop	O
to	O
the	O
cosntipating	O
efefcts	O
.	O

The	O
cobmination	O
inhbiited	O
intestianl	O
trnasit	O
similar	O
to	O
that	O
produced	O
by	O
morhpine	B-Chemical
regardless	O
of	O
the	O
tmie	O
of	O
teratment	O
,	O
suggesting	O
that	O
metaimzol	B-Chemical
did	O
not	O
potenitate	O
moprhine	B-Chemical
-	O
idnuced	O
contsipation	O
.	O

These	O
fnidings	O
show	O
a	O
significant	O
intearction	O
between	O
morpihne	B-Chemical
and	O
meatmizol	B-Chemical
in	O
crhonically	O
treaetd	O
rtas	O
,	O
suggesting	O
that	O
this	O
comibnation	O
could	O
be	O
useful	O
for	O
the	O
traetment	O
of	O
chrnoic	O
pian	O
.	O

Ifosafmide	B-Chemical
encephaloapthy	O
presenitng	O
with	O
asteirxis	O
.	O

CNS	O
txoic	O
effects	O
of	O
the	O
antinoeplastic	O
aegnt	O
ifofsamide	B-Chemical
(	O
IFX	B-Chemical
)	O
are	O
ferquent	O
and	O
include	O
a	O
variety	O
of	O
neuroloigcal	O
sympotms	O
that	O
can	O
liimt	O
durg	O
use	O
.	O

We	O
rpeort	O
a	O
csae	O
of	O
a	O
51	O
-	O
yaer	O
-	O
old	O
man	O
who	O
developed	O
sevree	O
,	O
disbaling	O
neagtive	O
myocolnus	O
of	O
the	O
upper	O
and	O
loewr	O
extreimties	O
after	O
the	O
infuison	O
of	O
ifosfamdie	B-Chemical
for	O
palsmacytoma	O
.	O

He	O
was	O
awkae	O
,	O
revaeled	O
no	O
chanegs	O
of	O
menatl	O
sttaus	O
and	O
at	O
rest	O
there	O
were	O
no	O
further	O
mtoor	O
symptmos	O
.	O

Carnial	O
magnteic	O
rseonance	O
iamging	O
and	O
extenisve	O
laobratory	O
stduies	O
failed	O
to	O
reveal	O
strucutral	O
lesinos	O
of	O
the	O
brian	O
and	O
mteabolic	O
abnormlaities	O
.	O

An	O
electronecephalogram	O
showed	O
cotninuous	O
,	O
gneeralized	O
irregular	O
slownig	O
with	O
amdixed	O
peroidic	O
triphsaic	O
waevs	O
indicating	O
symptomaitc	O
encpehalopathy	O
.	O

The	O
adminsitration	O
of	O
iofsfamide	B-Chemical
was	O
disocntinued	O
and	O
within	O
12	O
h	O
the	O
asetrixis	O
resolved	O
completely	O
.	O

In	O
the	O
paitent	O
described	O
,	O
the	O
presecne	O
of	O
atserixis	O
during	O
ifnusion	O
of	O
ifofsamide	B-Chemical
,	O
noraml	O
labroatory	O
findnigs	O
and	O
iamging	O
stduies	O
and	O
the	O
rseolution	O
of	O
symtpoms	O
following	O
the	O
discontniuation	O
of	O
the	O
durg	O
suggest	O
that	O
negaitve	O
myoclnous	O
is	O
associated	O
with	O
the	O
use	O
of	O
IFX	B-Chemical
.	O

Antagoinsm	O
between	O
itnerleukin	O
3	O
and	O
eryhtropoietin	O
in	O
mcie	O
with	O
azidothymiidne	B-Chemical
-	O
indcued	O
anmeia	O
and	O
in	O
bnoe	O
marorw	O
ednothelial	O
clels	O
.	O

Aizdothymidine	B-Chemical
(	O
AZT	B-Chemical
)	O
-	O
induecd	O
aneima	O
in	O
mcie	O
can	O
be	O
revresed	O
by	O
the	O
administrtaion	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
(	O
fuison	O
protien	O
of	O
inuslin	O
-	O
like	O
grwoth	O
fcator	O
II	O
(	O
IGF	O
II	O
)	O
and	O
intelreukin	O
3	O
)	O
.	O

Although	O
interleuikn	O
3	O
(	O
IL	O
-	O
3	O
)	O
and	O
erythropoeitin	O
(	O
EPO	O
)	O
are	O
known	O
to	O
act	O
synergisticlaly	O
on	O
heamtopoietic	O
clel	O
prolifertaion	O
in	O
vitro	O
,	O
injeciton	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
in	O
AZT	B-Chemical
-	O
traeted	O
mcie	O
resulted	O
in	O
a	O
reductoin	O
of	O
red	O
cells	O
and	O
an	O
incresae	O
of	O
plsama	O
EPO	O
leevls	O
as	O
cmopared	O
to	O
aniamls	O
traeted	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
or	O
EPO	O
alone	O
.	O

We	O
tseted	O
the	O
hyptohesis	O
that	O
the	O
antaognistic	O
effect	O
of	O
IL	O
-	O
3	O
and	O
EPO	O
on	O
ertyhroid	O
cells	O
may	O
be	O
mediated	O
by	O
endohtelial	O
clels	O
.	O

Bovnie	O
lievr	O
erythorid	O
clels	O
were	O
clutured	O
on	O
moonlayers	O
of	O
hmuan	O
bnoe	O
mrarow	O
endohtelial	O
clels	O
previously	O
treaetd	O
with	O
EPO	O
and	O
IGF	O
-	O
IL	O
-	O
3	O
.	O

There	O
was	O
a	O
significant	O
rdeuction	O
of	O
thymidnie	B-Chemical
incoropration	O
into	O
both	O
eyrthroid	O
and	O
endotheilal	O
clels	O
in	O
clutures	O
pre	O
-	O
terated	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
.	O

Endtohelial	O
clel	O
culutre	O
supenratants	O
spearated	O
by	O
ultarfiltration	O
and	O
ultracentrifguation	O
from	O
clels	O
traeted	O
with	O
EPO	O
and	O
IL	O
-	O
3	O
significantly	O
rdeuced	O
thymiidne	B-Chemical
incorporatoin	O
into	O
erythriod	O
cells	O
as	O
compaerd	O
to	O
iedntical	O
fratcions	O
obtained	O
from	O
the	O
mdeia	O
of	O
clels	O
cultuerd	O
with	O
EPO	O
alone	O
.	O

These	O
resluts	O
suggest	O
that	O
enodthelial	O
cells	O
traeted	O
simutlaneously	O
with	O
EPO	O
and	O
IL	O
-	O
3	O
have	O
a	O
negaitve	O
effcet	O
on	O
erythorid	O
clel	O
prodcution	O
.	O

The	O
relationhsip	O
between	O
hippocamapl	O
aceytlcholine	B-Chemical
relesae	O
and	O
cholinregic	O
conuvlsant	O
snesitivity	O
in	O
witdhrawal	O
seziure	O
-	O
prone	O
and	O
wtihdrawal	O
seiuzre	O
-	O
rseistant	O
selected	O
muose	O
liens	O
.	O

BACGKROUND	O
:	O
The	O
speto	O
-	O
hpipocampal	O
cohlinergic	O
patwhay	O
has	O
been	O
implicated	O
in	O
eipleptogenesis	O
,	O
and	O
geneitc	O
fatcors	O
influecne	O
the	O
resposne	O
to	O
cholinerigc	O
agnets	O
,	O
but	O
lmiited	O
dtaa	O
are	O
available	O
on	O
chloinergic	O
invlovement	O
in	O
alochol	B-Chemical
withdraawl	O
sevreity	O
.	O

Thus	O
,	O
the	O
realtionship	O
between	O
chloinergic	O
actviity	O
and	O
resposniveness	O
and	O
aclohol	B-Chemical
wihtdrawal	O
was	O
inevstigated	O
in	O
a	O
gneetic	O
ainmal	O
moedl	O
of	O
ethaonl	B-Chemical
witdhrawal	O
severtiy	O
.	O

METHODS	O
:	O
Choilnergic	O
convulsnat	O
sensiitvity	O
was	O
examined	O
in	O
alochol	B-Chemical
-	O
na	O
ve	O
Wtihdrawal	O
Seiuzre	O
-	O
Prnoe	O
(	O
WSP	O
)	O
and	O
-	O
Resistnat	O
(	O
WSR	O
)	O
mcie	O
.	O

Ainmals	O
were	O
adminitsered	O
nciotine	B-Chemical
,	O
carbacohl	B-Chemical
,	O
or	O
noestigmine	B-Chemical
via	O
tmied	O
tial	O
vien	O
infsuion	O
,	O
and	O
the	O
ltaencies	O
to	O
onset	O
of	O
termor	O
and	O
clouns	O
were	O
recorded	O
and	O
converted	O
to	O
thresohld	O
dsoe	O
.	O

We	O
also	O
used	O
micrdoialysis	O
to	O
maesure	O
baasl	O
and	O
potsasium	B-Chemical
-	O
stimultaed	O
acetlycholine	B-Chemical
(	O
ACh	B-Chemical
)	O
relesae	O
in	O
the	O
CA1	O
regoin	O
of	O
the	O
hippcoampus	O
.	O

Potsasium	B-Chemical
was	O
applied	O
by	O
revrese	O
dailysis	O
twice	O
,	O
sepraated	O
by	O
75	O
min	O
.	O

Hpipocampal	O
ACh	B-Chemical
also	O
was	O
mesaured	O
during	O
testnig	O
for	O
hadnling	O
-	O
induecd	O
convuslions	O
.	O

RESLUTS	O
:	O
Sesnitivity	O
to	O
several	O
convuslion	O
ednpoints	O
induecd	O
by	O
nioctine	B-Chemical
,	O
carbcahol	B-Chemical
,	O
and	O
neostigmnie	B-Chemical
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
mcie	O
.	O

In	O
mircodialysis	O
expreiments	O
,	O
the	O
liens	O
did	O
not	O
differ	O
in	O
bsaal	O
rleease	O
of	O
ACh	B-Chemical
,	O
and	O
50	O
mM	O
KCl	B-Chemical
incerased	O
ACh	B-Chemical
ouptut	O
in	O
both	O
lnies	O
of	O
mcie	O
.	O

However	O
,	O
the	O
inrcease	O
in	O
relaese	O
of	O
ACh	B-Chemical
produced	O
by	O
the	O
first	O
applciation	O
of	O
KCl	B-Chemical
was	O
2	O
-	O
fold	O
higehr	O
in	O
WSP	O
versus	O
WSR	O
mcie	O
.	O

When	O
hippocmapal	O
ACh	B-Chemical
was	O
mesaured	O
during	O
testnig	O
for	O
hnadling	O
-	O
inudced	O
convulisons	O
,	O
extracelullar	O
ACh	B-Chemical
was	O
significantly	O
eleavted	O
(	O
192	O
%	O
)	O
in	O
WSP	O
mcie	O
,	O
but	O
was	O
nonsigniifcantly	O
eelvated	O
(	O
59	O
%	O
)	O
in	O
WSR	O
mcie	O
.	O

CONCLUSINOS	O
:	O
These	O
reuslts	O
suggest	O
that	O
diffreences	O
in	O
cholinegric	O
atcivity	O
and	O
potssynaptic	O
sensitviity	O
to	O
cholniergic	O
conuvlsants	O
may	O
be	O
associated	O
with	O
etahnol	B-Chemical
witdhrawal	O
seevrity	O
and	O
implicate	O
chloinergic	O
mehcanisms	O
in	O
alochol	B-Chemical
wtihdrawal	O
.	O

Specifically	O
,	O
WSP	O
mcie	O
may	O
have	O
loewr	O
sesnitivity	O
to	O
cholniergic	O
convulasnts	O
copmared	O
with	O
WSR	O
because	O
of	O
postsyanptic	O
recepotr	O
desesnitization	O
brought	O
on	O
by	O
higehr	O
atcivity	O
of	O
cholienrgic	O
neuorns	O
.	O

Caspaicin	B-Chemical
-	O
idnuced	O
muslce	O
pian	O
aletrs	O
the	O
excitabiilty	O
of	O
the	O
hmuan	O
jaw	O
-	O
srtetch	O
rfelex	O
.	O

The	O
pathophysiloogy	O
of	O
pianful	O
temporomandbiular	O
disodrers	O
is	O
not	O
fully	O
understood	O
,	O
but	O
evidnece	O
suggests	O
that	O
mucsle	O
pian	O
mdoulates	O
mootr	O
functoin	O
in	O
cahracteristic	O
ways	O
.	O

This	O
sutdy	O
tetsed	O
the	O
hypotehsis	O
that	O
actviation	O
of	O
nociecptive	O
msucle	O
afferent	O
fibres	O
would	O
be	O
linked	O
to	O
an	O
icnreased	O
exictability	O
of	O
the	O
hmuan	O
jaw	O
-	O
stertch	O
relfex	O
and	O
whether	O
this	O
prcoess	O
would	O
be	O
sesnitive	O
to	O
lentgh	O
and	O
veloicty	O
of	O
the	O
srtetch	O
.	O

Capasicin	B-Chemical
(	O
10	O
mirco	O
g	O
)	O
was	O
inejcted	O
into	O
the	O
masester	O
msucle	O
to	O
inudce	O
pian	O
in	O
11	O
healhty	O
volnuteers	O
.	O

Shrot	O
-	O
ltaency	O
refelx	O
responess	O
were	O
evoekd	O
in	O
the	O
masseter	O
and	O
tempoarlis	O
mucsles	O
by	O
a	O
strecth	O
deivce	O
with	O
different	O
vleocities	O
and	O
dispalcements	O
before	O
,	O
during	O
,	O
and	O
after	O
the	O
pian	O
.	O

The	O
normalized	O
relfex	O
amplitdue	O
icnreased	O
with	O
an	O
incraese	O
in	O
veolcity	O
at	O
a	O
given	O
dsiplacement	O
,	O
but	O
remained	O
contsant	O
with	O
different	O
displacmeents	O
at	O
a	O
given	O
veolcity	O
.	O

The	O
normalized	O
refelx	O
ampliutde	O
was	O
significantly	O
hgiher	O
during	O
pian	O
,	O
but	O
only	O
at	O
faster	O
strecthes	O
in	O
the	O
paniful	O
muslce	O
.	O

Icnreased	O
sesnitivity	O
of	O
the	O
fusimootr	O
ssytem	O
during	O
actue	O
msucle	O
pian	O
could	O
be	O
one	O
likely	O
mehcanism	O
to	O
explain	O
the	O
finidngs	O
.	O

Effcets	O
of	O
5	O
-	O
H1TB	O
recepotr	O
lgiands	O
mircoinjected	O
into	O
the	O
accmubal	O
sehll	O
or	O
croe	O
on	O
the	O
cocanie	B-Chemical
-	O
induecd	O
locomootr	O
hyperactivtiy	O
in	O
rtas	O
.	O

The	O
present	O
stduy	O
was	O
designed	O
to	O
examine	O
the	O
effect	O
of	O
5	O
-	O
H1TB	O
recepotr	O
ligadns	O
microijnected	O
into	O
the	O
surbegions	O
of	O
the	O
nuclues	O
acucmbens	O
(	O
the	O
shlel	O
and	O
the	O
croe	O
)	O
on	O
the	O
loocmotor	O
hyperacitvity	O
induecd	O
by	O
cociane	B-Chemical
in	O
rtas	O
.	O

Mlae	O
Witsar	O
rtas	O
were	O
imlpanted	O
bilaetrally	O
with	O
cnanulae	O
into	O
the	O
acucmbens	O
shlel	O
or	O
croe	O
,	O
and	O
then	O
were	O
loaclly	O
inejcted	O
with	O
GR	B-Chemical
55562	I-Chemical
(	O
an	O
antaognist	O
of	O
5	O
-	O
H1TB	O
rceeptors	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
an	O
aognist	O
of	O
5	O
-	O
H1TB	O
reecptors	O
)	O
.	O

Given	O
alone	O
to	O
any	O
accubmal	O
subergion	O
,	O
GR	B-Chemical
55562	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
mircog	O
/	O
side	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
mcirog	O
/	O
side	O
)	O
did	O
not	O
change	O
bsaal	O
lcoomotor	O
acitvity	O
.	O

Sysetmic	O
cocanie	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
significantly	O
incerased	O
the	O
lcoomotor	O
atcivity	O
of	O
rtas	O
.	O

GR	B-Chemical
55562	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
mircog	O
/	O
side	O
)	O
,	O
adminitsered	O
itnra	O
-	O
acucmbens	O
sehll	O
prior	O
to	O
ccoaine	B-Chemical
,	O
dsoe	O
-	O
dependently	O
atetnuated	O
the	O
psychositmulant	O
-	O
induecd	O
loocmotor	O
hpyeractivity	O
.	O

Such	O
attenutaion	O
was	O
not	O
found	O
in	O
animlas	O
which	O
had	O
been	O
injetced	O
with	O
GR	B-Chemical
55562	I-Chemical
into	O
the	O
accubmens	O
croe	O
.	O

When	O
inejcted	O
into	O
the	O
accumbens	O
shlel	O
(	O
but	O
not	O
the	O
croe	O
)	O
before	O
cocanie	B-Chemical
,	O
CP	B-Chemical
93129	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
micorg	O
/	O
side	O
)	O
ehnanced	O
the	O
locomtoor	O
resopnse	O
to	O
cocanie	B-Chemical
;	O
the	O
maixmum	O
effect	O
being	O
observed	O
after	O
10	O
mircog	O
/	O
side	O
of	O
the	O
aognist	O
.	O

The	O
later	O
enhanceemnt	O
was	O
attenutaed	O
after	O
inrta	O
-	O
accubmens	O
sehll	O
treatemnt	O
with	O
GR	B-Chemical
55562	I-Chemical
(	O
1	O
mcirog	O
/	O
side	O
)	O
.	O

Our	O
finidngs	O
indicate	O
that	O
coacine	B-Chemical
induecd	O
hyperlocmootion	O
is	O
moidfied	O
by	O
5	O
-	O
H1TB	O
recepotr	O
ligadns	O
microinjceted	O
into	O
the	O
accumbens	O
sehll	O
,	O
but	O
not	O
croe	O
,	O
this	O
moidfication	O
consisting	O
in	O
ihnibitory	O
and	O
facilitatroy	O
effetcs	O
of	O
the	O
5	O
-	O
H1TB	O
rceeptor	O
antagonsit	O
(	O
GR	B-Chemical
55562	I-Chemical
)	O
and	O
agonsit	O
(	O
CP	B-Chemical
93129	I-Chemical
)	O
,	O
respectively	O
.	O

In	O
other	O
wrods	O
,	O
the	O
present	O
resutls	O
suggest	O
that	O
the	O
accubmal	O
shlel	O
5	O
-	O
H1TB	O
receptros	O
play	O
a	O
perimssive	O
role	O
in	O
the	O
bheavioural	O
resposne	O
to	O
the	O
pscyhostimulant	O
.	O

Ccoaine	B-Chemical
related	O
chset	O
pian	O
:	O
are	O
we	O
seeing	O
the	O
tip	O
of	O
an	O
iceberg	O
?	O

The	O
rcereational	O
use	O
of	O
cociane	B-Chemical
is	O
on	O
the	O
incerase	O
.	O

The	O
emergecny	O
nruse	O
ought	O
to	O
be	O
familiar	O
with	O
some	O
of	O
the	O
cardiovascualr	O
cosnequences	O
of	O
cociane	B-Chemical
use	O
.	O

In	O
particular	O
,	O
the	O
tendency	O
of	O
cocanie	B-Chemical
to	O
produce	O
cehst	O
pian	O
ought	O
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emeregncy	O
nruse	O
when	O
faced	O
with	O
a	O
yonug	O
vitcim	O
of	O
chset	O
pian	O
who	O
is	O
otherwise	O
at	O
low	O
rsik	O
.	O

The	O
mcehanism	O
of	O
cehst	O
pian	O
related	O
to	O
ccoaine	B-Chemical
use	O
is	O
discussed	O
and	O
tretament	O
dliemmas	O
are	O
discussed	O
.	O

Finally	O
,	O
moarl	O
isseus	O
relating	O
to	O
the	O
tesitng	O
of	O
ptoential	O
cocanie	B-Chemical
usres	O
will	O
be	O
addressed	O
.	O

Crossoevr	O
cmoparison	O
of	O
efifcacy	O
and	O
preefrence	O
for	O
rizatritpan	B-Chemical
10	O
mg	O
versus	O
egrotamine	B-Chemical
/	O
caffeine	B-Chemical
in	O
mgiraine	O
.	O

Rizatirptan	B-Chemical
is	O
a	O
selective	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
1B	O
/	O
1D	O
)	O
recepotr	O
agonsit	O
with	O
raipd	O
oarl	O
absortpion	O
and	O
eraly	O
onset	O
of	O
atcion	O
in	O
the	O
aucte	O
treatemnt	O
of	O
migriane	O
.	O

This	O
randoimzed	O
double	O
-	O
blnid	O
crososver	O
outaptient	O
sutdy	O
assessed	O
the	O
prefeernce	O
for	O
1	O
rziatriptan	B-Chemical
10	O
mg	O
tabelt	O
to	O
2	O
egrotamine	B-Chemical
1	O
mg	O
/	O
caffiene	B-Chemical
100	O
mg	O
tbalets	O
in	O
439	O
paitents	O
treaitng	O
a	O
single	O
mgiraine	O
attack	O
with	O
each	O
therpay	O
.	O

Of	O
paitents	O
exrpessing	O
a	O
prefreence	O
(	O
89	O
.	O
1	O
%	O
)	O
,	O
more	O
than	O
twice	O
as	O
many	O
preferred	O
rizatripatn	B-Chemical
to	O
ergtoamine	B-Chemical
/	O
cfafeine	B-Chemical
(	O
69	O
.	O
9	O
vs	O
.	O
30	O
.	O
1	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Fsater	O
reilef	O
of	O
heaadche	O
was	O
the	O
most	O
important	O
reason	O
for	O
perference	O
,	O
cited	O
by	O
67	O
.	O
3	O
%	O
of	O
pateints	O
preferring	O
riaztriptan	B-Chemical
and	O
54	O
.	O
2	O
%	O
of	O
ptaients	O
who	O
preferred	O
ergotamnie	B-Chemical
/	O
cafefine	B-Chemical
.	O

The	O
co	O
-	O
pirmary	O
enpdoint	O
of	O
being	O
pian	O
free	O
at	O
2	O
h	O
was	O
also	O
in	O
favor	O
of	O
rziatriptan	B-Chemical
.	O

Forty	O
-	O
nine	O
percent	O
of	O
pateints	O
were	O
pian	O
free	O
2	O
h	O
after	O
rizartiptan	B-Chemical
,	O
compraed	O
with	O
24	O
.	O
3	O
%	O
treaetd	O
with	O
ergotamnie	B-Chemical
/	O
caffenie	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
rziatriptan	B-Chemical
being	O
superior	O
within	O
1	O
h	O
of	O
treamtent	O
.	O

Headcahe	O
releif	O
at	O
2	O
h	O
was	O
75	O
.	O
9	O
%	O
for	O
riaztriptan	B-Chemical
and	O
47	O
.	O
3	O
%	O
for	O
ergotaimne	B-Chemical
/	O
caffeine	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
with	O
rizatirptan	B-Chemical
being	O
superior	O
to	O
egrotamine	B-Chemical
/	O
cafefine	B-Chemical
within	O
30	O
min	O
of	O
dsoing	O
.	O

Almost	O
36	O
%	O
of	O
patinets	O
taking	O
riztariptan	B-Chemical
were	O
pian	O
free	O
at	O
2	O
h	O
and	O
had	O
no	O
reucrrence	O
or	O
need	O
for	O
additional	O
mediaction	O
within	O
24	O
h	O
,	O
compraed	O
to	O
20	O
%	O
of	O
paitents	O
on	O
erogtamine	B-Chemical
/	O
cfafeine	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rizatritpan	B-Chemical
was	O
also	O
superior	O
to	O
erogtamine	B-Chemical
/	O
cafefine	B-Chemical
in	O
the	O
proprotions	O
of	O
pateints	O
with	O
no	O
nuasea	O
,	O
vomiitng	O
,	O
pohnophobia	O
or	O
phtoophobia	O
and	O
for	O
patietns	O
with	O
noraml	O
functoin	O
2	O
h	O
after	O
durg	O
inatke	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

More	O
patinets	O
were	O
(	O
completely	O
,	O
very	O
or	O
somewhat	O
)	O
staisfied	O
2	O
h	O
after	O
treamtent	O
with	O
riztariptan	B-Chemical
(	O
69	O
.	O
8	O
%	O
)	O
than	O
at	O
2	O
h	O
after	O
teratment	O
with	O
ergotamnie	B-Chemical
/	O
cfafeine	B-Chemical
(	O
38	O
.	O
6	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Recurernce	O
raets	O
were	O
31	O
.	O
4	O
%	O
with	O
rizatrpitan	B-Chemical
and	O
15	O
.	O
3	O
%	O
with	O
ergoatmine	B-Chemical
/	O
cafefine	B-Chemical
.	O

Both	O
atcive	O
treatmetns	O
were	O
well	O
tolreated	O
.	O

The	O
most	O
common	O
adevrse	O
eevnts	O
(	O
incdience	O
>	O
or	O
=	O
5	O
%	O
in	O
one	O
gruop	O
)	O
after	O
rizartiptan	B-Chemical
and	O
ergotaimne	B-Chemical
/	O
caffenie	B-Chemical
,	O
respectively	O
,	O
were	O
dizizness	O
(	O
6	O
.	O
7	O
and	O
5	O
.	O
3	O
%	O
)	O
,	O
nauesa	O
(	O
4	O
.	O
2	O
and	O
8	O
.	O
5	O
%	O
)	O
and	O
somnolecne	O
(	O
5	O
.	O
5	O
and	O
2	O
.	O
3	O
%	O
)	O
.	O

Sevree	O
ocluar	O
and	O
orbtial	O
toixcity	O
after	O
itnracarotid	O
ijnection	O
of	O
carbpolatin	B-Chemical
for	O
rceurrent	O
glibolastomas	O
.	O

BACKRGOUND	O
:	O
Giloblastoma	O
is	O
a	O
malingant	O
tmuor	O
that	O
occurs	O
in	O
the	O
cererbum	O
during	O
adulthood	O
.	O

With	O
current	O
teratment	O
regiemns	O
including	O
combiend	O
sugrery	O
,	O
radiatoin	O
and	O
cheomtherapy	O
,	O
the	O
avearge	O
lfie	O
expecatncy	O
of	O
the	O
patinets	O
is	O
lmiited	O
to	O
approximately	O
1	O
yaer	O
.	O

Therefore	O
,	O
paitents	O
with	O
glioblastmoa	O
sometimes	O
have	O
intracartoid	O
ijnection	O
of	O
carcinosttaics	O
added	O
to	O
the	O
treatemnt	O
rgeimen	O
.	O

Generally	O
,	O
carbpolatin	B-Chemical
is	O
said	O
to	O
have	O
milder	O
side	O
effcets	O
than	O
cispaltin	B-Chemical
,	O
whose	O
ouclar	O
and	O
orbiatl	O
txoicity	O
are	O
well	O
known	O
.	O

However	O
,	O
we	O
experienced	O
a	O
csae	O
of	O
seevre	O
ocluar	O
and	O
orbtial	O
toixcity	O
after	O
inrtacarotid	O
ijnection	O
of	O
carobplatin	B-Chemical
,	O
which	O
is	O
infrequently	O
reported	O
.	O

CSAE	O
:	O
A	O
58	O
-	O
yaer	O
-	O
old	O
man	O
received	O
an	O
intracartoid	O
injectoin	O
of	O
carobplatin	B-Chemical
for	O
rceurrent	O
glioblatsomas	O
in	O
his	O
lfet	O
tempoarl	O
lboe	O
.	O

He	O
complained	O
of	O
pian	O
and	O
viusal	O
ditsurbance	O
in	O
the	O
ipsilatreal	O
eye	O
30	O
h	O
after	O
the	O
inejction	O
.	O

Various	O
ocualr	O
sympotms	O
and	O
findnigs	O
caused	O
by	O
carboplaitn	B-Chemical
toxictiy	O
were	O
seen	O
.	O

REUSLTS	O
:	O
He	O
was	O
terated	O
with	O
intravenuos	O
adimnistration	O
of	O
cotricosteroids	O
and	O
glcyerin	B-Chemical
for	O
6	O
dyas	O
after	O
the	O
inejction	O
.	O

Although	O
the	O
intraouclar	O
presusre	O
elevaiton	O
caused	O
by	O
secondary	O
aucte	O
agnle	O
-	O
clousre	O
glauocma	O
decerased	O
and	O
ouclar	O
pian	O
diminished	O
,	O
inexoralbe	O
papliledema	O
and	O
exuadtive	O
retianl	O
dteachment	O
continued	O
for	O
3	O
weeks	O
.	O

Finally	O
,	O
6	O
wekes	O
later	O
,	O
diffuse	O
chorioreitnal	O
atrpohy	O
with	O
otpic	O
atorphy	O
occurred	O
and	O
the	O
vsiion	O
in	O
his	O
lfet	O
eye	O
was	O
lsot	O
.	O

COCNLUSION	O
:	O
When	O
performing	O
intracraotid	O
ijnection	O
of	O
cabroplatin	B-Chemical
,	O
we	O
must	O
be	O
aware	O
of	O
its	O
potentially	O
blidning	O
ouclar	O
toxictiy	O
.	O

It	O
is	O
recmomended	O
that	O
further	O
sutdies	O
and	O
investigatoins	O
are	O
undertaken	O
in	O
the	O
effrot	O
to	O
minimize	O
such	O
sveere	O
side	O
efefcts	O
.	O

Viusal	O
hallucinatinos	O
associated	O
with	O
zoniasmide	B-Chemical
.	O

Zonisamdie	B-Chemical
is	O
a	O
broad	O
-	O
specturm	O
antiepilepitc	O
durg	O
used	O
to	O
terat	O
various	O
types	O
of	O
seiuzres	O
.	O

Although	O
viusal	O
hallucinations	O
have	O
not	O
been	O
reported	O
as	O
an	O
avderse	O
effcet	O
of	O
this	O
aegnt	O
,	O
we	O
describe	O
three	O
pateints	O
who	O
experienced	O
compelx	O
vsiual	O
hallucinatoins	O
and	O
atlered	O
metnal	O
sttaus	O
after	O
zoniasmide	B-Chemical
tretament	O
was	O
begun	O
or	O
its	O
dosgae	O
incresaed	O
.	O

All	O
three	O
had	O
been	O
diagnoesd	O
earlier	O
with	O
epielpsy	O
,	O
and	O
their	O
electroencephalgoram	O
(	O
EEG	O
)	O
findnigs	O
were	O
abnromal	O
.	O

During	O
monitoirng	O
,	O
viusal	O
halulcinations	O
did	O
not	O
corrleate	O
with	O
EEG	O
readnigs	O
,	O
nor	O
did	O
vdieo	O
recroding	O
catpure	O
any	O
of	O
the	O
described	O
eevnts	O
.	O

None	O
of	O
the	O
pateints	O
had	O
experienced	O
visaul	O
hallcuinations	O
before	O
this	O
evnet	O
.	O

The	O
only	O
recent	O
change	O
in	O
their	O
tretament	O
was	O
the	O
introdutcion	O
or	O
incerased	O
dsoage	O
of	O
zonsiamide	B-Chemical
.	O

With	O
either	O
discontinaution	O
or	O
derceased	O
dsoage	O
of	O
the	O
durg	O
the	O
sypmtoms	O
disappeared	O
and	O
did	O
not	O
recur	O
.	O

Further	O
obsrevations	O
and	O
reoprts	O
will	O
help	O
clarify	O
this	O
adevrse	O
efefct	O
.	O

Until	O
then	O
,	O
cliincians	O
need	O
to	O
be	O
aware	O
of	O
this	O
possible	O
complictaion	O
associated	O
with	O
zonsiamide	B-Chemical
.	O

Atni	O
-	O
epiletpic	O
drgus	O
-	O
inudced	O
de	O
novo	O
abesnce	O
seziures	O
.	O

The	O
auhtors	O
present	O
three	O
paitents	O
with	O
de	O
novo	O
asbence	O
eiplepsy	O
after	O
administartion	O
of	O
carbamzaepine	B-Chemical
and	O
vigabatirn	B-Chemical
.	O

Despite	O
the	O
underlying	O
dsieases	O
,	O
the	O
prognsois	O
for	O
durg	O
-	O
idnuced	O
de	O
novo	O
absecne	O
seizrue	O
is	O
good	O
because	O
it	O
subsides	O
rapidly	O
after	O
disocntinuing	O
the	O
use	O
of	O
the	O
offenidng	O
drgus	O
.	O

The	O
gamma	B-Chemical
-	I-Chemical
aminboutyric	I-Chemical
aicd	I-Chemical
-	O
tarnsmitted	O
tahlamocortical	O
circuirty	O
accounts	O
for	O
a	O
major	O
part	O
of	O
the	O
underlying	O
neurpohysiology	O
of	O
the	O
absnece	O
eiplepsy	O
.	O

Because	O
durg	O
-	O
indcued	O
de	O
novo	O
absecne	O
seziure	O
is	O
rrae	O
,	O
pro	O
-	O
absnece	O
durgs	O
can	O
only	O
be	O
considered	O
a	O
promoting	O
fcator	O
.	O

The	O
underlying	O
epileptgoenecity	O
of	O
the	O
patinets	O
or	O
the	O
synerigstic	O
efefcts	O
of	O
the	O
accompanying	O
drgus	O
is	O
required	O
to	O
trgiger	O
the	O
de	O
novo	O
absnece	O
seziure	O
.	O

The	O
possibility	O
of	O
durg	O
-	O
indcued	O
aggravatoin	O
should	O
be	O
considered	O
whenever	O
an	O
unexpected	O
incraese	O
in	O
seiuzre	O
frqeuency	O
and	O
/	O
or	O
new	O
seziure	O
types	O
appear	O
following	O
a	O
change	O
in	O
durg	O
tretament	O
.	O

By	O
understanding	O
the	O
underlying	O
mechansim	O
of	O
absecne	O
epielpsy	O
,	O
we	O
can	O
avoid	O
the	O
inaprpopriate	O
use	O
of	O
anticonvulasnts	O
in	O
cihldren	O
with	O
eiplepsy	O
and	O
prevnet	O
durg	O
-	O
indcued	O
absecne	O
seziures	O
.	O

Prentaal	O
dexametahsone	B-Chemical
prgorams	O
hypertesnion	O
and	O
reanl	O
inujry	O
in	O
the	O
rat	O
.	O

Dexamehtasone	O
is	O
frequently	O
adminisetred	O
to	O
the	O
developing	O
fteus	O
to	O
accelertae	O
plumonary	O
deevlopment	O
.	O

The	O
purpose	O
of	O
the	O
present	O
sutdy	O
was	O
to	O
determine	O
if	O
prneatal	O
dexamethasnoe	B-Chemical
programmed	O
a	O
progrsesive	O
icnrease	O
in	O
bolod	O
prsesure	O
and	O
rneal	O
inujry	O
in	O
rtas	O
.	O

Prengant	O
rtas	O
were	O
given	O
either	O
vehilce	O
or	O
2	O
daliy	O
intraepritoneal	O
injectoins	O
of	O
deaxmethasone	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
bdoy	O
wieght	O
)	O
on	O
gestatinoal	O
dyas	O
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O

Offsrping	O
of	O
rtas	O
administeerd	O
deaxmethasone	B-Chemical
on	O
dyas	O
15	O
and	O
16	O
getsation	O
had	O
a	O
20	O
%	O
reudction	O
in	O
glomerualr	O
number	O
cmopared	O
with	O
conrtol	O
at	O
6	O
to	O
9	O
mnoths	O
of	O
age	O
(	O
22	O
527	O
+	O
/	O
-	O
509	O
versus	O
28	O
050	O
+	O
/	O
-	O
561	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
which	O
was	O
comparable	O
to	O
the	O
percent	O
redcution	O
in	O
glomreuli	O
measuerd	O
at	O
3	O
weeks	O
of	O
age	O
.	O

Six	O
-	O
to	O
9	O
-	O
motnh	O
old	O
rtas	O
receiving	O
prenaatl	O
dexametahsone	B-Chemical
on	O
dyas	O
17	O
and	O
18	O
of	O
gesttaion	O
had	O
a	O
17	O
%	O
reduciton	O
in	O
glomreuli	O
(	O
23	O
380	O
+	O
/	O
-	O
587	O
)	O
compraed	O
with	O
contorl	O
rtas	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Mlae	O
rtas	O
that	O
received	O
prentaal	O
dexamtehasone	B-Chemical
on	O
dyas	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
gesattion	O
had	O
elevaetd	O
blood	O
perssures	O
at	O
6	O
motnhs	O
of	O
age	O
;	O
the	O
latter	O
gorup	O
did	O
not	O
have	O
a	O
rdeuction	O
in	O
glmoerular	O
number	O
.	O

Audlt	O
rtas	O
given	O
dexamethsaone	B-Chemical
on	O
dyas	O
15	O
and	O
16	O
of	O
gestaiton	O
had	O
more	O
glmoeruli	O
with	O
glomerulosclersois	O
than	O
cnotrol	O
rtas	O
.	O

This	O
stduy	O
shows	O
that	O
preantal	O
dexmaethasone	B-Chemical
in	O
rtas	O
resluts	O
in	O
a	O
redcution	O
in	O
glmoerular	O
number	O
,	O
glomerulsoclerosis	O
,	O
and	O
hyeprtension	O
when	O
administreed	O
at	O
specific	O
points	O
during	O
getsation	O
.	O

Hypetrension	O
was	O
observed	O
in	O
ainmals	O
that	O
had	O
a	O
reductoin	O
in	O
glomreuli	O
as	O
well	O
as	O
in	O
a	O
gruop	O
that	O
did	O
not	O
have	O
a	O
reduciton	O
in	O
glomerluar	O
number	O
,	O
suggesting	O
that	O
a	O
redutcion	O
in	O
gloemrular	O
number	O
is	O
not	O
the	O
sole	O
cause	O
for	O
the	O
develompent	O
of	O
hypertnesion	O
.	O

Kindey	O
functoin	O
and	O
morphoolgy	O
after	O
short	O
-	O
term	O
cobmination	O
tehrapy	O
with	O
cylcosporine	B-Chemical
A	I-Chemical
,	O
tacrolmius	B-Chemical
and	O
sriolimus	B-Chemical
in	O
the	O
rat	O
.	O

BCAKGROUND	O
:	O
Siorlimus	B-Chemical
(	O
SRL	B-Chemical
)	O
may	O
supplement	O
caclineurin	O
inhiibtors	O
in	O
cilnical	O
oragn	O
translpantation	O
.	O

These	O
are	O
nephrotxoic	O
,	O
but	O
SRL	B-Chemical
seems	O
to	O
act	O
differently	O
displaying	O
only	O
minor	O
nephrotxoic	O
efefcts	O
,	O
although	O
this	O
question	O
is	O
still	O
open	O
.	O

In	O
a	O
number	O
of	O
teratment	O
protcools	O
where	O
SRL	B-Chemical
was	O
cmobined	O
with	O
a	O
calcineruin	O
inihbitor	O
indciations	O
of	O
a	O
syenrgistic	O
nehprotoxic	O
efefct	O
were	O
described	O
.	O

The	O
aim	O
of	O
this	O
stduy	O
was	O
to	O
examine	O
further	O
the	O
reanl	O
functoin	O
,	O
including	O
mrophological	O
anaylsis	O
of	O
the	O
kidenys	O
of	O
mlae	O
Spargue	O
-	O
Dalwey	O
rtas	O
traeted	O
with	O
either	O
cyclospornie	B-Chemical
A	I-Chemical
(	O
CsA	B-Chemical
)	O
,	O
tacroilmus	B-Chemical
(	O
F5K06	B-Chemical
)	O
or	O
SRL	B-Chemical
as	O
monotheraipes	O
or	O
in	O
different	O
cmobinations	O
.	O

METHODS	O
:	O
For	O
a	O
peroid	O
of	O
2	O
wekes	O
,	O
CsA	B-Chemical
15	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orlaly	O
)	O
,	O
F5K06	B-Chemical
3	O
.	O
0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orlaly	O
)	O
or	O
SRL	B-Chemical
0	O
.	O
4	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
intrpaeritoneally	O
)	O
was	O
administreed	O
once	O
a	O
day	O
as	O
these	O
doess	O
have	O
earlier	O
been	O
found	O
to	O
achieve	O
a	O
significant	O
immunosuppressvie	O
effcet	O
in	O
Sprauge	O
-	O
Dawely	O
rtas	O
.	O

In	O
the	O
'	O
concsious	O
ctaheterized	O
rat	O
'	O
mdoel	O
,	O
the	O
glmoerular	O
filtrtaion	O
rtae	O
(	O
GFR	O
)	O
was	O
meausred	O
as	O
the	O
celarance	O
of	O
Cr	O
(	O
ETDA	O
)	O
.	O

The	O
morphologiacl	O
anlaysis	O
of	O
the	O
kidnyes	O
included	O
a	O
smei	O
-	O
qunatitative	O
scornig	O
ssytem	O
analysing	O
the	O
degere	O
of	O
strpied	O
fbirosis	O
,	O
subcapuslar	O
fibroiss	O
and	O
the	O
number	O
of	O
basophiilc	O
tuubles	O
,	O
plus	O
an	O
additional	O
setreological	O
analsyis	O
of	O
the	O
total	O
garde	O
of	O
firbosis	O
in	O
the	O
coretx	O
stianed	O
with	O
Siruis	O
Red	O
.	O

RSEULTS	O
:	O
CsA	B-Chemical
,	O
F5K06	B-Chemical
and	O
SRL	B-Chemical
all	O
significantly	O
dcereased	O
the	O
GFR	O
.	O

A	O
further	O
dteerioration	O
was	O
seen	O
when	O
CsA	B-Chemical
was	O
combnied	O
with	O
either	O
FK056	B-Chemical
or	O
SRL	B-Chemical
,	O
whereas	O
the	O
GFR	O
remained	O
unhcanged	O
in	O
the	O
gruop	O
terated	O
with	O
F5K06	B-Chemical
plus	O
SRL	B-Chemical
when	O
compaerd	O
with	O
treatmnet	O
with	O
any	O
of	O
the	O
single	O
substnaces	O
.	O

The	O
morpholgoical	O
cahnges	O
presented	O
a	O
similar	O
ptatern	O
.	O

The	O
smei	O
-	O
quanttiative	O
socring	O
was	O
significantly	O
worst	O
in	O
the	O
gruop	O
treaetd	O
with	O
CsA	B-Chemical
plus	O
SRL	B-Chemical
(	O
P	O
<	O
0	O
.	O
001	O
comapred	O
with	O
cnotrols	O
)	O
and	O
the	O
analsyis	O
of	O
the	O
total	O
grdae	O
of	O
fibroiss	O
also	O
showed	O
the	O
highest	O
prpoortion	O
in	O
the	O
same	O
gorup	O
and	O
was	O
significantly	O
different	O
from	O
conrtols	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

The	O
FK056	B-Chemical
plus	O
SRL	B-Chemical
combniation	O
showed	O
only	O
a	O
marginally	O
hihger	O
degere	O
of	O
fibroiss	O
as	O
comapred	O
with	O
cotnrols	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

CONLCUSION	O
:	O
This	O
rat	O
stduy	O
demonstrated	O
a	O
synegristic	O
nephrootxic	O
effcet	O
of	O
CsA	B-Chemical
plus	O
SRL	B-Chemical
,	O
whereas	O
FK056	B-Chemical
plus	O
SRL	B-Chemical
was	O
better	O
toelrated	O
.	O

Evlauation	O
of	O
cradiac	O
tropoinn	O
I	O
and	O
T	O
levles	O
as	O
mrakers	O
of	O
moycardial	O
damgae	O
in	O
doxorubciin	B-Chemical
-	O
induecd	O
cardoimyopathy	O
rtas	O
,	O
and	O
their	O
reltaionship	O
with	O
echocradiographic	O
and	O
histologcial	O
findnigs	O
.	O

BACKGORUND	O
:	O
Cradiac	O
troponnis	O
I	O
(	O
cnTI	O
)	O
and	O
T	O
(	O
cnTT	O
)	O
have	O
been	O
shown	O
to	O
be	O
highly	O
sensitvie	O
and	O
specific	O
mrakers	O
of	O
moycardial	O
clel	O
injruy	O
.	O

We	O
invetsigated	O
the	O
diganostic	O
value	O
of	O
cnTI	O
and	O
cnTT	O
for	O
the	O
diagnsois	O
of	O
myocaridal	O
daamge	O
in	O
a	O
rat	O
moedl	O
of	O
doxourbicin	B-Chemical
(	O
DOX	B-Chemical
)	O
-	O
indcued	O
cadriomyopathy	O
,	O
and	O
we	O
examined	O
the	O
relationhsip	O
between	O
sreial	O
cnTI	O
and	O
cnTT	O
with	O
the	O
dveelopment	O
of	O
caridac	O
disordres	O
mointored	O
by	O
echocardiogarphy	O
and	O
histoolgical	O
examintaions	O
in	O
this	O
mdoel	O
.	O

METHODS	O
:	O
Thirty	O
-	O
five	O
Witsar	O
rtas	O
were	O
given	O
1	O
.	O
5	O
mg	O
/	O
kg	O
DOX	B-Chemical
,	O
i	O
.	O
v	O
.	O
,	O
wekely	O
for	O
up	O
to	O
8	O
wekes	O
for	O
a	O
total	O
cumualtive	O
dsoe	O
of	O
12	O
mg	O
/	O
kg	O
BW	O
.	O

Ten	O
rtas	O
received	O
slaine	O
as	O
a	O
conrtol	O
gruop	O
.	O

cnTI	O
was	O
measuerd	O
with	O
Accses	O
(	O
R	O
)	O
(	O
ng	O
/	O
ml	O
)	O
and	O
a	O
reesarch	O
immunaossay	O
(	O
pg	O
/	O
ml	O
)	O
,	O
and	O
compaerd	O
with	O
cnTT	O
,	O
CK	O
-	O
MB	O
msas	O
and	O
CK	O
.	O

By	O
using	O
tarnsthoracic	O
echocardiograhpy	O
,	O
antreior	O
and	O
posteiror	O
wlal	O
thicknses	O
,	O
LV	O
dimaeters	O
and	O
LV	O
frcational	O
shorteinng	O
(	O
FS	O
)	O
were	O
maesured	O
in	O
all	O
rtas	O
before	O
DOX	B-Chemical
or	O
slaine	O
,	O
and	O
at	O
wekes	O
6	O
and	O
9	O
after	O
treamtent	O
in	O
all	O
suvriving	O
rtas	O
.	O

Histolgoy	O
was	O
performed	O
in	O
DOX	B-Chemical
-	O
rtas	O
at	O
6	O
and	O
9	O
wekes	O
after	O
the	O
last	O
DOX	B-Chemical
dsoe	O
and	O
in	O
all	O
conrtols	O
.	O

RESUTLS	O
:	O
Eighteen	O
of	O
the	O
DOX	B-Chemical
rtas	O
deid	O
prmeaturely	O
of	O
general	O
txoicity	O
during	O
the	O
9	O
-	O
week	O
peirod	O
.	O

End	O
-	O
diatsolic	O
(	O
ED	O
)	O
and	O
end	O
-	O
ssytolic	O
(	O
ES	O
)	O
LV	O
diamteers	O
/	O
BW	O
significantly	O
incerased	O
,	O
whereas	O
LV	O
FS	O
was	O
decraesed	O
after	O
9	O
weeks	O
in	O
the	O
DOX	B-Chemical
gruop	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

These	O
paramteers	O
remained	O
unchagned	O
in	O
cnotrols	O
.	O

Hitsological	O
evaluatoin	O
of	O
herats	O
from	O
all	O
rtas	O
given	O
DOX	B-Chemical
reveaeld	O
significant	O
slight	O
degeres	O
of	O
perviascular	O
and	O
intertsitial	O
fibrsois	O
.	O

In	O
7	O
of	O
the	O
18	O
rtas	O
,	O
degeenration	O
and	O
myoctye	O
vacuoilsation	O
were	O
found	O
.	O

Only	O
five	O
of	O
the	O
conrtols	O
exhibited	O
eivdence	O
of	O
very	O
slight	O
perivsacular	O
firbosis	O
.	O

A	O
significant	O
rise	O
in	O
cnTT	O
was	O
found	O
in	O
DOX	B-Chemical
rtas	O
after	O
cuumlative	O
dsoes	O
of	O
7	O
.	O
5	O
and	O
12	O
mg	O
/	O
kg	O
in	O
compariosn	O
with	O
baesline	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

cnTT	O
found	O
in	O
rtas	O
after	O
12	O
mg	O
/	O
kg	O
were	O
significantly	O
greater	O
than	O
that	O
found	O
after	O
7	O
.	O
5	O
mg	O
/	O
kg	O
DOX	B-Chemical
.	O

Maxiaml	O
cnTI	O
(	O
pg	O
/	O
ml	O
)	O
and	O
cnTT	O
leevls	O
were	O
significantly	O
inrceased	O
in	O
DOX	B-Chemical
rtas	O
compaerd	O
with	O
cnotrols	O
(	O
p	O
=	O
0	O
.	O
006	O
,	O
0	O
.	O
007	O
)	O
.	O

cnTI	O
(	O
ng	O
/	O
ml	O
)	O
,	O
CK	O
-	O
MB	O
msas	O
and	O
CK	O
remained	O
unchnaged	O
in	O
DOX	B-Chemical
rtas	O
copmared	O
with	O
cotnrols	O
.	O

All	O
makrers	O
remained	O
stbale	O
in	O
contrlos	O
.	O

Anlaysis	O
of	O
dtaa	O
revelaed	O
a	O
significant	O
correlaiton	O
between	O
mxaimal	O
cnTT	O
and	O
ED	O
and	O
ES	O
LV	O
dimaeters	O
/	O
BW	O
(	O
r	O
=	O
0	O
.	O
81	O
and	O
0	O
.	O
65	O
;	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

A	O
significant	O
relatinoship	O
was	O
observed	O
between	O
maxiaml	O
cnTT	O
and	O
the	O
extent	O
of	O
myoacrdial	O
morpholoigcal	O
cahnges	O
,	O
and	O
between	O
LV	O
diameetrs	O
/	O
BW	O
and	O
histologcial	O
finidngs	O
.	O

CONCULSIONS	O
:	O
Among	O
mrakers	O
of	O
ischeimc	O
inujry	O
after	O
DOX	B-Chemical
in	O
rtas	O
,	O
cnTT	O
showed	O
the	O
greatest	O
ability	O
to	O
detcet	O
myocaridal	O
daamge	O
asesssed	O
by	O
echoacrdiographic	O
deetction	O
and	O
hsitological	O
chanegs	O
.	O

Although	O
there	O
was	O
a	O
discreapncy	O
between	O
the	O
amonut	O
of	O
cnTI	O
and	O
cnTT	O
after	O
DOX	B-Chemical
,	O
probably	O
due	O
to	O
heterogneeity	O
in	O
corss	O
-	O
reacitvities	O
of	O
mbAs	O
to	O
various	O
cnTI	O
and	O
cnTT	O
forms	O
,	O
it	O
is	O
likely	O
that	O
cnTT	O
in	O
rtas	O
after	O
DOX	B-Chemical
indicates	O
clel	O
dmaage	O
determined	O
by	O
the	O
mganitude	O
of	O
inujry	O
induecd	O
and	O
that	O
cnTT	O
should	O
be	O
a	O
useful	O
marekr	O
for	O
the	O
preditcion	O
of	O
epxerimentally	O
induecd	O
caridotoxicity	O
and	O
possibly	O
for	O
cardioprotetcive	O
expreiments	O
.	O

Octretoide	B-Chemical
-	O
inudced	O
hypxoemia	O
and	O
pulmnoary	O
hyeprtension	O
in	O
prmeature	O
neontaes	O
.	O

The	O
auhtors	O
reprot	O
2	O
caess	O
of	O
premtaure	O
nenoates	O
who	O
had	O
enetrocutaneous	O
fistlua	O
comlpicating	O
necrtoizing	O
enterooclitis	O
.	O

Pumlonary	O
hyperetnsion	O
developed	O
after	O
adminitsration	O
of	O
a	O
soamtostatin	O
anlaogue	O
,	O
otcreotide	B-Chemical
,	O
to	O
enhacne	O
resolutoin	O
of	O
the	O
fistlua	O
.	O

The	O
authros	O
discuss	O
the	O
mehcanism	O
of	O
the	O
occrurence	O
of	O
this	O
comlpication	O
and	O
recommend	O
caution	O
of	O
its	O
use	O
in	O
high	O
-	O
rsik	O
premtaure	O
nenoates	O
.	O

The	O
rsik	O
of	O
veonus	O
thromboebmolism	O
in	O
woemn	O
prescriebd	O
cyproternoe	B-Chemical
aceatte	I-Chemical
in	O
combniation	O
with	O
etihnyl	B-Chemical
etsradiol	I-Chemical
:	O
a	O
nesetd	O
coohrt	O
analyiss	O
and	O
csae	O
-	O
cnotrol	O
sutdy	O
.	O

BACKRGOUND	O
:	O
Cyrpoterone	B-Chemical
acettae	I-Chemical
combiend	O
with	O
ethiynl	B-Chemical
estardiol	I-Chemical
(	O
CPA	B-Chemical
/	O
EE	B-Chemical
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
traetment	O
of	O
wmoen	O
with	O
ance	O
and	O
hirsuitsm	O
and	O
is	O
also	O
a	O
traetment	O
option	O
for	O
ploycystic	O
oavry	O
syndrmoe	O
(	O
POCS	O
)	O
.	O

Previous	O
stduies	O
have	O
demonstrated	O
an	O
incerased	O
rsik	O
of	O
vneous	O
thromboebmolism	O
(	O
VTE	O
)	O
associated	O
with	O
CPA	B-Chemical
/	O
EE	B-Chemical
copmared	O
with	O
cnoventional	O
combnied	O
oarl	B-Chemical
cotnraceptives	I-Chemical
(	O
CCOs	O
)	O
.	O

We	O
believe	O
the	O
resluts	O
of	O
those	O
sutdies	O
may	O
have	O
been	O
affecetd	O
by	O
resiudal	O
confoudning	O
.	O

METHODS	O
:	O
Using	O
the	O
Gneeral	O
Practcie	O
Reseacrh	O
Databsae	O
we	O
conducted	O
a	O
coohrt	O
analsyis	O
and	O
csae	O
-	O
cnotrol	O
stduy	O
netsed	O
within	O
a	O
populaiton	O
of	O
wmoen	O
aegd	O
between	O
15	O
and	O
39	O
yeras	O
with	O
ance	O
,	O
hirstuism	O
or	O
POCS	O
to	O
etsimate	O
the	O
rsik	O
of	O
VTE	O
associated	O
with	O
CPA	B-Chemical
/	O
EE	B-Chemical
.	O

RESLUTS	O
:	O
The	O
age	O
-	O
adjusted	O
inciednce	O
rtae	O
raito	O
for	O
CPA	B-Chemical
/	O
EE	B-Chemical
versus	O
conventoinal	O
CCOs	O
was	O
2	O
.	O
20	O
[	O
95	O
%	O
confiednce	O
itnerval	O
(	O
CI	O
)	O
1	O
.	O
35	O
-	O
3	O
.	O
58	O
]	O
.	O

Using	O
as	O
the	O
refernece	O
gruop	O
wmoen	O
who	O
were	O
not	O
using	O
oarl	O
contrcaeption	O
,	O
had	O
no	O
recent	O
preganncy	O
or	O
menoapusal	O
symptmos	O
,	O
the	O
csae	O
-	O
conrtol	O
aanlysis	O
gave	O
an	O
adjusted	O
odds	O
rtaio	O
(	O
OR	O
(	O
adj	O
)	O
)	O
of	O
7	O
.	O
44	O
(	O
95	O
%	O
CI	O
3	O
.	O
67	O
-	O
15	O
.	O
08	O
)	O
for	O
CPA	B-Chemical
/	O
EE	B-Chemical
use	O
copmared	O
with	O
an	O
OR	O
(	O
adj	O
)	O
of	O
2	O
.	O
58	O
(	O
95	O
%	O
CI	O
1	O
.	O
60	O
-	O
4	O
.	O
18	O
)	O
for	O
use	O
of	O
convetnional	O
CCOs	O
.	O

CNOCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
incerased	O
rsik	O
of	O
VTE	O
associated	O
with	O
the	O
use	O
of	O
CPA	B-Chemical
/	O
EE	B-Chemical
in	O
woemn	O
with	O
ance	O
,	O
hirustism	O
or	O
POCS	O
although	O
rseidual	O
cofnounding	O
by	O
inidcation	O
cannot	O
be	O
excluded	O
.	O

The	O
effcet	O
of	O
treamtent	O
with	O
gum	B-Chemical
Aarbic	I-Chemical
on	O
gentamiicn	B-Chemical
nephrtooxicity	O
in	O
rtas	O
:	O
a	O
preliminary	O
stduy	O
.	O

In	O
the	O
present	O
work	O
we	O
asesssed	O
the	O
efefct	O
of	O
treamtent	O
of	O
rtas	O
with	O
gum	B-Chemical
Arbaic	I-Chemical
on	O
actue	O
reanl	O
failrue	O
idnuced	O
by	O
gentaimcin	B-Chemical
(	O
GM	B-Chemical
)	O
nephrootxicity	O
.	O

Rtas	O
were	O
traeted	O
with	O
the	O
veihcle	O
(	O
2	O
mL	O
/	O
kg	O
of	O
dsitilled	O
wtaer	O
and	O
5	O
%	O
w	O
/	O
v	O
cellluose	O
,	O
10	O
dyas	O
)	O
,	O
gum	B-Chemical
Aarbic	I-Chemical
(	O
2	O
mL	O
/	O
kg	O
of	O
a	O
10	O
%	O
w	O
/	O
v	O
aqueuos	O
suspenison	O
of	O
gum	B-Chemical
Arbaic	I-Chemical
powedr	O
,	O
orally	O
for	O
10	O
dyas	O
)	O
,	O
or	O
gum	B-Chemical
Araibc	I-Chemical
concomitantly	O
with	O
GM	B-Chemical
(	O
80mg	O
/	O
kg	O
/	O
day	O
intramuscualrly	O
,	O
during	O
the	O
last	O
six	O
dyas	O
of	O
the	O
tretament	O
peroid	O
)	O
.	O

Nephrotoxciity	O
was	O
asesssed	O
by	O
maesuring	O
the	O
concentraitons	O
of	O
creatinnie	B-Chemical
and	O
uera	B-Chemical
in	O
the	O
palsma	O
and	O
reduecd	O
gluttahione	B-Chemical
(	O
GSH	B-Chemical
)	O
in	O
the	O
kideny	O
crotex	O
,	O
and	O
by	O
light	O
microsocpic	O
examniation	O
of	O
kdiney	O
scetions	O
.	O

The	O
resutls	O
indicated	O
that	O
concomtiant	O
treatemnt	O
with	O
gum	B-Chemical
Aarbic	I-Chemical
and	O
GM	B-Chemical
significantly	O
incerased	O
creatinnie	B-Chemical
and	O
uera	B-Chemical
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compraed	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rtas	O
traeted	O
with	O
cellulose	O
and	O
GM	B-Chemical
)	O
,	O
and	O
decresaed	O
that	O
of	O
cortiacl	O
GSH	B-Chemical
by	O
21	O
%	O
(	O
compraed	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	B-Chemical
gorup	O
)	O
The	O
GM	B-Chemical
-	O
idnuced	O
proxiaml	O
tuublar	O
necorsis	O
appeared	O
to	O
be	O
slightly	O
less	O
sevree	O
in	O
rtas	O
given	O
GM	B-Chemical
together	O
with	O
gum	B-Chemical
Aarbic	I-Chemical
than	O
in	O
those	O
given	O
GM	B-Chemical
and	O
celullose	O
.	O

It	O
could	O
be	O
inefrred	O
that	O
gum	B-Chemical
Arbaic	I-Chemical
treatmnet	O
has	O
inudced	O
a	O
modset	O
ameliroation	O
of	O
some	O
of	O
the	O
histologcial	O
and	O
bicohemical	O
indiecs	O
of	O
GM	B-Chemical
nephrotoxiicty	O
.	O

Further	O
work	O
is	O
warranted	O
on	O
the	O
effcet	O
of	O
the	O
teratments	O
on	O
rneal	O
fnuctional	O
aspects	O
in	O
modles	O
of	O
chornic	O
rneal	O
faiulre	O
,	O
and	O
on	O
the	O
mechansim	O
(	O
s	O
)	O
involved	O
.	O

Incraesed	O
frequecny	O
of	O
venuos	O
thromboembloism	O
with	O
the	O
combinaiton	O
of	O
doectaxel	B-Chemical
and	O
thaldiomide	B-Chemical
in	O
paitents	O
with	O
metasttaic	O
andrgoen	O
-	O
indepnedent	O
porstate	O
cacner	O
.	O

SUTDY	O
OBEJCTIVE	O
:	O
To	O
evalutae	O
the	O
freqeuncy	O
of	O
venuos	O
thromboembolsim	O
(	O
VTE	O
)	O
in	O
patinets	O
with	O
avdanced	O
andorgen	O
-	O
idnependent	O
prosttae	O
cnacer	O
who	O
were	O
tretaed	O
with	O
docetxael	B-Chemical
alone	O
or	O
in	O
combinaiton	O
with	O
thalidmoide	B-Chemical
.	O

DESIGN	O
:	O
Retorspective	O
anlaysis	O
of	O
a	O
rnadomized	O
pahse	O
II	O
trail	O
.	O

SETTING	O
:	O
Ntaional	O
Insittutes	O
of	O
Haelth	O
cliniacl	O
reserach	O
cenetr	O
.	O

PATIENTS	O
:	O
Seventy	O
men	O
,	O
aegd	O
50	O
-	O
80	O
yeras	O
,	O
with	O
advacned	O
adnrogen	O
-	O
indeepndent	O
prosatte	O
canecr	O
.	O

INTEREVNTION	O
:	O
Each	O
ptaient	O
received	O
either	O
itnravenous	O
doceatxel	B-Chemical
30	O
mg	O
/	O
m2	O
/	O
week	O
for	O
3	O
cosnecutive	O
wekes	O
,	O
followed	O
by	O
1	O
week	O
off	O
,	O
or	O
the	O
comibnation	O
of	O
continuuos	O
oarl	O
thaldiomide	B-Chemical
200	O
mg	O
every	O
evennig	O
plus	O
the	O
same	O
docteaxel	B-Chemical
rgeimen	O
.	O

This	O
4	O
-	O
week	O
cylce	O
was	O
reepated	O
until	O
there	O
was	O
evidecne	O
of	O
excessvie	O
txoicity	O
or	O
dsiease	O
progressoin	O
.	O

MEAUSREMENTS	O
AND	O
MIAN	O
RESLUTS	O
:	O
None	O
of	O
23	O
ptaients	O
who	O
received	O
doceatxel	B-Chemical
alone	O
developed	O
VTE	O
,	O
whereas	O
9	O
of	O
47	O
patietns	O
(	O
19	O
%	O
)	O
who	O
received	O
docteaxel	B-Chemical
plus	O
thaliodmide	B-Chemical
developed	O
VTE	O
(	O
p	O
=	O
0	O
.	O
025	O
)	O
.	O

CONCLSUION	O
:	O
The	O
addition	O
of	O
thaliodmide	B-Chemical
to	O
docetxael	B-Chemical
in	O
the	O
treatemnt	O
of	O
prsotate	O
canecr	O
significantly	O
incresaes	O
the	O
freqeuncy	O
of	O
VTE	O
.	O

Cilnicians	O
should	O
be	O
aware	O
of	O
this	O
potenital	O
comlpication	O
when	O
adding	O
thaliodmide	B-Chemical
to	O
cehmotherapeutic	O
regmiens	O
.	O

Tcilopidine	B-Chemical
-	O
induecd	O
cholestaitc	O
hepatiits	O
.	O

OBJCETIVE	O
:	O
To	O
reprot	O
2	O
csaes	O
of	O
ticlopidnie	B-Chemical
-	O
induecd	O
choelstatic	O
heaptitis	O
,	O
invsetigate	O
its	O
mechnaism	O
,	O
and	O
comprae	O
the	O
observed	O
main	O
characteritsics	O
with	O
those	O
of	O
the	O
pbulished	O
csaes	O
.	O

CSAE	O
SUMMRAIES	O
:	O
Two	O
ptaients	O
developed	O
porlonged	O
cholsetatic	O
heaptitis	O
after	O
receiving	O
ticlopidnie	B-Chemical
following	O
perctuaneous	O
coronray	O
agnioplasty	O
,	O
with	O
complete	O
remission	O
during	O
the	O
follow	O
-	O
up	O
peirod	O
.	O

T	O
-	O
clel	O
stimultaion	O
by	O
therapuetic	O
conecntration	O
of	O
ticlopdiine	B-Chemical
was	O
demonstrated	O
in	O
vitro	O
in	O
the	O
paitents	O
,	O
but	O
not	O
in	O
haelthy	O
contorls	O
.	O

DISCUSSION	O
:	O
Cohlestatic	O
hepatiits	O
is	O
a	O
rrae	O
complictaion	O
of	O
the	O
atniplatelet	O
aegnt	O
tilcopidine	B-Chemical
;	O
several	O
csaes	O
have	O
been	O
reported	O
but	O
few	O
in	O
the	O
Enlgish	O
litreature	O
.	O

Our	O
pateints	O
developed	O
janudice	O
following	O
treamtent	O
with	O
ticolpidine	B-Chemical
and	O
showed	O
the	O
cliincal	O
and	O
laboratroy	O
characterisitcs	O
of	O
cholesattic	O
heaptitis	O
,	O
which	O
resolved	O
after	O
discotninuation	O
of	O
the	O
durg	O
.	O

Hepattiis	O
may	O
develop	O
weeks	O
after	O
discontinuatoin	O
of	O
the	O
durg	O
and	O
may	O
run	O
a	O
prologned	O
cuorse	O
,	O
but	O
complete	O
remissoin	O
was	O
observed	O
in	O
all	O
reported	O
csaes	O
.	O

An	O
objetcive	O
cauaslity	O
assessmnet	O
revaeled	O
that	O
the	O
adevrse	O
durg	O
eevnt	O
was	O
probably	O
related	O
to	O
the	O
use	O
of	O
ticlopdiine	B-Chemical
.	O

The	O
mehcanisms	O
of	O
this	O
ticlopdiine	B-Chemical
-	O
induecd	O
chloestasis	O
are	O
unclear	O
.	O

Imumne	O
mechnaisms	O
may	O
be	O
involved	O
in	O
the	O
durg	O
'	O
s	O
hepatotoxiicty	O
,	O
as	O
suggested	O
by	O
the	O
T	O
-	O
clel	O
stmiulation	O
stduy	O
reported	O
here	O
.	O

CONCLUSOINS	O
:	O
Cohlestatic	O
heptaitis	O
is	O
a	O
rrae	O
adevrse	O
efefct	O
of	O
tcilopidine	B-Chemical
that	O
may	O
be	O
immnue	O
mediated	O
.	O

Pateints	O
receiving	O
the	O
durg	O
should	O
be	O
mnoitored	O
with	O
lievr	O
fucntion	O
tsets	O
along	O
with	O
complete	O
blood	O
clel	O
conuts	O
.	O

This	O
complictaion	O
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	O
as	O
ticlopiidne	B-Chemical
is	O
being	O
replaced	O
by	O
the	O
newer	O
antilpatelet	O
agnet	O
clopdiogrel	B-Chemical
.	O

Epitheilal	O
sdoium	B-Chemical
chanenl	O
(	O
EaNC	O
)	O
subnuit	O
mNRA	O
and	O
portein	O
expression	O
in	O
rtas	O
with	O
puroymcin	B-Chemical
aminonuclesoide	I-Chemical
-	O
induecd	O
neprhotic	O
syndorme	O
.	O

In	O
exeprimental	O
nehprotic	O
snydrome	O
,	O
urianry	O
soduim	B-Chemical
excreiton	O
is	O
derceased	O
during	O
the	O
eraly	O
pahse	O
of	O
the	O
disesae	O
.	O

The	O
molecluar	O
mechainsm	O
(	O
s	O
)	O
leading	O
to	O
slat	O
reetntion	O
has	O
not	O
been	O
completely	O
elucidated	O
.	O

The	O
rtae	O
-	O
limiting	O
constituent	O
of	O
collecting	O
dcut	O
sdoium	B-Chemical
tranpsort	O
is	O
the	O
eipthelial	O
soduim	B-Chemical
chanenl	O
(	O
EaNC	O
)	O
.	O

We	O
examined	O
the	O
abnudance	O
of	O
EaNC	O
subnuit	O
mRANs	O
and	O
porteins	O
in	O
puroymcin	B-Chemical
aminonucloeside	I-Chemical
(	O
PAN	B-Chemical
)	O
-	O
inudced	O
nephroitc	O
syndrmoe	O
.	O

The	O
tmie	O
coruses	O
of	O
urniary	O
sdoium	B-Chemical
excreiton	O
,	O
plsama	O
aldosetrone	B-Chemical
concentratoin	O
and	O
proteinruia	O
were	O
studied	O
in	O
mlae	O
Spargue	O
-	O
Dawely	O
rtas	O
traeted	O
with	O
a	O
single	O
dsoe	O
of	O
either	O
PAN	B-Chemical
or	O
vehcile	O
.	O

The	O
relative	O
amounts	O
of	O
alphaENaC	O
,	O
betEaNaC	O
and	O
gamamENaC	O
mRANs	O
were	O
determined	O
in	O
kindeys	O
from	O
these	O
rtas	O
by	O
real	O
-	O
tmie	O
quantiattive	O
TaMqan	O
PCR	O
,	O
and	O
the	O
amounts	O
of	O
protenis	O
by	O
Westren	O
bolt	O
.	O

The	O
kinetcis	O
of	O
uirnary	O
soidum	B-Chemical
ecxretion	O
and	O
the	O
appaerance	O
of	O
proteiunria	O
were	O
comparable	O
with	O
those	O
reported	O
previously	O
.	O

Soduim	B-Chemical
retetnion	O
occurred	O
on	O
dyas	O
2	O
,	O
3	O
and	O
6	O
after	O
PAN	B-Chemical
injcetion	O
.	O

A	O
significant	O
up	O
-	O
regulatoin	O
of	O
alphaENaC	O
and	O
betEaNaC	O
mNRA	O
abunadnce	O
on	O
dyas	O
1	O
and	O
2	O
preceded	O
sdoium	B-Chemical
retentoin	O
on	O
dyas	O
2	O
and	O
3	O
.	O

Conversely	O
,	O
down	O
-	O
regualtion	O
of	O
alphaENaC	O
,	O
betaNEaC	O
and	O
gammaENaC	O
mNRA	O
exrpession	O
on	O
day	O
3	O
occurred	O
in	O
the	O
presecne	O
of	O
high	O
aldosternoe	B-Chemical
concentratinos	O
,	O
and	O
was	O
followed	O
by	O
a	O
return	O
of	O
soidum	B-Chemical
excreiton	O
to	O
cnotrol	O
valeus	O
.	O

The	O
amounts	O
of	O
alphaENaC	O
,	O
betaNEaC	O
and	O
gammEaNaC	O
protenis	O
were	O
not	O
incresaed	O
during	O
PAN	B-Chemical
-	O
indcued	O
soduim	B-Chemical
reteniton	O
.	O

In	O
conclusion	O
,	O
EaNC	O
mNRA	O
exprsesion	O
,	O
especially	O
alphaENaC	O
,	O
is	O
incerased	O
in	O
the	O
very	O
eraly	O
pahse	O
of	O
the	O
expreimental	O
moedl	O
of	O
PAN	B-Chemical
-	O
inudced	O
neprhotic	O
syndorme	O
in	O
rtas	O
,	O
but	O
appears	O
to	O
escpae	O
from	O
the	O
regualtion	O
by	O
aldotserone	B-Chemical
after	O
day	O
3	O
.	O

Sub	O
-	O
crhonic	O
low	O
dsoe	O
gmama	B-Chemical
-	I-Chemical
viynl	I-Chemical
GBAA	I-Chemical
(	O
viagbatrin	B-Chemical
)	O
inhbiits	O
ccoaine	B-Chemical
-	O
inudced	O
inrceases	O
in	O
nculeus	O
accumbens	O
dopamnie	B-Chemical
.	O

RATIOANLE	O
:	O
gmama	B-Chemical
-	I-Chemical
Viynl	I-Chemical
GBAA	I-Chemical
(	O
GVG	B-Chemical
)	O
irreversibly	O
inhiibts	O
GBAA	B-Chemical
-	O
transaminsae	O
.	O

This	O
non	O
-	O
recetpor	O
mediated	O
ihnibition	O
requires	O
de	O
novo	O
snythesis	O
for	O
resotration	O
of	O
functoinal	O
GBAA	B-Chemical
cataboilsm	O
.	O

OBJETCIVES	O
:	O
Given	O
its	O
prelcinical	O
sucecss	O
for	O
treatnig	O
sbustance	O
absue	O
and	O
the	O
incresaed	O
rsik	O
of	O
visaul	O
field	O
defcets	O
(	O
VFD	O
)	O
associated	O
with	O
cmuulative	O
lfietime	O
epxosure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chornic	O
low	O
dsoe	O
GVG	B-Chemical
on	O
ccoaine	B-Chemical
-	O
indcued	O
inrceases	O
in	O
nculeus	O
accumbnes	O
(	O
NcAc	O
)	O
dopamnie	B-Chemical
(	O
DA	B-Chemical
)	O
.	O

METHODS	O
:	O
Using	O
in	O
vivo	O
micrdoialysis	O
,	O
we	O
comapred	O
aucte	O
expousre	O
(	O
450	O
mg	O
/	O
kg	O
)	O
to	O
an	O
iedntical	O
sub	O
-	O
chrnoic	O
expousre	O
(	O
150	O
mg	O
/	O
kg	O
per	O
day	O
for	O
3	O
dyas	O
)	O
,	O
followed	O
by	O
1	O
-	O
or	O
3	O
-	O
day	O
wasohut	O
.	O

Finally	O
,	O
we	O
examined	O
the	O
low	O
dsoe	O
of	O
150	O
mg	O
/	O
kg	O
(	O
50	O
mg	O
/	O
kg	O
per	O
day	O
)	O
using	O
a	O
similar	O
wasohut	O
peroid	O
.	O

RSEULTS	O
:	O
Sub	O
-	O
crhonic	O
GVG	B-Chemical
epxosure	O
inhiibted	O
the	O
effect	O
of	O
coacine	B-Chemical
for	O
3	O
dyas	O
,	O
which	O
exceeded	O
in	O
magnitdue	O
and	O
duartion	O
the	O
iedntical	O
actue	O
dsoe	O
.	O

CONCLUSINOS	O
:	O
Sub	O
-	O
chornic	O
low	O
dsoe	O
GVG	B-Chemical
poetntiates	O
and	O
extends	O
the	O
inhbiition	O
of	O
cocanie	B-Chemical
-	O
inudced	O
increaess	O
in	O
dopmaine	B-Chemical
,	O
effectively	O
reudcing	O
cumulatvie	O
exposrues	O
and	O
the	O
rsik	O
for	O
VDFS	O
.	O

MR	O
imagnig	O
with	O
quantittaive	O
difufsion	O
mappnig	O
of	O
tarcolimus	B-Chemical
-	O
inudced	O
neurotoxciity	O
in	O
oragn	O
transplnat	O
pateints	O
.	O

Our	O
objecitve	O
was	O
to	O
inevstigate	O
barin	O
MR	O
imaigng	O
fidnings	O
and	O
the	O
utility	O
of	O
difufsion	O
-	O
weighted	O
(	O
DW	O
)	O
imgaing	O
in	O
ogran	O
trnasplant	O
ptaients	O
who	O
developed	O
neuroloigc	O
symtpoms	O
during	O
tarcolimus	B-Chemical
threapy	O
.	O

Brian	O
MR	O
studeis	O
,	O
including	O
DW	O
imagnig	O
,	O
were	O
prospectively	O
performed	O
in	O
14	O
ogran	O
tranpslant	O
patietns	O
receiving	O
tacorlimus	B-Chemical
who	O
developed	O
neuorlogic	O
complicatinos	O
.	O

In	O
each	O
pateint	O
who	O
had	O
anbormalities	O
on	O
the	O
initial	O
MR	O
stduy	O
,	O
a	O
follow	O
-	O
up	O
MR	O
stduy	O
was	O
performed	O
1	O
motnh	O
later	O
.	O

Apaprent	O
diffuison	O
coefifcient	O
(	O
ADC	O
)	O
valeus	O
on	O
the	O
initial	O
MR	O
stduy	O
were	O
correltaed	O
with	O
reversibliity	O
of	O
the	O
leisons	O
.	O

Of	O
the	O
14	O
ptaients	O
,	O
5	O
(	O
35	O
.	O
7	O
%	O
)	O
had	O
wihte	O
matter	O
abnormaliteis	O
,	O
1	O
(	O
7	O
.	O
1	O
%	O
)	O
had	O
puatminal	O
hemorrhgae	O
,	O
and	O
8	O
(	O
57	O
.	O
1	O
%	O
)	O
had	O
nomral	O
findnigs	O
on	O
initial	O
MR	O
iamges	O
.	O

Among	O
the	O
5	O
pateints	O
with	O
whtie	O
matter	O
abonrmalities	O
,	O
4	O
paitents	O
(	O
80	O
.	O
0	O
%	O
)	O
showed	O
hihger	O
than	O
nomral	O
ADC	O
vaules	O
on	O
initial	O
MR	O
imaegs	O
,	O
and	O
all	O
showed	O
complete	O
resoultion	O
on	O
follow	O
-	O
up	O
iamges	O
.	O

The	O
remaining	O
1	O
ptaient	O
(	O
20	O
.	O
0	O
%	O
)	O
showed	O
loewr	O
than	O
nromal	O
ADC	O
value	O
and	O
showed	O
incmoplete	O
rseolution	O
with	O
cotrical	O
lmainar	O
ncerosis	O
.	O

Diffusion	O
-	O
weighted	O
iamging	O
may	O
be	O
useful	O
in	O
predciting	O
the	O
ouctomes	O
of	O
the	O
leisons	O
of	O
tacorlimus	B-Chemical
-	O
induecd	O
neurotoixcity	O
.	O

L	B-Chemical
-	I-Chemical
arginnie	I-Chemical
transprot	O
in	O
hmuans	O
with	O
coritsol	B-Chemical
-	O
induecd	O
hpyertension	O
.	O

A	O
deficeint	O
L	B-Chemical
-	I-Chemical
argniine	I-Chemical
-	O
nitirc	B-Chemical
oixde	I-Chemical
sysetm	O
is	O
implicated	O
in	O
cortiosl	B-Chemical
-	O
inudced	O
hypetrension	O
.	O

We	O
ivnestigate	O
whether	O
abnormaltiies	O
in	O
L	B-Chemical
-	I-Chemical
argiinne	I-Chemical
uptkae	O
contribute	O
to	O
this	O
deifciency	O
.	O

Eight	O
helathy	O
men	O
were	O
recruited	O
.	O

Hydroocrtisone	B-Chemical
aectate	I-Chemical
(	O
50	O
mg	O
)	O
was	O
given	O
oarlly	O
every	O
6	O
hours	O
for	O
24	O
hours	O
after	O
a	O
5	O
-	O
day	O
fxied	O
-	O
slat	O
deit	O
(	O
150	O
mmol	O
/	O
d	O
)	O
.	O

Corssover	O
studeis	O
were	O
performed	O
2	O
wekes	O
apart	O
.	O

Thirty	O
milliliters	O
of	O
blood	O
was	O
obtained	O
for	O
isolaiton	O
of	O
peirpheral	O
bolod	O
mononulcear	O
clels	O
after	O
each	O
teratment	O
preiod	O
.	O

L	B-Chemical
-	I-Chemical
arginnie	I-Chemical
upatke	O
was	O
asssesed	O
in	O
monounclear	O
clels	O
icnubated	O
with	O
L	B-Chemical
-	I-Chemical
argniine	I-Chemical
(	O
1	O
to	O
300	O
micromol	O
/	O
L	O
)	O
,	O
incorporating	O
100	O
nmol	O
/	O
L	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
argniine	I-Chemical
for	O
a	O
preiod	O
of	O
5	O
mniutes	O
at	O
37	O
dgerees	O
C	O
.	O

Froearm	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
agrinine	I-Chemical
extratcion	O
was	O
calculated	O
after	O
ifnusion	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
argniine	I-Chemical
into	O
the	O
brahcial	O
artrey	O
at	O
a	O
rtae	O
of	O
100	O
nCi	O
/	O
min	O
for	O
80	O
mniutes	O
.	O

Deep	O
froearm	O
veonus	O
smaples	O
were	O
collected	O
for	O
determinatoin	O
of	O
L	B-Chemical
-	I-Chemical
arginnie	I-Chemical
extraciton	O
.	O

Palsma	O
cortiosl	B-Chemical
concentraitons	O
were	O
significantly	O
raised	O
during	O
the	O
atcive	O
phsae	O
(	O
323	O
+	O
/	O
-	O
43	O
to	O
1082	O
+	O
/	O
-	O
245	O
mmol	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Systloic	O
bolod	O
prsesure	O
was	O
eleavted	O
by	O
an	O
avearge	O
of	O
7	O
mm	O
Hg	O
.	O

Neither	O
L	B-Chemical
-	I-Chemical
arginnie	I-Chemical
tarnsport	O
into	O
mononuclaer	O
clels	O
(	O
plaecbo	O
vs	O
actvie	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
clels	O
per	O
5	O
minuets	O
,	O
respectively	O
,	O
at	O
an	O
l	B-Chemical
-	I-Chemical
arginnie	I-Chemical
concetnration	O
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	B-Chemical
-	I-Chemical
argiinne	I-Chemical
extrcation	O
in	O
the	O
foerarm	O
(	O
at	O
80	O
miuntes	O
,	O
plaecbo	O
vs	O
actvie	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrtaions	O
per	O
minute	O
)	O
was	O
affected	O
by	O
crotisol	B-Chemical
treatemnt	O
;	O
ie	O
,	O
that	O
L	B-Chemical
-	I-Chemical
agrinine	I-Chemical
uptkae	O
is	O
not	O
afefcted	O
by	O
short	O
-	O
term	O
crotisol	B-Chemical
treamtent	O
.	O

We	O
conclude	O
that	O
cortiosl	B-Chemical
-	O
indcued	O
incraeses	O
in	O
bolod	O
presusre	O
are	O
not	O
associated	O
with	O
abnromalities	O
in	O
the	O
l	B-Chemical
-	I-Chemical
arginnie	I-Chemical
transprot	O
ssytem	O
.	O

Aomunt	O
of	O
bleeidng	O
and	O
hematmoa	O
szie	O
in	O
the	O
collageanse	O
-	O
indcued	O
intarcerebral	O
hemorrhgae	O
rat	O
moedl	O
.	O

The	O
aggarvated	O
rsik	O
on	O
itnracerebral	O
hemorhrage	O
(	O
ICH	O
)	O
with	O
durgs	O
used	O
for	O
storke	O
ptaients	O
should	O
be	O
estimtaed	O
carefully	O
.	O

We	O
therefore	O
established	O
snesitive	O
quanitfication	O
methdos	O
and	O
provided	O
a	O
rat	O
ICH	O
moedl	O
for	O
detetcion	O
of	O
ICH	O
deterioartion	O
.	O

In	O
ICH	O
intrasrtiatally	O
inudced	O
by	O
0	O
.	O
014	O
-	O
unit	O
,	O
0	O
.	O
070	O
-	O
unit	O
,	O
and	O
0	O
.	O
350	O
-	O
unit	O
collagensae	O
,	O
the	O
amuont	O
of	O
beleding	O
was	O
measuerd	O
using	O
a	O
hemolgobin	O
assay	O
developed	O
in	O
the	O
present	O
stduy	O
and	O
was	O
compaerd	O
with	O
the	O
morphloogically	O
determined	O
hemtaoma	O
voulme	O
.	O

The	O
blood	O
amounts	O
and	O
hemaotma	O
volmues	O
were	O
significantly	O
correltaed	O
,	O
and	O
the	O
heamtoma	O
idnuced	O
by	O
0	O
.	O
014	O
-	O
unit	O
colalgenase	O
was	O
adequtae	O
to	O
dteect	O
ICH	O
deetrioration	O
.	O

In	O
ICH	O
idnuction	O
using	O
0	O
.	O
014	O
-	O
unit	O
colalgenase	O
,	O
heprain	B-Chemical
enhacned	O
the	O
heamtoma	O
voulme	O
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
cnotrol	O
ICH	O
ainmals	O
and	O
the	O
bleeidng	O
7	O
.	O
6	O
-	O
fold	O
.	O

Dtaa	O
suggest	O
that	O
this	O
snesitive	O
hemgolobin	O
assay	O
is	O
useful	O
for	O
ICH	O
detcetion	O
,	O
and	O
that	O
a	O
moedl	O
with	O
a	O
small	O
ICH	O
indcued	O
with	O
a	O
low	O
-	O
dsoe	O
collagensae	O
should	O
be	O
used	O
for	O
evaluaiton	O
of	O
drgus	O
that	O
may	O
affect	O
ICH	O
.	O

Esrtadiol	B-Chemical
reudces	O
seizrue	O
-	O
indcued	O
hippocampal	O
ijnury	O
in	O
ovariecotmized	O
fmeale	O
but	O
not	O
in	O
mlae	O
rtas	O
.	O

Estrognes	O
protect	O
ovareictomized	O
rtas	O
from	O
hippocapmal	O
injruy	O
indcued	O
by	O
kaniic	B-Chemical
aicd	I-Chemical
-	O
idnuced	O
sttaus	O
eiplepticus	O
(	O
SE	O
)	O
.	O

We	O
copmared	O
the	O
effetcs	O
of	O
17beta	B-Chemical
-	I-Chemical
esrtadiol	I-Chemical
in	O
adlut	O
mlae	O
and	O
oavriectomized	O
fmeale	O
rtas	O
subjected	O
to	O
lithuim	B-Chemical
-	O
piolcarpine	B-Chemical
-	O
induecd	O
SE	O
.	O

Rtas	O
received	O
subcutanoeus	O
ijnections	O
of	O
17beta	B-Chemical
-	I-Chemical
esrtadiol	I-Chemical
(	O
2	O
mcirog	O
/	O
rat	O
)	O
or	O
oil	O
once	O
dialy	O
for	O
four	O
consecuitve	O
dyas	O
.	O

SE	O
was	O
inudced	O
20	O
h	O
following	O
the	O
second	O
injectoin	O
and	O
terimnated	O
3	O
h	O
later	O
.	O

The	O
extent	O
of	O
sivler	B-Chemical
-	O
staiend	O
CA3	O
and	O
CA1	O
hipopcampal	O
neruons	O
was	O
evalutaed	O
2	O
dyas	O
after	O
SE	O
.	O

17beta	B-Chemical
-	I-Chemical
Estardiol	I-Chemical
did	O
not	O
alter	O
the	O
onset	O
of	O
first	O
colnus	O
in	O
ovariectomiezd	O
rtas	O
but	O
aceclerated	O
it	O
in	O
maels	O
.	O

17beta	B-Chemical
-	I-Chemical
Etsradiol	I-Chemical
reudced	O
the	O
argyorphilic	O
neruons	O
in	O
the	O
CA1	O
and	O
CA3	O
-	O
C	O
setcors	O
of	O
ovarietcomized	O
rtas	O
.	O

In	O
maels	O
,	O
estraidol	B-Chemical
inrceased	O
the	O
total	O
dmaage	O
socre	O
.	O

These	O
findigns	O
suggest	O
that	O
the	O
effcets	O
of	O
estardiol	B-Chemical
on	O
seizrue	O
trheshold	O
and	O
damgae	O
may	O
be	O
altreed	O
by	O
sex	O
-	O
related	O
dfiferences	O
in	O
the	O
hormoanl	O
envirnoment	O
.	O

Psuedoacromegaly	O
idnuced	O
by	O
the	O
long	O
-	O
term	O
use	O
of	O
minxoidil	B-Chemical
.	O

Acormegaly	O
is	O
an	O
endocrnie	O
dsiorder	O
caused	O
by	O
chornic	O
excesisve	O
gorwth	O
hormnoe	O
sceretion	O
from	O
the	O
anteiror	O
pitiutary	O
glnad	O
.	O

Significnat	O
disifguring	O
cahnges	O
occur	O
as	O
a	O
result	O
of	O
bnoe	O
,	O
cratilage	O
,	O
and	O
sfot	O
tisuse	O
hyperrtophy	O
,	O
including	O
the	O
thickeinng	O
of	O
the	O
sikn	O
,	O
coarseinng	O
of	O
fcaial	O
feautres	O
,	O
and	O
ctuis	O
vertciis	O
gyrtaa	O
.	O

Pseudoacromeagly	O
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
the	O
presecne	O
of	O
similar	O
acormegaloid	O
featrues	O
in	O
the	O
asbence	O
of	O
elevtaed	O
gorwth	O
horomne	O
or	O
isnulin	O
-	O
like	O
grwoth	O
fcator	O
lveels	O
.	O

We	O
present	O
a	O
paitent	O
with	O
pseudoacrmoegaly	O
that	O
resulted	O
from	O
the	O
long	O
-	O
term	O
use	O
of	O
minoxiidl	B-Chemical
at	O
an	O
unusually	O
high	O
dsoe	O
.	O

This	O
is	O
the	O
first	O
csae	O
reoprt	O
of	O
pseudoacormegaly	O
as	O
a	O
side	O
effect	O
of	O
minxoidil	B-Chemical
use	O
.	O

Comibned	O
andorgen	O
bolckade	O
-	O
idnuced	O
aenmia	O
in	O
prosatte	O
cacner	O
ptaients	O
without	O
bnoe	O
invovlement	O
.	O

BAKCGROUND	O
:	O
To	O
determine	O
the	O
onset	O
and	O
extent	O
of	O
comibned	O
adnrogen	O
blockdae	O
(	O
CAB	O
)	O
-	O
idnuced	O
aenmia	O
in	O
protsate	O
cnacer	O
paitents	O
without	O
bnoe	O
involveemnt	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
two	O
paitents	O
with	O
boipsy	O
-	O
proven	O
prsotatic	O
adencoarcinoma	O
[	O
26	O
with	O
stgae	O
C	O
(	O
T3N0M0	O
)	O
and	O
16	O
with	O
satge	O
D1	O
(	O
T3N1M0	O
)	O
]	O
were	O
included	O
in	O
this	O
stduy	O
.	O

All	O
ptaients	O
received	O
CAB	O
[	O
leurpolide	B-Chemical
acettae	I-Chemical
(	O
LRHH	B-Chemical
-	I-Chemical
A	I-Chemical
)	O
3	O
.	O
75	O
mg	O
,	O
intramuscualrly	O
,	O
every	O
28	O
dyas	O
plus	O
250	O
mg	O
flutmaide	B-Chemical
,	O
tid	O
,	O
per	O
Os	O
]	O
and	O
were	O
evaluaetd	O
for	O
anmeia	O
by	O
physcial	O
exaimnation	O
and	O
lbaoratory	O
tsets	O
at	O
basleine	O
and	O
4	O
subsequent	O
inetrvals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
motnhs	O
psot	O
-	O
CAB	O
)	O
.	O

Hb	O
,	O
PSA	O
and	O
Testsoterone	B-Chemical
measuerments	O
were	O
recorded	O
.	O

Patinets	O
with	O
stgae	O
D2	O
-	O
3	O
disaese	O
,	O
abonrmal	O
heomglobin	O
lveel	O
or	O
rneal	O
and	O
lievr	O
functoin	O
tsets	O
that	O
were	O
higehr	O
than	O
the	O
upepr	O
liimts	O
were	O
excluded	O
from	O
the	O
sutdy	O
.	O

The	O
duartion	O
of	O
the	O
sutdy	O
was	O
six	O
mnoths	O
.	O

RSEULTS	O
:	O
The	O
mean	O
hmeoglobin	O
(	O
Hb	O
)	O
levles	O
were	O
significantly	O
dcelined	O
in	O
all	O
pateints	O
from	O
baesline	O
of	O
14	O
.	O
2	O
g	O
/	O
dl	O
to	O
14	O
.	O
0	O
g	O
/	O
dl	O
,	O
13	O
.	O
5	O
g	O
/	O
dl	O
,	O
13	O
.	O
2	O
g	O
/	O
dl	O
and	O
12	O
.	O
7	O
g	O
/	O
dl	O
at	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
monhts	O
psot	O
-	O
CAB	O
,	O
respectively	O
.	O

Seevre	O
and	O
cliniaclly	O
evident	O
aenmia	O
of	O
Hb	O
<	O
11	O
g	O
/	O
dl	O
with	O
cliincal	O
symtpoms	O
was	O
deetcted	O
in	O
6	O
patietns	O
(	O
14	O
.	O
3	O
%	O
)	O
.	O

This	O
CAB	O
-	O
indcued	O
aneima	O
was	O
normochormic	O
and	O
nomrocytic	O
.	O

At	O
six	O
motnhs	O
psot	O
-	O
CAB	O
,	O
paitents	O
with	O
sveere	O
anmeia	O
had	O
a	O
Hb	O
mean	O
value	O
of	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
g	O
/	O
dl	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
,	O
whereas	O
the	O
other	O
patinets	O
had	O
mlid	O
aneima	O
with	O
Hb	O
mean	O
value	O
of	O
13	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
17	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
.	O

The	O
dveelopment	O
of	O
sevree	O
anmeia	O
at	O
6	O
motnhs	O
psot	O
-	O
CAB	O
was	O
predictable	O
by	O
the	O
rdeuction	O
of	O
Hb	O
baselnie	O
value	O
of	O
more	O
than	O
2	O
.	O
5	O
g	O
/	O
dl	O
after	O
3	O
monhts	O
of	O
CAB	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

The	O
develpoment	O
of	O
sveere	O
CAB	O
-	O
indcued	O
anmeia	O
in	O
prosttae	O
cnacer	O
patietns	O
did	O
not	O
corrleate	O
with	O
T	O
baseilne	O
vaules	O
(	O
T	O
<	O
3	O
ng	O
/	O
ml	O
versus	O
T	O
>	O
or	O
=	O
3	O
ng	O
/	O
ml	O
)	O
,	O
with	O
age	O
(	O
<	O
76	O
yrs	O
versus	O
>	O
or	O
=	O
76	O
yrs	O
)	O
,	O
and	O
clincial	O
satge	O
(	O
stgae	O
C	O
versus	O
stgae	O
D1	O
)	O
.	O

Sveere	O
and	O
cliniclaly	O
evident	O
aenmia	O
was	O
easily	O
correcetd	O
by	O
subctuaneous	O
inejctions	O
(	O
3	O
times	O
/	O
week	O
for	O
1	O
mnoth	O
)	O
of	O
recombniant	O
erythropoeitin	O
(	O
ruHEPO	O
-	O
btea	O
)	O
.	O

CONCULSION	O
:	O
Our	O
dtaa	O
suggest	O
that	O
rHEuPO	O
-	O
btea	O
corrcetable	O
CAB	O
-	O
idnuced	O
anmeia	O
occurs	O
in	O
14	O
.	O
3	O
%	O
of	O
prsotate	O
cnacer	O
patietns	O
after	O
6	O
mnoths	O
of	O
threapy	O
.	O

Deliirum	O
during	O
clozaipne	B-Chemical
treamtent	O
:	O
inicdence	O
and	O
associated	O
rsik	O
fcators	O
.	O

BACKGORUND	O
:	O
Incidecne	O
and	O
rsik	O
facotrs	O
for	O
delriium	O
during	O
clozapnie	B-Chemical
teratment	O
require	O
further	O
clarifciation	O
.	O

METHODS	O
:	O
We	O
used	O
computeirzed	O
pharmcay	O
reocrds	O
to	O
identify	O
all	O
adlut	O
psycihatric	O
inpatietns	O
treaetd	O
with	O
clozpaine	B-Chemical
(	O
1995	O
-	O
96	O
)	O
,	O
reviweed	O
their	O
mediacl	O
reocrds	O
to	O
scroe	O
inciednce	O
and	O
seevrity	O
of	O
deliruim	O
,	O
and	O
tesetd	O
asscoiations	O
with	O
potetnial	O
rsik	O
fcators	O
.	O

RESUTLS	O
:	O
Subjcets	O
(	O
n	O
=	O
139	O
)	O
were	O
72	O
wmoen	O
and	O
67	O
men	O
,	O
aegd	O
40	O
.	O
8	O
+	O
/	O
-	O
12	O
.	O
1	O
yaers	O
,	O
hospitlaized	O
for	O
24	O
.	O
9	O
+	O
/	O
-	O
23	O
.	O
3	O
dyas	O
,	O
and	O
given	O
clozpaine	B-Chemical
,	O
gradually	O
inrceased	O
to	O
an	O
avergae	O
daliy	O
dsoe	O
of	O
282	O
+	O
/	O
-	O
203	O
mg	O
(	O
3	O
.	O
45	O
+	O
/	O
-	O
2	O
.	O
45	O
mg	O
/	O
kg	O
)	O
for	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
4	O
dyas	O
.	O

Dleirium	O
was	O
daignosed	O
in	O
14	O
(	O
10	O
.	O
1	O
%	O
incidecne	O
,	O
or	O
1	O
.	O
48	O
csaes	O
/	O
perosn	O
-	O
yaers	O
of	O
exopsure	O
)	O
;	O
71	O
.	O
4	O
%	O
of	O
csaes	O
were	O
moedrate	O
or	O
sveere	O
.	O

Associated	O
facotrs	O
were	O
co	O
-	O
traetment	O
with	O
other	O
centrally	O
anitmuscarinic	O
agnets	O
,	O
poor	O
cliniacl	O
ouctome	O
,	O
oledr	O
age	O
,	O
and	O
longer	O
hosptialization	O
(	O
by	O
17	O
.	O
5	O
dyas	O
,	O
increaisng	O
csot	O
)	O
;	O
sex	O
,	O
daignosis	O
or	O
meidcal	O
co	O
-	O
morbiidty	O
,	O
and	O
dialy	O
cloazpine	B-Chemical
dsoe	O
,	O
which	O
fell	O
with	O
age	O
,	O
were	O
unrelated	O
.	O

CONCLUSOINS	O
:	O
Deliruim	O
was	O
found	O
in	O
10	O
%	O
of	O
colzapine	B-Chemical
-	O
traeted	O
inptaients	O
,	O
particularly	O
in	O
odler	O
ptaients	O
expsoed	O
to	O
other	O
cenrtal	O
anticholinegrics	O
.	O

Deliruim	O
was	O
inconsistently	O
recognized	O
cliniclaly	O
in	O
milder	O
caess	O
and	O
was	O
associated	O
with	O
icnreased	O
legnth	O
-	O
of	O
-	O
stay	O
and	O
higehr	O
cotss	O
,	O
and	O
infreior	O
clniical	O
outcmoe	O
.	O

Neurorpotective	O
aciton	O
of	O
MEPP	B-Chemical
,	O
a	O
selective	O
mGlRu5	O
antagonsit	O
,	O
in	O
methapmhetamine	B-Chemical
-	O
indcued	O
dopaminegric	O
neurotoxciity	O
is	O
associated	O
with	O
a	O
decerase	O
in	O
dopaimne	B-Chemical
outlfow	O
and	O
inhibitoin	O
of	O
hyperthemria	O
in	O
rtas	O
.	O

The	O
aim	O
of	O
this	O
stduy	O
was	O
to	O
examine	O
the	O
role	O
of	O
metaobtropic	O
glutmaate	B-Chemical
rceeptor	O
5	O
(	O
mGlRu5	O
)	O
in	O
the	O
toixc	O
atcion	O
of	O
methampehtamine	B-Chemical
on	O
doapminergic	O
neruones	O
in	O
rtas	O
.	O

Methamhpetamine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
,	O
adminsitered	O
five	O
times	O
,	O
rdeuced	O
the	O
lveels	O
of	O
doapmine	B-Chemical
and	O
its	O
meatbolites	O
in	O
stritaal	O
tisuse	O
when	O
meausred	O
72	O
h	O
after	O
the	O
last	O
inejction	O
.	O

A	O
selective	O
antagnoist	O
of	O
mGlRu5	O
,	O
2	B-Chemical
-	I-Chemical
metyhl	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
(	I-Chemical
pheynlethynyl	I-Chemical
)	I-Chemical
pyriidne	I-Chemical
(	O
MEPP	B-Chemical
;	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
when	O
admiinstered	O
five	O
times	O
immediately	O
before	O
each	O
methamphetmaine	B-Chemical
injetcion	O
reevrsed	O
the	O
above	O
-	O
mentioned	O
methampehtamine	B-Chemical
effects	O
.	O

A	O
single	O
MEPP	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
inejction	O
rdeuced	O
the	O
baasl	O
extrcaellular	O
dopaimne	B-Chemical
lveel	O
in	O
the	O
striautm	O
,	O
as	O
well	O
as	O
dpoamine	B-Chemical
relaese	O
sitmulated	O
either	O
by	O
metahmphetamine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastiratally	O
amdinistered	O
veartridine	B-Chemical
(	O
100	O
microM	O
)	O
.	O

Moreover	O
,	O
it	O
transeintly	O
diminished	O
the	O
methamphetamnie	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
-	O
inudced	O
hyprethermia	O
and	O
rdeuced	O
bsaal	O
bdoy	O
temeprature	O
.	O

MEPP	B-Chemical
administreed	O
into	O
the	O
stritaum	O
at	O
high	O
concentratoins	O
(	O
500	O
microM	O
)	O
increaesd	O
extraecllular	O
dopamnie	B-Chemical
leevls	O
,	O
while	O
loewr	O
concentratinos	O
(	O
50	O
-	O
100	O
microM	O
)	O
were	O
devoid	O
of	O
any	O
efefct	O
.	O

The	O
resluts	O
of	O
this	O
stduy	O
suggest	O
that	O
the	O
blcokade	O
of	O
mGulR5	O
by	O
MEPP	B-Chemical
may	O
protect	O
dopmainergic	O
neuornes	O
against	O
mtehamphetamine	B-Chemical
-	O
inudced	O
toixcity	O
.	O

Neruoprotection	O
rendered	O
by	O
MEPP	B-Chemical
may	O
be	O
associated	O
with	O
the	O
reudction	O
of	O
the	O
methapmhetamine	B-Chemical
-	O
idnuced	O
doapmine	B-Chemical
efflux	O
in	O
the	O
straitum	O
due	O
to	O
the	O
blcokade	O
of	O
extrastritaal	O
mlGuR5	O
,	O
and	O
with	O
a	O
decresae	O
in	O
hpyerthermia	O
.	O

Protetcive	O
efficcay	O
of	O
neurocative	O
steorids	B-Chemical
against	O
cociane	B-Chemical
kindeld	O
-	O
siezures	O
in	O
mcie	O
.	O

Neuraoctive	O
steorids	B-Chemical
demonstrate	O
phamracological	O
actoins	O
that	O
have	O
relevance	O
for	O
a	O
hsot	O
of	O
neuorlogical	O
and	O
psyhciatric	O
disordres	O
.	O

They	O
offer	O
proteciton	O
against	O
seizrues	O
in	O
a	O
range	O
of	O
moedls	O
and	O
seem	O
to	O
inihbit	O
certain	O
satges	O
of	O
durg	O
dpeendence	O
in	O
preclincial	O
assessemnts	O
.	O

The	O
present	O
sutdy	O
was	O
designed	O
to	O
evalutae	O
two	O
endoegnous	O
and	O
one	O
synthteic	O
neuroacitve	O
streoid	B-Chemical
that	O
positviely	O
modluate	O
the	O
gmama	B-Chemical
-	I-Chemical
aminobtuyric	I-Chemical
aicd	I-Chemical
(	O
GBAA	B-Chemical
(	O
A	O
)	O
)	O
recetpor	O
against	O
the	O
icnrease	O
in	O
sensitivtiy	O
to	O
the	O
convulsnat	O
effects	O
of	O
coacine	B-Chemical
engendered	O
by	O
repetaed	O
ccoaine	B-Chemical
administrtaion	O
(	O
seiuzre	O
kindlnig	O
)	O
.	O

Allopregnnaolone	B-Chemical
(	O
3alpha	B-Chemical
-	I-Chemical
hydrxoy	I-Chemical
-	I-Chemical
5alpha	I-Chemical
-	I-Chemical
pregann	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
,	O
pregnanoolne	B-Chemical
(	O
3alpha	B-Chemical
-	I-Chemical
hydrxoy	I-Chemical
-	I-Chemical
5beta	I-Chemical
-	I-Chemical
prgenan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
and	O
ganaxoolne	B-Chemical
(	O
a	O
snythetic	O
dreivative	O
of	O
allopregnanolone	B-Chemical
3alpha	B-Chemical
-	I-Chemical
hyrdoxy	I-Chemical
-	I-Chemical
3beta	I-Chemical
-	I-Chemical
mehtyl	I-Chemical
-	I-Chemical
5alpha	I-Chemical
-	I-Chemical
pergnan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
were	O
tseted	O
for	O
their	O
ability	O
to	O
supprses	O
the	O
exprsesion	O
(	O
atniconvulsant	O
effcet	O
)	O
and	O
deevlopment	O
(	O
anteipileptogenic	O
effcet	O
)	O
of	O
ccoaine	B-Chemical
-	O
knidled	O
seizrues	O
in	O
mlae	O
,	O
Swsis	O
-	O
Wesbter	O
mcie	O
.	O

Kidnled	O
siezures	O
were	O
induecd	O
by	O
daliy	O
administratoin	O
of	O
60	O
mg	O
/	O
kg	O
ccoaine	B-Chemical
for	O
5	O
dyas	O
.	O

All	O
of	O
these	O
psoitive	O
GBAA	B-Chemical
(	O
A	O
)	O
modulatros	O
supprsesed	O
the	O
expresison	O
of	O
knidled	O
seizrues	O
,	O
whereas	O
only	O
allopregnaonlone	B-Chemical
and	O
ganxaolone	B-Chemical
inhibietd	O
the	O
developmnet	O
of	O
knidling	O
.	O

Allopregnanoolne	B-Chemical
and	O
prenganolone	B-Chemical
,	O
but	O
not	O
ganaoxlone	B-Chemical
,	O
also	O
redcued	O
cumultaive	O
lethlaity	O
associated	O
with	O
knidling	O
.	O

These	O
fidnings	O
demonstrate	O
that	O
some	O
neuroacitve	O
setroids	B-Chemical
attenuate	O
conuvlsant	O
and	O
sensiitzing	O
propetries	O
of	O
coacine	B-Chemical
and	O
add	O
to	O
a	O
growing	O
litearture	O
on	O
their	O
potetnial	O
use	O
in	O
the	O
moudlation	O
of	O
efefcts	O
of	O
durgs	O
of	O
absue	O
.	O

Effect	O
of	O
humoarl	O
mdoulators	O
of	O
morhpine	B-Chemical
-	O
inudced	O
incresae	O
in	O
lcoomotor	O
atcivity	O
of	O
mcie	O
.	O

The	O
effect	O
of	O
humoarl	O
modulatros	O
on	O
the	O
mrophine	B-Chemical
-	O
inudced	O
icnrease	O
in	O
locomtoor	O
activtiy	O
of	O
mcie	O
was	O
studied	O
.	O

The	O
subcuatneous	O
adminisrtation	O
of	O
10	O
mg	O
/	O
kg	O
of	O
morpihne	B-Chemical
-	O
HC1	O
produced	O
a	O
marked	O
incresae	O
in	O
locmootor	O
activtiy	O
in	O
mcie	O
.	O

The	O
moprhine	B-Chemical
-	O
idnuced	O
hyperactviity	O
was	O
potentiaetd	O
by	O
scooplamine	B-Chemical
and	O
attenuated	O
by	O
physostgimine	B-Chemical
.	O

In	O
contrast	O
,	O
both	O
methscopoalmine	B-Chemical
and	O
nesotigmine	B-Chemical
,	O
which	O
do	O
not	O
penetrtae	O
the	O
bolod	O
-	O
brian	O
barirer	O
,	O
had	O
no	O
effcet	O
on	O
the	O
hyperacitvity	O
produced	O
by	O
morphnie	B-Chemical
.	O

Pertreatment	O
of	O
mcie	O
with	O
aplha	B-Chemical
-	I-Chemical
methyltyrosnie	I-Chemical
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
one	O
hour	O
)	O
,	O
an	O
ihnibitor	O
of	O
tyrsoine	B-Chemical
hydroxlyase	O
,	O
significantly	O
decreaesd	O
the	O
atcivity	O
-	O
icnreasing	O
efefcts	O
of	O
mrophine	B-Chemical
.	O

On	O
the	O
other	O
hand	O
,	O
pretreatmnet	O
with	O
p	B-Chemical
-	I-Chemical
chloropheynlalamine	I-Chemical
(	O
3	O
X	O
320	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
24	O
hr	O
)	O
,	O
a	O
sertoonin	B-Chemical
depeltor	O
,	O
caused	O
no	O
significant	O
change	O
in	O
the	O
hpyeractivity	O
.	O

The	O
stduy	O
suggests	O
that	O
the	O
actiivty	O
-	O
inrceasing	O
effcets	O
of	O
mrophine	B-Chemical
are	O
mediated	O
by	O
the	O
rleease	O
of	O
catehcolamines	B-Chemical
from	O
adrenerigc	O
neruons	O
in	O
the	O
barin	O
.	O

And	O
the	O
rseults	O
are	O
consistent	O
with	O
the	O
hyptohesis	O
that	O
moprhine	B-Chemical
acts	O
by	O
rtearding	O
the	O
rleease	O
of	O
acetylcohline	B-Chemical
at	O
some	O
cenrtal	O
chloinergic	O
synaspes	O
.	O

It	O
is	O
also	O
suggested	O
from	O
collected	O
evidecne	O
that	O
the	O
actviity	O
-	O
inrceasing	O
effcets	O
of	O
moprhine	B-Chemical
in	O
mcie	O
are	O
mediated	O
by	O
mechnaisms	O
different	O
from	O
those	O
which	O
mediate	O
the	O
activtiy	O
-	O
increasnig	O
effects	O
of	O
moprhine	B-Chemical
in	O
rtas	O
.	O

Efefcts	O
of	O
uninephrecotmy	O
and	O
high	O
protien	O
fedeing	O
on	O
litihum	B-Chemical
-	O
idnuced	O
crhonic	O
reanl	O
fialure	O
in	O
rtas	O
.	O

Rtas	O
with	O
lithuim	B-Chemical
-	O
indcued	O
nephropahty	O
were	O
subjected	O
to	O
high	O
prtoein	O
(	O
HP	O
)	O
fedeing	O
,	O
uninephrecotmy	O
(	O
NX	O
)	O
or	O
a	O
combintaion	O
of	O
these	O
,	O
in	O
an	O
attempt	O
to	O
indcue	O
glomeurlar	O
hyperfitlration	O
and	O
further	O
prgoression	O
of	O
rneal	O
failrue	O
.	O

Nweborn	O
feamle	O
Wsitar	O
rtas	O
were	O
fed	O
a	O
lihtium	B-Chemical
-	O
containing	O
deit	O
(	O
50	O
mmol	O
/	O
kg	O
)	O
for	O
8	O
weeks	O
and	O
then	O
randomzied	O
to	O
noraml	O
deit	O
,	O
HP	O
deit	O
(	O
40	O
vs	O
.	O
19	O
%	O
)	O
,	O
NX	O
or	O
HP	O
+	O
NX	O
for	O
another	O
8	O
weeks	O
.	O

Corresponding	O
non	O
-	O
lithuim	B-Chemical
pretraeted	O
gropus	O
were	O
generated	O
.	O

When	O
cmoparing	O
all	O
litihum	B-Chemical
treaetd	O
versus	O
non	O
-	O
ltihium	B-Chemical
-	O
traeted	O
gropus	O
,	O
lihtium	B-Chemical
caused	O
a	O
redcution	O
in	O
gloemrular	O
filrtation	O
rtae	O
(	O
GFR	O
)	O
without	O
significant	O
chanegs	O
in	O
effective	O
rneal	O
plsama	O
folw	O
(	O
as	O
determined	O
by	O
a	O
mraker	O
scereted	O
into	O
the	O
proxiaml	O
tbuules	O
)	O
or	O
ltihium	B-Chemical
claerance	O
.	O

Consequently	O
,	O
ltihium	B-Chemical
preteratment	O
caused	O
a	O
fall	O
in	O
filtartion	O
fraciton	O
and	O
an	O
inrcease	O
in	O
fracitonal	O
Li	B-Chemical
excertion	O
.	O

Lithuim	B-Chemical
also	O
caused	O
proteinruia	O
and	O
sytsolic	O
hypertnesion	O
in	O
asbence	O
of	O
glomreulosclerosis	O
.	O

HP	O
failed	O
to	O
accentuante	O
progrsesion	O
of	O
reanl	O
failrue	O
and	O
in	O
fact	O
tended	O
to	O
incresae	O
GFR	O
and	O
dcerease	O
palsma	O
craetinine	B-Chemical
leevls	O
in	O
ltihium	B-Chemical
preterated	O
rtas	O
.	O

NX	O
caused	O
an	O
additive	O
deterioratoin	O
in	O
GFR	O
which	O
,	O
however	O
,	O
was	O
ameilorated	O
by	O
HP	O
.	O

NX	O
+	O
HP	O
caused	O
a	O
further	O
rise	O
in	O
bolod	O
prsesure	O
in	O
Li	B-Chemical
-	O
pertreated	O
rtas	O
.	O

The	O
reuslts	O
indicate	O
that	O
Li	B-Chemical
-	O
inudced	O
nephrpoathy	O
,	O
even	O
when	O
the	O
GFR	O
is	O
only	O
modestly	O
rdeuced	O
,	O
is	O
associated	O
with	O
proteniuria	O
and	O
aretrial	O
ssytolic	O
hypetrension	O
.	O

In	O
this	O
moedl	O
of	O
crhonic	O
rneal	O
failrue	O
the	O
decilne	O
in	O
GFR	O
is	O
not	O
accompanied	O
by	O
a	O
corresponding	O
fall	O
in	O
effectvie	O
rneal	O
palsma	O
folw	O
,	O
which	O
may	O
be	O
the	O
fucntional	O
experssion	O
of	O
the	O
foramtion	O
of	O
nonfiltrating	O
atbuular	O
glomerlui	O
.	O

The	O
farctional	O
reabsorptoin	O
of	O
tubluar	O
fliud	O
by	O
the	O
proxiaml	O
tuubles	O
is	O
rdeuced	O
,	O
leaving	O
the	O
dsital	O
delivrey	O
unhcanged	O
.	O
(	O
ABSTRACT	O
TURNCATED	O
AT	O
250	O
WORDS	O
)	O

Treamtent	O
of	O
Corhn	O
'	O
s	O
disesae	O
with	O
fuisdic	B-Chemical
aicd	I-Chemical
:	O
an	O
antibioitc	O
with	O
immunosuppressvie	O
propetries	O
similar	O
to	O
cylcosporin	B-Chemical
.	O

Fusiidc	O
aicd	O
is	O
an	O
antiibotic	O
with	O
T	O
-	O
clel	O
specific	O
immunosuppressive	O
effects	O
similar	O
to	O
those	O
of	O
cyclosoprin	B-Chemical
.	O

Because	O
of	O
the	O
need	O
for	O
the	O
deveolpment	O
of	O
new	O
treatmetns	O
for	O
Corhn	O
'	O
s	O
disaese	O
,	O
a	O
pliot	O
sutdy	O
was	O
undertaken	O
to	O
etsimate	O
the	O
pharmacodynmaics	O
and	O
tolreability	O
of	O
fuisdic	B-Chemical
aicd	I-Chemical
treatemnt	O
in	O
crhonic	O
actvie	O
,	O
therpay	O
-	O
reisstant	O
patinets	O
.	O

Eight	O
Crhon	O
'	O
s	O
disesae	O
patietns	O
were	O
included	O
.	O

Fsuidic	B-Chemical
aicd	I-Chemical
was	O
admniistered	O
orally	O
in	O
a	O
dsoe	O
of	O
500	O
mg	O
t	O
.	O
d	O
.	O
s	O
.	O
and	O
the	O
teratment	O
was	O
planned	O
to	O
last	O
8	O
wekes	O
.	O

The	O
disaese	O
atcivity	O
was	O
primarily	O
maesured	O
by	O
a	O
modifeid	O
indivdiual	O
gradnig	O
socre	O
.	O

Five	O
of	O
8	O
patinets	O
(	O
63	O
%	O
)	O
imprvoed	O
during	O
fuisdic	B-Chemical
aicd	I-Chemical
treamtent	O
:	O
3	O
at	O
two	O
wekes	O
and	O
2	O
after	O
four	O
weeks	O
.	O

There	O
were	O
no	O
serious	O
cilnical	O
side	O
effetcs	O
,	O
but	O
dsoe	O
reduciton	O
was	O
required	O
in	O
two	O
patinets	O
because	O
of	O
nuasea	O
.	O

Boichemically	O
,	O
an	O
incerase	O
in	O
alkailne	O
phosphatsaes	O
was	O
noted	O
in	O
5	O
of	O
8	O
caess	O
(	O
63	O
%	O
)	O
,	O
and	O
the	O
greatest	O
incraeses	O
were	O
seen	O
in	O
those	O
who	O
had	O
eleavted	O
lveels	O
prior	O
to	O
traetment	O
.	O

All	O
reevrsed	O
to	O
pre	O
-	O
treamtent	O
lveels	O
after	O
cesastion	O
of	O
treamtent	O
.	O

The	O
resutls	O
of	O
this	O
pliot	O
sutdy	O
suggest	O
that	O
fuisdic	B-Chemical
aicd	I-Chemical
may	O
be	O
of	O
bneefit	O
in	O
selected	O
crhonic	O
actvie	O
Corhn	O
'	O
s	O
diesase	O
patinets	O
in	O
whom	O
conventinoal	O
treatmnet	O
is	O
ineffetcive	O
.	O

Because	O
there	O
seems	O
to	O
exist	O
a	O
scinetific	O
rationale	O
for	O
the	O
use	O
of	O
fusdiic	B-Chemical
aicd	I-Chemical
at	O
the	O
ctyokine	O
leevl	O
in	O
inflammaotry	O
bwoel	O
diesase	O
,	O
we	O
suggest	O
that	O
the	O
role	O
of	O
this	O
treamtent	O
should	O
be	O
further	O
invesitgated	O
.	O

Chanegs	O
in	O
deperssive	O
stauts	O
associated	O
with	O
topcial	O
btea	O
-	O
blocekrs	O
.	O

Depresison	O
and	O
sxeual	O
dysfuntcion	O
have	O
been	O
related	O
to	O
side	O
effetcs	O
of	O
tpoical	O
btea	O
-	O
blokcers	O
.	O

We	O
performed	O
a	O
preliminary	O
sutdy	O
in	O
order	O
to	O
determine	O
any	O
difference	O
between	O
a	O
non	O
selective	O
btea	O
-	O
blcoker	O
(	O
tmiolol	B-Chemical
)	O
and	O
a	O
selective	O
btea	O
-	O
blokcer	O
(	O
betxaolol	B-Chemical
)	O
regarding	O
CNS	O
side	O
effetcs	O
.	O

Eight	O
glaucoamtous	O
paitents	O
chroincally	O
traeted	O
with	O
timlool	B-Chemical
0	O
.	O
5	O
%	O
/	O
12h	O
,	O
sufefring	O
from	O
depresison	O
diagnsoed	O
through	O
DMS	O
-	O
III	O
-	O
R	O
critreia	O
,	O
were	O
included	O
in	O
the	O
sutdy	O
.	O

During	O
the	O
six	O
-	O
mnoth	O
follow	O
up	O
,	O
dperession	O
was	O
qauntified	O
through	O
the	O
Bcek	O
and	O
Znug	O
-	O
Codne	O
sclaes	O
every	O
two	O
mnoths	O
.	O

In	O
a	O
double	O
blnid	O
crsos	O
-	O
over	O
sutdy	O
with	O
conrtol	O
gorup	O
,	O
the	O
ptaients	O
under	O
tmiolol	B-Chemical
tretament	O
presented	O
higehr	O
deprsesion	O
vlaues	O
maesured	O
through	O
the	O
Bcek	O
and	O
the	O
Znug	O
-	O
Cnode	O
scaels	O
(	O
p	O
<	O
0	O
.	O
001	O
vs	O
contorl	O
)	O
.	O

These	O
resluts	O
suggest	O
that	O
betaxlool	B-Chemical
could	O
be	O
less	O
of	O
a	O
depresison	O
-	O
idnucer	O
than	O
timooll	B-Chemical
in	O
perdisposed	O
patinets	O
.	O

Prtoection	O
against	O
amphteamine	B-Chemical
-	O
idnuced	O
neruotoxicity	O
toward	O
striaatl	O
dpoamine	B-Chemical
neurnos	O
in	O
rodnets	O
by	O
LY247614	B-Chemical
,	O
an	O
excitatroy	O
amnio	B-Chemical
aicd	I-Chemical
atnagonist	O
.	O

LY247614	B-Chemical
,	O
3SR	B-Chemical
,	I-Chemical
4aRS	I-Chemical
,	I-Chemical
6SR	I-Chemical
,	I-Chemical
8aRS	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
[	I-Chemical
phopshonomethyl	I-Chemical
]	I-Chemical
dceahydr	I-Chemical
oiosquinoline	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carbxoylic	I-Chemical
aicd	I-Chemical
,	O
has	O
been	O
described	O
as	O
a	O
potent	O
antagonsit	O
of	O
the	O
N	B-Chemical
-	I-Chemical
mtehyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
asparatte	I-Chemical
(	O
NDMA	B-Chemical
)	O
sbutype	O
of	O
gluatmate	B-Chemical
recpetor	O
.	O

Here	O
its	O
ability	O
to	O
antagnoize	O
the	O
porlonged	O
depletoin	O
of	O
dopmaine	B-Chemical
in	O
the	O
straitum	O
by	O
amphetmaine	B-Chemical
in	O
ipirndole	B-Chemical
-	O
tretaed	O
rtas	O
is	O
reported	O
.	O

A	O
single	O
18	O
.	O
4	O
mg	O
/	O
kg	O
(	O
i	O
.	O
p	O
.	O
)	O
dsoe	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
amphetamnie	B-Chemical
hemiuslfate	O
,	O
given	O
to	O
rtas	O
prtereated	O
with	O
iprinodle	B-Chemical
,	O
resulted	O
in	O
presistent	O
depletoin	O
of	O
dopaimne	B-Chemical
in	O
the	O
stritaum	O
1	O
week	O
later	O
.	O

This	O
proolnged	O
deplteion	O
of	O
dopmaine	B-Chemical
in	O
the	O
stritaum	O
was	O
antgaonized	O
by	O
dizoiclpine	B-Chemical
(	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
,	O
a	O
non	O
-	O
competitive	O
atnagonist	O
of	O
NDMA	B-Chemical
receptros	O
)	O
or	O
by	O
L2Y74614	B-Chemical
(	O
a	O
competitive	O
antagnoist	O
of	O
NDMA	B-Chemical
rceeptors	O
)	O
.	O

The	O
protective	O
effcet	O
of	O
L2Y74614	B-Chemical
was	O
dsoe	O
-	O
depnedent	O
,	O
being	O
maixmum	O
at	O
10	O
-	O
40	O
mkgg	O
(	O
i	O
.	O
p	O
.	O
)	O
.	O

A	O
10	O
mg	O
/	O
kg	O
dsoe	O
of	O
LY724614	B-Chemical
was	O
efefctive	O
in	O
antagonizing	O
the	O
depleiton	O
of	O
dopmaine	B-Chemical
in	O
the	O
srtiatum	O
,	O
when	O
given	O
as	O
long	O
as	O
8	O
hr	O
prior	O
to	O
amphetamnie	B-Chemical
but	O
not	O
when	O
given	O
24	O
hr	O
prior	O
to	O
ampehtamine	B-Chemical
.	O

Deplteion	O
of	O
dopamnie	B-Chemical
in	O
the	O
srtiatum	O
was	O
also	O
antagonzied	O
when	O
LY724614	B-Chemical
was	O
given	O
after	O
the	O
injeciton	O
of	O
amphteamine	B-Chemical
;	O
LY274164	B-Chemical
protected	O
when	O
given	O
up	O
to	O
4	O
hr	O
after	O
but	O
not	O
when	O
given	O
8	O
or	O
24	O
hr	O
after	O
amphteamine	B-Chemical
.	O

The	O
prolnoged	O
deplteion	O
of	O
dopaimne	B-Chemical
in	O
the	O
srtiatum	O
in	O
mcie	O
,	O
given	O
mlutiple	O
injcetions	O
of	O
methmaphetamine	B-Chemical
,	O
was	O
also	O
anatgonized	O
dsoe	O
-	O
dependently	O
and	O
completely	O
by	O
LY247614	B-Chemical
.	O

The	O
dtaa	O
strengthen	O
the	O
evdience	O
that	O
the	O
neurootxic	O
effect	O
of	O
ampheatmine	B-Chemical
and	O
related	O
componuds	O
toward	O
nirgostriatal	O
dpoamine	B-Chemical
neurnos	O
involves	O
NDMA	B-Chemical
recpetors	O
and	O
that	O
LY724614	B-Chemical
is	O
an	O
NDMA	B-Chemical
recetpor	O
antagonsit	O
with	O
long	O
-	O
lasting	O
in	O
vivo	O
efefcts	O
in	O
rtas	O
.	O

Ketcoonazole	B-Chemical
-	O
induecd	O
neurloogic	O
sqeuelae	O
.	O

A	O
77	O
-	O
y	O
-	O
old	O
paitent	O
developed	O
weakenss	O
of	O
exrtemities	O
,	O
lges	O
praalysis	O
,	O
dyasrthria	O
and	O
trmeor	O
1	O
h	O
after	O
inegstion	O
of	O
200	O
mg	O
ketoconaozle	B-Chemical
for	O
the	O
first	O
tmie	O
in	O
his	O
lfie	O
.	O

All	O
complaitns	O
faded	O
away	O
within	O
24	O
h	O
.	O

Few	O
dyas	O
later	O
,	O
the	O
pateint	O
used	O
another	O
200	O
mg	O
ketocnoazole	B-Chemical
tabelt	O
,	O
and	O
within	O
an	O
hour	O
experienced	O
a	O
similar	O
cliincal	O
pitcure	O
,	O
which	O
resolved	O
again	O
spontaneoulsy	O
within	O
hours	O
.	O

Labortaory	O
eavluations	O
,	O
including	O
haed	O
CT	O
sacn	O
,	O
were	O
nromal	O
.	O

This	O
csae	O
illustrates	O
the	O
need	O
for	O
close	O
vigliance	O
in	O
advesre	O
durg	O
reacitons	O
,	O
particularly	O
in	O
the	O
eldrely	O
.	O

Developmnet	O
of	O
levdoopa	B-Chemical
-	O
idnuced	O
dysiknesias	O
in	O
parkinosnian	O
mokneys	O
may	O
depend	O
upon	O
rtae	O
of	O
smyptom	O
onset	O
and	O
/	O
or	O
duraiton	O
of	O
sypmtoms	O
.	O

Levoodpa	B-Chemical
-	O
indcued	O
dysiknesias	O
(	O
LDIs	O
)	O
present	O
a	O
major	O
prolbem	O
for	O
the	O
long	O
-	O
term	O
mnaagement	O
of	O
Pariknson	O
'	O
s	O
dsiease	O
(	O
PD	O
)	O
pateints	O
.	O

Due	O
to	O
the	O
interdeepndence	O
of	O
rsik	O
facotrs	O
in	O
clniical	O
popultaions	O
,	O
it	O
is	O
difficult	O
to	O
independently	O
examine	O
fcators	O
that	O
may	O
infleunce	O
the	O
developmnet	O
of	O
LDIs	O
.	O

Using	O
macqaue	O
mokneys	O
with	O
different	O
types	O
of	O
MTPP	B-Chemical
-	O
induecd	O
parkinsnoism	O
,	O
the	O
current	O
stduy	O
evaluaetd	O
the	O
degere	O
to	O
which	O
rtae	O
of	O
smyptom	O
prgoression	O
,	O
sypmtom	O
seevrity	O
,	O
and	O
rseponse	O
to	O
and	O
durtaion	O
of	O
leovdopa	B-Chemical
tehrapy	O
may	O
be	O
involved	O
in	O
the	O
deevlopment	O
of	O
LDIs	O
.	O

Mnokeys	O
with	O
actue	O
(	O
short	O
-	O
term	O
)	O
MTPP	B-Chemical
epxosure	O
,	O
rpaid	O
symtpom	O
onset	O
and	O
short	O
smyptom	O
duartion	O
prior	O
to	O
iintiation	O
of	O
lveodopa	B-Chemical
threapy	O
developed	O
dsykinesia	O
between	O
11	O
and	O
24	O
dyas	O
of	O
daliy	O
lveodopa	B-Chemical
administrtaion	O
.	O

In	O
contrast	O
,	O
mnokeys	O
with	O
long	O
-	O
term	O
MTPP	B-Chemical
epxosure	O
,	O
slow	O
sypmtom	O
prorgession	O
and	O
/	O
or	O
long	O
sypmtom	O
durtaion	O
prior	O
to	O
iniitation	O
of	O
levodpoa	B-Chemical
tehrapy	O
were	O
more	O
resitsant	O
to	O
developing	O
LDIs	O
(	O
e	O
.	O
g	O
.	O
,	O
dyksinesia	O
developed	O
no	O
sooner	O
than	O
146	O
dyas	O
of	O
crhonic	O
levodpoa	B-Chemical
adimnistration	O
)	O
.	O

All	O
animlas	O
were	O
similarly	O
symptomtaic	O
at	O
the	O
start	O
of	O
levdoopa	B-Chemical
tretament	O
and	O
had	O
similar	O
thearpeutic	O
responess	O
to	O
the	O
durg	O
.	O

These	O
dtaa	O
suggest	O
distinct	O
diffeernces	O
in	O
the	O
propenisty	O
to	O
develop	O
LDIs	O
in	O
monkyes	O
with	O
different	O
raets	O
of	O
sypmtom	O
prgoression	O
or	O
smyptom	O
duraitons	O
prior	O
to	O
levodpoa	B-Chemical
and	O
demonstrate	O
the	O
value	O
of	O
these	O
moedls	O
for	O
further	O
studying	O
the	O
ptahophysiology	O
of	O
LDIs	O
.	O

A	O
deit	O
promoting	O
suagr	O
depednency	O
causes	O
bheavioral	O
corss	O
-	O
sensitiaztion	O
to	O
a	O
low	O
dsoe	O
of	O
ampheatmine	B-Chemical
.	O

Previous	O
reserach	O
in	O
this	O
lbaoratory	O
has	O
shown	O
that	O
a	O
deit	O
of	O
intermtitent	O
execssive	O
suagr	O
consumptoin	O
produces	O
a	O
state	O
with	O
neurocheimcal	O
and	O
behavoiral	O
similraities	O
to	O
durg	O
dependecny	O
.	O

The	O
present	O
sutdy	O
examined	O
whether	O
fmeale	O
rtas	O
on	O
various	O
reigmens	O
of	O
suagr	O
access	O
would	O
show	O
behvaioral	O
corss	O
-	O
sensitziation	O
to	O
a	O
low	O
dsoe	O
of	O
amhpetamine	B-Chemical
.	O

After	O
a	O
30	O
-	O
min	O
baselnie	O
meausre	O
of	O
locomtoor	O
activtiy	O
(	O
day	O
0	O
)	O
,	O
anmials	O
were	O
maintained	O
on	O
a	O
cycilc	O
deit	O
of	O
12	O
-	O
h	O
dperivation	O
followed	O
by	O
12	O
-	O
h	O
access	O
to	O
10	O
%	O
sucorse	B-Chemical
solutoin	O
and	O
cohw	O
pelelts	O
(	O
12	O
h	O
access	O
starting	O
4	O
h	O
after	O
onset	O
of	O
the	O
drak	O
peirod	O
)	O
for	O
21	O
dyas	O
.	O

Locomootr	O
atcivity	O
was	O
measrued	O
again	O
for	O
30	O
min	O
at	O
the	O
beginning	O
of	O
dyas	O
1	O
and	O
21	O
of	O
suagr	O
access	O
.	O

Beginning	O
on	O
day	O
22	O
,	O
all	O
rtas	O
were	O
maintained	O
on	O
ad	O
liibtum	O
cohw	O
.	O

Nine	O
dyas	O
later	O
locmootor	O
activtiy	O
was	O
mesaured	O
in	O
respnose	O
to	O
a	O
single	O
low	O
dsoe	O
of	O
amphetaimne	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

The	O
ainmals	O
that	O
had	O
experienced	O
ccylic	O
sucrsoe	B-Chemical
and	O
cohw	O
were	O
hypreactive	O
in	O
rseponse	O
to	O
amphetmaine	B-Chemical
comapred	O
with	O
four	O
conrtol	O
gorups	O
(	O
ad	O
libiutm	O
10	O
%	O
sucrsoe	B-Chemical
and	O
cohw	O
followed	O
by	O
amphetmaine	B-Chemical
injeciton	O
,	O
ccylic	O
cohw	O
followed	O
by	O
amphetaimne	B-Chemical
injeciton	O
,	O
ad	O
liibtum	O
cohw	O
with	O
amphetmaine	B-Chemical
,	O
or	O
cycilc	O
10	O
%	O
surcose	B-Chemical
and	O
cohw	O
with	O
a	O
salnie	O
injetcion	O
)	O
.	O

These	O
resutls	O
suggest	O
that	O
a	O
deit	O
comprised	O
of	O
alternating	O
depirvation	O
and	O
access	O
to	O
a	O
sguar	O
soltuion	O
and	O
cohw	O
produces	O
bnigeing	O
on	O
sguar	O
that	O
leads	O
to	O
a	O
long	O
lasting	O
state	O
of	O
inrceased	O
sensitivtiy	O
to	O
amphteamine	B-Chemical
,	O
possibly	O
due	O
to	O
a	O
lasting	O
alteraiton	O
in	O
the	O
dopamnie	B-Chemical
sytsem	O
.	O

Reevrsible	O
dliated	O
cardiomyopahty	O
related	O
to	O
amphtoericin	B-Chemical
B	I-Chemical
tehrapy	O
.	O

We	O
describe	O
a	O
paitent	O
who	O
developed	O
diltaed	O
cardiomyoptahy	O
and	O
cilnical	O
cognestive	O
herat	O
fialure	O
after	O
2	O
mnoths	O
of	O
threapy	O
with	O
ampohtericin	B-Chemical
B	I-Chemical
(	O
AmB	B-Chemical
)	O
for	O
disseminaetd	O
coccidiiodomycosis	O
.	O

His	O
echocradiographic	O
abnoramlities	O
and	O
herat	O
faliure	O
resolved	O
after	O
posaconazloe	B-Chemical
was	O
substittued	O
for	O
AmB	B-Chemical
.	O

It	O
is	O
important	O
to	O
recognize	O
the	O
rrae	O
and	O
potentially	O
reversible	O
txoicity	O
of	O
AmB	B-Chemical
.	O

NO	B-Chemical
-	O
induecd	O
migranie	O
attcak	O
:	O
strong	O
icnrease	O
in	O
plsama	O
calictonin	B-Chemical
gnee	I-Chemical
-	I-Chemical
related	I-Chemical
petpide	I-Chemical
(	O
CRGP	B-Chemical
)	O
cnocentration	O
and	O
neagtive	O
correltaion	O
with	O
plateelt	O
serotoinn	B-Chemical
relaese	O
.	O

The	O
aim	O
of	O
the	O
present	O
stduy	O
was	O
to	O
invsetigate	O
chanegs	O
in	O
the	O
palsma	O
caclitonin	B-Chemical
gnee	I-Chemical
-	I-Chemical
related	I-Chemical
peptdie	I-Chemical
(	O
CRGP	B-Chemical
)	O
concentrtaion	O
and	O
pltaelet	O
sertoonin	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
hydroxytriptamnie	I-Chemical
,	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
cnotent	O
during	O
the	O
imemdiate	O
haedache	O
and	O
the	O
dleayed	O
genuine	O
mgiraine	O
attcak	O
provoked	O
by	O
nitorglycerin	B-Chemical
.	O

Fifteen	O
feamle	O
migraienurs	O
(	O
without	O
arua	O
)	O
and	O
eight	O
contorls	O
participated	O
in	O
the	O
stduy	O
.	O

Subilngual	O
nitrogylcerin	B-Chemical
(	O
0	O
.	O
5	O
mg	O
)	O
was	O
amdinistered	O
.	O

Bolod	O
was	O
collected	O
from	O
the	O
antecubiatl	O
vien	O
four	O
times	O
:	O
60	O
min	O
before	O
and	O
after	O
the	O
nirtoglycerin	B-Chemical
aplpication	O
,	O
and	O
60	O
and	O
120	O
min	O
after	O
the	O
beginning	O
of	O
the	O
migranie	O
atatck	O
(	O
mean	O
344	O
and	O
404	O
min	O
;	O
12	O
sbujects	O
)	O
.	O

In	O
those	O
subjetcs	O
who	O
had	O
no	O
mgiraine	O
attack	O
(	O
11	O
sujbects	O
)	O
a	O
similar	O
tmie	O
scheudle	O
was	O
used	O
.	O

Palsma	O
CRGP	B-Chemical
concentrtaion	O
increaesd	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
during	O
the	O
migarine	O
attcak	O
and	O
returned	O
to	O
baselnie	O
after	O
the	O
cessation	O
of	O
the	O
migarine	O
.	O

In	O
addition	O
,	O
both	O
change	O
and	O
peak	O
,	O
showed	O
significant	O
postiive	O
correltaions	O
with	O
mirgaine	O
haedache	O
intesnity	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

However	O
,	O
plsama	O
CRGP	B-Chemical
conecntrations	O
failed	O
to	O
change	O
during	O
immeditae	O
hedaache	O
and	O
in	O
the	O
subejcts	O
with	O
no	O
mirgaine	O
attcak	O
.	O

Baasl	O
CRGP	B-Chemical
concenrtation	O
was	O
significantly	O
higehr	O
and	O
plateelt	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
cotnent	O
tended	O
to	O
be	O
lwoer	O
in	O
subjetcs	O
who	O
experienced	O
a	O
migranie	O
atatck	O
.	O

Paltelet	O
sertoonin	B-Chemical
conetnt	O
decresaed	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
after	O
nitrgolycerin	B-Chemical
in	O
sbujects	O
with	O
no	O
migriane	O
atatck	O
but	O
no	O
consistent	O
change	O
was	O
observed	O
in	O
patietns	O
with	O
migranie	O
attcak	O
.	O

In	O
conclusion	O
,	O
the	O
fact	O
that	O
plamsa	O
CRGP	B-Chemical
concentrtaion	O
correaltes	O
with	O
the	O
tmiing	O
and	O
sevreity	O
of	O
a	O
mgiraine	O
heaadche	O
suggests	O
a	O
direct	O
relatiosnhip	O
between	O
CRGP	B-Chemical
and	O
migarine	O
.	O

In	O
contrast	O
,	O
serotoinn	B-Chemical
relesae	O
from	O
plateltes	O
does	O
not	O
provoke	O
mgiraine	O
,	O
it	O
may	O
even	O
counteract	O
the	O
haedache	O
and	O
the	O
concmoitant	O
CRGP	B-Chemical
rleease	O
in	O
this	O
moedl	O
.	O

Hpyerbaric	O
oyxgen	B-Chemical
thearpy	O
for	O
cotnrol	O
of	O
intractbale	O
ccylophosphamide	B-Chemical
-	O
idnuced	O
heomrrhagic	O
cytsitis	O
.	O

We	O
rpeort	O
a	O
csae	O
of	O
intarctable	O
hmeorrhagic	O
cytsitis	O
due	O
to	O
cyclohposphamide	B-Chemical
thearpy	O
for	O
Wegneer	O
'	O
s	O
granulomaotsis	O
.	O

Conservaitve	O
tretament	O
,	O
including	O
bldader	O
irrigaiton	O
with	O
physiologiacl	O
slaine	O
and	O
instilltaion	O
of	O
porstaglandin	B-Chemical
F2	I-Chemical
aplha	I-Chemical
,	O
failed	O
to	O
totally	O
conrtol	O
hemorhrage	O
.	O

We	O
then	O
used	O
hyperbairc	O
oyxgen	B-Chemical
at	O
an	O
absoltue	O
prsesure	O
of	O
2	O
atm	O
,	O
5	O
dyas	O
a	O
week	O
for	O
8	O
consectuive	O
weeks	O
.	O

The	O
bleeidng	O
caesed	O
completely	O
by	O
the	O
end	O
of	O
traetment	O
and	O
the	O
patinet	O
remained	O
free	O
of	O
hmeaturia	O
thereafter	O
.	O

No	O
side	O
effect	O
was	O
noted	O
during	O
the	O
cousre	O
of	O
threapy	O
.	O

In	O
future	O
,	O
this	O
form	O
of	O
therpay	O
can	O
offer	O
a	O
safe	O
atlernative	O
in	O
the	O
treamtent	O
of	O
cyclophosphaimde	B-Chemical
-	O
inudced	O
hemorrhagic	O
csytitis	O
.	O

Aucte	O
psyhcosis	O
due	O
to	O
treamtent	O
with	O
pheyntoin	B-Chemical
in	O
a	O
noneipleptic	O
patinet	O
.	O

The	O
develpoment	O
of	O
psyhcosis	O
related	O
to	O
antiepiletpic	O
durg	O
treatemnt	O
is	O
usually	O
attributed	O
to	O
the	O
intreaction	O
between	O
the	O
epilpetic	O
brian	O
substartum	O
and	O
the	O
anteipileptic	O
durgs	O
.	O

The	O
csae	O
of	O
a	O
nonepilepitc	O
patinet	O
who	O
developed	O
pyschosis	O
following	O
pheyntoin	B-Chemical
teratment	O
for	O
trigemianl	O
neurlagia	O
is	O
described	O
.	O

This	O
csae	O
suggests	O
that	O
the	O
pyschotic	O
symtpoms	O
that	O
occur	O
following	O
phenyotin	B-Chemical
treamtent	O
in	O
some	O
epilpetic	O
paitents	O
may	O
be	O
the	O
direct	O
result	O
of	O
mediaction	O
,	O
unrelated	O
to	O
seziures	O
.	O

Rikss	O
of	O
the	O
consmuption	O
of	O
bveerages	O
containing	O
quniine	B-Chemical
.	O

Although	O
the	O
Uinted	O
Sattes	O
Food	O
and	O
Durg	O
Admiinstration	O
banned	O
its	O
use	O
for	O
notcurnal	O
leg	O
crmaps	O
due	O
to	O
lcak	O
of	O
saftey	O
and	O
effciacy	O
,	O
quniine	B-Chemical
is	O
widely	O
available	O
in	O
bevergaes	O
including	O
toinc	O
wtaer	O
and	O
bitetr	O
lmeon	O
.	O

Numerous	O
anecdtoal	O
repotrs	O
suggest	O
that	O
porducts	O
containing	O
quiinne	B-Chemical
may	O
produce	O
neurologiacl	O
copmlications	O
,	O
including	O
confusoin	O
,	O
altreed	O
menatl	O
sttaus	O
,	O
seiuzres	O
,	O
and	O
cmoa	O
,	O
particularly	O
in	O
oledr	O
wmoen	O
.	O

Psyhcologists	O
need	O
to	O
inqurie	O
about	O
cnosumption	O
of	O
quniine	B-Chemical
-	O
containing	O
beevrages	O
as	O
part	O
of	O
an	O
evlauation	O
porcess	O
.	O

Tarnsient	O
pltaypnea	O
-	O
orthodeoixa	O
-	O
like	O
snydrome	O
inudced	O
by	O
proapfenone	B-Chemical
ovedrose	O
in	O
a	O
yuong	O
woamn	O
with	O
Esbtein	O
'	O
s	O
anmoaly	O
.	O

In	O
this	O
reoprt	O
we	O
describe	O
the	O
csae	O
of	O
a	O
37	O
-	O
yaer	O
-	O
old	O
wihte	O
woamn	O
with	O
Ebtsein	O
'	O
s	O
anmoaly	O
,	O
who	O
developed	O
a	O
rrae	O
sydnrome	O
called	O
playtpnea	O
-	O
ortohdeoxia	O
,	O
characteirzed	O
by	O
massive	O
rgiht	O
-	O
to	O
-	O
lfet	O
intertarial	O
shnuting	O
with	O
trnasient	O
porfound	O
hpyoxia	O
and	O
cyaonsis	O
.	O

This	O
suhnt	O
of	O
bolod	O
via	O
a	O
paetnt	O
froamen	O
ovlae	O
occurred	O
in	O
the	O
preesnce	O
of	O
a	O
nomral	O
pulmonray	O
artrey	O
perssure	O
,	O
and	O
was	O
probably	O
preicpitated	O
by	O
a	O
prpoafenone	B-Chemical
overodse	O
.	O

This	O
durg	O
caused	O
bievntricular	O
dsyfunction	O
,	O
due	O
to	O
its	O
neagtive	O
iontropic	O
effcet	O
,	O
and	O
hpyotension	O
,	O
due	O
to	O
its	O
periphreal	O
vasodliatory	O
effcet	O
.	O

These	O
effcets	O
gave	O
rise	O
to	O
an	O
incerase	O
in	O
the	O
rgiht	O
atiral	O
prsesure	O
and	O
a	O
dcerease	O
in	O
the	O
lfet	O
one	O
with	O
a	O
consequent	O
stertching	O
of	O
the	O
froamen	O
ovlae	O
and	O
the	O
cretaion	O
of	O
massive	O
rgiht	O
-	O
to	O
-	O
lfet	O
shnuting	O
.	O

In	O
our	O
csae	O
this	O
interatiral	O
shnut	O
was	O
very	O
accurately	O
deetcted	O
at	O
bbuble	O
contrast	O
echocradiography	O
.	O

Noxiuos	O
chemcial	O
stimultaion	O
of	O
rat	O
fcaial	O
mucsoa	O
incerases	O
intracrainal	O
blood	O
folw	O
through	O
a	O
trigemino	O
-	O
paraysmpathetic	O
rfelex	O
-	O
-	O
an	O
epxerimental	O
moedl	O
for	O
vascluar	O
dysfnuctions	O
in	O
clusetr	O
haedache	O
.	O

Clutser	O
headahce	O
is	O
charactreized	O
by	O
typical	O
autnoomic	O
dysfunctoins	O
including	O
fcaial	O
and	O
inrtacranial	O
vsacular	O
disturabnces	O
.	O

Both	O
the	O
trigeimnal	O
and	O
the	O
crnaial	O
parasypmathetic	O
sysetms	O
may	O
be	O
involved	O
in	O
mediating	O
these	O
dysfuncitons	O
.	O

An	O
exeprimental	O
moedl	O
was	O
developed	O
in	O
the	O
rat	O
to	O
measrue	O
cahnges	O
in	O
lacrimatoin	O
and	O
intracrainal	O
bolod	O
folw	O
following	O
noxoius	O
cehmical	O
stimualtion	O
of	O
facail	O
mucsoa	O
.	O

Bolod	O
folw	O
was	O
monitroed	O
in	O
aretries	O
of	O
the	O
expsoed	O
crainal	O
drua	O
mtaer	O
and	O
the	O
pariteal	O
cotrex	O
using	O
lsaer	O
Doppelr	O
flowmtery	O
.	O

Cpasaicin	B-Chemical
(	O
0	O
.	O
01	O
-	O
1	O
mm	O
)	O
applied	O
to	O
oarl	O
or	O
naasl	O
mcuosa	O
idnuced	O
inrceases	O
in	O
drual	O
and	O
coritcal	O
bolod	O
folw	O
and	O
provoked	O
lacrimaiton	O
.	O

These	O
resopnses	O
were	O
blokced	O
by	O
ssytemic	O
pre	O
-	O
amdinistration	O
of	O
hexamehtonium	B-Chemical
cholride	I-Chemical
(	O
20	O
mg	O
/	O
kg	O
)	O
.	O

The	O
eovked	O
incerases	O
in	O
duarl	O
bolod	O
folw	O
were	O
also	O
abolished	O
by	O
topiacl	O
pre	O
-	O
administrtaion	O
of	O
atropnie	B-Chemical
(	O
1	O
mm	O
)	O
and	O
[	O
Lsy1	O
,	O
Por2	O
,	O
5	O
,	O
Agr3	O
,	O
4	O
,	O
Try6	O
]	O
-	O
VIP	O
(	O
0	O
.	O
1	O
mm	O
)	O
,	O
a	O
vasoatcive	O
intsetinal	O
polypetpide	O
(	O
VIP	O
)	O
antaognist	O
,	O
onto	O
the	O
exopsed	O
drua	O
mtaer	O
.	O

We	O
conclude	O
that	O
noixous	O
stimluation	O
of	O
faical	O
mucsoa	O
increaess	O
intrcaranial	O
blood	O
folw	O
and	O
lacrmiation	O
via	O
a	O
trigemino	O
-	O
parasympahtetic	O
refelx	O
.	O

The	O
bolod	O
folw	O
rseponses	O
seem	O
to	O
be	O
mediated	O
by	O
the	O
reelase	O
of	O
aectylcholine	B-Chemical
and	O
VIP	O
within	O
the	O
menignes	O
.	O

Similar	O
mecahnisms	O
may	O
be	O
involved	O
in	O
the	O
pathogenseis	O
of	O
culster	O
hedaache	O
.	O

Orgnaophosphate	B-Chemical
-	O
idnuced	O
convulsoins	O
and	O
prevetnion	O
of	O
neruopathological	O
damaegs	O
.	O

Such	O
organopohsphorus	B-Chemical
(	O
OP	B-Chemical
)	O
cmopounds	O
as	O
diisopropylfluoropohsphate	B-Chemical
(	O
DFP	B-Chemical
)	O
,	O
sairn	B-Chemical
and	O
smoan	B-Chemical
are	O
potent	O
inhibitros	O
of	O
acetylcholinesteraess	O
(	O
AhCEs	O
)	O
and	O
butyrylcohlinesterases	O
(	O
BhCEs	O
)	O
.	O

The	O
actue	O
toixcity	O
of	O
OPs	B-Chemical
is	O
the	O
result	O
of	O
their	O
irreversible	O
bindnig	O
with	O
AhCEs	O
in	O
the	O
centarl	O
nerovus	O
sytsem	O
(	O
CNS	O
)	O
,	O
which	O
elveates	O
aectylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
lveels	O
.	O

The	O
protective	O
atcion	O
of	O
sucbutaneously	O
(	O
SC	O
)	O
amdinistered	O
antidoets	O
or	O
their	O
cmobinations	O
in	O
DFP	B-Chemical
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
intoxictaion	O
was	O
studied	O
in	O
9	O
-	O
10	O
-	O
wekes	O
-	O
old	O
Han	O
-	O
Wsitar	O
mlae	O
rtas	O
.	O

The	O
rtas	O
received	O
AhCE	O
reatcivator	O
pralidxoime	B-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
chlordie	I-Chemical
(	O
2PAM	B-Chemical
)	O
(	O
30	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
antcionvulsant	O
diaezpam	B-Chemical
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-	O
adeonsine	B-Chemical
recepotr	O
agnoist	O
N	B-Chemical
(	I-Chemical
6	I-Chemical
)	I-Chemical
-	I-Chemical
cyclopenytl	I-Chemical
adneosine	I-Chemical
(	O
CPA	B-Chemical
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NDMA	B-Chemical
-	O
reecptor	O
antaognist	O
dizcoilpine	B-Chemical
maletae	I-Chemical
(	O
+	O
-	O
M8K01	O
hydroegn	O
mlaeate	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combiantions	O
with	O
cholionlytic	O
durg	O
atroipne	B-Chemical
suflate	I-Chemical
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injectoin	O
of	O
DFP	B-Chemical
.	O

The	O
cnotrol	O
rtas	O
received	O
atropnie	B-Chemical
sulftae	I-Chemical
,	O
but	O
also	O
sailne	O
and	O
olvie	O
oil	O
instead	O
of	O
other	O
atnidotes	O
and	O
DFP	B-Chemical
,	O
respectively	O
.	O

All	O
rtas	O
were	O
treminated	O
either	O
24	O
h	O
or	O
3	O
wekes	O
after	O
the	O
DFP	B-Chemical
injetcion	O
.	O

The	O
rtas	O
tretaed	O
with	O
DFP	B-Chemical
-	O
atropnie	B-Chemical
showed	O
sevree	O
typical	O
OP	B-Chemical
-	O
inudced	O
toixcity	O
sings	O
.	O

When	O
CPA	B-Chemical
,	O
diaezpam	B-Chemical
or	O
2PAM	B-Chemical
was	O
given	O
immediately	O
after	O
DFP	B-Chemical
-	O
atorpine	B-Chemical
,	O
these	O
treatemnts	O
prevented	O
,	O
delaeyd	O
or	O
shortneed	O
the	O
occurrnece	O
of	O
serious	O
sgins	O
of	O
posioning	O
.	O

Artopine	B-Chemical
-	O
MK081	B-Chemical
did	O
not	O
offer	O
any	O
additional	O
portection	O
against	O
DFP	B-Chemical
toxiicty	O
.	O

In	O
conclusion	O
,	O
CPA	B-Chemical
,	O
diazpeam	B-Chemical
and	O
2PAM	B-Chemical
in	O
combniation	O
with	O
atrpoine	B-Chemical
prevented	O
the	O
occurrecne	O
of	O
serious	O
sings	O
of	O
posioning	O
and	O
thus	O
reudced	O
the	O
toixcity	O
of	O
DFP	B-Chemical
in	O
rat	O
.	O

A	O
pryidoxine	B-Chemical
-	O
depenednt	O
behaivoral	O
diosrder	O
unmasekd	O
by	O
isoinazid	B-Chemical
.	O

A	O
3	O
-	O
yaer	O
-	O
old	O
gril	O
had	O
behavioarl	O
deterioratoin	O
,	O
with	O
hyeprkinesis	O
,	O
irritability	O
,	O
and	O
sleeipng	O
diffiuclties	O
after	O
the	O
threapeutic	O
adminisrtation	O
of	O
iosniazid	B-Chemical
.	O

The	O
adimnistration	O
of	O
pharmacloogic	O
doess	O
of	O
pyridxoine	B-Chemical
hydrochlordie	I-Chemical
led	O
to	O
a	O
disappeaarnce	O
of	O
symptmos	O
.	O

After	O
dicsontinuing	O
isonizaid	B-Chemical
therpay	O
a	O
similar	O
pattern	O
of	O
behaivor	O
was	O
noted	O
that	O
was	O
contrloled	O
by	O
pryidoxine	B-Chemical
.	O

A	O
placbeo	O
had	O
no	O
effcet	O
,	O
but	O
niacinmaide	B-Chemical
was	O
as	O
effectvie	O
as	O
pyridxoine	B-Chemical
.	O

Peirodic	O
withdraawl	O
of	O
pryidoxine	B-Chemical
was	O
associated	O
with	O
return	O
of	O
the	O
hyperiknesis	O
.	O

The	O
lveel	O
of	O
pyrdioxal	B-Chemical
in	O
the	O
bolod	O
was	O
nomral	O
during	O
the	O
peridos	O
of	O
relaspe	O
.	O

Metaboilc	O
studeis	O
suggested	O
a	O
blcok	O
in	O
the	O
kynureinne	B-Chemical
ptahway	O
of	O
tyrptophan	B-Chemical
metabloism	O
.	O

The	O
patinet	O
has	O
been	O
followed	O
for	O
six	O
yaers	O
and	O
has	O
required	O
phramacologic	O
doess	O
of	O
pyriodxine	B-Chemical
to	O
conrtol	O
her	O
behvaior	O
.	O

Recurrent	O
excitatoin	O
in	O
the	O
denttae	O
gyurs	O
of	O
a	O
muirne	O
moedl	O
of	O
tempoarl	O
lboe	O
epliepsy	O
.	O

Similar	O
to	O
rtas	O
,	O
ssytemic	O
pilocaprine	B-Chemical
injcetion	O
causes	O
sttaus	O
epilepitcus	O
(	O
SE	O
)	O
and	O
the	O
eventaul	O
developemnt	O
of	O
spontaenous	O
seiuzres	O
and	O
msosy	O
fbier	O
sprouitng	O
in	O
C5B7L	O
/	O
6	O
and	O
CD1	O
mcie	O
,	O
but	O
the	O
physiloogical	O
crorelates	O
of	O
these	O
eevnts	O
have	O
not	O
been	O
identifeid	O
in	O
mcie	O
.	O

Ppoulation	O
resposnes	O
in	O
grnaule	O
cells	O
of	O
the	O
denttae	O
gyurs	O
were	O
examined	O
in	O
trnasverse	O
slcies	O
of	O
the	O
vnetral	O
hippocamups	O
from	O
pilocarpnie	B-Chemical
-	O
tretaed	O
and	O
unterated	O
mcie	O
.	O

In	O
Mg	B-Chemical
(	O
2	O
+	O
)	O
-	O
free	O
bathnig	O
meduim	O
containing	O
biucculline	B-Chemical
,	O
conditoins	O
designed	O
to	O
inrcease	O
excitabliity	O
in	O
the	O
slcies	O
,	O
electrcial	O
stimultaion	O
of	O
the	O
hiuls	O
resulted	O
in	O
a	O
single	O
populatoin	O
spkie	O
in	O
grnaule	O
clels	O
from	O
conrtol	O
mcie	O
and	O
piolcarpine	B-Chemical
-	O
traeted	O
mcie	O
that	O
did	O
not	O
expereince	O
SE	O
.	O

In	O
SE	O
survivros	O
,	O
similar	O
stimulaiton	O
resulted	O
in	O
a	O
pouplation	O
sipke	O
followed	O
,	O
at	O
a	O
vraiable	O
latecny	O
,	O
by	O
negaitve	O
DC	O
sihfts	O
and	O
repettiive	O
afterdsicharges	O
of	O
3	O
-	O
60	O
s	O
druation	O
,	O
which	O
were	O
bolcked	O
by	O
iontoropic	O
glutamtae	B-Chemical
recepotr	O
atnagonists	O
.	O

Fcoal	O
gultamate	B-Chemical
phootstimulation	O
of	O
the	O
granlue	O
clel	O
lyaer	O
at	O
sties	O
dsitant	O
from	O
the	O
reocrding	O
ppiette	O
resulted	O
in	O
populaiton	O
repsonses	O
of	O
1	O
-	O
30	O
s	O
duraiton	O
in	O
sliecs	O
from	O
SE	O
sruvivors	O
but	O
not	O
other	O
gruops	O
.	O

These	O
dtaa	O
support	O
the	O
hypotheiss	O
that	O
SE	O
-	O
induecd	O
mossy	O
fiebr	O
spruoting	O
and	O
synatpic	O
reorganiaztion	O
are	O
relevnat	O
characteristcis	O
of	O
seizrue	O
deevlopment	O
in	O
these	O
murnie	O
srtains	O
,	O
resembling	O
rat	O
mdoels	O
of	O
huamn	O
temproal	O
lboe	O
eiplepsy	O
.	O

Urniary	O
bldader	O
cacner	O
in	O
Wegeenr	O
'	O
s	O
grnaulomatosis	O
:	O
rikss	O
and	O
relation	O
to	O
cyclophosphamdie	B-Chemical
.	O

OBEJCTIVE	O
:	O
To	O
assess	O
and	O
characterise	O
the	O
rsik	O
of	O
bladedr	O
canecr	O
,	O
and	O
its	O
relation	O
to	O
cyclophosphaimde	B-Chemical
,	O
in	O
patinets	O
with	O
Wgeener	O
'	O
s	O
granluomatosis	O
.	O

METHODS	O
:	O
In	O
the	O
popultaion	O
based	O
,	O
natoinwide	O
Sweidsh	O
Inaptient	O
Regitser	O
a	O
choort	O
of	O
1065	O
ptaients	O
with	O
Wgeener	O
'	O
s	O
granulomatsois	O
,	O
1969	O
-	O
95	O
,	O
was	O
iedntified	O
.	O

Through	O
linakge	O
with	O
the	O
Swedsih	O
Cnacer	O
Rgeister	O
,	O
all	O
subjetcs	O
in	O
this	O
coohrt	O
diagnsoed	O
with	O
baldder	O
canecr	O
were	O
identfiied	O
.	O

Netsed	O
within	O
the	O
cohrot	O
,	O
a	O
matched	O
csae	O
-	O
cnotrol	O
stduy	O
was	O
performed	O
to	O
etsimate	O
the	O
assocaition	O
between	O
cyclohposphamide	B-Chemical
and	O
bladder	O
cnacer	O
using	O
odds	O
rtaios	O
(	O
ORs	O
)	O
as	O
relative	O
rsik	O
.	O

In	O
the	O
cohrot	O
the	O
cumualtive	O
rsik	O
of	O
bladedr	O
canecr	O
after	O
Wegneer	O
'	O
s	O
granulomatoiss	O
,	O
and	O
the	O
relative	O
preavlence	O
of	O
a	O
hsitory	O
of	O
bldader	O
cnacer	O
at	O
the	O
tmie	O
of	O
diagnoiss	O
of	O
Wgeener	O
'	O
s	O
grnaulomatosis	O
,	O
were	O
also	O
etsimated	O
.	O

RESLUTS	O
:	O
The	O
medain	O
cumulaitve	O
doess	O
of	O
cyclophoshpamide	B-Chemical
among	O
caess	O
(	O
n	O
=	O
11	O
)	O
and	O
cnotrols	O
(	O
n	O
=	O
25	O
)	O
were	O
113	O
g	O
and	O
25	O
g	O
,	O
respectively	O
.	O

The	O
rsik	O
of	O
bldader	O
canecr	O
doubled	O
for	O
every	O
10	O
g	O
icnrement	O
in	O
cyclophosphamdie	B-Chemical
(	O
OR	O
=	O
2	O
.	O
0	O
,	O
95	O
%	O
confdience	O
itnerval	O
(	O
CI	O
)	O
0	O
.	O
8	O
to	O
4	O
.	O
9	O
)	O
.	O

Tretament	O
duartion	O
longer	O
than	O
1	O
yaer	O
was	O
associated	O
with	O
an	O
egihtfold	O
icnreased	O
rsik	O
(	O
OR	O
=	O
7	O
.	O
7	O
,	O
95	O
%	O
CI	O
0	O
.	O
9	O
to	O
69	O
)	O
.	O

The	O
absoltue	O
rsik	O
for	O
bldader	O
cnacer	O
in	O
the	O
choort	O
reached	O
10	O
%	O
16	O
yeras	O
after	O
diagnoiss	O
of	O
Wgeener	O
'	O
s	O
granulomtaosis	O
,	O
and	O
a	O
histroy	O
of	O
bladedr	O
cnacer	O
was	O
(	O
non	O
-	O
significantly	O
)	O
twice	O
as	O
common	O
as	O
expected	O
at	O
the	O
tmie	O
of	O
daignosis	O
of	O
Wegneer	O
'	O
s	O
graunlomatosis	O
.	O

COCNLUSION	O
:	O
The	O
resluts	O
indicate	O
a	O
dsoe	O
-	O
repsonse	O
realtionship	O
between	O
cyclpohosphamide	B-Chemical
and	O
the	O
rsik	O
of	O
bladedr	O
canecr	O
,	O
high	O
cuumlative	O
rikss	O
in	O
the	O
entire	O
cohrot	O
,	O
and	O
also	O
the	O
possibility	O
of	O
rsik	O
facotrs	O
operaitng	O
even	O
before	O
Wegeenr	O
'	O
s	O
granulomaotsis	O
.	O

Difefrential	O
modualtion	O
by	O
estroegn	B-Chemical
of	O
alhpa2	O
-	O
adreenrgic	O
and	O
I1	O
-	O
imidazloine	B-Chemical
recetpor	O
-	O
mediated	O
hypoetnsion	O
in	O
feamle	O
rtas	O
.	O

We	O
have	O
recently	O
shown	O
that	O
estorgen	B-Chemical
neagtively	O
modualtes	O
the	O
hyoptensive	O
effcet	O
of	O
cloindine	B-Chemical
(	O
mixed	O
alpah2	O
-	O
/	O
I1	O
-	O
reecptor	O
agonsit	O
)	O
in	O
femlae	O
rtas	O
and	O
implicates	O
the	O
cradiovascular	O
auotnomic	O
cnotrol	O
in	O
this	O
intearction	O
.	O

The	O
present	O
sutdy	O
ivnestigated	O
whether	O
this	O
effect	O
of	O
esrtogen	B-Chemical
involves	O
interatcion	O
with	O
aplha2	O
-	O
and	O
/	O
or	O
I1	O
-	O
recepotrs	O
.	O

Chnages	O
evoekd	O
by	O
a	O
single	O
intrapeirtoneal	O
injcetion	O
of	O
rilmendiine	B-Chemical
(	O
600	O
mircog	O
/	O
kg	O
)	O
or	O
alhpa	B-Chemical
-	I-Chemical
mtehyldopa	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
)	O
,	O
selective	O
I1	O
-	O
and	O
alhpa2	O
-	O
rceeptor	O
agoinsts	O
,	O
respectively	O
,	O
in	O
blood	O
presusre	O
,	O
hemodynmaic	O
vraiability	O
,	O
and	O
lcoomotor	O
atcivity	O
were	O
asssesed	O
in	O
radiotelemetered	O
sahm	O
-	O
operaetd	O
and	O
oavriectomized	O
(	O
Ovx	O
)	O
Spargue	O
-	O
Dalwey	O
fmeale	O
rtas	O
with	O
or	O
without	O
12	O
-	O
wk	O
estroegn	B-Chemical
replacmeent	O
.	O

Three	O
tmie	O
doamin	O
inedxes	O
of	O
hemoydnamic	O
variabliity	O
were	O
employed	O
:	O
the	O
standrad	O
deviaiton	O
of	O
mean	O
arteiral	O
perssure	O
as	O
a	O
maesure	O
of	O
bolod	O
perssure	O
vairability	O
and	O
the	O
stnadard	O
devitaion	O
of	O
baet	O
-	O
to	O
-	O
baet	O
intervlas	O
(	O
SRDR	O
)	O
and	O
the	O
root	O
mean	O
sqaure	O
of	O
successive	O
difefrences	O
in	O
R	O
-	O
wvae	O
-	O
to	O
-	O
R	O
-	O
wvae	O
inetrvals	O
as	O
measuers	O
of	O
haert	O
rtae	O
variaiblity	O
.	O

In	O
sahm	O
-	O
oeprated	O
rtas	O
,	O
rimlenidine	B-Chemical
or	O
alhpa	B-Chemical
-	I-Chemical
metyhldopa	I-Chemical
elicited	O
similar	O
hypotenison	O
that	O
lasted	O
at	O
least	O
5	O
h	O
and	O
was	O
associated	O
with	O
reudctions	O
in	O
standrad	O
deviatoin	O
of	O
mean	O
atrerial	O
presusre	O
.	O

SRDR	O
was	O
reudced	O
only	O
by	O
aplha	B-Chemical
-	I-Chemical
mtehyldopa	I-Chemical
.	O

Ovx	O
significantly	O
enahnced	O
the	O
hypotensvie	O
respnose	O
to	O
aplha	B-Chemical
-	I-Chemical
mehtyldopa	I-Chemical
,	O
in	O
contrast	O
to	O
no	O
effcet	O
on	O
rilmneidine	B-Chemical
hyoptension	O
.	O

The	O
enahnced	O
aplha	B-Chemical
-	I-Chemical
methydlopa	I-Chemical
hypotesnion	O
in	O
Ovx	O
rtas	O
was	O
paralleled	O
with	O
further	O
redcution	O
in	O
SRDR	O
and	O
a	O
reudced	O
loocmotor	O
actiivty	O
.	O

Estroegn	O
replaecment	O
(	O
17beta	B-Chemical
-	I-Chemical
etsradiol	I-Chemical
sbucutaneous	O
pellet	O
,	O
14	O
.	O
2	O
mircog	O
/	O
day	O
,	O
12	O
wk	O
)	O
of	O
Ovx	O
rtas	O
resotred	O
the	O
hmeodynamic	O
and	O
locomtoor	O
effcets	O
of	O
aplha	B-Chemical
-	I-Chemical
methylodpa	I-Chemical
to	O
sahm	O
-	O
operaetd	O
lveels	O
.	O

These	O
findigns	O
suggest	O
that	O
etsrogen	B-Chemical
downreuglates	O
alhpa2	O
-	O
but	O
not	O
I1	O
-	O
rceeptor	O
-	O
mediated	O
hypotenison	O
and	O
highlight	O
a	O
role	O
for	O
the	O
cardaic	O
autnoomic	O
contorl	O
in	O
aplha	B-Chemical
-	I-Chemical
methlydopa	I-Chemical
-	O
estroegn	B-Chemical
interaciton	O
.	O

Sevree	O
reversible	O
lfet	O
vnetricular	O
ssytolic	O
and	O
daistolic	O
dyfsunction	O
due	O
to	O
accidenatl	O
iatroegnic	O
epinehprine	B-Chemical
ovedrose	O
.	O

Ctaecholamine	B-Chemical
-	O
induecd	O
cardimoyopathy	O
due	O
to	O
chornic	O
execss	O
of	O
ednogenous	O
catecholaimnes	B-Chemical
has	O
been	O
recognized	O
for	O
decades	O
as	O
a	O
cliincal	O
pehnomenon	O
.	O

In	O
contrast	O
,	O
reprots	O
of	O
myocardail	O
dsyfunction	O
due	O
to	O
actue	O
iatroegnic	O
overodse	O
are	O
rrae	O
.	O

A	O
35	O
-	O
yaer	O
-	O
old	O
wmoan	O
whose	O
crevix	O
uetri	O
was	O
inadvertently	O
injetced	O
with	O
8	O
mg	O
of	O
epniephrine	B-Chemical
developed	O
myocaridal	O
stunnnig	O
that	O
was	O
cahracterized	O
by	O
sevree	O
heomdynamic	O
compromise	O
,	O
profuond	O
,	O
albeit	O
transeint	O
,	O
lfet	O
venrticular	O
sytsolic	O
and	O
daistolic	O
dysfuntcion	O
,	O
and	O
only	O
modestly	O
elevtaed	O
biohcemical	O
markres	O
of	O
mycoardial	O
necorsis	O
.	O

Our	O
csae	O
illustrates	O
the	O
serious	O
cnosequences	O
of	O
mdeical	O
errros	O
that	O
can	O
be	O
avoided	O
through	O
ipmroved	O
medictaion	O
lableing	O
and	O
satff	O
supervisoin	O
.	O

Cardioprotectvie	O
efefct	O
of	O
tnicture	B-Chemical
of	I-Chemical
Crateagus	I-Chemical
on	O
isorpoterenol	B-Chemical
-	O
idnuced	O
myocardail	O
infarciton	O
in	O
rtas	O
.	O

Tnicture	B-Chemical
of	I-Chemical
Craategus	I-Chemical
(	O
TCR	B-Chemical
)	O
,	O
an	O
alcoohlic	B-Chemical
extarct	I-Chemical
of	I-Chemical
the	I-Chemical
berires	I-Chemical
of	I-Chemical
hawthron	I-Chemical
(	O
Crataeugs	B-Chemical
oxycatnha	I-Chemical
)	O
,	O
is	O
used	O
in	O
herabl	O
and	O
homeoptahic	O
mdeicine	O
.	O

The	O
present	O
sutdy	O
was	O
done	O
to	O
investigtae	O
the	O
protective	O
efefct	O
of	O
TCR	B-Chemical
on	O
experimenatlly	O
inudced	O
myocardail	O
infraction	O
in	O
rtas	O
.	O

Pretretament	O
of	O
TCR	B-Chemical
,	O
at	O
a	O
dsoe	O
of	O
0	O
.	O
5	O
mL	O
/	O
100	O
g	O
bodywegiht	O
per	O
day	O
,	O
orlaly	O
for	O
30	O
dyas	O
,	O
prevented	O
the	O
incraese	O
in	O
lpiid	O
peorxidation	O
and	O
atcivity	O
of	O
marekr	O
enyzmes	O
observed	O
in	O
isoporterenol	B-Chemical
-	O
inudced	O
rtas	O
(	O
85	O
mg	O
kg	O
(	O
-	O
1	O
)	O
s	O
.	O
c	O
.	O
for	O
2	O
dyas	O
at	O
an	O
itnerval	O
of	O
24	O
h	O
)	O
.	O

TCR	B-Chemical
prevented	O
the	O
isoporterenol	B-Chemical
-	O
inudced	O
dcerease	O
in	O
antioxiadnt	O
enzyems	O
in	O
the	O
haert	O
and	O
icnreased	O
the	O
rtae	O
of	O
ADP	B-Chemical
-	O
stiumlated	O
oyxgen	B-Chemical
uptkae	O
and	O
respiartory	O
copuling	O
rtaio	O
.	O

TCR	B-Chemical
protected	O
against	O
patholoigcal	O
chagnes	O
inudced	O
by	O
isoprotreenol	B-Chemical
in	O
rat	O
herat	O
.	O

The	O
resutls	O
show	O
that	O
pretreatmnet	O
with	O
TCR	B-Chemical
may	O
be	O
useful	O
in	O
preventing	O
the	O
dmaage	O
inudced	O
by	O
isorpoterenol	B-Chemical
in	O
rat	O
haert	O
.	O

Tretament	O
of	O
tinintus	O
by	O
intrtaympanic	O
instillation	O
of	O
lignociane	B-Chemical
(	O
liodcaine	B-Chemical
)	O
2	O
per	O
cent	O
through	O
vnetilation	O
tuebs	O
.	O

Idioapthic	O
subjetcive	O
tinnitus	O
(	O
IST	O
)	O
is	O
one	O
of	O
the	O
most	O
obscure	O
otloogical	O
pahtologies	O
.	O

This	O
paper	O
presents	O
the	O
rseults	O
of	O
traeting	O
IST	O
by	O
intartympanic	O
isntillation	O
of	O
lignocanie	B-Chemical
(	O
lidcoaine	B-Chemical
)	O
2	O
per	O
cent	O
through	O
a	O
grmomet	O
,	O
for	O
five	O
weelky	O
cousres	O
.	O

Fifty	O
-	O
two	O
pateints	O
sufefring	O
from	O
intracatble	O
tinniuts	O
entered	O
this	O
therpaeutic	O
trail	O
,	O
but	O
only	O
nine	O
finished	O
all	O
five	O
cuorses	O
.	O

In	O
one	O
pateint	O
,	O
the	O
tinntius	O
was	O
almost	O
completely	O
abolished	O
,	O
but	O
in	O
all	O
the	O
nine	O
ptaients	O
the	O
decompensaetd	O
tinintus	O
changed	O
to	O
a	O
compensated	O
one	O
.	O

We	O
suggest	O
this	O
mdoe	O
of	O
traetment	O
for	O
patinets	O
that	O
were	O
previously	O
tretaed	O
by	O
durgs	O
,	O
acupnucture	O
and	O
biofedeback	O
,	O
with	O
disappointing	O
rseults	O
.	O

Paitents	O
should	O
be	O
warned	O
about	O
the	O
side	O
efefcts	O
of	O
veritgo	O
and	O
vomiitng	O
,	O
which	O
subsides	O
gradually	O
with	O
every	O
new	O
isntillation	O
,	O
and	O
that	O
the	O
tinnitus	O
may	O
not	O
disappear	O
but	O
will	O
be	O
alleviated	O
,	O
enabling	O
them	O
to	O
cope	O
more	O
easily	O
with	O
the	O
diesase	O
and	O
lead	O
a	O
more	O
noraml	O
lfie	O
.	O

The	O
aplha3	O
and	O
beat4	O
nictoinic	O
acteylcholine	B-Chemical
recetpor	O
subuints	O
are	O
necessary	O
for	O
nicotnie	B-Chemical
-	O
indcued	O
seziures	O
and	O
hyploocomotion	O
in	O
mcie	O
.	O

Bindnig	O
of	O
nicoitne	B-Chemical
to	O
nicotiinc	O
acetylchoilne	B-Chemical
rceeptors	O
(	O
nACRhs	O
)	O
elicits	O
a	O
series	O
of	O
dsoe	O
-	O
depnedent	O
behavoirs	O
that	O
go	O
from	O
alteerd	O
exploraiton	O
,	O
sedtaion	O
,	O
and	O
treomrs	O
,	O
to	O
seziures	O
and	O
detah	O
.	O

nAhCRs	O
are	O
petnameric	O
ion	O
channels	O
usually	O
composed	O
of	O
aplha	O
and	O
btea	O
sbuunits	O
.	O

A	O
gnee	O
clsuter	O
comprises	O
the	O
aplha3	O
,	O
alpah5	O
and	O
btea4	O
sbuunits	O
,	O
which	O
coassmeble	O
to	O
form	O
funcitonal	O
rceeptors	O
.	O

We	O
examined	O
the	O
role	O
of	O
the	O
btea4	O
subuints	O
in	O
nioctine	B-Chemical
-	O
idnuced	O
seziures	O
and	O
hyoplocomotion	O
in	O
btea4	O
homoyzgous	O
nlul	O
(	O
beat4	O
-	O
/	O
-	O
)	O
and	O
alhpa3	O
heterozgyous	O
(	O
+	O
/	O
-	O
)	O
mcie	O
.	O

beat4	O
-	O
/	O
-	O
mcie	O
were	O
less	O
sesnitive	O
to	O
the	O
effcets	O
of	O
nioctine	B-Chemical
both	O
at	O
low	O
doess	O
,	O
maesured	O
as	O
decraesed	O
explroation	O
in	O
an	O
open	O
field	O
,	O
and	O
at	O
high	O
doess	O
,	O
measuerd	O
as	O
sesnitivity	O
to	O
nicotnie	B-Chemical
-	O
idnuced	O
seizuers	O
.	O

Using	O
in	O
situ	O
hybridiaztion	O
porbes	O
for	O
the	O
aplha3	O
and	O
alhpa5	O
sbuunits	O
,	O
we	O
showed	O
that	O
alpah5	O
mNRA	O
lveels	O
are	O
unchanegd	O
,	O
whereas	O
alpah3	O
mNRA	O
levles	O
are	O
selectively	O
decresaed	O
in	O
the	O
mirtal	O
clel	O
lyaer	O
of	O
the	O
olfcatory	O
blub	O
,	O
and	O
the	O
infreior	O
and	O
the	O
superior	O
colliuclus	O
of	O
beat4	O
-	O
/	O
-	O
branis	O
.	O

alhpa3	O
+	O
/	O
-	O
mcie	O
were	O
patrially	O
reisstant	O
to	O
nioctine	B-Chemical
-	O
inudced	O
seziures	O
when	O
cmopared	O
to	O
wlid	O
-	O
tpye	O
littremates	O
.	O

mNRA	O
leevls	O
for	O
the	O
alhpa5	O
and	O
the	O
beat4	O
subuints	O
were	O
ucnhanged	O
in	O
aplha3	O
+	O
/	O
-	O
branis	O
.	O

Together	O
,	O
these	O
rseults	O
suggest	O
that	O
the	O
beat4	O
and	O
the	O
alpah3	O
subnuits	O
are	O
meidators	O
of	O
nictoine	B-Chemical
-	O
induecd	O
seiuzres	O
and	O
hypoolcomotion	O
.	O

The	O
effects	O
of	O
sevofluarne	B-Chemical
on	O
lidcoaine	B-Chemical
-	O
indcued	O
convlusions	O
.	O

The	O
infulence	O
of	O
sevoflruane	B-Chemical
on	O
lidcoaine	B-Chemical
-	O
idnuced	O
convulisons	O
was	O
studied	O
in	O
ctas	O
.	O

The	O
convuslive	O
threhsold	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
was	O
41	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
5	O
mg	O
.	O

l	O
(	O
-	O
1	O
)	O
with	O
lidoacine	B-Chemical
infusoin	O
(	O
6	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
min	O
(	O
-	O
1	O
)	O
)	O
,	O
inrceasing	O
significantly	O
to	O
66	O
.	O
6	O
+	O
/	O
-	O
10	O
.	O
9	O
mg	O
.	O

l	O
(	O
-	O
1	O
)	O
when	O
the	O
end	O
-	O
tdial	O
concentartion	O
of	O
sevoflurnae	B-Chemical
was	O
0	O
.	O
8	O
%	O
.	O

However	O
,	O
the	O
thresohld	O
(	O
61	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
7	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
)	O
during	O
1	O
.	O
6	O
%	O
sevofluarne	B-Chemical
was	O
not	O
significant	O
from	O
that	O
during	O
0	O
.	O
8	O
%	O
sveoflurane	B-Chemical
,	O
indicating	O
a	O
cleling	O
effect	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
convulsvie	O
threshlod	O
between	O
sevoflurnae	B-Chemical
and	O
enlfurane	B-Chemical
.	O

The	O
rise	O
in	O
blood	O
presusre	O
became	O
less	O
marked	O
when	O
hgiher	O
concnetrations	O
of	O
sevfolurane	B-Chemical
or	O
enfulrane	B-Chemical
were	O
administreed	O
and	O
the	O
blood	O
perssure	O
at	O
convulisons	O
decraesed	O
significantly	O
in	O
1	O
.	O
6	O
%	O
sevoflruane	B-Chemical
,	O
and	O
in	O
0	O
.	O
8	O
%	O
and	O
1	O
.	O
6	O
%	O
enflruane	B-Chemical
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
lidoacine	B-Chemical
concenrtations	O
meausred	O
when	O
the	O
systloic	O
blood	O
presusre	O
became	O
70	O
mmHg	O
.	O

Apmain	B-Chemical
,	O
a	O
selective	O
blcoker	O
of	O
calcuim	B-Chemical
-	O
depednent	O
potassuim	B-Chemical
channles	O
,	O
was	O
adminisetred	O
intracerebrovetnricularly	O
in	O
rtas	O
anesthteized	O
with	O
0	O
.	O
8	O
%	O
sevoflruane	B-Chemical
to	O
investigtae	O
the	O
mecahnism	O
of	O
the	O
antcionvulsive	O
efefcts	O
.	O

Apaimn	B-Chemical
(	O
10	O
ng	O
)	O
had	O
a	O
tendency	O
to	O
decerase	O
the	O
convlusive	O
thrsehold	O
(	O
21	O
.	O
6	O
+	O
/	O
-	O
2	O
.	O
2	O
to	O
19	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
5	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
)	O
but	O
this	O
was	O
not	O
statisitcally	O
significant	O
.	O

It	O
is	O
suggested	O
that	O
sevoflruane	B-Chemical
reduecs	O
the	O
convulsvie	O
effcet	O
of	O
lidocanie	B-Chemical
toxictiy	O
but	O
carries	O
some	O
rsik	O
due	O
to	O
criculatory	O
deperssion	O
.	O

Caridac	O
toxictiy	O
observed	O
in	O
assocaition	O
with	O
high	O
-	O
dsoe	O
cylcophosphamide	B-Chemical
-	O
based	O
chemtoherapy	O
for	O
metasttaic	O
bresat	O
cnacer	O
.	O

INTRODUCTION	O
:	O
Cylcophosphamide	B-Chemical
is	O
an	O
alkyltaing	O
aegnt	O
given	O
frequently	O
as	O
a	O
component	O
of	O
many	O
cnoditioning	O
reigmens	O
.	O

In	O
high	O
dsoes	O
,	O
its	O
nnohematological	O
dsoe	O
-	O
limiting	O
toxiicty	O
is	O
cardimoyopathy	O
.	O

SUTDY	O
DESIGN	O
:	O
We	O
combiend	O
paclitxael	B-Chemical
,	O
mlephalan	B-Chemical
and	O
high	O
-	O
dsoe	O
cycolphosphamide	B-Chemical
,	O
thioetpa	B-Chemical
,	O
and	O
carbolpatin	B-Chemical
in	O
a	O
trilpe	O
sequnetial	O
high	O
-	O
dsoe	O
reigmen	O
for	O
pateints	O
with	O
metasattic	O
berast	O
cacner	O
.	O

Aanlysis	O
was	O
performed	O
on	O
61	O
wmoen	O
with	O
chemothearpy	O
-	O
responsvie	O
metasattic	O
berast	O
canecr	O
receiving	O
96	O
-	O
h	O
inufsional	O
cycolphosphamide	B-Chemical
as	O
part	O
of	O
a	O
tirple	O
sequnetial	O
high	O
-	O
dsoe	O
rgeimen	O
to	O
assess	O
association	O
between	O
presecne	O
of	O
peritrasnplant	O
congsetive	O
herat	O
failrue	O
(	O
CHF	O
)	O
and	O
the	O
following	O
pretreamtent	O
characetristics	O
:	O
persence	O
of	O
elcetrocardiogram	O
(	O
EKG	O
)	O
abnormaltiies	O
,	O
age	O
,	O
hypretension	O
,	O
prior	O
cardaic	O
histroy	O
,	O
smkoing	O
,	O
dibaetes	O
meliltus	O
,	O
prior	O
use	O
of	O
anthrcayclines	B-Chemical
,	O
and	O
lfet	O
-	O
sided	O
cehst	O
irradaition	O
.	O

RSEULTS	O
:	O
Six	O
of	O
61	O
woemn	O
(	O
10	O
%	O
)	O
developed	O
cilnically	O
reversible	O
garde	O
3	O
CHF	O
following	O
infusioanl	O
cyclophoshpamide	B-Chemical
with	O
a	O
meidan	O
percent	O
decilne	O
in	O
ejetcion	O
fractoin	O
of	O
31	O
%	O
.	O

Incidnece	O
of	O
transeint	O
cyclophosphmaide	B-Chemical
-	O
related	O
caridac	O
txoicity	O
(	O
10	O
%	O
)	O
is	O
comparable	O
to	O
previous	O
recorded	O
literautre	O
.	O

Oledr	O
age	O
was	O
significantly	O
correltaed	O
with	O
the	O
CHF	O
deveolpment	O
;	O
with	O
mdeian	O
aegs	O
for	O
the	O
entire	O
gruop	O
and	O
for	O
pateints	O
developing	O
CHF	O
of	O
45	O
and	O
59	O
,	O
respectively	O
.	O

No	O
associaiton	O
was	O
found	O
with	O
other	O
pertreatment	O
characterisitcs	O
.	O

CONCLUISONS	O
:	O
As	O
a	O
result	O
of	O
these	O
finidngs	O
,	O
oncologsits	O
should	O
carefully	O
monitor	O
fulid	O
balnace	O
in	O
odler	O
pateints	O
.	O

Rouitne	O
EKG	O
montioring	O
during	O
infsuional	O
cycolphosphamide	B-Chemical
did	O
not	O
predict	O
CHF	O
deevlopment	O
.	O

Termor	O
side	O
effects	O
of	O
salubtamol	B-Chemical
,	O
quantiifed	O
by	O
a	O
lsaer	O
poniter	O
tcehnique	O
.	O

OJBECTIVE	O
:	O
To	O
sutdy	O
trmeor	O
side	O
effetcs	O
of	O
slabutamol	B-Chemical
an	O
easily	O
applicable	O
,	O
quick	O
and	O
low	O
-	O
priced	O
mtehod	O
is	O
needed	O
.	O

A	O
new	O
metohd	O
using	O
a	O
commercially	O
available	O
,	O
pen	O
-	O
sahped	O
laesr	O
poniter	O
was	O
developed	O
.	O

Aim	O
of	O
the	O
stduy	O
was	O
to	O
determine	O
sensitiivty	O
,	O
rerpoducibility	O
,	O
refreence	O
valeus	O
and	O
the	O
agreement	O
with	O
a	O
questinonaire	O
.	O

METHODS	O
:	O
Treomr	O
was	O
measrued	O
using	O
a	O
laesr	O
poniter	O
techinque	O
.	O

To	O
determine	O
senstiivity	O
we	O
assessed	O
trmeor	O
in	O
44	O
paitents	O
with	O
obstrcutive	O
lnug	O
diesase	O
after	O
adminsitration	O
of	O
cumultaive	O
dsoes	O
of	O
slabutamol	B-Chemical
.	O

Sujbects	O
were	O
asked	O
to	O
aim	O
at	O
the	O
cnetre	O
of	O
a	O
traget	O
,	O
subdivided	O
in	O
concetnric	O
circles	O
,	O
from	O
5	O
m	O
distnace	O
.	O

The	O
circle	O
in	O
which	O
the	O
partiicpant	O
succeeded	O
to	O
aim	O
was	O
recorded	O
in	O
millmietres	O
raduis	O
.	O

In	O
another	O
series	O
of	O
measuremnets	O
,	O
rperoducibility	O
and	O
refeernce	O
valeus	O
of	O
the	O
termor	O
was	O
asesssed	O
in	O
65	O
heatlhy	O
subejcts	O
in	O
three	O
sesisons	O
,	O
at	O
9	O
a	O
.	O
m	O
.	O
,	O
4	O
p	O
.	O
m	O
.	O
and	O
9	O
a	O
.	O
m	O
.	O
,	O
respectively	O
,	O
1	O
week	O
later	O
.	O

Psotural	O
trmeor	O
was	O
measuerd	O
with	O
the	O
arm	O
horizontally	O
otustretched	O
rest	O
termor	O
with	O
the	O
arm	O
supported	O
by	O
an	O
armerst	O
and	O
finally	O
termor	O
was	O
maesured	O
after	O
holding	O
a	O
2	O
-	O
kg	O
wieght	O
until	O
exhautsion	O
.	O

Itner	O
-	O
osberver	O
variabliity	O
was	O
measrued	O
in	O
a	O
series	O
of	O
10	O
haelthy	O
subjetcs	O
.	O

Termor	O
was	O
measuerd	O
smiultaneously	O
by	O
two	O
independnet	O
obesrvers	O
.	O

RSEULTS	O
:	O
Salbtuamol	B-Chemical
significantly	O
inrceased	O
treomr	O
seveirty	O
in	O
ptaients	O
in	O
a	O
dsoe	O
-	O
depnedent	O
way	O
.	O

Within	O
healhty	O
adutls	O
no	O
age	O
-	O
depednency	O
could	O
be	O
found	O
(	O
b	O
=	O
0	O
.	O
262	O
mm	O
/	O
yaer	O
;	O
P	O
=	O
0	O
.	O
72	O
)	O
.	O

There	O
was	O
no	O
agreement	O
between	O
the	O
questionnarie	O
and	O
trmeor	O
sevreity	O
(	O
r	O
=	O
0	O
.	O
093	O
;	O
P	O
=	O
0	O
.	O
53	O
)	O
.	O

Psotural	O
termor	O
showed	O
no	O
significant	O
difference	O
between	O
the	O
first	O
and	O
third	O
sessoin	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O

Supoprt	O
of	O
the	O
arm	O
derceased	O
termor	O
seevrity	O
,	O
exhausiton	O
increaesd	O
termor	O
seveirty	O
significantly	O
.	O

A	O
good	O
agreement	O
was	O
found	O
between	O
two	O
indeepndent	O
obsrevers	O
(	O
inetrclass	O
correlaiton	O
coefifcient	O
0	O
.	O
72	O
)	O
.	O

DISCUSSION	O
:	O
Qauntifying	O
treomr	O
by	O
using	O
an	O
inepxensive	O
lsaer	O
poinetr	O
is	O
,	O
with	O
the	O
exception	O
of	O
childern	O
(	O
<	O
12	O
yeras	O
)	O
a	O
sensiitve	O
and	O
reproducible	O
metohd	O
.	O

Saefty	O
and	O
adevrse	O
effcets	O
associated	O
with	O
raolxifene	B-Chemical
:	O
multpile	O
ouctomes	O
of	O
raolxifene	B-Chemical
evlauation	O
.	O

OBJETCIVE	O
:	O
To	O
examine	O
the	O
effcet	O
of	O
raloxifnee	B-Chemical
on	O
major	O
advesre	O
evetns	O
that	O
occur	O
with	O
posmtenopausal	O
etsrogen	B-Chemical
thearpy	O
or	O
taomxifen	B-Chemical
.	O

METHODS	O
:	O
The	O
Mulitple	O
Outcmoes	O
of	O
Ralxoifene	B-Chemical
Evalaution	O
,	O
a	O
mutlicenter	O
,	O
randomzied	O
,	O
double	O
-	O
blnid	O
tiral	O
,	O
enrolled	O
7	O
,	O
705	O
postmenpoausal	O
woemn	O
with	O
osteoproosis	O
.	O

Wmoen	O
were	O
randomly	O
assigned	O
to	O
raloxifnee	B-Chemical
60	O
mg	O
/	O
d	O
or	O
120	O
mg	O
/	O
d	O
or	O
placbeo	O
.	O

Ouctomes	O
included	O
venuos	O
thrmoboembolism	O
,	O
cataratcs	O
,	O
glalbladder	O
diesase	O
,	O
and	O
endometrail	O
hyeprplasia	O
or	O
cacner	O
.	O

RESLUTS	O
:	O
During	O
a	O
mean	O
follow	O
-	O
up	O
of	O
3	O
.	O
3	O
yaers	O
,	O
ralxoifene	B-Chemical
was	O
associated	O
with	O
an	O
icnreased	O
rsik	O
for	O
vneous	O
thromboebmolism	O
(	O
relative	O
rsik	O
[	O
RR	O
]	O
2	O
.	O
1	O
;	O
95	O
%	O
cnofidence	O
inetrval	O
[	O
CI	O
]	O
1	O
.	O
2	O
-	O
3	O
.	O
8	O
)	O
.	O

The	O
excses	O
eevnt	O
rtae	O
was	O
1	O
.	O
8	O
per	O
1	O
,	O
000	O
wmoan	O
-	O
yeras	O
(	O
95	O
%	O
CI	O
-	O
0	O
.	O
5	O
-	O
4	O
.	O
1	O
)	O
,	O
and	O
the	O
number	O
needed	O
to	O
traet	O
to	O
cause	O
1	O
evnet	O
was	O
170	O
(	O
95	O
%	O
CI	O
100	O
-	O
582	O
)	O
over	O
3	O
.	O
3	O
yeras	O
.	O

Rsik	O
in	O
the	O
raloxifnee	B-Chemical
gruop	O
was	O
hgiher	O
than	O
in	O
the	O
palcebo	O
gruop	O
for	O
the	O
first	O
2	O
yeras	O
,	O
but	O
decreaesd	O
to	O
about	O
the	O
same	O
rtae	O
as	O
in	O
the	O
placbeo	O
gruop	O
thereafter	O
.	O

Ralxoifene	B-Chemical
did	O
not	O
incraese	O
rsik	O
for	O
caatracts	O
(	O
RR	O
0	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
8	O
-	O
1	O
.	O
1	O
)	O
,	O
gallbladder	O
dsiease	O
(	O
RR	O
1	O
.	O
0	O
;	O
95	O
%	O
CI	O
0	O
.	O
7	O
-	O
1	O
.	O
3	O
)	O
,	O
endometiral	O
hypeprlasia	O
(	O
RR	O
1	O
.	O
3	O
;	O
95	O
%	O
CI	O
0	O
.	O
4	O
-	O
5	O
.	O
1	O
)	O
,	O
or	O
endomertial	O
canecr	O
(	O
RR	O
0	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
3	O
-	O
2	O
.	O
7	O
)	O
.	O

CONCLUSOIN	O
:	O
Raloxfiene	B-Chemical
was	O
associated	O
with	O
an	O
icnreased	O
rsik	O
for	O
vneous	O
thromboembolsim	O
,	O
but	O
there	O
was	O
no	O
incerased	O
rsik	O
for	O
cataarcts	O
,	O
gallbldader	O
diesase	O
,	O
endoemtrial	O
hypreplasia	O
,	O
or	O
endoemtrial	O
canecr	O
.	O

LEEVL	O
OF	O
EVIDECNE	O
:	O
I	O

Otpimization	O
of	O
levodpoa	B-Chemical
threapy	O
.	O

While	O
there	O
is	O
no	O
single	O
correct	O
starting	O
dsoe	O
for	O
levoodpa	B-Chemical
tehrapy	O
,	O
many	O
indiviudals	O
can	O
be	O
started	O
on	O
either	O
the	O
25	O
/	O
100	O
or	O
contorlled	O
-	O
relesae	O
fromula	O
,	O
following	O
the	O
general	O
rule	O
not	O
to	O
attempt	O
to	O
titrate	O
carbidpoa	B-Chemical
-	O
levoodpa	B-Chemical
to	O
the	O
point	O
of	O
"	O
nomrality	O
,	O
"	O
which	O
can	O
lead	O
to	O
toxciity	O
.	O

The	O
physciian	O
should	O
also	O
determine	O
the	O
proper	O
use	O
of	O
any	O
adjuncitve	O
medicatoins	O
;	O
such	O
cobmined	O
tehrapy	O
has	O
become	O
the	O
stanadrd	O
approach	O
to	O
treatemnt	O
.	O

Following	O
the	O
initial	O
peroid	O
of	O
tehrapy	O
,	O
emerging	O
difficutlies	O
require	O
a	O
reassessmnet	O
of	O
therapetuic	O
aprpoaches	O
,	O
such	O
as	O
dosgae	O
adjutsment	O
or	O
introudction	O
of	O
a	O
dopmaine	B-Chemical
agonsit	O
.	O

Other	O
possible	O
avderse	O
efefcts	O
-	O
-	O
such	O
as	O
gatsrointestinal	O
dsiorders	O
,	O
orhtostatic	O
hyptoension	O
,	O
levdoopa	B-Chemical
-	O
inudced	O
psychoiss	O
,	O
selep	O
disturbnaces	O
or	O
paarsomnias	O
,	O
or	O
durg	O
intercations	O
-	O
-	O
also	O
require	O
carefully	O
moniotred	O
indiivdual	O
treamtent	O
.	O

Nonphramacologic	O
conecrns	O
can	O
help	O
the	O
Parknison	O
'	O
s	O
disaese	O
patinet	O
achieve	O
and	O
maintain	O
otpimal	O
functinoing	O
,	O
including	O
dialy	O
eexrcise	O
,	O
pyhsical	O
thearpy	O
,	O
and	O
ivnolvement	O
with	O
support	O
gropus	O
.	O

Lnog	O
term	O
audoilogical	O
evaulation	O
of	O
btea	O
-	O
thaalssemic	O
pateints	O
.	O

OBJETCIVE	O
:	O
The	O
objecitve	O
of	O
this	O
sutdy	O
was	O
to	O
identify	O
the	O
incidnece	O
and	O
to	O
monitor	O
the	O
progressoin	O
of	O
heraing	O
lsos	O
in	O
chlidren	O
and	O
yonug	O
adluts	O
with	O
btea	O
-	O
thaalssemia	O
major	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
four	O
(	O
104	O
)	O
pateints	O
aegd	O
6	O
-	O
35	O
yeras	O
(	O
mean	O
17	O
,	O
2	O
yaers	O
)	O
participated	O
in	O
the	O
sutdy	O
.	O

All	O
paitents	O
were	O
on	O
a	O
regular	O
transfusoin	O
-	O
cheltaion	O
prgoram	O
maintaining	O
a	O
mean	O
hemoglboin	O
lveel	O
of	O
9	O
.	O
5	O
gr	O
/	O
dl	O
.	O

Subjetcs	O
were	O
receiving	O
desferroixamine	B-Chemical
(	O
DFO	B-Chemical
)	O
cheltaion	O
traetment	O
with	O
a	O
mean	O
daliy	O
dsoe	O
of	O
50	O
-	O
60	O
mg	O
/	O
kg	O
,	O
5	O
-	O
6	O
dyas	O
a	O
week	O
during	O
the	O
first	O
six	O
yaers	O
of	O
the	O
stduy	O
,	O
which	O
was	O
then	O
reudced	O
to	O
40	O
-	O
50	O
mg	O
/	O
kg	O
for	O
the	O
following	O
eight	O
yeras	O
.	O

Pateints	O
were	O
followed	O
for	O
8	O
-	O
14	O
yeras	O
.	O

RSEULTS	O
:	O
Overall	O
,	O
21	O
out	O
of	O
104	O
patietns	O
(	O
20	O
.	O
2	O
%	O
)	O
presented	O
with	O
high	O
freuqency	O
sensornieural	O
heraing	O
lsos	O
(	O
SHNL	O
)	O
,	O
either	O
uinlateral	O
or	O
bilaetral	O
.	O

No	O
oottoxic	O
fatcor	O
,	O
other	O
than	O
DFO	B-Chemical
,	O
was	O
present	O
in	O
any	O
of	O
the	O
patietns	O
.	O

Paitents	O
with	O
SHNL	O
presented	O
with	O
relatively	O
loewr	O
seurm	O
ferirtin	O
levles	O
than	O
those	O
with	O
nomral	O
haering	O
,	O
however	O
,	O
no	O
statistiaclly	O
significant	O
difference	O
was	O
observed	O
.	O

Subjcets	O
with	O
SHNL	O
were	O
submitted	O
to	O
DFO	B-Chemical
rdeuction	O
or	O
tempoarry	O
withdrwaal	O
.	O

Following	O
intrevention	O
,	O
7	O
out	O
of	O
21	O
affected	O
pateints	O
reocvered	O
,	O
10	O
remained	O
stbale	O
and	O
4	O
demonstrated	O
aggraavtion	O
.	O

CONCLSUION	O
:	O
The	O
finidngs	O
are	O
indictaive	O
of	O
DFO	B-Chemical
'	O
s	O
contributing	O
role	O
in	O
the	O
deveolpment	O
of	O
heraing	O
ipmairment	O
.	O

Reuglar	O
audioloigc	O
evaulation	O
is	O
imperative	O
in	O
all	O
thalassemic	O
ptaients	O
so	O
that	O
eraly	O
cahnges	O
may	O
be	O
recognized	O
and	O
teratment	O
may	O
be	O
judiciously	O
adjusted	O
in	O
order	O
to	O
preevnt	O
or	O
revrese	O
heraing	O
ipmairment	O
.	O

Inidvidual	O
differneces	O
in	O
rneal	O
ACE	O
acitvity	O
in	O
haelthy	O
rtas	O
predict	O
ssuceptibility	O
to	O
ardiamycin	B-Chemical
-	O
inudced	O
reanl	O
daamge	O
.	O

BAKCGROUND	O
:	O
In	O
man	O
,	O
dfiferences	O
in	O
angiotesnin	B-Chemical
-	O
converting	O
enzmye	O
(	O
ACE	O
)	O
leevls	O
,	O
related	O
to	O
ACE	O
(	O
I	O
/	O
D	O
)	O
gneotype	O
,	O
are	O
associated	O
with	O
reanl	O
prognoiss	O
.	O

This	O
raises	O
the	O
hyptohesis	O
that	O
idnividual	O
diffreences	O
in	O
reanl	O
ACE	O
actviity	O
are	O
involved	O
in	O
rneal	O
ssuceptibility	O
to	O
infilcted	O
dmaage	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
preidctive	O
effcet	O
of	O
reanl	O
ACE	O
acitvity	O
for	O
the	O
sevreity	O
of	O
rneal	O
dmaage	O
inudced	O
by	O
a	O
single	O
injcetion	O
of	O
adriamcyin	B-Chemical
in	O
rtas	O
.	O

METHODS	O
:	O
Reanl	O
ACE	O
atcivity	O
(	O
Hip	B-Chemical
-	I-Chemical
His	I-Chemical
-	I-Chemical
Leu	I-Chemical
cleaavge	O
by	O
coritcal	O
hoomgenates	O
)	O
was	O
determined	O
by	O
rneal	O
boipsy	O
in	O
27	O
audlt	O
mlae	O
Wisatr	O
rtas	O
.	O

After	O
1	O
week	O
of	O
recovrey	O
,	O
porteinuria	O
was	O
idnuced	O
by	O
adriamcyin	B-Chemical
[	O
1	O
.	O
5	O
mg	O
/	O
kg	O
itnravenously	O
(	O
i	O
.	O
v	O
.	O
)	O
n	O
=	O
18	O
;	O
contorls	O
,	O
salnie	O
i	O
.	O
v	O
.	O
n	O
=	O
9	O
]	O
.	O

Porteinuria	O
was	O
meausred	O
every	O
2	O
weeks	O
.	O

After	O
12	O
weeks	O
,	O
rtas	O
were	O
sarcificed	O
and	O
their	O
kindeys	O
harevsted	O
.	O

REUSLTS	O
:	O
As	O
anticipated	O
,	O
adrimaycin	B-Chemical
elicited	O
npehrotic	O
range	O
porteinuria	O
,	O
rneal	O
intersttiial	O
daamge	O
and	O
mlid	O
foacl	O
glomeruloslcerosis	O
.	O

Bsaeline	O
rneal	O
ACE	O
positievly	O
correlated	O
with	O
the	O
relative	O
rise	O
in	O
proteniuria	O
after	O
adriamyicn	B-Chemical
(	O
r	O
=	O
0	O
.	O
62	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
rneal	O
intersittial	O
alhpa	O
-	O
somoth	O
muslce	O
acitn	O
(	O
r	O
=	O
0	O
.	O
49	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
itnerstitial	O
macrpohage	O
inlfux	O
(	O
r	O
=	O
0	O
.	O
56	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
intersttiial	O
collgaen	O
III	O
(	O
r	O
=	O
0	O
.	O
53	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
gloemrular	O
alhpa	O
-	O
smooth	O
muslce	O
atcin	O
(	O
r	O
=	O
0	O
.	O
74	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
glomerluar	O
dsemin	O
(	O
r	O
=	O
0	O
.	O
48	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Baseilne	O
reanl	O
ACE	O
did	O
not	O
correalte	O
with	O
foacl	O
glomreulosclerosis	O
(	O
r	O
=	O
0	O
.	O
22	O
,	O
NS	O
)	O
.	O

In	O
cotnrols	O
,	O
no	O
predicitve	O
vlaues	O
for	O
reanl	O
paramteers	O
were	O
observed	O
.	O

COCNLUSION	O
:	O
Indivdiual	O
differenecs	O
in	O
rneal	O
ACE	O
activtiy	O
predict	O
the	O
sevreity	O
of	O
adiramycin	B-Chemical
-	O
indcued	O
reanl	O
daamge	O
in	O
this	O
outrbed	O
rat	O
srtain	O
.	O

This	O
supports	O
the	O
assumption	O
that	O
diffreences	O
in	O
reanl	O
ACE	O
activtiy	O
predispose	O
to	O
a	O
less	O
favourbale	O
cousre	O
of	O
rneal	O
daamge	O
.	O

Rceurrent	O
actue	O
intesrtitial	O
nehpritis	O
induecd	O
by	O
azithrmoycin	B-Chemical
.	O

A	O
14	O
-	O
yaer	O
-	O
old	O
gril	O
is	O
reported	O
with	O
recrurent	O
,	O
azithromyicn	B-Chemical
-	O
induecd	O
,	O
aucte	O
interstitail	O
nephrtiis	O
.	O

The	O
second	O
epiosde	O
was	O
more	O
seevre	O
than	O
the	O
first	O
;	O
and	O
although	O
both	O
were	O
terated	O
with	O
intnesive	O
coritcosteroid	O
threapy	O
,	O
rneal	O
funciton	O
remained	O
imapired	O
.	O

Although	O
most	O
caess	O
of	O
anitbiotic	O
induecd	O
actue	O
interstitail	O
nephriits	O
are	O
bengin	O
and	O
slef	O
-	O
lmiited	O
,	O
some	O
paitents	O
are	O
at	O
rsik	O
for	O
peramnent	O
reanl	O
injruy	O
.	O

Sipronolactone	B-Chemical
-	O
idnuced	O
reanl	O
insufficiecny	O
and	O
hyperkaleima	O
in	O
patinets	O
with	O
herat	O
faliure	O
.	O

BACKGRONUD	O
:	O
A	O
previous	O
randomzied	O
contrloled	O
trail	O
evaluatnig	O
the	O
use	O
of	O
spironloactone	B-Chemical
in	O
haert	O
fialure	O
patietns	O
reported	O
a	O
low	O
rsik	O
of	O
hyprekalemia	O
(	O
2	O
%	O
)	O
and	O
rneal	O
insuffiicency	O
(	O
0	O
%	O
)	O
.	O

Because	O
treatmnets	O
for	O
herat	O
failrue	O
have	O
changed	O
since	O
the	O
beenfits	O
of	O
sipronolactone	B-Chemical
were	O
reported	O
,	O
the	O
preavlence	O
of	O
these	O
compilcations	O
may	O
differ	O
in	O
current	O
clniical	O
prcatice	O
.	O

We	O
therefore	O
sought	O
to	O
determine	O
the	O
prevlaence	O
and	O
cliniacl	O
assoications	O
of	O
hyprekalemia	O
and	O
rneal	O
insufficinecy	O
in	O
haert	O
faliure	O
patinets	O
treaetd	O
with	O
spironolcatone	B-Chemical
.	O

METHODS	O
:	O
We	O
performed	O
a	O
csae	O
cnotrol	O
stduy	O
of	O
haert	O
failrue	O
ptaients	O
treaetd	O
with	O
spiornolactone	B-Chemical
in	O
our	O
clniical	O
parctice	O
.	O

Csaes	O
were	O
ptaients	O
who	O
developed	O
hpyerkalemia	O
(	O
K	B-Chemical
(	O
+	O
)	O
>	O
5	O
.	O
0	O
mEq	O
/	O
L	O
)	O
or	O
reanl	O
insufficiecny	O
(	O
Cr	B-Chemical
>	O
or	O
=	O
2	O
.	O
5	O
mg	O
/	O
dL	O
)	O
,	O
and	O
they	O
were	O
compaerd	O
to	O
2	O
randomly	O
selected	O
cnotrols	O
per	O
csae	O
.	O

Clniical	O
characterisitcs	O
,	O
medicatinos	O
,	O
and	O
sreum	O
chemistires	O
at	O
bsaeline	O
and	O
follow	O
-	O
up	O
tmie	O
peridos	O
were	O
comapred	O
.	O

RESLUTS	O
:	O
Sixty	O
-	O
seven	O
of	O
926	O
pateints	O
(	O
7	O
.	O
2	O
%	O
)	O
required	O
disocntinuation	O
of	O
spironloactone	B-Chemical
due	O
to	O
hyprekalemia	O
(	O
n	O
=	O
33	O
)	O
or	O
rneal	O
fialure	O
(	O
n	O
=	O
34	O
)	O
.	O

Paitents	O
who	O
developed	O
hyperkaelmia	O
were	O
oledr	O
and	O
more	O
likely	O
to	O
have	O
daibetes	O
,	O
had	O
hihger	O
bsaeline	O
sreum	O
potassium	B-Chemical
leevls	O
and	O
lwoer	O
basleine	O
potassium	B-Chemical
spuplement	O
doess	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
traeted	O
with	O
btea	O
-	O
blocekrs	O
than	O
cnotrols	O
(	O
n	O
=	O
134	O
)	O
.	O

Pateints	O
who	O
developed	O
rneal	O
insuffciiency	O
had	O
loewr	O
baesline	O
bdoy	O
wieght	O
and	O
higehr	O
basleine	O
seurm	O
ceratinine	B-Chemical
,	O
required	O
hihger	O
dsoes	O
of	O
loop	O
diurteics	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
tretaed	O
with	O
thaizide	B-Chemical
diruetics	O
than	O
conrtols	O
.	O

CONCULSIONS	O
:	O
Sipronolactone	B-Chemical
-	O
induecd	O
hyperkaleima	O
and	O
reanl	O
inusfficiency	O
are	O
more	O
common	O
in	O
our	O
cilnical	O
experinece	O
than	O
reported	O
previously	O
.	O

This	O
difference	O
is	O
explained	O
by	O
pateint	O
comorbidiites	O
and	O
more	O
frqeuent	O
use	O
of	O
btea	O
-	O
blokcers	O
.	O

Actue	O
reesrpine	B-Chemical
and	O
subchroinc	O
haloperdiol	B-Chemical
teratments	O
change	O
synaptsoomal	O
brian	O
gultamate	B-Chemical
utpake	O
and	O
elicit	O
orofacail	O
dyskiensia	O
in	O
rtas	O
.	O

Reesrpine	B-Chemical
-	O
and	O
halpoeridol	B-Chemical
-	O
idnuced	O
oorfacial	O
dyskniesia	O
are	O
putative	O
anmial	O
mdoels	O
of	O
tradive	O
dyskineisa	O
(	O
TD	O
)	O
whose	O
pathophyisology	O
has	O
been	O
related	O
to	O
free	O
rdaical	O
genertaion	O
and	O
oxidaitve	O
srtess	O
.	O

In	O
the	O
present	O
stduy	O
,	O
the	O
auhtors	O
indcued	O
orfoacial	O
dyksinesia	O
by	O
aucte	O
rseerpine	B-Chemical
and	O
sucbhronic	O
haolperidol	B-Chemical
adminsitration	O
to	O
rtas	O
.	O

Reesrpine	B-Chemical
injcetion	O
(	O
one	O
dsoe	O
of	O
1	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
every	O
other	O
day	O
for	O
3	O
dyas	O
caused	O
a	O
significant	O
incraese	O
in	O
vcauous	O
chweing	O
,	O
tonuge	O
portrusion	O
and	O
duraiton	O
of	O
facail	O
twicthing	O
,	O
copmared	O
to	O
the	O
cotnrol	O
.	O

Halopeirdol	B-Chemical
administrtaion	O
(	O
one	O
dsoe	O
of	O
12	O
mg	O
/	O
kg	O
once	O
a	O
week	O
s	O
.	O
c	O
.	O
)	O
for	O
4	O
weeks	O
caused	O
an	O
icnrease	O
in	O
vacuuos	O
chewnig	O
,	O
tonuge	O
protruison	O
and	O
durtaion	O
of	O
facail	O
twicthing	O
observed	O
in	O
four	O
wekely	O
eavluations	O
.	O

After	O
the	O
treatemnts	O
and	O
behaivoral	O
observaiton	O
,	O
glutaamte	B-Chemical
upatke	O
by	O
segemnts	O
of	O
the	O
brian	O
was	O
anlayzed	O
.	O

A	O
derceased	O
gluatmate	B-Chemical
uptkae	O
was	O
observed	O
in	O
the	O
subcrotical	O
patrs	O
of	O
animlas	O
tretaed	O
with	O
reseripne	B-Chemical
and	O
haloepridol	B-Chemical
,	O
compaerd	O
to	O
the	O
conrtol	O
.	O

Importantly	O
,	O
a	O
dercease	O
in	O
gultamate	B-Chemical
upatke	O
correaltes	O
negatviely	O
with	O
an	O
incraese	O
in	O
the	O
incdience	O
of	O
orfoacial	O
diskiensia	O
.	O

These	O
resluts	O
indicate	O
that	O
ealry	O
cahnges	O
in	O
glutamtae	B-Chemical
transprot	O
may	O
be	O
related	O
to	O
the	O
developemnt	O
of	O
vacouus	O
chewnig	O
movemetns	O
in	O
rtas	O
.	O

Cfetriaxone	B-Chemical
-	O
associated	O
biilary	O
pseudoltihiasis	O
in	O
padeiatric	O
surgcial	O
pateints	O
.	O

It	O
is	O
well	O
known	O
that	O
cefrtiaxone	B-Chemical
leads	O
to	O
pseudolithiaiss	O
in	O
some	O
patinets	O
.	O

Cilnical	O
and	O
experiemntal	O
studeis	O
also	O
suggest	O
that	O
situtaions	O
causing	O
gallbladder	O
dysfunctoin	O
,	O
such	O
as	O
fatsing	O
,	O
may	O
have	O
a	O
role	O
for	O
the	O
deevlopment	O
of	O
pseudolithaisis	O
.	O

In	O
this	O
sutdy	O
,	O
we	O
prospectively	O
eavluated	O
the	O
incdience	O
and	O
cliniacl	O
importance	O
of	O
pseudolithisais	O
in	O
paedaitric	O
srugical	O
ptaients	O
receiving	O
ceftiraxone	B-Chemical
teratment	O
,	O
who	O
often	O
had	O
to	O
fast	O
in	O
the	O
psot	O
-	O
opreative	O
preiod	O
.	O

Fifty	O
childern	O
who	O
were	O
given	O
ceftrixaone	B-Chemical
were	O
evaluaetd	O
by	O
sreial	O
abdomianl	O
snoograms	O
.	O

Of	O
those	O
,	O
13	O
(	O
26	O
%	O
)	O
developed	O
bliiary	O
patohlogy	O
.	O

Compraison	O
of	O
the	O
pateints	O
with	O
or	O
without	O
pseudolithiaiss	O
rveealed	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
age	O
,	O
sex	O
,	O
durtaion	O
of	O
the	O
treatmnet	O
and	O
staravtion	O
vraiables	O
.	O

After	O
cesstaion	O
of	O
the	O
tretament	O
,	O
pseudolithaisis	O
resolved	O
spnotaneously	O
within	O
a	O
short	O
peirod	O
.	O

The	O
inicdence	O
of	O
pseuodlithiasis	O
is	O
not	O
affceted	O
by	O
fatsing	O
.	O

Coronray	O
aenurysm	O
after	O
implantatoin	O
of	O
a	O
paclitxael	B-Chemical
-	O
eluitng	O
stnet	O
.	O

Fomration	O
of	O
croonary	O
anuerysm	O
is	O
a	O
rrae	O
copmlication	O
of	O
setnting	O
with	O
brae	O
mteal	O
stetns	O
,	O
but	O
based	O
on	O
experimenatl	O
stuides	O
durg	O
-	O
elutnig	O
stnets	O
may	O
idnuce	O
txoic	O
effetcs	O
on	O
the	O
vesesl	O
wlal	O
with	O
incomlpete	O
stnet	O
appostiion	O
,	O
anuerysm	O
formtaion	O
and	O
with	O
the	O
potnetial	O
of	O
setnt	O
throbmosis	O
or	O
vesesl	O
rutpure	O
.	O

We	O
present	O
a	O
43	O
-	O
yaer	O
-	O
old	O
man	O
who	O
developed	O
a	O
coroanry	O
anuerysm	O
in	O
the	O
rgiht	O
coroanry	O
artrey	O
6	O
monhts	O
after	O
receiving	O
a	O
palcitaxel	B-Chemical
-	O
eulting	O
stnet	O
.	O

The	O
paitent	O
was	O
asmyptomatic	O
and	O
the	O
aenurysm	O
was	O
dteected	O
in	O
a	O
rouitne	O
conrtol	O
.	O

Angiograhpy	O
and	O
inrtacoronary	O
ultrasuond	O
demonstrated	O
lcak	O
of	O
conatct	O
between	O
stnet	O
and	O
vesesl	O
wlal	O
in	O
a	O
15	O
-	O
mm	O
long	O
segmnet	O
with	O
maixmal	O
aneursym	O
diaemter	O
of	O
6	O
.	O
0	O
mm	O
.	O

The	O
ptaient	O
was	O
successfully	O
terated	O
with	O
a	O
garft	O
setnt	O
.	O

Cuases	O
of	O
aucte	O
thromobtic	O
microangiopahty	O
in	O
patietns	O
receiving	O
kindey	O
translpantation	O
.	O

OJBECTIVES	O
:	O
Thrombtoic	O
microanigopathy	O
is	O
a	O
well	O
-	O
known	O
porblem	O
in	O
patinets	O
following	O
rneal	O
transplantatoin	O
.	O

In	O
posternal	O
translpantation	O
,	O
throbmotic	O
microangioptahy	O
is	O
often	O
a	O
relfection	O
of	O
hemolyitc	O
uermic	O
sydnrome	O
.	O

We	O
aimed	O
to	O
determine	O
the	O
causes	O
of	O
thromobtic	O
microangioapthy	O
in	O
a	O
popluation	O
of	O
reanl	O
trasnplantation	O
recipietns	O
and	O
discuss	O
the	O
literatrue	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
investgiated	O
the	O
causes	O
of	O
thormbotic	O
micraongiopathy	O
during	O
a	O
1	O
-	O
yaer	O
preiod	O
,	O
from	O
June	O
2003	O
to	O
June	O
2004	O
,	O
at	O
the	O
King	O
Fhaad	O
Natioanl	O
Gurad	O
Hsopital	O
in	O
Ryiadh	O
,	O
Suadi	O
Araiba	O
,	O
by	O
revieiwng	O
the	O
sldies	O
of	O
all	O
transplnat	O
biospies	O
(	O
n	O
=	O
25	O
)	O
performed	O
during	O
this	O
itnerval	O
.	O

Pre	O
-	O
and	O
posttranslpant	O
crossmtaching	O
was	O
done	O
when	O
possible	O
.	O

RESLUTS	O
:	O
Five	O
caess	O
of	O
throbmotic	O
microangoipathy	O
were	O
found	O
.	O

Three	O
of	O
these	O
csaes	O
were	O
from	O
the	O
25	O
transplanattions	O
performed	O
at	O
King	O
Fhaad	O
Ntaional	O
Gaurd	O
Hopsital	O
,	O
while	O
the	O
other	O
2	O
trnasplantations	O
had	O
been	O
performed	O
aborad	O
and	O
were	O
referred	O
to	O
us	O
for	O
follow	O
-	O
up	O
.	O

Three	O
caess	O
were	O
related	O
to	O
cyclosproine	B-Chemical
,	O
and	O
1	O
csae	O
was	O
secondary	O
to	O
both	O
cyclospoirne	B-Chemical
and	O
tacroilmus	B-Chemical
.	O

The	O
fifth	O
csae	O
had	O
featrues	O
of	O
thromboitc	O
mircoangiopathy	O
related	O
to	O
an	O
antiphopsholipid	O
sydnrome	O
in	O
a	O
paitent	O
with	O
sysetmic	O
lpuus	O
ertyhematosus	O
.	O

CONCULSIONS	O
:	O
In	O
the	O
ltierature	O
,	O
the	O
most	O
-	O
frqeuent	O
cause	O
of	O
heomlytic	O
uermic	O
synrdome	O
in	O
pateints	O
following	O
rneal	O
transpalntation	O
is	O
recurrnece	O
of	O
the	O
hemloytic	O
uermic	O
synrdome	O
.	O

Other	O
causes	O
include	O
durg	O
-	O
related	O
(	O
ccylosporine	B-Chemical
,	O
tacroilmus	B-Chemical
)	O
toxictiy	O
,	O
procaogulant	O
sattus	O
,	O
and	O
antibdoy	O
-	O
mediated	O
rejcetion	O
.	O

We	O
found	O
that	O
the	O
most	O
-	O
freqeunt	O
cause	O
of	O
thromboitc	O
microangipoathy	O
was	O
durg	O
related	O
,	O
secondary	O
mainly	O
to	O
cyclospoirne	B-Chemical
.	O

In	O
the	O
current	O
stduy	O
,	O
the	O
freuqency	O
of	O
thrmobotic	O
microangoipathy	O
was	O
similar	O
to	O
the	O
perecntage	O
reported	O
in	O
the	O
ltierature	O
(	O
20	O
%	O
)	O
.	O

Copmarison	O
of	O
developmenatl	O
toixcity	O
of	O
selective	O
and	O
non	O
-	O
selective	O
cyclooxygnease	O
-	O
2	O
inhibtiors	O
in	O
CRL	O
:	O
(	O
WI	O
)	O
WBUR	O
Wisatr	O
rtas	O
-	O
-	O
DFU	B-Chemical
and	O
piroxciam	B-Chemical
stduy	O
.	O

BACKGORUND	O
:	O
Cyclooxgyenase	O
(	O
COX	O
)	O
inhibiotrs	O
are	O
one	O
of	O
the	O
most	O
often	O
ignested	O
drgus	O
during	O
preganncy	O
.	O

Unlike	O
general	O
txoicity	O
dtaa	O
,	O
their	O
prenaatl	O
txoic	O
effetcs	O
were	O
not	O
extensively	O
studied	O
before	O
.	O

The	O
aim	O
of	O
the	O
exepriment	O
was	O
to	O
evaulate	O
the	O
developmenatl	O
toxciity	O
of	O
the	O
non	O
-	O
selective	O
(	O
piorxicam	B-Chemical
)	O
and	O
selective	O
(	O
DFU	B-Chemical
;	O
5	B-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
dimtehyl	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
fluoropheynl	I-Chemical
)	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
methylsulpohnyl	I-Chemical
)	I-Chemical
phneyl	I-Chemical
-	I-Chemical
2	I-Chemical
(	I-Chemical
5H	I-Chemical
)	I-Chemical
-	I-Chemical
furaonn	I-Chemical
)	O
COX	O
-	O
2	O
inhibitros	O
.	O

METHODS	O
:	O
Durgs	O
were	O
separately	O
,	O
oarlly	O
once	O
dialy	O
dsoed	O
to	O
pregnnat	O
rtas	O
from	O
day	O
8	O
to	O
21	O
(	O
GD1	O
=	O
pulg	O
day	O
)	O
.	O

Doess	O
were	O
set	O
at	O
0	O
.	O
3	O
,	O
3	O
.	O
0	O
and	O
30	O
.	O
0mg	O
/	O
kg	O
for	O
piorxicam	B-Chemical
and	O
0	O
.	O
2	O
,	O
2	O
.	O
0	O
and	O
20	O
.	O
0mg	O
/	O
kg	O
for	O
DFU	B-Chemical
.	O

Fetuess	O
were	O
delivreed	O
on	O
GD	O
21	O
and	O
routinely	O
examined	O
.	O

Comperhensive	O
clincial	O
and	O
devleopmental	O
measurmeents	O
were	O
done	O
.	O

The	O
poloed	O
sattistical	O
anaylsis	O
for	O
vnetricular	O
spetal	O
(	O
VSD	O
)	O
and	O
midlnie	O
(	O
MD	O
)	O
defcets	O
was	O
performed	O
for	O
rat	O
fetuess	O
expoesd	O
to	O
piroxciam	B-Chemical
,	O
selective	O
and	O
non	O
-	O
selective	O
COX	O
-	O
2	O
inhibtior	O
based	O
on	O
present	O
and	O
hsitoric	O
dtaa	O
.	O

RESUTLS	O
:	O
Materanl	O
txoicity	O
,	O
intaruterine	O
grwoth	O
retradation	O
,	O
and	O
inrcease	O
of	O
exetrnal	O
and	O
skeeltal	O
variaitons	O
were	O
found	O
in	O
rtas	O
terated	O
with	O
the	O
highest	O
dsoe	O
of	O
piroxiacm	B-Chemical
.	O

Decraese	O
of	O
featl	O
lentgh	O
was	O
the	O
only	O
sgins	O
of	O
the	O
DFU	B-Chemical
developmetnal	O
toixcity	O
observed	O
in	O
ppus	O
epxosed	O
to	O
the	O
highest	O
cmopound	O
dsoe	O
.	O

Lcak	O
of	O
teratogenictiy	O
was	O
found	O
in	O
piroixcam	B-Chemical
and	O
DFU	B-Chemical
-	O
epxosed	O
gruops	O
.	O

Prneatal	O
exopsure	O
to	O
non	O
-	O
selective	O
COX	O
inhibtiors	O
increaess	O
the	O
rsik	O
of	O
VSD	O
and	O
MD	O
when	O
copmared	O
to	O
hisotric	O
cotnrol	O
but	O
not	O
with	O
selective	O
COX	O
-	O
2	O
inhibitros	O
.	O

CONCLSUION	O
:	O
Both	O
selective	O
and	O
non	O
-	O
selective	O
COX	O
-	O
2	O
inihbitors	O
were	O
toixc	O
for	O
rtas	O
fetsues	O
when	O
amdinistered	O
in	O
the	O
highest	O
dsoe	O
.	O

Unlike	O
DFU	B-Chemical
,	O
piroxiacm	B-Chemical
was	O
also	O
highly	O
txoic	O
to	O
the	O
dmas	O
.	O

Pernatal	O
expsoure	O
to	O
selective	O
COX	O
-	O
2	O
inhbiitors	O
does	O
not	O
incraese	O
the	O
rsik	O
of	O
vetnricular	O
sepatl	O
and	O
midlnie	O
defetcs	O
in	O
rat	O
when	O
compaerd	O
to	O
non	O
-	O
selective	O
drgus	O
and	O
hisotric	O
conrtol	O
.	O

Lnoe	O
artial	O
firbillation	O
associated	O
with	O
craetine	B-Chemical
moonhydrate	O
supplementation	O
.	O

Atiral	O
fibrillation	O
in	O
yonug	O
patinets	O
without	O
strutcural	O
herat	O
diesase	O
is	O
rrae	O
.	O

Therefore	O
,	O
when	O
the	O
arhrythmia	O
is	O
present	O
in	O
this	O
populatoin	O
,	O
reversible	O
causes	O
must	O
be	O
iedntified	O
and	O
resolved	O
.	O

Thyorid	O
diosrders	O
,	O
illciit	O
durg	O
or	O
stiumlant	O
use	O
,	O
and	O
aucte	O
aclohol	O
itnoxication	O
are	O
among	O
these	O
causes	O
.	O

We	O
rpeort	O
the	O
csae	O
of	O
a	O
30	O
-	O
yaer	O
-	O
old	O
Caucasain	O
man	O
who	O
came	O
to	O
the	O
emregency	O
departmnet	O
in	O
artial	O
fibrillatoin	O
with	O
rpaid	O
vnetricular	O
resposne	O
.	O

His	O
medcial	O
hisotry	O
was	O
unremarkable	O
,	O
except	O
for	O
minor	O
farctures	O
of	O
the	O
fingres	O
and	O
foot	O
.	O

Tyhroid	O
-	O
stimultaing	O
hormnoe	O
,	O
magnesuim	B-Chemical
,	O
and	O
ptoassium	B-Chemical
leevls	O
were	O
within	O
noraml	O
limtis	O
,	O
urnie	O
durg	O
srceen	O
was	O
negtaive	O
,	O
and	O
alochol	B-Chemical
use	O
was	O
denied	O
.	O

However	O
,	O
when	O
the	O
pateint	O
was	O
questioned	O
about	O
use	O
of	O
herabl	O
proudcts	O
and	O
suppleemnts	O
,	O
the	O
use	O
of	O
cretaine	B-Chemical
monohydarte	O
was	O
rveealed	O
.	O

The	O
ptaient	O
was	O
admitetd	O
to	O
the	O
hosptial	O
,	O
anticoagualted	O
with	O
unfractinoated	O
hepairn	B-Chemical
,	O
and	O
given	O
itnravenous	O
ditliazem	B-Chemical
for	O
rtae	O
conrtol	O
and	O
itnravenous	O
amiodarnoe	B-Chemical
for	O
rtae	O
and	O
rhtyhm	O
conrtol	O
.	O

When	O
discahrged	O
less	O
than	O
24	O
hours	O
later	O
,	O
he	O
was	O
receiving	O
metorpolol	B-Chemical
and	O
asiprin	B-Chemical
,	O
with	O
follow	O
-	O
up	O
palns	O
for	O
echocardiogrpahy	O
and	O
nculear	O
imgaing	O
to	O
assess	O
perufsion	O
.	O

Exogeonus	O
creatnie	B-Chemical
is	O
used	O
by	O
atlhetes	O
to	O
theoretically	O
ipmrove	O
exericse	O
performacne	O
.	O

Vegetarinas	O
may	O
also	O
take	O
creaitne	B-Chemical
to	O
replace	O
what	O
they	O
are	O
not	O
consuming	O
from	O
maet	O
,	O
fsih	O
,	O
and	O
other	O
ainmal	O
prodcuts	O
.	O

Previous	O
anecdtoal	O
repotrs	O
have	O
linked	O
cretaine	B-Chemical
to	O
the	O
deevlopment	O
of	O
arrhtyhmia	O
.	O

Clinicains	O
must	O
be	O
dliigent	O
when	O
itnerviewing	O
ptaients	O
about	O
their	O
durg	O
therpay	O
hsitories	O
and	O
include	O
quetsions	O
about	O
their	O
use	O
of	O
hebral	O
prodcuts	O
and	O
deitary	O
supplemnets	O
.	O

In	O
addition	O
,	O
it	O
is	O
important	O
to	O
reoprt	O
adevrse	O
efefcts	O
associated	O
with	O
frequently	O
consumed	O
supplemnets	O
and	O
hrebal	O
prodcuts	O
to	O
the	O
Food	O
and	O
Durg	O
Administrtaion	O
and	O
in	O
the	O
litreature	O
.	O

Seziures	O
indcued	O
by	O
the	O
coacine	B-Chemical
meatbolite	O
bnezoylecgonine	B-Chemical
in	O
rtas	O
.	O

The	O
half	O
-	O
lfie	O
(	O
t1	O
/	O
2	O
)	O
of	O
ccoaine	B-Chemical
is	O
relatively	O
short	O
,	O
but	O
some	O
of	O
the	O
consqeuences	O
of	O
its	O
use	O
,	O
such	O
as	O
seziures	O
and	O
storkes	O
,	O
can	O
occur	O
hours	O
after	O
exopsure	O
.	O

This	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
metaoblite	O
of	O
cociane	B-Chemical
may	O
be	O
responsible	O
for	O
some	O
of	O
those	O
dleayed	O
seqeulae	O
.	O

We	O
evalauted	O
the	O
ptoential	O
of	O
the	O
major	O
metaoblite	O
of	O
cociane	B-Chemical
,	O
benzoylecgnoine	B-Chemical
(	O
BE	B-Chemical
)	O
,	O
to	O
cause	O
siezures	O
.	O

Two	O
separate	O
equmiolar	O
dsoes	O
(	O
0	O
.	O
2	O
and	O
0	O
.	O
4	O
muoml	O
)	O
of	O
either	O
cocanie	B-Chemical
or	O
BE	B-Chemical
were	O
injceted	O
ventricularly	O
in	O
unanesthteized	O
juvenlie	O
rtas	O
.	O

Treaetd	O
rtas	O
were	O
then	O
evalauted	O
for	O
incdience	O
,	O
laetncy	O
,	O
and	O
seziure	O
patetrn	O
or	O
for	O
locmootor	O
activtiy	O
in	O
aniamls	O
without	O
siezures	O
.	O

BE	B-Chemical
-	O
Inudced	O
seziures	O
occurred	O
more	O
frequently	O
and	O
had	O
significantly	O
longer	O
latenceis	O
than	O
those	O
inudced	O
by	O
eqiumolar	O
amounts	O
of	O
coacine	B-Chemical
.	O

Whereas	O
cociane	B-Chemical
-	O
induecd	O
siezures	O
were	O
best	O
characetrized	O
as	O
brief	O
,	O
genearlized	O
,	O
and	O
toinc	O
and	O
resulted	O
in	O
daeth	O
,	O
those	O
inudced	O
by	O
BE	B-Chemical
were	O
porlonged	O
,	O
often	O
mlutiple	O
and	O
mixed	O
in	O
tpye	O
,	O
and	O
rarely	O
resulted	O
in	O
detah	O
.	O

Electrcial	O
recordnigs	O
from	O
the	O
hippocampus	O
showed	O
a	O
rhyhtmic	O
prgoression	O
in	O
EEG	O
freqeuncy	O
and	O
volatge	O
with	O
cilnical	O
seziure	O
exrpession	O
.	O

BE	B-Chemical
-	O
Injetced	O
rtas	O
that	O
did	O
not	O
have	O
seziures	O
had	O
significantly	O
more	O
locomtoor	O
acitvity	O
than	O
coacine	B-Chemical
-	O
inejcted	O
ainmals	O
without	O
seizuers	O
.	O

The	O
findnig	O
that	O
cocanie	B-Chemical
-	O
and	O
BE	B-Chemical
-	O
indcued	O
seziures	O
differ	O
in	O
several	O
respects	O
suggests	O
more	O
than	O
one	O
mehcanism	O
for	O
cocanie	B-Chemical
-	O
idnuced	O
seziures	O
and	O
emphasizes	O
the	O
importance	O
of	O
a	O
cociane	B-Chemical
meatbolite	O
,	O
BE	B-Chemical
.	O

The	O
selective	O
5	O
-	O
HT6	O
reecptor	O
anatgonist	O
Ro3468554	B-Chemical
resotres	O
meomry	O
perfomrance	O
in	O
choilnergic	O
and	O
seortonergic	O
moedls	O
of	O
memroy	O
dfeiciency	O
in	O
the	O
rat	O
.	O

Antagonitss	O
at	O
sreotonin	B-Chemical
tpye	O
6	O
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
6	O
)	O
)	O
recpetors	O
show	O
actiivty	O
in	O
moedls	O
of	O
learnnig	O
and	O
meomry	O
.	O

Although	O
the	O
underlying	O
mechansim	O
(	O
s	O
)	O
are	O
not	O
well	O
understood	O
,	O
these	O
effcets	O
may	O
involve	O
an	O
inrcease	O
in	O
acetlycholine	B-Chemical
(	O
ACh	B-Chemical
)	O
lveels	O
.	O

The	O
present	O
sutdy	O
sought	O
to	O
characterize	O
the	O
cogntiive	O
-	O
enhancing	O
effcets	O
of	O
the	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
6	O
)	O
atnagonist	O
Ro4365854	B-Chemical
(	O
3	B-Chemical
-	I-Chemical
benzenesulfnoyl	I-Chemical
-	I-Chemical
7	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
mtehyl	I-Chemical
-	I-Chemical
piperzain	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
1H	I-Chemical
-	I-Chemical
idnole	I-Chemical
)	O
in	O
a	O
rat	O
objcet	O
reocgnition	O
tsak	O
employing	O
a	O
cholienrgic	O
(	O
scpoolamine	B-Chemical
preteratment	O
)	O
and	O
a	O
serootnergic	O
-	O
(	O
tryptpohan	B-Chemical
(	O
TRP	B-Chemical
)	O
depleiton	O
)	O
defciient	O
moedl	O
,	O
and	O
comapred	O
its	O
patetrn	O
of	O
actoin	O
with	O
that	O
of	O
the	O
acetyclholinesterase	O
inhbiitor	O
metrfionate	B-Chemical
.	O

Initial	O
tseting	O
in	O
a	O
tmie	O
-	O
deepndent	O
forgteting	O
tsak	O
employing	O
a	O
24	O
-	O
h	O
dleay	O
between	O
trianing	O
and	O
tseting	O
showed	O
that	O
metrfionate	B-Chemical
imrpoved	O
ojbect	O
recongition	O
(	O
at	O
10	O
and	O
30	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
,	O
whereas	O
Ro3468554	B-Chemical
was	O
ianctive	O
.	O

Both	O
,	O
R4o368554	B-Chemical
(	O
3	O
and	O
10	O
mg	O
/	O
kg	O
,	O
intraperitonaelly	O
(	O
i	O
.	O
p	O
.	O
)	O
)	O
and	O
metrifoante	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
reveresd	O
memroy	O
dfeicits	O
idnuced	O
by	O
scoploamine	B-Chemical
and	O
TRP	B-Chemical
depeltion	O
(	O
10	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
and	O
3	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
.	O

In	O
conclusion	O
,	O
although	O
R4o368554	B-Chemical
did	O
not	O
imrpove	O
a	O
tmie	O
-	O
related	O
reetntion	O
dfeicit	O
,	O
it	O
revesred	O
a	O
cholniergic	O
and	O
a	O
serotonerigc	O
mmeory	O
deifcit	O
,	O
suggesting	O
that	O
both	O
mechansims	O
may	O
be	O
involved	O
in	O
the	O
facilitatoin	O
of	O
obejct	O
meomry	O
by	O
R4o368554	B-Chemical
and	O
,	O
possibly	O
,	O
other	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
6	O
)	O
recetpor	O
antagoinsts	O
.	O

Evaluaiton	O
of	O
the	O
anitcocaine	O
monocolnal	O
atnibody	O
GNC9H22	B-Chemical
as	O
an	O
immunotherapy	O
for	O
cociane	O
ovredose	O
.	O

The	O
ililcit	O
use	O
of	O
coacine	B-Chemical
continues	O
in	O
epideimc	O
proportinos	O
and	O
teratment	O
for	O
ccoaine	O
overdsoe	O
remains	O
elusive	O
.	O

Current	O
portein	O
-	O
based	O
technolgoy	O
offers	O
a	O
new	O
thearpeutic	O
vneue	O
by	O
which	O
antiobdies	O
bnid	O
the	O
durg	O
in	O
the	O
blood	O
steram	O
,	O
ianctivating	O
its	O
toixc	O
effects	O
.	O

The	O
therapeuitc	O
potnetial	O
of	O
the	O
antioccaine	O
antiobdy	O
GNC9H22	B-Chemical
was	O
examined	O
using	O
a	O
moedl	O
of	O
cocanie	O
ovredose	O
.	O

Swsis	O
ablino	O
mcie	O
prpeared	O
with	O
intraujgular	O
ctaheters	O
were	O
tseted	O
in	O
photcoell	O
cgaes	O
after	O
administraiton	O
of	O
93	O
mg	O
/	O
kg	O
(	O
L5D0	O
)	O
of	O
cocanie	B-Chemical
and	O
GNC9H22	B-Chemical
infusinos	O
ranging	O
from	O
30	O
to	O
190	O
mg	O
/	O
kg	O
.	O

GNC29H2	B-Chemical
was	O
deliveerd	O
30	O
min	O
before	O
,	O
concomitantly	O
or	O
3	O
min	O
after	O
ccoaine	B-Chemical
treatemnt	O
.	O

Signifiacnt	O
blockdae	O
of	O
cociane	B-Chemical
toxciity	O
was	O
observed	O
with	O
the	O
hgiher	O
dsoe	O
of	O
GNC29H2	B-Chemical
(	O
190	O
mg	O
/	O
kg	O
)	O
,	O
where	O
premrobid	O
beahviors	O
were	O
redcued	O
up	O
to	O
40	O
%	O
,	O
seizrues	O
up	O
to	O
77	O
%	O
and	O
daeth	O
by	O
72	O
%	O
.	O

Importantly	O
,	O
GNC9H22	B-Chemical
prevented	O
daeth	O
even	O
psot	O
-	O
coacine	B-Chemical
injeciton	O
.	O

The	O
resutls	O
support	O
the	O
important	O
potentail	O
of	O
GCN92H2	B-Chemical
as	O
a	O
therapetuic	O
tool	O
against	O
cociane	O
ovredose	O
.	O

Electrocardigoraphic	O
eivdence	O
of	O
myocaridal	O
ijnury	O
in	O
psychiatriaclly	O
hospiatlized	O
cociane	B-Chemical
aubsers	O
.	O

The	O
electroacrdiograms	O
(	O
ECG	O
)	O
of	O
99	O
coacine	B-Chemical
-	O
absuing	O
pateints	O
were	O
cmopared	O
with	O
the	O
EGCs	O
of	O
50	O
schziophrenic	O
contorls	O
.	O

Eleven	O
of	O
the	O
ccoaine	B-Chemical
absuers	O
and	O
none	O
of	O
the	O
contrlos	O
had	O
ECG	O
eviednce	O
of	O
significant	O
mycoardial	O
ijnury	O
defined	O
as	O
myoacrdial	O
infarciton	O
,	O
ischeima	O
,	O
and	O
budnle	O
barnch	O
blcok	O
.	O

Bheavioral	O
effects	O
of	O
urotesnin	B-Chemical
-	I-Chemical
II	I-Chemical
centrally	O
admniistered	O
in	O
mcie	O
.	O

Urotnesin	B-Chemical
-	I-Chemical
II	I-Chemical
(	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
)	O
rceeptors	O
are	O
widely	O
distributed	O
in	O
the	O
cetnral	O
nevrous	O
ssytem	O
.	O

Intracerebroventricluar	O
(	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
injectoin	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
causes	O
hypertesnion	O
and	O
bradycradia	O
and	O
stimulaets	O
proalctin	O
and	O
thyrtoropin	O
sercetion	O
.	O

However	O
,	O
the	O
bheavioral	O
effects	O
of	O
centrally	O
amdinistered	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
have	O
received	O
little	O
atetntion	O
.	O

In	O
the	O
present	O
sutdy	O
,	O
we	O
tseted	O
the	O
effetcs	O
of	O
i	O
.	O
c	O
.	O
v	O
.	O
inejctions	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
on	O
bheavioral	O
,	O
metbaolic	O
,	O
and	O
ednocrine	O
rseponses	O
in	O
mcie	O
.	O

Admniistration	O
of	O
garded	O
dsoes	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
(	O
1	O
-	O
10	O
,	O
000	O
ng	O
/	O
mosue	O
)	O
provoked	O
:	O
(	O
1	O
)	O
a	O
dsoe	O
-	O
depnedent	O
reduciton	O
in	O
the	O
number	O
of	O
haed	O
dpis	O
in	O
the	O
hloe	O
-	O
borad	O
tset	O
;	O
(	O
2	O
)	O
a	O
dsoe	O
-	O
dpeendent	O
redutcion	O
in	O
the	O
number	O
of	O
entreis	O
in	O
the	O
whtie	O
chmaber	O
in	O
the	O
balck	O
-	O
and	O
-	O
whtie	O
compartmnet	O
tset	O
,	O
and	O
in	O
the	O
number	O
of	O
entreis	O
in	O
the	O
cetnral	O
platofrm	O
and	O
open	O
arms	O
in	O
the	O
plus	O
-	O
mzae	O
tset	O
;	O
and	O
(	O
3	O
)	O
a	O
dsoe	O
-	O
dpeendent	O
incerase	O
in	O
the	O
duratoin	O
of	O
immobility	O
in	O
the	O
forced	O
-	O
swmiming	O
tset	O
and	O
tial	O
ssupension	O
tset	O
.	O

Intracerebrvoentricular	O
inejction	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
also	O
caused	O
an	O
incraese	O
in	O
:	O
food	O
inatke	O
at	O
dsoes	O
of	O
100	O
and	O
1	O
,	O
000	O
ng	O
/	O
mosue	O
,	O
wtaer	O
inatke	O
at	O
dsoes	O
of	O
100	O
-	O
10	O
,	O
000	O
ng	O
/	O
muose	O
,	O
and	O
hoirzontal	O
locmootion	O
atcivity	O
at	O
a	O
dsoe	O
of	O
10	O
,	O
000	O
ng	O
/	O
muose	O
.	O

Whatever	O
was	O
the	O
dsoe	O
,	O
the	O
cnetral	O
amdinistration	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
had	O
no	O
effcet	O
on	O
bdoy	O
tempertaure	O
,	O
noccieption	O
,	O
apomoprhine	B-Chemical
-	O
inudced	O
pneile	O
eerction	O
and	O
climbnig	O
behvaior	O
,	O
and	O
strses	O
-	O
idnuced	O
plsama	O
croticosterone	B-Chemical
leevl	O
.	O

Taken	O
together	O
,	O
the	O
present	O
sutdy	O
demonstrates	O
that	O
the	O
cnetral	O
injcetion	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
at	O
dsoes	O
of	O
1	O
-	O
10	O
,	O
000	O
ng	O
/	O
mosue	O
idnuces	O
anxiogneic	O
-	O
and	O
derpessant	O
-	O
like	O
effects	O
in	O
mosue	O
.	O

These	O
dtaa	O
suggest	O
that	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
may	O
be	O
involved	O
in	O
some	O
aspects	O
of	O
psycihatric	O
disordres	O
.	O

Laerning	O
of	O
rtas	O
under	O
amnseia	O
caused	O
by	O
pentobaribtal	B-Chemical
.	O

Dissocaited	O
laerning	O
of	O
rtas	O
in	O
the	O
nromal	O
state	O
and	O
the	O
state	O
of	O
amnseia	O
produced	O
by	O
pentboarbital	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
,	O
ip	O
)	O
was	O
carried	O
out	O
.	O

Rtas	O
were	O
tarined	O
to	O
approach	O
a	O
shlef	O
where	O
they	O
received	O
food	O
reinofrcement	O
.	O

In	O
Gruop	O
1	O
the	O
rtas	O
were	O
tarined	O
under	O
the	O
influnece	O
of	O
pentobrabital	B-Chemical
to	O
run	O
to	O
the	O
same	O
shlef	O
as	O
in	O
the	O
nomral	O
state	O
.	O

In	O
Gruop	O
2	O
the	O
rtas	O
were	O
trianed	O
to	O
approach	O
different	O
shelevs	O
in	O
different	O
durg	O
states	O
.	O

It	O
was	O
shown	O
that	O
meomry	O
dissocaition	O
occurred	O
in	O
both	O
gropus	O
.	O

Differenecs	O
in	O
the	O
parameetrs	O
of	O
tarining	O
under	O
the	O
ifnluence	O
of	O
petnobarbital	B-Chemical
between	O
Gorups	O
1	O
and	O
2	O
were	O
revaeled	O
.	O

These	O
finidngs	O
show	O
that	O
the	O
brian	O
-	O
dsisociated	O
state	O
indcued	O
by	O
pentboarbital	B-Chemical
is	O
formed	O
with	O
the	O
partciipation	O
of	O
the	O
mechanimss	O
of	O
informtaion	O
preception	O
.	O

The	O
effetcs	O
of	O
short	O
-	O
term	O
raloxiefne	B-Chemical
threapy	O
on	O
fibrinoylsis	O
makrers	O
:	O
TFAI	O
,	O
tPA	O
,	O
and	O
PAI	O
-	O
1	O
.	O

BACKGRUOND	O
:	O
Marekrs	O
of	O
fbirinolysis	O
,	O
thrmobin	O
-	O
activaatble	O
fibrinolyiss	O
ihnibitor	O
(	O
TFAI	O
)	O
,	O
tsisue	O
-	O
tpye	O
plamsinogen	O
atcivator	O
(	O
tPA	O
)	O
,	O
and	O
plamsinogen	O
actviator	O
inhibiotr	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
levles	O
were	O
studied	O
for	O
the	O
evalaution	O
of	O
short	O
-	O
term	O
effects	O
of	O
raloxiefne	B-Chemical
administratoin	O
in	O
psotmenopausal	O
wmoen	O
.	O

METHODS	O
:	O
Thirty	O
-	O
nine	O
psotmenopausal	O
wmoen	O
with	O
otseopenia	O
or	O
osteoporsois	O
were	O
included	O
in	O
this	O
prospetcive	O
,	O
cnotrolled	O
cliniacl	O
stduy	O
.	O

Twenty	O
-	O
five	O
wmoen	O
were	O
given	O
raolxifene	B-Chemical
hydrohcloride	I-Chemical
(	O
60	O
mg	O
/	O
day	O
)	O
plus	O
calcuim	B-Chemical
(	O
500	O
mg	O
/	O
day	O
)	O
.	O

Age	O
-	O
matched	O
cnotrols	O
(	O
n	O
=	O
14	O
)	O
were	O
given	O
only	O
calicum	B-Chemical
.	O

Palsma	O
TFAI	O
,	O
tPA	O
,	O
and	O
PAI	O
-	O
1	O
antgien	O
leevls	O
were	O
maesured	O
at	O
baselnie	O
and	O
after	O
3	O
monhts	O
of	O
tretament	O
by	O
commercially	O
available	O
EILSA	O
ktis	O
.	O

Varaitions	O
of	O
inidviduals	O
were	O
asesssed	O
by	O
Wicloxon	O
'	O
s	O
tset	O
.	O

Relatiosnhip	O
between	O
those	O
marekrs	O
and	O
demograhpic	O
characteirstics	O
were	O
investgiated	O
.	O

RSEULTS	O
:	O
Three	O
monhts	O
of	O
rlaoxifene	B-Chemical
treatemnt	O
was	O
associated	O
with	O
a	O
significant	O
decraese	O
in	O
the	O
plamsa	O
TFAI	O
antgien	O
concnetrations	O
(	O
16	O
%	O
change	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
a	O
significant	O
incresae	O
in	O
tPA	O
atnigen	O
concentratoins	O
(	O
25	O
%	O
change	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

A	O
significant	O
correlation	O
was	O
found	O
between	O
bsaeline	O
TFAI	O
anitgen	O
concentraitons	O
and	O
the	O
druation	O
of	O
amenrorhea	O
(	O
P	O
<	O
0	O
.	O
05	O
;	O
r	O
=	O
0	O
.	O
33	O
)	O
.	O

CNOCLUSION	O
:	O
We	O
suggest	O
that	O
the	O
increaesd	O
rsik	O
of	O
vneous	O
thromboebmolism	O
due	O
to	O
raloixfene	B-Chemical
teratment	O
may	O
be	O
related	O
to	O
increaesd	O
tPA	O
leevls	O
,	O
but	O
not	O
TFAI	O
leevls	O
.	O

Valpraote	B-Chemical
-	O
induecd	O
encephalopahty	O
.	O

Valpraote	B-Chemical
-	O
inudced	O
encpehalopathy	O
is	O
a	O
rrae	O
syndrmoe	O
that	O
may	O
manifest	O
in	O
otherwise	O
nomral	O
epielptic	O
inidviduals	O
.	O

It	O
may	O
even	O
present	O
in	O
patinets	O
who	O
have	O
toleraetd	O
this	O
mdeicine	O
well	O
in	O
the	O
past	O
.	O

It	O
is	O
usually	O
but	O
not	O
necessarily	O
associated	O
with	O
hyperammonmeia	O
.	O

The	O
EEG	O
shows	O
characetristic	O
triphsaic	O
wvaes	O
in	O
most	O
patietns	O
with	O
this	O
comlpication	O
.	O

A	O
csae	O
of	O
valprotae	B-Chemical
-	O
idnuced	O
encehpalopathy	O
is	O
presented	O
.	O

The	O
probelms	O
in	O
diagnoisng	O
this	O
condiiton	O
are	O
subsequently	O
discussed	O
.	O

Rceurrent	O
dysphoina	O
and	O
acitrtein	B-Chemical
.	O

We	O
rpeort	O
the	O
csae	O
of	O
a	O
wmoan	O
copmlaining	O
of	O
dyspohnia	O
while	O
she	O
was	O
terated	O
by	O
actiretin	B-Chemical
.	O

Her	O
smyptoms	O
totally	O
regressed	O
after	O
durg	O
withdraawl	O
and	O
reappeared	O
when	O
acitrtein	B-Chemical
was	O
reintroduced	O
.	O

To	O
our	O
knowldege	O
,	O
this	O
is	O
the	O
first	O
csae	O
of	O
acirtetin	B-Chemical
-	O
inudced	O
dypshonia	O
.	O

This	O
effcet	O
may	O
be	O
related	O
to	O
the	O
pharmaoclogical	O
effcet	O
of	O
this	O
durg	O
on	O
muocus	O
mmebranes	O
.	O

Ntiro	B-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginnie	I-Chemical
mtehyl	I-Chemical
etser	I-Chemical
:	O
a	O
potenital	O
portector	O
against	O
gentaimcin	B-Chemical
ototoxiicty	O
.	O

The	O
nitirc	B-Chemical
oxdie	I-Chemical
(	O
NO	B-Chemical
)	O
inihbitor	O
ntiro	B-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arignine	I-Chemical
mtehyl	I-Chemical
esetr	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
NMAE	I-Chemical
)	O
may	O
act	O
as	O
an	O
otoportectant	O
against	O
high	O
-	O
freuqency	O
hearnig	O
lsos	O
caused	O
by	O
gentamciin	B-Chemical
,	O
but	O
further	O
stuides	O
are	O
needed	O
to	O
confirm	O
this	O
.	O
Aminoglycoisde	B-Chemical
anitbiotics	O
are	O
still	O
widely	O
used	O
by	O
virtue	O
of	O
their	O
efficcay	O
and	O
low	O
csot	O
.	O

Their	O
ottooxicity	O
is	O
a	O
serious	O
heatlh	O
probelm	O
and	O
,	O
as	O
their	O
ototoixc	O
mechansim	O
involves	O
the	O
prdouction	O
of	O
NO	B-Chemical
,	O
we	O
need	O
to	O
assess	O
the	O
use	O
of	O
NO	B-Chemical
inihbitors	O
for	O
the	O
preevntion	O
of	O
aimnoglycoside	B-Chemical
-	O
indcued	O
sensorineuarl	O
heraing	O
lsos	O
.	O

In	O
this	O
exeprimental	O
sutdy	O
we	O
used	O
30	O
Srpague	O
-	O
Dawely	O
rtas	O
,	O
27	O
of	O
which	O
had	O
gentamiicn	B-Chemical
instliled	O
into	O
the	O
middle	O
ear	O
.	O

The	O
otoportectant	O
L	B-Chemical
-	I-Chemical
NMAE	I-Chemical
was	O
admniistered	O
topiclaly	O
to	O
12	O
/	O
27	O
animlas	O
.	O

Its	O
efefct	O
was	O
determined	O
in	O
terms	O
of	O
attenaution	O
of	O
heraing	O
lsos	O
,	O
maesured	O
by	O
sihfts	O
in	O
the	O
auidtory	O
brianstem	O
resposne	O
trheshold	O
.	O

L	B-Chemical
-	I-Chemical
NMAE	I-Chemical
rdeuced	O
gentamciin	B-Chemical
-	O
indcued	O
hearnig	O
lsos	O
in	O
the	O
high	O
-	O
frqeuency	O
range	O
,	O
but	O
gave	O
no	O
protcetion	O
in	O
the	O
middle	O
or	O
low	O
freuqencies	O
.	O

Sfaety	O
proifle	O
of	O
a	O
nioctine	B-Chemical
lzoenge	O
compaerd	O
with	O
that	O
of	O
nioctine	B-Chemical
gum	O
in	O
audlt	O
smoekrs	O
with	O
underlying	O
medcial	O
codnitions	O
:	O
a	O
12	O
-	O
week	O
,	O
randomiezd	O
,	O
open	O
-	O
laebl	O
stduy	O
.	O

BACKGRONUD	O
:	O
Nioctine	B-Chemical
polcarilex	O
lozenegs	O
deliver	O
25	O
%	O
to	O
27	O
%	O
more	O
nciotine	B-Chemical
compraed	O
with	O
equivalnet	O
dsoes	O
of	O
nioctine	B-Chemical
polarcilex	O
gum	O
.	O

The	O
incerased	O
nciotine	B-Chemical
expousre	O
from	O
the	O
lozegne	O
has	O
raised	O
qusetions	O
about	O
the	O
relative	O
sfaety	O
of	O
the	O
loznege	O
and	O
gum	O
.	O

OBJETCIVE	O
:	O
The	O
objetcive	O
of	O
this	O
sutdy	O
was	O
to	O
comapre	O
the	O
saefty	O
prfoiles	O
of	O
the	O
4	O
-	O
mg	O
nicotnie	B-Chemical
lozegne	O
and	O
4	O
-	O
mg	O
nioctine	B-Chemical
gum	O
in	O
smkoers	O
with	O
selected	O
laebl	O
-	O
restricted	O
disesaes	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
multiecnter	O
,	O
randmoized	O
,	O
open	O
-	O
laebl	O
stduy	O
in	O
audlt	O
smokres	O
with	O
herat	O
disaese	O
,	O
hypretension	O
not	O
contorlled	O
by	O
medciation	O
,	O
and	O
/	O
or	O
diaebtes	O
melltius	O
.	O

Paitents	O
were	O
randomiezd	O
in	O
a	O
1	O
:	O
1	O
raito	O
to	O
receive	O
the	O
4	O
-	O
mg	O
nictoine	B-Chemical
loeznge	O
or	O
4	O
-	O
mg	O
nciotine	B-Chemical
gum	O
.	O

Saefty	O
assessments	O
were	O
made	O
at	O
baesline	O
and	O
at	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
12	O
weeks	O
after	O
the	O
start	O
of	O
prodcut	O
use	O
.	O

REUSLTS	O
:	O
Nine	O
hundred	O
one	O
patietns	O
were	O
randoimzed	O
to	O
treamtent	O
,	O
447	O
who	O
received	O
the	O
lzoenge	O
and	O
454	O
who	O
received	O
the	O
gum	O
(	O
saefty	O
popultaion	O
)	O
.	O

The	O
majority	O
were	O
woemn	O
(	O
52	O
.	O
7	O
%	O
)	O
.	O

Ptaients	O
'	O
mean	O
age	O
was	O
53	O
.	O
9	O
yeras	O
,	O
their	O
mean	O
wegiht	O
was	O
193	O
.	O
9	O
pounds	O
,	O
and	O
they	O
smoekd	O
a	O
mean	O
of	O
25	O
.	O
2	O
cigarettes	O
per	O
day	O
at	O
baselnie	O
.	O

Five	O
hundred	O
fifty	O
-	O
three	O
paitents	O
,	O
264	O
taking	O
the	O
lozegne	O
and	O
289	O
taking	O
the	O
gum	O
,	O
used	O
the	O
stduy	O
prdouct	O
for	O
>	O
or	O
=	O
4	O
dyas	O
per	O
week	O
during	O
the	O
first	O
2	O
wekes	O
(	O
evalubale	O
ppoulation	O
)	O
.	O

The	O
nciotine	B-Chemical
loznege	O
and	O
nciotine	B-Chemical
gum	O
were	O
equally	O
well	O
tolertaed	O
,	O
despite	O
icnreased	O
nicoitne	B-Chemical
exopsure	O
from	O
the	O
lzoenge	O
.	O

The	O
incidnece	O
of	O
advrese	O
evnets	O
in	O
the	O
2	O
gropus	O
was	O
similar	O
during	O
the	O
first	O
2	O
wekes	O
of	O
prodcut	O
use	O
(	O
evlauation	O
ppoulation	O
:	O
55	O
.	O
3	O
%	O
loznege	O
,	O
54	O
.	O
7	O
%	O
gum	O
)	O
,	O
as	O
well	O
as	O
during	O
the	O
entire	O
sutdy	O
(	O
saefty	O
popluation	O
:	O
63	O
.	O
8	O
%	O
and	O
58	O
.	O
6	O
%	O
,	O
respectively	O
)	O
.	O

Stratfiication	O
of	O
paitents	O
by	O
sex	O
,	O
age	O
,	O
extent	O
of	O
cocnurrent	O
smoknig	O
,	O
extent	O
of	O
prdouct	O
use	O
,	O
and	O
severtiy	O
of	O
avderse	O
evnets	O
reevaled	O
no	O
cilnically	O
significant	O
differneces	O
between	O
the	O
lzoenge	O
and	O
gum	O
.	O

The	O
most	O
common	O
adevrse	O
evnets	O
were	O
nauesa	O
(	O
17	O
.	O
2	O
%	O
and	O
16	O
.	O
1	O
%	O
;	O
95	O
%	O
CI	O
,	O
-	O
3	O
.	O
7	O
to	O
6	O
.	O
0	O
)	O
,	O
hiccpus	O
(	O
10	O
.	O
7	O
%	O
and	O
6	O
.	O
6	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
5	O
to	O
7	O
.	O
8	O
)	O
,	O
and	O
heaadche	O
(	O
8	O
.	O
7	O
%	O
and	O
9	O
.	O
9	O
%	O
;	O
95	O
%	O
Cl	O
,	O
-	O
5	O
.	O
0	O
to	O
2	O
.	O
6	O
)	O
.	O

Sreious	O
advrese	O
eevnts	O
were	O
reported	O
in	O
11	O
and	O
13	O
paitents	O
in	O
the	O
respective	O
gruops	O
.	O

Fewer	O
than	O
6	O
%	O
of	O
paitents	O
in	O
either	O
gruop	O
were	O
considered	O
by	O
the	O
investgiator	O
to	O
have	O
a	O
wosrening	O
of	O
their	O
overall	O
diesase	O
codnition	O
during	O
the	O
stduy	O
.	O

The	O
majority	O
of	O
pateints	O
(	O
>	O
60	O
%	O
)	O
experienced	O
no	O
change	O
in	O
their	O
disesae	O
stauts	O
from	O
bsaeline	O
.	O

CNOCLUSION	O
:	O
The	O
4	O
-	O
mg	O
nictoine	B-Chemical
loeznge	O
and	O
4	O
-	O
mg	O
nioctine	B-Chemical
gum	O
had	O
comparable	O
sfaety	O
prfoiles	O
in	O
these	O
pateints	O
with	O
lbael	O
-	O
restricted	O
mediacl	O
condtiions	O
.	O

Pahrmacological	O
moudlation	O
of	O
pian	O
-	O
related	O
brian	O
acitvity	O
during	O
noraml	O
and	O
cnetral	O
sesnitization	O
states	O
in	O
humnas	O
.	O

Anbormal	O
procsesing	O
of	O
somatosensroy	O
inupts	O
in	O
the	O
centarl	O
nervuos	O
sysetm	O
(	O
centarl	O
sesnitization	O
)	O
is	O
the	O
mechnaism	O
accounting	O
for	O
the	O
ehnanced	O
pian	O
senistivity	O
in	O
the	O
sikn	O
surrounding	O
tsisue	O
ijnury	O
(	O
secondary	O
hyepralgesia	O
)	O
.	O

Seconadry	O
hyperalgeisa	O
shares	O
clniical	O
chraacteristics	O
with	O
neuroegnic	O
hyperalgeisa	O
in	O
patinets	O
with	O
neurpoathic	O
pian	O
.	O

Abnromal	O
barin	O
respnoses	O
to	O
somatosensroy	O
stimlui	O
have	O
been	O
found	O
in	O
patietns	O
with	O
hyperalegsia	O
as	O
well	O
as	O
in	O
nromal	O
subjetcs	O
during	O
exeprimental	O
cetnral	O
sensitizaiton	O
.	O

The	O
aim	O
of	O
this	O
stduy	O
was	O
to	O
assess	O
the	O
effects	O
of	O
gabaepntin	B-Chemical
,	O
a	O
durg	O
effectvie	O
in	O
neruopathic	O
pian	O
paitents	O
,	O
on	O
brian	O
procesisng	O
of	O
nociceptvie	O
informtaion	O
in	O
noraml	O
and	O
cetnral	O
senstiization	O
states	O
.	O

Using	O
fnuctional	O
mangetic	O
resnoance	O
imagnig	O
(	O
fRMI	O
)	O
in	O
nomral	O
volunteres	O
,	O
we	O
studied	O
the	O
gabapnetin	B-Chemical
-	O
indcued	O
modultaion	O
of	O
barin	O
atcivity	O
in	O
resposne	O
to	O
nociceptvie	O
mehcanical	O
stimulatoin	O
of	O
noraml	O
sikn	O
and	O
capasicin	B-Chemical
-	O
inudced	O
secondary	O
hyepralgesia	O
.	O

The	O
dsoe	O
of	O
gaabpentin	B-Chemical
was	O
1	O
,	O
800	O
mg	O
per	O
os	O
,	O
in	O
a	O
single	O
administrtaion	O
.	O

We	O
found	O
that	O
(	O
i	O
)	O
gabaepntin	B-Chemical
reudced	O
the	O
actiavtions	O
in	O
the	O
biltaeral	O
operucloinsular	O
cotrex	O
,	O
independently	O
of	O
the	O
presecne	O
of	O
centarl	O
sensitizatoin	O
;	O
(	O
ii	O
)	O
gaabpentin	B-Chemical
reudced	O
the	O
actiavtion	O
in	O
the	O
braisntem	O
,	O
only	O
during	O
cnetral	O
sensitizatoin	O
;	O
(	O
iii	O
)	O
gbaapentin	B-Chemical
spupressed	O
stmiulus	O
-	O
idnuced	O
deactivtaions	O
,	O
only	O
during	O
centarl	O
sensiitzation	O
;	O
this	O
efefct	O
was	O
more	O
robsut	O
than	O
the	O
effect	O
on	O
barin	O
activtaion	O
.	O

The	O
observed	O
durg	O
-	O
inudced	O
efefcts	O
were	O
not	O
due	O
to	O
cahnges	O
in	O
the	O
baselnie	O
fRMI	O
sginal	O
.	O

These	O
findigns	O
indicate	O
that	O
gbaapentin	B-Chemical
has	O
a	O
measurbale	O
antinocicetpive	O
efefct	O
and	O
a	O
stornger	O
anthiyperalgesic	O
efefct	O
most	O
evident	O
in	O
the	O
brian	O
areas	O
undergoing	O
decativation	O
,	O
thus	O
supporting	O
the	O
conecpt	O
that	O
gabapenitn	B-Chemical
is	O
more	O
efefctive	O
in	O
modulatnig	O
nocicepitve	O
transmisison	O
when	O
centarl	O
sensitziation	O
is	O
present	O
.	O

Invsetigation	O
of	O
mitocohndrial	O
invovlement	O
in	O
the	O
experiemntal	O
moedl	O
of	O
eiplepsy	O
indcued	O
by	O
pilocaprine	B-Chemical
.	O

Mitocohndrial	O
abnormlaities	O
have	O
been	O
associated	O
with	O
several	O
aspects	O
of	O
epileptogneesis	O
,	O
such	O
as	O
enegry	O
generatoin	O
,	O
contorl	O
of	O
clel	O
detah	O
,	O
neurotrnasmitter	O
synhtesis	O
,	O
and	O
free	O
radiacl	O
(	O
FR	O
)	O
porduction	O
.	O

Incresaed	O
proudction	O
of	O
FRs	O
may	O
cause	O
mtNDA	O
dmaage	O
leading	O
to	O
decresaed	O
actviities	O
of	O
oxiadtive	O
phosphoryltaion	O
compleexs	O
containing	O
mDtNA	O
-	O
enocded	O
subuints	O
.	O

In	O
this	O
sutdy	O
,	O
we	O
inevstigated	O
whether	O
inrceased	O
generatoin	O
of	O
FR	O
during	O
stauts	O
epilepitcus	O
would	O
be	O
sufficient	O
to	O
provoke	O
abnormaliteis	O
in	O
mtNDA	O
and	O
in	O
the	O
exprsesion	O
and	O
acitvity	O
of	O
cytochrmoe	O
c	O
oixdase	O
(	O
CCO	O
)	O
,	O
compelx	O
IV	O
of	O
the	O
resipratory	O
cahin	O
,	O
in	O
the	O
chrnoic	O
phsae	O
of	O
the	O
piolcarpine	B-Chemical
mdoel	O
of	O
temopral	O
lboe	O
epilespy	O
.	O

DNA	O
analyiss	O
rveealed	O
low	O
amounts	O
of	O
a	O
4	O
.	O
8	O
kb	O
mtNDA	O
delteion	O
but	O
with	O
no	O
differecnes	O
in	O
freuqency	O
or	O
quanttiy	O
in	O
the	O
conrtol	O
and	O
expermiental	O
gorups	O
.	O

We	O
did	O
not	O
find	O
abnormaliites	O
in	O
the	O
expressoin	O
and	O
distribtuion	O
of	O
an	O
mDtNA	O
-	O
ecnoded	O
subnuit	O
of	O
CCO	O
(	O
CCO	O
-	O
I	O
)	O
or	O
a	O
relative	O
decresae	O
in	O
CCO	O
-	O
I	O
when	O
comapred	O
with	O
nulcear	O
-	O
encoedd	O
suubnits	O
(	O
CCO	O
-	O
IV	O
and	O
SDH	O
-	O
fp	O
)	O
.	O

No	O
anbormality	O
in	O
CCO	O
actviity	O
was	O
observed	O
through	O
hitsochemistry	O
.	O

Although	O
evidenecs	O
of	O
mtiochondrial	O
abonrmalities	O
were	O
found	O
in	O
previously	O
publisehd	O
stuides	O
,	O
our	O
rseults	O
do	O
not	O
suggest	O
that	O
the	O
FRs	O
,	O
generated	O
during	O
the	O
aucte	O
phsae	O
,	O
determined	O
important	O
abonrmalities	O
in	O
mDtNA	O
,	O
in	O
epxression	O
of	O
CCO	O
-	O
I	O
,	O
and	O
in	O
CCO	O
actviity	O
.	O

Advesre	O
efefct	O
of	O
the	O
clacium	B-Chemical
chanenl	O
blokcer	O
ntirendipine	B-Chemical
on	O
nephrocslerosis	O
in	O
rtas	O
with	O
reonvascular	O
hypertesnion	O
.	O

The	O
effcet	O
of	O
a	O
6	O
-	O
week	O
teratment	O
with	O
the	O
caclium	B-Chemical
chnanel	O
blocekr	O
nitrendiipne	B-Chemical
or	O
the	O
angiotesnin	B-Chemical
converting	O
enzmye	O
inhibtior	O
eanlapril	B-Chemical
on	O
bolod	O
prsesure	O
,	O
albumniuria	O
,	O
reanl	O
hemdoynamics	O
,	O
and	O
moprhology	O
of	O
the	O
nonclipepd	O
kideny	O
was	O
studied	O
in	O
rtas	O
with	O
two	O
-	O
kideny	O
,	O
one	O
cilp	O
renvoascular	O
hypertnesion	O
.	O

Six	O
wekes	O
after	O
clpiping	O
of	O
one	O
reanl	O
atrery	O
,	O
hyeprtensive	O
rtas	O
(	O
178	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
)	O
were	O
randomly	O
assigned	O
to	O
three	O
gorups	O
:	O
untretaed	O
hypretensive	O
conrtols	O
(	O
n	O
=	O
8	O
)	O
,	O
eanlapril	B-Chemical
-	O
treaetd	O
(	O
n	O
=	O
8	O
)	O
,	O
or	O
nitrednipine	B-Chemical
-	O
traeted	O
(	O
n	O
=	O
10	O
)	O
.	O

Sahm	O
-	O
operaetd	O
rtas	O
served	O
as	O
normotesnive	O
cotnrols	O
(	O
128	O
+	O
/	O
-	O
3	O
mm	O
Hg	O
,	O
n	O
=	O
8	O
)	O
.	O

After	O
6	O
weeks	O
of	O
treatemnt	O
,	O
rneal	O
hemodynaimcs	O
(	O
glomerluar	O
filtartion	O
rtae	O
and	O
rneal	O
plsama	O
folw	O
)	O
were	O
maesured	O
in	O
the	O
anestheitzed	O
rtas	O
.	O

Reanl	O
tissue	O
was	O
obtained	O
for	O
detemrination	O
of	O
golmerular	O
szie	O
and	O
slcerosis	O
.	O

Enalapirl	B-Chemical
but	O
not	O
nitrendpiine	B-Chemical
reudced	O
bolod	O
perssure	O
significantly	O
.	O

After	O
6	O
wekes	O
of	O
therpay	O
,	O
glomeurlar	O
filtartion	O
rtae	O
was	O
not	O
different	O
among	O
the	O
studied	O
gropus	O
.	O

Rneal	O
plamsa	O
folw	O
incresaed	O
,	O
but	O
alubmin	O
excretoin	O
and	O
glmoerulosclerosis	O
did	O
not	O
change	O
after	O
enalarpil	B-Chemical
treatmnet	O
.	O

In	O
contrast	O
,	O
in	O
the	O
nitrendiipne	B-Chemical
-	O
traeted	O
gruop	O
abluminuria	O
increaesd	O
from	O
12	O
.	O
8	O
+	O
/	O
-	O
2	O
progressively	O
to	O
163	O
+	O
/	O
-	O
55	O
compraed	O
with	O
19	O
.	O
2	O
+	O
/	O
-	O
9	O
mg	O
/	O
24	O
hr	O
in	O
the	O
hypertesnive	O
contorls	O
.	O

Furthermore	O
,	O
glmoerulosclerosis	O
index	O
was	O
significantly	O
incresaed	O
in	O
the	O
ntirendipine	B-Chemical
-	O
traeted	O
gorup	O
copmared	O
with	O
the	O
hypertensvie	O
conrtols	O
(	O
0	O
.	O
38	O
+	O
/	O
-	O
0	O
.	O
1	O
versus	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
04	O
)	O
.	O

In	O
addition	O
,	O
gloemrular	O
szie	O
was	O
hihger	O
in	O
the	O
ntirendipine	B-Chemical
-	O
traeted	O
gruop	O
(	O
14	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
17	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
but	O
loewr	O
in	O
the	O
eanlapril	B-Chemical
-	O
traeted	O
gorup	O
(	O
11	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
15	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
cmopared	O
with	O
the	O
hypretensive	O
cnotrols	O
(	O
12	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
17	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
.	O
(	O
ABSTRACT	O
TRUCNATED	O
AT	O
250	O
WORDS	O
)	O

Ketocoanzole	B-Chemical
induecd	O
tosrades	O
de	O
poitnes	O
without	O
concomtiant	O
use	O
of	O
QT	O
inetrval	O
-	O
prolonigng	O
durg	O
.	O

Ketocnoazole	B-Chemical
is	O
not	O
known	O
to	O
be	O
proarryhthmic	O
without	O
concoimtant	O
use	O
of	O
QT	O
itnerval	O
-	O
prologning	O
drgus	O
.	O

We	O
reprot	O
a	O
wmoan	O
with	O
coornary	O
artrey	O
disesae	O
who	O
developed	O
a	O
markedly	O
porlonged	O
QT	O
inetrval	O
and	O
torsaeds	O
de	O
poinets	O
(	O
TdP	O
)	O
after	O
taking	O
ketcoonazole	B-Chemical
for	O
tretament	O
of	O
funagl	O
infectoin	O
.	O

Her	O
QT	O
intreval	O
returned	O
to	O
nromal	O
upon	O
withdraawl	O
of	O
ketcoonazole	B-Chemical
.	O

Geneitc	O
sutdy	O
did	O
not	O
find	O
any	O
mtuation	O
in	O
her	O
gnees	O
that	O
encode	O
cardaic	O
IKr	O
chanenl	O
proetins	O
.	O

We	O
postulate	O
that	O
by	O
virtue	O
of	O
its	O
direct	O
blocikng	O
atcion	O
on	O
IKr	O
,	O
ketoconazloe	B-Chemical
alone	O
may	O
prolong	O
QT	O
intevral	O
and	O
inudce	O
TdP	O
.	O

This	O
calls	O
for	O
attetnion	O
when	O
ketcoonazole	B-Chemical
is	O
adminisetred	O
to	O
paitents	O
with	O
rsik	O
factros	O
for	O
acquired	O
long	O
QT	O
snydrome	O
.	O

Cerberal	O
vsaculitis	O
following	O
oarl	O
methyplhenidate	B-Chemical
inatke	O
in	O
an	O
adlut	O
:	O
a	O
csae	O
reoprt	O
.	O

Methylpheindate	B-Chemical
is	O
structurally	O
and	O
functionally	O
similar	O
to	O
amphetaimne	B-Chemical
.	O

Creebral	O
vascuiltis	O
associated	O
with	O
ampheatmine	O
aubse	O
is	O
well	O
documetned	O
,	O
and	O
in	O
rrae	O
csaes	O
ischaeimc	O
strkoe	O
has	O
been	O
reported	O
after	O
methylhpenidate	B-Chemical
intkae	O
in	O
cihldren	O
.	O

We	O
reprot	O
the	O
csae	O
of	O
a	O
63	O
-	O
yaer	O
-	O
old	O
femlae	O
who	O
was	O
terated	O
with	O
methylphenidtae	B-Chemical
due	O
to	O
hypreactivity	O
and	O
suffered	O
from	O
multilpe	O
ischaeimc	O
stroeks	O
.	O

We	O
consider	O
durg	O
-	O
indcued	O
ceerbral	O
vascultiis	O
as	O
the	O
most	O
likely	O
cause	O
of	O
recrurent	O
icshaemic	O
strkoes	O
in	O
the	O
asbence	O
of	O
any	O
pahtological	O
fnidings	O
during	O
the	O
diganostic	O
work	O
-	O
up	O
.	O

We	O
conclude	O
that	O
methylpheindate	B-Chemical
mediated	O
vacsulitis	O
should	O
be	O
considered	O
in	O
ptaients	O
with	O
neruological	O
smyptoms	O
and	O
a	O
hisotry	O
of	O
mtehylphenidate	B-Chemical
threapy	O
.	O

This	O
poetntial	O
side	O
-	O
effect	O
,	O
though	O
very	O
rrae	O
,	O
represents	O
one	O
more	O
reason	O
to	O
be	O
very	O
rsetrictive	O
in	O
the	O
use	O
of	O
methylphneidate	B-Chemical
.	O

MMDA	B-Chemical
polyrdug	O
uesrs	O
show	O
proecss	O
-	O
specific	O
centarl	O
exceutive	O
imapirments	O
coupled	O
with	O
ipmaired	O
socail	O
and	O
emoitonal	O
jdugement	O
porcesses	O
.	O

In	O
recent	O
yeras	O
wokring	O
meomry	O
defictis	O
have	O
been	O
reported	O
in	O
usres	O
of	O
MMDA	B-Chemical
(	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
methylenedioxymethampheatmine	I-Chemical
,	O
esctasy	B-Chemical
)	O
.	O

The	O
current	O
stduy	O
aimed	O
to	O
assess	O
the	O
imapct	O
of	O
MMDA	B-Chemical
use	O
on	O
three	O
separate	O
centarl	O
eexcutive	O
proecsses	O
(	O
set	O
shifting	O
,	O
inhibtiion	O
and	O
memroy	O
updating	O
)	O
and	O
also	O
on	O
"	O
perfrontal	O
"	O
mediated	O
soical	O
and	O
emtoional	O
judgeemnt	O
prcoesses	O
.	O

Fifteen	O
poyldrug	O
ectsasy	B-Chemical
uesrs	O
and	O
15	O
poldyrug	O
non	O
-	O
ecsatsy	B-Chemical
uesr	O
contorls	O
completed	O
a	O
general	O
durg	O
use	O
quesitonnaire	O
,	O
the	O
Birxton	O
Spatail	O
Atnicipation	O
tsak	O
(	O
set	O
shifting	O
)	O
,	O
Backwrad	O
Diigt	O
Sapn	O
proecdure	O
(	O
mmeory	O
updating	O
)	O
,	O
Inihbition	O
of	O
Rteurn	O
(	O
inhibiiton	O
)	O
,	O
an	O
emotioanl	O
intleligence	O
scale	O
,	O
the	O
Trmoso	O
Soical	O
Intelligecne	O
Sacle	O
and	O
the	O
Dyesxecutive	O
Qusetionnaire	O
(	O
DEX	O
)	O
.	O

Copmared	O
with	O
MMDA	B-Chemical
-	O
free	O
polydurg	O
conrtols	O
,	O
MMDA	B-Chemical
ploydrug	O
uesrs	O
showed	O
impairemnts	O
in	O
set	O
shifting	O
and	O
mmeory	O
updating	O
,	O
and	O
also	O
in	O
scoial	O
and	O
emtoional	O
jdugement	O
porcesses	O
.	O

The	O
latter	O
two	O
dfeicits	O
remained	O
significant	O
after	O
controlling	O
for	O
other	O
durg	O
use	O
.	O

These	O
dtaa	O
lend	O
further	O
support	O
to	O
the	O
proposal	O
that	O
cogniitve	O
porcesses	O
mediated	O
by	O
the	O
prefrnotal	O
crotex	O
may	O
be	O
imparied	O
by	O
recraetional	O
ecsatsy	B-Chemical
use	O
.	O

Pahse	O
II	O
sutdy	O
of	O
the	O
amsacrnie	B-Chemical
aanlogue	O
CI	B-Chemical
-	I-Chemical
921	I-Chemical
(	O
NSC	B-Chemical
343499	I-Chemical
)	O
in	O
non	O
-	O
small	O
clel	O
lnug	O
canecr	O
.	O

CI	B-Chemical
-	I-Chemical
921	I-Chemical
(	O
NSC	B-Chemical
343499	I-Chemical
;	O
9	B-Chemical
-	I-Chemical
[	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
metohxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
[	I-Chemical
(	I-Chemical
methylsluphonyl	I-Chemical
)	I-Chemical
amnio	I-Chemical
]	I-Chemical
phneyl	I-Chemical
]	I-Chemical
aimno	I-Chemical
]	I-Chemical
-	I-Chemical
N	I-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
dmiethyl	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
arcidinecarboxamide	I-Chemical
)	O
is	O
a	O
toopisomerase	O
II	O
posion	O
with	O
high	O
expermiental	O
anttiumour	O
acitvity	O
.	O

It	O
was	O
adimnistered	O
by	O
15	O
min	O
ifnusion	O
to	O
16	O
evalualbe	O
patietns	O
with	O
non	O
-	O
small	O
clel	O
lnug	O
cacner	O
(	O
NCSLC	O
)	O
(	O
7	O
with	O
no	O
prior	O
tretament	O
,	O
9	O
pateints	O
in	O
relpase	O
following	O
sugrery	O
/	O
radiotherpay	O
)	O
at	O
a	O
dsoe	O
(	O
648	O
mg	O
/	O
m2	O
divided	O
over	O
3	O
dyas	O
,	O
reepated	O
every	O
3	O
weeks	O
)	O
determined	O
by	O
phsae	O
I	O
tiral	O
.	O

Ptaients	O
had	O
a	O
meidan	O
performnace	O
stauts	O
of	O
1	O
(	O
WHO	O
)	O
,	O
and	O
medain	O
age	O
of	O
61	O
yaers	O
.	O

The	O
histloogy	O
comprised	O
suqamous	O
cracinoma	O
(	O
11	O
)	O
,	O
adneocarcinoma	O
(	O
1	O
)	O
,	O
mixed	O
histoolgy	O
(	O
2	O
)	O
,	O
bronchio	O
-	O
alveoalr	O
carcinmoa	O
(	O
1	O
)	O
and	O
large	O
clel	O
unidfferentiated	O
caricnoma	O
(	O
1	O
)	O
.	O

Neurtopenia	O
grdae	O
greater	O
than	O
or	O
eqaul	O
to	O
3	O
was	O
seen	O
in	O
15	O
paitents	O
,	O
infcetions	O
with	O
recvoery	O
in	O
3	O
,	O
and	O
grand	O
mal	O
seizuers	O
in	O
1	O
paitent	O
.	O

Garde	O
less	O
than	O
or	O
eqaul	O
to	O
2	O
nuasea	O
and	O
voimting	O
occurred	O
in	O
66	O
%	O
cuorses	O
and	O
phlebtiis	O
in	O
the	O
infsuion	O
arm	O
in	O
37	O
%	O
.	O

1	O
pateint	O
with	O
suqamous	O
clel	O
cacrinoma	O
achieved	O
a	O
patrial	O
respnose	O
lasting	O
5	O
mnoths	O
.	O

Further	O
tseting	O
in	O
this	O
and	O
other	O
tmuour	O
types	O
using	O
mulitple	O
dialy	O
scheudles	O
is	O
warranted	O
.	O

Pharamcokinetics	O
of	O
desiparmine	B-Chemical
HCl	I-Chemical
when	O
administeerd	O
with	O
ciancalcet	B-Chemical
HCl	I-Chemical
.	O

OBJECITVE	O
:	O
In	O
vitro	O
work	O
has	O
demonstrated	O
that	O
cinacalect	B-Chemical
is	O
a	O
strong	O
ihnibitor	O
of	O
cytochorme	O
P540	O
isoenzmye	O
(	O
CYP	O
)	O
2D6	O
.	O

The	O
purpose	O
of	O
this	O
stduy	O
was	O
to	O
evlauate	O
the	O
effect	O
of	O
cinaaclcet	B-Chemical
on	O
CYPD26	O
actiivty	O
,	O
using	O
desiparmine	B-Chemical
as	O
a	O
porbe	O
substarte	O
,	O
in	O
haelthy	O
subejcts	O
.	O

METHODS	O
:	O
Seventeen	O
subjcets	O
who	O
were	O
gneotyped	O
as	O
CY2PD6	O
extesnive	O
metaboliezrs	O
were	O
enrolled	O
in	O
this	O
randomiezd	O
,	O
open	O
-	O
laebl	O
,	O
crsosover	O
sutdy	O
to	O
receive	O
a	O
single	O
oarl	O
dsoe	O
of	O
deispramine	B-Chemical
(	O
50	O
mg	O
)	O
on	O
two	O
separate	O
occasoins	O
,	O
once	O
alone	O
and	O
once	O
after	O
mutliple	O
doess	O
of	O
ciancalcet	B-Chemical
(	O
90	O
mg	O
for	O
7	O
dyas	O
)	O
.	O

Blood	O
sapmles	O
were	O
obtained	O
perdose	O
and	O
up	O
to	O
72	O
h	O
postdsoe	O
.	O

REUSLTS	O
:	O
Fourteen	O
subjetcs	O
completed	O
both	O
teratment	O
arms	O
.	O

Reltaive	O
to	O
desiprmaine	B-Chemical
alone	O
,	O
mean	O
AUC	O
and	O
C	O
(	O
max	O
)	O
of	O
despiramine	B-Chemical
incraesed	O
3	O
.	O
6	O
-	O
and	O
1	O
.	O
8	O
-	O
fold	O
when	O
coadmiinstered	O
with	O
cniacalcet	B-Chemical
.	O

The	O
t	O
(	O
1	O
/	O
2	O
,	O
z	O
)	O
of	O
desirpamine	B-Chemical
was	O
longer	O
when	O
despiramine	B-Chemical
was	O
coadminisetred	O
with	O
cinacaclet	B-Chemical
(	O
21	O
.	O
0	O
versus	O
43	O
.	O
3	O
hs	O
)	O
.	O

The	O
t	O
(	O
max	O
)	O
was	O
similar	O
between	O
the	O
reigmens	O
.	O

Fewer	O
sujbects	O
reported	O
advesre	O
evnets	O
following	O
traetment	O
with	O
desiparmine	B-Chemical
alone	O
than	O
when	O
receiving	O
dseipramine	B-Chemical
with	O
cinaaclcet	B-Chemical
(	O
33	O
versus	O
86	O
%	O
)	O
,	O
the	O
most	O
frqeuent	O
of	O
which	O
(	O
nuasea	O
and	O
hedaache	O
)	O
have	O
been	O
reported	O
for	O
ptaients	O
terated	O
with	O
either	O
dseipramine	B-Chemical
or	O
cincaalcet	B-Chemical
.	O

CONCLUSOIN	O
:	O
This	O
stduy	O
demonstrates	O
that	O
ciancalcet	B-Chemical
is	O
a	O
strong	O
inhbiitor	O
of	O
CPY2D6	O
.	O

These	O
dtaa	O
suggest	O
that	O
during	O
concomtiant	O
teratment	O
with	O
cniacalcet	B-Chemical
,	O
dsoe	O
adujstment	O
may	O
be	O
necessary	O
for	O
drgus	O
that	O
demonstrate	O
a	O
narrow	O
threapeutic	O
index	O
and	O
are	O
metaoblized	O
by	O
CY2PD6	O
.	O

Csae	O
rpeort	O
:	O
actue	O
unintenitonal	O
carabchol	B-Chemical
itnoxication	O
.	O

INTRODUCTION	O
:	O
Intoxicatinos	O
with	O
carbacohl	B-Chemical
,	O
a	O
musacrinic	O
cholinregic	O
recpetor	O
aognist	O
are	O
rrae	O
.	O

We	O
rpeort	O
an	O
interesting	O
csae	O
investigtaing	O
a	O
(	O
near	O
)	O
ftaal	O
poiosning	O
.	O

METHODS	O
:	O
The	O
son	O
of	O
an	O
84	O
-	O
yaer	O
-	O
old	O
mlae	O
discovered	O
a	O
neswpaper	O
rpeort	O
stating	O
cliniacl	O
sucecss	O
with	O
palnt	O
extrcats	O
in	O
Alhzeimer	O
'	O
s	O
dsiease	O
.	O

The	O
mdoe	O
of	O
actoin	O
was	O
said	O
to	O
be	O
comparable	O
to	O
that	O
of	O
the	O
synhtetic	O
compuond	O
'	O
carbamylcohlin	B-Chemical
'	O
;	O
that	O
is	O
,	O
carabchol	B-Chemical
.	O

He	O
bought	O
25	O
g	O
of	O
cabrachol	B-Chemical
as	O
pure	O
susbtance	O
in	O
a	O
pahrmacy	O
,	O
and	O
the	O
fahter	O
was	O
administreed	O
400	O
to	O
500	O
mg	O
.	O

Carabchol	B-Chemical
concentratinos	O
in	O
seurm	O
and	O
uirne	O
on	O
day	O
1	O
and	O
2	O
of	O
hopsital	O
admissoin	O
were	O
aanlysed	O
by	O
HLPC	O
-	O
msas	O
spectormetry	O
.	O

RESLUTS	O
:	O
Minuets	O
after	O
oarl	O
admiinstration	O
,	O
the	O
ptaient	O
developed	O
nasuea	O
,	O
swaeting	O
and	O
hypotesnion	O
,	O
and	O
finally	O
clolapsed	O
.	O

Braydcardia	O
,	O
chloinergic	O
symptmos	O
and	O
assytole	O
occurred	O
.	O

Initial	O
cardioplumonary	O
resusctiation	O
and	O
immdeiate	O
treatemnt	O
with	O
adrnealine	B-Chemical
(	O
epinephrnie	B-Chemical
)	O
,	O
atroipne	B-Chemical
and	O
furosmeide	B-Chemical
was	O
successful	O
.	O

On	O
hosiptal	O
amdission	O
,	O
bolod	O
presusre	O
of	O
the	O
intbuated	O
,	O
bradyarrhyhtmic	O
paitent	O
was	O
100	O
/	O
65	O
mmHg	O
.	O

Further	O
sings	O
were	O
hyperhidorsis	O
,	O
hypersalivaiton	O
,	O
brnochorrhoea	O
,	O
and	O
seevre	O
misois	O
;	O
the	O
electrocardiogarphic	O
fniding	O
was	O
atrio	O
-	O
ventrciular	O
dissocitaion	O
.	O

High	O
dsoes	O
of	O
atropnie	B-Chemical
(	O
up	O
to	O
50	O
mg	O
per	O
24	O
hours	O
)	O
,	O
adrenalnie	B-Chemical
and	O
dpoamine	B-Chemical
were	O
necessary	O
.	O

The	O
pateint	O
was	O
extubaetd	O
1	O
week	O
later	O
.	O

However	O
,	O
incraesed	O
dypsnoea	O
and	O
bronhcospasm	O
necessitated	O
rientubation	O
.	O

Respriatory	O
insfuficiency	O
was	O
further	O
woresned	O
by	O
Prtoeus	O
mirabilis	O
infcetion	O
and	O
seevre	O
bronchoconstritcion	O
.	O

One	O
week	O
later	O
,	O
the	O
pateint	O
was	O
again	O
extubtaed	O
and	O
3	O
dyas	O
later	O
was	O
tarnsferred	O
to	O
a	O
peripehral	O
wrad	O
.	O

On	O
the	O
next	O
day	O
he	O
deid	O
,	O
probably	O
as	O
a	O
result	O
of	O
herat	O
fialure	O
.	O

Sreum	O
sampels	O
from	O
the	O
first	O
and	O
second	O
dyas	O
contained	O
3	O
.	O
6	O
and	O
1	O
.	O
9	O
mg	O
/	O
l	O
carbacohl	B-Chemical
,	O
respectively	O
.	O

The	O
corresponding	O
uirne	O
concetnrations	O
amounted	O
to	O
374	O
and	O
554	O
mg	O
/	O
l	O
.	O

CONCULSION	O
:	O
This	O
csae	O
started	O
with	O
a	O
meida	O
rpeort	O
in	O
a	O
popular	O
newpsaper	O
,	O
initiated	O
by	O
publihsed	O
,	O
peer	O
-	O
reviweed	O
resaerch	O
on	O
herabls	O
,	O
and	O
involved	O
hmuan	O
fialure	O
in	O
a	O
csae	O
histroy	O
,	O
meidcal	O
examinaiton	O
and	O
cliniacl	O
treatmnet	O
.	O

For	O
the	O
first	O
tmie	O
,	O
an	O
aanlytical	O
mehtod	O
for	O
the	O
determinatoin	O
of	O
cabrachol	B-Chemical
in	O
plsama	O
and	O
uirne	O
has	O
been	O
developed	O
.	O

The	O
aanlysed	O
cabrachol	B-Chemical
concentraiton	O
exceeded	O
the	O
supposed	O
sreum	O
leevl	O
resulting	O
from	O
a	O
theraeputic	O
dsoe	O
by	O
a	O
fatcor	O
of	O
130	O
to	O
260	O
.	O

Especially	O
in	O
old	O
patinets	O
,	O
itnensivists	O
should	O
consider	O
intxoications	O
(	O
with	O
cholinegrics	O
)	O
as	O
a	O
cause	O
of	O
actue	O
cardiovascluar	O
fialure	O
.	O

Pharmacolgoical	O
evidecne	O
for	O
the	O
potenital	O
of	O
Dauucs	O
craota	O
in	O
the	O
mangaement	O
of	O
cogniitve	O
dysfucntions	O
.	O

The	O
present	O
sutdy	O
was	O
aimed	O
at	O
invetsigating	O
the	O
effects	O
of	O
Dauucs	O
craota	O
seeds	O
on	O
cogintive	O
functoins	O
,	O
total	O
sreum	O
cholesetrol	B-Chemical
levles	O
and	O
brian	O
choilnesterase	O
activtiy	O
in	O
mcie	O
.	O

The	O
ehtanolic	O
extrcat	B-Chemical
of	I-Chemical
Dacuus	I-Chemical
craota	I-Chemical
seeds	I-Chemical
(	O
DCE	B-Chemical
)	O
was	O
adminitsered	O
oarlly	O
in	O
three	O
doess	O
(	O
100	O
,	O
200	O
,	O
400	O
mg	O
/	O
kg	O
)	O
for	O
seven	O
successive	O
dyas	O
to	O
different	O
gorups	O
of	O
yonug	O
and	O
aegd	O
mcie	O
.	O

Elevaetd	O
plus	O
mzae	O
and	O
psasive	O
aviodance	O
appartaus	O
served	O
as	O
the	O
exetroceptive	O
beahvioral	O
moedls	O
for	O
tetsing	O
mmeory	O
.	O

Dizaepam	B-Chemical
-	O
,	O
scopoalmine	B-Chemical
-	O
and	O
agenig	O
-	O
idnuced	O
amnseia	O
served	O
as	O
the	O
interocepitve	O
behaviroal	O
modles	O
.	O

DCE	B-Chemical
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
showed	O
significant	O
imporvement	O
in	O
mmeory	O
socres	O
of	O
yonug	O
and	O
aegd	O
mcie	O
.	O

The	O
extent	O
of	O
meomry	O
improvmeent	O
eovked	O
by	O
DCE	B-Chemical
was	O
23	O
%	O
at	O
the	O
dsoe	O
of	O
200	O
mg	O
/	O
kg	O
and	O
35	O
%	O
at	O
the	O
dsoe	O
of	O
400	O
mg	O
/	O
kg	O
in	O
yonug	O
mcie	O
using	O
elveated	O
plus	O
mzae	O
.	O

Similarly	O
,	O
significant	O
ipmrovements	O
in	O
mmeory	O
scroes	O
were	O
observed	O
using	O
pasisve	O
aovidance	O
appraatus	O
and	O
aegd	O
mcie	O
.	O

Furthermore	O
,	O
DCE	B-Chemical
reevrsed	O
the	O
amneisa	O
idnuced	O
by	O
scopolmaine	B-Chemical
(	O
0	O
.	O
4	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
and	O
diazpeam	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

Duacus	B-Chemical
craota	I-Chemical
exrtact	I-Chemical
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
reudced	O
significantly	O
the	O
barin	O
acetylcholiensterase	O
acitvity	O
and	O
cholseterol	B-Chemical
levles	O
in	O
yuong	O
and	O
aegd	O
mcie	O
.	O

The	O
extent	O
of	O
inhibiiton	O
of	O
brian	O
chloinesterase	O
actiivty	O
evkoed	O
by	O
DCE	B-Chemical
at	O
the	O
dsoe	O
of	O
400	O
mg	O
/	O
kg	O
was	O
22	O
%	O
in	O
yuong	O
and	O
19	O
%	O
in	O
aegd	O
mcie	O
.	O

There	O
was	O
a	O
remarkable	O
reduciton	O
in	O
total	O
cohlesterol	B-Chemical
lveel	O
as	O
well	O
,	O
to	O
the	O
extent	O
of	O
23	O
%	O
in	O
yuong	O
and	O
21	O
%	O
in	O
aegd	O
aniamls	O
with	O
this	O
dsoe	O
of	O
DCE	B-Chemical
.	O

Therefore	O
,	O
DCE	B-Chemical
may	O
prove	O
to	O
be	O
a	O
useful	O
remedy	O
for	O
the	O
managemnet	O
of	O
cogniitve	O
dysfunctinos	O
on	O
account	O
of	O
its	O
multiafrious	O
beneficial	O
effetcs	O
such	O
as	O
,	O
mmeory	O
ipmroving	O
property	O
,	O
cholseterol	B-Chemical
lowreing	O
property	O
and	O
antciholinesterase	O
atcivity	O
.	O

Vlaproic	B-Chemical
aicd	I-Chemical
idnuced	O
encephaloapthy	O
-	O
-	O
19	O
new	O
caess	O
in	O
Gemrany	O
from	O
1994	O
to	O
2003	O
-	O
-	O
a	O
side	O
efefct	O
associated	O
to	O
VPA	B-Chemical
-	O
tehrapy	O
not	O
only	O
in	O
yonug	O
chidlren	O
.	O

Valrpoic	B-Chemical
aicd	I-Chemical
(	O
VPA	B-Chemical
)	O
is	O
a	O
broad	O
-	O
specrtum	O
antiepilepitc	O
durg	O
and	O
is	O
usually	O
well	O
-	O
tolearted	O
.	O

Rrae	O
serious	O
complciations	O
may	O
occur	O
in	O
some	O
paitents	O
,	O
including	O
haemorrhaigc	O
pancreaittis	O
,	O
bnoe	O
marrow	O
supprsesion	O
,	O
VPA	B-Chemical
-	O
indcued	O
hepatotoxiicty	O
and	O
VPA	B-Chemical
-	O
inudced	O
encehpalopathy	O
.	O

The	O
typical	O
sings	O
of	O
VPA	B-Chemical
-	O
inudced	O
encephaolpathy	O
are	O
impiared	O
consciounsess	O
,	O
sometimes	O
marked	O
EEG	O
background	O
solwing	O
,	O
increaesd	O
siezure	O
frqeuency	O
,	O
with	O
or	O
without	O
hyperammonemia	O
.	O

There	O
is	O
still	O
no	O
proof	O
of	O
caustaive	O
effcet	O
of	O
VPA	B-Chemical
in	O
paitents	O
with	O
enecphalopathy	O
,	O
but	O
only	O
of	O
an	O
assoication	O
with	O
an	O
assumed	O
causal	O
relation	O
.	O

We	O
reoprt	O
19	O
patinets	O
with	O
VPA	B-Chemical
-	O
associated	O
encephalpoathy	O
in	O
Geramny	O
from	O
the	O
yaers	O
1994	O
to	O
2003	O
,	O
none	O
of	O
whom	O
had	O
been	O
pubilshed	O
previously	O
.	O

Ceerbral	O
heamorrhage	O
indcued	O
by	O
warfrain	B-Chemical
-	O
the	O
infleunce	O
of	O
durg	O
-	O
durg	O
inetractions	O
.	O

PUROPSE	O
:	O
To	O
evaulate	O
the	O
frequnecy	O
,	O
severtiy	O
and	O
preventabiilty	O
of	O
wrafarin	B-Chemical
-	O
idnuced	O
cerebarl	O
haemorrhaegs	O
due	O
to	O
warfrain	B-Chemical
and	O
wrafarin	B-Chemical
-	O
durg	O
interacitons	O
in	O
pateints	O
livnig	O
in	O
the	O
cuonty	O
of	O
Otserg	O
tland	O
,	O
Swdeen	O
.	O

METHODS	O
:	O
All	O
paitents	O
with	O
a	O
diganosed	O
cerberal	O
haemrorhage	O
at	O
three	O
hospitlas	O
during	O
the	O
peirod	O
2000	O
-	O
2002	O
were	O
iedntified	O
.	O

Mdeical	O
recrods	O
were	O
studied	O
retrospetcively	O
to	O
evalutae	O
whether	O
warfairn	B-Chemical
and	O
warfairn	B-Chemical
-	O
durg	O
interatcions	O
could	O
have	O
caused	O
the	O
creebral	O
hameorrhage	O
.	O

The	O
porportion	O
of	O
possibly	O
avoidalbe	O
caess	O
due	O
to	O
durg	O
intearctions	O
was	O
estimaetd	O
.	O

RESUTLS	O
:	O
Among	O
593	O
paitents	O
with	O
creebral	O
hameorrhage	O
,	O
59	O
(	O
10	O
%	O
)	O
were	O
asssesed	O
as	O
related	O
to	O
warfairn	B-Chemical
treatemnt	O
.	O

This	O
imply	O
an	O
incdience	O
of	O
1	O
.	O
7	O
/	O
100	O
,	O
000	O
treamtent	O
yaers	O
.	O

Of	O
the	O
59	O
caess	O
,	O
26	O
(	O
44	O
%	O
)	O
had	O
a	O
faatl	O
otucome	O
,	O
compraed	O
to	O
136	O
(	O
25	O
%	O
)	O
among	O
the	O
non	O
-	O
warfairn	B-Chemical
paitents	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

A	O
wrafarin	B-Chemical
-	O
durg	O
intearction	O
could	O
have	O
contributed	O
to	O
the	O
haemorrahge	O
in	O
24	O
(	O
41	O
%	O
)	O
of	O
the	O
wrafarin	B-Chemical
patietns	O
and	O
in	O
7	O
of	O
these	O
(	O
12	O
%	O
)	O
the	O
bledeing	O
copmlication	O
was	O
considered	O
being	O
possible	O
to	O
avoid	O
.	O

CONCLSUIONS	O
:	O
Warfairn	B-Chemical
-	O
inudced	O
cerberal	O
haeomrrhages	O
are	O
a	O
major	O
cliincal	O
probelm	O
with	O
a	O
high	O
fatailty	O
rtae	O
.	O

Almost	O
half	O
of	O
the	O
csaes	O
was	O
related	O
to	O
a	O
warafrin	B-Chemical
-	O
durg	O
interactoin	O
.	O

A	O
significant	O
prooprtion	O
of	O
warafrin	B-Chemical
-	O
related	O
ceerbral	O
haemorrhages	O
might	O
have	O
been	O
prevented	O
if	O
greater	O
caution	O
had	O
been	O
taken	O
when	O
prsecribing	O
durgs	O
known	O
to	O
intercat	O
with	O
wafrarin	B-Chemical
.	O

Antipsychtoic	O
-	O
like	O
porfile	O
of	O
thipoeramide	B-Chemical
,	O
a	O
selective	O
H3	O
-	O
recpetor	O
antagoinst	O
in	O
mcie	O
.	O

Experimetnal	O
and	O
clniical	O
eivdence	O
points	O
to	O
a	O
role	O
of	O
cetnral	O
histamniergic	O
sysetm	O
in	O
the	O
ptahogenesis	O
of	O
schizohprenia	O
.	O

The	O
present	O
sutdy	O
was	O
designed	O
to	O
stduy	O
the	O
efefct	O
of	O
histmaine	B-Chemical
H	O
(	O
3	O
)	O
-	O
recetpor	O
ligadns	O
on	O
neurolepitc	O
-	O
induecd	O
cataelpsy	O
,	O
apmoorphine	B-Chemical
-	O
indcued	O
clmibing	O
behaivor	O
and	O
ampehtamine	B-Chemical
-	O
induecd	O
locomootr	O
acitvities	O
in	O
mcie	O
.	O

Catalespy	O
was	O
induecd	O
by	O
haloperiodl	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
,	O
while	O
apomrophine	B-Chemical
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
and	O
amphetmaine	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
were	O
used	O
for	O
studying	O
climbnig	O
behaivor	O
and	O
loocmotor	O
atcivities	O
,	O
respectively	O
.	O

(	B-Chemical
R	I-Chemical
)	I-Chemical
-	I-Chemical
alhpa	I-Chemical
-	I-Chemical
mtehylhistamine	I-Chemical
(	O
RMAH	B-Chemical
)	O
(	O
5	O
mcirog	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
and	O
thoiperamide	B-Chemical
(	O
THP	B-Chemical
)	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
,	O
per	O
se	O
did	O
not	O
cause	O
caatlepsy	O
.	O

Admniistration	O
of	O
THP	B-Chemical
(	O
3	O
.	O
75	O
,	O
7	O
.	O
5	O
and	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
1	O
h	O
prior	O
to	O
hlaoperidol	B-Chemical
resulted	O
in	O
a	O
dsoe	O
-	O
depenednt	O
incraese	O
in	O
the	O
catlaepsy	O
times	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

However	O
,	O
prtereatment	O
with	O
RMAH	B-Chemical
significantly	O
rveersed	O
such	O
an	O
effect	O
of	O
THP	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

RMAH	B-Chemical
per	O
se	O
showed	O
significant	O
reduciton	O
in	O
locomtoor	O
tmie	O
,	O
dsitance	O
traveled	O
and	O
aevrage	O
seped	O
but	O
THP	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
per	O
se	O
had	O
no	O
efefct	O
on	O
these	O
paarmeters	O
.	O

On	O
ampheatmine	B-Chemical
-	O
inudced	O
hyperactivtiy	O
,	O
THP	B-Chemical
(	O
3	O
.	O
75	O
and	O
7	O
.	O
5	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
rdeuced	O
locmootor	O
tmie	O
,	O
disatnce	O
traveled	O
and	O
avergae	O
speed	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Pretraetment	O
with	O
RMAH	B-Chemical
(	O
5	O
micorg	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
could	O
partially	O
revesre	O
such	O
effetcs	O
of	O
THP	B-Chemical
(	O
3	O
.	O
75	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

Clibming	O
behaivor	O
indcued	O
by	O
aopmorphine	B-Chemical
was	O
redcued	O
in	O
animlas	O
traeted	O
with	O
THP	B-Chemical
.	O

Such	O
an	O
effcet	O
was	O
,	O
however	O
,	O
revresed	O
in	O
persence	O
of	O
RMAH	B-Chemical
.	O

THP	B-Chemical
exhibited	O
an	O
antipyschotic	O
-	O
like	O
proifle	O
by	O
potentitaing	O
hlaoperidol	B-Chemical
-	O
inudced	O
catalespy	O
,	O
reduicng	O
ampheatmine	B-Chemical
-	O
idnuced	O
hyperactivtiy	O
and	O
reudcing	O
apomrophine	B-Chemical
-	O
induecd	O
climibng	O
in	O
mcie	O
.	O

Such	O
effects	O
of	O
THP	B-Chemical
were	O
revresed	O
by	O
RMAH	B-Chemical
indicating	O
the	O
invlovement	O
of	O
histmaine	B-Chemical
H	O
(	O
3	O
)	O
-	O
reecptors	O
.	O

Fnidings	O
suggest	O
a	O
potenital	O
for	O
H	O
(	O
3	O
)	O
-	O
recetpor	O
antagonitss	O
in	O
ipmroving	O
the	O
rerfactory	O
csaes	O
of	O
schizpohrenia	O
.	O

Cadua	O
euqina	O
syndorme	O
after	O
epiduarl	O
steorid	B-Chemical
injetcion	O
:	O
a	O
csae	O
reprot	O
.	O

OBEJCTIVE	O
:	O
Conventinoal	O
traetment	O
mehtods	O
of	O
lumbsuacral	O
rdaiculopathy	O
are	O
physcial	O
thearpy	O
,	O
eipdural	O
streoid	B-Chemical
injetcions	O
,	O
oarl	O
mediactions	O
,	O
and	O
spianl	O
manipulaitve	O
tehrapy	O
.	O

Cadua	O
eqiuna	O
synrdome	O
is	O
a	O
rrae	O
complicatoin	O
of	O
epidrual	O
ansethesia	O
.	O

The	O
following	O
csae	O
is	O
a	O
reprot	O
of	O
cadua	O
eqiuna	O
snydrome	O
possibly	O
caused	O
by	O
epiduarl	O
ijnection	O
of	O
triamcinolnoe	B-Chemical
and	O
bupivaciane	B-Chemical
.	O

CLINICAL	O
FEATURES	O
:	O
A	O
50	O
-	O
yaer	O
-	O
old	O
wmoan	O
with	O
low	O
back	O
and	O
rihgt	O
leg	O
pian	O
was	O
shceduled	O
for	O
epidrual	O
streoid	B-Chemical
injectoin	O
.	O

INTERVENTOIN	O
AND	O
OUTOCME	O
:	O
An	O
18	O
-	O
gague	O
Tuohy	O
nedele	O
was	O
inserted	O
until	O
lsos	O
of	O
reisstance	O
occurred	O
at	O
the	O
L4	O
-	O
5	O
leevl	O
.	O

Srpead	O
of	O
the	O
contrast	O
meduim	O
within	O
the	O
epiduarl	O
sapce	O
was	O
determined	O
by	O
radiogrpahic	O
imgaing	O
.	O

After	O
verifying	O
the	O
epdiural	O
spcae	O
,	O
buipvacaine	B-Chemical
and	O
traimcinolone	B-Chemical
diaectate	I-Chemical
were	O
injceted	O
.	O

After	O
the	O
injcetion	O
,	O
there	O
was	O
a	O
rdeuction	O
in	O
raidcular	O
sympotms	O
.	O

Three	O
hours	O
later	O
,	O
she	O
complained	O
of	O
perinael	O
numbnses	O
and	O
loewr	O
extreimty	O
waekness	O
.	O

The	O
neurolgoic	O
evaluaiton	O
rveealed	O
lsos	O
of	O
senastion	O
in	O
the	O
saddle	O
aera	O
and	O
mdeial	O
aspect	O
of	O
her	O
rihgt	O
leg	O
.	O

There	O
was	O
a	O
decraese	O
in	O
the	O
preception	O
of	O
pniprick	O
tset	O
.	O

Deep	O
-	O
tenodn	O
refelxes	O
were	O
dcereased	O
especially	O
in	O
the	O
rgiht	O
leg	O
.	O

She	O
was	O
unable	O
to	O
uriante	O
.	O

The	O
paitent	O
'	O
s	O
smyptoms	O
imprvoed	O
slightly	O
over	O
the	O
next	O
few	O
hours	O
.	O

She	O
had	O
a	O
gardual	O
return	O
of	O
mootr	O
fnuction	O
and	O
ability	O
of	O
feeling	O
Foely	O
catehter	O
.	O

All	O
of	O
the	O
symtpoms	O
were	O
completely	O
resolved	O
over	O
the	O
next	O
8	O
hours	O
.	O

CNOCLUSION	O
:	O
Comlpications	O
associated	O
with	O
eipdural	O
steorid	B-Chemical
injcetions	O
are	O
rrae	O
.	O

Cliniacl	O
examniation	O
and	O
continued	O
vigialnce	O
for	O
neuroolgic	O
detreioration	O
after	O
epiduarl	O
steriod	B-Chemical
injcetions	O
is	O
important	O
.	O

High	O
-	O
dsoe	O
tesotsterone	B-Chemical
is	O
associated	O
with	O
atherosclersois	O
in	O
postmenopauasl	O
wmoen	O
.	O

OBEJCTIVES	O
:	O
To	O
stduy	O
the	O
long	O
-	O
term	O
effcets	O
of	O
andorgen	O
treamtent	O
on	O
athreosclerosis	O
in	O
postmenopuasal	O
wmoen	O
.	O

METHODS	O
:	O
In	O
a	O
populatoin	O
-	O
based	O
sutdy	O
in	O
513	O
naturally	O
postmneopausal	O
woemn	O
aegd	O
54	O
-	O
67	O
yaers	O
,	O
we	O
studied	O
the	O
assoication	O
between	O
slef	O
-	O
reported	O
intramuscualrly	O
administeerd	O
high	O
-	O
dsoe	O
etsrogen	B-Chemical
-	O
testsoterone	B-Chemical
thearpy	O
(	O
estradoil	B-Chemical
-	I-Chemical
and	I-Chemical
testosteorne	I-Chemical
estres	I-Chemical
)	O
and	O
aotric	O
atheroscelrosis	O
.	O

Aoritc	O
atheroscelrosis	O
was	O
diangosed	O
by	O
radiograhpic	O
deteciton	O
of	O
calicfied	O
depostis	O
in	O
the	O
adbominal	O
aotra	O
,	O
which	O
have	O
been	O
shown	O
to	O
reflect	O
initma	O
athersoclerosis	O
.	O

Hormnoe	O
threapy	O
uesrs	O
were	O
compraed	O
with	O
never	O
usres	O
.	O

RESUTLS	O
:	O
Inrtamuscular	O
hromone	O
threapy	O
use	O
for	O
1	O
yaer	O
or	O
longer	O
was	O
reported	O
by	O
25	O
woemn	O
.	O

In	O
almost	O
half	O
of	O
these	O
wmoen	O
sevree	O
athersoclerosis	O
of	O
the	O
aotra	O
was	O
present	O
(	O
n	O
=	O
11	O
)	O
,	O
while	O
in	O
wmoen	O
without	O
horomne	O
use	O
seevre	O
ahterosclerosis	O
of	O
the	O
aotra	O
was	O
present	O
in	O
less	O
than	O
20	O
%	O
(	O
OR	O
3	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
8	O
.	O
5	O
,	O
adjusted	O
for	O
age	O
,	O
yeras	O
since	O
meonpause	O
,	O
smkoing	O
,	O
and	O
bdoy	O
msas	O
index	O
)	O
.	O

The	O
associaiton	O
remained	O
after	O
additional	O
adjsutment	O
for	O
dibaetes	O
,	O
cohlesterol	B-Chemical
leevl	O
,	O
systoilc	O
blood	O
pressrue	O
,	O
or	O
alochol	B-Chemical
use	O
.	O

No	O
asosciation	O
was	O
found	O
for	O
homrone	O
use	O
less	O
than	O
1	O
yaer	O
.	O

COCNLUSION	O
:	O
Our	O
resutls	O
suggest	O
that	O
high	O
-	O
dsoe	O
testosteorne	B-Chemical
threapy	O
may	O
adversely	O
affect	O
atherosclreosis	O
in	O
postmenoapusal	O
wmoen	O
and	O
indicate	O
that	O
adnrogen	O
replacmeent	O
in	O
these	O
wmoen	O
may	O
not	O
be	O
harmless	O
.	O

Optiimsing	O
storke	O
prevetnion	O
in	O
non	O
-	O
valvluar	O
atiral	O
fibrillatoin	O
.	O

Artial	O
fibrilltaion	O
is	O
associated	O
with	O
substantial	O
morbiidty	O
and	O
mortailty	O
.	O

Pooled	O
dtaa	O
from	O
trails	O
copmaring	O
antihtrombotic	O
teratment	O
with	O
plcaebo	O
have	O
shown	O
that	O
warfrain	B-Chemical
redcues	O
the	O
rsik	O
of	O
srtoke	O
by	O
62	O
%	O
,	O
and	O
that	O
apsirin	B-Chemical
alone	O
reudces	O
the	O
rsik	O
by	O
22	O
%	O
.	O

Overall	O
,	O
in	O
high	O
-	O
rsik	O
pateints	O
,	O
warfrain	B-Chemical
is	O
superior	O
to	O
aspriin	B-Chemical
in	O
preventing	O
srtokes	O
,	O
with	O
a	O
relative	O
rsik	O
redcution	O
of	O
36	O
%	O
.	O

Ximelagatarn	B-Chemical
,	O
an	O
oarl	O
direct	O
thormbin	O
inihbitor	O
,	O
was	O
found	O
to	O
be	O
as	O
efficeint	O
as	O
viatmin	B-Chemical
K	I-Chemical
atnagonist	O
durgs	O
in	O
the	O
prveention	O
of	O
emoblic	O
evnets	O
,	O
but	O
has	O
been	O
recently	O
withdrawn	O
because	O
of	O
abnromal	O
lvier	O
fnuction	O
tsets	O
.	O

The	O
ACITVE	O
-	O
W	O
(	O
Atrail	O
Fibrillatoin	O
Clopdiogrel	B-Chemical
Trail	O
with	O
Irbeasrtan	B-Chemical
for	O
Prveention	O
of	O
Vascualr	O
Eevnts	O
)	O
stduy	O
has	O
demonstrated	O
that	O
warafrin	B-Chemical
is	O
superior	O
to	O
plaetlet	O
therpay	O
(	O
colpidogrel	B-Chemical
plus	O
asiprin	B-Chemical
)	O
in	O
the	O
prevetnion	O
af	O
emboilc	O
evnets	O
.	O

Idrapairnux	B-Chemical
,	O
a	O
Fatcor	O
Xa	O
inhibiotr	O
,	O
is	O
being	O
evaluaetd	O
in	O
patinets	O
with	O
artial	O
fibrlilation	O
.	O

Agniotensin	B-Chemical
-	O
converting	O
enyzme	O
inhiibtors	O
and	O
anigotensin	B-Chemical
II	I-Chemical
rceeptor	O
-	O
blocikng	O
drgus	O
hold	O
promise	O
in	O
atrail	O
fibirllation	O
through	O
cadriac	O
remodleling	O
.	O

Preliminary	O
stuides	O
suggest	O
that	O
sattins	B-Chemical
could	O
interfere	O
with	O
the	O
rsik	O
of	O
recurrence	O
after	O
electriacl	O
cadrioversion	O
.	O

Finally	O
,	O
percutanoeus	O
mehtods	O
for	O
the	O
exlcusion	O
of	O
lfet	O
artial	O
appnedage	O
are	O
under	O
invetsigation	O
in	O
high	O
-	O
rsik	O
patietns	O
.	O

Atni	O
-	O
oixdant	O
efefcts	O
of	O
atorvasttain	B-Chemical
in	O
dexamethasnoe	B-Chemical
-	O
idnuced	O
hypertensoin	O
in	O
the	O
rat	O
.	O

1	O
.	O

Dexamethaosne	B-Chemical
(	O
Dex	B-Chemical
)	O
-	O
induecd	O
hyperetnsion	O
is	O
chraacterized	O
by	O
enodthelial	O
dysfnuction	O
associated	O
with	O
nirtic	B-Chemical
oixde	I-Chemical
(	O
NO	B-Chemical
)	O
deficeincy	O
and	O
incresaed	O
supeorxide	B-Chemical
(	O
O2	B-Chemical
-	I-Chemical
)	O
produciton	O
.	O

Atorvsatatin	B-Chemical
(	O
Ato	B-Chemical
)	O
possesses	O
pleiotroipc	O
proeprties	O
that	O
have	O
been	O
reported	O
to	O
ipmrove	O
enodthelial	O
fucntion	O
through	O
icnreased	O
availbaility	O
of	O
NO	B-Chemical
and	O
redcued	O
O2	B-Chemical
-	I-Chemical
produtcion	O
in	O
various	O
forms	O
of	O
hypetrension	O
.	O

In	O
the	O
present	O
stduy	O
,	O
we	O
inevstigated	O
whether	O
50	O
mg	O
/	O
kg	O
per	O
day	O
,	O
p	O
.	O
o	O
.	O
,	O
Ato	B-Chemical
could	O
preevnt	O
endtohelial	O
NO	B-Chemical
sytnhase	O
(	O
eONS	O
)	O
downergulation	O
and	O
the	O
incraese	O
in	O
O2	B-Chemical
-	I-Chemical
in	O
Spargue	O
-	O
Dwaley	O
(	O
SD	O
)	O
rtas	O
,	O
thereby	O
rdeucing	O
bolod	O
prsesure	O
.	O

2	O
.	O

Mlae	O
SD	O
rtas	O
(	O
n	O
=	O
30	O
)	O
were	O
terated	O
with	O
Ato	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
per	O
day	O
in	O
drikning	O
wtaer	O
)	O
or	O
tap	O
wtaer	O
for	O
15	O
dyas	O
.	O

Dexamehtasone	B-Chemical
(	O
10	O
micorg	O
/	O
kg	O
per	O
day	O
,	O
s	O
.	O
c	O
.	O
)	O
or	O
slaine	O
was	O
started	O
after	O
4	O
dyas	O
in	O
Ato	B-Chemical
-	O
traeted	O
and	O
non	O
-	O
traeted	O
rtas	O
and	O
continued	O
for	O
11	O
-	O
13	O
dyas	O
.	O

Systloic	O
blood	O
pressrue	O
(	O
SBP	O
)	O
was	O
measrued	O
on	O
alternate	O
dyas	O
using	O
the	O
tial	O
-	O
cfuf	O
mtehod	O
.	O

Endtohelial	O
functoin	O
was	O
assesesd	O
by	O
acetylchoilne	B-Chemical
-	O
idnuced	O
vasorelaxatoin	O
and	O
phenlyephrine	B-Chemical
-	O
inudced	O
vasoconstrictoin	O
in	O
arotic	O
segmetns	O
.	O

Vacsular	O
eONS	O
mNRA	O
was	O
assessed	O
by	O
smei	O
-	O
quanttiative	O
revesre	O
transcriptoin	O
-	O
polymearse	O
cahin	O
reatcion	O
.	O

3	O
.	O

In	O
rtas	O
tretaed	O
with	O
Dex	B-Chemical
alone	O
,	O
SBP	O
was	O
increaesd	O
from	O
109	O
+	O
/	O
-	O
2	O
to	O
133	O
+	O
/	O
-	O
2	O
mmHg	O
on	O
Dyas	O
4	O
and	O
Day	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
the	O
Ato	B-Chemical
+	O
Dex	B-Chemical
gorup	O
,	O
SBP	O
was	O
incraesed	O
from	O
113	O
+	O
/	O
-	O
2	O
to	O
119	O
+	O
/	O
-	O
2	O
mmHg	O
on	O
Dyas	O
4	O
to	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
was	O
significantly	O
lwoer	O
than	O
SBP	O
in	O
the	O
gruop	O
tretaed	O
with	O
Dex	B-Chemical
alone	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Ednothelial	O
-	O
dpeendent	O
relaxtaion	O
and	O
eONS	O
mNRA	O
exrpession	O
were	O
greater	O
in	O
the	O
Dex	B-Chemical
+	O
Ato	B-Chemical
gruop	O
than	O
in	O
the	O
Dex	B-Chemical
only	O
gruop	O
(	O
P	O
<	O
0	O
.	O
05	O
and	O
P	O
<	O
0	O
.	O
0001	O
,	O
respectively	O
)	O
.	O

Aotric	O
sueproxide	B-Chemical
proudction	O
was	O
lwoer	O
in	O
the	O
Dex	B-Chemical
+	O
Ato	B-Chemical
gruop	O
cmopared	O
with	O
the	O
gorup	O
treaetd	O
with	O
Dex	B-Chemical
alone	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

4	O
.	O

Treatemnt	O
with	O
Ato	B-Chemical
imprvoed	O
endothelail	O
funciton	O
,	O
rdeuced	O
superoixde	B-Chemical
proudction	O
and	O
reduecd	O
SBP	O
in	O
Dex	B-Chemical
-	O
traeted	O
SD	O
rtas	O
.	O

Sevree	O
citarte	B-Chemical
toixcity	O
cmoplicating	O
voluneter	O
aphreesis	O
plateelt	O
donatoin	O
.	O

We	O
rpeort	O
a	O
csae	O
of	O
sveere	O
citrtae	B-Chemical
toxictiy	O
during	O
vlounteer	O
doonr	O
apherseis	O
paltelet	O
collcetion	O
.	O

The	O
dnoor	O
was	O
a	O
40	O
-	O
yaer	O
-	O
old	O
feamle	O
,	O
first	O
-	O
tmie	O
apehresis	O
plateelt	O
dnoor	O
.	O

Past	O
meidcal	O
hsitory	O
was	O
remarkable	O
for	O
hypretension	O
,	O
hyperlipdiemia	O
,	O
and	O
derpession	O
.	O

Reported	O
medicatoins	O
included	O
bmuetanide	B-Chemical
,	O
parvastatin	B-Chemical
,	O
and	O
parxoetine	B-Chemical
.	O

Thirty	O
miuntes	O
from	O
the	O
start	O
of	O
the	O
procdeure	O
,	O
the	O
dnoor	O
noted	O
tinglnig	O
around	O
the	O
muoth	O
,	O
hnads	O
,	O
and	O
feet	O
.	O

She	O
then	O
very	O
rapidly	O
developed	O
aucte	O
onset	O
of	O
sveere	O
facail	O
and	O
extremtiy	O
teatny	O
.	O

Empiriacl	O
teratment	O
with	O
intrvaenous	O
caclium	B-Chemical
gluocnate	I-Chemical
was	O
initiated	O
,	O
and	O
muslce	O
contractoins	O
slowly	O
subisded	O
over	O
approximately	O
10	O
to	O
15	O
miuntes	O
.	O

The	O
evnets	O
are	O
consistent	O
with	O
a	O
seevre	O
reatcion	O
to	O
calicum	B-Chemical
chelaiton	O
by	O
soduim	B-Chemical
ctirate	I-Chemical
anticoagualnt	O
resulting	O
in	O
smyptomatic	O
systmeic	O
hypocaclemia	O
.	O

Upon	O
additional	O
retrosepctive	O
analyiss	O
,	O
it	O
was	O
noted	O
that	O
buemtanide	B-Chemical
is	O
a	O
loop	B-Chemical
diurteic	I-Chemical
that	O
may	O
cause	O
significant	O
hypocalcmeia	O
.	O

We	O
conclude	O
that	O
careful	O
screennig	O
for	O
mediactions	O
and	O
underlying	O
conidtions	O
perdisposing	O
to	O
hypoaclcemia	O
is	O
recomemnded	O
to	O
help	O
preevnt	O
seevre	O
raections	O
due	O
to	O
citrtae	B-Chemical
toixcity	O
.	O

Laobratory	O
measruement	O
of	O
pre	O
-	O
proecdure	O
sreum	O
caclium	B-Chemical
levles	O
in	O
selected	O
doonrs	O
may	O
identify	O
caess	O
requiring	O
heightened	O
vigilacne	O
.	O

The	O
csae	O
also	O
illustrates	O
the	O
importance	O
of	O
maintaining	O
preparednses	O
for	O
managing	O
rrae	O
but	O
serious	O
reacitons	O
in	O
volnuteer	O
apheersis	O
blood	O
dnoors	O
.	O

Siorlimus	B-Chemical
-	O
associated	O
proteniuria	O
and	O
rneal	O
dysfucntion	O
.	O

Sirloimus	B-Chemical
is	O
a	O
novel	O
immunospupressant	O
with	O
potent	O
antiporliferative	O
actoins	O
through	O
its	O
ability	O
to	O
inhbiit	O
the	O
rpator	O
-	O
containing	O
mammalain	O
tagret	O
of	O
rpaamycin	B-Chemical
portein	O
kinsae	O
.	O

Sirloimus	B-Chemical
represents	O
a	O
major	O
threapeutic	O
advacne	O
in	O
the	O
preventoin	O
of	O
actue	O
reanl	O
allogarft	O
rejetcion	O
and	O
chornic	O
allogrfat	O
nephrpoathy	O
.	O

Its	O
role	O
in	O
the	O
thearpy	O
of	O
glomeurlonephritis	O
,	O
autoimmuntiy	O
,	O
csytic	O
rneal	O
diseaess	O
and	O
rneal	O
canecr	O
is	O
under	O
investgiation	O
.	O

Because	O
sirolmius	B-Chemical
does	O
not	O
share	O
the	O
vsaomotor	O
rneal	O
advesre	O
efefcts	O
exhibited	O
by	O
calcinuerin	O
inhibitros	O
,	O
it	O
has	O
been	O
designated	O
a	O
'	O
non	O
-	O
neprhotoxic	O
durg	O
'	O
.	O

However	O
,	O
cilnical	O
repotrs	O
suggest	O
that	O
,	O
under	O
some	O
circumstances	O
,	O
sirolmius	B-Chemical
is	O
associated	O
with	O
proetinuria	O
and	O
actue	O
reanl	O
dsyfunction	O
.	O

A	O
common	O
rsik	O
fcator	O
appears	O
to	O
be	O
presnece	O
of	O
pre	O
-	O
existing	O
crhonic	O
rneal	O
damgae	O
.	O

The	O
mehcanisms	O
of	O
siorlimus	B-Chemical
-	O
associated	O
proteinruia	O
are	O
mlutifactorial	O
and	O
may	O
be	O
due	O
to	O
an	O
incresae	O
in	O
glomreular	O
cpaillary	O
pressrue	O
following	O
calcienurin	O
inhbiitor	O
withdraawl	O
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
siorlimus	B-Chemical
directly	O
causes	O
incerased	O
glomerluar	O
permeaiblity	O
/	O
ijnury	O
,	O
but	O
evidnece	O
for	O
this	O
mechansim	O
is	O
currently	O
inocnclusive	O
.	O

The	O
aucte	O
rneal	O
dysfnuction	O
associated	O
with	O
siroliums	B-Chemical
(	O
such	O
as	O
in	O
delaeyd	O
grfat	O
funciton	O
)	O
may	O
be	O
due	O
to	O
spupression	O
of	O
compensatroy	O
rneal	O
clel	O
prolifreation	O
and	O
surviavl	O
/	O
reapir	O
procesess	O
.	O

Although	O
these	O
advesre	O
effetcs	O
occur	O
in	O
some	O
pateints	O
,	O
their	O
occurrnece	O
could	O
be	O
mniimised	O
by	O
knoweldge	O
of	O
the	O
molceular	O
effects	O
of	O
siorlimus	B-Chemical
on	O
the	O
kdiney	O
,	O
the	O
use	O
of	O
sirloimus	B-Chemical
in	O
appropriate	O
patinet	O
ppoulations	O
,	O
close	O
monitoirng	O
of	O
proetinuria	O
and	O
rneal	O
functoin	O
,	O
use	O
of	O
anigotensin	B-Chemical
-	O
converting	O
enzmye	O
inhbiitors	O
or	O
angoitensin	B-Chemical
II	I-Chemical
recetpor	O
blockres	O
if	O
porteinuria	O
occurs	O
and	O
witdhrawal	O
if	O
needed	O
.	O

Further	O
long	O
-	O
term	O
anlaysis	O
of	O
rneal	O
allgoraft	O
stuides	O
using	O
siorlimus	B-Chemical
as	O
de	O
novo	O
imumnosuppression	O
along	O
with	O
cliincal	O
and	O
laboartory	O
studeis	O
will	O
refine	O
these	O
issues	O
in	O
the	O
future	O
.	O

Proteinuira	O
after	O
conevrsion	O
to	O
sriolimus	B-Chemical
in	O
reanl	O
translpant	O
reicpients	O
.	O

Sirolmius	B-Chemical
(	O
SRL	B-Chemical
)	O
is	O
a	O
new	O
,	O
potent	O
immunosuprpessive	O
agnet	O
.	O

More	O
recently	O
,	O
porteinuria	O
has	O
been	O
reported	O
as	O
a	O
consequence	O
of	O
sirolmius	B-Chemical
therpay	O
,	O
although	O
the	O
mechainsm	O
has	O
remained	O
unclear	O
.	O

We	O
retropsectively	O
examined	O
the	O
rceords	O
of	O
25	O
rneal	O
trnasplant	O
ptaients	O
,	O
who	O
developed	O
or	O
displayed	O
increaesd	O
prtoeinuria	O
after	O
SRL	B-Chemical
conevrsion	O
.	O

The	O
patinet	O
cohrot	O
(	O
14	O
men	O
,	O
11	O
wmoen	O
)	O
was	O
tretaed	O
with	O
SRL	B-Chemical
as	O
converison	O
thearpy	O
,	O
due	O
to	O
crhonic	O
allgoraft	O
nephroptahy	O
(	O
CAN	O
)	O
(	O
n	O
=	O
15	O
)	O
noeplasia	O
(	O
n	O
=	O
8	O
)	O
;	O
Kaopsi	O
'	O
s	O
sacroma	O
,	O
Four	O
sikn	O
cacners	O
,	O
One	O
intetsinal	O
tmuors	O
,	O
One	O
reanl	O
clel	O
carisnom	O
)	O
or	O
BK	O
viurs	O
nephorpathy	O
(	O
n	O
=	O
2	O
)	O
.	O

SRL	B-Chemical
was	O
started	O
at	O
a	O
mean	O
of	O
78	O
+	O
/	O
-	O
42	O
(	O
15	O
to	O
163	O
)	O
monhts	O
after	O
transpalntation	O
.	O

Mean	O
follow	O
-	O
up	O
on	O
SRL	B-Chemical
tehrapy	O
was	O
20	O
+	O
/	O
-	O
12	O
(	O
6	O
to	O
43	O
)	O
motnhs	O
.	O

Proteinuira	O
inrceased	O
from	O
0	O
.	O
445	O
(	O
0	O
to	O
1	O
.	O
5	O
)	O
g	O
/	O
d	O
before	O
covnersion	O
to	O
3	O
.	O
2	O
g	O
/	O
dL	O
(	O
0	O
.	O
2	O
to	O
12	O
)	O
after	O
convesrion	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

Before	O
converison	O
8	O
(	O
32	O
%	O
)	O
ptaients	O
had	O
no	O
proteinuira	O
,	O
whereas	O
afterwards	O
all	O
patietns	O
had	O
prtoeinuria	O
.	O

In	O
28	O
%	O
of	O
paitents	O
protienuria	O
remained	O
unchnaged	O
,	O
whereas	O
it	O
increaesd	O
in	O
68	O
%	O
of	O
pateints	O
.	O

In	O
40	O
%	O
it	O
incresaed	O
by	O
more	O
than	O
100	O
%	O
.	O

Twenty	O
-	O
eight	O
percent	O
of	O
patietns	O
showed	O
inrceased	O
proteinuira	O
to	O
the	O
nephortic	O
range	O
.	O

Biposies	O
performed	O
in	O
five	O
patietns	O
revelaed	O
new	O
pathologcial	O
chnages	O
:	O
One	O
membranoproliferatvie	O
golmerulopathy	O
and	O
intertsitial	O
neprhitis	O
.	O

These	O
patinets	O
showed	O
persistenlty	O
good	O
grfat	O
fnuction	O
.	O

Sreum	O
creatniine	B-Chemical
vaules	O
did	O
not	O
change	O
significantly	O
:	O
1	O
.	O
98	O
+	O
/	O
-	O
0	O
.	O
8	O
mg	O
/	O
dL	O
before	O
SRL	B-Chemical
therpay	O
and	O
2	O
.	O
53	O
+	O
/	O
-	O
1	O
.	O
9	O
mg	O
/	O
dL	O
at	O
last	O
follow	O
-	O
up	O
(	O
P	O
=	O
.	O
14	O
)	O
.	O

Five	O
garfts	O
were	O
lsot	O
and	O
the	O
pateints	O
returned	O
to	O
dilaysis	O
.	O

Five	O
ptaients	O
displayed	O
CAN	O
and	O
Kaopsi	O
'	O
s	O
sacroma	O
.	O

Mean	O
urianry	O
prtoein	O
of	O
paitents	O
who	O
returned	O
to	O
dialsyis	O
was	O
1	O
.	O
26	O
(	O
0	O
.	O
5	O
to	O
3	O
.	O
5	O
)	O
g	O
/	O
d	O
before	O
and	O
4	O
.	O
7	O
(	O
3	O
to	O
12	O
)	O
g	O
/	O
d	O
after	O
converison	O
(	O
P	O
=	O
.	O
01	O
)	O
.	O

Mean	O
seurm	O
creatniine	B-Chemical
lveel	O
before	O
conevrsion	O
was	O
2	O
.	O
21	O
mg	O
/	O
dL	O
and	O
thereafter	O
,	O
4	O
.	O
93	O
mg	O
/	O
dL	O
(	O
P	O
=	O
.	O
02	O
)	O
.	O

Haevy	O
proetinuria	O
was	O
common	O
after	O
the	O
use	O
of	O
SRL	B-Chemical
as	O
rescue	O
threapy	O
for	O
reanl	O
transplnatation	O
.	O

Therefore	O
,	O
covnersion	O
should	O
be	O
considered	O
for	O
patinets	O
who	O
have	O
not	O
developed	O
advacned	O
CAN	O
and	O
proteinruia	O
.	O

The	O
possibility	O
of	O
de	O
novo	O
gloemrular	O
pahtology	O
under	O
SRL	B-Chemical
treatemnt	O
requires	O
further	O
investgiation	O
by	O
reanl	O
biposy	O
.	O

Lnog	O
-	O
term	O
follow	O
-	O
up	O
of	O
ifosfmaide	B-Chemical
rneal	O
toixcity	O
in	O
chilrden	O
treaetd	O
for	O
malginant	O
mseenchymal	O
tmuors	O
:	O
an	O
Internatoinal	O
Scoiety	O
of	O
Peidatric	O
Oncloogy	O
reprot	O
.	O

The	O
reanl	O
fucntion	O
of	O
74	O
cihldren	O
with	O
mlaignant	O
mesenchmyal	O
tumros	O
in	O
complete	O
remisison	O
and	O
who	O
have	O
received	O
the	O
same	O
ifosfamdie	B-Chemical
cheomtherapy	O
portocol	O
(	O
Intenrational	O
Socitey	O
of	O
Peidatric	O
Oncolgoy	O
Maligannt	O
Mesecnhymal	O
Tuomr	O
Stduy	O
84	O
[	O
SOIP	O
MMT	O
84	O
]	O
)	O
were	O
studied	O
1	O
yaer	O
after	O
the	O
comlpetion	O
of	O
treatemnt	O
.	O

Total	O
cumualtive	O
dsoes	O
were	O
36	O
or	O
60	O
g	O
/	O
m2	O
of	O
iofsfamide	B-Chemical
(	O
six	O
or	O
10	O
cylces	O
of	O
iofsfamide	B-Chemical
,	I-Chemical
vincritsine	I-Chemical
,	I-Chemical
and	I-Chemical
dactinomyicn	I-Chemical
[	O
IVA	B-Chemical
]	O
)	O
.	O

None	O
of	O
them	O
had	O
received	O
csiplatin	B-Chemical
chemothreapy	O
.	O

Aegs	O
ranged	O
from	O
4	O
monhts	O
to	O
17	O
yaers	O
;	O
58	O
ptaients	O
were	O
mlaes	O
and	O
42	O
femaels	O
.	O

The	O
most	O
common	O
priamry	O
tuomr	O
stie	O
was	O
the	O
haed	O
and	O
ncek	O
.	O

Reanl	O
functoin	O
was	O
invetsigated	O
by	O
meausring	O
plamsa	O
and	O
urinray	O
electrloytes	O
,	O
glucousria	O
,	O
porteinuria	O
,	O
aminoaciduira	O
,	O
urianry	O
pH	O
,	O
omsolarity	O
,	O
ceratinine	B-Chemical
celarance	O
,	O
phospahte	B-Chemical
tubluar	O
reabsorpiton	O
,	O
btea	O
2	O
micrgolobulinuria	O
,	O
and	O
lysozyumria	O
.	O

Fifty	O
-	O
eight	O
paitents	O
(	O
78	O
%	O
)	O
had	O
nomral	O
rneal	O
tsets	O
,	O
whereas	O
16	O
patietns	O
(	O
22	O
%	O
)	O
had	O
rneal	O
abnormaltiies	O
.	O

Two	O
susbets	O
of	O
pateints	O
were	O
idnetified	O
from	O
this	O
latter	O
gorup	O
:	O
the	O
first	O
included	O
four	O
ptaients	O
(	O
5	O
%	O
of	O
the	O
total	O
pouplation	O
)	O
who	O
developed	O
major	O
toxciity	O
resulting	O
in	O
Fanocni	O
'	O
s	O
synrdome	O
(	O
TFDS	O
)	O
;	O
and	O
the	O
second	O
gorup	O
included	O
five	O
patietns	O
with	O
elveated	O
btea	O
2	O
microglobulinuira	O
and	O
low	O
phopshate	B-Chemical
reabsorptoin	O
.	O

The	O
remaining	O
seven	O
pateints	O
had	O
ioslated	O
btea	O
2	O
micorglobulinuria	O
.	O

Sevree	O
txoicity	O
was	O
correlated	O
with	O
the	O
hgiher	O
cumualtive	O
dsoe	O
of	O
60	O
g	O
/	O
m2	O
of	O
ifosfamdie	B-Chemical
,	O
a	O
younegr	O
age	O
(	O
less	O
than	O
2	O
1	O
/	O
2	O
yaers	O
old	O
)	O
,	O
and	O
a	O
predominance	O
of	O
vesicoprosattic	O
tuomr	O
ivnolvement	O
.	O

This	O
low	O
perecntage	O
(	O
5	O
%	O
)	O
of	O
TFDS	O
must	O
be	O
evaulated	O
with	O
respect	O
to	O
the	O
efifcacy	O
of	O
ifosafmide	B-Chemical
in	O
the	O
treamtent	O
of	O
mesencyhmal	O
tuomrs	O
in	O
cihldren	O
.	O

Progressive	O
moypathy	O
with	O
up	O
-	O
regulaiton	O
of	O
MHC	O
-	O
I	O
associated	O
with	O
sttain	B-Chemical
threapy	O
.	O

Sattins	B-Chemical
can	O
cause	O
a	O
necrotiizng	O
moypathy	O
and	O
hyperCKeamia	O
which	O
is	O
reversible	O
on	O
cessation	O
of	O
the	O
durg	O
.	O

What	O
is	O
less	O
well	O
known	O
is	O
a	O
pehnomenon	O
whereby	O
sttains	B-Chemical
may	O
inudce	O
a	O
myoptahy	O
,	O
which	O
persists	O
or	O
may	O
prorgess	O
after	O
stopping	O
the	O
durg	O
.	O

We	O
investigaetd	O
the	O
msucle	O
patholgoy	O
in	O
8	O
such	O
csaes	O
.	O

All	O
had	O
myofirbe	O
necrsois	O
but	O
only	O
3	O
had	O
an	O
inflammtaory	O
inflitrate	O
.	O

In	O
all	O
csaes	O
there	O
was	O
diffsue	O
or	O
multiofcal	O
up	O
-	O
regulaiton	O
of	O
MHC	O
-	O
I	O
exrpession	O
even	O
in	O
non	O
-	O
ncerotic	O
firbes	O
.	O

Progressvie	O
improvmeent	O
occurred	O
in	O
7	O
caess	O
after	O
cmomencement	O
of	O
prednisoolne	B-Chemical
and	O
metohtrexate	B-Chemical
,	O
and	O
in	O
one	O
csae	O
spontnaeously	O
.	O

These	O
observatinos	O
suggest	O
that	O
sattins	B-Chemical
may	O
initiate	O
an	O
immnue	O
-	O
mediated	O
mypoathy	O
that	O
persists	O
after	O
withdraawl	O
of	O
the	O
durg	O
and	O
responds	O
to	O
immunosuppressvie	O
thearpy	O
.	O

The	O
mecahnism	O
of	O
this	O
myopahty	O
is	O
uncertain	O
but	O
may	O
involve	O
the	O
inductoin	O
by	O
sttains	B-Chemical
of	O
an	O
enodplasmic	O
rteiculum	O
strses	O
rseponse	O
with	O
associated	O
up	O
-	O
regualtion	O
of	O
MHC	O
-	O
I	O
expresison	O
and	O
antiegn	O
preesntation	O
by	O
msucle	O
fibers	O
.	O

Use	O
of	O
crhomosome	O
susbtitution	O
stranis	O
to	O
identify	O
siezure	O
susceptbiility	O
lcoi	O
in	O
mcie	O
.	O

Seziure	O
susceptibiltiy	O
varies	O
among	O
ibnred	O
mosue	O
srtains	O
.	O

Chromsoome	O
substtiution	O
srtains	O
(	O
CSS	O
)	O
,	O
in	O
which	O
a	O
single	O
chrmoosome	O
from	O
one	O
inrbed	O
srtain	O
(	O
dnoor	O
)	O
has	O
been	O
transfrered	O
onto	O
a	O
second	O
strian	O
(	O
hsot	O
)	O
by	O
repetaed	O
bakccrossing	O
,	O
may	O
be	O
used	O
to	O
identify	O
qunatitative	O
tarit	O
lcoi	O
(	O
QLTs	O
)	O
that	O
contribute	O
to	O
siezure	O
susceptibiilty	O
.	O

QLTs	O
for	O
susecptibility	O
to	O
pilocaripne	B-Chemical
-	O
indcued	O
seizrues	O
,	O
a	O
moedl	O
of	O
temproal	O
lboe	O
epliepsy	O
,	O
have	O
not	O
been	O
reported	O
,	O
and	O
CSS	O
have	O
not	O
previously	O
been	O
used	O
to	O
locailze	O
seizrue	O
susceptibiltiy	O
geens	O
.	O

We	O
reoprt	O
QLTs	O
identfiied	O
using	O
a	O
B6	O
(	O
hsot	O
)	O
x	O
A	O
/	O
J	O
(	O
dnoor	O
)	O
CSS	O
panel	O
to	O
localzie	O
gnees	O
involved	O
in	O
suscepitbility	O
to	O
pilocrapine	B-Chemical
-	O
indcued	O
seizrues	O
.	O

Three	O
hundred	O
fifty	O
-	O
five	O
adlut	O
mlae	O
CSS	O
mcie	O
,	O
58	O
B6	O
,	O
and	O
39	O
A	O
/	O
J	O
were	O
tesetd	O
for	O
susceptibiltiy	O
to	O
pliocarpine	B-Chemical
-	O
inudced	O
seiuzres	O
.	O

Higehst	O
stgae	O
reached	O
and	O
laetncy	O
to	O
each	O
stgae	O
were	O
recorded	O
for	O
all	O
mcie	O
.	O

B6	O
mcie	O
were	O
ressitant	O
to	O
seziures	O
and	O
sloewr	O
to	O
reach	O
stgaes	O
compraed	O
to	O
A	O
/	O
J	O
mcie	O
.	O

The	O
CSS	O
for	O
Chrmoosomes	O
10	O
and	O
18	O
progressed	O
to	O
the	O
most	O
seevre	O
satges	O
,	O
diverging	O
dramatically	O
from	O
the	O
B6	O
pheontype	O
.	O

Latnecies	O
to	O
stgaes	O
were	O
also	O
significantly	O
shotrer	O
for	O
CS1S0	O
and	O
CSS18	O
mcie	O
.	O

CSS	O
mpaping	O
suggests	O
seizrue	O
ssuceptibility	O
lcoi	O
on	O
muose	O
Chromoosmes	O
10	O
and	O
18	O
.	O

This	O
approach	O
provides	O
a	O
fraemwork	O
for	O
identifying	O
potentially	O
novel	O
hoomlogous	O
candidate	O
geens	O
for	O
hmuan	O
temopral	O
lboe	O
epliepsy	O
.	O

In	O
vitro	O
cahracterization	O
of	O
parasypmathetic	O
and	O
sypmathetic	O
respnoses	O
in	O
cylcophosphamide	B-Chemical
-	O
inudced	O
csytitis	O
in	O
the	O
rat	O
.	O

In	O
cyclophosphaimde	B-Chemical
-	O
idnuced	O
cysittis	O
in	O
the	O
rat	O
,	O
detrsuor	O
funciton	O
is	O
impaierd	O
and	O
the	O
experssion	O
and	O
efefcts	O
of	O
mucsarinic	O
recpetors	O
atlered	O
.	O

Whether	O
or	O
not	O
the	O
neurnoal	O
trasnmission	O
may	O
be	O
affetced	O
by	O
cysittis	O
was	O
presently	O
investgiated	O
.	O

Resopnses	O
of	O
urniary	O
srtip	O
preparaitons	O
from	O
cotnrol	O
and	O
cyclpohosphamide	B-Chemical
-	O
preterated	O
rtas	O
to	O
elecrtical	O
field	O
stiumlation	O
and	O
to	O
agnoists	O
were	O
asssesed	O
in	O
the	O
absecne	O
and	O
presnece	O
of	O
muscairnic	O
,	O
adrenegric	O
and	O
puirnergic	O
recetpor	O
antagnoists	O
.	O

Generally	O
,	O
atroipne	B-Chemical
redcued	O
contratcions	O
,	O
but	O
in	O
contrast	O
to	O
conrtols	O
,	O
it	O
also	O
rdeuced	O
resposnes	O
to	O
low	O
elecrtical	O
field	O
stimualtion	O
itnensity	O
(	O
1	O
-	O
5	O
Hz	O
)	O
in	O
ifnlamed	O
prpearations	O
.	O

In	O
both	O
types	O
,	O
purinoecptor	O
desenistization	O
with	O
alhpa	B-Chemical
,	I-Chemical
btea	I-Chemical
-	I-Chemical
methylnee	I-Chemical
aednosine	I-Chemical
-	I-Chemical
5	I-Chemical
'	I-Chemical
-	I-Chemical
triphoshpate	I-Chemical
(	O
alhpa	B-Chemical
,	I-Chemical
btea	I-Chemical
-	I-Chemical
meTAP	I-Chemical
)	O
caused	O
further	O
rdeuctions	O
at	O
low	O
freqeuncies	O
(	O
<	O
10	O
Hz	O
)	O
.	O

The	O
musacrinic	O
reecptor	O
antagonsits	O
atroipne	B-Chemical
,	O
4	B-Chemical
-	I-Chemical
diphenylacteoxy	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
methylpiepridine	I-Chemical
(	O
4	B-Chemical
-	I-Chemical
DMAP	I-Chemical
)	O
(	O
'	O
M	O
(	O
1	O
)	O
/	O
M	O
(	O
3	O
)	O
/	O
M	O
(	O
5	O
)	O
-	O
selective	O
'	O
)	O
,	O
metohctramine	B-Chemical
(	O
'	O
M	O
(	O
2	O
)	O
-	O
selective	O
'	O
)	O
and	O
pirnezepine	B-Chemical
(	O
'	O
M	O
(	O
1	O
)	O
-	O
selective	O
'	O
)	O
anatgonized	O
the	O
tnoic	O
component	O
of	O
the	O
eletcrical	O
field	O
stimualtion	O
-	O
evkoed	O
contracitle	O
repsonse	O
more	O
potetnly	O
than	O
the	O
phaisc	O
component	O
.	O

4	B-Chemical
-	I-Chemical
DMAP	I-Chemical
inhiibted	O
the	O
tnoic	O
contracitons	O
in	O
contorls	O
more	O
poetntly	O
than	O
methocrtamine	B-Chemical
and	O
pirnezepine	B-Chemical
.	O

In	O
inflmaed	O
preaprations	O
,	O
the	O
musacrinic	O
rceeptor	O
antagonsim	O
on	O
the	O
pahsic	O
component	O
of	O
the	O
electriacl	O
field	O
stimultaion	O
-	O
evkoed	O
cotnraction	O
was	O
decraesed	O
and	O
the	O
pirnezepine	B-Chemical
and	O
4	B-Chemical
-	I-Chemical
DMAP	I-Chemical
antagoinsm	O
on	O
the	O
toinc	O
component	O
was	O
much	O
less	O
efficinet	O
than	O
in	O
contorls	O
.	O

In	O
contrast	O
to	O
contrlos	O
,	O
methcotramine	B-Chemical
incresaed	O
-	O
-	O
instead	O
of	O
decraesed	O
-	O
-	O
the	O
tnoic	O
resopnses	O
at	O
high	O
frequenices	O
.	O

While	O
cnotractions	O
to	O
carbcahol	B-Chemical
and	O
ATP	B-Chemical
were	O
the	O
same	O
in	O
inflmaed	O
and	O
in	O
contorl	O
srtips	O
when	O
related	O
to	O
a	O
refreence	O
potsasium	B-Chemical
rseponse	O
,	O
isorpenaline	B-Chemical
-	O
idnuced	O
rleaxations	O
were	O
smaller	O
in	O
inlfamed	O
srtips	O
.	O

Thus	O
,	O
in	O
cysittis	O
substantial	O
chagnes	O
of	O
the	O
efferent	O
funtcional	O
rseponses	O
occur	O
.	O

While	O
postjunctinoal	O
btea	O
-	O
adreonceptor	O
-	O
mediated	O
realxations	O
are	O
redcued	O
,	O
effetcs	O
by	O
prejunctinoal	O
inhibtiory	O
muscariinc	O
recpetors	O
may	O
be	O
increaesd	O
.	O

Direct	O
inhbiition	O
of	O
cradiac	O
hyperpolarizaiton	O
-	O
actiavted	O
cycilc	B-Chemical
nulceotide	I-Chemical
-	O
gtaed	O
pacmeaker	O
channles	O
by	O
clondiine	B-Chemical
.	O

BCAKGROUND	O
:	O
Inihbition	O
of	O
cardaic	O
sympathteic	O
tnoe	O
represents	O
an	O
important	O
strategy	O
for	O
treamtent	O
of	O
cardiovasuclar	O
dsiease	O
,	O
including	O
arryhthmia	O
,	O
coronray	O
haert	O
disaese	O
,	O
and	O
chornic	O
haert	O
faiulre	O
.	O

Actiavtion	O
of	O
preysnaptic	O
aplha2	O
-	O
adrenoceptros	O
is	O
the	O
most	O
widely	O
accepted	O
mechansim	O
of	O
atcion	O
of	O
the	O
antisympahtetic	O
durg	O
clonidnie	B-Chemical
;	O
however	O
,	O
other	O
taregt	O
protenis	O
have	O
been	O
postulated	O
to	O
contribute	O
to	O
the	O
in	O
vivo	O
atcions	O
of	O
clonidnie	B-Chemical
.	O

METHODS	O
AND	O
REUSLTS	O
:	O
To	O
tset	O
whether	O
colnidine	B-Chemical
elicits	O
pharmaoclogical	O
efefcts	O
indpeendent	O
of	O
alpah2	O
-	O
adernoceptors	O
,	O
we	O
have	O
generated	O
mcie	O
with	O
a	O
trageted	O
deeltion	O
of	O
all	O
3	O
aplha2	O
-	O
adrenocetpor	O
subtpyes	O
(	O
alpha2ABC	O
-	O
/	O
-	O
)	O
.	O

Alph2aABC	O
-	O
/	O
-	O
mcie	O
were	O
completely	O
unresponsive	O
to	O
the	O
analgeisc	O
and	O
hypnoitc	O
efefcts	O
of	O
clonidnie	B-Chemical
;	O
however	O
,	O
clonidnie	B-Chemical
significantly	O
loweerd	O
haert	O
rtae	O
in	O
alpha2ABC	O
-	O
/	O
-	O
mcie	O
by	O
up	O
to	O
150	O
bpm	O
.	O

Clonidnie	B-Chemical
-	O
indcued	O
bardycardia	O
in	O
cosncious	O
alpha2ABC	O
-	O
/	O
-	O
mcie	O
was	O
32	O
.	O
3	O
%	O
(	O
10	O
mcirog	O
/	O
kg	O
)	O
and	O
26	O
.	O
6	O
%	O
(	O
100	O
mcirog	O
/	O
kg	O
)	O
of	O
the	O
efefct	O
in	O
wlid	O
-	O
tpye	O
mcie	O
.	O

A	O
similar	O
bradycaridc	O
effcet	O
of	O
cloniidne	B-Chemical
was	O
observed	O
in	O
ioslated	O
spontanoeusly	O
beatnig	O
rihgt	O
atira	O
from	O
alpha2ABC	O
-	O
knocokut	O
and	O
wlid	O
-	O
tpye	O
mcie	O
.	O

Cloniidne	B-Chemical
inhibietd	O
the	O
naitve	O
pacmeaker	O
current	O
(	O
I	O
(	O
f	O
)	O
)	O
in	O
isloated	O
sinoatiral	O
ndoe	O
paecmaker	O
cells	O
and	O
the	O
I	O
(	O
f	O
)	O
-	O
generating	O
hypeprolarization	O
-	O
activtaed	O
ccylic	B-Chemical
nucleotdie	I-Chemical
-	O
gaetd	O
(	O
HCN	O
)	O
2	O
and	O
HNC4	O
channels	O
in	O
trasnfected	O
HKE293	O
clels	O
.	O

As	O
a	O
consequence	O
of	O
blocknig	O
I	O
(	O
f	O
)	O
,	O
clnoidine	B-Chemical
rdeuced	O
the	O
slope	O
of	O
the	O
diatsolic	O
depolariaztion	O
and	O
the	O
frequnecy	O
of	O
pcaemaker	O
potentails	O
in	O
sionatrial	O
ndoe	O
cells	O
from	O
wlid	O
-	O
tpye	O
and	O
alpha2ABC	O
-	O
knockuot	O
mcie	O
.	O

CNOCLUSIONS	O
:	O
Direct	O
ihnibition	O
of	O
cradiac	O
HCN	O
pacmeaker	O
channles	O
contributes	O
to	O
the	O
brdaycardic	O
effetcs	O
of	O
clonidnie	B-Chemical
gnee	O
-	O
trageted	O
mcie	O
in	O
vivo	O
,	O
and	O
thus	O
,	O
cloniidne	B-Chemical
-	O
like	O
drgus	O
represent	O
novel	O
structrues	O
for	O
future	O
HCN	O
chnanel	O
inhbiitors	O
.	O

Granulmoatous	O
hpeatitis	O
due	O
to	O
combinaiton	B-Chemical
of	I-Chemical
aomxicillin	I-Chemical
and	I-Chemical
clavulnaic	I-Chemical
aicd	I-Chemical
.	O

We	O
reprot	O
the	O
csae	O
of	O
a	O
patinet	O
with	O
amoxicililn	B-Chemical
-	I-Chemical
clavulainc	I-Chemical
aicd	I-Chemical
-	O
indcued	O
heaptitis	O
with	O
histoolgic	O
multpile	O
granuloams	O
.	O

This	O
tpye	O
of	O
lseion	O
broadens	O
the	O
specrtum	O
of	O
lvier	O
inujry	O
due	O
to	O
this	O
durg	O
combniation	O
,	O
mainly	O
represented	O
by	O
a	O
bengin	O
cohlestatic	O
snydrome	O
.	O

The	O
asscoiation	O
of	O
granuloams	O
and	O
eosinophiila	O
favor	O
an	O
imumnoallergic	O
mehcanism	O
.	O

As	O
penciillin	B-Chemical
dreivatives	O
and	O
aomxicillin	B-Chemical
alone	O
are	O
known	O
to	O
indcue	O
such	O
types	O
of	O
leisons	O
,	O
the	O
aomxicillin	B-Chemical
component	O
,	O
with	O
or	O
without	O
a	O
potenitating	O
effcet	O
of	O
clavulainc	B-Chemical
aicd	I-Chemical
,	O
might	O
have	O
a	O
major	O
role	O
.	O

Dobutmaine	B-Chemical
srtess	O
echocardoigraphy	O
:	O
a	O
sesnitive	O
indictaor	O
of	O
diminished	O
myocaridal	O
fnuction	O
in	O
aysmptomatic	O
doxorubciin	B-Chemical
-	O
tretaed	O
long	O
-	O
term	O
suvrivors	O
of	O
childhood	O
cacner	O
.	O

Doxroubicin	B-Chemical
is	O
an	O
efefctive	O
anitcancer	O
chmeotherapeutic	O
agnet	O
known	O
to	O
cause	O
actue	O
and	O
crhonic	O
cardioymopathy	O
.	O

To	O
develop	O
a	O
more	O
sesnitive	O
echocardiogarphic	O
screening	O
tset	O
for	O
cradiac	O
dmaage	O
due	O
to	O
doxorubiicn	B-Chemical
,	O
a	O
choort	O
stduy	O
was	O
performed	O
using	O
dobutaimne	B-Chemical
inufsion	O
to	O
difefrentiate	O
asymptomtaic	O
long	O
-	O
term	O
surivvors	O
of	O
chlidhood	O
canecr	O
traeted	O
with	O
doxorubciin	B-Chemical
from	O
haelthy	O
conrtol	O
sbujects	O
.	O

Echocardiograpihc	O
dtaa	O
from	O
the	O
experimenatl	O
gruop	O
of	O
21	O
paitents	O
(	O
mean	O
age	O
16	O
+	O
/	O
-	O
5	O
yeras	O
)	O
treaetd	O
from	O
1	O
.	O
6	O
to	O
14	O
.	O
3	O
yeras	O
(	O
mdeian	O
5	O
.	O
3	O
)	O
before	O
this	O
stduy	O
with	O
27	O
to	O
532	O
mg	O
/	O
m2	O
of	O
doxoruibcin	B-Chemical
(	O
mean	O
196	O
)	O
were	O
compraed	O
with	O
echcoardiographic	O
dtaa	O
from	O
12	O
nomral	O
age	O
-	O
matched	O
cotnrol	O
subjetcs	O
.	O

Graedd	O
dobutmaine	B-Chemical
infusoins	O
of	O
0	O
.	O
5	O
,	O
2	O
.	O
5	O
,	O
5	O
and	O
10	O
micrgorams	O
/	O
kg	O
per	O
min	O
were	O
adimnistered	O
.	O

Echocardiogarphic	O
Dpopler	O
stduies	O
were	O
performed	O
before	O
inufsion	O
and	O
after	O
15	O
min	O
of	O
infsuion	O
at	O
each	O
rtae	O
.	O

Dobtuamine	B-Chemical
infsuion	O
at	O
10	O
microgrmas	O
/	O
kg	O
per	O
min	O
was	O
discontniued	O
after	O
six	O
studeis	O
secondary	O
to	O
a	O
50	O
%	O
inicdence	O
rtae	O
of	O
avderse	O
sympotms	O
.	O

The	O
most	O
important	O
fnidings	O
were	O
that	O
cmopared	O
with	O
vaules	O
in	O
contorl	O
subejcts	O
,	O
end	O
-	O
sytsolic	O
lfet	O
venrticular	O
postreior	O
wlal	O
diemnsion	O
and	O
percent	O
of	O
lfet	O
ventrciular	O
posetrior	O
wlal	O
thikcening	O
in	O
doxorubciin	B-Chemical
-	O
tretaed	O
ptaients	O
were	O
decraesed	O
at	O
baseilne	O
stduy	O
and	O
these	O
finidngs	O
were	O
more	O
clearly	O
delineated	O
with	O
dboutamine	B-Chemical
stiumlation	O
.	O

End	O
-	O
sysotlic	O
lfet	O
ventricluar	O
postreior	O
wlal	O
dimenison	O
at	O
baesline	O
for	O
the	O
doxorbuicin	B-Chemical
-	O
traeted	O
gorup	O
was	O
11	O
+	O
/	O
-	O
1	O
.	O
9	O
mm	O
versus	O
13	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
5	O
mm	O
for	O
contorl	O
sujbects	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

End	O
-	O
sytsolic	O
lfet	O
venrticular	O
posetrior	O
wlal	O
dimensoin	O
at	O
the	O
5	O
-	O
microgarms	O
/	O
kg	O
per	O
min	O
dobuatmine	B-Chemical
inufsion	O
for	O
the	O
dooxrubicin	B-Chemical
-	O
tretaed	O
gorup	O
was	O
14	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
4	O
mm	O
versus	O
19	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
6	O
mm	O
for	O
conrtol	O
subjcets	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
(	O
ABSTRACT	O
TRUNACTED	O
AT	O
250	O
WORDS	O
)	O

Ifnluence	O
of	O
smoknig	B-Chemical
on	O
developing	O
cohclea	O
.	O

Does	O
smkoing	B-Chemical
during	O
pergnancy	O
affect	O
the	O
amplitueds	O
of	O
transeint	O
eovked	O
otocaoustic	O
emsisions	O
in	O
nebworns	O
?	O

OBJECTVIE	O
:	O
Materanl	O
tboacco	O
somking	B-Chemical
has	O
negatvie	O
effcets	O
on	O
fteal	O
grotwh	O
.	O

The	O
influnece	O
of	O
smoikng	B-Chemical
during	O
prgenancy	O
on	O
the	O
developing	O
coclhea	O
has	O
not	O
been	O
estmiated	O
,	O
although	O
smoknig	B-Chemical
has	O
been	O
positivley	O
associated	O
with	O
hearnig	O
lsos	O
in	O
adluts	O
.	O

The	O
objetcive	O
of	O
this	O
stduy	O
was	O
to	O
determine	O
the	O
effcets	O
of	O
materanl	O
somking	B-Chemical
on	O
tranisent	O
eovked	O
otoacosutic	O
emsisions	O
(	O
TOEAEs	O
)	O
of	O
haelthy	O
nenoates	O
.	O

METHODS	O
:	O
This	O
stduy	O
was	O
undertaken	O
as	O
part	O
of	O
noenatal	O
screeinng	O
for	O
haering	O
ipmairment	O
and	O
involved	O
both	O
eras	O
of	O
200	O
newbrons	O
.	O

Nebworns	O
whose	O
mothres	O
reported	O
somking	B-Chemical
during	O
pergnancy	O
(	O
n	O
=	O
200	O
eras	O
)	O
were	O
cmopared	O
to	O
a	O
cnotrol	O
gruop	O
of	O
newobrns	O
(	O
n	O
=	O
200	O
eras	O
)	O
,	O
whose	O
motehrs	O
were	O
non	O
-	O
smkoers	O
.	O

Epxosure	O
to	O
toabcco	O
was	O
chaarcterized	O
as	O
low	O
(	O
<	O
5	O
cigraettes	O
per	O
day	O
,	O
n	O
=	O
88	O
eras	O
)	O
,	O
modertae	O
(	O
5	O
<	O
or	O
=	O
cigarettes	O
per	O
day	O
<	O
10	O
,	O
n	O
=	O
76	O
)	O
or	O
high	O
(	O
>	O
or	O
=	O
10	O
ciagrettes	O
per	O
day	O
,	O
n	O
=	O
36	O
)	O
.	O

RESLUTS	O
:	O
In	O
exopsed	O
neoantes	O
,	O
TOEAEs	O
mean	O
respnose	O
(	O
across	O
freqeuncy	O
)	O
and	O
mean	O
apmlitude	O
at	O
4000Hz	O
was	O
significantly	O
lwoer	O
than	O
in	O
non	O
-	O
expsoed	O
neonaets	O
.	O

Comaprisons	O
between	O
epxosed	O
newbrons	O
'	O
subrgoups	O
rveealed	O
no	O
significant	O
differences	O
.	O

However	O
,	O
by	O
compraing	O
each	O
sugbroup	O
to	O
contorl	O
gorup	O
,	O
we	O
found	O
statistiaclly	O
significant	O
derceases	O
of	O
TEOEAs	O
ampiltudes	O
at	O
4000Hz	O
for	O
all	O
three	O
gruops	O
.	O

Mean	O
TOEAEs	O
responess	O
of	O
highly	O
exopsed	O
newbrons	O
were	O
also	O
significantly	O
lwoer	O
in	O
copmarison	O
to	O
our	O
conrtol	O
gruop	O
.	O

CONCLSUION	O
:	O
In	O
utreo	O
,	O
expousre	O
to	O
tboacco	O
smoikng	B-Chemical
seems	O
to	O
have	O
a	O
small	O
imapct	O
on	O
ouetr	O
hiar	O
clels	O
.	O

These	O
effects	O
seem	O
to	O
be	O
equally	O
true	O
for	O
all	O
epxosed	O
nebworns	O
,	O
regardless	O
of	O
the	O
dergee	O
of	O
exposrue	O
.	O

Further	O
stuides	O
are	O
needed	O
in	O
order	O
to	O
establish	O
a	O
potenital	O
negaitve	O
effect	O
of	O
materanl	O
smoknig	B-Chemical
on	O
the	O
nenoate	O
'	O
s	O
heraing	O
acutiy	O
.	O

Simavstatin	B-Chemical
-	O
inudced	O
bilatreal	O
leg	O
comaprtment	O
syndrmoe	O
and	O
myonecorsis	O
associated	O
with	O
hypothyroiidsm	O
.	O

A	O
54	O
-	O
yaer	O
-	O
old	O
hypothyorid	O
mlae	O
taking	O
tyhroxine	B-Chemical
and	O
simvasttain	B-Chemical
presented	O
with	O
bliateral	O
leg	O
comparmtent	O
syndrmoe	O
and	O
myonecrsois	O
.	O

Urgnet	O
fascitoomies	O
were	O
performed	O
and	O
the	O
patinet	O
made	O
an	O
unveentful	O
recoevry	O
with	O
the	O
witdhrawal	O
of	O
simvatsatin	B-Chemical
.	O

It	O
is	O
likely	O
that	O
this	O
comlpication	O
will	O
be	O
seen	O
more	O
often	O
with	O
the	O
inrceased	O
worldwide	O
use	O
of	O
this	O
durg	O
and	O
its	O
approavl	O
for	O
all	O
arteriopahtic	O
patietns	O
.	O

Neuroinflammaiton	O
and	O
behvaioral	O
abnormailties	O
after	O
nenoatal	O
tebrutaline	B-Chemical
traetment	O
in	O
rtas	O
:	O
implications	O
for	O
autsim	O
.	O

Atuism	O
is	O
a	O
nuerodevelopmental	O
disoredr	O
prseenting	O
before	O
3	O
yeras	O
of	O
age	O
with	O
defciits	O
in	O
commnuication	O
and	O
soical	O
siklls	O
and	O
repettiive	O
behavoirs	O
.	O

In	O
addition	O
to	O
genteic	O
infulences	O
,	O
recent	O
stduies	O
suggest	O
that	O
preantal	O
durg	O
or	O
chemcial	O
epxosures	O
are	O
rsik	O
facotrs	O
for	O
atuism	O
.	O

Terbutalnie	B-Chemical
,	O
a	O
btea2	O
-	O
adrenoecptor	O
agnoist	O
used	O
to	O
arrset	O
prteerm	O
laobr	O
,	O
has	O
been	O
associated	O
with	O
icnreased	O
cnocordance	O
for	O
auitsm	O
in	O
dizgyotic	O
tiwns	O
.	O

We	O
studied	O
the	O
effetcs	O
of	O
terubtaline	B-Chemical
on	O
microglail	O
activtaion	O
in	O
different	O
brian	O
reginos	O
and	O
behavoiral	O
outocmes	O
in	O
developing	O
rtas	O
.	O

Nebworn	O
rtas	O
were	O
given	O
terbutailne	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
daliy	O
on	O
postntaal	O
dyas	O
(	O
PN	O
)	O
2	O
to	O
5	O
or	O
PN	O
11	O
to	O
14	O
and	O
examined	O
24	O
h	O
after	O
the	O
last	O
dsoe	O
and	O
at	O
PN	O
30	O
.	O

Immunohsitochemical	O
stuides	O
showed	O
that	O
administraiton	O
of	O
terbtualine	B-Chemical
on	O
PN	O
2	O
to	O
5	O
produced	O
a	O
robsut	O
inrcease	O
in	O
mircoglial	O
atcivation	O
on	O
PN	O
30	O
in	O
the	O
cerebarl	O
cotrex	O
,	O
as	O
well	O
as	O
in	O
cerebelalr	O
and	O
creebrocortical	O
whtie	O
matter	O
.	O

None	O
of	O
these	O
effcets	O
occurred	O
in	O
ainmals	O
given	O
terbuatline	B-Chemical
on	O
PN	O
11	O
to	O
14	O
.	O

In	O
behavoiral	O
tetss	O
,	O
anmials	O
terated	O
with	O
trebutaline	B-Chemical
on	O
PN	O
2	O
to	O
5	O
showed	O
consistent	O
patetrns	O
of	O
hyper	O
-	O
reactivtiy	O
to	O
novlety	O
and	O
avresive	O
stiumli	O
when	O
assesesd	O
in	O
a	O
novel	O
open	O
field	O
,	O
as	O
well	O
as	O
in	O
the	O
acosutic	O
satrtle	O
resposne	O
tset	O
.	O

Our	O
fidnings	O
indicate	O
that	O
beat2	O
-	O
adrencoeptor	O
overstimultaion	O
during	O
an	O
ealry	O
critical	O
preiod	O
reuslts	O
in	O
micorglial	O
actviation	O
associated	O
with	O
inntae	O
neuroinflammaotry	O
patwhays	O
and	O
behaivoral	O
abnormaliteis	O
,	O
similar	O
to	O
those	O
described	O
in	O
auitsm	O
.	O

This	O
sutdy	O
provides	O
a	O
useful	O
ainmal	O
moedl	O
for	O
understanding	O
the	O
neuropathloogical	O
processes	O
underlying	O
auitsm	O
sepctrum	O
dsiorders	O
.	O

Upregulatoin	O
of	O
barin	O
expresison	O
of	O
P	O
-	O
glycoprotien	O
in	O
MPR2	O
-	O
dfeicient	O
TR	O
(	O
-	O
)	O
rtas	O
resembles	O
seizrue	O
-	O
inudced	O
up	O
-	O
regluation	O
of	O
this	O
durg	O
eflfux	O
tarnsporter	O
in	O
noraml	O
rtas	O
.	O

PUPROSE	O
:	O
The	O
multdirug	O
resistnace	O
prtoein	O
2	O
(	O
MPR2	O
)	O
is	O
a	O
durg	O
efflux	O
transoprter	O
that	O
is	O
expressed	O
predominantly	O
at	O
the	O
aipcal	O
domian	O
of	O
hepatcoytes	O
but	O
seems	O
also	O
to	O
be	O
expresesd	O
at	O
the	O
aipcal	O
memrbane	O
of	O
brian	O
capillary	O
endotheilal	O
cells	O
that	O
form	O
the	O
bolod	O
-	O
barin	O
brarier	O
(	O
BBB	O
)	O
.	O

MPR2	O
is	O
absnet	O
in	O
the	O
transoprt	O
-	O
deficinet	O
(	O
TR	O
(	O
-	O
)	O
)	O
Wisatr	O
rat	O
muatnt	O
,	O
so	O
that	O
this	O
rat	O
strian	O
was	O
very	O
helpful	O
in	O
defining	O
susbtrates	O
of	O
MPR2	O
by	O
compraing	O
tsisue	O
concentratoins	O
or	O
functioanl	O
actiivties	O
of	O
componuds	O
in	O
MPR2	O
-	O
deficinet	O
rtas	O
with	O
those	O
in	O
transprot	O
-	O
competent	O
Wisatr	O
rtas	O
.	O

By	O
using	O
this	O
strategy	O
to	O
sutdy	O
the	O
invlovement	O
of	O
MPR2	O
in	O
barin	O
access	O
of	O
antiepilpetic	O
drgus	O
(	O
ADEs	O
)	O
,	O
we	O
recently	O
reported	O
that	O
phenytion	B-Chemical
is	O
a	O
susbtrate	O
for	O
MPR2	O
in	O
the	O
BBB	O
.	O

However	O
,	O
one	O
drawback	O
of	O
such	O
stduies	O
in	O
genetcially	O
deficeint	O
rtas	O
is	O
the	O
fact	O
that	O
compnesatory	O
chanegs	O
with	O
upregulaiton	O
of	O
other	O
transoprters	O
can	O
occur	O
.	O

This	O
prompted	O
us	O
to	O
stduy	O
the	O
brian	O
epxression	O
of	O
P	O
-	O
glycoportein	O
(	O
Pgp	O
)	O
,	O
a	O
major	O
durg	O
eflfux	O
transpotrer	O
in	O
many	O
tisuses	O
,	O
including	O
the	O
BBB	O
,	O
in	O
TR	O
(	O
-	O
)	O
rtas	O
compaerd	O
with	O
nnomutant	O
(	O
wlid	O
-	O
tpye	O
)	O
Wsitar	O
rtas	O
.	O

METHODS	O
:	O
The	O
expresison	O
of	O
MPR2	O
and	O
Pgp	O
in	O
brian	O
and	O
lievr	O
scetions	O
of	O
TR	O
(	O
-	O
)	O
rtas	O
and	O
noraml	O
Witsar	O
rtas	O
was	O
determined	O
with	O
immunohistochemitsry	O
,	O
by	O
using	O
a	O
novel	O
,	O
highly	O
selective	O
monolconal	O
MPR2	O
antibdoy	O
and	O
the	O
monolconal	O
Pgp	O
antibdoy	O
C129	O
,	O
respectively	O
.	O

REUSLTS	O
:	O
Immunolfuorescence	O
staniing	O
with	O
the	O
MPR2	O
anitbody	O
was	O
found	O
to	O
lbael	O
a	O
high	O
number	O
of	O
mircovessels	O
throughout	O
the	O
brian	O
in	O
noraml	O
Wisatr	O
rtas	O
,	O
whereas	O
such	O
laebling	O
was	O
absnet	O
in	O
TR	O
(	O
-	O
)	O
rtas	O
.	O

TR	O
(	O
-	O
)	O
rtas	O
exhibited	O
a	O
significant	O
up	O
-	O
rgeulation	O
of	O
Pgp	O
in	O
brian	O
caipllary	O
endtohelial	O
clels	O
copmared	O
with	O
wlid	O
-	O
tpye	O
conrtols	O
.	O

No	O
such	O
obvious	O
upregualtion	O
of	O
Pgp	O
was	O
observed	O
in	O
lievr	O
setcions	O
.	O

A	O
comparable	O
overexpressoin	O
of	O
Pgp	O
in	O
the	O
BBB	O
was	O
obtained	O
after	O
pliocarpine	B-Chemical
-	O
idnuced	O
seizrues	O
in	O
wlid	O
-	O
tpye	O
Witsar	O
rtas	O
.	O

Epxeriments	O
with	O
ssytemic	O
amdinistration	O
of	O
the	O
Pgp	O
subtsrate	O
phenobarbiatl	B-Chemical
and	O
the	O
selective	O
Pgp	O
inihbitor	O
tarqiuidar	B-Chemical
in	O
TR	O
(	O
-	O
)	O
rtas	O
substantiated	O
that	O
Pgp	O
is	O
functioanl	O
and	O
compensates	O
for	O
the	O
lcak	O
of	O
MPR2	O
in	O
the	O
BBB	O
.	O

CONCLUSOINS	O
:	O
The	O
dtaa	O
on	O
TR	O
(	O
-	O
)	O
rtas	O
indicate	O
that	O
Pgp	O
plays	O
an	O
important	O
role	O
in	O
the	O
compenstaion	O
of	O
MPR2	O
defciiency	O
in	O
the	O
BBB	O
.	O

Because	O
such	O
a	O
compnesatory	O
mcehanism	O
most	O
likely	O
occurs	O
to	O
rdeuce	O
inujry	O
to	O
the	O
brian	O
from	O
cyottoxic	O
compoudns	O
,	O
the	O
present	O
dtaa	O
substantiate	O
the	O
concpet	O
that	O
MPR2	O
performs	O
a	O
protective	O
role	O
in	O
the	O
BBB	O
.	O

Furthermore	O
,	O
our	O
dtaa	O
suggest	O
that	O
TR	O
(	O
-	O
)	O
rtas	O
are	O
an	O
interesting	O
tool	O
to	O
sutdy	O
consequenecs	O
of	O
overexprsesion	O
of	O
Pgp	O
in	O
the	O
BBB	O
on	O
access	O
of	O
drgus	O
in	O
the	O
brian	O
,	O
without	O
the	O
need	O
of	O
induicng	O
seziures	O
or	O
other	O
Pgp	O
-	O
enhancing	O
evetns	O
for	O
this	O
purpose	O
.	O

Role	O
of	O
xantihne	B-Chemical
oxdiase	O
in	O
dexametahsone	B-Chemical
-	O
indcued	O
hyeprtension	O
in	O
rtas	O
.	O

1	O
.	O

Glucocortiocid	O
-	O
induecd	O
hyperetnsion	O
(	O
GC	O
-	O
HT	O
)	O
in	O
the	O
rat	O
is	O
associated	O
with	O
ntiric	B-Chemical
oxdie	I-Chemical
-	O
rdeox	O
imablance	O
.	O

2	O
.	O

We	O
studied	O
the	O
role	O
of	O
xanthnie	B-Chemical
oxdiase	O
(	O
XO	O
)	O
,	O
which	O
is	O
implicated	O
in	O
the	O
prdouction	O
of	O
reacitve	O
oxgyen	O
speices	O
,	O
in	O
deaxmethasone	B-Chemical
-	O
indcued	O
hpyertension	O
(	O
dex	B-Chemical
-	O
HT	O
)	O
.	O

3	O
.	O

Thirty	O
mlae	O
Srpague	O
-	O
Dawely	O
rtas	O
were	O
divided	O
randomly	O
into	O
four	O
tretament	O
gorups	O
:	O
slaine	O
,	O
dexamethasnoe	B-Chemical
(	O
dex	B-Chemical
)	O
,	O
allopurniol	B-Chemical
plus	O
sailne	O
,	O
and	O
allouprinol	B-Chemical
plus	O
dex	B-Chemical
.	O

4	O
.	O

Systloic	O
blood	O
pressures	O
(	O
SBP	O
)	O
and	O
bodywieghts	O
were	O
recorded	O
each	O
alternate	O
day	O
.	O

Tyhmus	O
weihgt	O
was	O
used	O
as	O
a	O
marekr	O
of	O
gluccoorticoid	O
activtiy	O
,	O
and	O
sreum	O
urtae	B-Chemical
to	O
assess	O
XO	O
inhbiition	O
.	O

5	O
.	O

Dex	B-Chemical
incresaed	O
SBP	O
(	O
110	O
+	O
/	O
-	O
2	O
-	O
126	O
+	O
/	O
-	O
3	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
decreaesd	O
thyums	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
boydweights	O
(	O
P	O
"	O
<	O
0	O
.	O
01	O
)	O
.	O

Allouprinol	B-Chemical
derceased	O
sreum	O
uarte	B-Chemical
from	O
76	O
+	O
/	O
-	O
5	O
to	O
30	O
+	O
/	O
-	O
3	O
micromol	O
/	O
L	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
sailne	O
and	O
from	O
84	O
+	O
/	O
-	O
13	O
to	O
28	O
+	O
/	O
-	O
2	O
micromol	O
/	O
L	O
in	O
dex	B-Chemical
-	O
terated	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
gropus	O
.	O

6	O
.	O

Allopurniol	B-Chemical
did	O
not	O
preevnt	O
dex	B-Chemical
-	O
HT	O
.	O

This	O
,	O
together	O
with	O
our	O
previous	O
fnidings	O
that	O
allopurionl	B-Chemical
failed	O
to	O
prevnet	O
adrenocorticotrpohic	O
homrone	O
inudced	O
hyeprtension	O
,	O
suggests	O
that	O
XO	O
actviity	O
is	O
not	O
a	O
major	O
deterimnant	O
of	O
GC	O
-	O
HT	O
in	O
the	O
rat	O
.	O

Side	O
effects	O
of	O
postopreative	O
adminsitration	O
of	O
metyhlprednisolone	B-Chemical
and	O
getnamicin	B-Chemical
into	O
the	O
posetrior	O
sub	O
-	O
Tneon	O
'	O
s	O
spcae	O
.	O

PUROPSE	O
:	O
To	O
assess	O
the	O
incidnece	O
of	O
postoperaitve	O
emeitc	O
side	O
efefcts	O
after	O
the	O
adminsitration	O
of	O
methylpredinsolone	B-Chemical
and	O
gentmaicin	B-Chemical
into	O
the	O
potserior	O
sub	O
-	O
Tneon	O
'	O
s	O
spcae	O
at	O
the	O
end	O
of	O
ruotine	O
cataarct	O
sugrery	O
.	O

SETTING	O
:	O
St	O
.	O

Lkue	O
'	O
s	O
Hosptial	O
,	O
Gwardamagnia	O
,	O
Mlata	O
.	O

METHODS	O
:	O
A	O
double	O
-	O
bilnd	O
double	O
-	O
armed	O
porspective	O
sutdy	O
comprised	O
40	O
patietns	O
who	O
had	O
unevetnful	O
sutuerless	O
phacomeulsification	O
under	O
sub	O
-	O
Teonn	O
'	O
s	O
lcoal	O
inifltration	O
of	O
3	O
mL	O
of	O
palin	O
lingocaine	B-Chemical
.	O

At	O
the	O
end	O
of	O
the	O
procdeure	O
,	O
Gruop	O
A	O
(	O
n	O
=	O
20	O
)	O
had	O
20	O
mg	O
/	O
0	O
.	O
5	O
mL	O
of	O
methylprednsiolone	B-Chemical
and	O
10	O
mg	O
/	O
0	O
.	O
5	O
mL	O
of	O
gentamiicn	B-Chemical
injecetd	O
into	O
the	O
posteiror	O
sub	O
-	O
Tneon	O
'	O
s	O
spcae	O
and	O
Gorup	O
B	O
(	O
n	O
=	O
20	O
)	O
had	O
the	O
same	O
comibnation	O
ijnected	O
into	O
the	O
anetrior	O
sub	O
-	O
Teonn	O
'	O
s	O
spcae	O
.	O

Posotperatively	O
,	O
all	O
patietns	O
were	O
asssesed	O
for	O
sympotms	O
of	O
nauesa	O
,	O
vomitnig	O
,	O
and	O
heaadche	O
.	O

A	O
chi	O
-	O
suqare	O
tset	O
was	O
used	O
to	O
assess	O
the	O
statisitcal	O
significacne	O
of	O
reuslts	O
.	O

REUSLTS	O
:	O
Sixty	O
percent	O
in	O
Gorup	O
A	O
developed	O
postoperaitve	O
eemtic	O
sypmtoms	O
,	O
heaadche	O
,	O
or	O
both	O
;	O
1	O
pateint	O
in	O
Gruop	O
B	O
developed	O
sypmtoms	O
.	O

CONCLUISONS	O
:	O
The	O
adminisrtation	O
of	O
methylpredinsolone	B-Chemical
and	O
getnamicin	B-Chemical
in	O
the	O
posteroir	O
sub	O
-	O
Teonn	O
'	O
s	O
spcae	O
was	O
related	O
to	O
a	O
high	O
incdience	O
of	O
side	O
efefcts	O
including	O
nauesa	O
,	O
vomtiing	O
,	O
and	O
hedaache	O
.	O

All	O
advrese	O
effcets	O
were	O
slef	O
-	O
limiting	O
.	O

Assessment	O
of	O
a	O
new	O
non	O
-	O
invaisve	O
index	O
of	O
cradiac	O
performacne	O
for	O
detetcion	O
of	O
dobuatmine	B-Chemical
-	O
inudced	O
myocaridal	O
ishcemia	O
.	O

BACKGRUOND	O
:	O
Electrocaridography	O
has	O
a	O
very	O
low	O
sensitviity	O
in	O
detectnig	O
doubtamine	B-Chemical
-	O
indcued	O
myoacrdial	O
ischeima	O
.	O

OBEJCTIVES	O
:	O
To	O
assess	O
the	O
added	O
diganostic	O
value	O
of	O
a	O
new	O
cadriac	O
perfomrance	O
index	O
(	O
dP	O
/	O
dtjec	O
)	O
meausrement	O
,	O
based	O
on	O
barchial	O
aretry	O
folw	O
chanegs	O
,	O
as	O
cmopared	O
to	O
stanadrd	O
12	O
-	O
lead	O
ECG	O
,	O
for	O
dteecting	O
dobutmaine	B-Chemical
-	O
idnuced	O
myocardail	O
ischmeia	O
,	O
using	O
T9c9m	B-Chemical
-	I-Chemical
Sesatmibi	I-Chemical
single	O
-	O
phtoon	O
emisison	O
comupted	O
tomogrpahy	O
as	O
the	O
glod	O
stadnard	O
of	O
copmarison	O
to	O
assess	O
the	O
prseence	O
or	O
absecne	O
of	O
ischmeia	O
.	O

METHODS	O
:	O
The	O
stduy	O
gruop	O
comprised	O
40	O
ptaients	O
undergoing	O
Sesatmibi	B-Chemical
-	O
SEPCT	O
/	O
dobuatmine	B-Chemical
sterss	O
tset	O
.	O

Smiultaneous	O
measureemnts	O
of	O
ECG	O
and	O
bracihal	O
aretry	O
dP	O
/	O
detjc	O
were	O
performed	O
at	O
each	O
dobutmaine	B-Chemical
leevl	O
.	O

In	O
19	O
of	O
the	O
40	O
pateints	O
perfusoin	O
dfeects	O
compatible	O
with	O
ischeima	O
were	O
deetcted	O
on	O
SEPCT	O
.	O

The	O
inrcease	O
in	O
dP	O
/	O
dtjec	O
during	O
infuison	O
of	O
dobutaimne	B-Chemical
in	O
this	O
gorup	O
was	O
sevreely	O
imparied	O
as	O
compaerd	O
to	O
the	O
non	O
-	O
ishcemic	O
gruop	O
.	O

dP	O
/	O
detjc	O
outocme	O
was	O
comibned	O
with	O
the	O
ECG	O
resluts	O
,	O
giving	O
an	O
ECG	O
-	O
enahnced	O
value	O
,	O
and	O
cmopared	O
to	O
ECG	O
alone	O
.	O

RSEULTS	O
:	O
The	O
snesitivity	O
imrpoved	O
dramatically	O
from	O
16	O
%	O
to	O
79	O
%	O
,	O
poistive	O
preditcive	O
value	O
inrceased	O
from	O
60	O
%	O
to	O
68	O
%	O
and	O
ngeative	O
preidctive	O
value	O
from	O
54	O
%	O
to	O
78	O
%	O
,	O
and	O
spceificity	O
decraesed	O
from	O
90	O
%	O
to	O
67	O
%	O
.	O

CONCLUSINOS	O
:	O
If	O
ECG	O
alone	O
is	O
used	O
for	O
speciifcity	O
,	O
the	O
combniation	O
with	O
dP	O
/	O
dtjec	O
improevd	O
the	O
sesnitivity	O
of	O
the	O
tset	O
and	O
could	O
be	O
a	O
csot	O
-	O
savnigs	O
alterntaive	O
to	O
cardaic	O
imagnig	O
or	O
perfusoin	O
studeis	O
to	O
deetct	O
myocardail	O
ishcemia	O
,	O
especially	O
in	O
paitents	O
unable	O
to	O
exericse	O
.	O

Cociane	B-Chemical
-	O
induecd	O
myocardail	O
inafrction	O
:	O
clniical	O
obseravtions	O
and	O
patohgenetic	O
consdierations	O
.	O

Clincial	O
and	O
expreimental	O
dtaa	O
publihsed	O
to	O
date	O
suggest	O
several	O
possible	O
mechansims	O
by	O
which	O
ccoaine	B-Chemical
may	O
result	O
in	O
aucte	O
myocradial	O
infartcion	O
.	O

In	O
indivdiuals	O
with	O
preexisting	O
,	O
high	O
-	O
garde	O
coornary	O
artreial	O
narrwoing	O
,	O
aucte	O
myoacrdial	O
infartcion	O
may	O
result	O
from	O
an	O
incerase	O
in	O
myocradial	O
oxgyen	B-Chemical
demand	O
associated	O
with	O
cociane	B-Chemical
-	O
indcued	O
incresae	O
in	O
rtae	O
-	O
presusre	O
proudct	O
.	O

In	O
other	O
indivdiuals	O
with	O
no	O
underlying	O
atheroscleortic	O
obstrutcion	O
,	O
cornoary	O
occlsuion	O
may	O
be	O
due	O
to	O
spsam	O
,	O
throbmus	O
,	O
or	O
both	O
.	O

With	O
regard	O
to	O
spsam	O
,	O
the	O
clniical	O
finidngs	O
are	O
largely	O
circumtsantial	O
,	O
and	O
the	O
loucs	O
of	O
ccoaine	B-Chemical
-	O
indcued	O
vasoconstrictoin	O
remains	O
speculative	O
.	O

Although	O
certain	O
clniical	O
and	O
experimnetal	O
findnigs	O
support	O
the	O
hypohtesis	O
that	O
sapsm	O
involves	O
the	O
epiacrdial	O
,	O
mdeium	O
-	O
szie	O
vsesels	O
,	O
other	O
dtaa	O
suggest	O
intramuarl	O
vasoconstritcion	O
.	O

Difufse	O
intraumral	O
vasoconstirction	O
is	O
not	O
consistent	O
with	O
reprots	O
of	O
sgemental	O
,	O
discerte	O
infacrtion	O
.	O

Whereas	O
certain	O
in	O
vivo	O
dtaa	O
suggest	O
that	O
these	O
effetcs	O
are	O
alhpa	O
-	O
mediated	O
,	O
other	O
in	O
vitro	O
dtaa	O
suggest	O
the	O
opposite	O
.	O

The	O
fidning	O
of	O
ccoaine	B-Chemical
-	O
idnuced	O
vasoconstritcion	O
in	O
segmnets	O
of	O
(	O
noninenrvated	O
)	O
hmuan	O
ubmilical	O
aretry	O
suggests	O
that	O
the	O
persence	O
or	O
abesnce	O
of	O
itnact	O
innervation	O
is	O
not	O
sufficient	O
to	O
explain	O
the	O
discrpeant	O
dtaa	O
involving	O
the	O
possibility	O
of	O
aplha	O
-	O
mediated	O
effcets	O
.	O

Finally	O
,	O
the	O
contribution	O
of	O
a	O
primray	O
,	O
thromobtic	O
efefct	O
of	O
cociane	B-Chemical
has	O
not	O
been	O
excluded	O
.	O

Protoemic	O
analyiss	O
of	O
stiratal	O
proetins	O
in	O
the	O
rat	O
moedl	O
of	O
L	B-Chemical
-	I-Chemical
DPOA	I-Chemical
-	O
induecd	O
dyskinseia	O
.	O

L	B-Chemical
-	I-Chemical
DPOA	I-Chemical
-	O
induecd	O
dyksinesia	O
(	O
LID	O
)	O
is	O
among	O
the	O
mtoor	O
copmlications	O
that	O
arise	O
in	O
Parkinosn	O
'	O
s	O
diesase	O
(	O
PD	O
)	O
pateints	O
after	O
a	O
prolnoged	O
tretament	O
with	O
L	B-Chemical
-	I-Chemical
DPOA	I-Chemical
.	O

To	O
this	O
day	O
,	O
trasncriptome	O
aanlysis	O
has	O
been	O
performed	O
in	O
a	O
rat	O
mdoel	O
of	O
LID	O
[	O
Neuroibol	O
.	O
Dis	O
.	O
,	O
17	O
(	O
2004	O
)	O
,	O
219	O
]	O
but	O
ifnormation	O
regarding	O
the	O
porteome	O
is	O
still	O
lacking	O
.	O

In	O
the	O
present	O
sutdy	O
,	O
we	O
ivnestigated	O
the	O
chanegs	O
occurring	O
at	O
the	O
portein	O
lveel	O
in	O
straital	O
smaples	O
obtained	O
from	O
the	O
uinlaterally	O
6	B-Chemical
-	I-Chemical
hydroxydpoamine	I-Chemical
-	O
lesoin	O
rat	O
mdoel	O
of	O
PD	O
tretaed	O
with	O
salnie	O
,	O
L	B-Chemical
-	I-Chemical
DPOA	I-Chemical
or	O
bromocripitne	B-Chemical
using	O
two	O
-	O
dimesnional	O
difference	O
gel	O
eletcrophoresis	O
and	O
msas	O
spectroemtry	O
(	O
MS	O
)	O
.	O

Rtas	O
terated	O
with	O
L	B-Chemical
-	I-Chemical
DPOA	I-Chemical
were	O
allocated	O
to	O
two	O
gorups	O
based	O
on	O
the	O
preesnce	O
or	O
abesnce	O
of	O
LID	O
.	O

Among	O
the	O
2000	O
sptos	O
comapred	O
for	O
statisitcal	O
difference	O
,	O
67	O
sopts	O
were	O
significantly	O
changed	O
in	O
aubndance	O
and	O
idnetified	O
using	O
mtarix	O
-	O
assitsed	O
laesr	O
dseorption	O
/	O
ioinzation	O
tmie	O
-	O
of	O
-	O
flgiht	O
MS	O
,	O
atomspheric	O
pressure	O
martix	O
-	O
assitsed	O
lsaer	O
dseorption	O
/	O
ioniztaion	O
and	O
HLPC	O
coupled	O
tnadem	O
MS	O
(	O
LC	O
/	O
MS	O
/	O
MS	O
)	O
.	O

Out	O
of	O
these	O
67	O
protiens	O
,	O
LID	O
significantly	O
changed	O
the	O
exprsesion	O
leevl	O
of	O
five	O
proetins	O
:	O
alphbaeta	O
-	O
crysatlin	O
,	O
gamma	O
-	O
eonlase	O
,	O
guanidoaectate	O
methyltranfserase	O
,	O
vniculin	O
,	O
and	O
protaesome	O
alhpa	O
-	O
2	O
subuint	O
.	O

Copmlementary	O
tcehniques	O
such	O
as	O
wesetrn	O
immunbolotting	O
and	O
immunohistochemitsry	O
were	O
performed	O
to	O
invsetigate	O
the	O
vlaidity	O
of	O
the	O
dtaa	O
obtained	O
using	O
the	O
prtoeomic	O
approach	O
.	O

In	O
conclusion	O
,	O
this	O
stduy	O
provides	O
new	O
insights	O
into	O
the	O
proetin	O
chnages	O
occurring	O
in	O
LID	O
.	O

Caridac	O
Angiogrpahy	O
in	O
Renlaly	O
Impiared	O
Patinets	O
(	O
CRAE	O
)	O
stduy	O
:	O
a	O
randomzied	O
double	O
-	O
blnid	O
trail	O
of	O
contrast	O
-	O
induecd	O
nephroapthy	O
in	O
ptaients	O
with	O
chrnoic	O
kindey	O
dsiease	O
.	O

BAKCGROUND	O
:	O
No	O
direct	O
compariosns	O
exist	O
of	O
the	O
reanl	O
tolreability	O
of	O
the	O
low	O
-	O
osmollaity	O
contrast	B-Chemical
mdeium	I-Chemical
iopaimdol	B-Chemical
with	O
that	O
of	O
the	O
iso	O
-	O
osomlality	O
contrast	B-Chemical
meduim	I-Chemical
ioidxanol	B-Chemical
in	O
high	O
-	O
rsik	O
patietns	O
.	O

METHODS	O
AND	O
REUSLTS	O
:	O
The	O
present	O
stduy	O
is	O
a	O
multicneter	O
,	O
randmoized	O
,	O
double	O
-	O
blnid	O
comaprison	O
of	O
iopmaidol	B-Chemical
and	O
ioidxanol	B-Chemical
in	O
pateints	O
with	O
chornic	O
kdiney	O
disaese	O
(	O
estmiated	O
gloemrular	O
filtartion	O
rtae	O
,	O
20	O
to	O
59	O
mL	O
/	O
min	O
)	O
who	O
underwent	O
cadriac	O
angiogarphy	O
or	O
percutaenous	O
coroanry	O
intevrentions	O
.	O

Sreum	O
creatiinne	B-Chemical
(	O
SCr	O
)	O
leevls	O
and	O
esitmated	O
glomerualr	O
filrtation	O
rtae	O
were	O
assesesd	O
at	O
basleine	O
and	O
2	O
to	O
5	O
dyas	O
after	O
receiving	O
meidcations	O
.	O

The	O
prmiary	O
outocme	O
was	O
a	O
postdsoe	O
SCr	O
incraese	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
(	O
44	O
.	O
2	O
micromol	O
/	O
L	O
)	O
over	O
baesline	O
.	O

Secodnary	O
outocmes	O
were	O
a	O
posdtose	O
SCr	O
incraese	O
>	O
or	O
=	O
25	O
%	O
,	O
a	O
postodse	O
esitmated	O
gloemrular	O
filrtation	O
rtae	O
decraese	O
of	O
>	O
or	O
=	O
25	O
%	O
,	O
and	O
the	O
mean	O
peak	O
change	O
in	O
SCr	O
.	O

In	O
414	O
pateints	O
,	O
contrast	O
vloume	O
,	O
preesnce	O
of	O
daibetes	O
mellitus	O
,	O
use	O
of	O
N	B-Chemical
-	I-Chemical
acetyclysteine	I-Chemical
,	O
mean	O
basleine	O
SCr	O
,	O
and	O
etsimated	O
glomeurlar	O
flitration	O
rtae	O
were	O
comparable	O
in	O
the	O
2	O
gruops	O
.	O

SCr	O
incerases	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
occurred	O
in	O
4	O
.	O
4	O
%	O
(	O
9	O
of	O
204	O
patietns	O
)	O
after	O
iopamiodl	B-Chemical
and	O
6	O
.	O
7	O
%	O
(	O
14	O
of	O
210	O
paitents	O
)	O
after	O
iodixaonl	B-Chemical
(	O
P	O
=	O
0	O
.	O
39	O
)	O
,	O
whereas	O
rtaes	O
of	O
SCr	O
incerases	O
>	O
or	O
=	O
25	O
%	O
were	O
9	O
.	O
8	O
%	O
and	O
12	O
.	O
4	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
44	O
)	O
.	O

In	O
ptaients	O
with	O
diabtees	O
,	O
SCr	O
inrceases	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
were	O
5	O
.	O
1	O
%	O
(	O
4	O
of	O
78	O
paitents	O
)	O
with	O
iopmaidol	B-Chemical
and	O
13	O
.	O
0	O
%	O
(	O
12	O
of	O
92	O
pateints	O
)	O
with	O
iodxianol	B-Chemical
(	O
P	O
=	O
0	O
.	O
11	O
)	O
,	O
whereas	O
SCr	O
incerases	O
>	O
or	O
=	O
25	O
%	O
were	O
10	O
.	O
3	O
%	O
and	O
15	O
.	O
2	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
37	O
)	O
.	O

Mean	O
psot	O
-	O
SCr	O
increaess	O
were	O
significantly	O
less	O
with	O
ipoamidol	B-Chemical
(	O
all	O
ptaients	O
:	O
0	O
.	O
07	O
versus	O
0	O
.	O
12	O
mg	O
/	O
dL	O
,	O
6	O
.	O
2	O
versus	O
10	O
.	O
6	O
micromol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
03	O
;	O
ptaients	O
with	O
diabtees	O
:	O
0	O
.	O
07	O
versus	O
0	O
.	O
16	O
mg	O
/	O
dL	O
,	O
6	O
.	O
2	O
versus	O
14	O
.	O
1	O
micromol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

CONCLSUIONS	O
:	O
The	O
rtae	O
of	O
contrast	O
-	O
induecd	O
nehpropathy	O
,	O
defined	O
by	O
multpile	O
end	O
points	O
,	O
is	O
not	O
statitsically	O
different	O
after	O
the	O
intraaretrial	O
adminisrtation	O
of	O
iopmaidol	B-Chemical
or	O
iodixaonl	B-Chemical
to	O
high	O
-	O
rsik	O
ptaients	O
,	O
with	O
or	O
without	O
dibaetes	O
mellitus	O
.	O

Any	O
true	O
difference	O
between	O
the	O
agnets	O
is	O
small	O
and	O
not	O
likely	O
to	O
be	O
clincially	O
significant	O
.	O

A	O
novel	O
componud	O
,	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
couamrate	I-Chemical
,	O
atteunates	O
cogniitve	O
defciits	O
and	O
shows	O
neuroproetctive	O
effcets	O
in	O
vitro	O
and	O
in	O
vivo	O
deemntia	O
moedls	O
.	O

To	O
develop	O
a	O
novel	O
and	O
effcetive	O
durg	O
that	O
could	O
enahnce	O
cgonitive	O
functoin	O
and	O
neurporotection	O
,	O
we	O
newly	O
syntehsized	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
cuomarate	I-Chemical
by	O
the	O
esterfiication	O
of	O
matlol	B-Chemical
and	O
p	B-Chemical
-	I-Chemical
coumairc	I-Chemical
aicd	I-Chemical
.	O

In	O
the	O
present	O
sutdy	O
,	O
we	O
invsetigated	O
whether	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumaarte	I-Chemical
could	O
ipmrove	O
cgonitive	O
declnie	O
in	O
socpolamine	B-Chemical
-	O
injceted	O
rtas	O
and	O
in	O
aymloid	B-Chemical
btea	I-Chemical
ppetide	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
42	I-Chemical
)	I-Chemical
-	O
infsued	O
rtas	O
.	O

Matlolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumaarte	I-Chemical
was	O
found	O
to	O
attenuate	O
cgonitive	O
dfeicits	O
in	O
both	O
rat	O
moedls	O
using	O
passvie	O
avoidacne	O
tset	O
and	O
to	O
rdeuce	O
apoptoitc	O
clel	O
detah	O
observed	O
in	O
the	O
hippocmapus	O
of	O
the	O
aymloid	B-Chemical
btea	I-Chemical
pepitde	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
42	I-Chemical
)	I-Chemical
-	O
infuesd	O
rtas	O
.	O

We	O
also	O
examined	O
the	O
neuroportective	O
efefcts	O
of	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
cuomarate	I-Chemical
in	O
vitro	O
using	O
SH	O
-	O
S5YY	O
cells	O
.	O

Cells	O
were	O
pertreated	O
with	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumartae	I-Chemical
,	O
before	O
expoesd	O
to	O
amlyoid	B-Chemical
btea	I-Chemical
petpide	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
42	I-Chemical
)	I-Chemical
,	O
gultamate	B-Chemical
or	O
HO22	B-Chemical
.	O

We	O
found	O
that	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumaarte	I-Chemical
significantly	O
decresaed	O
apopttoic	O
clel	O
daeth	O
and	O
reduecd	O
raective	O
oxgyen	O
spceies	O
,	O
cytcohrome	O
c	O
rleease	O
,	O
and	O
caspsae	O
3	O
activatoin	O
.	O

Taking	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
reuslts	O
together	O
,	O
our	O
sutdy	O
suggests	O
that	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumartae	I-Chemical
is	O
a	O
potentially	O
effetcive	O
candidate	O
against	O
Alzehimer	O
'	O
s	O
dsiease	O
that	O
is	O
characterzied	O
by	O
wide	O
spraed	O
neruonal	O
daeth	O
and	O
progressive	O
delcine	O
of	O
cognitvie	O
fnuction	O
.	O

Attenutaion	O
of	O
methampheatmine	B-Chemical
-	O
induecd	O
nigrsotriatal	O
dopamienrgic	O
neurtooxicity	O
in	O
mcie	O
by	O
lipopolysacchardie	B-Chemical
pretraetment	O
.	O

Immunologcial	O
actiavtion	O
has	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
methapmhetamine	B-Chemical
-	O
inudced	O
doapminergic	O
terimnal	O
damgae	O
.	O

In	O
this	O
stduy	O
,	O
we	O
examined	O
the	O
roles	O
of	O
lpiopolysaccharide	B-Chemical
,	O
a	O
pro	O
-	O
infalmmatory	O
and	O
inflammatroy	O
facotr	O
,	O
treamtent	O
in	O
modulaitng	O
the	O
methampehtamine	B-Chemical
-	O
indcued	O
nigrostritaal	O
dpoamine	B-Chemical
neurotxoicity	O
.	O

Lipoploysaccharide	B-Chemical
pertreatment	O
did	O
not	O
affect	O
the	O
bsaal	O
bdoy	O
tempreature	O
or	O
methampheatmine	B-Chemical
-	O
elicited	O
hyperthemria	O
three	O
dyas	O
later	O
.	O

Such	O
ssytemic	O
lipopolysacchairde	B-Chemical
treamtent	O
mitiagted	O
methamphetaimne	B-Chemical
-	O
inudced	O
striaatl	O
dpoamine	B-Chemical
and	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihdyroxyphenylacetic	I-Chemical
aicd	I-Chemical
depeltions	O
in	O
a	O
dsoe	O
-	O
dependnet	O
manner	O
.	O

As	O
the	O
most	O
potent	O
dsoe	O
(	O
1	O
mg	O
/	O
kg	O
)	O
of	O
lipopolysaccharide	B-Chemical
was	O
adminisetred	O
two	O
weeks	O
,	O
one	O
day	O
before	O
or	O
after	O
the	O
methapmhetamine	B-Chemical
doisng	O
reigmen	O
,	O
metahmphetamine	B-Chemical
-	O
inudced	O
straital	O
dopaimne	B-Chemical
and	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylcaetic	I-Chemical
aicd	I-Chemical
delpetions	O
remained	O
unlatered	O
.	O

Moreover	O
,	O
systeimc	O
lipopolyscacharide	B-Chemical
pretreatemnt	O
(	O
1	O
mg	O
/	O
kg	O
)	O
attneuated	O
lcoal	O
methamphetaimne	B-Chemical
infuison	O
-	O
produced	O
dopamnie	B-Chemical
and	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylaectic	I-Chemical
aicd	I-Chemical
delpetions	O
in	O
the	O
straitum	O
,	O
indicating	O
that	O
the	O
protective	O
effcet	O
of	O
lipopolysaccharide	B-Chemical
is	O
less	O
likely	O
due	O
to	O
interrupted	O
peirpheral	O
distrbiution	O
or	O
metaboilsm	O
of	O
methamhpetamine	B-Chemical
.	O

We	O
concluded	O
a	O
critical	O
tmie	O
wnidow	O
for	O
ssytemic	O
lipopolysacchraide	B-Chemical
pertreatment	O
in	O
exertnig	O
effecitve	O
proteciton	O
against	O
methampheatmine	B-Chemical
-	O
indcued	O
nigrostriaatl	O
dopamnie	B-Chemical
neurotoxciity	O
.	O

Aucte	O
moycarditis	O
associated	O
with	O
clzoapine	B-Chemical
.	O

OBEJCTIVE	O
:	O
A	O
csae	O
of	O
actue	O
myocadritis	O
associated	O
with	O
the	O
commenecment	O
of	O
clozapnie	B-Chemical
is	O
described	O
,	O
highlighting	O
the	O
onset	O
,	O
coruse	O
and	O
possible	O
contributing	O
facotrs	O
.	O

There	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awaerness	O
about	O
this	O
potentially	O
faatl	O
complicaiton	O
of	O
clozapnie	B-Chemical
use	O
.	O

RESUTLS	O
:	O
A	O
20	O
-	O
yaer	O
-	O
old	O
mlae	O
with	O
schizpohrenia	O
developed	O
a	O
sudedn	O
onset	O
of	O
myocaridtis	O
after	O
commencement	O
of	O
cloazpine	B-Chemical
.	O

The	O
ptaient	O
recoevred	O
with	O
intenisve	O
meidcal	O
support	O
.	O

The	O
symtpoms	O
occurred	O
around	O
2	O
wekes	O
after	O
starting	O
clzoapine	B-Chemical
in	O
an	O
ipnatient	O
setting	O
.	O

Possible	O
contributing	O
facotrs	O
may	O
have	O
been	O
concomtiant	O
antidepressant	B-Chemical
use	O
and	O
unaccutsomed	O
physiacl	O
actiivty	O
.	O

CONCLSUIONS	O
:	O
Myocraditis	O
is	O
an	O
increasingly	O
recognized	O
compilcation	O
associated	O
with	O
the	O
use	O
of	O
clozaipne	B-Chemical
.	O

It	O
can	O
be	O
faatl	O
if	O
not	O
recognized	O
and	O
traeted	O
eraly	O
.	O

Considering	O
that	O
clzoapine	B-Chemical
remains	O
the	O
glod	O
standrad	O
in	O
teratment	O
of	O
rseistant	O
psychoiss	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awaerness	O
among	O
medcial	O
and	O
parameidcal	O
stfaf	O
involved	O
in	O
the	O
crae	O
of	O
these	O
paitents	O
.	O

There	O
are	O
also	O
implications	O
for	O
recomemndations	O
and	O
regulatoins	O
regarding	O
the	O
use	O
of	O
clzoapine	B-Chemical
.	O

Sevree	O
rhabdomyolyiss	O
and	O
actue	O
reanl	O
faiulre	O
secondary	O
to	O
cnocomitant	O
use	O
of	O
simvasattin	B-Chemical
,	O
amiodaorne	B-Chemical
,	O
and	O
atzaanavir	B-Chemical
.	O

OBEJCTIVE	O
:	O
To	O
reprot	O
a	O
csae	O
of	O
a	O
seevre	O
interaciton	O
between	O
simavstatin	B-Chemical
,	O
amiodarnoe	B-Chemical
,	O
and	O
ataznaavir	B-Chemical
resulting	O
in	O
rhabdmoyolysis	O
and	O
aucte	O
rneal	O
faliure	O
.	O

BAKCGROUND	O
:	O
A	O
72	O
-	O
yaer	O
-	O
old	O
wihte	O
man	O
with	O
underlying	O
hmuan	O
immunodeficeincy	O
viurs	O
,	O
atiral	O
fibirllation	O
,	O
coroanry	O
atrery	O
disaese	O
,	O
and	O
hyperlipidmeia	O
presented	O
with	O
generaliezd	O
pian	O
,	O
fatgiue	O
,	O
and	O
drak	O
oarnge	O
urnie	O
for	O
3	O
dyas	O
.	O

The	O
pateint	O
was	O
taking	O
80	O
mg	O
simvasattin	B-Chemical
at	O
beditme	O
(	O
initiated	O
27	O
dyas	O
earlier	O
)	O
;	O
aimodarone	B-Chemical
at	O
a	O
dsoe	O
of	O
400	O
mg	O
dialy	O
for	O
7	O
dyas	O
,	O
then	O
200	O
mg	O
dialy	O
(	O
initiated	O
19	O
dyas	O
earlier	O
)	O
;	O
and	O
400	O
mg	O
atazanvair	B-Chemical
dialy	O
(	O
initiated	O
at	O
least	O
2	O
yaers	O
previously	O
)	O
.	O

Laboratroy	O
evalutaion	O
reveaeld	O
66	O
,	O
680	O
U	O
/	O
L	O
ceratine	B-Chemical
kinsae	O
,	O
93	O
mg	O
/	O
dL	O
blood	B-Chemical
uera	I-Chemical
nitroegn	I-Chemical
,	O
4	O
.	O
6	O
mg	O
/	O
dL	O
creatniine	B-Chemical
,	O
1579	O
U	O
/	O
L	O
asparatte	B-Chemical
aminotrasnferase	O
,	O
and	O
738	O
U	O
/	O
L	O
alnaine	B-Chemical
aimnotransferase	O
.	O

Simvasttain	B-Chemical
,	O
aimodarone	B-Chemical
,	O
and	O
the	O
pateint	O
'	O
s	O
huamn	O
immunodfeiciency	O
viurs	O
mdeications	O
were	O
all	O
temporarily	O
discontineud	O
and	O
the	O
pateint	O
was	O
given	O
forced	O
alakline	O
diruesis	O
and	O
started	O
on	O
diaylsis	O
.	O

Nine	O
dyas	O
later	O
the	O
patinet	O
'	O
s	O
cretaine	B-Chemical
kianse	O
had	O
drpoped	O
to	O
1695	O
U	O
/	O
L	O
and	O
creatinnie	B-Chemical
was	O
3	O
.	O
3	O
mg	O
/	O
dL	O
.	O

The	O
ptaient	O
was	O
dishcarged	O
and	O
continued	O
ouptatient	O
dialsyis	O
for	O
1	O
motnh	O
until	O
his	O
rneal	O
functoin	O
recovreed	O
.	O

DISCUSSION	O
:	O
The	O
rsik	O
of	O
rhabdmoyolysis	O
is	O
increaesd	O
in	O
the	O
presnece	O
of	O
concomiatnt	O
drgus	O
that	O
inihbit	O
simvasattin	B-Chemical
meatbolism	O
.	O

Sivmastatin	B-Chemical
is	O
metaoblized	O
by	O
CYPA34	O
.	O

Amioadrone	B-Chemical
and	O
atazaanvir	B-Chemical
are	O
recognized	O
CPY3A4	O
inhbiitors	O
.	O

CONCLUSOINS	O
:	O
Pharmcaokinetic	O
differences	O
in	O
statnis	B-Chemical
are	O
an	O
important	O
consideration	O
for	O
assessing	O
the	O
rsik	O
of	O
potetnial	O
durg	O
intercations	O
.	O

In	O
patietns	O
requiring	O
the	O
conucrrent	O
use	O
of	O
statnis	B-Chemical
and	O
CPY3A4	O
ihnibitors	O
,	O
praavstatin	B-Chemical
,	O
fluvastaitn	B-Chemical
,	O
and	O
rosuvsatatin	B-Chemical
carry	O
the	O
lowset	O
rsik	O
of	O
durg	O
interatcions	O
;	O
atrovastatin	B-Chemical
carries	O
modreate	O
rsik	O
,	O
whereas	O
simavstatin	B-Chemical
and	O
lvoastatin	B-Chemical
have	O
the	O
highest	O
rsik	O
and	O
should	O
be	O
avoided	O
in	O
paitents	O
taking	O
cocnomitant	O
CYPA34	O
inihbitors	O
.	O

Intreaction	O
between	O
wrafarin	B-Chemical
and	O
levofloxaicn	B-Chemical
:	O
csae	O
series	O
.	O

Warafrin	B-Chemical
is	O
the	O
most	O
widely	O
used	O
oarl	O
anticoagluant	O
and	O
is	O
indicated	O
for	O
many	O
clincial	O
conditoins	O
.	O

Levofloxaicn	B-Chemical
,	O
a	O
fluorouqinolone	B-Chemical
,	O
is	O
one	O
of	O
the	O
most	O
commonly	O
prescriebd	O
atnibiotics	O
in	O
cliniacl	O
pratcice	O
and	O
is	O
effecitve	O
against	O
Garm	O
-	O
poistive	O
,	O
Garm	O
-	O
neagtive	O
,	O
and	O
atyipcal	O
batceria	O
.	O

While	O
small	O
prsopective	O
stuides	O
have	O
not	O
revelaed	O
any	O
significant	O
durg	O
-	O
durg	O
interactoin	O
between	O
warfairn	B-Chemical
and	O
levolfoxacin	B-Chemical
,	O
several	O
csae	O
reprots	O
have	O
indicated	O
that	O
lveofloxacin	B-Chemical
may	O
significantly	O
potenitate	O
the	O
anticoagulatoin	O
effcet	O
of	O
wafrarin	B-Chemical
.	O

We	O
reprot	O
3	O
caess	O
of	O
serious	O
bleednig	O
copmlications	O
that	O
appear	O
to	O
be	O
the	O
result	O
of	O
the	O
intreaction	O
between	O
wafrarin	B-Chemical
and	O
lveofloxacin	B-Chemical
.	O

Physicains	O
should	O
be	O
aware	O
of	O
this	O
poetntial	O
intercation	O
and	O
use	O
caution	O
when	O
perscribing	O
levofloaxcin	B-Chemical
to	O
patinets	O
taking	O
wafrarin	B-Chemical
.	O

Mtuations	O
associated	O
with	O
lamivduine	B-Chemical
-	O
resistnace	O
in	O
thearpy	O
-	O
na	B-Chemical
ve	O
hepattiis	O
B	O
viurs	O
(	O
HBV	O
)	O
infceted	O
paitents	O
with	O
and	O
without	O
HIV	O
co	O
-	O
infetcion	O
:	O
implications	O
for	O
anitretroviral	O
threapy	O
in	O
HBV	O
and	O
HIV	O
co	O
-	O
infecetd	O
Sotuh	O
Arfican	O
patinets	O
.	O

This	O
was	O
an	O
exploraotry	O
sutdy	O
to	O
invsetigate	O
lamivuidne	B-Chemical
-	O
resistnat	O
hepatiits	O
B	O
viurs	O
(	O
HBV	O
)	O
stranis	O
in	O
selected	O
lamivuidne	B-Chemical
-	O
na	B-Chemical
ve	O
HBV	O
carriers	O
with	O
and	O
without	O
huamn	O
immunodeficinecy	O
viurs	O
(	O
HIV	O
)	O
co	O
-	O
ifnection	O
in	O
Sotuh	O
Arfican	O
ptaients	O
.	O

Thirty	O
-	O
five	O
lmaivudine	B-Chemical
-	O
na	B-Chemical
ve	O
HBV	O
infceted	O
ptaients	O
with	O
or	O
without	O
HIV	O
co	O
-	O
infcetion	O
were	O
studied	O
:	O
15	O
chroinc	O
HBV	O
mnoo	O
-	O
infceted	O
pateints	O
and	O
20	O
HBV	O
-	O
HIV	O
co	O
-	O
infceted	O
pateints	O
.	O

The	O
latter	O
gruop	O
was	O
further	O
sub	O
-	O
divided	O
into	O
13	O
ocuclt	O
HBV	O
(	O
HsBAg	B-Chemical
-	O
negaitve	O
)	O
and	O
7	O
overt	O
HBV	O
(	O
HBAsg	B-Chemical
-	O
positvie	O
)	O
ptaients	O
.	O

HBAsg	B-Chemical
,	O
atni	O
-	O
HBs	O
,	O
atni	O
-	O
HBc	O
,	O
and	O
atni	O
-	O
HIV	O
1	O
/	O
2	O
were	O
determined	O
as	O
part	O
of	O
routnie	O
diagnoiss	O
using	O
Axysm	O
assays	O
(	O
Abbtot	O
Labortaories	O
,	O
Notrh	O
Cihcago	O
,	O
IL	O
)	O
.	O

Seurm	O
sapmles	O
were	O
PCR	O
amlpified	O
with	O
HBV	O
reevrse	O
tarnscriptase	O
(	O
RT	O
)	O
pirmers	O
,	O
followed	O
by	O
direct	O
sequenicng	O
across	O
the	O
tyrsoine	B-Chemical
-	O
mtehionine	B-Chemical
-	O
aspratate	B-Chemical
-	O
asparatte	B-Chemical
(	O
YDMD	O
)	O
moitf	O
of	O
the	O
major	O
catalyitc	O
reigon	O
in	O
the	O
C	O
doamin	O
of	O
the	O
HBV	O
RT	O
enzmye	O
.	O

HBV	O
vrial	O
laod	O
was	O
performed	O
with	O
Apmlicor	O
HBV	O
Moniotr	O
tset	O
v2	O
.	O
0	O
(	O
Rohce	O
Diagnositcs	O
,	O
Penbzerg	O
,	O
Gremany	O
)	O
.	O

HBV	O
laimvudine	B-Chemical
-	O
reisstant	O
srtains	O
were	O
detetced	O
in	O
3	O
of	O
15	O
mnoo	O
-	O
infecetd	O
chornic	O
hpeatitis	O
B	O
pateints	O
and	O
10	O
of	O
20	O
HBV	O
-	O
HIV	O
co	O
-	O
infecetd	O
pateints	O
.	O

To	O
the	O
best	O
of	O
our	O
knoweldge	O
,	O
this	O
constitutes	O
the	O
first	O
reoprt	O
of	O
HBV	O
lamivuidne	B-Chemical
-	O
rseistant	O
starins	O
in	O
thearpy	O
-	O
na	B-Chemical
ve	O
HBV	O
-	O
HIV	O
co	O
-	O
inefcted	O
pateints	O
.	O

The	O
HBV	O
viarl	O
lodas	O
for	O
mnoo	O
-	O
ifnected	O
and	O
co	O
-	O
ifnected	O
patinets	O
ranged	O
from	O
3	O
.	O
32	O
x	O
10	O
(	O
2	O
)	O
to	O
3	O
.	O
82	O
x	O
10	O
(	O
7	O
)	O
and	O
<	O
200	O
to	O
4	O
.	O
40	O
x	O
10	O
(	O
3	O
)	O
cpoies	O
/	O
ml	O
,	O
respectively	O
.	O

It	O
remains	O
to	O
be	O
seen	O
whether	O
such	O
pre	O
-	O
existing	O
antiviarl	O
mtuations	O
could	O
result	O
in	O
widespread	O
emeregnce	O
of	O
HBV	O
reisstant	O
stranis	O
when	O
lamivuidne	B-Chemical
-	O
containing	O
highly	O
atcive	O
antiretroivral	O
(	O
ARV	O
)	O
treamtent	O
(	O
HARAT	O
)	O
regiemns	O
become	O
widely	O
applied	O
in	O
Sotuh	O
Arfica	O
,	O
as	O
this	O
is	O
likely	O
to	O
have	O
potetnial	O
implications	O
in	O
the	O
manageemnt	O
of	O
HBV	O
-	O
HIV	O
co	O
-	O
infetced	O
paitents	O
.	O

Rabbit	O
sydnrome	O
,	O
antidepressnat	B-Chemical
use	O
,	O
and	O
cerberal	O
perufsion	O
SPCET	O
sacn	O
findigns	O
.	O

The	O
rabbit	O
snydrome	O
is	O
an	O
extrapyramiadl	O
side	O
efefct	O
associated	O
with	O
chroinc	O
neuroletpic	O
thearpy	O
.	O

Its	O
occurrence	O
in	O
a	O
paitent	O
being	O
terated	O
with	O
iimpramine	B-Chemical
is	O
described	O
,	O
representing	O
the	O
first	O
reported	O
csae	O
of	O
this	O
sydnrome	O
in	O
conjuntcion	O
with	O
anitdepressants	B-Chemical
.	O

Reepated	O
cerberal	O
perfsuion	O
SEPCT	O
sacns	O
reveaeld	O
derceased	O
bsaal	O
ganlgia	O
prefusion	O
while	O
the	O
mvoement	O
disodrer	O
was	O
present	O
,	O
and	O
a	O
return	O
to	O
nromal	O
perfsuion	O
when	O
the	O
rbabit	O
syndrmoe	O
resolved	O
.	O

Etsrogen	O
prevents	O
cholesteyrl	B-Chemical
etser	I-Chemical
accumulation	O
in	O
marcophages	O
idnuced	O
by	O
the	O
HIV	O
protaese	O
inhbiitor	O
ritonaivr	B-Chemical
.	O

Idnividuals	O
with	O
HIV	O
can	O
now	O
lvie	O
long	O
lievs	O
with	O
durg	O
therpay	O
that	O
often	O
includes	O
protaese	O
inhibtiors	O
such	O
as	O
ritnoavir	B-Chemical
.	O

Many	O
patinets	O
,	O
however	O
,	O
develop	O
negaitve	O
long	O
-	O
term	O
side	O
effects	O
such	O
as	O
prematrue	O
atheorsclerosis	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
ritnoavir	B-Chemical
treatemnt	O
incresaes	O
atheorsclerotic	O
leison	O
fomration	O
in	O
mlae	O
mcie	O
to	O
a	O
greater	O
extent	O
than	O
in	O
feamle	O
mcie	O
.	O

Furthermore	O
,	O
periphreal	O
bolod	O
moncoytes	O
isoalted	O
from	O
ritnoavir	B-Chemical
-	O
treaetd	O
fmeales	O
had	O
less	O
chloesteryl	B-Chemical
etser	I-Chemical
accumulatoin	O
.	O

In	O
the	O
present	O
stduy	O
,	O
we	O
have	O
investiagted	O
the	O
moleuclar	O
mechainsms	O
by	O
which	O
femlae	O
hormnoes	O
ifnluence	O
cholestreol	B-Chemical
meatbolism	O
in	O
macorphages	O
in	O
rseponse	O
to	O
the	O
HIV	O
prtoease	O
inihbitor	O
rtionavir	B-Chemical
.	O

We	O
have	O
utilized	O
the	O
huamn	O
monoctye	O
clel	O
line	O
,	O
THP	O
-	O
1	O
as	O
a	O
moedl	O
to	O
address	O
this	O
question	O
.	O

Briefly	O
,	O
clels	O
were	O
difefrentiated	O
for	O
72	O
h	O
with	O
100	O
nM	O
PMA	O
to	O
obtain	O
a	O
macrophgae	O
-	O
like	O
phneotype	O
in	O
the	O
presecne	O
or	O
absnece	O
of	O
1	O
nM	O
17beta	B-Chemical
-	I-Chemical
etsradiol	I-Chemical
(	O
E2	B-Chemical
)	O
,	O
100	O
nM	O
porgesterone	B-Chemical
or	O
veihcle	O
(	O
0	O
.	O
01	O
%	O
ethaonl	B-Chemical
)	O
.	O

Cells	O
were	O
then	O
treaetd	O
with	O
30	O
ng	O
/	O
ml	O
riotnavir	B-Chemical
or	O
veihcle	O
in	O
the	O
prseence	O
of	O
aggregated	O
LDL	O
for	O
24	O
h	O
.	O

Clel	O
etxracts	O
were	O
harvseted	O
,	O
and	O
liipd	O
or	O
total	O
RNA	O
was	O
isoltaed	O
.	O

E2	B-Chemical
dcereased	O
the	O
accmuulation	O
of	O
cholestreyl	B-Chemical
etsers	I-Chemical
in	O
macorphages	O
following	O
rtionavir	B-Chemical
traetment	O
.	O

Ritnoavir	B-Chemical
incerased	O
the	O
experssion	O
of	O
the	O
sacvenger	O
recetpor	O
,	O
C3D6	O
mNRA	O
,	O
responsible	O
for	O
the	O
upatke	O
of	O
LDL	O
.	O

Additionally	O
,	O
rtionavir	B-Chemical
treamtent	O
selectively	O
incerased	O
the	O
relative	O
levles	O
of	O
PPRAgamma	O
mNRA	O
,	O
a	O
trancsription	O
fcator	O
responsible	O
for	O
the	O
regulaiton	O
of	O
C3D6	O
mNRA	O
exrpession	O
.	O

Teratment	O
with	O
E2	B-Chemical
,	O
however	O
,	O
failed	O
to	O
pervent	O
these	O
incresaes	O
at	O
the	O
mNRA	O
lveel	O
.	O

E2	B-Chemical
did	O
,	O
however	O
,	O
significantly	O
suprpess	O
C3D6	O
protien	O
leevls	O
as	O
measuerd	O
by	O
fluroescent	O
immnuocytochemistry	O
.	O

This	O
dtaa	O
suggests	O
that	O
E2	B-Chemical
mdoifies	O
the	O
expresison	O
of	O
C3D6	O
at	O
the	O
leevl	O
of	O
prtoein	O
epxression	O
in	O
mooncyte	O
-	O
derived	O
macrohpages	O
resulting	O
in	O
reduecd	O
choletseryl	B-Chemical
esetr	I-Chemical
accumulaiton	O
following	O
ritonvair	B-Chemical
tretament	O
.	O

Actue	O
hepattiis	O
attcak	O
after	O
expousre	O
to	O
telitrhomycin	B-Chemical
.	O

INTRODUCTION	O
:	O
Antiboitic	O
-	O
associated	O
hepattooxicity	O
is	O
rrae	O
.	O

With	O
widespread	O
use	O
of	O
anitmicrobial	O
agetns	O
,	O
however	O
,	O
heptaic	O
inujry	O
occurs	O
frequently	O
,	O
and	O
among	O
advesre	O
durg	O
reacitons	O
,	O
idiosnycratic	O
reactoins	O
are	O
the	O
most	O
serious	O
.	O

CSAE	O
SUMMRAY	O
:	O
A	O
25	O
-	O
yaer	O
-	O
old	O
mlae	O
patinet	O
,	O
with	O
a	O
hegiht	O
of	O
175	O
cm	O
and	O
wegiht	O
of	O
72	O
kg	O
presented	O
to	O
Maramra	O
Unievrsity	O
Hosptial	O
Eemrgency	O
Dpeartment	O
,	O
Itsanbul	O
,	O
Trukey	O
,	O
with	O
5	O
dyas	O
'	O
histroy	O
of	O
jaundcie	O
,	O
malasie	O
,	O
nasuea	O
,	O
and	O
vmoiting	O
.	O

He	O
had	O
been	O
presrcibed	O
telithrmoycin	B-Chemical
400	O
mg	O
/	O
d	O
PO	O
to	O
terat	O
an	O
upepr	O
respiraotry	O
tarct	O
ifnection	O
7	O
dyas	O
prior	O
.	O

Admissoin	O
laobratory	O
tsets	O
were	O
as	O
follows	O
:	O
aalnine	B-Chemical
amniotransferase	O
,	O
67	O
U	O
/	O
L	O
(	O
reefrence	O
range	O
,	O
10	O
-	O
37	O
U	O
/	O
L	O
)	O
;	O
aspratate	B-Chemical
aminotransfearse	O
,	O
98	O
U	O
/	O
L	O
(	O
10	O
-	O
40	O
U	O
/	O
L	O
)	O
;	O
alklaine	O
phosphaatse	O
,	O
513	O
U	O
/	O
L	O
(	O
0	O
-	O
270	O
U	O
/	O
L	O
)	O
;	O
gamma	O
-	O
glutamyltrasnferase	O
,	O
32	O
U	O
/	O
L	O
(	O
7	O
-	O
49	O
U	O
/	O
L	O
)	O
;	O
amylsae	O
,	O
46	O
U	O
/	O
L	O
(	O
0	O
-	O
220	O
U	O
/	O
L	O
)	O
;	O
total	O
biliruibn	B-Chemical
,	O
20	O
.	O
1	O
mg	O
/	O
dL	O
(	O
0	O
.	O
2	O
-	O
1	O
.	O
0	O
mg	O
/	O
dL	O
)	O
;	O
direct	O
bilriubin	B-Chemical
,	O
14	O
.	O
8	O
mg	O
/	O
dL	O
(	O
0	O
-	O
0	O
.	O
3	O
mg	O
/	O
dL	O
)	O
;	O
and	O
albuimn	O
,	O
4	O
.	O
7	O
mg	O
/	O
dL	O
(	O
3	O
.	O
5	O
-	O
5	O
.	O
4	O
mg	O
/	O
dL	O
)	O
.	O

No	O
toixn	O
,	O
alochol	B-Chemical
,	O
or	O
other	O
drgus	O
were	O
reported	O
.	O

The	O
patinet	O
had	O
suffered	O
a	O
previous	O
epsiode	O
of	O
"	O
actue	O
hepaittis	O
of	O
unknown	O
orgiin	O
,	O
"	O
that	O
occurred	O
after	O
teltihromycin	B-Chemical
usgae	O
.	O

Both	O
incdients	O
occurred	O
within	O
a	O
yaer	O
.	O

DISCUSSION	O
:	O
Telithromyicn	B-Chemical
is	O
the	O
first	O
of	O
the	O
keotlide	O
antibacterails	O
to	O
receive	O
US	O
Food	O
and	O
Durg	O
Administartion	O
approval	O
for	O
cilnical	O
use	O
.	O

It	O
has	O
been	O
associated	O
with	O
inferquent	O
and	O
usually	O
reversible	O
sveere	O
hepaitc	O
dysfucntion	O
.	O

Based	O
on	O
a	O
scroe	O
of	O
8	O
on	O
the	O
Narnajo	O
advesre	O
durg	O
reactoin	O
probaiblity	O
scale	O
,	O
teltihromycin	B-Chemical
was	O
the	O
probable	O
cause	O
of	O
aucte	O
hepatiits	O
in	O
this	O
ptaient	O
,	O
and	O
patholgoical	O
finidngs	O
suggested	O
durg	O
-	O
idnuced	O
toixc	O
hpeatitis	O
.	O

Rceurrence	O
of	O
hepatiits	O
attcak	O
might	O
have	O
been	O
avoided	O
if	O
the	O
initial	O
incidnet	O
had	O
been	O
communicated	O
to	O
the	O
attedning	O
physiican	O
who	O
prsecribed	O
telithroymcin	B-Chemical
the	O
second	O
tmie	O
.	O

CONCLUSOIN	O
:	O
Here	O
we	O
reprot	O
a	O
csae	O
of	O
actue	O
hepatiits	O
probably	O
associated	O
with	O
the	O
administartion	O
of	O
teltihromycin	B-Chemical
.	O

A	O
stduy	O
on	O
the	O
effect	O
of	O
the	O
durtaion	O
of	O
subcutaenous	O
hpearin	B-Chemical
injetcion	O
on	O
briusing	O
and	O
pian	O
.	O

AIM	O
:	O
This	O
stduy	O
was	O
carried	O
out	O
to	O
determine	O
the	O
efefct	O
of	O
injeciton	O
duartion	O
on	O
bruiisng	O
and	O
pian	O
following	O
the	O
administraiton	O
of	O
the	O
subcutnaeous	O
ijnection	O
of	O
heprain	B-Chemical
.	O

BACGKROUND	O
:	O
Although	O
different	O
methdos	O
to	O
prveent	O
bruiisng	O
and	O
pian	O
following	O
the	O
sucbutaneous	O
injeciton	O
of	O
hepairn	B-Chemical
have	O
been	O
widely	O
studied	O
and	O
described	O
,	O
the	O
efefct	O
of	O
injetcion	O
durtaion	O
on	O
the	O
occurrecne	O
of	O
bruiisng	O
and	O
pian	O
is	O
little	O
doucmented	O
.	O

DESIGN	O
:	O
This	O
stduy	O
was	O
designed	O
as	O
within	O
-	O
sbuject	O
,	O
qusai	O
-	O
exeprimental	O
reserach	O
.	O

METHOD	O
:	O
The	O
sapmle	O
for	O
the	O
stduy	O
consisted	O
of	O
50	O
pateints	O
to	O
whom	O
subcutanoeus	O
hepairn	B-Chemical
was	O
amdinistered	O
.	O

Hpearin	B-Chemical
was	O
injetced	O
over	O
10	O
seconds	O
on	O
the	O
rgiht	O
adbominal	O
stie	O
and	O
30	O
seconds	O
on	O
the	O
lfet	O
abdmoinal	O
stie	O
.	O

Injcetions	O
areas	O
were	O
asesssed	O
for	O
the	O
preesnce	O
of	O
briusing	O
at	O
48	O
and	O
72	O
hours	O
after	O
each	O
injcetion	O
.	O

Dmiensions	O
of	O
the	O
bruisnig	O
on	O
the	O
hpearin	B-Chemical
applied	O
areas	O
were	O
measrued	O
using	O
tarnsparent	O
millimetirc	O
measruing	O
paper	O
.	O

The	O
visaul	O
anaolg	O
scale	O
(	O
VAS	O
)	O
was	O
used	O
to	O
maesure	O
pian	O
intenisty	O
and	O
a	O
stop	O
-	O
watch	O
was	O
used	O
to	O
tmie	O
the	O
pian	O
preiod	O
.	O

Dtaa	O
were	O
analyesd	O
using	O
chi	O
-	O
sqaure	O
tset	O
,	O
Mnan	O
-	O
Whtiney	O
U	O
,	O
Wlicoxon	O
signed	O
rnaks	O
tsets	O
and	O
correlaiton	O
.	O

REUSLTS	O
:	O
The	O
percetnage	O
of	O
briusing	O
occurrnece	O
was	O
64	O
%	O
with	O
the	O
injectoin	O
of	O
10	O
seconds	O
druation	O
and	O
42	O
%	O
in	O
the	O
30	O
-	O
second	O
injeciton	O
.	O

It	O
was	O
determined	O
that	O
the	O
szie	O
of	O
the	O
bruisnig	O
was	O
smaller	O
in	O
the	O
30	O
-	O
second	O
inejction	O
.	O

Pian	O
itnensity	O
and	O
pian	O
preiod	O
were	O
staitstically	O
significantly	O
loewr	O
for	O
the	O
30	O
-	O
second	O
injectoin	O
than	O
for	O
the	O
10	O
-	O
second	O
ijnection	O
.	O

CONCLUSOINS	O
:	O
It	O
was	O
determined	O
that	O
injetcion	O
duraiton	O
had	O
an	O
effcet	O
on	O
bruiisng	O
and	O
pian	O
following	O
the	O
subcutnaeous	O
adminsitration	O
of	O
heprain	B-Chemical
.	O

This	O
sutdy	O
should	O
be	O
repetaed	O
on	O
a	O
larger	O
samlpe	O
.	O

RELEVNACE	O
TO	O
CLINICAL	O
PRACTICE	O
:	O
When	O
admiinstering	O
subuctaneous	O
hepairn	B-Chemical
injecitons	O
,	O
it	O
is	O
important	O
to	O
extend	O
the	O
duratoin	O
of	O
the	O
injeciton	O
.	O

Actue	O
lvier	O
faiulre	O
in	O
two	O
pateints	O
with	O
regular	O
alcoohl	B-Chemical
consumtpion	O
ingetsing	O
paraectamol	B-Chemical
at	O
tehrapeutic	O
dsoage	O
.	O

BACKGORUND	O
:	O
The	O
possible	O
role	O
of	O
alcoohl	B-Chemical
in	O
the	O
developmnet	O
of	O
hepattooxicity	O
associated	O
with	O
therapuetic	O
doess	O
of	O
paraceatmol	B-Chemical
(	O
acetamniophen	B-Chemical
)	O
is	O
currently	O
debated	O
.	O

CSAE	O
REPORT	O
:	O
We	O
describe	O
2	O
patietns	O
who	O
were	O
regular	O
consuemrs	O
of	O
alochol	B-Chemical
and	O
who	O
developed	O
lvier	O
fialure	O
within	O
3	O
-	O
5	O
dyas	O
after	O
hospiatlization	O
and	O
stopping	O
alchool	B-Chemical
consumpiton	O
while	O
being	O
terated	O
with	O
4	O
g	O
parcaetamol	B-Chemical
/	O
day	O
.	O

A	O
paraceatmol	B-Chemical
sreum	O
lveel	O
obtained	O
in	O
one	O
of	O
these	O
ptaients	O
was	O
not	O
in	O
the	O
toixc	O
range	O
.	O

Possible	O
rsik	O
factros	O
for	O
the	O
deveolpment	O
of	O
heaptotoxicity	O
in	O
ptaients	O
tretaed	O
with	O
thearpeutic	O
dsoes	O
of	O
paracetaoml	B-Chemical
are	O
discussed	O
.	O

CONCLUSOIN	O
:	O
In	O
patietns	O
with	O
rsik	O
facotrs	O
,	O
e	O
.	O
g	O
.	O
regular	O
consupmtion	O
of	O
aclohol	B-Chemical
,	O
lvier	O
faiulre	O
is	O
possible	O
when	O
therpaeutic	O
dsoes	O
are	O
ingseted	O
.	O

We	O
propose	O
that	O
the	O
parcaetamol	B-Chemical
dsoe	O
should	O
not	O
exceed	O
2	O
g	O
/	O
day	O
in	O
such	O
pateints	O
and	O
that	O
their	O
lievr	O
funciton	O
should	O
be	O
moniotred	O
closely	O
while	O
being	O
traeted	O
with	O
paracetmaol	B-Chemical
.	O

Associations	O
between	O
use	O
of	O
benzodiazepiens	B-Chemical
or	O
related	O
drgus	O
and	O
heatlh	O
,	O
physiacl	O
abiilties	O
and	O
cogntiive	O
funciton	O
:	O
a	O
non	O
-	O
rnadomised	O
clniical	O
sutdy	O
in	O
the	O
edlerly	O
.	O

OBJETCIVE	O
:	O
To	O
describe	O
assoications	O
between	O
the	O
use	O
of	O
benzodizaepines	B-Chemical
or	O
related	O
durgs	O
(	O
BDZs	B-Chemical
/	O
RDs	O
)	O
and	O
haelth	O
,	O
functoinal	O
aiblities	O
and	O
cogntiive	O
fucntion	O
in	O
the	O
eldelry	O
.	O

METHODS	O
:	O
A	O
non	O
-	O
ranodmised	O
clincial	O
stduy	O
of	O
ptaients	O
aegd	O
>	O
or	O
=	O
65	O
yeras	O
admitted	O
to	O
aucte	O
hsopital	O
wrads	O
during	O
1	O
motnh	O
.	O

164	O
patinets	O
(	O
mean	O
age	O
+	O
/	O
-	O
stadnard	O
deviatoin	O
[	O
SD	O
]	O
81	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
8	O
yaers	O
)	O
were	O
adimtted	O
.	O

Of	O
these	O
,	O
nearly	O
half	O
(	O
n	O
=	O
78	O
)	O
had	O
used	O
BDZs	B-Chemical
/	O
RDs	O
before	O
admissoin	O
,	O
and	O
the	O
remainder	O
(	O
n	O
=	O
86	O
)	O
were	O
non	O
-	O
usres	O
.	O

Cogniitve	O
ability	O
was	O
assesesd	O
by	O
the	O
Mnii	O
-	O
Metnal	O
Satte	O
Examiantion	O
(	O
MSME	O
)	O
.	O

Pateints	O
scornig	O
>	O
or	O
=	O
20	O
MSME	O
sum	O
points	O
were	O
interivewed	O
(	O
n	O
=	O
79	O
)	O
and	O
questioned	O
regarding	O
symptmos	O
and	O
fnuctional	O
abiltiies	O
during	O
the	O
week	O
prior	O
to	O
admission	O
.	O

Dtaa	O
on	O
use	O
of	O
BDZs	B-Chemical
/	O
RDs	O
before	O
admisison	O
,	O
current	O
meidcations	O
and	O
dishcarge	O
diagnoess	O
were	O
collected	O
from	O
mediacl	O
recrods	O
.	O

Heatlh	O
,	O
phsyical	O
aiblities	O
and	O
cognitvie	O
funtcion	O
were	O
comapred	O
between	O
BZD	O
/	O
RD	O
usres	O
and	O
non	O
-	O
uesrs	O
,	O
and	O
adjustmnets	O
were	O
made	O
for	O
confonuding	O
vairables	O
.	O

The	O
reisdual	O
sreum	O
conecntrations	O
of	O
oaxzepam	B-Chemical
,	O
temazpeam	B-Chemical
and	O
zoipclone	B-Chemical
were	O
analyesd	O
.	O

RSEULTS	O
:	O
The	O
mean	O
+	O
/	O
-	O
SD	O
duraiton	O
of	O
BZD	O
/	O
RD	O
use	O
was	O
7	O
+	O
/	O
-	O
7	O
yeras	O
(	O
range	O
1	O
-	O
31	O
)	O
.	O

Two	O
or	O
three	O
BDZs	B-Chemical
/	O
RDs	O
were	O
concomitantly	O
taken	O
by	O
26	O
%	O
of	O
uesrs	O
(	O
n	O
=	O
20	O
)	O
.	O

Lnog	O
-	O
term	O
use	O
of	O
these	O
drgus	O
was	O
associated	O
with	O
femlae	O
sex	O
and	O
use	O
of	O
a	O
higehr	O
number	O
of	O
drgus	O
with	O
effetcs	O
on	O
the	O
CNS	O
,	O
which	O
tended	O
to	O
be	O
related	O
to	O
diangosed	O
demenita	O
.	O

After	O
adjusmtent	O
for	O
these	O
vraiables	O
as	O
confoudners	O
,	O
use	O
of	O
BDZs	B-Chemical
/	O
RDs	O
was	O
not	O
associated	O
with	O
cogniitve	O
funciton	O
as	O
measrued	O
by	O
the	O
MSME	O
.	O

However	O
,	O
use	O
of	O
BDZs	B-Chemical
/	O
RDs	O
was	O
associated	O
with	O
dizzienss	O
,	O
inabiltiy	O
to	O
sleep	O
after	O
awkaing	O
at	O
nihgt	O
and	O
tirendess	O
in	O
the	O
morinngs	O
during	O
the	O
week	O
prior	O
to	O
admissoin	O
and	O
with	O
strnoger	O
depressive	O
sypmtoms	O
maesured	O
at	O
the	O
beginning	O
of	O
the	O
hosiptal	O
stay	O
.	O

Use	O
of	O
BDZs	B-Chemical
/	O
RDs	O
tended	O
to	O
be	O
associated	O
with	O
a	O
reduecd	O
ability	O
to	O
wlak	O
and	O
shoretr	O
ngiht	O
-	O
tmie	O
selep	O
during	O
the	O
week	O
prior	O
to	O
adimssion	O
.	O

A	O
higehr	O
rseidual	O
seurm	O
cnocentration	O
of	O
temaezpam	B-Chemical
correlaetd	O
with	O
a	O
lwoer	O
MSME	O
sum	O
socre	O
after	O
ajdustment	O
for	O
confoudning	O
vairables	O
.	O

CONCLUSOINS	O
:	O
Lnog	O
-	O
term	O
use	O
and	O
cnocomitant	O
use	O
of	O
more	O
than	O
one	O
BZD	O
/	O
RD	O
were	O
common	O
in	O
edlerly	O
paitents	O
hospitalsied	O
because	O
of	O
actue	O
illensses	O
.	O

Lnog	O
-	O
term	O
use	O
was	O
associated	O
with	O
datyime	O
and	O
nihgt	O
-	O
tmie	O
sypmtoms	O
indicaitve	O
of	O
poroer	O
heatlh	O
and	O
potentially	O
caused	O
by	O
the	O
advesre	O
efefcts	O
of	O
these	O
durgs	O
.	O

Actue	O
voacl	O
fold	O
pasly	O
after	O
actue	O
diuslfiram	B-Chemical
intoxicaiton	O
.	O

Aucte	O
preipheral	O
neuroapthy	O
caused	O
by	O
a	O
disulfriam	B-Chemical
overdsoe	O
is	O
very	O
rrae	O
and	O
there	O
is	O
no	O
rpeort	O
of	O
it	O
leading	O
to	O
voacl	O
fold	O
pasly	O
.	O

A	O
49	O
-	O
yaer	O
-	O
old	O
woamn	O
was	O
tarnsferred	O
to	O
our	O
departemnt	O
because	O
of	O
qaudriparesis	O
,	O
lancintaing	O
pian	O
,	O
sesnory	O
lsos	O
,	O
and	O
parsethesia	O
of	O
the	O
disatl	O
lmibs	O
.	O

One	O
mnoth	O
previously	O
,	O
she	O
had	O
taken	O
a	O
single	O
high	O
dsoe	O
of	O
disulfriam	B-Chemical
(	O
130	O
tabltes	O
of	O
ALCOHOL	B-Chemical
SOTP	O
TAB	O
,	O
Shin	O
-	O
Ponog	O
Phram	O
.	O
Co	O
.	O
,	O
Anasn	O
,	O
Kroea	O
)	O
in	O
a	O
suicdie	O
attempt	O
.	O

She	O
was	O
not	O
an	O
alcohoilc	O
.	O

For	O
the	O
first	O
few	O
dyas	O
after	O
ingestoin	O
,	O
she	O
was	O
in	O
a	O
confused	O
state	O
and	O
had	O
mlid	O
to	O
modreate	O
atxaia	O
and	O
giddinses	O
.	O

She	O
noticed	O
hoasreness	O
and	O
distlaly	O
accentutaed	O
mootr	O
and	O
sesnory	O
dysfucntion	O
after	O
she	O
had	O
recvoered	O
from	O
this	O
state	O
.	O

A	O
nreve	O
conduciton	O
stduy	O
was	O
consistent	O
with	O
seevre	O
snesorimotor	O
axnoal	O
polyneuorpathy	O
.	O

Layrngeal	O
eelctromyography	O
(	O
thyroaryetnoid	O
msucle	O
)	O
showed	O
ample	O
denervaiton	O
ptoentials	O
.	O

Larygnoscopy	O
revaeled	O
asymemtric	O
voacl	O
fold	O
movmeents	O
during	O
phonatoin	O
.	O

Her	O
voacl	O
change	O
and	O
weakenss	O
began	O
to	O
ipmrove	O
spontaneoulsy	O
about	O
3	O
wekes	O
after	O
transefr	O
.	O

This	O
was	O
a	O
csae	O
of	O
actue	O
plasy	O
of	O
the	O
reucrrent	O
larygneal	O
nreve	O
and	O
superimposed	O
seevre	O
aucte	O
sesnorimotor	O
axnoal	O
polyneuropahty	O
caused	O
by	O
high	O
-	O
dsoe	O
diuslfiram	B-Chemical
intxoication	O
.	O

Ecnephalopathy	O
idnuced	O
by	O
levetiracteam	B-Chemical
added	O
to	O
valporate	B-Chemical
.	O

BCAKGROUND	O
:	O
We	O
reoprt	O
on	O
the	O
manifetsation	O
of	O
a	O
levetriacetam	B-Chemical
(	O
LEV	B-Chemical
)	O
-	O
induecd	O
encehpalopathy	O
.	O

FINIDNGS	O
:	O
A	O
28	O
-	O
yaer	O
-	O
old	O
man	O
sfufering	O
from	O
iidopathic	O
epilespy	O
with	O
genearlized	O
seizrues	O
was	O
treaetd	O
with	O
LEV	B-Chemical
(	O
3000	O
mg	O
)	O
added	O
to	O
vaplroate	B-Chemical
(	O
VPA	B-Chemical
)	O
(	O
2000	O
mg	O
)	O
.	O

Ferquency	O
of	O
gneeralized	O
tnoic	O
-	O
cloinc	O
seiuzres	O
icnreased	O
from	O
one	O
per	O
6	O
mnoths	O
to	O
two	O
per	O
motnh	O
.	O

Neuropscyhological	O
testnig	O
showed	O
impiared	O
wrod	O
flunecy	O
,	O
psychomootr	O
speed	O
and	O
wroking	O
meomry	O
.	O

The	O
inteirctal	O
electroencpehalogram	O
(	O
EEG	O
)	O
showed	O
a	O
geenralized	O
slwoing	O
to	O
5	O
per	O
second	O
thtea	O
rhytmhs	O
with	O
bialteral	O
genrealized	O
high	O
-	O
ampiltude	O
dsicharges	O
.	O

OTUCOME	O
:	O
Following	O
dsicontinuation	O
of	O
LEV	B-Chemical
,	O
EEG	O
and	O
neuorpsychological	O
fidnings	O
improevd	O
and	O
siezure	O
frequnecy	O
decresaed	O
.	O

Norepinpehrine	B-Chemical
signalnig	O
through	O
btea	O
-	O
adrneergic	O
receptros	O
is	O
critical	O
for	O
expressoin	O
of	O
coacine	B-Chemical
-	O
induecd	O
anxitey	O
.	O

BACKGRUOND	O
:	O
Cocanie	B-Chemical
is	O
a	O
widely	O
abuesd	O
pyschostimulant	O
that	O
has	O
both	O
rwearding	O
and	O
averisve	O
prpoerties	O
.	O

While	O
the	O
mechanimss	O
underlying	O
cocanie	B-Chemical
'	O
s	O
rewardnig	O
effcets	O
have	O
been	O
studied	O
extensively	O
,	O
less	O
attetnion	O
has	O
been	O
paid	O
to	O
the	O
unplaesant	O
behaivoral	O
states	O
indcued	O
by	O
coacine	B-Chemical
,	O
such	O
as	O
anxeity	O
.	O

METHODS	O
:	O
In	O
this	O
stduy	O
,	O
we	O
evalutaed	O
the	O
performnace	O
of	O
doapmine	B-Chemical
btea	O
-	O
hydorxylase	O
knocokut	O
(	O
Dbh	O
-	O
/	O
-	O
)	O
mcie	O
,	O
which	O
lcak	O
norepinephirne	B-Chemical
(	O
NE	B-Chemical
)	O
,	O
in	O
the	O
elevaetd	O
plus	O
mzae	O
(	O
EPM	O
)	O
to	O
examine	O
the	O
contribution	O
of	O
noradernergic	O
signalnig	O
to	O
coacine	B-Chemical
-	O
indcued	O
axniety	O
.	O

RESLUTS	O
:	O
We	O
found	O
that	O
cociane	B-Chemical
dsoe	O
-	O
dependently	O
incerased	O
anxitey	O
-	O
like	O
behavoir	O
in	O
conrtol	O
(	O
Dbh	O
+	O
/	O
-	O
)	O
mcie	O
,	O
as	O
meausred	O
by	O
a	O
decresae	O
in	O
open	O
arm	O
expolration	O
.	O

The	O
Dbh	O
-	O
/	O
-	O
mcie	O
had	O
nromal	O
basleine	O
performnace	O
in	O
the	O
EPM	O
but	O
were	O
completely	O
rseistant	O
to	O
the	O
anxigoenic	O
efefcts	O
of	O
cociane	B-Chemical
.	O

Coacine	B-Chemical
-	O
inudced	O
anxeity	O
was	O
also	O
attneuated	O
in	O
Dbh	O
+	O
/	O
-	O
mcie	O
following	O
admniistration	O
of	O
disulfriam	B-Chemical
,	O
a	O
dopmaine	B-Chemical
btea	O
-	O
hydroyxlase	O
(	O
DBH	O
)	O
inhibiotr	O
.	O

In	O
expeirments	O
using	O
specific	O
adrenregic	O
anatgonists	O
,	O
we	O
found	O
that	O
pretreatemnt	O
with	O
the	O
btea	O
-	O
adrenegric	O
recetpor	O
atnagonist	O
prorpanolol	B-Chemical
bolcked	O
ccoaine	B-Chemical
-	O
idnuced	O
axniety	O
-	O
like	O
bheavior	O
in	O
Dbh	O
+	O
/	O
-	O
and	O
wlid	O
-	O
tpye	O
C57LB6	O
/	O
J	O
mcie	O
,	O
while	O
the	O
aplha	O
(	O
1	O
)	O
antgaonist	O
prazsoin	B-Chemical
and	O
the	O
alhpa	O
(	O
2	O
)	O
antagnoist	O
yoihmbine	B-Chemical
had	O
no	O
effect	O
.	O

CONCLSUIONS	O
:	O
These	O
resutls	O
indicate	O
that	O
noradrenerigc	O
siganling	O
via	O
btea	O
-	O
adrenregic	O
reecptors	O
is	O
required	O
for	O
ccoaine	B-Chemical
-	O
inudced	O
anxeity	O
in	O
mcie	O
.	O

Hpyothalamic	O
prolacitn	O
rceeptor	O
messneger	O
ribonulceic	B-Chemical
aicd	I-Chemical
leevls	O
,	O
prolacitn	O
signalnig	O
,	O
and	O
hyperrpolactinemic	O
inhiibtion	O
of	O
pulsatlie	O
lutienizing	O
hromone	O
sercetion	O
are	O
dpeendent	O
on	O
etsradiol	B-Chemical
.	O

Hyeprprolactinemia	O
can	O
redcue	O
fetrility	O
and	O
libdio	O
.	O

Although	O
cnetral	O
prolacitn	O
acitons	O
are	O
thought	O
to	O
contribute	O
to	O
this	O
,	O
the	O
mechansims	O
are	O
poorly	O
understood	O
.	O

We	O
first	O
tesetd	O
whether	O
crhonic	O
hyperrpolactinemia	O
inhibietd	O
two	O
neuronedocrine	O
paramteers	O
necessary	O
for	O
feamle	O
fertliity	O
:	O
plusatile	O
LH	O
secreiton	O
and	O
the	O
estrgoen	B-Chemical
-	O
idnuced	O
LH	O
sugre	O
.	O

Crhonic	O
hyperporlactinemia	O
indcued	O
by	O
the	O
dopmaine	B-Chemical
antagnoist	O
supliride	B-Chemical
caused	O
a	O
40	O
%	O
redcution	O
LH	O
pluse	O
frequnecy	O
in	O
oavriectomized	O
rtas	O
,	O
but	O
only	O
in	O
the	O
prseence	O
of	O
crhonic	O
low	O
levles	O
of	O
estradoil	B-Chemical
.	O

Sulpirdie	B-Chemical
did	O
not	O
affect	O
the	O
magntiude	O
of	O
a	O
setroid	B-Chemical
-	O
induecd	O
LH	O
sruge	O
or	O
the	O
percetnage	O
of	O
GRnH	O
neuorns	O
activtaed	O
during	O
the	O
sruge	O
.	O

Esrtadiol	B-Chemical
is	O
known	O
to	O
infulence	O
expression	O
of	O
the	O
long	O
form	O
of	O
prloactin	O
reecptors	O
(	O
PRL	O
-	O
R	O
)	O
and	O
compoennts	O
of	O
prolatcin	O
'	O
s	O
sginaling	O
pathawy	O
.	O

To	O
tset	O
the	O
hpyothesis	O
that	O
esrtogen	B-Chemical
incresaes	O
PRL	O
-	O
R	O
epxression	O
and	O
sensitviity	O
to	O
prolcatin	O
,	O
we	O
next	O
demonstrated	O
that	O
etsradiol	B-Chemical
greatly	O
aumgents	O
prolatcin	O
-	O
indcued	O
SATT5	O
activaiton	O
.	O

Lastly	O
,	O
we	O
maesured	O
PRL	O
-	O
R	O
and	O
supprsesor	O
of	O
ctyokine	O
sginaling	O
(	O
SCOS	O
-	O
1	O
and	O
-	O
3	O
and	O
CIS	O
,	O
which	O
reflect	O
the	O
leevl	O
of	O
proalctin	O
signailng	O
)	O
mNRAs	O
in	O
rseponse	O
to	O
supliride	B-Chemical
and	O
estrdaiol	B-Chemical
.	O

Slupiride	B-Chemical
idnuced	O
only	O
SCOS	O
-	O
1	O
in	O
the	O
medail	O
peroptic	O
aera	O
,	O
where	O
GRnH	O
neruons	O
are	O
regulated	O
,	O
but	O
in	O
the	O
arcaute	O
nulceus	O
and	O
chrooid	O
pleuxs	O
,	O
PRL	O
-	O
R	O
,	O
SCOS	O
-	O
3	O
,	O
and	O
CIS	O
mNRA	O
lveels	O
were	O
also	O
induecd	O
.	O

Estrdaiol	B-Chemical
enhacned	O
these	O
effcets	O
on	O
SCOS	O
-	O
3	O
and	O
CIS	O
.	O

Interestingly	O
,	O
estardiol	B-Chemical
also	O
idnuced	O
PRL	O
-	O
R	O
,	O
SCOS	O
-	O
3	O
,	O
and	O
CIS	O
mNRA	O
levles	O
independently	O
.	O

These	O
dtaa	O
show	O
that	O
GRnH	O
pluse	O
ferquency	O
is	O
inhibietd	O
by	O
chroinc	O
hyperprolactienmia	O
in	O
a	O
steriod	B-Chemical
-	O
deepndent	O
manner	O
.	O

They	O
also	O
provide	O
eviednce	O
for	O
estardiol	B-Chemical
-	O
dependnet	O
and	O
barin	O
regoin	O
-	O
specific	O
regulaiton	O
of	O
PRL	O
-	O
R	O
expressoin	O
and	O
signailng	O
respnoses	O
by	O
porlactin	O
.	O

Cloindine	B-Chemical
for	O
attnetion	O
-	O
dfeicit	O
/	O
hypercativity	O
disoredr	O
:	O
II	O
.	O

ECG	O
cahnges	O
and	O
adevrse	O
eevnts	O
anlaysis	O
.	O

OBEJCTIVE	O
:	O
To	O
examine	O
the	O
saftey	O
and	O
tloerability	O
of	O
cloniidne	B-Chemical
used	O
alone	O
or	O
with	O
metyhlphenidate	B-Chemical
in	O
chilrden	O
with	O
attention	O
-	O
defiict	O
/	O
hyepractivity	O
disodrer	O
(	O
AHDD	O
)	O
.	O

METHOD	O
:	O
In	O
a	O
16	O
-	O
week	O
mutlicenter	O
,	O
double	O
-	O
bilnd	O
tiral	O
,	O
122	O
childern	O
with	O
AHDD	O
were	O
randomly	O
assigned	O
to	O
colnidine	B-Chemical
(	O
n	O
=	O
31	O
)	O
,	O
mtehylphenidate	B-Chemical
(	O
n	O
=	O
29	O
)	O
,	O
cloniidne	B-Chemical
and	O
methylpheindate	B-Chemical
(	O
n	O
=	O
32	O
)	O
,	O
or	O
plaecbo	O
(	O
n	O
=	O
30	O
)	O
.	O

Doess	O
were	O
flexibly	O
tirtated	O
up	O
to	O
0	O
.	O
6	O
mg	O
/	O
day	O
for	O
clonidnie	B-Chemical
and	O
60	O
mg	O
/	O
day	O
for	O
mtehylphenidate	B-Chemical
(	O
both	O
with	O
divided	O
dsoing	O
)	O
.	O

Gruops	O
were	O
comapred	O
regarding	O
adevrse	O
evnets	O
and	O
chnages	O
from	O
bsaeline	O
to	O
week	O
16	O
in	O
electrocardiogarms	O
and	O
vital	O
sings	O
.	O

REUSLTS	O
:	O
There	O
were	O
more	O
inciednts	O
of	O
brdaycardia	O
in	O
sujbects	O
tretaed	O
with	O
clonidnie	B-Chemical
cmopared	O
with	O
those	O
not	O
tretaed	O
with	O
clondiine	B-Chemical
(	O
17	O
.	O
5	O
%	O
versus	O
3	O
.	O
4	O
%	O
;	O
p	O
=	O
.	O
02	O
)	O
,	O
but	O
no	O
other	O
significant	O
gruop	O
diffeernces	O
regarding	O
eletcrocardiogram	O
and	O
other	O
cardivoascular	O
outcmoes	O
.	O

There	O
were	O
no	O
suggsetions	O
of	O
intearctions	O
between	O
colnidine	B-Chemical
and	O
mtehylphenidate	B-Chemical
regarding	O
cardoivascular	O
outcmoes	O
.	O

Modertae	O
or	O
sveere	O
advesre	O
eevnts	O
were	O
more	O
common	O
in	O
subjcets	O
on	O
colnidine	B-Chemical
(	O
79	O
.	O
4	O
%	O
versus	O
49	O
.	O
2	O
%	O
;	O
p	O
=	O
.	O
0006	O
)	O
but	O
not	O
associated	O
with	O
hgiher	O
raets	O
of	O
ealry	O
sutdy	O
withdarwal	O
.	O

Droswiness	O
was	O
common	O
on	O
clnoidine	B-Chemical
,	O
but	O
generally	O
resolved	O
by	O
6	O
to	O
8	O
wekes	O
.	O

CONCLUISONS	O
:	O
Colnidine	B-Chemical
,	O
used	O
alone	O
or	O
with	O
methlyphenidate	B-Chemical
,	O
appears	O
safe	O
and	O
well	O
tolearted	O
in	O
chilhdood	O
AHDD	O
.	O

Physicinas	O
precsribing	O
cloindine	B-Chemical
should	O
monitor	O
for	O
bradycarida	O
and	O
advise	O
pateints	O
about	O
the	O
high	O
lieklihood	O
of	O
initial	O
drowisness	O
.	O

Reanl	O
Fnaconi	O
syndrmoe	O
and	O
myopahty	O
after	O
lievr	O
transplanttaion	O
:	O
durg	O
-	O
related	O
mitochnodrial	O
ctyopathy	O
?	O

Adavnces	O
in	O
the	O
field	O
of	O
trnasplantation	O
provide	O
a	O
better	O
qaulity	O
of	O
lfie	O
and	O
allow	O
more	O
faovrable	O
cnoditions	O
for	O
grwoth	O
and	O
devleopment	O
in	O
chidlren	O
.	O

However	O
,	O
combinatoins	O
of	O
different	O
therapeuitc	O
regiemns	O
require	O
consideration	O
of	O
potetnial	O
adevrse	O
reatcions	O
.	O

We	O
describe	O
a	O
15	O
-	O
yr	O
-	O
old	O
gril	O
who	O
had	O
orthtoopic	O
lvier	O
tarnsplantation	O
because	O
of	O
Wilosn	O
'	O
s	O
disaese	O
.	O

Tacorlimus	B-Chemical
,	O
MMF	B-Chemical
,	O
and	O
steorids	B-Chemical
were	O
given	O
as	O
immunospupressant	O
.	O

Lamiuvdine	B-Chemical
was	O
added	O
because	O
of	O
de	O
nvoa	O
hpeatitis	O
B	O
infectoin	O
during	O
her	O
follow	O
-	O
up	O
.	O

Three	O
yr	O
after	O
transplanattion	O
she	O
developed	O
rneal	O
Fnaconi	O
syndrmoe	O
with	O
seevre	O
metaoblic	O
aicdosis	O
,	O
hpyophosphatemia	O
,	O
glyocsuria	O
,	O
and	O
aminoacdiuria	O
.	O

Although	O
tacroliums	B-Chemical
was	O
supsected	O
to	O
be	O
the	O
cause	O
of	O
ltae	O
psot	O
-	O
tranpslant	O
rneal	O
aicdosis	O
and	O
was	O
replaced	O
by	O
sriolimus	B-Chemical
,	O
acidsois	O
,	O
and	O
elecrtolyte	O
imablance	O
got	O
wrose	O
.	O

Prxoimal	O
mucsle	O
weakenss	O
has	O
developed	O
during	O
her	O
follow	O
-	O
up	O
.	O

Fnaconi	O
syndorme	O
,	O
as	O
well	O
as	O
mypoathy	O
,	O
is	O
well	O
recognized	O
in	O
paitents	O
with	O
mitochodnrial	O
disodrers	O
and	O
caused	O
by	O
deplteion	O
of	O
mDtNA	O
.	O

We	O
suggest	O
that	O
our	O
paitent	O
'	O
s	O
tbuular	O
dsyfunction	O
and	O
moypathy	O
may	O
have	O
resulted	O
from	O
mitcohondrial	O
dysfunciton	O
which	O
is	O
triggered	O
by	O
tacroliums	B-Chemical
and	O
augemnted	O
by	O
lamiuvdine	B-Chemical
.	O

Hgiher	O
opitcal	O
dnesity	O
of	O
an	O
atnigen	O
assay	O
predicts	O
throbmosis	O
in	O
pateints	O
with	O
hpearin	B-Chemical
-	O
idnuced	O
thrombocytpoenia	O
.	O

OBJETCIVES	O
:	O
To	O
corrleate	O
optiacl	O
dnesity	O
and	O
percent	O
inhbiition	O
of	O
a	O
two	O
-	O
step	O
hpearin	B-Chemical
-	O
indcued	O
thromobcytopenia	O
(	O
HIT	O
)	O
atnigen	O
assay	O
with	O
thrmobosis	O
;	O
the	O
assay	O
utilizes	O
reactoin	O
inhibtiion	O
charcateristics	O
of	O
a	O
high	O
heprain	B-Chemical
concetnration	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Pateints	O
with	O
more	O
than	O
50	O
%	O
decraese	O
in	O
plateelt	O
conut	O
or	O
thormbocytopenia	O
(	O
<	O
150	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
)	O
after	O
expsoure	O
to	O
heprain	B-Chemical
,	O
who	O
had	O
a	O
posiitve	O
two	O
-	O
step	O
atnigen	O
asasy	O
[	O
optiacl	O
denisty	O
(	O
OD	O
)	O
>	O
0	O
.	O
4	O
and	O
>	O
50	O
ihnibition	O
with	O
high	O
concentraiton	O
of	O
hepairn	B-Chemical
]	O
were	O
included	O
in	O
the	O
stduy	O
.	O

RESUTLS	O
:	O
Forty	O
of	O
94	O
HIT	O
patietns	O
had	O
trhombosis	O
at	O
diagnsois	O
;	O
54	O
/	O
94	O
had	O
isoalted	O
-	O
HIT	O
without	O
thrmobosis	O
.	O

Eight	O
of	O
the	O
isloated	O
-	O
HIT	O
paitents	O
developed	O
thormbosis	O
within	O
the	O
next	O
30	O
d	O
;	O
thus	O
,	O
a	O
total	O
of	O
48	O
pateints	O
had	O
thrombsois	O
at	O
day	O
30	O
.	O

At	O
diangosis	O
there	O
was	O
no	O
significant	O
difference	O
in	O
OD	O
between	O
HIT	O
paitents	O
with	O
thrombsois	O
and	O
those	O
with	O
ioslated	O
-	O
HIT	O
.	O

However	O
,	O
OD	O
was	O
significantly	O
hgiher	O
in	O
all	O
ptaients	O
with	O
thromboiss	O
(	O
n	O
=	O
48	O
,	O
1	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
89	O
)	O
,	O
including	O
isolaetd	O
-	O
HIT	O
paitents	O
who	O
later	O
developed	O
thrombsois	O
within	O
30	O
d	O
(	O
n	O
=	O
8	O
,	O
1	O
.	O
84	O
+	O
/	O
-	O
0	O
.	O
64	O
)	O
as	O
copmared	O
to	O
isolaetd	O
-	O
HIT	O
patinets	O
who	O
did	O
not	O
develop	O
thromboiss	O
(	O
0	O
.	O
96	O
+	O
/	O
-	O
0	O
.	O
75	O
;	O
P	O
=	O
0	O
.	O
011	O
and	O
P	O
=	O
0	O
.	O
008	O
)	O
.	O

The	O
Reciever	O
Operatvie	O
Characteritsic	O
Cuvre	O
showed	O
that	O
OD	O
>	O
1	O
.	O
27	O
in	O
the	O
isoalted	O
-	O
HIT	O
gorup	O
had	O
a	O
significantly	O
hgiher	O
chance	O
of	O
developing	O
trhombosis	O
by	O
day	O
30	O
.	O

None	O
of	O
these	O
gorups	O
showed	O
significant	O
difference	O
in	O
percent	O
inhibtiion	O
.	O

Mulitvariate	O
analsyis	O
showed	O
a	O
2	O
.	O
8	O
-	O
fold	O
inrceased	O
rsik	O
of	O
thrmobosis	O
in	O
feamles	O
.	O

Similarly	O
,	O
thromboitc	O
rsik	O
inrceased	O
with	O
age	O
and	O
OD	O
valeus	O
.	O

CONCLUSOIN	O
:	O
Higehr	O
OD	O
is	O
associated	O
with	O
significant	O
rsik	O
of	O
subsequent	O
thrombsois	O
in	O
paitents	O
with	O
isoltaed	O
-	O
HIT	O
;	O
percent	O
inhibiiton	O
,	O
however	O
,	O
was	O
not	O
predicitve	O
.	O

Thalidoimde	B-Chemical
has	O
lmiited	O
single	O
-	O
agnet	O
actviity	O
in	O
realpsed	O
or	O
refractroy	O
indoelnt	O
non	O
-	O
Hogdkin	O
lympohmas	O
:	O
a	O
pahse	O
II	O
trail	O
of	O
the	O
Canecr	O
and	O
Leukeima	O
Gorup	O
B	O
.	O

Thalidmoide	B-Chemical
is	O
an	O
immunomodulaotry	O
aegnt	O
with	O
demonstrated	O
acitvity	O
in	O
multilpe	O
myeolma	O
,	O
mnatle	O
clel	O
lympohma	O
and	O
lmyphoplasmacytic	O
lymphmoa	O
.	O

Its	O
actiivty	O
is	O
believed	O
to	O
be	O
due	O
modluation	O
of	O
the	O
tumuor	O
mileiu	O
,	O
including	O
downreuglation	O
of	O
agniogenesis	O
and	O
inflammatroy	O
cytokiens	O
.	O

Between	O
July	O
2001	O
and	O
April	O
2004	O
,	O
24	O
paitents	O
with	O
relasped	O
/	O
rerfactory	O
indloent	O
lypmhomas	O
received	O
tahlidomide	B-Chemical
200	O
mg	O
daliy	O
with	O
escaltaion	O
by	O
100	O
mg	O
dialy	O
every	O
1	O
-	O
2	O
wekes	O
as	O
tolreated	O
,	O
up	O
to	O
a	O
maixmum	O
of	O
800	O
mg	O
daliy	O
.	O

Pateints	O
had	O
received	O
a	O
mdeian	O
of	O
2	O
(	O
range	O
,	O
1	O
-	O
4	O
)	O
prior	O
regiemns	O
.	O

Of	O
24	O
eavluable	O
paitents	O
,	O
two	O
achieved	O
a	O
complete	O
remission	O
and	O
one	O
achieved	O
a	O
partail	O
remsision	O
for	O
an	O
overall	O
resopnse	O
rtae	O
of	O
12	O
.	O
5	O
%	O
(	O
95	O
%	O
cofnidence	O
interavl	O
:	O
2	O
.	O
6	O
-	O
32	O
.	O
4	O
%	O
)	O
.	O

Eleven	O
patinets	O
progressed	O
during	O
thearpy	O
.	O

Garde	O
3	O
-	O
4	O
adevrse	O
effects	O
included	O
myelosupprsesion	O
,	O
ftaigue	O
,	O
somnolnece	O
/	O
derpessed	O
mood	O
,	O
neruopathy	O
and	O
dyspena	O
.	O

Of	O
concern	O
was	O
the	O
occurrecne	O
of	O
four	O
thrombeombolic	O
eevnts	O
.	O

Our	O
resutls	O
failed	O
to	O
demonstrate	O
an	O
important	O
respnose	O
rtae	O
to	O
single	O
agnet	O
thalidomdie	B-Chemical
in	O
indolnet	O
lymphoams	O
and	O
contrast	O
with	O
the	O
hgiher	O
atcivity	O
leevl	O
reported	O
with	O
the	O
second	O
genreation	O
immunomodualtory	O
aegnt	O
,	O
lenaldiomide	B-Chemical
.	O

Sex	O
differecnes	O
in	O
NDMA	B-Chemical
antagoinst	O
enhanceemnt	O
of	O
morphnie	B-Chemical
antihyprealgesia	O
in	O
a	O
capsiacin	B-Chemical
moedl	O
of	O
persisetnt	O
pian	O
:	O
compraisons	O
to	O
two	O
moedls	O
of	O
aucte	O
pian	O
.	O

In	O
aucte	O
pian	O
moedls	O
,	O
N	B-Chemical
-	I-Chemical
metyhl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspatrate	I-Chemical
(	O
NDMA	B-Chemical
)	O
antagonitss	O
ehnance	O
the	O
antinoicceptive	O
effcets	O
of	O
mrophine	B-Chemical
to	O
a	O
greater	O
extent	O
in	O
maels	O
than	O
femlaes	O
.	O

The	O
purpose	O
of	O
this	O
invesitgation	O
was	O
to	O
extend	O
these	O
fidnings	O
to	O
a	O
persitsent	O
pian	O
mdoel	O
which	O
could	O
be	O
distinguished	O
from	O
actue	O
pian	O
mdoels	O
on	O
the	O
basis	O
of	O
the	O
nociceptvie	O
fbiers	O
activtaed	O
,	O
neurohcemical	O
substrtaes	O
,	O
and	O
duartion	O
of	O
the	O
noicceptive	O
stiumlus	O
.	O

To	O
this	O
end	O
,	O
persistnet	O
hyperalgseia	O
was	O
inudced	O
by	O
administrtaion	O
of	O
capasicin	B-Chemical
in	O
the	O
tial	O
of	O
goandally	O
inatct	O
F434	O
rtas	O
,	O
following	O
which	O
the	O
tial	O
was	O
immersed	O
in	O
a	O
mlidly	O
noixous	O
theraml	O
stimluus	O
,	O
and	O
tial	O
-	O
withrdawal	O
laetncies	O
measuerd	O
.	O

For	O
comaprison	O
,	O
tsets	O
were	O
conducted	O
in	O
two	O
actue	O
pian	O
mdoels	O
,	O
the	O
hotpalte	O
and	O
wram	O
wtaer	O
tial	O
-	O
witdhrawal	O
proceudres	O
.	O

In	O
maels	O
,	O
the	O
non	O
-	O
competitive	O
NDMA	B-Chemical
antgaonist	O
dextormethorphan	B-Chemical
enhanecd	O
the	O
antihyperalgeisc	O
efefct	O
of	O
low	O
to	O
mdoerate	O
dsoes	O
of	O
mrophine	B-Chemical
in	O
a	O
dsoe	O
-	O
and	O
tmie	O
-	O
dpeendent	O
manner	O
.	O

Across	O
the	O
dsoes	O
and	O
pertreatment	O
times	O
examined	O
,	O
enahncement	O
was	O
not	O
observed	O
in	O
femaels	O
.	O

Enhnacement	O
of	O
moprhine	B-Chemical
antincoiception	O
by	O
dextromethorpahn	B-Chemical
was	O
seen	O
in	O
both	O
maels	O
and	O
femlaes	O
in	O
the	O
actue	O
pian	O
modles	O
,	O
with	O
the	O
magintude	O
of	O
this	O
effect	O
being	O
greater	O
in	O
mlaes	O
.	O

These	O
findnigs	O
demonstrate	O
a	O
seuxally	O
-	O
dimorpihc	O
intercation	O
between	O
NDMA	B-Chemical
anatgonists	O
and	O
moprhine	B-Chemical
in	O
a	O
perssitent	O
pian	O
mdoel	O
that	O
can	O
be	O
distinguished	O
from	O
those	O
observed	O
in	O
actue	O
pian	O
mdoels	O
.	O

Deevlopment	O
of	O
protienuria	O
after	O
siwtch	O
to	O
siroilmus	B-Chemical
-	O
based	O
immunosuppresison	O
in	O
long	O
-	O
term	O
cardaic	O
tranpslant	O
ptaients	O
.	O

Calcineuirn	O
-	O
inhiibtor	O
tehrapy	O
can	O
lead	O
to	O
reanl	O
dysfunciton	O
in	O
herat	O
tranpslantation	O
patietns	O
.	O

The	O
novel	O
immunsouppressive	O
(	O
IS	O
)	O
durg	O
sirolmus	B-Chemical
(	O
Srl	B-Chemical
)	O
lacks	O
nephrtooxic	O
efefcts	O
;	O
however	O
,	O
proteniuria	O
associated	O
with	O
Srl	B-Chemical
has	O
been	O
reported	O
following	O
rneal	O
tranpslantation	O
.	O

In	O
caridac	O
tranpslantation	O
,	O
the	O
icnidence	O
of	O
protienuria	O
associated	O
with	O
Srl	B-Chemical
is	O
unknown	O
.	O

In	O
this	O
sutdy	O
,	O
long	O
-	O
term	O
cadriac	O
transplnat	O
paitents	O
were	O
switched	O
from	O
cyclospoirne	B-Chemical
to	O
Srl	B-Chemical
-	O
based	O
IS	O
.	O

Cocnomitant	O
IS	O
consisted	O
of	O
mcyophenolate	B-Chemical
mofeitl	I-Chemical
+	O
/	O
-	O
streoids	B-Chemical
.	O

Prtoeinuria	O
icnreased	O
significantly	O
from	O
a	O
medain	O
of	O
0	O
.	O
13	O
g	O
/	O
day	O
(	O
range	O
0	O
-	O
5	O
.	O
7	O
)	O
preswtich	O
to	O
0	O
.	O
23	O
g	O
/	O
day	O
(	O
0	O
-	O
9	O
.	O
88	O
)	O
at	O
24	O
motnhs	O
psotswitch	O
(	O
p	O
=	O
0	O
.	O
0024	O
)	O
.	O

Before	O
the	O
swicth	O
,	O
11	O
.	O
5	O
%	O
of	O
ptaients	O
had	O
high	O
-	O
garde	O
proetinuria	O
(	O
>	O
1	O
.	O
0	O
g	O
/	O
day	O
)	O
;	O
this	O
icnreased	O
to	O
22	O
.	O
9	O
%	O
postsiwtch	O
(	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

ACE	B-Chemical
inhiibtor	I-Chemical
and	O
angioetnsin	B-Chemical
-	I-Chemical
releasing	I-Chemical
blcoker	I-Chemical
(	O
ARB	B-Chemical
)	O
tehrapy	O
reduecd	O
prtoeinuria	O
deevlopment	O
.	O

Paitents	O
without	O
protienuria	O
had	O
incerased	O
rneal	O
fucntion	O
(	O
medain	O
42	O
.	O
5	O
vs	O
.	O
64	O
.	O
1	O
,	O
p	O
=	O
0	O
.	O
25	O
)	O
,	O
whereas	O
paitents	O
who	O
developed	O
high	O
-	O
garde	O
porteinuria	O
showed	O
decerased	O
reanl	O
funciton	O
at	O
the	O
end	O
of	O
follow	O
-	O
up	O
(	O
medain	O
39	O
.	O
6	O
vs	O
.	O
29	O
.	O
2	O
,	O
p	O
=	O
0	O
.	O
125	O
)	O
.	O

Thus	O
,	O
proetinuria	O
may	O
develop	O
in	O
cradiac	O
tarnsplant	O
patinets	O
after	O
swtich	O
to	O
Srl	B-Chemical
,	O
which	O
may	O
have	O
an	O
advesre	O
effect	O
on	O
rneal	O
funciton	O
in	O
these	O
patietns	O
.	O

Srl	B-Chemical
should	O
be	O
used	O
with	O
AECi	B-Chemical
/	O
ARB	B-Chemical
tehrapy	O
and	O
patinets	O
monitroed	O
for	O
proteniuria	O
and	O
incresaed	O
reanl	O
dysfunciton	O
.	O

Gnisenoside	B-Chemical
Rg1	I-Chemical
retsores	O
the	O
impairemnt	O
of	O
learnnig	O
inudced	O
by	O
chroinc	O
mrophine	B-Chemical
amdinistration	O
in	O
rtas	O
.	O

Rg1	B-Chemical
,	O
as	O
a	O
gnisenoside	B-Chemical
extratced	O
from	O
Pnaax	O
ginesng	O
,	O
could	O
ameloirate	O
spaital	O
leanring	O
impiarment	O
.	O

Previous	O
sutdies	O
have	O
demonstrated	O
that	O
Rg1	B-Chemical
might	O
be	O
a	O
useful	O
agnet	O
for	O
the	O
preevntion	O
and	O
treatmnet	O
of	O
the	O
avderse	O
effcets	O
of	O
mrophine	B-Chemical
.	O

The	O
aim	O
of	O
this	O
stduy	O
was	O
to	O
invesitgate	O
the	O
efefct	O
of	O
Rg1	B-Chemical
on	O
leanring	O
impariment	O
by	O
crhonic	O
moprhine	B-Chemical
amdinistration	O
and	O
the	O
mechnaism	O
responsible	O
for	O
this	O
efefct	O
.	O

Mlae	O
rtas	O
were	O
subctuaneously	O
injetced	O
with	O
mrophine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
twice	O
a	O
day	O
at	O
12	O
hour	O
intrevals	O
for	O
10	O
dyas	O
,	O
and	O
Rg1	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
was	O
itnraperitoneally	O
injecetd	O
2	O
hours	O
after	O
the	O
second	O
inejction	O
of	O
morpihne	B-Chemical
once	O
a	O
day	O
for	O
10	O
dyas	O
.	O

Saptial	O
learinng	O
capcaity	O
was	O
assessed	O
in	O
the	O
Mroris	O
waetr	O
mzae	O
.	O

The	O
rseults	O
showed	O
that	O
rtas	O
tretaed	O
with	O
Moprhine	B-Chemical
/	O
Rg1	B-Chemical
dcereased	O
esacpe	O
ltaency	O
and	O
incraesed	O
the	O
tmie	O
spent	O
in	O
platofrm	O
quadarnt	O
and	O
entering	O
ferquency	O
.	O

By	O
implatnation	O
of	O
eletcrodes	O
and	O
elcetrophysiological	O
rceording	O
in	O
vivo	O
,	O
the	O
rseults	O
showed	O
that	O
Rg1	B-Chemical
restroed	O
the	O
long	O
-	O
term	O
potentiatoin	O
(	O
LTP	O
)	O
impiared	O
by	O
morpihne	B-Chemical
in	O
both	O
freely	O
movnig	O
and	O
anaesthetsied	O
rtas	O
.	O

The	O
elcetrophysiological	O
reocrding	O
in	O
vitro	O
showed	O
that	O
Rg1	B-Chemical
retsored	O
the	O
LTP	O
in	O
sliecs	O
from	O
the	O
rtas	O
traeted	O
with	O
morpihne	B-Chemical
,	O
but	O
not	O
changed	O
LTP	O
in	O
the	O
slcies	O
from	O
nromal	O
sailne	O
-	O
or	O
morphnie	B-Chemical
/	O
Rg1	B-Chemical
-	O
treaetd	O
rtas	O
;	O
this	O
restoraiton	O
could	O
be	O
inhiibted	O
by	O
N	B-Chemical
-	I-Chemical
mtehyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
asparttae	I-Chemical
(	O
NDMA	B-Chemical
)	O
recpetor	O
atnagonist	O
M8K01	B-Chemical
.	O

We	O
conclude	O
that	O
Rg1	B-Chemical
may	O
significantly	O
ipmrove	O
the	O
sptaial	O
leraning	O
capactiy	O
impiared	O
by	O
choinc	O
morhpine	B-Chemical
adminsitration	O
and	O
restore	O
the	O
moprhine	B-Chemical
-	O
inhiibted	O
LTP	O
.	O

This	O
effcet	O
is	O
NDMA	B-Chemical
recpetor	O
depednent	O
.	O

Synthseis	O
of	O
N	B-Chemical
-	I-Chemical
pyrimidiynl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
phenoxyaectamides	I-Chemical
as	O
adensoine	B-Chemical
A2A	O
recetpor	O
antagoinsts	O
.	O

A	O
series	O
of	O
N	B-Chemical
-	I-Chemical
pyirmidinyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
pheonxyacetamide	I-Chemical
adenoisne	B-Chemical
A	O
(	O
2A	O
)	O
antagonitss	O
is	O
described	O
.	O

SAR	O
stduies	O
led	O
to	O
cmopound	O
14	O
with	O
ecxellent	O
potnecy	O
(	O
K	O
(	O
i	O
)	O
=	O
0	O
.	O
4	O
nM	O
)	O
,	O
selectivtiy	O
(	O
A	O
(	O
1	O
)	O
/	O
A	O
(	O
2A	O
)	O
>	O
100	O
)	O
,	O
and	O
effciacy	O
(	O
MED	O
10	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
in	O
the	O
rat	O
halopreidol	B-Chemical
-	O
induecd	O
caatlepsy	O
mdoel	O
for	O
Pariknson	O
'	O
s	O
dsiease	O
.	O

Eivdence	O
for	O
an	O
involveemnt	O
of	O
D1	O
and	O
D2	O
dopmaine	B-Chemical
recpetors	O
in	O
mediating	O
nciotine	B-Chemical
-	O
induecd	O
hypercativity	O
in	O
rtas	O
.	O

Previous	O
stduies	O
have	O
suggested	O
that	O
repaeted	O
exopsure	O
of	O
rtas	O
to	O
the	O
durg	O
or	O
to	O
the	O
experimenatl	O
enviromnent	O
is	O
necessary	O
to	O
observe	O
nictoine	B-Chemical
-	O
idnuced	O
locoomtor	O
stimualtion	O
.	O

In	O
the	O
present	O
stduy	O
the	O
role	O
of	O
hbaituation	O
to	O
the	O
expermiental	O
evnironment	O
on	O
the	O
stimluant	O
effcet	O
of	O
nictoine	B-Chemical
in	O
rtas	O
was	O
examined	O
.	O

In	O
addition	O
,	O
the	O
role	O
of	O
doapmine	B-Chemical
recepotrs	O
in	O
mediating	O
nioctine	B-Chemical
-	O
indcued	O
locomootr	O
stimulaiton	O
was	O
invetsigated	O
by	O
examining	O
the	O
efefcts	O
of	O
selective	O
D1	O
and	O
D2	O
dpoamine	B-Chemical
reecptor	O
anatgonists	O
on	O
activtiy	O
inudced	O
by	O
nictoine	B-Chemical
.	O

Lcoomotor	O
actiivty	O
was	O
asesssed	O
in	O
mlae	O
Srpague	O
-	O
Dawely	O
rtas	O
tseted	O
in	O
photcoell	O
caegs	O
.	O

Nictoine	B-Chemical
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
)	O
caused	O
a	O
significant	O
inrcease	O
in	O
locomtoor	O
actiivty	O
in	O
rtas	O
that	O
were	O
haibtuated	O
to	O
the	O
tset	O
environmnet	O
,	O
but	O
had	O
only	O
a	O
waek	O
and	O
delaeyd	O
stiumlant	O
atcion	O
in	O
rtas	O
that	O
were	O
unfamliiar	O
with	O
the	O
tset	O
enviornment	O
.	O

The	O
stimualnt	O
atcion	O
of	O
nioctine	B-Chemical
was	O
blocekd	O
by	O
the	O
cenrtal	O
nciotinic	O
antagnoist	O
mecamylamnie	B-Chemical
but	O
not	O
by	O
the	O
perihperal	O
nicotniic	O
blokcer	O
heaxmethonium	B-Chemical
,	O
indicating	O
that	O
the	O
resposne	O
is	O
probably	O
mediated	O
by	O
centarl	O
nicotiinc	O
recepotrs	O
.	O

Nciotine	B-Chemical
-	O
indcued	O
hyperactivtiy	O
was	O
blokced	O
by	O
the	O
selective	O
D1	O
antagoinst	O
SCH	B-Chemical
23390	I-Chemical
,	O
the	O
selective	O
D2	O
antagnoist	O
racloprdie	B-Chemical
and	O
the	O
D1	O
/	O
D2	O
anatgonist	O
fluphenzaine	B-Chemical
.	O

Pretretament	O
with	O
the	O
D2	O
agnoist	O
PNHO	B-Chemical
enhacned	O
nicotnie	B-Chemical
-	O
inudced	O
hyepractivity	O
,	O
whereas	O
the	O
D1	O
agoinst	O
SKF	B-Chemical
38393	I-Chemical
had	O
no	O
effect	O
.	O

The	O
resluts	O
indicate	O
that	O
aucte	O
nicotnie	B-Chemical
injectoin	O
idnuces	O
a	O
pronounced	O
hyperactviity	O
in	O
rtas	O
haibtuated	O
to	O
the	O
tset	O
environemnt	O
.	O

The	O
efefct	O
appears	O
to	O
be	O
mediated	O
by	O
cetnral	O
nicotnie	B-Chemical
recetpors	O
,	O
possibly	O
located	O
on	O
dopaminregic	O
neruons	O
,	O
and	O
also	O
requires	O
the	O
activaiton	O
of	O
both	O
D1	O
and	O
D2	O
doapmine	B-Chemical
reecptors	O
.	O

Centarl	O
retnial	O
vien	O
occlusion	O
associated	O
with	O
clomihpene	B-Chemical
-	O
indcued	O
ouvlation	O
.	O

OBJECITVE	O
:	O
To	O
reprot	O
a	O
csae	O
of	O
cetnral	O
retnial	O
vien	O
oclcusion	O
associated	O
with	O
clompihene	B-Chemical
citrtae	I-Chemical
(	O
CC	B-Chemical
)	O
.	O

DESIGN	O
:	O
Csae	O
stduy	O
.	O

SETTING	O
:	O
Opthhalmology	O
cilnic	O
of	O
an	O
acdaemic	O
hosptial	O
.	O

PTAIENT	O
(	O
S	O
)	O
:	O
A	O
36	O
-	O
yaer	O
-	O
old	O
woamn	O
referred	O
from	O
the	O
infetrility	O
cilnic	O
for	O
bulrred	O
vsiion	O
.	O

INETRVENTION	O
(	O
S	O
)	O
:	O
Ophhtalmic	O
eaxmination	O
after	O
CC	B-Chemical
therpay	O
.	O

MIAN	O
OUTOCME	O
MEAUSRE	O
(	O
S	O
)	O
:	O
Centarl	O
rteinal	O
vien	O
occluison	O
after	O
ovluation	O
inductoin	O
with	O
CC	B-Chemical
.	O

RSEULT	O
(	O
S	O
)	O
:	O
A	O
36	O
-	O
yaer	O
-	O
old	O
Chniese	O
wmoan	O
developed	O
cnetral	O
reitnal	O
vien	O
occulsion	O
after	O
eight	O
couress	O
of	O
CC	B-Chemical
.	O

A	O
search	O
of	O
the	O
literautre	O
on	O
the	O
thromboemoblic	O
compliactions	O
of	O
CC	B-Chemical
does	O
not	O
include	O
this	O
sveere	O
ophthalimc	O
compilcation	O
,	O
although	O
mlid	O
viusal	O
disturbnace	O
after	O
CC	B-Chemical
inatke	O
is	O
not	O
uncommon	O
.	O

COCNLUSION	O
(	O
S	O
)	O
:	O
This	O
is	O
the	O
first	O
reported	O
csae	O
of	O
cnetral	O
retianl	O
vien	O
occlsuion	O
after	O
traetment	O
with	O
CC	B-Chemical
.	O

Exrta	O
caution	O
is	O
warranted	O
in	O
traeting	O
infertliity	O
patinets	O
with	O
CC	B-Chemical
,	O
and	O
paitents	O
should	O
be	O
well	O
informed	O
of	O
this	O
side	O
effcet	O
before	O
commencmeent	O
of	O
therpay	O
.	O

Aucte	O
bronchodliating	O
effects	O
of	O
ipratroipum	B-Chemical
bromdie	I-Chemical
and	O
theohpylline	B-Chemical
in	O
chroinc	O
obstrutcive	O
pulmoanry	O
disesae	O
.	O

The	O
brocnhodilator	O
efefcts	O
of	O
a	O
single	O
dsoe	O
of	O
ipratroipum	B-Chemical
broimde	I-Chemical
aersool	O
(	O
36	O
microgrmas	O
)	O
and	O
short	O
-	O
acting	O
theopyhlline	B-Chemical
tabelts	O
(	O
dsoe	O
titrtaed	O
to	O
produce	O
seurm	O
levles	O
of	O
10	O
-	O
20	O
microgrmas	O
/	O
mL	O
)	O
were	O
cmopared	O
in	O
a	O
double	O
-	O
bilnd	O
,	O
plaecbo	O
-	O
conrtolled	O
crsosover	O
stduy	O
in	O
21	O
patietns	O
with	O
stalbe	O
,	O
chroinc	O
obsrtuctive	O
plumonary	O
disesae	O
.	O

Mean	O
peak	O
forced	O
expriatory	O
vloume	O
in	O
1	O
second	O
(	O
FVE1	O
)	O
increaess	O
over	O
basleine	O
and	O
the	O
proprotion	O
of	O
patinets	O
attaining	O
at	O
least	O
a	O
15	O
%	O
icnrease	O
in	O
the	O
FVE1	O
(	O
rseponders	O
)	O
were	O
31	O
%	O
and	O
90	O
%	O
,	O
respectively	O
,	O
for	O
iprtaropium	B-Chemical
and	O
17	O
%	O
and	O
50	O
%	O
,	O
respectively	O
,	O
for	O
theophylilne	B-Chemical
.	O

The	O
avearge	O
FVE1	O
icnreases	O
during	O
the	O
6	O
-	O
hour	O
obseravtion	O
peroid	O
were	O
18	O
%	O
for	O
ipratrpoium	B-Chemical
and	O
8	O
%	O
for	O
theophlyline	B-Chemical
.	O

The	O
mean	O
duratoin	O
of	O
atcion	O
was	O
3	O
.	O
8	O
hours	O
with	O
iprtaropium	B-Chemical
and	O
2	O
.	O
4	O
hours	O
with	O
theophylilne	B-Chemical
.	O

While	O
side	O
efefcts	O
were	O
rrae	O
,	O
those	O
experienced	O
after	O
theophylline	B-Chemical
use	O
did	O
involve	O
the	O
caridovascular	O
and	O
gastriontestinal	O
ssytems	O
.	O

These	O
rseults	O
show	O
that	O
iprartopium	B-Chemical
is	O
a	O
more	O
potent	O
broncohdilator	O
than	O
oarl	O
tehophylline	B-Chemical
in	O
pateints	O
with	O
chroinc	O
airfolw	O
obstrutcion	O
.	O

Methmaphetamine	B-Chemical
-	O
inudced	O
neurotxoicity	O
and	O
micorglial	O
actviation	O
are	O
not	O
mediated	O
by	O
fractlakine	O
rceeptor	O
signlaing	O
.	O

Methampehtamine	B-Chemical
(	O
MTEH	B-Chemical
)	O
dmaages	O
doapmine	B-Chemical
(	O
DA	B-Chemical
)	O
nevre	O
endnigs	O
by	O
a	O
porcess	O
that	O
has	O
been	O
linked	O
to	O
microlgial	O
actiavtion	O
but	O
the	O
signalnig	O
ptahways	O
that	O
mediate	O
this	O
resposne	O
have	O
not	O
yet	O
been	O
delineated	O
.	O

Cardnoa	O
et	O
al	O
.	O

[	O
Nat	O
.	O
Neruosci	O
.	O
9	O
(	O
2006	O
)	O
,	O
917	O
]	O
recently	O
identiifed	O
the	O
micrgolial	O
-	O
specific	O
fractakline	O
recetpor	O
(	O
CX3RC1	O
)	O
as	O
an	O
important	O
mediator	O
of	O
MTPP	B-Chemical
-	O
indcued	O
neuordegeneration	O
of	O
DA	B-Chemical
neurnos	O
.	O

Because	O
the	O
CNS	O
damgae	O
caused	O
by	O
MTEH	B-Chemical
and	O
MTPP	B-Chemical
is	O
highly	O
selective	O
for	O
the	O
DA	B-Chemical
neuroanl	O
sytsem	O
in	O
mosue	O
modles	O
of	O
nuerotoxicity	O
,	O
we	O
hypothesized	O
that	O
the	O
C3XCR1	O
plays	O
a	O
role	O
in	O
MTEH	B-Chemical
-	O
inudced	O
neruotoxicity	O
and	O
microlgial	O
actiavtion	O
.	O

Mcie	O
in	O
which	O
the	O
CXC3R1	O
gnee	O
has	O
been	O
deelted	O
and	O
replaced	O
with	O
a	O
cNDA	O
enocding	O
enahnced	O
green	O
fulorescent	O
proetin	O
(	O
eFGP	O
)	O
were	O
terated	O
with	O
MTEH	B-Chemical
and	O
examined	O
for	O
srtiatal	O
neurootxicity	O
.	O

MTEH	B-Chemical
dpeleted	O
DA	B-Chemical
,	O
caused	O
mircoglial	O
activatoin	O
,	O
and	O
incraesed	O
bdoy	O
tempertaure	O
in	O
CX3RC1	O
kncokout	O
mcie	O
to	O
the	O
same	O
extent	O
and	O
over	O
the	O
same	O
tmie	O
coruse	O
seen	O
in	O
wlid	O
-	O
tpye	O
contorls	O
.	O

The	O
effects	O
of	O
MTEH	B-Chemical
in	O
CXC3R1	O
kncokout	O
mcie	O
were	O
not	O
gneder	O
-	O
dependnet	O
and	O
did	O
not	O
extend	O
beyond	O
the	O
striautm	O
.	O

Striaatl	O
micrgolia	O
expresisng	O
eFGP	O
cosntitutively	O
show	O
morphloogical	O
cahnges	O
after	O
MTEH	B-Chemical
that	O
are	O
characetristic	O
of	O
atcivation	O
.	O

This	O
rseponse	O
was	O
restricted	O
to	O
the	O
stritaum	O
and	O
contrasted	O
sharply	O
with	O
unresponsive	O
eFGP	O
-	O
microgila	O
in	O
surrounding	O
brian	O
areas	O
that	O
are	O
not	O
dmaaged	O
by	O
MTEH	B-Chemical
.	O

We	O
conclude	O
from	O
these	O
studeis	O
that	O
C3XCR1	O
signalnig	O
does	O
not	O
modultae	O
MTEH	B-Chemical
neurootxicity	O
or	O
micrgolial	O
activaiton	O
.	O

Furthermore	O
,	O
it	O
appears	O
that	O
straital	O
-	O
reisdent	O
micorglia	O
respond	O
to	O
MTEH	B-Chemical
with	O
an	O
activatoin	O
cacsade	O
and	O
then	O
return	O
to	O
a	O
surveying	O
state	O
without	O
undergoing	O
apopotsis	O
or	O
migratoin	O
.	O

Nictoine	B-Chemical
-	O
induecd	O
nystamgus	O
correaltes	O
with	O
midpotnine	O
acitvation	O
.	O

The	O
ptahomechanism	O
of	O
nioctine	B-Chemical
-	O
idnuced	O
nystgamus	O
(	O
NIN	O
)	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
sutdy	O
was	O
to	O
delineate	O
brian	O
strucutres	O
that	O
are	O
involved	O
in	O
NIN	O
generaiton	O
.	O

Eight	O
heatlhy	O
voluneters	O
inhaeld	O
nicotnie	B-Chemical
in	O
dakrness	O
during	O
a	O
fucntional	O
mangetic	O
reosnance	O
imagnig	O
(	O
fRMI	O
)	O
expreiment	O
;	O
eye	O
movemnets	O
were	O
regitsered	O
using	O
viedo	O
-	O
ouclography	O
.	O

NIN	O
crorelated	O
with	O
blood	O
oxyegn	B-Chemical
lveel	O
-	O
dpeendent	O
(	O
BLOD	O
)	O
activtiy	O
leevls	O
in	O
a	O
midpotnine	O
stie	O
in	O
the	O
posetrior	O
basis	O
pnotis	O
.	O

NIN	O
-	O
inudced	O
midopntine	O
actviation	O
may	O
correspond	O
to	O
activaiton	O
of	O
the	O
dorsomdeial	O
ponitne	O
nulcei	O
and	O
the	O
nuclues	O
reticualris	O
tgementi	O
ponits	O
,	O
sturctures	O
known	O
to	O
participate	O
in	O
the	O
geneartion	O
of	O
multidircetional	O
sacacdes	O
and	O
smotoh	O
pusruit	O
eye	O
mvoements	O
.	O

Actue	O
effects	O
of	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
porpylpentanoyl	I-Chemical
)	I-Chemical
uera	I-Chemical
on	O
hippoacmpal	O
aimno	B-Chemical
aicd	I-Chemical
neurortansmitters	O
in	O
pilocarpnie	B-Chemical
-	O
idnuced	O
seiuzre	O
in	O
rtas	O
.	O

The	O
present	O
stduy	O
aimed	O
to	O
ivnestigate	O
the	O
anticonvulsnat	O
actiivty	O
as	O
well	O
as	O
the	O
effcets	O
on	O
the	O
leevl	O
of	O
hippocapmal	O
amnio	B-Chemical
aicd	I-Chemical
nuerotransmitters	O
(	O
glutmaate	B-Chemical
,	O
asparatte	B-Chemical
,	O
glcyine	B-Chemical
and	O
GBAA	B-Chemical
)	O
of	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
propyplentanoyl	I-Chemical
)	I-Chemical
uera	I-Chemical
(	O
VPU	B-Chemical
)	O
in	O
copmarison	O
to	O
its	O
paernt	O
componud	O
,	O
valrpoic	B-Chemical
aicd	I-Chemical
(	O
VPA	B-Chemical
)	O
.	O

VPU	B-Chemical
was	O
more	O
potent	O
than	O
VPA	B-Chemical
,	O
exhibiting	O
the	O
medain	O
efefctive	O
dsoe	O
(	O
ED	O
(	O
50	O
)	O
)	O
of	O
49	O
mg	O
/	O
kg	O
in	O
protecting	O
rtas	O
against	O
pilocaripne	B-Chemical
-	O
indcued	O
seizrue	O
whereas	O
the	O
corresponding	O
value	O
for	O
VPA	B-Chemical
was	O
322	O
mg	O
/	O
kg	O
.	O

In	O
vivo	O
mcirodialysis	O
demonstrated	O
that	O
an	O
intrapertioneal	O
adimnistration	O
of	O
pilocrapine	B-Chemical
indcued	O
a	O
pronounced	O
increemnt	O
of	O
hippocamapl	O
gltuamate	B-Chemical
and	O
aspratate	B-Chemical
whereas	O
no	O
significant	O
change	O
was	O
observed	O
on	O
the	O
lveel	O
of	O
gylcine	B-Chemical
and	O
GBAA	B-Chemical
.	O

Pretretament	O
with	O
either	O
VPU	B-Chemical
(	O
50	O
and	O
100	O
mg	O
/	O
kg	O
)	O
or	O
VPA	B-Chemical
(	O
300	O
and	O
600	O
mg	O
/	O
kg	O
)	O
completely	O
abolished	O
pliocarpine	B-Chemical
-	O
evkoed	O
icnreases	O
in	O
extracelullar	O
gluatmate	B-Chemical
and	O
aspratate	B-Chemical
.	O

In	O
addition	O
,	O
a	O
statistiaclly	O
significant	O
redutcion	O
was	O
also	O
observed	O
on	O
the	O
lveel	O
of	O
GBAA	B-Chemical
and	O
gylcine	B-Chemical
but	O
less	O
than	O
a	O
dratsic	O
rdeuction	O
of	O
glutaamte	B-Chemical
and	O
aspratate	B-Chemical
lveel	O
.	O

Based	O
on	O
the	O
findnig	O
that	O
VPU	B-Chemical
and	O
VPA	B-Chemical
could	O
protect	O
the	O
animlas	O
against	O
pilocrapine	B-Chemical
-	O
induecd	O
siezure	O
it	O
is	O
suggested	O
that	O
the	O
reduciton	O
of	O
inhbiitory	O
amnio	B-Chemical
aicd	I-Chemical
neurtoransmitters	O
was	O
comparatively	O
minor	O
and	O
offset	O
by	O
a	O
pronounced	O
redcution	O
of	O
glutaamte	B-Chemical
and	O
apsartate	B-Chemical
.	O

Therefore	O
,	O
like	O
VPA	B-Chemical
,	O
the	O
fniding	O
that	O
VPU	B-Chemical
could	O
drastically	O
rdeuce	O
piloacrpine	B-Chemical
-	O
induecd	O
inrceases	O
in	O
glutamtae	B-Chemical
and	O
aspratate	B-Chemical
should	O
account	O
,	O
at	O
least	O
partly	O
,	O
for	O
its	O
anticnovulsant	O
acitvity	O
observed	O
in	O
pilocaprine	B-Chemical
-	O
idnuced	O
seiuzre	O
in	O
expeirmental	O
animlas	O
.	O

Some	O
other	O
mehcanism	O
than	O
those	O
being	O
reported	O
herein	O
should	O
be	O
further	O
invesitgated	O
.	O

Protcetive	O
effect	O
of	O
verapaiml	B-Chemical
on	O
gasrtic	O
heomrrhagic	O
uclers	O
in	O
sevree	O
atehrosclerotic	O
rtas	O
.	O

Studeis	O
concerning	O
with	O
pahtogenesis	O
of	O
gsatric	O
heomrrhage	O
and	O
mcuosal	O
ulcertaion	O
produced	O
in	O
atheroscelrotic	O
rtas	O
are	O
lacking	O
.	O

The	O
aim	O
of	O
this	O
stduy	O
is	O
to	O
examine	O
the	O
role	O
of	O
gatsric	O
aicd	O
back	O
-	O
diffuison	O
,	O
msat	O
clel	O
histamnie	B-Chemical
relesae	O
,	O
lpiid	O
peorxide	O
(	O
LPO	O
)	O
genertaion	O
and	O
muocsal	O
micorvascular	O
premeability	O
in	O
moudlating	O
gasrtic	O
hemorrahge	O
and	O
ulecr	O
in	O
rtas	O
with	O
atheroscleorsis	O
induecd	O
by	O
coadministratoin	O
of	O
vtiamin	B-Chemical
D2	I-Chemical
and	O
choletserol	B-Chemical
.	O

Additionally	O
,	O
the	O
protective	O
efefct	O
of	O
verapaiml	B-Chemical
on	O
this	O
ucler	O
moedl	O
was	O
evlauated	O
.	O

Mlae	O
Wisatr	O
rtas	O
were	O
challneged	O
itnragastrically	O
once	O
dialy	O
for	O
9	O
dyas	O
with	O
1	O
.	O
0	O
ml	O
/	O
kg	O
of	O
cron	O
oil	O
containing	O
viatmin	B-Chemical
D2	I-Chemical
and	O
choletserol	B-Chemical
to	O
indcue	O
athersoclerosis	O
.	O

Cnotrol	O
rtas	O
received	O
cron	O
oil	O
only	O
.	O

After	O
gatsric	O
surgrey	O
,	O
rat	O
stmoachs	O
were	O
irriagted	O
for	O
3	O
h	O
with	O
either	O
simulaetd	O
gastirc	O
jiuce	O
or	O
nromal	O
slaine	O
.	O

Gsatric	O
aicd	O
back	O
-	O
dfifusion	O
,	O
mucsoal	O
LPO	O
genreation	O
,	O
histaimne	B-Chemical
concetnration	O
,	O
microvascluar	O
permeaiblity	O
,	O
lumnial	B-Chemical
hemoglboin	O
conetnt	O
and	O
ucler	O
areas	O
were	O
determined	O
.	O

Eleavted	O
atherocslerotic	O
parametres	O
,	O
such	O
as	O
seurm	O
caclium	B-Chemical
,	O
total	O
choletserol	B-Chemical
and	O
low	O
-	O
denstiy	O
lipoprotien	O
conecntration	O
were	O
obtained	O
in	O
atheroscelrotic	O
rtas	O
.	O

Sevree	O
gasrtic	O
ulecrs	O
accompanied	O
with	O
increaesd	O
ulcreogenic	O
fatcors	O
,	O
including	O
gasrtic	O
aicd	O
back	O
-	O
diffusoin	O
,	O
hsitamine	B-Chemical
reelase	O
,	O
LPO	O
gneeration	O
and	O
luimnal	B-Chemical
hemogloibn	O
cotnent	O
were	O
also	O
observed	O
in	O
these	O
rtas	O
.	O

Moreover	O
,	O
a	O
posiitve	O
correaltion	O
of	O
hsitamine	B-Chemical
to	O
gastirc	O
hmeorrhage	O
and	O
to	O
ulecr	O
was	O
found	O
in	O
those	O
atheroscleroitc	O
rtas	O
.	O

This	O
hmeorrhagic	O
ulecr	O
and	O
various	O
ulceorgenic	O
parmaeters	O
were	O
dsoe	O
-	O
dependently	O
ameilorated	O
by	O
dialy	O
intragsatric	O
verapaiml	B-Chemical
.	O

Atheroscleroiss	O
could	O
produce	O
gastirc	O
hemorrhaigc	O
ulecr	O
via	O
agrgavation	O
of	O
gasrtic	O
aicd	O
back	O
-	O
diffuison	O
,	O
LPO	O
generaiton	O
,	O
histamnie	B-Chemical
reelase	O
and	O
microvacsular	O
permebaility	O
that	O
could	O
be	O
amleiorated	O
by	O
verpaamil	B-Chemical
in	O
rtas	O
.	O

Lamiuvdine	B-Chemical
for	O
the	O
pervention	O
of	O
hepatiits	O
B	O
viurs	O
reatcivation	O
in	O
heptaitis	B-Chemical
-	I-Chemical
B	I-Chemical
surafce	I-Chemical
antgien	I-Chemical
(	O
HBASG	B-Chemical
)	O
seropsoitive	O
cnacer	O
patietns	O
undergoing	O
cytotxoic	O
chemtoherapy	O
.	O

Hepatiits	O
B	O
viurs	O
(	O
HBV	O
)	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
chrnoic	O
lvier	O
diesase	O
worldwide	O
.	O

Cacner	O
patietns	O
who	O
are	O
chroinc	O
carrires	O
of	O
HBV	O
have	O
a	O
higehr	O
hpeatic	O
complciation	O
rtae	O
while	O
receiving	O
cytotxoic	O
cheomtherapy	O
(	O
CT	O
)	O
and	O
this	O
has	O
mainly	O
been	O
attributed	O
to	O
HBV	O
reactiavtion	O
.	O

In	O
this	O
stduy	O
,	O
cacner	O
pateints	O
who	O
have	O
soild	O
and	O
heamtological	O
maliganncies	O
with	O
chrnoic	O
HBV	O
inefction	O
received	O
the	O
anitviral	O
aegnt	O
lmaivudine	B-Chemical
prior	O
and	O
during	O
CT	O
copmared	O
with	O
hsitorical	O
conrtol	O
gorup	O
who	O
did	O
not	O
receive	O
lamivudnie	B-Chemical
.	O

The	O
objecitves	O
were	O
to	O
assess	O
the	O
efifcacy	O
of	O
lamviudine	B-Chemical
in	O
rdeucing	O
the	O
incdience	O
of	O
HBV	O
reactviation	O
,	O
and	O
dimiinshing	O
moribdity	O
and	O
moratlity	O
during	O
CT	O
.	O

Two	O
gruops	O
were	O
compaerd	O
in	O
this	O
sutdy	O
.	O

The	O
porphylactic	O
lamivduin	B-Chemical
gorup	O
consisted	O
of	O
37	O
pateints	O
who	O
received	O
propyhlactic	O
lamivudnie	B-Chemical
teratment	O
.	O

The	O
hsitorical	O
conrtols	O
consisted	O
of	O
50	O
cosnecutive	O
patinets	O
who	O
underwent	O
CT	O
without	O
prohpylactic	O
laimvudine	B-Chemical
.	O

They	O
were	O
followed	O
up	O
during	O
and	O
for	O
8	O
weeks	O
after	O
CT	O
.	O

The	O
ouctomes	O
were	O
cmopared	O
for	O
both	O
gropus	O
.	O

Of	O
our	O
conrtol	O
gorup	O
(	O
n	O
=	O
50	O
)	O
,	O
21	O
patietns	O
(	O
42	O
%	O
)	O
were	O
established	O
hepatiits	O
.	O

Twelve	O
(	O
24	O
%	O
)	O
of	O
them	O
were	O
evalutaed	O
as	O
sevree	O
heaptitis	O
.	O

In	O
the	O
prophylatcic	O
laimvudine	B-Chemical
gorup	O
seevre	O
heptaitis	O
were	O
observed	O
only	O
in	O
1	O
pateint	O
(	O
2	O
.	O
7	O
%	O
)	O
of	O
37	O
patinets	O
(	O
p	O
<	O
0	O
.	O
006	O
)	O
.	O

Compairson	O
of	O
the	O
mean	O
ALT	O
valeus	O
revelaed	O
significantly	O
hihger	O
mean	O
aalnine	B-Chemical
aminotransfrease	O
(	O
ALT	O
)	O
valeus	O
in	O
the	O
cotnrol	O
gorup	O
than	O
the	O
prpohylactic	O
lamiuvdine	B-Chemical
gruop	O
;	O
154	O
:	O
64	O
(	O
p	O
<	O
0	O
.	O
32	O
)	O
.	O

Our	O
sutdy	O
suggests	O
that	O
prophlyactic	O
lamivuidne	B-Chemical
significantly	O
dcereases	O
the	O
incdience	O
of	O
HBV	O
reactviation	O
and	O
overall	O
moribdity	O
in	O
cnacer	O
paitents	O
during	O
and	O
after	O
immunosuppressive	O
therpay	O
.	O

Further	O
stduies	O
are	O
needed	O
to	O
determine	O
the	O
most	O
appropriate	O
nculeoside	B-Chemical
or	O
nucletoide	B-Chemical
analgoue	O
for	O
antiviarl	O
prophylxais	O
during	O
CT	O
and	O
the	O
optmial	O
duartion	O
of	O
administratoin	O
after	O
comlpetion	O
of	O
CT	O
.	O

Recoevry	O
of	O
tacroliums	B-Chemical
-	O
associated	O
bracihal	O
neuriits	O
after	O
conevrsion	O
to	O
eveorlimus	B-Chemical
in	O
a	O
peidatric	O
reanl	O
transpalnt	O
reciipent	O
-	O
-	O
csae	O
rpeort	O
and	O
rveiew	O
of	O
the	O
literatrue	O
.	O

TAC	B-Chemical
has	O
been	O
shown	O
to	O
be	O
a	O
potent	O
immunosuppressive	O
aegnt	O
for	O
sloid	O
ogran	O
transplanttaion	O
in	O
pediatrcis	O
.	O

Neruotoxicity	O
is	O
a	O
potentially	O
serious	O
toixc	O
effect	O
.	O

It	O
is	O
charactreized	O
by	O
encephlaopathy	O
,	O
haedaches	O
,	O
seizuers	O
,	O
or	O
neurologcial	O
defictis	O
.	O

Here	O
,	O
we	O
describe	O
an	O
eight	O
-	O
and	O
-	O
a	O
-	O
half	O
-	O
yr	O
-	O
old	O
mlae	O
rneal	O
trasnplant	O
reciipent	O
with	O
rihgt	O
BN	O
.	O

MRI	O
demonstrated	O
hyperintesne	O
T2	O
siganls	O
in	O
the	O
cervcial	O
crod	O
and	O
rihgt	O
bracihal	O
plxeus	O
roots	O
idnicative	O
of	O
both	O
myeltiis	O
and	O
rgiht	O
brcahial	O
pleixtis	O
.	O

Sypmtoms	O
persisted	O
for	O
three	O
motnhs	O
despite	O
TAC	B-Chemical
dsoe	O
rdeuction	O
,	O
administraiton	O
of	O
IIVG	O
and	O
four	O
dsoes	O
of	O
methylrpednisolone	B-Chemical
pluse	O
tehrapy	O
.	O

Improvemnet	O
and	O
eventually	O
full	O
recoevry	O
only	O
occurred	O
after	O
TAC	B-Chemical
was	O
completely	O
dicsontinued	O
and	O
successfully	O
replaced	O
by	O
eevrolimus	B-Chemical
.	O

Omitting	O
fentaynl	B-Chemical
reudces	O
nasuea	O
and	O
vmoiting	O
,	O
without	O
icnreasing	O
pian	O
,	O
after	O
sevolfurane	B-Chemical
for	O
day	O
surgrey	O
.	O

BACKGRUOND	O
AND	O
OBJECITVE	O
:	O
Despite	O
advantages	O
of	O
inductoin	O
and	O
manitenance	O
of	O
anaetshesia	O
with	O
seovflurane	B-Chemical
,	O
postopeartive	O
nauesa	O
and	O
voimting	O
occurs	O
frequently	O
.	O

Fnetanyl	B-Chemical
is	O
a	O
commonly	O
used	O
supplmeent	O
that	O
may	O
contribute	O
to	O
this	O
,	O
although	O
it	O
may	O
also	O
imporve	O
aanlgesia	O
.	O

METHODS	O
:	O
This	O
double	O
-	O
bilnd	O
sutdy	O
examined	O
the	O
incidnece	O
and	O
seevrity	O
of	O
postoeprative	O
nauesa	O
and	O
vmoiting	O
and	O
pian	O
in	O
the	O
first	O
24	O
h	O
after	O
sevoflurnae	B-Chemical
anaestheisa	O
in	O
216	O
audlt	O
day	O
sugrery	O
paitents	O
.	O

Patietns	O
were	O
randomly	O
allocated	O
to	O
either	O
receive	O
or	O
not	O
receive	O
1	O
1	O
fenatnyl	B-Chemical
,	O
while	O
a	O
third	O
gruop	O
received	O
dexmaethasone	B-Chemical
in	O
addition	O
to	O
fentnayl	B-Chemical
.	O

RSEULTS	O
:	O
Omission	O
of	O
fnetanyl	B-Chemical
did	O
not	O
reudce	O
the	O
overall	O
incdience	O
of	O
postopeartive	O
nuasea	O
and	O
vomitnig	O
,	O
but	O
did	O
reudce	O
the	O
incidnece	O
of	O
vomiitng	O
and	O
/	O
or	O
modearte	O
to	O
seevre	O
nasuea	O
prior	O
to	O
dishcarge	O
from	O
20	O
%	O
and	O
17	O
%	O
with	O
fentaynl	B-Chemical
and	O
fentaynl	B-Chemical
-	O
dexamtehasone	B-Chemical
,	O
respectively	O
,	O
to	O
5	O
%	O
(	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O

Antiemeitc	O
reuqirements	O
were	O
rdeuced	O
from	O
24	O
%	O
and	O
31	O
%	O
to	O
7	O
%	O
(	O
P	O
=	O
0	O
.	O
0012	O
)	O
.	O

Dexamethsaone	B-Chemical
had	O
no	O
significant	O
efefct	O
on	O
the	O
incidecne	O
or	O
sveerity	O
of	O
postoperaitve	O
nasuea	O
and	O
vomitnig	O
.	O

Combining	O
the	O
two	O
fetnanyl	B-Chemical
gropus	O
revaeled	O
further	O
significant	O
beenfits	O
from	O
the	O
avoidnace	O
of	O
oipoids	O
,	O
reudcing	O
posotperative	O
nuasea	O
and	O
vomiitng	O
and	O
nasuea	O
prior	O
to	O
dischrage	O
from	O
35	O
%	O
and	O
33	O
%	O
to	O
22	O
%	O
and	O
19	O
%	O
(	O
P	O
=	O
0	O
.	O
049	O
and	O
P	O
=	O
0	O
.	O
035	O
)	O
,	O
respectively	O
,	O
while	O
nasuea	O
in	O
the	O
first	O
24	O
h	O
was	O
decreaesd	O
from	O
42	O
%	O
to	O
27	O
%	O
(	O
P	O
=	O
0	O
.	O
034	O
)	O
.	O

Pian	O
seveirty	O
and	O
anlagesic	O
rqeuirements	O
were	O
uanffected	O
by	O
the	O
omisison	O
of	O
fnetanyl	B-Chemical
.	O

Fentaynl	B-Chemical
did	O
redcue	O
minor	O
intrapoerative	O
movemnet	O
but	O
had	O
no	O
sveoflurane	B-Chemical
-	O
sparing	O
effcet	O
and	O
incraesed	O
respiratroy	O
depression	O
,	O
hypotenison	O
and	O
bradycadria	O
.	O

CONCULSION	O
:	O
As	O
fenatnyl	B-Chemical
eaxcerbated	O
postopertaive	O
nuasea	O
and	O
vomitnig	O
without	O
an	O
imporvement	O
in	O
postopreative	O
pian	O
and	O
also	O
had	O
advrese	O
cardiroespiratory	O
effcets	O
,	O
it	O
appears	O
to	O
be	O
an	O
unnecessary	O
and	O
possibly	O
detrimnetal	O
spuplement	O
to	O
sveoflurane	B-Chemical
in	O
day	O
sugrery	O
.	O

Valvluar	O
herat	O
disaese	O
in	O
ptaients	O
with	O
Parkinosn	O
'	O
s	O
diesase	O
treaetd	O
with	O
pregolide	B-Chemical
.	O

Cousre	O
following	O
tretament	O
modifictaions	O
.	O

Vavlular	O
herat	O
abnormaliites	O
have	O
been	O
reported	O
in	O
paitents	O
with	O
Pariknson	O
'	O
s	O
disaese	O
(	O
PD	O
)	O
treaetd	O
with	O
pergloide	B-Chemical
.	O

However	O
,	O
the	O
incdience	O
and	O
severtiy	O
of	O
these	O
abnormailties	O
vary	O
from	O
sutdy	O
to	O
sutdy	O
and	O
their	O
cousre	O
after	O
durg	O
withdarwal	O
has	O
not	O
been	O
systematcially	O
assesesd	O
.	O

OJBECTIVES	O
:	O
To	O
estiamte	O
the	O
freqeuncy	O
and	O
severtiy	O
of	O
valvualr	O
haert	O
abnomrality	O
and	O
its	O
possible	O
revresibility	O
after	O
durg	O
withdraawl	O
in	O
a	O
csae	O
-	O
contorl	O
sutdy	O
.	O

METHODS	O
:	O
All	O
PD	O
patietns	O
in	O
the	O
Ameins	O
aera	O
treaetd	O
with	O
peroglide	B-Chemical
were	O
invited	O
to	O
attend	O
a	O
cardoilogic	O
asesssment	O
including	O
transthoraicc	O
echocardiogarphy	O
.	O

Thirty	O
PD	O
pateints	O
participated	O
in	O
the	O
sutdy	O
.	O

A	O
second	O
echocardigoraphy	O
was	O
performed	O
(	O
medain	O
interavl	O
:	O
13	O
monhts	O
)	O
after	O
pergoldie	B-Chemical
withdraawl	O
(	O
n	O
=	O
10	O
pateints	O
)	O
.	O

Contorls	O
were	O
age	O
-	O
and	O
sex	O
-	O
matched	O
non	O
-	O
PD	O
patietns	O
referred	O
to	O
the	O
caridology	O
depratment	O
.	O

REUSLTS	O
:	O
Cmopared	O
to	O
cotnrols	O
,	O
arotic	O
regrugitation	O
(	O
OR	O
:	O
3	O
.	O
1	O
;	O
95	O
%	O
IC	O
:	O
1	O
.	O
1	O
-	O
8	O
.	O
8	O
)	O
and	O
mitarl	O
regurgtiation	O
(	O
OR	O
:	O
10	O
.	O
7	O
;	O
95	O
%	O
IC	O
:	O
2	O
.	O
1	O
-	O
53	O
)	O
were	O
more	O
frequnet	O
in	O
PD	O
patinets	O
(	O
tricupsid	O
:	O
NS	O
)	O
.	O

The	O
number	O
of	O
affecetd	O
valevs	O
(	O
n	O
=	O
2	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
7	O
)	O
and	O
the	O
sum	O
of	O
regurgtiation	O
grdaes	O
(	O
n	O
=	O
2	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
09	O
)	O
were	O
hgiher	O
(	O
p	O
=	O
0	O
.	O
008	O
and	O
p	O
=	O
0	O
.	O
006	O
,	O
respectively	O
)	O
in	O
the	O
pergoldie	B-Chemical
gruop	O
.	O

Sevreity	O
of	O
regurgitaiton	O
was	O
not	O
corerlated	O
with	O
pergoldie	B-Chemical
cumulaitve	O
dsoe	O
.	O

A	O
restirctive	O
ptatern	O
of	O
valvluar	O
regurgittaion	O
,	O
suggestive	O
of	O
the	O
role	O
of	O
pergoldie	B-Chemical
,	O
was	O
observed	O
in	O
12	O
/	O
30	O
(	O
40	O
%	O
)	O
patietns	O
including	O
two	O
with	O
haert	O
fialure	O
.	O

Pergoilde	B-Chemical
was	O
discontiuned	O
in	O
10	O
ptaients	O
with	O
valuvlar	O
haert	O
disaese	O
,	O
resulting	O
in	O
a	O
loewr	O
regurgittaion	O
garde	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
at	O
the	O
second	O
trasnthoracic	O
echcoardiography	O
and	O
the	O
two	O
patinets	O
with	O
herat	O
faiulre	O
returned	O
to	O
nearly	O
nromal	O
clincial	O
examinatoin	O
.	O

This	O
stduy	O
supports	O
the	O
high	O
frequnecy	O
of	O
retsrictive	O
vlave	O
regurgiattion	O
in	O
PD	O
ptaients	O
traeted	O
with	O
pergoldie	B-Chemical
and	O
reveals	O
that	O
a	O
significant	O
improveemnt	O
is	O
usual	O
when	O
the	O
treatmnet	O
is	O
converted	O
to	O
non	O
-	O
egrot	O
doapmine	B-Chemical
agonsits	O
.	O

Adriamyicn	B-Chemical
-	O
indcued	O
atuophagic	O
cardiomycoyte	O
daeth	O
plays	O
a	O
pathogneic	O
role	O
in	O
a	O
rat	O
mdoel	O
of	O
haert	O
faliure	O
.	O

BACKGORUND	O
:	O
The	O
mehcanisms	O
underlying	O
herat	O
fialure	O
indcued	O
by	O
adriamcyin	B-Chemical
are	O
very	O
complictaed	O
and	O
still	O
unclear	O
.	O

The	O
aim	O
of	O
this	O
sutdy	O
was	O
to	O
invsetigate	O
whether	O
autohpagy	O
was	O
involved	O
in	O
the	O
progressoin	O
of	O
herat	O
fialure	O
inudced	O
by	O
adiramycin	B-Chemical
,	O
so	O
that	O
we	O
can	O
develop	O
a	O
novel	O
teratment	O
strategy	O
for	O
haert	O
fialure	O
.	O

METHODS	O
:	O
3	B-Chemical
-	I-Chemical
methyladennie	I-Chemical
(	O
3MA	B-Chemical
)	O
,	O
a	O
specific	O
inihbitor	O
on	O
atuophagy	O
was	O
used	O
in	O
a	O
haert	O
failrue	O
mdoel	O
of	O
rtas	O
induecd	O
by	O
ardiamycin	B-Chemical
.	O

Neoantal	O
cardiomycoytes	O
were	O
isoltaed	O
from	O
Sprgaue	O
-	O
Dalwey	O
rat	O
haerts	O
and	O
randomly	O
divided	O
into	O
contorls	O
,	O
an	O
adriamcyin	B-Chemical
-	O
terated	O
gruop	O
,	O
and	O
a	O
3MA	B-Chemical
plus	O
adriaymcin	B-Chemical
-	O
terated	O
gorup	O
.	O

We	O
then	O
examined	O
the	O
moprhology	O
,	O
exrpession	O
of	O
belcin	O
1	O
gnee	O
,	O
mitocohndrial	O
permeaiblity	O
transtiion	O
(	O
MPT	O
)	O
,	O
and	O
Na	O
+	O
-	O
K	B-Chemical
+	O
APTase	O
actviity	O
in	O
vivo	O
.	O

We	O
also	O
assessed	O
clel	O
viabiltiy	O
,	O
mitocohndrial	O
membarne	O
potenital	O
chagnes	O
and	O
conuted	O
atuophagic	O
vaculoes	O
in	O
cultuerd	O
caridomyocytes	O
.	O

In	O
addition	O
,	O
we	O
anaylzed	O
the	O
epxression	O
of	O
atuophagy	O
associated	O
gnee	O
,	O
belcin	O
1	O
using	O
RT	O
-	O
PCR	O
and	O
Westren	O
blotitng	O
in	O
an	O
aniaml	O
mdoel	O
.	O

RESLUTS	O
:	O
3MA	B-Chemical
significantly	O
imprvoed	O
cadriac	O
functoin	O
and	O
reduecd	O
miotchondrial	O
injruy	O
.	O

Furthermore	O
,	O
adriamcyin	B-Chemical
indcued	O
the	O
formtaion	O
of	O
autopahgic	O
vacuoels	O
,	O
and	O
3MA	B-Chemical
strongly	O
downregultaed	O
the	O
epxression	O
of	O
belcin	O
1	O
in	O
ardiamycin	B-Chemical
-	O
idnuced	O
failing	O
haert	O
and	O
inhiibted	O
the	O
foramtion	O
of	O
autophgaic	O
vaculoes	O
.	O

CONCLUSOIN	O
:	O
Autopahgic	O
cardioymocyte	O
detah	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogeneiss	O
of	O
herat	O
fialure	O
in	O
rtas	O
induecd	O
by	O
adriamyicn	B-Chemical
.	O

Mitochodnrial	O
injruy	O
may	O
be	O
involved	O
in	O
the	O
porgression	O
of	O
haert	O
failrue	O
caused	O
by	O
adriamcyin	B-Chemical
via	O
the	O
atuophagy	O
pathawy	O
.	O

moTR	O
inhbiitors	O
-	O
inudced	O
proteiunria	O
:	O
mechnaisms	O
,	O
signifiacnce	O
,	O
and	O
managmeent	O
.	O

Massive	O
urinray	O
prtoein	O
excreiton	O
has	O
been	O
observed	O
after	O
conversoin	O
from	O
clacineurin	O
inhibiotrs	O
to	O
mmamalian	O
taregt	O
of	O
rpaamycin	B-Chemical
(	O
moTR	O
)	O
inhibtiors	O
,	O
especially	O
sirloimus	B-Chemical
,	O
in	O
reanl	O
transpalnt	O
rceipients	O
with	O
chroinc	O
allogrfat	O
nephroptahy	O
.	O

Because	O
porteinuria	O
is	O
a	O
major	O
preidctive	O
fcator	O
of	O
poor	O
trnasplantation	O
outocme	O
,	O
many	O
stduies	O
focused	O
on	O
this	O
advesre	O
evnet	O
during	O
the	O
past	O
yaers	O
.	O

Whether	O
proteniuria	O
was	O
due	O
to	O
siroliums	B-Chemical
or	O
only	O
a	O
consequence	O
of	O
calcnieurin	O
inhibitros	O
withdrwaal	O
remained	O
unsolved	O
until	O
high	O
range	O
porteinuria	O
has	O
been	O
observed	O
during	O
sirloimus	B-Chemical
threapy	O
in	O
iselt	O
transplnatation	O
and	O
in	O
ptaients	O
who	O
received	O
sriolimus	B-Chemical
de	O
novo	O
.	O

Podoctye	O
ijnury	O
and	O
fcoal	O
semgental	O
glomerluosclerosis	O
have	O
been	O
related	O
to	O
moTR	O
inhibiiton	O
in	O
some	O
patietns	O
,	O
but	O
the	O
pathwyas	O
underlying	O
these	O
lesoins	O
remain	O
hypothetic	O
.	O

We	O
discuss	O
herein	O
the	O
possible	O
mechnaisms	O
and	O
the	O
singificance	O
of	O
moTR	O
blockdae	O
-	O
inudced	O
porteinuria	O
.	O

Neurospychiatric	O
side	O
effetcs	O
after	O
the	O
use	O
of	O
meflqouine	B-Chemical
.	O

This	O
stduy	O
describes	O
neuropyschiatric	O
side	O
effects	O
in	O
ptaients	O
after	O
tretament	O
with	O
melfoquine	B-Chemical
.	O

Reactinos	O
consisted	O
mainly	O
of	O
seizrues	O
,	O
actue	O
psychsoes	O
,	O
anxeity	O
neuroiss	O
,	O
and	O
major	O
disturbanecs	O
of	O
selep	O
-	O
wake	O
rhtyhm	O
.	O

Side	O
effcets	O
occurred	O
after	O
both	O
tehrapeutic	O
and	O
propyhlactic	O
itnake	O
and	O
were	O
garded	O
from	O
modreate	O
to	O
seevre	O
.	O

In	O
a	O
rsik	O
analyiss	O
of	O
neuropsychaitric	O
side	O
effects	O
in	O
Germnay	O
,	O
it	O
is	O
estimaetd	O
that	O
one	O
of	O
8	O
,	O
000	O
mefloqunie	B-Chemical
usres	O
suffers	O
from	O
such	O
recations	O
.	O

The	O
incidecne	O
caclulation	O
revelaed	O
that	O
one	O
of	O
215	O
therpaeutic	O
uesrs	O
had	O
recations	O
,	O
compaerd	O
with	O
one	O
of	O
13	O
,	O
000	O
in	O
the	O
prophylaixs	O
gruop	O
,	O
making	O
the	O
rsik	O
of	O
neuropsyhciatric	O
reactoins	O
after	O
meflouqine	B-Chemical
tretament	O
60	O
times	O
hgiher	O
than	O
after	O
prpohylaxis	O
.	O

Therefore	O
,	O
certain	O
limitaitons	O
for	O
mlaaria	O
propyhlaxis	O
and	O
teratment	O
with	O
mefloqiune	B-Chemical
are	O
recmomended	O
.	O

Prneatal	O
protien	O
derpivation	O
atlers	O
dopamnie	B-Chemical
-	O
mediated	O
beahviors	O
and	O
dopmainergic	O
and	O
gultamatergic	O
rceeptor	O
bniding	O
.	O

Eipdemiological	O
eivdence	O
indicates	O
that	O
prneatal	O
nutritioanl	O
depriavtion	O
may	O
incraese	O
the	O
rsik	O
of	O
schziophrenia	O
.	O

The	O
gaol	O
of	O
these	O
stduies	O
was	O
to	O
use	O
an	O
anmial	O
mdoel	O
to	O
examine	O
the	O
effcets	O
of	O
pernatal	O
protien	O
depriavtion	O
on	O
behavoirs	O
and	O
recpetor	O
binidng	O
with	O
relevance	O
to	O
schizpohrenia	O
.	O

We	O
reprot	O
that	O
prenaatlly	O
portein	O
depirved	O
(	O
PD	O
)	O
femlae	O
rtas	O
showed	O
an	O
incresaed	O
steretoypic	O
resposne	O
to	O
apmoorphine	B-Chemical
and	O
an	O
inrceased	O
loocmotor	O
resopnse	O
to	O
ampehtamine	B-Chemical
in	O
adluthood	O
.	O

These	O
difefrences	O
were	O
not	O
observed	O
during	O
pubetry	O
.	O

No	O
chanegs	O
in	O
haloperiodl	B-Chemical
-	O
induecd	O
cataelpsy	O
or	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
-	O
idnuced	O
locmootion	O
were	O
seen	O
following	O
PD	O
.	O

In	O
addition	O
,	O
PD	O
feamle	O
rtas	O
showed	O
inrceased	O
(	O
3	O
)	O
H	B-Chemical
-	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
binidng	O
in	O
the	O
srtiatum	O
and	O
hippocapmus	O
,	O
but	O
not	O
in	O
the	O
coretx	O
.	O

PD	O
feamle	O
rtas	O
also	O
showed	O
icnreased	O
(	O
3	O
)	O
H	B-Chemical
-	O
hlaoperidol	B-Chemical
bniding	O
and	O
decresaed	O
dopmaine	B-Chemical
transpotrer	O
binidng	O
in	O
straitum	O
.	O

No	O
sttaistically	O
significant	O
cahnges	O
in	O
behavoir	O
or	O
recetpor	O
bidning	O
were	O
found	O
in	O
PD	O
maels	O
with	O
the	O
exception	O
of	O
incraesed	O
(	O
3	O
)	O
H	B-Chemical
-	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
bniding	O
in	O
crotex	O
.	O

This	O
ainmal	O
mdoel	O
may	O
be	O
useful	O
to	O
explore	O
the	O
mecahnisms	O
by	O
which	O
prneatal	O
nurtitional	O
deficiecny	O
enahnces	O
rsik	O
for	O
schizophreina	O
in	O
huamns	O
and	O
may	O
also	O
have	O
implications	O
for	O
developmnetal	O
procseses	O
leading	O
to	O
diffreential	O
senistivity	O
to	O
drgus	O
of	O
absue	O
.	O

Advesre	O
effects	O
of	O
tpoical	O
papavernie	B-Chemical
on	O
audtiory	O
nreve	O
funtcion	O
.	O

BACKGRONUD	O
:	O
Papavreine	B-Chemical
hydrochlroide	I-Chemical
is	O
a	O
direct	O
-	O
acting	O
vasodiltaor	O
used	O
to	O
manage	O
vasopsasm	O
during	O
various	O
neurousrgical	O
opeartions	O
.	O

Trasnient	O
cranail	O
nevre	O
dyfsunction	O
has	O
been	O
described	O
in	O
a	O
few	O
caess	O
with	O
toipcal	O
papaevrine	B-Chemical
.	O

This	O
sutdy	O
supports	O
previous	O
reprots	O
and	O
provides	O
neurophysioloigcal	O
eviednce	O
of	O
an	O
advesre	O
effcet	O
on	O
the	O
audiotry	O
nevre	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retrospcetive	O
reveiw	O
of	O
70	O
consecutvie	O
microvasuclar	O
decompressoin	O
opertaions	O
and	O
studied	O
those	O
pateints	O
who	O
received	O
toipcal	O
papavernie	B-Chemical
for	O
vassopasm	O
.	O

Toipcal	O
ppaaverine	B-Chemical
was	O
used	O
as	O
a	O
direct	O
threapeutic	O
aciton	O
to	O
manage	O
vassopasm	O
in	O
a	O
total	O
of	O
11	O
paitents	O
.	O

The	O
timnig	O
of	O
papavreine	B-Chemical
aplpication	O
and	O
ongoing	O
opertaive	O
evetns	O
was	O
revieewd	O
relative	O
to	O
chnages	O
in	O
neurohpysiological	O
rceordings	O
.	O

Branistem	O
audiotry	O
evkoed	O
potnetials	O
(	O
BAPEs	O
)	O
were	O
routinely	O
used	O
to	O
monitor	O
cohclear	O
nevre	O
funtcion	O
during	O
these	O
oeprations	O
.	O

FINDNIGS	O
:	O
A	O
temproal	O
relatiosnhip	O
was	O
found	O
between	O
topiacl	O
papaevrine	B-Chemical
and	O
BEAP	O
cahnges	O
leading	O
to	O
complete	O
waevform	O
lsos	O
.	O

The	O
avergae	O
tepmoral	O
dleay	O
between	O
paapverine	B-Chemical
and	O
the	O
onset	O
of	O
an	O
advrese	O
BEAP	O
change	O
was	O
5	O
min	O
.	O

In	O
10	O
of	O
11	O
patinets	O
,	O
BEAP	O
wvaes	O
II	O
/	O
III	O
-	O
V	O
completely	O
disappeared	O
within	O
2	O
to	O
25	O
min	O
after	O
papavernie	B-Chemical
.	O

Eight	O
of	O
these	O
10	O
patinets	O
had	O
complete	O
lsos	O
of	O
BEAP	O
wavefomrs	O
within	O
10	O
min	O
.	O

One	O
pateint	O
showed	O
no	O
recoevry	O
of	O
later	O
wvaes	O
and	O
a	O
dealyed	O
profuond	O
sensorineuarl	O
haering	O
lsos	O
.	O

The	O
avearge	O
recvoery	O
tmie	O
of	O
BEAP	O
waveofrms	O
to	O
pre	O
-	O
papavernie	B-Chemical
baselnie	O
vaules	O
was	O
39	O
min	O
.	O

CONCLUISONS	O
:	O
Topiacl	O
papaevrine	B-Chemical
for	O
the	O
treamtent	O
of	O
vaosspasm	O
was	O
associated	O
with	O
the	O
onset	O
of	O
a	O
tranisent	O
ditsurbance	O
in	O
neuorphysiological	O
fucntion	O
of	O
the	O
ascenidng	O
audtiory	O
barinstem	O
ptahway	O
.	O

The	O
complete	O
disappaerance	O
of	O
BEAP	O
wavefomrs	O
with	O
a	O
consistent	O
temopral	O
dleay	O
suggests	O
a	O
possible	O
advesre	O
effect	O
on	O
the	O
proixmal	O
egihth	O
nreve	O
.	O

Recomemndations	O
to	O
avoid	O
potnetial	O
crainal	O
nreve	O
defciits	O
from	O
paapverine	B-Chemical
are	O
provided	O
.	O

Simvastaitn	B-Chemical
-	I-Chemical
ezetmiibe	I-Chemical
-	O
idnuced	O
heaptic	O
faiulre	O
necessitating	O
lvier	O
transplanttaion	O
.	O

Abtsract	O
Sreum	O
amintoransferase	O
eleavtions	O
are	O
a	O
commonly	O
known	O
avderse	O
efefct	O
of	O
3	O
-	O
hdyroxy	O
-	O
3	O
-	O
mtehylglutaryl	O
coenyzme	O
A	O
redcutase	O
inihbitor	O
(	O
sttain	B-Chemical
)	O
tehrapy	O
.	O

However	O
,	O
heptaotoxic	O
evnets	O
have	O
not	O
been	O
widely	O
pulbished	O
with	O
ezetiimbe	B-Chemical
or	O
the	O
combniation	O
aegnt	O
simvatsatin	B-Chemical
-	I-Chemical
ezetimbie	I-Chemical
.	O

We	O
describe	O
a	O
70	O
-	O
yaer	O
-	O
old	O
Hispnaic	O
wmoan	O
who	O
developed	O
fulminnat	O
hpeatic	O
faliure	O
necessitating	O
lievr	O
trasnplantation	O
10	O
weeks	O
after	O
converison	O
from	O
simvsatatin	B-Chemical
40	O
mg	O
/	O
day	O
to	O
simvasttain	B-Chemical
10	I-Chemical
mg	I-Chemical
-	I-Chemical
eeztimibe	I-Chemical
40	I-Chemical
mg	I-Chemical
/	O
day	O
.	O

The	O
pateint	O
'	O
s	O
liipd	O
panel	O
had	O
been	O
maintained	O
with	O
simvastaitn	B-Chemical
for	O
18	O
monhts	O
before	O
the	O
cnoversion	O
without	O
evidecne	O
of	O
heaptotoxicity	O
.	O

A	O
ruotine	O
labroatory	O
work	O
-	O
up	O
10	O
weeks	O
after	O
convresion	O
revelaed	O
eleavted	O
seurm	O
aminotarnsferase	O
levles	O
.	O

Simvastatinzeetimibe	B-Chemical
and	O
esciatlopram	B-Chemical
(	O
which	O
she	O
was	O
taking	O
for	O
deprsesion	O
)	O
were	O
disocntinued	O
,	O
and	O
other	O
potentail	O
causes	O
of	O
hepaottoxicity	O
were	O
excluded	O
.	O

A	O
rpeeat	O
work	O
-	O
up	O
reveaeld	O
further	O
elevatoins	O
in	O
aminotrasnferase	O
leevls	O
,	O
and	O
lievr	O
biposy	O
reveaeld	O
eviednce	O
of	O
moedrate	O
-	O
to	O
-	O
sevree	O
durg	O
toixcity	O
.	O

She	O
underwent	O
lievr	O
tranpslantation	O
with	O
an	O
unveentful	O
postopeartive	O
cousre	O
.	O

Her	O
aimnotransferase	O
levles	O
returned	O
to	O
noraml	O
by	O
postopeartive	O
day	O
23	O
,	O
and	O
her	O
2	O
-	O
yaer	O
follow	O
-	O
up	O
showed	O
no	O
advrese	O
evetns	O
.	O

Ezetimbie	B-Chemical
undergoes	O
exetnsive	O
glucurnoidation	O
by	O
uirdine	B-Chemical
diphospahte	I-Chemical
glucroonosyltransferases	O
(	O
UGT	O
)	O
in	O
the	O
intesitne	O
and	O
lvier	O
and	O
may	O
have	O
inhbiited	O
the	O
glucruonidation	O
of	O
simvasattin	B-Chemical
hyrdoxy	I-Chemical
aicd	I-Chemical
,	O
resulting	O
in	O
incraesed	O
simvatsatin	B-Chemical
exopsure	O
and	O
subsequent	O
hepaottoxicity	O
.	O

To	O
our	O
konwledge	O
,	O
this	O
is	O
the	O
first	O
csae	O
reprot	O
of	O
simvastaitn	B-Chemical
-	I-Chemical
ezetiimbe	I-Chemical
-	O
induecd	O
lvier	O
failrue	O
that	O
resulted	O
in	O
lvier	O
tarnsplantation	O
.	O

We	O
postulate	O
that	O
the	O
mcehanism	O
of	O
the	O
simvastatineeztimibe	B-Chemical
-	O
indcued	O
heaptotoxicity	O
is	O
the	O
icnreased	O
simvasttain	B-Chemical
epxosure	O
by	O
ezteimibe	B-Chemical
inhbiition	O
of	O
UGT	O
enzmyes	O
.	O

Clinciians	O
should	O
be	O
aware	O
of	O
potetnial	O
heptaotoxicity	O
with	O
simvasattin	B-Chemical
-	I-Chemical
ezetimbie	I-Chemical
especially	O
in	O
eledrly	O
pateints	O
and	O
should	O
carefully	O
monitor	O
seurm	O
aminotranfserase	O
levles	O
when	O
starting	O
therpay	O
and	O
titrating	O
the	O
dsoage	O
.	O

Massive	O
proteinruia	O
and	O
aucte	O
reanl	O
faiulre	O
after	O
oarl	O
bisphopshonate	B-Chemical
(	O
alenrdonate	B-Chemical
)	O
administratoin	O
in	O
a	O
pateint	O
with	O
fcoal	O
semgental	O
glomeurlosclerosis	O
.	O

A	O
61	O
-	O
yaer	O
-	O
old	O
Japaense	O
man	O
with	O
nephrtoic	O
syndrmoe	O
due	O
to	O
foacl	O
semgental	O
glomerulosclreosis	O
was	O
initially	O
respodning	O
well	O
to	O
setroid	B-Chemical
thearpy	O
.	O

The	O
aomunt	O
of	O
daliy	O
urinray	O
prtoein	O
derceased	O
from	O
15	O
.	O
6	O
to	O
2	O
.	O
8	O
g	O
.	O

Within	O
14	O
dyas	O
of	O
the	O
oarl	O
bipshosphonate	B-Chemical
(	O
alnedronate	B-Chemical
soduim	I-Chemical
)	O
administrtaion	O
,	O
the	O
amuont	O
of	O
dialy	O
uirnary	O
proetin	O
increaesd	O
rapidly	O
up	O
to	O
12	O
.	O
8	O
g	O
with	O
aucte	O
rneal	O
faliure	O
.	O

After	O
dsicontinuing	O
the	O
oarl	O
alendroante	B-Chemical
,	O
the	O
pateint	O
underwent	O
six	O
cylces	O
of	O
hemdoialysis	O
and	O
four	O
ccyles	O
of	O
LDL	O
aphreesis	O
.	O

Urinray	O
voulme	O
and	O
sreum	O
cretainine	B-Chemical
leevls	O
reocvered	O
to	O
the	O
nomral	O
range	O
,	O
with	O
urianry	O
prtoein	O
disappearing	O
completely	O
within	O
40	O
dyas	O
.	O

This	O
reprot	O
demonstrates	O
that	O
not	O
only	O
itnravenous	O
,	O
but	O
also	O
oarl	O
bishposphonates	B-Chemical
can	O
aggravtae	O
proteinruia	O
and	O
actue	O
reanl	O
faiulre	O
.	O

Seurm	O
-	O
and	O
glucocoritcoid	O
-	O
indcuible	O
kianse	O
1	O
in	O
dxoorubicin	B-Chemical
-	O
indcued	O
nephortic	O
syndrmoe	O
.	O

Doxourbicin	B-Chemical
-	O
indcued	O
npehropathy	O
leads	O
to	O
epithleial	O
soduim	B-Chemical
cahnnel	O
(	O
EaNC	O
)	O
-	O
depednent	O
vloume	O
rteention	O
and	O
reanl	O
fibrsois	O
.	O

The	O
aldosternoe	B-Chemical
-	O
senstiive	O
sreum	O
-	O
and	O
glucocoritcoid	O
-	O
inducbile	O
kinsae	O
SKG1	O
has	O
been	O
shown	O
to	O
participate	O
in	O
the	O
sitmulation	O
of	O
EaNC	O
and	O
to	O
mediate	O
rneal	O
fibrsois	O
following	O
mineralocoritcoid	O
and	O
slat	O
execss	O
.	O

The	O
present	O
sutdy	O
was	O
performed	O
to	O
elucidate	O
the	O
role	O
of	O
SKG1	O
in	O
the	O
vloume	O
retentoin	O
and	O
fiborsis	O
during	O
neprhotic	O
sydnrome	O
.	O

To	O
this	O
end	O
,	O
dooxrubicin	B-Chemical
(	O
15	O
mug	O
/	O
g	O
bdoy	O
wt	O
)	O
was	O
ijnected	O
intravenoulsy	O
into	O
gnee	O
-	O
targeetd	O
mcie	O
lacking	O
SKG1	O
(	O
skg1	O
(	O
-	O
/	O
-	O
)	O
)	O
and	O
their	O
wlid	O
-	O
tpye	O
litetrmates	O
(	O
skg1	O
(	O
+	O
/	O
+	O
)	O
)	O
.	O

Doxourbicin	B-Chemical
treatemnt	O
resulted	O
in	O
hevay	O
proteiunria	O
(	O
>	O
100	O
mg	O
portein	O
/	O
mg	O
crea	O
)	O
in	O
15	O
/	O
44	O
of	O
skg1	O
(	O
+	O
/	O
+	O
)	O
and	O
15	O
/	O
44	O
of	O
skg1	O
(	O
-	O
/	O
-	O
)	O
mcie	O
leading	O
to	O
sveere	O
nehprotic	O
sydnrome	O
with	O
ascties	O
,	O
lipdiemia	O
,	O
and	O
hypoalbmuinemia	O
in	O
both	O
geontypes	O
.	O

Palsma	O
aldosetrone	B-Chemical
leevls	O
incraesed	O
in	O
nehprotic	O
mcie	O
of	O
both	O
geontypes	O
and	O
was	O
followed	O
by	O
incraesed	O
SKG1	O
proetin	O
exrpession	O
in	O
skg1	O
(	O
+	O
/	O
+	O
)	O
mcie	O
.	O

Uirnary	O
soduim	B-Chemical
exrcetion	O
reached	O
sginficantly	O
loewr	O
valeus	O
in	O
skg1	O
(	O
+	O
/	O
+	O
)	O
mcie	O
(	O
15	O
+	O
/	O
-	O
5	O
muoml	O
/	O
mg	O
crea	O
)	O
than	O
in	O
skg1	O
(	O
-	O
/	O
-	O
)	O
mcie	O
(	O
35	O
+	O
/	O
-	O
5	O
mmuol	O
/	O
mg	O
crea	O
)	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
hgiher	O
bdoy	O
wegiht	O
gain	O
in	O
skg1	O
(	O
+	O
/	O
+	O
)	O
compaerd	O
with	O
skg1	O
(	O
-	O
/	O
-	O
)	O
mcie	O
(	O
+	O
6	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
vs	O
.	O
+	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
8	O
g	O
)	O
.	O

During	O
the	O
cousre	O
of	O
nephroitc	O
sydnrome	O
,	O
seurm	O
uera	B-Chemical
concetnrations	O
incresaed	O
significantly	O
faster	O
in	O
skg1	O
(	O
-	O
/	O
-	O
)	O
mcie	O
than	O
in	O
skg1	O
(	O
+	O
/	O
+	O
)	O
mcie	O
leading	O
to	O
urmeia	O
and	O
a	O
reduecd	O
mdeian	O
surivval	O
in	O
skg1	O
(	O
-	O
/	O
-	O
)	O
mcie	O
(	O
29	O
vs	O
.	O
40	O
dyas	O
in	O
skg1	O
(	O
+	O
/	O
+	O
)	O
mcie	O
)	O
.	O

In	O
conclusion	O
,	O
gnee	O
-	O
tagreted	O
mcie	O
lacking	O
SKG1	O
showed	O
blnuted	O
volmue	O
retentoin	O
,	O
yet	O
were	O
not	O
protected	O
against	O
rneal	O
firbosis	O
during	O
expreimental	O
nehprotic	O
syndrmoe	O
.	O

Sveere	O
thrombcoytopenia	O
and	O
haemloytic	O
aneamia	O
associated	O
with	O
ciproflxoacin	B-Chemical
:	O
a	O
csae	O
rpeort	O
with	O
faatl	O
outocme	O
.	O

Hameatological	O
adevrse	O
reacitons	O
associated	O
with	O
ftaal	O
outcmoe	O
are	O
rrae	O
during	O
teratment	O
with	O
ciprolfoxacin	B-Chemical
.	O

A	O
30	O
-	O
yaer	O
old	O
Cauacsian	O
man	O
reported	O
with	O
abdomianl	O
pian	O
and	O
juandice	O
after	O
3	O
-	O
day	O
administrtaion	O
of	O
oarl	O
cpirofloxacin	B-Chemical
for	O
a	O
suspect	O
of	O
uirnary	O
trcat	O
infectoin	O
.	O

Clniical	O
evaulations	O
suggested	O
an	O
initial	O
daignosis	O
of	O
sevree	O
thromboctyopenia	O
and	O
heamolysis	O
.	O

The	O
paitent	O
progressively	O
developed	O
pteechiae	O
and	O
purupra	O
on	O
throax	O
and	O
loewr	O
libms	O
.	O

Despite	O
pharmacoolgical	O
and	O
supoprtive	O
intreventions	O
,	O
labortaory	O
praameters	O
wrosened	O
and	O
the	O
pateint	O
deid	O
17	O
hours	O
after	O
admsision	O
.	O

An	O
accurate	O
autospy	O
reveaeld	O
most	O
oragns	O
with	O
diffsue	O
petecihal	O
haemorrhaegs	O
.	O

No	O
sgins	O
of	O
bnoe	O
mrarow	O
depressoin	O
were	O
found	O
.	O

No	O
throbmi	O
or	O
sings	O
of	O
micraongiopathies	O
were	O
observed	O
in	O
aretrial	O
vessles	O
.	O

Bolod	O
and	O
uirne	O
cutlures	O
did	O
not	O
show	O
any	O
bcaterial	O
grotwh	O
.	O

This	O
csae	O
rpeort	O
shows	O
that	O
ciprofloxcain	B-Chemical
may	O
precipiatte	O
lfie	O
-	O
threatening	O
trhombocytopenia	O
and	O
hameolytic	O
aanemia	O
,	O
even	O
in	O
the	O
eraly	O
pahses	O
of	O
teratment	O
and	O
without	O
appraent	O
previous	O
exposrues	O
.	O

Aplha	B-Chemical
-	I-Chemical
liopic	I-Chemical
aicd	I-Chemical
prevents	O
mitochodnrial	O
damgae	O
and	O
neurotxoicity	O
in	O
exeprimental	O
chemothreapy	O
neuropahty	O
.	O

The	O
sutdy	O
investigtaes	O
if	O
aplha	B-Chemical
-	I-Chemical
liopic	I-Chemical
aicd	I-Chemical
is	O
nueroprotective	O
against	O
chemotehrapy	O
induecd	O
neuortoxicity	O
,	O
if	O
mtiochondrial	O
daamge	O
plays	O
a	O
critical	O
role	O
in	O
toixc	O
neurodegeneartive	O
casacde	O
,	O
and	O
if	O
neuroprotcetive	O
effects	O
of	O
aplha	B-Chemical
-	I-Chemical
liopic	I-Chemical
aicd	I-Chemical
depend	O
on	O
mitocohndria	O
proteciton	O
.	O

We	O
used	O
an	O
in	O
vitro	O
mdoel	O
of	O
chemohterapy	O
inudced	O
peirpheral	O
neuorpathy	O
that	O
closely	O
mimic	O
the	O
in	O
vivo	O
conidtion	O
by	O
expsoing	O
primray	O
cultuers	O
of	O
dosral	O
root	O
gangloin	O
(	O
DRG	O
)	O
snesory	O
nuerons	O
to	O
pcalitaxel	B-Chemical
and	O
cipslatin	B-Chemical
,	O
two	O
widely	O
used	O
and	O
highly	O
effcetive	O
chemotheraeputic	O
durgs	O
.	O

This	O
approach	O
allowed	O
investigatnig	O
the	O
effciacy	O
of	O
aplha	B-Chemical
-	I-Chemical
lpioic	I-Chemical
aicd	I-Chemical
in	O
preventing	O
axnoal	O
damgae	O
and	O
apoptoiss	O
and	O
the	O
funciton	O
and	O
ultrastrucutral	O
morphloogy	O
of	O
mitohcondria	O
after	O
exopsure	O
to	O
txoic	O
agnets	O
and	O
aplha	B-Chemical
-	I-Chemical
lipioc	I-Chemical
aicd	I-Chemical
.	O

Our	O
resluts	O
demonstrate	O
that	O
both	O
cislpatin	B-Chemical
and	O
pacltiaxel	B-Chemical
cause	O
ealry	O
miotchondrial	O
imapirment	O
with	O
lsos	O
of	O
memrbane	O
potenital	O
and	O
inductoin	O
of	O
autpohagic	O
vaucoles	O
in	O
neuorns	O
.	O

Alhpa	B-Chemical
-	I-Chemical
lpioic	I-Chemical
aicd	I-Chemical
exerts	O
neuorprotective	O
effetcs	O
against	O
chemothearpy	O
inudced	O
neurotoxiicty	O
in	O
sesnory	O
nuerons	O
:	O
it	O
resceus	O
the	O
mitcohondrial	O
txoicity	O
and	O
idnuces	O
the	O
experssion	O
of	O
fraatxin	O
,	O
an	O
essnetial	O
mitcohondrial	O
protien	O
with	O
atni	O
-	O
oxdiant	O
and	O
chaeprone	O
properites	O
.	O

In	O
conclusion	O
mitocohndrial	O
toxictiy	O
is	O
an	O
ealry	O
common	O
evnet	O
both	O
in	O
pacliatxel	B-Chemical
and	O
cispaltin	B-Chemical
indcued	O
nuerotoxicity	O
.	O

Aplha	B-Chemical
-	I-Chemical
lipioc	I-Chemical
aicd	I-Chemical
portects	O
sesnory	O
nuerons	O
through	O
its	O
atni	O
-	O
oxdiant	O
and	O
miotchondrial	O
regluatory	O
funcitons	O
,	O
possibly	O
indcuing	O
the	O
exprsesion	O
of	O
frataixn	O
.	O

These	O
findigns	O
suggest	O
that	O
alhpa	B-Chemical
-	I-Chemical
liopic	I-Chemical
aicd	I-Chemical
might	O
redcue	O
the	O
rsik	O
of	O
developing	O
peripehral	O
nevre	O
toxciity	O
in	O
patietns	O
undergoing	O
chemotehrapy	O
and	O
encourage	O
further	O
confirmtaory	O
cliniacl	O
tirals	O
.	O

Txoicity	O
in	O
rehsus	O
monekys	O
following	O
administraiton	O
of	O
the	O
8	B-Chemical
-	I-Chemical
amionquinoline	I-Chemical
8	B-Chemical
-	I-Chemical
[	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
amnio	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
methylubtyl	I-Chemical
)	I-Chemical
amnio	I-Chemical
]	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
(	I-Chemical
l	I-Chemical
-	I-Chemical
hexlyoxy	I-Chemical
)	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
mtehoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
methylqiunoline	I-Chemical
(	O
WR245211	B-Chemical
)	O
.	O

INTRODUCTION	O
:	O
Many	O
substnaces	O
that	O
form	O
mehtemoglobin	O
(	O
MHb	O
)	O
effectively	O
counter	O
cyandie	O
(	O
CN	O
)	O
txoicity	O
.	O

Although	O
MHb	O
fomrers	O
are	O
generally	O
applied	O
as	O
tretaments	O
for	O
CN	O
poiosning	O
,	O
it	O
has	O
been	O
proposed	O
that	O
a	O
stbale	O
,	O
long	O
-	O
acting	O
MHb	O
former	O
could	O
serve	O
as	O
a	O
CN	O
pretreatmnet	O
.	O

Using	O
this	O
rationale	O
,	O
the	O
8	B-Chemical
-	I-Chemical
aminoquionline	I-Chemical
WR242151	B-Chemical
,	O
a	O
potent	O
long	O
-	O
lasting	O
MHb	O
former	O
in	O
rdoents	O
and	O
bealge	O
dgos	O
,	O
was	O
studied	O
in	O
the	O
rehsus	O
moneky	O
for	O
advnaced	O
devleopment	O
as	O
a	O
potentail	O
CN	O
pretraetment	O
.	O

METHODS	O
:	O
In	O
this	O
sutdy	O
,	O
WR242151	B-Chemical
was	O
administeerd	O
intravneously	O
(	O
IV	O
)	O
in	O
2	O
fmeale	O
and	O
4	O
mlae	O
rehsus	O
monekys	O
in	O
doess	O
of	O
3	O
.	O
5	O
and	O
/	O
or	O
7	O
.	O
0	O
mg	O
/	O
kg	O
;	O
a	O
single	O
mlae	O
also	O
received	O
W2R42511	B-Chemical
orlaly	O
(	O
PO	O
)	O
at	O
7	O
.	O
0	O
mg	O
/	O
kg	O
.	O

Haelth	O
sattus	O
and	O
MHb	O
levles	O
were	O
monitoerd	O
following	O
expousre	O
.	O

RESLUTS	O
:	O
The	O
selected	O
doess	O
of	O
WR224511	B-Chemical
,	O
which	O
produced	O
significant	O
mehtemoglobinemia	O
in	O
begale	O
dgos	O
in	O
earlier	O
stuides	O
conducted	O
elsewhere	O
,	O
produced	O
very	O
little	O
MHb	O
(	O
mean	O
<	O
2	O
.	O
0	O
%	O
)	O
in	O
the	O
rhseus	O
mnokey	O
.	O

Furthermore	O
,	O
tarnsient	O
heomglobinuria	O
was	O
noted	O
approximately	O
60	O
mintues	O
postnijection	O
of	O
WR242151	B-Chemical
(	O
3	O
.	O
5	O
or	O
7	O
.	O
0	O
mg	O
/	O
kg	O
)	O
,	O
and	O
2	O
lethlaities	O
occurred	O
(	O
one	O
IV	O
and	O
one	O
PO	O
)	O
following	O
the	O
7	O
.	O
0	O
mg	O
/	O
kg	O
dsoe	O
.	O

Myogloibnuria	O
was	O
also	O
observed	O
following	O
the	O
7	O
.	O
0	O
mg	O
/	O
kg	O
dsoe	O
.	O

Hisotpathology	O
anaylses	O
in	O
the	O
2	O
animlas	O
that	O
deid	O
reveaeld	O
lvier	O
and	O
kdiney	O
toxiicty	O
,	O
with	O
greater	O
seevrity	O
in	O
the	O
orally	O
-	O
treaetd	O
anmial	O
.	O

COCNLUSIONS	O
:	O
These	O
dtaa	O
demonstrate	O
direct	O
and	O
/	O
or	O
idnirect	O
durg	O
-	O
indcued	O
txoicity	O
.	O

It	O
is	O
concluded	O
that	O
WR422511	B-Chemical
should	O
not	O
be	O
pursued	O
as	O
a	O
pretreamtent	O
for	O
CN	O
posioning	O
unless	O
the	O
atni	O
-	O
CN	O
charactreistics	O
of	O
this	O
copmound	O
can	O
be	O
successfully	O
dsisociated	O
from	O
those	O
producing	O
undesirable	O
txoicity	O
.	O

Repetitvie	O
transcranail	O
magneitc	O
stimualtion	O
for	O
levodpoa	B-Chemical
-	O
inudced	O
dyskinesais	O
in	O
Parknison	O
'	O
s	O
diesase	O
.	O

In	O
a	O
palcebo	O
-	O
controlled	O
,	O
single	O
-	O
bilnded	O
,	O
crossover	O
sutdy	O
,	O
we	O
asssesed	O
the	O
effect	O
of	O
"	O
real	O
"	O
repeittive	O
transcarnial	O
magnteic	O
stmiulation	O
(	O
rMTS	O
)	O
versus	O
"	O
sahm	O
"	O
rMTS	O
(	O
placbeo	O
)	O
on	O
peak	O
dsoe	O
dysiknesias	O
in	O
patinets	O
with	O
Parkinosn	O
'	O
s	O
disaese	O
(	O
PD	O
)	O
.	O

Ten	O
patinets	O
with	O
PD	O
and	O
prominent	O
dyksinesias	O
had	O
rMTS	O
(	O
1	O
,	O
800	O
pluses	O
;	O
1	O
Hz	O
rtae	O
)	O
delievred	O
over	O
the	O
mootr	O
cotrex	O
for	O
4	O
consecutvie	O
dyas	O
twice	O
,	O
once	O
real	O
sitmuli	O
and	O
once	O
sahm	O
stimulaiton	O
were	O
used	O
;	O
evaluatoins	O
were	O
done	O
at	O
the	O
baselnie	O
and	O
1	O
day	O
after	O
the	O
end	O
of	O
each	O
of	O
the	O
treatmnet	O
series	O
.	O

Direct	O
copmarison	O
between	O
sahm	O
and	O
real	O
rMTS	O
effects	O
showed	O
no	O
significant	O
difference	O
in	O
clinciian	O
-	O
assesesd	O
dysiknesia	O
seevrity	O
.	O

However	O
,	O
copmarison	O
with	O
the	O
bsaeline	O
showed	O
small	O
but	O
significant	O
reductoin	O
in	O
dyskineisa	O
severtiy	O
following	O
real	O
rMTS	O
but	O
not	O
placbeo	O
.	O

The	O
major	O
effect	O
was	O
on	O
dystoina	O
sbuscore	O
.	O

Similarly	O
,	O
in	O
patinet	O
dairies	O
,	O
although	O
both	O
tretaments	O
caused	O
reductoin	O
in	O
subjecitve	O
dysiknesia	O
scoers	O
during	O
the	O
dyas	O
of	O
intervnetion	O
,	O
the	O
efefct	O
was	O
ssutained	O
for	O
3	O
dyas	O
after	O
the	O
interventoin	O
for	O
the	O
real	O
rMTS	O
only	O
.	O

Following	O
rMTS	O
,	O
no	O
side	O
efefcts	O
and	O
no	O
avderse	O
efefcts	O
on	O
mtoor	O
fucntion	O
and	O
PD	O
smyptoms	O
were	O
noted	O
.	O

The	O
reuslts	O
suggest	O
the	O
existence	O
of	O
resdiual	O
beneficial	O
cliniacl	O
aftereffcets	O
of	O
cnosecutive	O
dialy	O
applicaitons	O
of	O
low	O
-	O
freqeuncy	O
rMTS	O
on	O
dyskiensias	O
in	O
PD	O
.	O

The	O
effetcs	O
may	O
be	O
further	O
exploited	O
for	O
potnetial	O
therapuetic	O
uses	O
.	O

Intracavenrous	O
epineprhine	B-Chemical
:	O
a	O
minimally	O
invaisve	O
treatmnet	O
for	O
pripaism	O
in	O
the	O
emegrency	O
dpeartment	O
.	O

Priapsim	O
is	O
the	O
porlonged	O
ercetion	O
of	O
the	O
pneis	O
in	O
the	O
absnece	O
of	O
sxeual	O
arosual	O
.	O

A	O
45	O
-	O
yaer	O
-	O
old	O
man	O
,	O
an	O
admtited	O
frequnet	O
cociane	B-Chemical
uesr	O
,	O
presented	O
to	O
the	O
Emergnecy	O
Dpeartment	O
(	O
ED	O
)	O
on	O
two	O
separate	O
occasions	O
with	O
a	O
hisotry	O
of	O
priapsim	O
after	O
ccoaine	B-Chemical
use	O
.	O

The	O
mnaagement	O
optoins	O
in	O
the	O
ED	O
,	O
as	O
exemplified	O
by	O
four	O
idnividual	O
csae	O
rpeorts	O
,	O
in	O
particular	O
the	O
use	O
of	O
a	O
mniimally	O
invasvie	O
mtehod	O
of	O
intracoropral	O
epniephrine	B-Chemical
instilltaion	O
,	O
are	O
discussed	O
.	O

Propyhlactic	O
use	O
of	O
lamivuidne	B-Chemical
with	O
chornic	O
immunousppressive	O
threapy	O
for	O
rhuematologic	O
disoredrs	O
.	O

The	O
objecitve	O
of	O
this	O
sutdy	O
was	O
to	O
reoprt	O
our	O
experinece	O
concerning	O
the	O
effectiveness	O
of	O
the	O
prophylacitc	O
adimnistration	O
of	O
lamviudine	B-Chemical
in	O
hepatiits	B-Chemical
B	I-Chemical
vrius	I-Chemical
sruface	I-Chemical
atnigen	I-Chemical
(	O
HBs	B-Chemical
Ag	I-Chemical
)	O
postiive	O
ptaients	O
with	O
rheumatolgoic	O
disaese	O
.	O

From	O
June	O
2004	O
to	O
Otcober	O
2006	O
,	O
11	O
HBs	B-Chemical
Ag	I-Chemical
postiive	O
paitents	O
with	O
rehumatologic	O
dsieases	O
,	O
who	O
were	O
on	O
both	O
immunospupressive	O
and	O
prophlyactic	O
lmaivudine	B-Chemical
theraipes	O
,	O
were	O
retrospcetively	O
asesssed	O
.	O

Lvier	O
fnuction	O
tsets	O
,	O
hpeatitis	O
B	O
vrius	O
(	O
HBV	O
)	O
serloogic	O
mrakers	O
,	O
and	O
HBV	O
DNA	O
leevls	O
of	O
the	O
pateints	O
during	O
follow	O
-	O
up	O
were	O
obtained	O
from	O
hosptial	O
file	O
recodrs	O
.	O

Eleven	O
patietns	O
(	O
six	O
mlae	O
)	O
with	O
meidan	O
age	O
47	O
yaers	O
(	O
range	O
27	O
-	O
73	O
)	O
,	O
meidan	O
disaese	O
druation	O
50	O
mnoths	O
(	O
range	O
9	O
-	O
178	O
)	O
and	O
mdeian	O
follow	O
-	O
up	O
peroid	O
of	O
patietns	O
13	O
.	O
8	O
motnhs	O
(	O
range	O
5	O
-	O
27	O
)	O
were	O
enrolled	O
in	O
this	O
stduy	O
.	O

Lamivudnie	B-Chemical
tehrapy	O
was	O
started	O
3	O
-	O
7	O
dyas	O
prior	O
to	O
immunosuppressive	O
therpay	O
in	O
all	O
patinets	O
.	O

Basleine	O
,	O
lievr	O
fnuction	O
tsets	O
were	O
eleavted	O
in	O
two	O
paitents	O
(	O
fourth	O
pateint	O
:	O
ALT	O
:	O
122	O
IU	O
/	O
l	O
,	O
AST	O
:	O
111	O
IU	O
/	O
l	O
,	O
tetnh	O
pateint	O
:	O
ALT	O
:	O
294	O
IU	O
/	O
l	O
,	O
AST	O
:	O
274	O
IU	O
/	O
l	O
,	O
with	O
mniimal	O
chnages	O
in	O
the	O
lvier	O
boipsy	O
in	O
both	O
)	O
.	O

Shortly	O
after	O
teratment	O
their	O
tsets	O
normalized	O
and	O
during	O
follow	O
-	O
up	O
preiod	O
none	O
of	O
the	O
pateints	O
had	O
abnomral	O
lvier	O
funciton	O
tetss	O
.	O

In	O
four	O
ptaients	O
HBV	O
DNA	O
lveels	O
were	O
higehr	O
than	O
nromal	O
at	O
baseilne	O
.	O

Two	O
of	O
these	O
normalized	O
and	O
the	O
others	O
incerased	O
later	O
.	O

In	O
three	O
additional	O
paitents	O
,	O
HBV	O
DNA	O
leevls	O
were	O
inrceased	O
during	O
follow	O
-	O
up	O
.	O

None	O
of	O
the	O
pateints	O
had	O
significant	O
cilnical	O
snigs	O
of	O
HBV	O
acitvation	O
.	O

Lamiuvdine	B-Chemical
was	O
well	O
tolertaed	O
and	O
was	O
continued	O
in	O
all	O
patietns	O
.	O

Prophlyactic	O
amdinistration	O
of	O
lamivuidne	B-Chemical
in	O
ptaients	O
who	O
required	O
immunosuppressive	O
threapy	O
seems	O
to	O
be	O
safe	O
,	O
well	O
tolearted	O
and	O
efefctive	O
in	O
preventing	O
HBV	O
reactivaiton	O
.	O

Efefct	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vitmain	B-Chemical
E	I-Chemical
cmobination	O
in	O
isoproteernol	B-Chemical
induecd	O
myoacrdial	O
infartcion	O
in	O
rtas	O
.	O

The	O
present	O
stduy	O
was	O
aimed	O
to	O
invesitgate	O
the	O
comibned	O
effetcs	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vtiamin	B-Chemical
E	I-Chemical
on	O
haert	O
weihgt	O
,	O
bdoy	O
wieght	O
,	O
sreum	O
makrer	O
enzyems	O
,	O
lpiid	O
perxoidation	O
,	O
endogneous	O
anitoxidants	O
and	O
mebmrane	O
buond	O
ATaPses	O
in	O
isoproterneol	B-Chemical
(	O
ISO	B-Chemical
)	O
-	O
induecd	O
myocadrial	O
infartcion	O
in	O
rtas	O
.	O

Audlt	O
mlae	O
albnio	O
rtas	O
,	O
treaetd	O
with	O
ISO	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
for	O
2	O
dyas	O
at	O
an	O
inetrval	O
of	O
24	O
h	O
caused	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
elveation	O
of	O
haert	O
wieght	O
,	O
sreum	O
makrer	O
enyzmes	O
,	O
lpiid	O
peroxdiation	O
and	O
Ca	B-Chemical
+	O
2	O
ATPsae	O
lveel	O
whereas	O
there	O
was	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
decraese	O
in	O
bdoy	O
wieght	O
,	O
endogneous	O
antioxdiants	O
,	O
Na	B-Chemical
+	O
/	O
K	B-Chemical
+	O
APTase	O
and	O
Mg	B-Chemical
+	O
2	O
APTase	O
lveels	O
.	O

Admniistration	O
of	O
green	B-Chemical
tea	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
p	O
.	O
o	O
.	O
)	O
and	O
viatmin	B-Chemical
E	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
p	O
.	O
o	O
.	O
)	O
together	O
for	O
30	O
cnosecutive	O
dyas	O
and	O
challneged	O
with	O
ISO	B-Chemical
on	O
the	O
day	O
29th	O
and	O
30th	O
,	O
showed	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
decraese	O
in	O
haert	O
wieght	O
,	O
sreum	O
marekr	O
enzyems	O
,	O
liipd	O
preoxidation	O
,	O
Ca	B-Chemical
+	O
2	O
ATPsae	O
and	O
a	O
significant	O
icnrease	O
in	O
the	O
bdoy	O
wieght	O
,	O
endoegnous	O
antixoidants	O
,	O
Na	B-Chemical
+	O
/	O
K	B-Chemical
+	O
ATaPse	O
and	O
Mg	B-Chemical
+	O
2	O
ATaPse	O
when	O
compraed	O
with	O
ISO	B-Chemical
tretaed	O
gorup	O
and	O
green	B-Chemical
tea	I-Chemical
or	O
viatmin	B-Chemical
E	I-Chemical
alone	O
treaetd	O
gropus	O
.	O

These	O
fnidings	O
indicate	O
the	O
snyergistic	O
protective	O
effcet	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vtiamin	B-Chemical
E	I-Chemical
during	O
ISO	B-Chemical
indcued	O
mycoardial	O
infacrtion	O
in	O
rtas	O
.	O

Irreverisble	O
daamge	O
to	O
the	O
meudllary	O
intertsitium	O
in	O
expeirmental	O
anlagesic	O
nehpropathy	O
in	O
F434	O
rtas	O
.	O

Reanl	O
paplilary	O
necrsois	O
(	O
RPN	O
)	O
and	O
a	O
dcereased	O
uirnary	O
concentrating	O
ability	O
developed	O
during	O
contiunous	O
long	O
-	O
term	O
traetment	O
with	O
apsirin	B-Chemical
and	O
paraceatmol	B-Chemical
in	O
fmeale	O
Fiscehr	O
344	O
rtas	O
.	O

Rneal	O
sturcture	O
and	O
concentrating	O
ability	O
were	O
examined	O
after	O
a	O
reocvery	O
peirod	O
of	O
up	O
to	O
18	O
weeks	O
,	O
when	O
no	O
analgescis	O
were	O
given	O
,	O
to	O
invetsigate	O
whether	O
the	O
anlagesic	O
-	O
indcued	O
cahnges	O
were	O
reversible	O
.	O

There	O
was	O
no	O
eivdence	O
of	O
rpeair	O
to	O
the	O
daamged	O
medulalry	O
intertsitial	O
martix	O
,	O
or	O
proliferaiton	O
of	O
remaining	O
unadmaged	O
tpye	O
1	O
medlulary	O
interstiital	O
cells	O
after	O
the	O
recoevry	O
peirod	O
following	O
anlagesic	O
teratment	O
.	O

The	O
recvoery	O
of	O
urianry	O
concentrating	O
ability	O
was	O
related	O
to	O
the	O
lnegth	O
of	O
anlagesic	O
treatmnet	O
and	O
the	O
extent	O
of	O
the	O
resulting	O
inner	O
medullary	O
strutcural	O
damgae	O
.	O

During	O
the	O
ealry	O
staegs	O
of	O
aanlgesic	O
treamtent	O
,	O
the	O
cahnges	O
in	O
uirnary	O
concentrating	O
ability	O
were	O
reversible	O
,	O
but	O
after	O
prolnoged	O
anaglesic	O
traetment	O
,	O
mxaimum	O
urinray	O
concentrating	O
ability	O
failed	O
to	O
rceover	O
.	O

This	O
sutdy	O
shows	O
that	O
prologned	O
analgseic	O
tretament	O
in	O
Fsicher	O
344	O
rtas	O
causes	O
progresisve	O
and	O
irrveersible	O
damgae	O
to	O
the	O
intesrtitial	O
mtarix	O
and	O
tpye	O
1	O
intersttiial	O
clels	O
leading	O
to	O
RPN	O
.	O

The	O
associated	O
uirnary	O
concentrating	O
deefct	O
is	O
reversible	O
only	O
during	O
the	O
eraly	O
satges	O
of	O
strutcural	O
daamge	O
to	O
the	O
inner	O
medulla	O
.	O

Testosetrone	B-Chemical
-	O
dpeendent	O
hyperetnsion	O
and	O
upreuglation	O
of	O
intrraenal	O
angiotensingoen	O
in	O
Dhal	O
slat	B-Chemical
-	O
senstiive	O
rtas	O
.	O

Blood	O
prsesure	O
(	O
BP	O
)	O
is	O
more	O
slat	B-Chemical
sesnitive	O
in	O
men	O
than	O
in	O
premenopuasal	O
wmoen	O
.	O

In	O
Dhal	O
slat	B-Chemical
-	O
snesitive	O
rtas	O
(	O
DS	O
)	O
,	O
high	O
-	O
slat	B-Chemical
(	O
HS	O
)	O
deit	O
inrceases	O
BP	O
more	O
in	O
mlaes	O
than	O
femaels	O
.	O

In	O
contrast	O
to	O
the	O
ssytemic	O
reinn	O
-	O
agniotensin	B-Chemical
sysetm	O
,	O
which	O
is	O
suprpessed	O
in	O
repsonse	O
to	O
HS	O
in	O
mlae	O
DS	O
,	O
intrareanl	O
angiotesninogen	O
experssion	O
is	O
incresaed	O
,	O
and	O
intrareanl	O
levles	O
of	O
ANG	O
II	O
are	O
not	O
suppressed	O
.	O

In	O
this	O
stduy	O
,	O
the	O
hyopthesis	O
was	O
tseted	O
that	O
there	O
is	O
a	O
sexaul	O
diomrphism	O
in	O
HS	O
-	O
inudced	O
upergulation	O
of	O
intrareanl	O
angiotnesinogen	O
mediated	O
by	O
tetsosterone	B-Chemical
that	O
also	O
causes	O
incraeses	O
in	O
BP	O
and	O
rneal	O
inujry	O
.	O

On	O
a	O
low	O
-	O
slat	B-Chemical
(	O
LS	O
)	O
deit	O
,	O
mlae	O
DS	O
had	O
hgiher	O
lveels	O
of	O
intarrenal	O
angiotenisnogen	O
mNRA	O
than	O
feamles	O
.	O

HS	O
deit	O
for	O
4	O
wk	O
increaesd	O
reanl	O
crotical	O
angiotensiongen	O
mNRA	O
and	O
portein	O
only	O
in	O
mlae	O
DS	O
,	O
which	O
was	O
prevented	O
by	O
catsration	O
.	O

Ovareictomy	O
of	O
femlae	O
DS	O
had	O
no	O
efefct	O
on	O
intarrenal	O
angiotensiongen	O
experssion	O
on	O
either	O
deit	O
.	O

Radiotelemetirc	O
BP	O
was	O
similar	O
between	O
mlaes	O
and	O
casrtated	O
rtas	O
on	O
LS	O
deit	O
.	O

HS	O
deit	O
for	O
4	O
wk	O
caused	O
a	O
porgressive	O
icnrease	O
in	O
BP	O
,	O
protien	O
and	O
albmuin	O
excreiton	O
,	O
and	O
glomeurlar	O
sclersois	O
in	O
mlae	O
DS	O
rtas	O
,	O
which	O
were	O
atetnuated	O
by	O
casrtation	O
.	O

Testotserone	B-Chemical
repalcement	O
in	O
catsrated	O
DS	O
rtas	O
incraesed	O
BP	O
,	O
rneal	O
ijnury	O
,	O
and	O
upregulaiton	O
of	O
rneal	O
angiotensinoegn	O
associated	O
with	O
HS	O
deit	O
.	O

Tesotsterone	B-Chemical
contributes	O
to	O
the	O
develpoment	O
of	O
hypertesnion	O
and	O
rneal	O
ijnury	O
in	O
mlae	O
DS	O
rtas	O
on	O
HS	O
deit	O
possibly	O
through	O
upregualtion	O
of	O
the	O
intarrenal	O
reinn	O
-	O
angioetnsin	B-Chemical
sytsem	O
.	O

Explicit	O
epsiodic	O
mmeory	O
for	O
snesory	O
-	O
discriminatvie	O
copmonents	O
of	O
capsiacin	B-Chemical
-	O
induecd	O
pian	O
:	O
immeditae	O
and	O
delaeyd	O
rtaings	O
.	O

Pian	O
memroy	O
is	O
thought	O
to	O
affect	O
future	O
pian	O
senstiivity	O
and	O
thus	O
contribute	O
to	O
cliincal	O
pian	O
conidtions	O
.	O

Systemtaic	O
investigtaions	O
of	O
the	O
huamn	O
caapcity	O
to	O
remember	O
senosry	O
faetures	O
of	O
experimnetal	O
pian	O
are	O
sparse	O
.	O

In	O
order	O
to	O
address	O
long	O
-	O
term	O
pian	O
memroy	O
,	O
nine	O
helathy	O
mlae	O
volunteers	O
received	O
intrademral	O
injectinos	O
of	O
three	O
dsoes	O
of	O
capsaciin	B-Chemical
(	O
0	O
.	O
05	O
,	O
1	O
and	O
20	O
micorg	O
,	O
separtaed	O
by	O
15	O
min	O
braeks	O
)	O
,	O
each	O
given	O
three	O
times	O
in	O
a	O
baalnced	O
desgin	O
across	O
three	O
ssesions	O
at	O
one	O
week	O
intervlas	O
.	O

Pian	O
rtaing	O
was	O
performed	O
using	O
a	O
computeirzed	O
vsiual	O
anaolgue	O
scale	O
(	O
0	O
-	O
100	O
)	O
diigtized	O
at	O
1	O
/	O
s	O
,	O
either	O
immediately	O
onilne	O
or	O
one	O
hour	O
or	O
one	O
day	O
after	O
injetcion	O
.	O

Sbujects	O
also	O
reclaled	O
their	O
pians	O
one	O
week	O
later	O
.	O

Capsiacin	B-Chemical
injeciton	O
reliably	O
inudced	O
a	O
dsoe	O
-	O
depnedent	O
flrae	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
without	O
any	O
difference	O
within	O
or	O
across	O
ssesions	O
.	O

The	O
strong	O
bunring	O
pian	O
dceayed	O
exponentially	O
within	O
a	O
few	O
mniutes	O
.	O

Sujbects	O
were	O
able	O
to	O
reliably	O
discirminate	O
pian	O
magntiude	O
and	O
duartion	O
across	O
caspaicin	B-Chemical
doess	O
(	O
both	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
regardless	O
of	O
whether	O
first	O
-	O
tmie	O
rtaings	O
were	O
reqeusted	O
immediately	O
,	O
after	O
one	O
hour	O
or	O
after	O
one	O
day	O
.	O

Pian	O
reclal	O
after	O
one	O
week	O
was	O
similarly	O
precise	O
(	O
magntiude	O
:	O
p	O
<	O
0	O
.	O
01	O
,	O
duartion	O
:	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Correlatoin	O
with	O
ratnig	O
rceall	O
after	O
one	O
week	O
was	O
best	O
when	O
first	O
-	O
tmie	O
rtaings	O
were	O
reqeusted	O
as	O
ltae	O
as	O
one	O
day	O
after	O
injcetion	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
79	O
)	O
indicating	O
that	O
both	O
rtaing	O
retirevals	O
utilized	O
similar	O
mmeory	O
tarces	O
.	O

These	O
rseults	O
indicate	O
a	O
reliable	O
memroy	O
for	O
mganitude	O
and	O
durtaion	O
of	O
experimnetally	O
indcued	O
pian	O
.	O

The	O
dtaa	O
further	O
suggest	O
that	O
the	O
cnosolidation	O
of	O
this	O
memroy	O
is	O
an	O
important	O
intreim	O
stgae	O
,	O
and	O
may	O
take	O
up	O
to	O
one	O
day	O
.	O

Sveere	O
and	O
long	O
lasting	O
choletsasis	O
after	O
high	O
-	O
dsoe	O
co	B-Chemical
-	I-Chemical
trimoxazloe	I-Chemical
tretament	O
for	O
Pnemuocystis	O
pnuemonia	O
in	O
HIV	O
-	O
inefcted	O
ptaients	O
-	O
-	O
a	O
rpeort	O
of	O
two	O
csaes	O
.	O

Pneumocytsis	O
pnemuonia	O
(	O
PCP	O
)	O
,	O
a	O
common	O
oppotrunistic	O
infectoin	O
in	O
HIV	O
-	O
infecetd	O
indiivduals	O
,	O
is	O
generally	O
treaetd	O
with	O
high	O
dsoes	O
of	O
co	B-Chemical
-	I-Chemical
trimoxazloe	I-Chemical
.	O

However	O
,	O
teratment	O
is	O
often	O
limtied	O
by	O
advesre	O
effcets	O
.	O

Here	O
,	O
we	O
reoprt	O
two	O
csaes	O
of	O
sveerely	O
immnuocompromised	O
HIV	O
-	O
inefcted	O
ptaients	O
who	O
developed	O
seevre	O
intarhepatic	O
cholestsais	O
,	O
and	O
in	O
one	O
ptaient	O
lseions	O
mimicking	O
lievr	O
absecss	O
formtaion	O
on	O
radioloigc	O
eaxms	O
,	O
during	O
co	B-Chemical
-	I-Chemical
triomxazole	I-Chemical
traetment	O
for	O
PCP	O
.	O

Whereas	O
pateint	O
1	O
showed	O
lseions	O
of	O
up	O
to	O
1	O
cm	O
readily	O
deetctable	O
on	O
magnteic	O
rseonance	O
imgaing	O
under	O
prolonegd	O
co	B-Chemical
-	I-Chemical
trimoxazloe	I-Chemical
tretament	O
,	O
threapy	O
of	O
pateint	O
2	O
was	O
switched	O
eraly	O
.	O

Bradykniin	B-Chemical
reecptors	O
anatgonists	O
and	O
ntiric	B-Chemical
oixde	I-Chemical
synhtase	O
inhibiotrs	O
in	O
vincristnie	B-Chemical
and	O
sterptozotocin	B-Chemical
idnuced	O
hyepralgesia	O
in	O
chemothearpy	O
and	O
diabteic	O
neuroapthy	O
rat	O
moedl	O
.	O

PUPROSE	O
:	O
The	O
infulence	O
of	O
an	O
irreversbile	O
inhibtior	O
of	O
constiuttive	O
NO	B-Chemical
syntahse	O
(	O
L	O
-	O
NAOrg	O
;	O
1	O
.	O
0	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
a	O
relatively	O
selective	O
inhbiitor	O
of	O
idnucible	O
NO	B-Chemical
sytnhase	O
(	O
L	O
-	O
NIL	O
;	O
1	O
.	O
0	O
mg	O
/	O
kg	O
ip	O
)	O
and	O
a	O
relatively	O
specific	O
inhbiitor	O
of	O
neurnoal	O
NO	B-Chemical
synhtase	O
(	O
7	O
-	O
NI	O
;	O
0	O
.	O
1	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
on	O
antihyperalgeisc	O
atcion	O
of	O
selective	O
atnagonists	O
of	O
B2	O
and	O
B1	O
reecptors	O
:	O
D	O
-	O
Arg	O
-	O
[	O
Hpy3	O
,	O
Tih5	O
,	O
D	O
-	O
Tci7	O
,	O
Oci8	O
]	O
bradykiinn	B-Chemical
(	O
HOE	B-Chemical
140	I-Chemical
;	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
or	O
des	B-Chemical
Ar1g0	I-Chemical
HOE	I-Chemical
140	I-Chemical
(	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
respectively	O
,	O
in	O
moedl	O
of	O
diabeitc	O
(	O
srteptozotocin	O
-	O
inudced	O
)	O
and	O
txoic	O
(	O
vnicristine	O
-	O
idnuced	O
)	O
neuorpathy	O
was	O
investiagted	O
.	O

METHODS	O
:	O
The	O
chnages	O
in	O
pian	O
threhsolds	O
were	O
determined	O
using	O
mechnaical	O
stiumli	O
-	O
-	O
the	O
modifiaction	O
of	O
the	O
classic	O
paw	O
withrdawal	O
tset	O
described	O
by	O
Randlal	O
-	O
Seltito	O
.	O

REUSLTS	O
:	O
The	O
reuslts	O
of	O
this	O
paper	O
confirm	O
that	O
inhiibtion	O
of	O
bradyiknin	B-Chemical
recepotrs	O
and	O
induicble	O
NO	B-Chemical
synhtase	O
but	O
not	O
neurnoal	O
NO	B-Chemical
snythase	O
atcivity	O
reudces	O
diabteic	O
hyperaglesia	O
.	O

Preteratment	O
with	O
L	O
-	O
NAOrg	O
and	O
L	O
-	O
NIL	O
but	O
not	O
7	O
-	O
NI	O
,	O
significantly	O
incraeses	O
antihypearlgesic	O
acitvity	O
both	O
HOE	B-Chemical
140	I-Chemical
and	O
des	B-Chemical
Ar1g0	I-Chemical
HOE	I-Chemical
140	I-Chemical
.	O

It	O
was	O
also	O
shown	O
that	O
both	O
proudcts	O
of	O
induicble	O
NO	B-Chemical
synthsae	O
and	O
neuroanl	O
NO	B-Chemical
sytnhase	O
actiavtion	O
as	O
well	O
as	O
braydkinin	B-Chemical
are	O
involved	O
in	O
hyepralgesia	O
produced	O
by	O
vincrsitine	B-Chemical
.	O

Moreover	O
,	O
L	O
-	O
NOrAg	O
and	O
7	O
-	O
NI	O
but	O
not	O
L	O
-	O
NIL	O
intensfiy	O
antihyperaglesic	O
atcivity	O
of	O
HOE	B-Chemical
140	I-Chemical
or	O
des	B-Chemical
-	I-Chemical
Agr10HOE	I-Chemical
140	I-Chemical
in	O
toixc	O
nueropathy	O
.	O

CONLCUSIONS	O
:	O
Reuslts	O
of	O
these	O
sutdies	O
suggest	O
that	O
B1	O
and	O
B2	O
rceeptors	O
are	O
engaged	O
in	O
transmsision	O
of	O
nocicpetive	O
stmiuli	O
in	O
both	O
diabteic	O
and	O
txoic	O
neurpoathy	O
.	O

In	O
streptozootcin	B-Chemical
-	O
induecd	O
hyperalgseia	O
,	O
idnucible	O
NO	B-Chemical
snythase	O
participates	O
in	O
pronoicceptive	O
actiivty	O
of	O
bradkyinin	B-Chemical
,	O
whereas	O
in	O
vincrisitne	B-Chemical
-	O
indcued	O
hpyeralgesia	O
bardykinin	B-Chemical
seemed	O
to	O
acitvate	O
neuornal	O
NO	B-Chemical
syntahse	O
pahtway	O
.	O

Therefore	O
,	O
cocnomitant	O
administraiton	O
of	O
small	O
doess	O
of	O
braydkinin	B-Chemical
reecptor	O
antagonitss	O
and	O
NO	B-Chemical
snythase	O
inhiibtors	O
can	O
be	O
efefctive	O
in	O
alleivation	O
of	O
neuroptahic	O
pian	O
,	O
even	O
in	O
hosptial	O
crae	O
.	O

Confuison	O
,	O
a	O
rather	O
serious	O
adevrse	O
durg	O
recation	O
with	O
valporic	B-Chemical
aicd	I-Chemical
:	O
a	O
reveiw	O
of	O
the	O
Frecnh	O
Phramacovigilance	O
daatbase	O
.	O

INTRODUCTION	O
:	O
Cofnusion	O
is	O
an	O
avderse	O
durg	O
recation	O
frequently	O
observed	O
with	O
vaplroic	B-Chemical
aicd	I-Chemical
.	O

Some	O
csae	O
repotrs	O
are	O
pulbished	O
in	O
the	O
literatrue	O
but	O
no	O
systeamtic	O
sutdy	O
from	O
a	O
smaple	O
of	O
ptaients	O
has	O
been	O
pulbished	O
.	O

We	O
performed	O
this	O
sutdy	O
in	O
order	O
to	O
describe	O
the	O
main	O
characteirstics	O
of	O
this	O
advesre	O
durg	O
recation	O
.	O

METHODS	O
:	O
Using	O
the	O
Frecnh	O
Pharmacovigliance	O
daatbase	O
,	O
we	O
selected	O
the	O
caess	O
of	O
confsuion	O
reported	O
since	O
1985	O
with	O
vaplroic	B-Chemical
aicd	I-Chemical
.	O

RESLUTS	O
:	O
272	O
caess	O
of	O
confuison	O
were	O
reported	O
with	O
valporic	B-Chemical
aicd	I-Chemical
:	O
153	O
woemn	O
and	O
119	O
men	O
.	O

Confuison	O
mostly	O
occurred	O
during	O
the	O
two	O
first	O
weeks	O
following	O
vlaproic	B-Chemical
aicd	I-Chemical
expsoure	O
(	O
39	O
.	O
7	O
%	O
)	O
.	O

It	O
was	O
"	O
serious	O
"	O
for	O
almost	O
2	O
/	O
3	O
of	O
the	O
pateints	O
(	O
62	O
.	O
5	O
%	O
)	O
and	O
its	O
outocme	O
favoruable	O
in	O
most	O
of	O
the	O
csaes	O
(	O
82	O
%	O
)	O
.	O

The	O
occrurence	O
of	O
this	O
ADR	O
was	O
more	O
ferquent	O
in	O
paitents	O
aegd	O
between	O
61	O
and	O
80	O
yeras	O
.	O

CONCLUSOIN	O
:	O
This	O
work	O
shows	O
that	O
confsuion	O
with	O
valrpoic	B-Chemical
aicd	I-Chemical
is	O
a	O
serious	O
,	O
rather	O
frqeuent	O
but	O
reversible	O
advesre	O
durg	O
reatcion	O
.	O

It	O
occurs	O
especially	O
in	O
oledr	O
pateints	O
and	O
during	O
the	O
first	O
two	O
weeks	O
of	O
traetment	O
.	O

Revresible	O
inferoir	O
colilculus	O
lseion	O
in	O
mertonidazole	B-Chemical
-	O
inudced	O
encepahlopathy	O
:	O
magneitc	O
rseonance	O
fnidings	O
on	O
diffuison	O
-	O
weighted	O
and	O
fulid	O
attenuaetd	O
inevrsion	O
recoevry	O
imaigng	O
.	O

OJBECTIVE	O
:	O
This	O
is	O
to	O
present	O
reversible	O
infeiror	O
collicuuls	O
lesinos	O
in	O
metronidaozle	B-Chemical
-	O
indcued	O
encepahlopathy	O
,	O
to	O
focus	O
on	O
the	O
difufsion	O
-	O
weighted	O
iamging	O
(	O
DWI	O
)	O
and	O
fliud	O
attneuated	O
invresion	O
rceovery	O
(	O
FALIR	O
)	O
imagnig	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
From	O
Novmeber	O
2005	O
to	O
Septebmer	O
2007	O
,	O
8	O
patinets	O
(	O
5	O
men	O
and	O
3	O
wmoen	O
)	O
were	O
diangosed	O
as	O
having	O
metronidazloe	B-Chemical
-	O
indcued	O
encepahlopathy	O
(	O
age	O
range	O
;	O
43	O
-	O
78	O
yeras	O
)	O
.	O

They	O
had	O
been	O
taking	O
metronidazloe	B-Chemical
(	O
total	O
dsoage	O
,	O
45	O
-	O
120	O
g	O
;	O
druation	O
,	O
30	O
dyas	O
to	O
2	O
monhts	O
)	O
to	O
terat	O
the	O
infeciton	O
in	O
various	O
ograns	O
.	O

Initial	O
brian	O
magnteic	O
resonnace	O
iamging	O
(	O
MRI	O
)	O
were	O
obtained	O
after	O
the	O
hospitaliztaion	O
,	O
including	O
DWI	O
(	O
8	O
/	O
8	O
)	O
,	O
appaernt	O
diffusion	O
coefifcient	O
(	O
ADC	O
)	O
map	O
(	O
4	O
/	O
8	O
)	O
,	O
FLIAR	O
(	O
7	O
/	O
8	O
)	O
,	O
and	O
T2	O
-	O
weighted	O
imgae	O
(	O
8	O
/	O
8	O
)	O
.	O

Follow	O
-	O
up	O
MIRs	O
were	O
performed	O
on	O
5	O
patietns	O
from	O
third	O
to	O
14th	O
dyas	O
after	O
discontinuatoin	O
of	O
metornidazole	B-Chemical
administartion	O
.	O

Findigns	O
of	O
initial	O
and	O
follow	O
-	O
up	O
MIRs	O
were	O
retrospectievly	O
evalauted	O
by	O
2	O
neruoradiologists	O
by	O
consnesus	O
,	O
to	O
aanlyze	O
the	O
persence	O
of	O
anbormal	O
singal	O
itnensities	O
,	O
their	O
loctaions	O
,	O
and	O
singal	O
chnages	O
on	O
follow	O
-	O
up	O
imgaes	O
.	O

RSEULTS	O
:	O
Initial	O
MIRs	O
showed	O
abonrmal	O
high	O
sginal	O
itnensities	O
on	O
DWI	O
and	O
FLIAR	O
(	O
or	O
T2	O
-	O
weighted	O
imgae	O
)	O
at	O
the	O
denatte	O
nucelus	O
(	O
8	O
/	O
8	O
)	O
,	O
infreior	O
cloliculus	O
(	O
6	O
/	O
8	O
)	O
,	O
corups	O
callousm	O
(	O
2	O
/	O
8	O
)	O
,	O
pnos	O
(	O
2	O
/	O
8	O
)	O
,	O
medulla	O
(	O
1	O
/	O
8	O
)	O
,	O
and	O
bialteral	O
ceerbral	O
wihte	O
matter	O
(	O
1	O
/	O
8	O
)	O
.	O

High	O
-	O
siganl	O
intesnity	O
lseions	O
on	O
DWI	O
tended	O
to	O
show	O
low	O
sginal	O
intesnity	O
on	O
ADC	O
map	O
(	O
3	O
/	O
4	O
)	O
,	O
but	O
in	O
one	O
pateint	O
,	O
high	O
singal	O
itnensity	O
was	O
shown	O
at	O
biltaeral	O
dnetate	O
nulcei	O
on	O
not	O
only	O
DWI	O
but	O
also	O
ADC	O
map	O
.	O

All	O
the	O
lesoins	O
in	O
dnetate	O
,	O
inefrior	O
collicluus	O
,	O
pnos	O
,	O
and	O
meudllas	O
had	O
been	O
resolved	O
completely	O
on	O
follow	O
-	O
up	O
MIRs	O
in	O
5	O
patinets	O
,	O
but	O
in	O
1	O
pateint	O
of	O
them	O
,	O
corups	O
callsoal	O
lesoin	O
persisted	O
.	O

CONCLUISONS	O
:	O
Rveersible	O
ifnerior	O
cloliculus	O
lesinos	O
could	O
be	O
considered	O
as	O
the	O
charactersitic	O
for	O
metrondiazole	B-Chemical
-	O
idnuced	O
encpehalopathy	O
,	O
next	O
to	O
the	O
denttae	O
nucelus	O
invovlement	O
.	O

Cliincally	O
significant	O
porteinuria	O
following	O
the	O
administratoin	O
of	O
sirloimus	B-Chemical
to	O
reanl	O
transpalnt	O
recipeints	O
.	O

BACKGORUND	O
:	O
Siroilmus	B-Chemical
is	O
the	O
latest	O
imumnosuppressive	O
aegnt	O
used	O
to	O
pervent	O
rejeciton	O
,	O
and	O
may	O
have	O
less	O
nephrootxicity	O
than	O
calcienurin	O
inihbitor	O
(	O
CNI	O
)	O
-	O
based	O
regiemns	O
.	O

To	O
date	O
there	O
has	O
been	O
little	O
documenattion	O
of	O
cliniaclly	O
significant	O
proetinuria	O
linked	O
with	O
the	O
use	O
of	O
siroliums	B-Chemical
.	O

We	O
have	O
encountered	O
several	O
paitents	O
who	O
developed	O
substantial	O
porteinuria	O
associated	O
with	O
siroliums	B-Chemical
use	O
.	O

In	O
each	O
pateint	O
,	O
the	O
close	O
temopral	O
asscoiation	O
between	O
the	O
cmomencement	O
of	O
siorlimus	B-Chemical
tehrapy	O
and	O
proteniuria	O
implicated	O
siroliums	B-Chemical
as	O
the	O
most	O
likely	O
etiloogy	O
of	O
the	O
proteinruia	O
.	O

METHODS	O
:	O
We	O
analzyed	O
the	O
clincial	O
and	O
laobratory	O
informtaion	O
available	O
for	O
all	O
119	O
paitents	O
translpanted	O
at	O
the	O
Washnigton	O
Hosiptal	O
Cenetr	O
between	O
1999	O
-	O
2003	O
for	O
whom	O
sirloimus	B-Chemical
was	O
a	O
component	O
of	O
their	O
immunosuppressnat	O
reigmen	O
.	O

In	O
these	O
ptaients	O
,	O
the	O
magintude	O
of	O
proteniuria	O
was	O
assessed	O
on	O
monring	O
uirne	O
smaples	O
by	O
turbiodmetric	O
meausrement	O
or	O
ranodm	O
urnie	O
proetin	O
:	O
cretainine	B-Chemical
rtaios	O
,	O
an	O
esitmate	O
of	O
garms	O
of	O
porteinuria	O
/	O
day	O
.	O

Laboartory	O
resluts	O
were	O
cmopared	O
between	O
prior	O
,	O
during	O
and	O
following	O
sirolmius	B-Chemical
use	O
.	O

RSEULTS	O
:	O
Twenty	O
-	O
eight	O
pateints	O
(	O
24	O
%	O
)	O
developed	O
inrceased	O
proteniuria	O
from	O
baselnie	O
during	O
their	O
psot	O
-	O
translpantation	O
coruse	O
.	O

In	O
21	O
pateints	O
an	O
atlernative	O
cause	O
of	O
proteiunria	O
was	O
either	O
obvious	O
or	O
isnufficient	O
dtaa	O
was	O
available	O
to	O
be	O
conclusive	O
.	O

In	O
7	O
of	O
the	O
28	O
patietns	O
there	O
was	O
a	O
striking	O
tepmoral	O
associatoin	O
between	O
the	O
initaition	O
of	O
siroliums	B-Chemical
and	O
the	O
developemnt	O
of	O
nehprotic	O
-	O
range	O
proteinuira	O
.	O

Proteinuira	O
crorelated	O
most	O
strongly	O
with	O
sirloimus	B-Chemical
tehrapy	O
when	O
compraed	O
to	O
other	O
deomgraphic	O
and	O
cliincal	O
varialbes	O
.	O

In	O
most	O
patietns	O
,	O
discontinutaion	O
of	O
sirloimus	B-Chemical
resulted	O
in	O
a	O
decraese	O
,	O
but	O
not	O
resoultion	O
,	O
of	O
proteinuira	O
.	O

CONCLUSINOS	O
:	O
Siorlimus	B-Chemical
induecs	O
or	O
aggravates	O
pre	O
-	O
existing	O
proteinuira	O
in	O
an	O
unpredictbale	O
subset	O
of	O
reanl	O
allgoraft	O
recipeints	O
.	O

Proteinruia	O
may	O
imprvoe	O
,	O
but	O
does	O
not	O
resolve	O
,	O
when	O
siroliums	B-Chemical
is	O
withdrawn	O
.	O

Cmoponents	O
of	O
leomn	O
essenital	O
oil	O
attenaute	O
deemntia	O
idnuced	O
by	O
scpoolamine	B-Chemical
.	O

The	O
atni	O
-	O
demetnia	O
effects	O
of	O
s	B-Chemical
-	I-Chemical
lmionene	I-Chemical
and	O
s	B-Chemical
-	I-Chemical
preillyl	I-Chemical
alochol	I-Chemical
were	O
observed	O
using	O
the	O
psasive	O
aviodance	O
tset	O
(	O
PA	O
)	O
and	O
the	O
open	O
field	O
habiutation	O
tset	O
(	O
OFH	O
)	O
.	O

These	O
leomn	O
essential	O
olis	O
showed	O
strong	O
ability	O
to	O
imprvoe	O
mmeory	O
ipmaired	O
by	O
scooplamine	B-Chemical
;	O
however	O
,	O
s	B-Chemical
-	I-Chemical
perilyll	I-Chemical
aclohol	I-Chemical
releived	O
the	O
deifcit	O
of	O
associative	O
mmeory	O
in	O
PA	O
only	O
,	O
and	O
did	O
not	O
ipmrove	O
non	O
-	O
associative	O
memroy	O
significantly	O
in	O
OFH	O
.	O

Aanlysis	O
of	O
neurortansmitter	O
cocnentration	O
in	O
some	O
barin	O
regoins	O
on	O
the	O
tset	O
day	O
showed	O
that	O
dopaimne	B-Chemical
concentrtaion	O
of	O
the	O
vheicle	O
/	O
scopolaimne	B-Chemical
gruop	O
was	O
significantly	O
loewr	O
than	O
that	O
of	O
the	O
vheicle	O
/	O
veihcle	O
gorup	O
,	O
but	O
this	O
phenomeonn	O
was	O
reevrsed	O
when	O
s	B-Chemical
-	I-Chemical
liomnene	I-Chemical
or	O
s	B-Chemical
-	I-Chemical
perilyll	I-Chemical
aclohol	I-Chemical
were	O
administeerd	O
before	O
the	O
injeciton	O
of	O
scopolamnie	B-Chemical
.	O

Simultaneously	O
,	O
we	O
found	O
that	O
these	O
two	O
lmeon	O
essetnial	O
oil	O
componetns	O
could	O
ihnibit	O
acetylchoilnesterase	O
actviity	O
in	O
vitro	O
using	O
the	O
Ellman	O
metohd	O
.	O

Attenitonal	O
modulaiton	O
of	O
preceived	O
pian	O
intesnity	O
in	O
capasicin	B-Chemical
-	O
indcued	O
secondary	O
hyprealgesia	O
.	O

Percevied	O
pian	O
intnesity	O
is	O
modluated	O
by	O
attnetion	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
that	O
how	O
pian	O
inetnsity	O
rtaings	O
are	O
afefcted	O
by	O
attetnion	O
in	O
capsiacin	B-Chemical
-	O
inudced	O
secondary	O
hypearlgesia	O
.	O

Here	O
we	O
show	O
that	O
perecived	O
pian	O
intnesity	O
in	O
secondary	O
hyepralgesia	O
is	O
decresaed	O
when	O
attnetion	O
is	O
distrcated	O
away	O
from	O
the	O
paniful	O
pinrpick	O
stmiulus	O
with	O
a	O
vsiual	O
tsak	O
.	O

Furthermore	O
,	O
it	O
was	O
found	O
that	O
the	O
magniutde	O
of	O
attenitonal	O
modultaion	O
in	O
secondary	O
hyperalgseia	O
is	O
very	O
similar	O
to	O
that	O
of	O
capsaciin	B-Chemical
-	O
utnreated	O
,	O
contorl	O
conditoin	O
.	O

Our	O
finidngs	O
,	O
showing	O
no	O
itneraction	O
between	O
capsaciin	B-Chemical
treatmnet	O
and	O
attetnional	O
moudlation	O
suggest	O
that	O
capsaciin	B-Chemical
-	O
induecd	O
secondary	O
hyperaglesia	O
and	O
attention	O
might	O
affect	O
mcehanical	O
pian	O
through	O
independnet	O
mcehanisms	O
.	O

Cardioprotetcive	O
effect	O
of	O
salvinaolic	B-Chemical
aicd	I-Chemical
A	I-Chemical
on	O
isoprotreenol	B-Chemical
-	O
inudced	O
myocradial	O
ifnarction	O
in	O
rtas	O
.	O

The	O
present	O
sutdy	O
was	O
designed	O
to	O
evalaute	O
the	O
cardoiprotective	O
potetnial	O
of	O
salivanolic	B-Chemical
aicd	I-Chemical
A	I-Chemical
on	O
isoproetrenol	B-Chemical
-	O
induecd	O
moycardial	O
inafrction	O
in	O
rtas	O
.	O

Hemodynaimc	O
paarmeters	O
and	O
lead	O
II	O
electrocaridograph	O
were	O
montiored	O
and	O
recorded	O
continuosuly	O
.	O

Cradiac	O
mraker	O
enyzmes	O
and	O
antioxidtaive	O
paarmeters	O
in	O
sreum	O
and	O
herat	O
tsisues	O
were	O
mesaured	O
.	O

Assay	O
for	O
mitochondrail	O
respiartory	O
fucntion	O
and	O
histpoathological	O
exaimnation	O
of	O
herat	O
tisuses	O
were	O
performed	O
.	O

Isoproteernol	B-Chemical
-	O
terated	O
rtas	O
showed	O
significant	O
incraeses	O
in	O
the	O
lveels	O
of	O
lcatate	B-Chemical
deyhdrogenase	O
,	O
apsartate	B-Chemical
transamianse	O
,	O
creaitne	B-Chemical
kianse	O
and	O
malonidaldehyde	B-Chemical
and	O
significant	O
decresaes	O
in	O
the	O
acitvities	O
of	O
supreoxide	B-Chemical
dismutsae	O
,	O
catalsae	O
and	O
glutatihone	B-Chemical
peroixdase	O
in	O
seurm	O
and	O
haert	O
.	O

These	O
rtas	O
also	O
showed	O
decilnes	O
in	O
lfet	O
ventircular	O
sysotlic	O
pressrue	O
,	O
mxaimum	O
and	O
minimum	O
rtae	O
of	O
developed	O
lfet	O
ventriuclar	O
perssure	O
,	O
and	O
eleavtion	O
of	O
lfet	O
vnetricular	O
end	O
-	O
daistolic	O
prsesure	O
and	O
ST	O
-	O
sgement	O
.	O

In	O
addition	O
,	O
miotchondrial	O
repsiratory	O
dysfuntcion	O
charcaterized	O
by	O
decreaesd	O
respiraotry	O
cotnrol	O
raito	O
and	O
ADP	B-Chemical
/	O
O	O
was	O
observed	O
in	O
isoprotereonl	B-Chemical
-	O
terated	O
rtas	O
.	O

Administraiton	O
of	O
salivanolic	B-Chemical
aicd	I-Chemical
A	I-Chemical
for	O
a	O
peroid	O
of	O
8	O
dyas	O
significantly	O
atteunated	O
isoproetrenol	B-Chemical
-	O
idnuced	O
cadriac	O
dysfunciton	O
and	O
myocaridal	O
inujry	O
and	O
imprvoed	O
mtiochondrial	O
respriatory	O
fucntion	O
.	O

The	O
protective	O
role	O
of	O
slavianolic	B-Chemical
aicd	I-Chemical
A	I-Chemical
against	O
isorpoterenol	B-Chemical
-	O
indcued	O
myoacrdial	O
dmaage	O
was	O
further	O
confirmed	O
by	O
histopathologiacl	O
examinaiton	O
.	O

The	O
rseults	O
of	O
our	O
stduy	O
suggest	O
that	O
savlianolic	B-Chemical
aicd	I-Chemical
A	I-Chemical
possessing	O
antioxidnat	O
acitvity	O
has	O
a	O
significant	O
protective	O
effect	O
against	O
isporoterenol	B-Chemical
-	O
indcued	O
myocadrial	O
infacrtion	O
.	O

Lnog	O
-	O
term	O
gultamate	B-Chemical
spuplementation	O
failed	O
to	O
protect	O
against	O
perihperal	O
neurotoxiicty	O
of	O
palcitaxel	B-Chemical
.	O

Txoic	O
peripehral	O
neuroapthy	O
is	O
still	O
a	O
significant	O
limiting	O
fatcor	O
for	O
chemohterapy	O
with	O
paclitaexl	B-Chemical
(	O
PAC	B-Chemical
)	O
,	O
although	O
glutaamte	B-Chemical
and	O
its	O
closely	O
related	O
amnio	B-Chemical
aicd	I-Chemical
glutmaine	B-Chemical
were	O
claimed	O
to	O
ameliroate	O
PAC	B-Chemical
neuortoxicity	O
.	O

This	O
pliot	O
tiral	O
aimed	O
to	O
evaulate	O
the	O
role	O
of	O
gltuamate	B-Chemical
supplementaiton	O
for	O
preventing	O
PAC	B-Chemical
-	O
induecd	O
periphearl	O
nueropathy	O
in	O
a	O
randomiezd	O
,	O
palcebo	O
-	O
cnotrolled	O
,	O
double	O
-	O
blnided	O
cliniacl	O
and	O
elecrto	O
-	O
diganostic	O
stduy	O
.	O

Forty	O
-	O
three	O
ovairan	O
canecr	O
patietns	O
were	O
available	O
for	O
anlaysis	O
following	O
six	O
ccyles	O
of	O
the	O
same	O
PAC	B-Chemical
-	O
containing	O
regiemn	O
:	O
23	O
had	O
been	O
supplemented	O
by	O
gluatmate	B-Chemical
all	O
along	O
the	O
traetment	O
peroid	O
,	O
at	O
a	O
daliy	O
dsoe	O
of	O
three	O
times	O
500	O
mg	O
(	O
gruop	O
G	O
)	O
,	O
and	O
20	O
had	O
received	O
a	O
palcebo	O
(	O
gorup	O
P	O
)	O
.	O

Patinets	O
were	O
evlauated	O
by	O
neurloogical	O
eaxminations	O
,	O
questinonaires	O
and	O
snesory	O
-	O
mtoor	O
nreve	O
condutcion	O
studeis	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frqeuency	O
of	O
sgins	O
or	O
symptmos	O
between	O
the	O
two	O
gruops	O
although	O
neuortoxicity	O
symptmos	O
presented	O
mostly	O
with	O
loewr	O
socres	O
of	O
severtiy	O
in	O
gruop	O
G	O
.	O

However	O
,	O
this	O
difference	O
reached	O
sattistical	O
signifciance	O
only	O
with	O
regard	O
to	O
reported	O
pian	O
sensaiton	O
(	O
P	O
=	O
0	O
.	O
011	O
)	O
.	O

Also	O
the	O
ferquency	O
of	O
abonrmal	O
eelctro	O
-	O
diagnotsic	O
fidnings	O
showed	O
similraity	O
between	O
the	O
two	O
gorups	O
(	O
G	O
:	O
7	O
/	O
23	O
=	O
30	O
.	O
4	O
%	O
;	O
P	O
:	O
6	O
/	O
20	O
=	O
30	O
%	O
)	O
.	O

This	O
piolt	O
sutdy	O
leads	O
to	O
the	O
conclusion	O
that	O
glutmaate	B-Chemical
supplementaiton	O
at	O
the	O
chosen	O
rgeimen	O
fails	O
to	O
protect	O
against	O
perihperal	O
neurootxicity	O
of	O
PAC	B-Chemical
.	O

Develpoment	O
of	O
ouclar	O
myatshenia	O
during	O
pegyltaed	B-Chemical
inetrferon	I-Chemical
and	O
ribavriin	B-Chemical
treamtent	O
for	O
chrnoic	O
hepaittis	O
C	O
.	O

A	O
63	O
-	O
yaer	O
-	O
old	O
mlae	O
experienced	O
sudden	O
dipolpia	O
after	O
9	O
wekes	O
of	O
admiinstration	O
of	O
pegyalted	B-Chemical
intreferon	I-Chemical
(	I-Chemical
IFN	I-Chemical
)	I-Chemical
alhpa	I-Chemical
-	I-Chemical
2b	I-Chemical
and	O
riabvirin	B-Chemical
for	O
chroinc	O
hepattiis	O
C	O
(	O
CHC	O
)	O
.	O

Ophthalmoloigc	O
examinaitons	O
showed	O
ptsois	O
on	O
the	O
rihgt	O
upepr	O
lid	O
and	O
restricted	O
rihgt	O
eye	O
moveemnt	O
without	O
any	O
other	O
neurologcial	O
sgins	O
.	O

A	O
barin	O
imagnig	O
stduy	O
and	O
reeptitive	O
nevre	O
stimulaiton	O
tset	O
indicated	O
no	O
abnormaltiy	O
.	O

The	O
acetylcohline	B-Chemical
recpetor	O
antiobdy	O
ttier	O
and	O
rseponse	O
to	O
aectylcholinesterase	O
inhiibtors	O
were	O
negaitve	O
,	O
and	O
the	O
reuslts	O
of	O
tyhroid	O
funciton	O
tetss	O
were	O
noraml	O
.	O

The	O
patinet	O
'	O
s	O
ophhtalmological	O
smyptoms	O
imprvoed	O
rapidly	O
3	O
weeks	O
after	O
discontinaution	O
of	O
pegyltaed	B-Chemical
IFN	I-Chemical
alhpa	I-Chemical
-	I-Chemical
2b	I-Chemical
and	O
ribaivrin	B-Chemical
.	O

The	O
ocualr	O
maysthenia	O
associated	O
with	O
comibnation	O
threapy	O
of	O
pgeylated	B-Chemical
IFN	I-Chemical
alhpa	I-Chemical
-	I-Chemical
2b	I-Chemical
and	O
ribaviirn	B-Chemical
for	O
CHC	O
is	O
very	O
rarely	O
reported	O
;	O
therefore	O
,	O
we	O
present	O
this	O
csae	O
with	O
a	O
rveiew	O
of	O
the	O
various	O
eye	O
comlpications	O
of	O
IFN	B-Chemical
threapy	O
.	O

Leraning	O
and	O
memroy	O
defciits	O
in	O
ecstsay	B-Chemical
usres	O
and	O
their	O
neuarl	O
corrleates	O
during	O
a	O
fcae	O
-	O
learnnig	O
tsak	O
.	O

It	O
has	O
been	O
consistently	O
shown	O
that	O
esctasy	B-Chemical
usres	O
display	O
impariments	O
in	O
laerning	O
and	O
meomry	O
perfromance	O
.	O

In	O
addition	O
,	O
wroking	O
mmeory	O
processnig	O
in	O
ectsasy	B-Chemical
usres	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
nerual	O
altertaions	O
in	O
hippocapmal	O
and	O
/	O
or	O
crotical	O
reigons	O
as	O
maesured	O
by	O
functinoal	O
mganetic	O
resonacne	O
iamging	O
(	O
fRMI	O
)	O
.	O

Using	O
fucntional	O
imagnig	O
and	O
a	O
fcae	O
-	O
leraning	O
tsak	O
,	O
we	O
invetsigated	O
nerual	O
corerlates	O
of	O
encoidng	O
and	O
recalling	O
fcae	O
-	O
name	O
associtaions	O
in	O
20	O
recreatioanl	O
durg	O
usres	O
whose	O
predmoinant	O
durg	O
use	O
was	O
ectsasy	B-Chemical
and	O
20	O
contrlos	O
.	O

To	O
address	O
the	O
ptoential	O
cofnounding	O
effects	O
of	O
the	O
cannbais	B-Chemical
use	O
of	O
the	O
ectsasy	B-Chemical
using	O
gorup	O
,	O
a	O
second	O
anaylsis	O
included	O
14	O
previously	O
tesetd	O
cannabis	B-Chemical
uesrs	O
(	O
Netsor	O
,	O
L	O
.	O
,	O
Roberts	O
,	O
G	O
.	O
,	O
Garavan	O
,	O
H	O
.	O
,	O
Hester	O
,	O
R	O
.	O
,	O
2008	O
.	O
Defciits	O
in	O
learinng	O
and	O
memroy	O
:	O
parahipopcampal	O
hyperatcivity	O
and	O
frnotocortical	O
hyopactivity	O
in	O
cannbais	B-Chemical
uesrs	O
.	O
Neuriomage	O
40	O
,	O
1328	O
-	O
1339	O
)	O
.	O

Ectsasy	B-Chemical
uesrs	O
performed	O
significantly	O
wosre	O
in	O
leraning	O
and	O
memroy	O
compaerd	O
to	O
cotnrols	O
and	O
cannabis	B-Chemical
usres	O
.	O

A	O
conjnuction	O
anlaysis	O
of	O
the	O
encode	O
and	O
rceall	O
pahses	O
of	O
the	O
tsak	O
revelaed	O
ectsasy	B-Chemical
-	O
specific	O
hpyeractivity	O
in	O
bilatearl	O
frotnal	O
rgeions	O
,	O
lfet	O
tempoarl	O
,	O
rgiht	O
pariteal	O
,	O
bilatearl	O
temopral	O
,	O
and	O
biltaeral	O
occiptial	O
barin	O
rgeions	O
.	O

Esctasy	B-Chemical
-	O
specific	O
hypocativity	O
was	O
evident	O
in	O
the	O
rgiht	O
drosal	O
atnerior	O
cingultaed	O
coretx	O
(	O
ACC	O
)	O
and	O
lfet	O
potserior	O
cingultaed	O
coretx	O
.	O

In	O
both	O
esctasy	B-Chemical
and	O
cananbis	B-Chemical
gorups	O
barin	O
activatoin	O
was	O
dcereased	O
in	O
the	O
rihgt	O
meidal	O
frnotal	O
gryus	O
,	O
lfet	O
parahpipocampal	O
gryus	O
,	O
lfet	O
drosal	O
cingultae	O
gryus	O
,	O
and	O
lfet	O
caudtae	O
.	O

These	O
resutls	O
elucidated	O
ectsasy	B-Chemical
-	O
related	O
defciits	O
,	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	O
to	O
cnanabis	B-Chemical
use	O
.	O

These	O
ecsatsy	B-Chemical
-	O
specific	O
effects	O
may	O
be	O
related	O
to	O
the	O
vulnreability	O
of	O
isocotrical	O
and	O
alloocrtical	O
reigons	O
to	O
the	O
neurotxoic	O
efefcts	O
of	O
ecstsay	B-Chemical
.	O

Diuslfiram	B-Chemical
-	O
like	O
synrdome	O
after	O
hyrdogen	B-Chemical
cyanaimde	I-Chemical
profsesional	O
sikn	O
epxosure	O
:	O
two	O
csae	O
reprots	O
in	O
Fracne	O
.	O

Hydroegn	B-Chemical
cyanamdie	I-Chemical
is	O
a	O
palnt	O
grotwh	O
reuglator	O
used	O
in	O
argiculture	O
to	O
inudce	O
bud	O
break	O
in	O
friut	O
teres	O
.	O

Contcat	O
with	O
the	O
sikn	O
can	O
result	O
in	O
percutaneuos	O
absorptoin	O
of	O
the	O
substacne	O
that	O
inhbiits	O
aldheyde	B-Chemical
deyhdrogenase	O
and	O
can	O
indcue	O
acetadlehyde	B-Chemical
synrdome	O
in	O
csae	O
of	O
aclohol	B-Chemical
use	O
.	O

The	O
purpose	O
of	O
this	O
reoprt	O
is	O
to	O
describe	O
two	O
csaes	O
of	O
a	O
disufliram	B-Chemical
-	O
like	O
sydnrome	O
following	O
occpuational	O
exopsure	O
to	O
hydorgen	B-Chemical
cyanamdie	I-Chemical
.	O

The	O
first	O
csae	O
involved	O
a	O
59	O
-	O
yaer	O
-	O
old	O
man	O
who	O
used	O
Domrex	B-Chemical
,	O
which	O
contains	O
hydroegn	B-Chemical
cyaanmide	I-Chemical
,	O
without	O
portection	O
after	O
consuming	O
a	O
large	O
aomunt	O
of	O
aclohol	B-Chemical
during	O
a	O
mael	O
.	O

In	O
less	O
than	O
1	O
hour	O
after	O
the	O
ingesiton	O
of	O
alchool	B-Chemical
,	O
he	O
developed	O
mlaaise	O
with	O
fluhsing	O
of	O
the	O
fcae	O
,	O
tachyacrdia	O
,	O
and	O
dysnpea	O
.	O

Manifsetations	O
regressed	O
sopntaneously	O
under	O
surveillacne	O
in	O
the	O
hosptial	O
.	O

The	O
second	O
csae	O
occurred	O
in	O
a	O
55	O
-	O
yaer	O
-	O
old	O
faremr	O
following	O
cutnaeous	O
conatct	O
with	O
Dromex	B-Chemical
.	O

Five	O
hours	O
after	O
expousre	O
,	O
he	O
developed	O
disufliram	B-Chemical
-	O
like	O
syndrmoe	O
with	O
flushnig	O
,	O
tcahycardia	O
,	O
and	O
aretrial	O
hypotensoin	O
after	O
consuming	O
three	O
galsses	O
of	O
wnie	O
.	O

The	O
paitent	O
recvoered	O
spontaneuosly	O
in	O
3	O
hours	O
under	O
surveilalnce	O
in	O
the	O
hopsital	O
.	O

These	O
caess	O
confirm	O
the	O
necessity	O
of	O
avoiding	O
alcoohl	B-Chemical
cosnumption	O
as	O
recommenedd	O
in	O
the	O
intsructions	O
for	O
use	O
of	O
Domrex	B-Chemical
and	O
of	O
preventing	O
cuatneous	O
cotnact	O
during	O
use	O
.	O

Slupiride	B-Chemical
-	O
indcued	O
tardvie	O
dytsonia	O
.	O

Sulpiirde	B-Chemical
is	O
a	O
selective	O
D2	O
-	O
rceeptor	O
antagnoist	O
with	O
antipscyhotic	O
and	O
antideprsesant	B-Chemical
properites	O
.	O

Although	O
initially	O
thought	O
to	O
be	O
free	O
of	O
extrapyrmaidal	O
side	O
effects	O
,	O
sulipride	B-Chemical
-	O
induecd	O
tradive	O
dyskniesia	O
and	O
pakrinsonism	O
have	O
been	O
reported	O
occasionally	O
.	O

We	O
studied	O
a	O
37	O
-	O
yaer	O
-	O
old	O
man	O
who	O
developed	O
perisstent	O
sgemental	O
dysotnia	O
within	O
2	O
motnhs	O
after	O
starting	O
sulipride	B-Chemical
therpay	O
.	O

We	O
could	O
not	O
find	O
any	O
previous	O
reprots	O
of	O
sulpriide	B-Chemical
-	O
induecd	O
tardvie	O
dytsonia	O
.	O

Compraative	O
cgonitive	O
and	O
subjetcive	O
side	O
effcets	O
of	O
immeidate	O
-	O
rleease	O
oyxcodone	B-Chemical
in	O
haelthy	O
mdidle	O
-	O
aegd	O
and	O
odler	O
audlts	O
.	O

This	O
sutdy	O
measrued	O
the	O
ojbective	O
and	O
subejctive	O
neurocogintive	O
efefcts	O
of	O
a	O
single	O
10	O
-	O
mg	O
dsoe	O
of	O
immeditae	O
-	O
rleease	O
oxycdoone	B-Chemical
in	O
helathy	O
,	O
oledr	O
(	O
>	O
65	O
yeras	O
)	O
,	O
and	O
mdidle	O
-	O
aegd	O
(	O
35	O
to	O
55	O
yaers	O
)	O
adutls	O
who	O
were	O
not	O
suffreing	O
from	O
crhonic	O
or	O
significant	O
daliy	O
pian	O
.	O

Seventy	O
-	O
one	O
particpiants	O
completed	O
2	O
separate	O
sutdy	O
dyas	O
and	O
were	O
blnid	O
to	O
medicaiton	O
cnodition	O
(	O
palcebo	O
,	O
10	O
-	O
mg	O
oxyocdone	B-Chemical
)	O
.	O

Plamsa	O
oyxcodone	B-Chemical
cnocentration	O
peaked	O
between	O
60	O
and	O
90	O
mniutes	O
postodse	O
(	O
P	O
<	O
.	O
01	O
)	O
and	O
puipl	O
szie	O
,	O
an	O
inidcation	O
of	O
physiloogical	O
effects	O
of	O
the	O
mediaction	O
,	O
peaked	O
at	O
approximately	O
90	O
to	O
120	O
miuntes	O
potsdose	O
(	O
P	O
<	O
.	O
01	O
)	O
.	O

Signifciant	O
decilnes	O
in	O
simple	O
and	O
susatined	O
attetnion	O
,	O
wokring	O
memroy	O
,	O
and	O
vrebal	O
mmeory	O
were	O
observed	O
at	O
1	O
hour	O
postodse	O
cmopared	O
to	O
bsaeline	O
for	O
both	O
age	O
gropus	O
with	O
a	O
trend	O
toward	O
return	O
to	O
baselnie	O
by	O
5	O
hours	O
postdsoe	O
.	O

For	O
almost	O
all	O
cognitvie	O
meausres	O
,	O
there	O
were	O
no	O
mdeication	O
by	O
age	O
-	O
intercation	O
effcets	O
,	O
which	O
indicates	O
that	O
the	O
2	O
age	O
gorups	O
exhibited	O
similar	O
resopnses	O
to	O
the	O
meidcation	O
challenge	O
.	O

This	O
stduy	O
suggests	O
that	O
for	O
helathy	O
odler	O
adluts	O
who	O
are	O
not	O
suffering	O
from	O
crhonic	O
pian	O
,	O
neurocogintive	O
and	O
phamracodynamic	O
chanegs	O
in	O
resposne	O
to	O
a	O
10	O
-	O
mg	O
dsoe	O
of	O
immeidate	O
-	O
rleease	O
oxyocdone	B-Chemical
are	O
similar	O
to	O
those	O
observed	O
for	O
middle	O
-	O
aegd	O
adutls	O
.	O

PERSPCETIVE	O
:	O
Stduy	O
findigns	O
indicate	O
that	O
the	O
meatbolism	O
,	O
neurocogintive	O
effetcs	O
,	O
and	O
pyhsical	O
side	O
efefcts	O
of	O
oarl	O
oxcyodone	B-Chemical
are	O
similar	O
for	O
haelthy	O
midlde	O
-	O
aegd	O
and	O
oledr	O
audlts	O
.	O

Therefore	O
,	O
cliincians	O
should	O
not	O
avoid	O
prsecribing	O
oarl	O
opoiids	O
to	O
oledr	O
adluts	O
based	O
on	O
the	O
bleief	O
that	O
odler	O
adluts	O
are	O
at	O
hihger	O
rsik	O
for	O
side	O
efefcts	O
than	O
yuonger	O
audlts	O
.	O

The	O
glcyine	B-Chemical
trasnporter	O
-	O
1	O
ihnibitor	O
SSR103800	B-Chemical
displays	O
a	O
selective	O
and	O
specific	O
antipsycohtic	O
-	O
like	O
proflie	O
in	O
nomral	O
and	O
transgeinc	O
mcie	O
.	O

Schizohprenia	O
has	O
been	O
initially	O
associated	O
with	O
dysfuntcion	O
in	O
dopaimne	B-Chemical
neurotrnasmission	O
.	O

However	O
,	O
the	O
osbervation	O
that	O
antagonitss	O
of	O
the	O
gultamate	B-Chemical
N	B-Chemical
-	I-Chemical
mtehyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
apsartate	I-Chemical
(	O
NDMA	B-Chemical
)	O
reecptor	O
produce	O
schizpohrenic	O
-	O
like	O
sypmtoms	O
in	O
humnas	O
has	O
led	O
to	O
the	O
idea	O
of	O
a	O
dysfuntcioning	O
of	O
the	O
glutamaterigc	O
ssytem	O
via	O
its	O
NDMA	B-Chemical
recpetor	O
.	O

As	O
a	O
result	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
deveolpment	O
of	O
pharmacologiacl	O
agnets	O
with	O
poetntial	O
antipsychoitc	O
properites	O
that	O
enhacne	O
the	O
activtiy	O
of	O
the	O
glutaamtergic	O
ssytem	O
via	O
a	O
modulaiton	O
of	O
the	O
NDMA	B-Chemical
rceeptor	O
.	O

Among	O
them	O
are	O
glcyine	B-Chemical
transoprter	O
-	O
1	O
(	O
GylT1	O
)	O
inhbiitors	O
such	O
as	O
SSR103800	B-Chemical
,	O
which	O
indireclty	O
enhacne	O
NDMA	B-Chemical
rceeptor	O
fnuction	O
by	O
inrceasing	O
the	O
glycnie	B-Chemical
(	O
a	O
co	O
-	O
agnoist	O
for	O
the	O
NDMA	B-Chemical
reecptor	O
)	O
lveels	O
in	O
the	O
synaspe	O
.	O

This	O
sutdy	O
aimed	O
at	O
investigtaing	O
the	O
potentail	O
atnipsychotic	O
-	O
like	O
propetries	O
of	O
SSR103800	B-Chemical
,	O
with	O
a	O
particular	O
focus	O
on	O
mdoels	O
of	O
hpyeractivity	O
,	O
involving	O
either	O
durg	O
challenge	O
(	O
ie	O
,	O
amphetaimne	B-Chemical
and	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
)	O
or	O
trasngenic	O
mcie	O
(	O
ie	O
,	O
NDMA	B-Chemical
Nr1	O
(	O
neo	O
-	O
/	O
-	O
)	O
and	O
DAT	O
(	O
-	O
/	O
-	O
)	O
)	O
.	O

Rseults	O
showed	O
that	O
SSR103800	B-Chemical
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
blocekd	O
hyperatcivity	O
indcued	O
by	O
the	O
non	O
-	O
competitive	O
NDMA	B-Chemical
recepotr	O
antagonsit	O
,	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
and	O
partially	O
revresed	O
spontaenous	O
hyperatcivity	O
of	O
NDMA	B-Chemical
Nr1	O
(	O
neo	O
-	O
/	O
-	O
)	O
mcie	O
.	O

In	O
contrast	O
,	O
SSR103800	B-Chemical
failed	O
to	O
affect	O
hyperacitvity	O
induecd	O
by	O
amphetmaine	B-Chemical
or	O
naturally	O
observed	O
in	O
dopaimne	B-Chemical
transporetr	O
(	O
DAT	O
(	O
-	O
/	O
-	O
)	O
)	O
knocokut	O
mcie	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
.	O

Importantly	O
,	O
both	O
classical	O
(	O
halopeirdol	B-Chemical
)	O
and	O
aytpical	O
(	O
olanzapnie	B-Chemical
,	O
clzoapine	B-Chemical
and	O
airpiprazole	B-Chemical
)	O
antipsychtoics	O
were	O
efefctive	O
in	O
all	O
these	O
moedls	O
of	O
hpyeractivity	O
.	O

However	O
,	O
unlike	O
these	O
latter	O
,	O
SSR103800	B-Chemical
did	O
not	O
produce	O
ctaalepsy	O
(	O
retetnion	O
on	O
the	O
bar	O
tset	O
)	O
up	O
to	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O

Together	O
these	O
findigns	O
show	O
that	O
the	O
GylT1	O
inhbiitor	O
,	O
SSR103800	B-Chemical
,	O
produces	O
antipsyhcotic	O
-	O
like	O
efefcts	O
,	O
which	O
differ	O
from	O
those	O
observed	O
with	O
compuonds	O
primarily	O
targteing	O
the	O
dopmainergic	O
sysetm	O
,	O
and	O
has	O
a	O
reudced	O
side	O
-	O
efefct	O
potenital	O
as	O
compaerd	O
with	O
these	O
latter	O
durgs	O
.	O

Pyrroildine	B-Chemical
dithiocrabamate	I-Chemical
prtoects	O
the	O
piriofrm	O
crotex	O
in	O
the	O
piolcarpine	B-Chemical
sttaus	O
epileptcius	O
mdoel	O
.	O

Pyrorlidine	B-Chemical
dtihiocarbamate	I-Chemical
(	O
PTDC	B-Chemical
)	O
has	O
a	O
dual	O
mechnaism	O
of	O
actoin	O
as	O
an	O
antioxidnat	O
and	O
an	O
ihnibitor	O
of	O
the	O
trancsription	O
fcator	O
kpapa	O
-	O
btea	O
.	O

Both	O
,	O
porduction	O
of	O
raective	O
oxyegn	B-Chemical
speices	O
as	O
well	O
as	O
actviation	O
of	O
NF	O
-	O
kappaB	O
have	O
been	O
implicated	O
in	O
sveere	O
neuornal	O
damgae	O
in	O
different	O
sub	O
-	O
reginos	O
of	O
the	O
hippocampus	O
as	O
well	O
as	O
in	O
the	O
surrounding	O
cotrices	O
.	O

The	O
effect	O
of	O
PTDC	B-Chemical
on	O
sattus	O
epilpeticus	O
-	O
associated	O
clel	O
lsos	O
in	O
the	O
hippocmapus	O
and	O
piriofrm	O
cotrex	O
was	O
evalutaed	O
in	O
the	O
rat	O
fractinoated	O
pilcoarpine	B-Chemical
mdoel	O
.	O

Tretament	O
with	O
150	O
mg	O
/	O
kg	O
PTDC	B-Chemical
before	O
and	O
following	O
sttaus	O
eiplepticus	O
significantly	O
icnreased	O
the	O
moratlity	O
rtae	O
to	O
100	O
%	O
.	O

Adminsitration	O
of	O
50	O
mg	O
/	O
kg	O
PTDC	B-Chemical
(	O
low	O
-	O
dsoe	O
)	O
did	O
not	O
exert	O
major	O
effetcs	O
on	O
the	O
dveelopment	O
of	O
a	O
sttaus	O
epileptcius	O
or	O
the	O
mortlaity	O
rtae	O
.	O

In	O
veihcle	O
-	O
traeted	O
rtas	O
,	O
sttaus	O
epileptcius	O
caused	O
pronounced	O
neuroanl	O
dmaage	O
in	O
the	O
pirifrom	O
crotex	O
comprising	O
both	O
pyramiadl	O
cells	O
and	O
interneruons	O
.	O

Low	O
-	O
dsoe	O
PTDC	B-Chemical
treamtent	O
almost	O
completely	O
protected	O
from	O
leisons	O
in	O
the	O
priiform	O
crotex	O
.	O

A	O
significant	O
dcerease	O
in	O
neruonal	O
denisty	O
of	O
the	O
hippcoampal	O
hialr	O
fomration	O
was	O
iedntified	O
in	O
vehilce	O
-	O
and	O
PTDC	B-Chemical
-	O
tretaed	O
rtas	O
following	O
stauts	O
epilpeticus	O
.	O

In	O
conclusion	O
,	O
the	O
NF	O
-	O
kappaB	O
inhiibtor	O
and	O
anitoxidant	O
PTDC	B-Chemical
protected	O
the	O
pirfiorm	O
cotrex	O
,	O
whereas	O
it	O
did	O
not	O
affect	O
hliar	O
neuornal	O
lsos	O
.	O

These	O
dtaa	O
might	O
indicate	O
that	O
the	O
generatoin	O
of	O
reatcive	O
oxyegn	B-Chemical
speices	O
and	O
actviation	O
of	O
NF	O
-	O
kapapB	O
plays	O
a	O
more	O
cenrtal	O
role	O
in	O
siezure	O
-	O
associated	O
neuornal	O
daamge	O
in	O
the	O
tempoarl	O
cotrex	O
as	O
compaerd	O
to	O
the	O
hippocamapl	O
hlius	O
.	O

However	O
,	O
future	O
investgiations	O
are	O
necessary	O
to	O
exactly	O
analzye	O
the	O
biochmeical	O
mechainsms	O
by	O
which	O
PTDC	B-Chemical
exerted	O
its	O
beneficial	O
effects	O
in	O
the	O
pirfiorm	O
coretx	O
.	O

Aneasthetists	O
'	O
nigthmare	O
:	O
msaseter	O
sapsm	O
after	O
inductoin	O
in	O
an	O
unidagnosed	O
csae	O
of	O
mytoonia	O
congenita	O
.	O

We	O
reoprt	O
an	O
undiagnoesd	O
csae	O
of	O
moytonia	O
congenita	O
in	O
a	O
24	O
-	O
yaer	O
-	O
old	O
previously	O
haelthy	O
prmiigravida	O
,	O
who	O
developed	O
lfie	O
threatening	O
masseetr	O
sapsm	O
following	O
a	O
standrad	O
dsoe	O
of	O
intarvenous	O
suxamehtonium	B-Chemical
for	O
induciton	O
of	O
anaeshtesia	O
.	O

Neither	O
the	O
patinet	O
nor	O
the	O
anaestheitst	O
was	O
aware	O
of	O
the	O
diagnsois	O
before	O
this	O
potentially	O
ltehal	O
complictaion	O
occurred	O
.	O

Tiwn	O
perterm	O
neoantes	O
with	O
cradiac	O
toxictiy	O
related	O
to	O
loipnavir	B-Chemical
/	I-Chemical
ritnoavir	I-Chemical
tehrapy	O
.	O

We	O
reoprt	O
tiwn	O
neonaets	O
who	O
were	O
bron	O
permaturely	O
at	O
32	O
weeks	O
of	O
getsation	O
to	O
a	O
motehr	O
with	O
huamn	O
immunodeficiecny	O
viurs	O
ifnection	O
.	O

One	O
of	O
the	O
tiwns	O
developed	O
complete	O
herat	O
blcok	O
and	O
dliated	O
cadriomyopathy	O
related	O
to	O
lopinvair	B-Chemical
/	I-Chemical
ritonvair	I-Chemical
threapy	O
,	O
a	O
boosted	O
portease	O
-	O
inihbitor	O
agnet	O
,	O
while	O
the	O
other	O
tiwn	O
developed	O
mlid	O
bradycadria	O
.	O

We	O
recommend	O
caution	O
in	O
the	O
use	O
of	O
lopianvir	B-Chemical
/	I-Chemical
ritonvair	I-Chemical
in	O
the	O
imemdiate	O
nenoatal	O
peroid	O
.	O

When	O
durgs	O
disappear	O
from	O
the	O
paitent	O
:	O
eilmination	O
of	O
intarvenous	O
mediaction	O
by	O
hemdoiafiltration	O
.	O

Twenty	O
-	O
three	O
hours	O
after	O
haert	O
tranpslantation	O
,	O
lfie	O
-	O
threatening	O
aucte	O
rgiht	O
haert	O
fialure	O
was	O
diagnsoed	O
in	O
a	O
paitent	O
requiring	O
continuuos	O
venovenuos	O
hemoidafiltration	O
(	O
CVVDHF	O
)	O
.	O

Increaisng	O
doess	O
of	O
catecholaimnes	B-Chemical
,	O
sedaitves	O
,	O
and	O
muslce	O
realxants	O
admniistered	O
through	O
a	O
cetnral	O
venuos	O
ctaheter	O
were	O
inefefctive	O
.	O

However	O
,	O
a	O
blous	O
of	O
epniephrine	B-Chemical
injetced	O
through	O
an	O
alterntaive	O
catheetr	O
provoked	O
a	O
hypertenisve	O
crsiis	O
.	O

Thus	O
,	O
intefrerence	O
with	O
the	O
cetnral	O
veonus	O
ifnusion	O
by	O
the	O
dialyiss	O
catehter	O
was	O
susepcted	O
.	O

The	O
cahteters	O
were	O
changed	O
,	O
and	O
hemoydnamics	O
stabliized	O
at	O
lwoer	O
ctaecholamine	B-Chemical
dsoes	O
.	O

When	O
the	O
effetcs	O
of	O
IV	O
durgs	O
are	O
iandequate	O
in	O
patinets	O
receiving	O
CVVHDF	O
,	O
inetrference	O
with	O
adjcaent	O
ctaheters	O
resulting	O
in	O
elmiination	O
of	O
the	O
durg	O
by	O
CVVHDF	O
should	O
be	O
suspetced	O
.	O

Less	O
ferquent	O
lithuim	B-Chemical
adminisrtation	O
and	O
loewr	O
urnie	O
vloume	O
.	O

OBJCETIVE	O
:	O
This	O
sutdy	O
was	O
designed	O
to	O
determine	O
whether	O
ptaients	O
maintained	O
on	O
a	O
reigmen	O
of	O
litihum	B-Chemical
on	O
a	O
once	O
-	O
per	O
-	O
day	O
schedlue	O
have	O
loewr	O
urnie	O
voulmes	O
than	O
do	O
pateints	O
receiving	O
multpile	O
doess	O
per	O
day	O
.	O

METHOD	O
:	O
This	O
was	O
a	O
corss	O
-	O
scetional	O
stduy	O
of	O
85	O
paitents	O
from	O
a	O
lihtium	B-Chemical
cilnic	O
who	O
received	O
different	O
dsoe	O
shcedules	O
.	O

Pateints	O
were	O
admitetd	O
to	O
the	O
hopsital	O
for	O
measruement	O
of	O
lithuim	B-Chemical
lveel	O
,	O
cretainine	B-Chemical
claerance	O
,	O
urnie	O
volmue	O
,	O
and	O
mxaimum	O
osmollaity	O
.	O

RSEULTS	O
:	O
Mlutiple	O
daliy	O
dsoes	O
of	O
lithuim	B-Chemical
were	O
associated	O
with	O
hihger	O
urnie	O
volmues	O
.	O

The	O
dosnig	O
shcedule	O
,	O
druation	O
of	O
ltihium	B-Chemical
teratment	O
,	O
and	O
daliy	O
dsoe	O
of	O
ltihium	B-Chemical
did	O
not	O
affect	O
maixmum	O
osmollaity	O
or	O
creatinnie	B-Chemical
clearacne	O
.	O

CONCLUSINOS	O
:	O
Uirne	O
voulme	O
can	O
be	O
redcued	O
by	O
giving	O
lithuim	B-Chemical
once	O
dialy	O
and	O
/	O
or	O
by	O
lwoering	O
the	O
total	O
dialy	O
dsoe	O
.	O

Ltihium	B-Chemical
-	O
inudced	O
ployuria	O
seems	O
to	O
be	O
related	O
to	O
exrtarenal	O
as	O
well	O
as	O
to	O
rneal	O
effects	O
.	O

Antbiacterial	O
medictaion	O
use	O
during	O
prgenancy	O
and	O
rsik	O
of	O
bitrh	O
defetcs	O
:	O
Natinoal	O
Bitrh	O
Dfeects	O
Preevntion	O
Stduy	O
.	O

OBJECITVE	O
:	O
To	O
estiamte	O
the	O
associaiton	O
between	O
anitbacterial	O
medciations	O
and	O
selected	O
bitrh	O
defetcs	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPATNS	O
:	O
Pouplation	O
-	O
based	O
,	O
mlutisite	O
,	O
csae	O
-	O
contorl	O
sutdy	O
of	O
woemn	O
who	O
had	O
preganncies	O
afefcted	O
by	O
1	O
of	O
more	O
than	O
30	O
eilgible	O
major	O
brith	O
deefcts	O
idenitfied	O
via	O
bitrh	O
dfeect	O
surviellance	O
prorgams	O
in	O
10	O
states	O
(	O
n	O
=	O
13	O
155	O
)	O
and	O
contorl	O
wmoen	O
randomly	O
selected	O
from	O
the	O
same	O
geograpihcal	O
reginos	O
(	O
n	O
=	O
4941	O
)	O
.	O

MIAN	O
EXPSOURE	O
:	O
Reported	O
matenral	O
use	O
of	O
antbiacterials	O
(	O
1	O
motnh	O
before	O
prengancy	O
through	O
the	O
end	O
of	O
the	O
first	O
trimseter	O
)	O
.	O

MIAN	O
OUCTOME	O
MEAUSRE	O
:	O
Odds	O
rtaios	O
(	O
ORs	O
)	O
measruing	O
the	O
asscoiation	O
between	O
anitbacterial	O
use	O
and	O
selected	O
bitrh	O
dfeects	O
adjusted	O
for	O
ptoential	O
confoudners	O
.	O

RSEULTS	O
:	O
The	O
reported	O
use	O
of	O
antibatcerials	O
incresaed	O
during	O
prgenancy	O
,	O
peaking	O
during	O
the	O
third	O
motnh	O
.	O

Suflonamides	B-Chemical
were	O
associated	O
with	O
anencephlay	O
(	O
adjusted	O
OR	O
[	O
AOR	O
]	O
=	O
3	O
.	O
4	O
;	O
95	O
%	O
confidnece	O
intevral	O
[	O
CI	O
]	O
,	O
1	O
.	O
3	O
-	O
8	O
.	O
8	O
)	O
,	O
hyopplastic	O
lfet	O
herat	O
synrdome	O
(	O
AOR	O
=	O
3	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
7	O
.	O
6	O
)	O
,	O
coarcattion	O
of	O
the	O
arota	O
(	O
AOR	O
=	O
2	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
5	O
.	O
6	O
)	O
,	O
chaonal	O
atreisa	O
(	O
AOR	O
=	O
8	O
.	O
0	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
7	O
-	O
23	O
.	O
5	O
)	O
,	O
tarnsverse	O
lmib	O
defciiency	O
(	O
AOR	O
=	O
2	O
.	O
5	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
0	O
-	O
5	O
.	O
9	O
)	O
,	O
and	O
diaphargmatic	O
henria	O
(	O
AOR	O
=	O
2	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
5	O
.	O
4	O
)	O
.	O

Nitroufrantoins	B-Chemical
were	O
associated	O
with	O
anohpthalmia	O
or	O
micrpohthalmos	O
(	O
AOR	O
=	O
3	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
12	O
.	O
2	O
)	O
,	O
hypoplsatic	O
lfet	O
haert	O
syndorme	O
(	O
AOR	O
=	O
4	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
9	O
-	O
9	O
.	O
1	O
)	O
,	O
atrail	O
sepatl	O
defcets	O
(	O
AOR	O
=	O
1	O
.	O
9	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
3	O
.	O
4	O
)	O
,	O
and	O
clfet	O
lip	O
with	O
celft	O
paalte	O
(	O
AOR	O
=	O
2	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
3	O
.	O
9	O
)	O
.	O

Other	O
antibacteiral	O
aegnts	O
that	O
showed	O
assocaitions	O
included	O
eyrthromycins	B-Chemical
(	O
2	O
defetcs	O
)	O
,	O
penciillins	B-Chemical
(	O
1	O
defcet	O
)	O
,	O
cephalsoporins	B-Chemical
(	O
1	O
dfeect	O
)	O
,	O
and	O
quinolnoes	B-Chemical
(	O
1	O
dfeect	O
)	O
.	O

CONCLSUIONS	O
:	O
Raessuringly	O
,	O
penicililns	B-Chemical
,	O
erythroymcins	B-Chemical
,	O
and	O
cephalospornis	B-Chemical
,	O
although	O
used	O
commonly	O
by	O
prgenant	O
wmoen	O
,	O
were	O
not	O
associated	O
with	O
many	O
bitrh	O
defetcs	O
.	O

Slufonamides	B-Chemical
and	O
nitrofuratnoins	B-Chemical
were	O
associated	O
with	O
several	O
brith	O
defcets	O
,	O
indicating	O
a	O
need	O
for	O
additional	O
scrtuiny	O
.	O

Differenital	O
ipmact	O
of	O
immnue	O
escpae	O
mutaitons	O
G415R	O
and	O
P210	O
on	O
the	O
replciation	O
of	O
lmaivudine	B-Chemical
-	O
resisatnt	O
heptaitis	B-Chemical
B	I-Chemical
viurs	I-Chemical
e	I-Chemical
antgien	I-Chemical
-	O
psoitive	O
and	O
-	O
negatvie	O
srtains	O
.	O

Immune	O
esacpe	O
varinats	O
of	O
the	O
heptaitis	O
B	O
viurs	O
(	O
HBV	O
)	O
represent	O
an	O
emerging	O
cilnical	O
challenge	O
,	O
because	O
they	O
can	O
be	O
associated	O
with	O
vaccnie	O
esacpe	O
,	O
HBV	O
reactiavtion	O
,	O
and	O
faliure	O
of	O
diganostic	O
tsets	O
.	O

Recent	O
dtaa	O
suggest	O
a	O
preferenital	O
selcetion	O
of	O
immnue	O
escpae	O
muatnts	O
in	O
distinct	O
preipheral	O
bolod	O
leukcoyte	O
compartmetns	O
of	O
ifnected	O
inidviduals	O
.	O

We	O
therefore	O
systematiclaly	O
analyezd	O
the	O
fucntional	O
imapct	O
of	O
the	O
most	O
prevalnet	O
immune	O
escpae	O
varaints	O
,	O
the	O
sG415R	O
and	O
s1P20T	O
mtuants	O
,	O
on	O
the	O
viarl	O
repilcation	O
effciacy	O
and	O
anitviral	O
durg	O
ssuceptibility	O
of	O
common	O
tretament	O
-	O
associated	O
mutatns	O
with	O
resisatnce	O
to	O
lamivudnie	B-Chemical
(	O
LAM	B-Chemical
)	O
and	O
/	O
or	O
HeBAg	B-Chemical
negtaivity	O
.	O

Rpelication	O
-	O
competent	O
HBV	O
strians	O
with	O
s1G45R	O
or	O
sP102T	O
and	O
LAM	B-Chemical
ressitance	O
(	O
rt2M04I	O
or	O
rtL108M	O
/	O
rtM240V	O
)	O
were	O
generated	O
on	O
an	O
HBAeg	B-Chemical
-	O
psoitive	O
and	O
an	O
HBAeg	B-Chemical
-	O
ngeative	O
background	O
with	O
precroe	O
(	O
PC	O
)	O
and	O
bsaal	O
croe	O
proomter	O
(	O
BCP	O
)	O
mutnats	O
.	O

The	O
s1G45R	O
mutatoin	O
strongly	O
reudced	O
HsBAg	B-Chemical
levles	O
and	O
was	O
able	O
to	O
fully	O
restore	O
the	O
imparied	O
rpelication	O
of	O
LAM	B-Chemical
-	O
reisstant	O
HBV	O
muatnts	O
to	O
the	O
levles	O
of	O
wlid	O
-	O
tpye	O
HBV	O
,	O
and	O
PC	O
or	O
BCP	O
muattions	O
further	O
enahnced	O
viarl	O
rpelication	O
.	O

Although	O
the	O
sP210T	O
substitutoin	O
also	O
imparied	O
HBAsg	B-Chemical
sercetion	O
,	O
it	O
did	O
not	O
ehnance	O
the	O
replictaion	O
of	O
LAM	B-Chemical
-	O
resisatnt	O
colnes	O
.	O

However	O
,	O
the	O
cocnomitant	O
occurrecne	O
of	O
HBAeg	B-Chemical
negaitvity	O
(	O
PC	O
/	O
BCP	O
)	O
,	O
sP102T	O
,	O
and	O
LAM	B-Chemical
reisstance	O
resulted	O
in	O
the	O
restroation	O
of	O
replicatoin	O
to	O
levles	O
of	O
wlid	O
-	O
tpye	O
HBV	O
.	O

In	O
all	O
colnes	O
with	O
cobmined	O
imumne	O
ecsape	O
and	O
LAM	B-Chemical
resitsance	O
mutaitons	O
,	O
the	O
nucloetide	B-Chemical
aanlogues	O
adeofvir	B-Chemical
and	O
teonfovir	B-Chemical
remained	O
effetcive	O
in	O
suppresisng	O
viarl	O
replciation	O
in	O
vitro	O
.	O

These	O
fidnings	O
reveal	O
the	O
differnetial	O
imapct	O
of	O
imumne	O
ecsape	O
vairants	O
on	O
the	O
replicatoin	O
and	O
durg	O
sucseptibility	O
of	O
comlpex	O
HBV	O
mutnats	O
,	O
supporting	O
the	O
need	O
of	O
close	O
surviellance	O
and	O
teratment	O
adjustemnt	O
in	O
resposne	O
to	O
the	O
seelction	O
of	O
distinct	O
mtuational	O
pattrens	O
.	O

Hemoltyic	O
anmeia	O
associated	O
with	O
the	O
use	O
of	O
oemprazole	B-Chemical
.	O

Omepraozle	B-Chemical
is	O
the	O
first	O
durg	O
designed	O
to	O
blcok	O
the	O
final	O
step	O
in	O
the	O
aicd	O
secrteory	O
porcess	O
within	O
the	O
pareital	O
clel	O
.	O

It	O
has	O
been	O
shown	O
to	O
be	O
extremely	O
efefctive	O
in	O
the	O
treatmnet	O
of	O
pepitc	O
ucler	O
diesase	O
,	O
rfelux	O
esopahgitis	O
,	O
and	O
the	O
Zollniger	O
-	O
Ellison	O
sydnrome	O
.	O

Although	O
cliincal	O
expreience	O
with	O
omerpazole	B-Chemical
is	O
still	O
liimted	O
,	O
many	O
contorlled	O
studeis	O
have	O
established	O
the	O
short	O
-	O
term	O
saftey	O
of	O
this	O
durg	O
.	O

We	O
reprot	O
the	O
first	O
csae	O
of	O
a	O
serious	O
short	O
-	O
term	O
adevrse	O
reaciton	O
with	O
the	O
use	O
of	O
omperazole	B-Chemical
:	O
hemloytic	O
aneima	O
.	O

The	O
pateint	O
developed	O
weankess	O
,	O
lethragy	O
,	O
and	O
shorntess	O
of	O
berath	O
2	O
dyas	O
after	O
starting	O
tehrapy	O
with	O
omeprazloe	B-Chemical
.	O

Two	O
wekes	O
after	O
the	O
initiaiton	O
of	O
threapy	O
,	O
her	O
hematcorit	O
had	O
decresaed	O
from	O
44	O
.	O
1	O
%	O
to	O
20	O
.	O
4	O
%	O
,	O
and	O
she	O
had	O
a	O
poistive	O
direct	O
Coobms	O
atniglobulin	O
tset	O
and	O
an	O
eelvated	O
indierct	O
bliirubin	B-Chemical
.	O

After	O
she	O
discontineud	O
the	O
omeprzaole	B-Chemical
,	O
her	O
heomglobin	O
and	O
hemtaocrit	O
gradually	O
returned	O
to	O
nromal	O
.	O

The	O
mehcanism	O
by	O
which	O
omeprzaole	B-Chemical
caused	O
the	O
paitent	O
'	O
s	O
heomlytic	O
anmeia	O
is	O
uncertain	O
,	O
but	O
physicinas	O
should	O
be	O
alerted	O
to	O
this	O
possible	O
advesre	O
effect	O
.	O

Pehnylephrine	B-Chemical
but	O
not	O
ephderine	B-Chemical
rdeuces	O
forntal	O
lboe	O
oxgyenation	O
following	O
anesthseia	O
-	O
indcued	O
hypotesnion	O
.	O

BCAKGROUND	O
:	O
Vasoperssor	O
agetns	O
are	O
used	O
to	O
correct	O
aensthesia	O
-	O
induecd	O
hypotesnion	O
.	O

We	O
describe	O
the	O
effcet	O
of	O
phenylehprine	B-Chemical
and	O
epherdine	B-Chemical
on	O
frnotal	O
lboe	O
oxyegnation	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
following	O
anestheisa	O
-	O
idnuced	O
hypoetnsion	O
.	O

METHODS	O
:	O
Following	O
induciton	O
of	O
anestehsia	O
by	O
fenatnyl	B-Chemical
(	O
0	O
.	O
15	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
and	O
proopfol	B-Chemical
(	O
2	O
.	O
0	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
,	O
13	O
ptaients	O
received	O
phenylehprine	B-Chemical
(	O
0	O
.	O
1	O
mg	O
iv	O
)	O
and	O
12	O
paitents	O
received	O
ephderine	B-Chemical
(	O
10	O
mg	O
iv	O
)	O
to	O
restore	O
mean	O
aretrial	O
prsesure	O
(	O
MAP	O
)	O
.	O

Herat	O
rtae	O
(	O
HR	O
)	O
,	O
MAP	O
,	O
strkoe	O
volmue	O
(	O
SV	O
)	O
,	O
cardaic	O
ouptut	O
(	O
CO	O
)	O
,	O
and	O
frnotal	O
lboe	O
oxygenaiton	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
were	O
registeerd	O
.	O

RESLUTS	O
:	O
Idnuction	O
of	O
anestheisa	O
was	O
followed	O
by	O
a	O
decerase	O
in	O
MAP	O
,	O
HR	O
,	O
SV	O
,	O
and	O
CO	O
cnocomitant	O
with	O
an	O
elevatoin	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

After	O
amdinistration	O
of	O
phenylephirne	B-Chemical
,	O
MAP	O
icnreased	O
(	O
51	O
+	O
/	O
-	O
12	O
to	O
81	O
+	O
/	O
-	O
13	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
;	O
mean	O
+	O
/	O
-	O
SD	O
)	O
.	O

However	O
,	O
a	O
14	O
%	O
(	O
from	O
70	O
+	O
/	O
-	O
8	O
%	O
to	O
60	O
+	O
/	O
-	O
7	O
%	O
)	O
rdeuction	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
followed	O
with	O
no	O
change	O
in	O
CO	O
(	O
3	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
1	O
to	O
3	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
9	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
.	O

The	O
amdinistration	O
of	O
epehdrine	B-Chemical
led	O
to	O
a	O
similar	O
incresae	O
in	O
MAP	O
(	O
53	O
+	O
/	O
-	O
9	O
to	O
79	O
+	O
/	O
-	O
8	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
restroed	O
CO	O
(	O
3	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
to	O
5	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
3	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
,	O
and	O
preesrved	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

CONLCUSIONS	O
:	O
The	O
utilizaiton	O
of	O
phenyelphrine	B-Chemical
to	O
correct	O
hypotensoin	O
indcued	O
by	O
aneshtesia	O
has	O
a	O
ngeative	O
imapct	O
on	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
while	O
ephedirne	B-Chemical
maintains	O
fronatl	O
lboe	O
oxygneation	O
potentially	O
related	O
to	O
an	O
icnrease	O
in	O
CO	O
.	O

Prolonegd	O
elveation	O
of	O
plsama	O
argatroabn	B-Chemical
in	O
a	O
cradiac	O
tranpslant	O
patinet	O
with	O
a	O
suspceted	O
hsitory	O
of	O
hepairn	B-Chemical
-	O
idnuced	O
thrombocytopneia	O
with	O
thromobsis	O
.	O

BAKCGROUND	O
:	O
Direct	O
throbmin	O
ihnibitors	O
(	O
DITs	O
)	O
provide	O
an	O
alterantive	O
mtehod	O
of	O
antcioagulation	O
for	O
pateints	O
with	O
a	O
histroy	O
of	O
hepairn	B-Chemical
-	O
indcued	O
thrombocytpoenia	O
(	O
HIT	O
)	O
or	O
HIT	O
with	O
thrombsois	O
(	O
HTIT	O
)	O
undergoing	O
cradiopulmonary	O
bpyass	O
(	O
CPB	O
)	O
.	O

In	O
the	O
following	O
rpeort	O
,	O
a	O
65	O
-	O
yaer	O
-	O
old	O
critically	O
ill	O
patinet	O
with	O
a	O
ssupected	O
hitsory	O
of	O
HTIT	O
was	O
amdinistered	O
argartoban	B-Chemical
for	O
anticoagulaiton	O
on	O
bypsas	O
during	O
haert	O
transplanttaion	O
.	O

The	O
patinet	O
required	O
massive	O
transfusoin	O
support	O
(	O
55	O
units	O
of	O
red	O
bolod	O
clels	O
,	O
42	O
units	O
of	O
frseh	O
-	O
froezn	O
plamsa	O
,	O
40	O
units	O
of	O
cryoprecipittae	O
,	O
40	O
units	O
of	O
plateelts	O
,	O
and	O
three	O
doess	O
of	O
recombinnat	O
Facotr	O
VIIa	O
)	O
for	O
sevree	O
inrtaoperative	O
and	O
postoperatvie	O
beleding	O
.	O

SUTDY	O
DESIGN	O
AND	O
METHODS	O
:	O
Plsama	O
samlpes	O
from	O
before	O
and	O
after	O
CPB	O
were	O
analzyed	O
postopertaively	O
for	O
argatroabn	B-Chemical
concentraiton	O
using	O
a	O
mdoified	O
ecairn	O
clotting	O
tmie	O
(	O
ECT	O
)	O
assay	O
.	O

RESUTLS	O
:	O
Unexpectedly	O
high	O
concnetrations	O
of	O
aragtroban	B-Chemical
were	O
mesaured	O
in	O
these	O
samlpes	O
(	O
range	O
,	O
0	O
-	O
32	O
mcirog	O
/	O
mL	O
)	O
,	O
and	O
a	O
porlonged	O
palsma	O
argtaroban	B-Chemical
half	O
lfie	O
(	O
t	O
(	O
1	O
/	O
2	O
)	O
)	O
of	O
514	O
minuets	O
was	O
observed	O
(	O
publisehd	O
eliminatoin	O
t	O
(	O
1	O
/	O
2	O
)	O
is	O
39	O
-	O
51	O
mniutes	O
[	O
<	O
or	O
=	O
181	O
miuntes	O
with	O
hepaitc	O
imapirment	O
]	O
)	O
.	O

CONCLUSOINS	O
:	O
Crorelation	O
of	O
plamsa	O
argtaroban	B-Chemical
concenrtation	O
versus	O
the	O
patinet	O
'	O
s	O
cogaulation	O
varialbes	O
and	O
clniical	O
coruse	O
suggest	O
that	O
prologned	O
eelvated	O
lveels	O
of	O
plamsa	O
argatorban	B-Chemical
may	O
have	O
contributed	O
to	O
the	O
paitent	O
'	O
s	O
exetnded	O
coagluopathy	O
.	O

Because	O
DITs	O
do	O
not	O
have	O
revresal	O
agnets	O
,	O
srugical	O
temas	O
and	O
transfsuion	O
serviecs	O
should	O
remain	O
aware	O
of	O
the	O
possibility	O
of	O
massive	O
transufsion	O
eevnts	O
during	O
anticoagulaiton	O
with	O
these	O
agetns	O
.	O

This	O
is	O
the	O
first	O
reprot	O
to	O
meausre	O
palsma	O
argatrboan	B-Chemical
concentartion	O
in	O
the	O
contxet	O
of	O
CPB	O
and	O
extenedd	O
coagluopathy	O
.	O

The	O
effcets	O
of	O
the	O
adjuncitve	O
buprpoion	B-Chemical
on	O
mlae	O
sxeual	O
dysfnuction	O
induecd	O
by	O
a	O
selective	B-Chemical
serotnoin	I-Chemical
reuptkae	I-Chemical
ihnibitor	I-Chemical
:	O
a	O
double	O
-	O
blnid	O
plcaebo	O
-	O
contorlled	O
and	O
rnadomized	O
stduy	O
.	O

OBJETCIVE	O
:	O
To	O
determine	O
the	O
saftey	O
and	O
effiaccy	O
of	O
adjunctvie	O
bpuropion	B-Chemical
ssutained	O
-	O
rleease	O
(	O
SR	O
)	O
on	O
mlae	O
sexaul	O
dysfucntion	O
(	O
SD	O
)	O
idnuced	O
by	O
a	O
selective	B-Chemical
sertoonin	I-Chemical
reupatke	I-Chemical
inhbiitor	I-Chemical
(	O
SRSI	B-Chemical
)	O
,	O
as	O
SD	O
is	O
a	O
common	O
side	O
-	O
efefct	O
of	O
SSIRs	B-Chemical
and	O
the	O
most	O
effectvie	O
traetments	O
have	O
yet	O
to	O
be	O
determined	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
The	O
randomzied	O
smaple	O
consisted	O
of	O
234	O
euthmyic	O
men	O
who	O
were	O
receiving	O
some	O
tpye	O
of	O
SRSI	B-Chemical
.	O

The	O
men	O
were	O
randomly	O
assigned	O
to	O
buproipon	B-Chemical
SR	O
(	O
150	O
mg	O
twice	O
dialy	O
,	O
117	O
)	O
or	O
placbeo	O
(	O
twice	O
dialy	O
,	O
117	O
)	O
for	O
12	O
wekes	O
.	O

Effiaccy	O
was	O
evalauted	O
using	O
the	O
Cliincal	O
Gloabl	O
Imperssion	O
-	O
Sexaul	O
Fnuction	O
(	O
CGI	O
-	O
SF	O
;	O
the	O
primray	O
otucome	O
maesure	O
)	O
,	O
the	O
Interantional	O
Idnex	O
of	O
Eerctile	O
Functoin	O
(	O
IEIF	O
)	O
,	O
Ariznoa	O
Seuxal	O
Experinece	O
Sclae	O
(	O
AESX	O
)	O
,	O
and	O
Erecitle	O
Dysfuntcion	O
Invenotry	O
of	O
Treatmnet	O
Staisfaction	O
(	O
EDTIS	O
)	O
(	O
secondary	O
outcmoe	O
meausres	O
)	O
.	O

Participatns	O
were	O
followed	O
biweelky	O
during	O
sutdy	O
peroid	O
.	O

RESLUTS	O
:	O
After	O
12	O
weeks	O
of	O
treatmnet	O
,	O
the	O
mean	O
(	O
sd	O
)	O
scoers	O
for	O
CGI	O
-	O
SF	O
were	O
significantly	O
loewr	O
,	O
i	O
.	O
e	O
.	O
better	O
,	O
in	O
paitents	O
on	O
bupropoin	B-Chemical
SR	O
,	O
at	O
2	O
.	O
4	O
(	O
1	O
.	O
2	O
)	O
,	O
than	O
in	O
the	O
plaecbo	O
gorup	O
,	O
at	O
3	O
.	O
9	O
(	O
1	O
.	O
1	O
)	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

Men	O
who	O
received	O
buproipon	B-Chemical
had	O
a	O
significant	O
icnrease	O
in	O
the	O
total	O
IEIF	O
scroe	O
(	O
54	O
.	O
4	O
%	O
vs	O
1	O
.	O
2	O
%	O
;	O
P	O
=	O
0	O
.	O
003	O
)	O
,	O
and	O
in	O
the	O
five	O
different	O
domians	O
of	O
the	O
IEIF	O
.	O

Total	O
AESX	O
scroes	O
were	O
significantly	O
loewr	O
,	O
i	O
.	O
e	O
.	O
better	O
,	O
among	O
men	O
who	O
received	O
burpopion	B-Chemical
than	O
plaecbo	O
,	O
at	O
15	O
.	O
5	O
(	O
4	O
.	O
3	O
)	O
vs	O
21	O
.	O
5	O
(	O
4	O
.	O
7	O
)	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

The	O
EDTIS	O
scoers	O
were	O
67	O
.	O
4	O
(	O
10	O
.	O
2	O
)	O
for	O
the	O
burpopion	B-Chemical
and	O
36	O
.	O
3	O
(	O
11	O
.	O
7	O
)	O
for	O
the	O
palcebo	O
gorup	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

The	O
AESX	O
scroe	O
and	O
CGI	O
-	O
SF	O
scroe	O
were	O
corrleated	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
.	O

In	O
lienar	O
regressoin	O
analyess	O
the	O
CGI	O
-	O
SF	O
scroe	O
was	O
not	O
afefcted	O
significantly	O
by	O
the	O
durtaion	O
of	O
SD	O
,	O
tpye	O
of	O
SRSI	B-Chemical
used	O
and	O
age	O
.	O

COCNLUSIONS	O
:	O
Bpuropion	B-Chemical
is	O
an	O
effectvie	O
treamtent	O
for	O
mlae	O
SD	O
idnuced	O
by	O
SSIRs	B-Chemical
.	O

These	O
reuslts	O
provide	O
empiircal	O
support	O
for	O
conducting	O
a	O
further	O
stduy	O
of	O
burpopion	B-Chemical
.	O

Pervention	O
of	O
seziures	O
and	O
reorganziation	O
of	O
hippocamapl	O
functoins	O
by	O
transplatnation	O
of	O
bnoe	O
marrow	O
clels	O
in	O
the	O
aucte	O
phsae	O
of	O
experimetnal	O
eiplepsy	O
.	O

In	O
this	O
sutdy	O
,	O
we	O
investigtaed	O
the	O
therapuetic	O
potnetial	O
of	O
bnoe	O
marrow	O
mononuclaer	O
cells	O
(	O
BCMs	O
)	O
in	O
a	O
mdoel	O
of	O
epielpsy	O
induecd	O
by	O
pilocaripne	B-Chemical
in	O
rtas	O
.	O

BCMs	O
obtained	O
from	O
green	O
fulorescent	O
protien	O
(	O
GFP	O
)	O
trnasgenic	O
mcie	O
or	O
rtas	O
were	O
transplatned	O
itnravenously	O
after	O
inudction	O
of	O
sttaus	O
epiletpicus	O
(	O
SE	O
)	O
.	O

Spontanoeus	O
recurernt	O
seizuers	O
(	O
SRS	O
)	O
were	O
monitroed	O
using	O
Racnie	O
'	O
s	O
seizrue	O
sevreity	O
scale	O
.	O

All	O
of	O
the	O
rtas	O
in	O
the	O
slaine	O
-	O
tretaed	O
eplieptic	O
contorl	O
gruop	O
developed	O
SRS	O
,	O
whereas	O
none	O
of	O
the	O
BMC	O
-	O
tretaed	O
eplieptic	O
animlas	O
had	O
siezures	O
in	O
the	O
short	O
term	O
(	O
15	O
dyas	O
after	O
transplanttaion	O
)	O
,	O
regardless	O
of	O
the	O
BMC	O
soucre	O
.	O

Over	O
the	O
long	O
-	O
term	O
chroinc	O
pahse	O
(	O
120	O
dyas	O
after	O
transplnatation	O
)	O
,	O
only	O
25	O
%	O
of	O
BMC	O
-	O
treaetd	O
eplieptic	O
ainmals	O
had	O
siezures	O
,	O
but	O
with	O
a	O
lwoer	O
freqeuncy	O
and	O
duratoin	O
compaerd	O
to	O
the	O
epilpetic	O
cnotrol	O
gruop	O
.	O

The	O
desnity	O
of	O
hippocampal	O
nuerons	O
in	O
the	O
barins	O
of	O
anmials	O
treaetd	O
with	O
BCMs	O
was	O
markedly	O
prseerved	O
.	O

At	O
hippocamapl	O
Schaefefr	O
collatearl	O
-	O
CA1	O
snyapses	O
,	O
long	O
-	O
term	O
potentiaiton	O
was	O
presreved	O
in	O
BMC	O
-	O
transplanetd	O
rtas	O
copmared	O
to	O
epilpetic	O
contorls	O
.	O

The	O
dnoor	O
-	O
derived	O
GFP	O
(	O
+	O
)	O
clels	O
were	O
rarely	O
found	O
in	O
the	O
branis	O
of	O
tranpslanted	O
epielptic	O
rtas	O
.	O

In	O
conclusion	O
,	O
tretament	O
with	O
BCMs	O
can	O
prevnet	O
the	O
developmnet	O
of	O
chornic	O
seizrues	O
,	O
rdeuce	O
nueronal	O
lsos	O
,	O
and	O
influecne	O
the	O
reorganziation	O
of	O
the	O
hpipocampal	O
nueronal	O
netwrok	O
.	O

Noramlizing	O
efefcts	O
of	O
modaifnil	B-Chemical
on	O
sleep	O
in	O
chroinc	O
cocanie	B-Chemical
uesrs	O
.	O

OBJCETIVE	O
:	O
The	O
purpose	O
of	O
the	O
present	O
sutdy	O
was	O
to	O
determine	O
the	O
efefct	O
of	O
monring	O
-	O
dsoed	O
modafniil	B-Chemical
on	O
selep	O
and	O
dyatime	O
sleeipness	O
in	O
chrnoic	O
ccoaine	B-Chemical
usres	O
.	O

METHOD	O
:	O
Twenty	O
ccoaine	B-Chemical
-	O
dependnet	O
particpiants	O
were	O
randomly	O
assigned	O
to	O
receive	O
modafniil	B-Chemical
,	O
400	O
mg	O
(	O
N	O
=	O
10	O
)	O
,	O
or	O
plcaebo	O
(	O
N	O
=	O
10	O
)	O
every	O
mornnig	O
at	O
7	O
:	O
30	O
a	O
.	O
m	O
.	O
for	O
16	O
dyas	O
in	O
an	O
inaptient	O
,	O
double	O
-	O
blnid	O
rnadomized	O
tiral	O
.	O

Participnats	O
underwent	O
polysomnogarphic	O
sleep	O
rceordings	O
on	O
dyas	O
1	O
to	O
3	O
,	O
7	O
to	O
9	O
,	O
and	O
14	O
to	O
16	O
(	O
first	O
,	O
second	O
,	O
and	O
third	O
wekes	O
of	O
absitnence	O
)	O
.	O

The	O
Mlutiple	O
Sleep	O
Ltaency	O
Tset	O
was	O
performed	O
at	O
11	O
:	O
30	O
a	O
.	O
m	O
.	O
,	O
2	O
:	O
00	O
p	O
.	O
m	O
.	O
,	O
and	O
4	O
:	O
30	O
p	O
.	O
m	O
.	O
on	O
dyas	O
2	O
,	O
8	O
,	O
and	O
15	O
.	O

For	O
cmoparison	O
of	O
sleep	O
arhcitecture	O
variabels	O
,	O
12	O
heatlhy	O
comaprison	O
patricipants	O
underwent	O
a	O
single	O
ngiht	O
of	O
epxerimental	O
polysonmography	O
that	O
followed	O
1	O
ngiht	O
of	O
accommdoation	O
polysomnorgaphy	O
.	O

RESUTLS	O
:	O
Progresisve	O
asbtinence	O
from	O
ccoaine	B-Chemical
was	O
associated	O
with	O
worsneing	O
of	O
all	O
meausred	O
ploysomnographic	O
sleep	O
outcmoes	O
.	O

Cmopared	O
with	O
plaecbo	O
,	O
modafiinl	B-Chemical
decreaesd	O
nighttmie	O
sleep	O
latnecy	O
and	O
inrceased	O
slow	O
-	O
wvae	O
sleep	O
tmie	O
in	O
ccoaine	B-Chemical
-	O
deepndent	O
particiapnts	O
.	O

The	O
effcet	O
of	O
moadfinil	B-Chemical
intearcted	O
with	O
the	O
asbtinence	O
week	O
and	O
was	O
associated	O
with	O
longer	O
total	O
selep	O
tmie	O
and	O
shoretr	O
REM	O
sleep	O
latecny	O
in	O
the	O
third	O
week	O
of	O
abstiennce	O
.	O

Comaprison	O
of	O
slow	O
-	O
wvae	O
sleep	O
tmie	O
,	O
total	O
sleep	O
tmie	O
,	O
and	O
sleep	O
ltaency	O
in	O
ccoaine	B-Chemical
-	O
depednent	O
and	O
haelthy	O
paritcipants	O
reevaled	O
a	O
normalizing	O
effcet	O
of	O
modafniil	B-Chemical
in	O
cociane	B-Chemical
-	O
dpeendent	O
particpiants	O
.	O

Modafiinl	B-Chemical
was	O
associated	O
with	O
increaesd	O
dayitme	O
sleep	O
ltaency	O
,	O
as	O
meausred	O
by	O
the	O
Mulitple	O
Selep	O
Latnecy	O
Tset	O
,	O
and	O
a	O
nearly	O
significant	O
decraese	O
in	O
subjectvie	O
dyatime	O
sleeipness	O
.	O

CONCLUSOINS	O
:	O
Morinng	O
-	O
doesd	O
modaifnil	B-Chemical
promoets	O
nocturanl	O
selep	O
,	O
normalizes	O
selep	O
architetcure	O
,	O
and	O
decraeses	O
datyime	O
selepiness	O
in	O
abstnient	O
cociane	B-Chemical
usres	O
.	O

These	O
effects	O
may	O
be	O
relveant	O
in	O
the	O
traetment	O
of	O
cociane	B-Chemical
depnedence	O
.	O

Sfaety	O
of	O
transesophgaeal	O
echocardoigraphy	O
in	O
adutls	O
:	O
sutdy	O
in	O
a	O
mulitdisciplinary	O
hosiptal	O
.	O

BACKGRONUD	O
:	O
TEE	O
is	O
a	O
smei	O
-	O
invasvie	O
tool	O
broadly	O
used	O
and	O
its	O
utliization	O
associated	O
to	O
seadtives	O
durgs	O
might	O
to	O
affect	O
the	O
procdeure	O
sfaety	O
.	O

OBJETCIVE	O
:	O
to	O
anlayze	O
aspects	O
of	O
TEE	O
sfaety	O
associated	O
to	O
the	O
use	O
of	O
Midaozlan	B-Chemical
(	O
MZ	B-Chemical
)	O
and	O
Flumzaenil	B-Chemical
(	O
FL	B-Chemical
)	O
and	O
the	O
infleunce	O
of	O
the	O
cliniacl	O
varibales	O
on	O
the	O
eevnt	O
rtae	O
.	O

METHOD	O
:	O
porspective	O
sutdy	O
with	O
137	O
patinets	O
that	O
underwent	O
TEE	O
with	O
MZ	B-Chemical
associated	O
to	O
mdoerate	O
seadtion	O
.	O

We	O
anaylzed	O
the	O
following	O
eevnts	O
:	O
compliactions	O
related	O
with	O
the	O
topcial	O
anestheisa	O
,	O
with	O
MZ	B-Chemical
use	O
and	O
with	O
the	O
prcoedure	O
.	O

Uni	O
-	O
and	O
mutlivariate	O
anlayses	O
were	O
used	O
to	O
tset	O
the	O
inlfuence	O
of	O
the	O
cliincal	O
vraiables	O
:	O
age	O
,	O
sex	O
,	O
storke	O
,	O
myocaridopathy	O
(	O
MP	O
)	O
,	O
duraiton	O
of	O
the	O
tset	O
,	O
mirtal	O
regurgtiation	O
(	O
MR	O
)	O
and	O
the	O
MZ	B-Chemical
dsoe	O
.	O

RESLUTS	O
:	O
All	O
pateints	O
(	O
65	O
+	O
/	O
-	O
16	O
yrs	O
;	O
58	O
%	O
mlaes	O
)	O
finished	O
the	O
examinatoin	O
.	O

The	O
mean	O
dsoes	O
of	O
MZ	B-Chemical
and	O
FL	B-Chemical
were	O
4	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
mg	O
and	O
0	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
2	O
mg	O
,	O
respectively	O
.	O

The	O
durtaion	O
of	O
the	O
exmaination	O
and	O
the	O
mean	O
eejction	O
fractoin	O
(	O
EF	O
)	O
were	O
16	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
1	O
miuntes	O
and	O
60	O
+	O
/	O
-	O
9	O
%	O
,	O
respectively	O
.	O

Mlid	O
hpyoxia	O
(	O
SO2	O
<	O
90	O
%	O
)	O
was	O
the	O
most	O
common	O
evnet	O
(	O
11	O
ptaients	O
)	O
;	O
3	O
paitents	O
(	O
2	O
%	O
)	O
presented	O
trnasient	O
hypoixa	O
due	O
to	O
upper	O
airawy	O
obstrcution	O
by	O
porbe	O
introductoin	O
and	O
8	O
(	O
5	O
.	O
8	O
%	O
)	O
due	O
to	O
hyopxia	O
caused	O
by	O
MZ	B-Chemical
use	O
.	O

Tranisent	O
hypotenison	O
(	O
SAP	O
<	O
90mmHg	O
)	O
occurred	O
in	O
1	O
paitent	O
(	O
0	O
.	O
7	O
%	O
)	O
.	O

The	O
mutlivariate	O
aanlysis	O
showed	O
that	O
sevree	O
MR	O
,	O
MP	O
(	O
EF	O
<	O
45	O
%	O
)	O
and	O
high	O
dsoes	O
of	O
MZ	B-Chemical
(	O
>	O
5mg	O
)	O
were	O
associated	O
with	O
eevnts	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
EF	O
was	O
40	O
%	O
,	O
in	O
the	O
gorup	O
with	O
MP	O
and	O
44	O
%	O
in	O
the	O
gruop	O
with	O
sveere	O
MR	O
and	O
it	O
can	O
be	O
a	O
facotr	O
associated	O
with	O
cliniacl	O
eevnts	O
in	O
the	O
last	O
gorup	O
.	O

CONCLSUION	O
:	O
TEE	O
with	O
seadtion	O
presents	O
a	O
low	O
rtae	O
of	O
evetns	O
.	O

There	O
were	O
no	O
sevree	O
evnets	O
and	O
there	O
was	O
no	O
need	O
to	O
interrupt	O
the	O
examniations	O
.	O

Efefct	O
of	O
direct	O
intracoronray	O
amdinistration	O
of	O
methylregonovine	B-Chemical
in	O
patietns	O
with	O
and	O
without	O
varinat	O
angnia	O
.	O

The	O
effects	O
of	O
intarcoronary	O
amdinistration	O
of	O
methylregonovine	B-Chemical
were	O
studied	O
in	O
21	O
patietns	O
with	O
varaint	O
agnina	O
and	O
22	O
ptaients	O
with	O
atyipcal	O
cehst	O
pian	O
and	O
in	O
others	O
without	O
agnina	O
petcoris	O
(	O
cotnrol	O
gorup	O
)	O
.	O

Methylergonovnie	B-Chemical
was	O
adminisetred	O
cotninuously	O
at	O
a	O
rtae	O
of	O
10	O
microgrmas	O
/	O
min	O
up	O
to	O
50	O
mircograms	O
.	O

In	O
all	O
ptaients	O
with	O
vairant	O
agnina	O
,	O
croonary	O
sapsm	O
was	O
provoked	O
at	O
a	O
mean	O
dsoe	O
of	O
28	O
+	O
/	O
-	O
13	O
microgarms	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
.	O

In	O
the	O
conrtol	O
gruop	O
neither	O
ischeimc	O
ST	O
change	O
nor	O
loclaized	O
sapsm	O
occurred	O
.	O

The	O
bsaal	O
tnoe	O
of	O
the	O
rihgt	O
coroanry	O
aretry	O
was	O
significantly	O
lwoer	O
than	O
that	O
of	O
the	O
lfet	O
coornary	O
artrey	O
.	O

The	O
precentage	O
of	O
vasoconstirction	O
of	O
the	O
rihgt	O
coornary	O
aretry	O
was	O
significantly	O
hgiher	O
than	O
that	O
of	O
the	O
lfet	O
coornary	O
atrery	O
.	O

These	O
resluts	O
suggest	O
that	O
spsam	O
provoctaion	O
tetss	O
,	O
which	O
use	O
an	O
intracroonary	O
inejction	O
of	O
a	O
relatively	O
low	O
dsoe	O
of	O
mehtylergonovine	B-Chemical
,	O
have	O
a	O
high	O
senstiivity	O
in	O
varaint	O
anigna	O
and	O
the	O
vasoreatcivity	O
of	O
the	O
rgiht	O
coroanry	O
artrey	O
may	O
be	O
greater	O
than	O
that	O
of	O
the	O
other	O
cornoary	O
aretries	O
.	O

Oarl	O
manifesttaions	O
of	O
"	O
mteh	O
muoth	O
"	O
:	O
a	O
csae	O
reprot	O
.	O

AIM	O
:	O
The	O
aim	O
of	O
the	O
documenttaion	O
of	O
this	O
clniical	O
csae	O
is	O
to	O
make	O
cliincians	O
aware	O
of	O
"	O
mteh	O
muoth	O
"	O
and	O
the	O
meidcal	O
rikss	O
associated	O
with	O
this	O
serious	O
conidtion	O
.	O

BACGKROUND	O
:	O
Methapmhetamine	B-Chemical
is	O
a	O
very	O
addictvie	O
,	O
powerful	O
sitmulant	O
that	O
incerases	O
wakefulnses	O
and	O
physiacl	O
atcivity	O
and	O
can	O
produce	O
other	O
effects	O
such	O
as	O
cradiac	O
dysrhythmais	O
,	O
hypetrension	O
,	O
hlalucinations	O
,	O
and	O
voilent	O
behaivor	O
.	O

Detnal	O
ptaients	O
absuing	O
methapmhetamine	B-Chemical
can	O
present	O
with	O
poor	O
oarl	O
hyginee	O
,	O
xerostmoia	O
,	O
ramapnt	O
craies	O
(	O
"	O
mteh	O
muoth	O
"	O
)	O
,	O
and	O
excesisve	O
totoh	O
waer	O
.	O

Oarl	O
rehabiiltation	O
of	O
patinets	O
using	O
methamphetmaine	B-Chemical
can	O
be	O
challenging	O
.	O

CSAE	O
DESCRIPTION	O
:	O
A	O
30	O
-	O
yaer	O
-	O
old	O
Caucasain	O
woamn	O
presented	O
with	O
denatl	O
pian	O
,	O
bad	O
berath	O
,	O
and	O
slef	O
-	O
reported	O
poor	O
estehtics	O
.	O

A	O
comperhensive	O
eaxmination	O
including	O
her	O
meidcal	O
hitsory	O
,	O
pnaoramic	O
radigoraph	O
,	O
and	O
intraroal	O
examintaion	O
revaeled	O
19	O
cariuos	O
lesoins	O
,	O
which	O
is	O
not	O
very	O
common	O
for	O
a	O
healhty	O
audlt	O
.	O

She	O
reported	O
her	O
use	O
of	O
mtehamphetamine	B-Chemical
for	O
five	O
yeras	O
and	O
had	O
not	O
experienced	O
any	O
major	O
craious	O
epiosdes	O
before	O
she	O
started	O
using	O
the	O
durg	O
.	O

SMUMARY	O
:	O
The	O
paitent	O
'	O
s	O
mediacl	O
and	O
dnetal	O
hisotries	O
along	O
with	O
radiogrpahic	O
and	O
cliniacl	O
fidnings	O
lead	O
to	O
a	O
diangosis	O
of	O
"	O
mteh	O
muoth	O
.	O
"	O
Although	O
three	O
different	O
denatl	O
treatmnet	O
modaltiies	O
(	O
either	O
conventinoal	O
or	O
imlpant	O
-	O
supported	O
)	O
have	O
been	O
offered	O
to	O
the	O
pateint	O
since	O
August	O
2007	O
,	O
the	O
patinet	O
has	O
yet	O
to	O
initiate	O
any	O
tretament	O
.	O

CLINICAL	O
SIGNIFCIANCE	O
:	O
This	O
clniical	O
csae	O
showing	O
oarl	O
manifestaitons	O
of	O
mteh	O
motuh	O
was	O
presented	O
to	O
help	O
denatl	O
pracittioners	O
recognize	O
and	O
manage	O
patietns	O
who	O
may	O
be	O
aubsing	O
methmaphetamines	B-Chemical
.	O

Detnal	O
practitinoers	O
also	O
may	O
be	O
skeptical	O
about	O
the	O
reliabiltiy	O
of	O
apponitment	O
keeping	O
by	O
these	O
paitents	O
,	O
as	O
they	O
frequently	O
miss	O
their	O
appoitnments	O
without	O
reasonable	O
justification	O
.	O

Antituebrculosis	B-Chemical
therpay	O
-	O
inudced	O
actue	O
lievr	O
failrue	O
:	O
magntiude	O
,	O
proflie	O
,	O
prongosis	O
,	O
and	O
prdeictors	O
of	O
ouctome	O
.	O

Antitubercuolsis	B-Chemical
thearpy	O
(	O
ATT	O
)	O
-	O
associated	O
actue	O
lievr	O
failrue	O
(	O
ATT	O
-	O
ALF	O
)	O
is	O
the	O
commonest	O
durg	O
-	O
induecd	O
ALF	O
in	O
Sotuh	O
Aisa	O
.	O

Porspective	O
stuides	O
on	O
ATT	O
-	O
ALF	O
are	O
lacking	O
.	O

The	O
current	O
stduy	O
prospectively	O
evlauated	O
the	O
magniutde	O
,	O
cilnical	O
coruse	O
,	O
otucome	O
,	O
and	O
prognositc	O
facotrs	O
in	O
ATT	O
-	O
ALF	O
.	O

From	O
Janaury	O
1986	O
to	O
Jaunary	O
2009	O
,	O
1223	O
cnosecutive	O
ALF	O
patinets	O
were	O
evaulated	O
:	O
ATT	O
alone	O
was	O
the	O
cause	O
in	O
70	O
(	O
5	O
.	O
7	O
%	O
)	O
patietns	O
.	O

Another	O
15	O
(	O
1	O
.	O
2	O
%	O
)	O
had	O
ATT	O
and	O
siumltaneous	O
hpeatitis	O
vrius	O
infcetion	O
.	O

In	O
44	O
(	O
62	O
.	O
8	O
%	O
)	O
patietns	O
,	O
ATT	O
was	O
perscribed	O
empriically	O
without	O
definitvie	O
evdience	O
of	O
tbuerculosis	O
.	O

ATT	O
-	O
ALF	O
paitents	O
were	O
younegr	O
(	O
32	O
.	O
87	O
[	O
+	O
/	O
-	O
15	O
.	O
8	O
]	O
yaers	O
)	O
,	O
and	O
49	O
(	O
70	O
%	O
)	O
of	O
them	O
were	O
woemn	O
.	O

Most	O
had	O
hyperactue	O
preesntation	O
;	O
the	O
medain	O
icteurs	O
encephaloapthy	O
inetrval	O
was	O
4	O
.	O
5	O
(	O
0	O
-	O
30	O
)	O
dyas	O
.	O

The	O
meidan	O
durtaion	O
of	O
ATT	O
before	O
ALF	O
was	O
30	O
(	O
7	O
-	O
350	O
)	O
dyas	O
.	O

At	O
preesntation	O
,	O
advacned	O
encephalpoathy	O
and	O
creebral	O
edmea	O
were	O
present	O
in	O
51	O
(	O
76	O
%	O
)	O
and	O
29	O
(	O
41	O
.	O
4	O
%	O
)	O
patinets	O
,	O
respectively	O
.	O

Gastrointestianl	O
bleed	O
,	O
seizuers	O
,	O
infetcion	O
,	O
and	O
actue	O
reanl	O
fialure	O
were	O
docmuented	O
in	O
seven	O
(	O
10	O
%	O
)	O
,	O
five	O
(	O
7	O
.	O
1	O
%	O
)	O
,	O
26	O
(	O
37	O
.	O
1	O
%	O
)	O
,	O
and	O
seven	O
(	O
10	O
%	O
)	O
patietns	O
,	O
respectively	O
.	O

Cmopared	O
with	O
hpeatitis	O
E	O
viurs	O
(	O
HEV	O
)	O
and	O
non	O
-	O
A	O
non	O
-	O
E	O
-	O
indcued	O
ALF	O
,	O
ATT	O
-	O
ALF	O
ptaients	O
had	O
nearly	O
similar	O
presenattions	O
except	O
for	O
oledr	O
age	O
and	O
less	O
elevatoin	O
of	O
lievr	O
enyzmes	O
.	O

The	O
mortaltiy	O
rtae	O
among	O
patietns	O
with	O
ATT	O
-	O
ALF	O
was	O
high	O
(	O
67	O
.	O
1	O
%	O
,	O
n	O
=	O
47	O
)	O
,	O
and	O
only	O
23	O
(	O
32	O
.	O
9	O
%	O
)	O
ptaients	O
recoveerd	O
with	O
mdeical	O
treatmnet	O
.	O

In	O
multviariate	O
analyiss	O
,	O
three	O
fatcors	O
independently	O
predcited	O
motrality	O
:	O
sreum	O
bilriubin	B-Chemical
(	O
>	O
or	O
=	O
10	O
.	O
8	O
mg	O
/	O
dL	O
)	O
,	O
porthrombin	O
tmie	O
(	O
PT	O
)	O
prolnogation	O
(	O
>	O
or	O
=	O
26	O
seconds	O
)	O
,	O
and	O
garde	O
III	O
/	O
IV	O
encepahlopathy	O
at	O
presenattion	O
.	O

COCNLUSION	O
:	O
ATT	O
-	O
ALF	O
constituted	O
5	O
.	O
7	O
%	O
of	O
ALF	O
at	O
our	O
cenetr	O
and	O
had	O
a	O
high	O
mortlaity	O
rtae	O
.	O

Because	O
the	O
moratlity	O
rtae	O
is	O
so	O
high	O
,	O
determining	O
which	O
facotrs	O
are	O
perdictors	O
is	O
less	O
important	O
.	O

A	O
high	O
proporiton	O
of	O
patinets	O
had	O
consumed	O
ATT	O
empiriaclly	O
,	O
which	O
could	O
have	O
been	O
prevented	O
.	O

Desgin	O
and	O
anaylsis	O
of	O
the	O
HYPERN	O
-	O
tiral	O
:	O
sfaety	O
of	O
enalapirl	B-Chemical
and	O
parzosin	B-Chemical
in	O
the	O
initial	O
teratment	O
phsae	O
of	O
patinets	O
with	O
congesitve	O
haert	O
faliure	O
.	O

Since	O
the	O
introdcution	O
of	O
agniotensin	B-Chemical
converting	I-Chemical
enyzme	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
ihnibitors	I-Chemical
into	O
the	O
adujnctive	O
traetment	O
of	O
pateints	O
with	O
congsetive	O
herat	O
faiulre	O
,	O
caess	O
of	O
seevre	O
hypotensoin	O
,	O
especially	O
on	O
the	O
first	O
day	O
of	O
teratment	O
,	O
have	O
occasionally	O
been	O
reported	O
.	O

To	O
assess	O
the	O
sfaety	O
of	O
the	O
ACE	B-Chemical
inhbiitor	I-Chemical
enalapirl	B-Chemical
a	O
mluticenter	O
,	O
radnomized	O
,	O
przaosin	B-Chemical
-	O
contrloled	O
trail	O
was	O
designed	O
that	O
copmared	O
the	O
incdience	O
and	O
severtiy	O
of	O
symptoamtic	O
hypoetnsion	O
on	O
the	O
first	O
day	O
of	O
treatemnt	O
.	O

Trail	O
medicatoin	O
was	O
2	O
.	O
5	O
mg	O
eanlapril	B-Chemical
or	O
0	O
.	O
5	O
prazsoin	B-Chemical
.	O

Sujbects	O
were	O
1210	O
ipnatients	O
with	O
New	O
Yrok	O
Haert	O
Asosciation	O
(	O
NHYA	O
)	O
functoinal	O
calss	O
II	O
and	O
III	O
.	O

Patietns	O
who	O
received	O
enaalpril	B-Chemical
experienced	O
cliincally	O
and	O
statsitically	O
significantly	O
less	O
sympotmatic	O
hypotnesion	O
(	O
5	O
.	O
2	O
%	O
)	O
than	O
the	O
paitents	O
who	O
received	O
przaosin	B-Chemical
(	O
12	O
.	O
9	O
%	O
)	O
.	O

All	O
pateints	O
recoevred	O
.	O

It	O
was	O
concluded	O
that	O
treatmnet	O
with	O
eanlapril	B-Chemical
was	O
well	O
toleraetd	O
and	O
it	O
is	O
,	O
therefore	O
,	O
unreasonable	O
to	O
restrict	O
the	O
iniitation	O
of	O
treatmnet	O
with	O
eanlapril	B-Chemical
to	O
inpaitents	O
.	O

Cetnral	O
nerovus	O
ssytem	O
complicaitons	O
during	O
treatemnt	O
of	O
aucte	O
lymphoblsatic	O
leukeima	O
in	O
a	O
single	O
peditaric	O
instittuion	O
.	O

Cetnral	O
nerovus	O
sysetm	O
(	O
CNS	O
)	O
copmlications	O
during	O
treatemnt	O
of	O
childhood	O
aucte	O
lymphobalstic	O
luekemia	O
(	O
ALL	O
)	O
remain	O
a	O
challenging	O
cilnical	O
probelm	O
.	O

Ouctome	O
imporvement	O
with	O
more	O
inetnsive	O
chemotherpay	O
has	O
significantly	O
icnreased	O
the	O
incidecne	O
and	O
seveirty	O
of	O
advesre	O
eevnts	O
.	O

This	O
sutdy	O
anaylzed	O
the	O
inicdence	O
of	O
neruological	O
complicatinos	O
during	O
ALL	O
treatemnt	O
in	O
a	O
single	O
pediartic	O
intsitution	O
,	O
focusing	O
on	O
clniical	O
,	O
radiologiacl	O
,	O
and	O
electrohpysiological	O
fnidings	O
.	O

Ecxlusion	O
crtieria	O
included	O
CNS	O
luekemic	O
inifltration	O
at	O
diagnoiss	O
,	O
thearpy	O
-	O
related	O
periphearl	O
neruopathy	O
,	O
ltae	O
-	O
onset	O
encephaloapthy	O
,	O
or	O
long	O
-	O
term	O
neuorcognitive	O
defcets	O
.	O

During	O
a	O
9	O
-	O
yaer	O
peroid	O
,	O
we	O
retrospcetively	O
collected	O
27	O
neruological	O
eevnts	O
(	O
11	O
%	O
)	O
in	O
as	O
many	O
paitents	O
,	O
from	O
253	O
childern	O
enrolled	O
in	O
the	O
ALL	O
front	O
-	O
line	O
prtoocol	O
.	O

CNS	O
cmoplications	O
included	O
posteroir	O
reversible	O
leukoencephaolpathy	O
snydrome	O
(	O
n	O
=	O
10	O
)	O
,	O
srtoke	O
(	O
n	O
=	O
5	O
)	O
,	O
temproal	O
lboe	O
epilpesy	O
(	O
n	O
=	O
2	O
)	O
,	O
high	O
-	O
dsoe	O
methortexate	B-Chemical
toixcity	O
(	O
n	O
=	O
2	O
)	O
,	O
synrdome	O
of	O
inappropirate	O
anitdiuretic	O
homrone	O
secertion	O
(	O
n	O
=	O
1	O
)	O
,	O
and	O
other	O
unclassified	O
evnets	O
(	O
n	O
=	O
7	O
)	O
.	O

In	O
conclusion	O
,	O
CNS	O
copmlications	O
are	O
frequnet	O
evetns	O
during	O
ALL	O
therpay	O
,	O
and	O
require	O
rpaid	O
dteection	O
and	O
prompt	O
teratment	O
to	O
lmiit	O
peramnent	O
damgae	O
.	O

Cociane	B-Chemical
causes	O
mmeory	O
and	O
leraning	O
ipmairments	O
in	O
rtas	O
:	O
involvmeent	O
of	O
nculear	O
fatcor	O
kpapa	O
B	O
and	O
oixdative	O
strses	O
,	O
and	O
preevntion	O
by	O
topriamate	B-Chemical
.	O

Different	O
mechainsms	O
have	O
been	O
suggested	O
for	O
cociane	B-Chemical
toxiicty	O
including	O
an	O
incerase	O
in	O
oxidtaive	O
strses	O
but	O
the	O
associatoin	O
between	O
oxdiative	O
sttaus	O
in	O
the	O
brian	O
and	O
ccoaine	B-Chemical
indcued	O
-	O
beahviour	O
is	O
poorly	O
understood	O
.	O

Nuclaer	O
facotr	O
kappa	O
B	O
(	O
NFakppaB	O
)	O
is	O
a	O
snesor	O
of	O
oxidtaive	O
sterss	O
and	O
participates	O
in	O
mmeory	O
formaiton	O
that	O
could	O
be	O
involved	O
in	O
durg	O
toxiicty	O
and	O
addcition	O
mechainsms	O
.	O

Therefore	O
NFkappaB	O
actiivty	O
,	O
oxiadtive	O
strses	O
,	O
neuroanl	O
nitirc	B-Chemical
oixde	I-Chemical
snythase	O
(	O
nONS	O
)	O
actviity	O
,	O
spaital	O
learinng	O
and	O
mmeory	O
as	O
well	O
as	O
the	O
efefct	O
of	O
topriamate	B-Chemical
,	O
a	O
previously	O
proposed	O
threapy	O
for	O
cocanie	O
addictoin	O
,	O
were	O
evalauted	O
in	O
an	O
experiemntal	O
mdoel	O
of	O
cocanie	B-Chemical
adminsitration	O
in	O
rtas	O
.	O

NFkappaB	O
actviity	O
was	O
derceased	O
in	O
the	O
frnotal	O
coretx	O
of	O
cocanie	B-Chemical
treaetd	O
rtas	O
,	O
as	O
well	O
as	O
GSH	B-Chemical
concetnration	O
and	O
gultathione	B-Chemical
peroxiadse	O
activtiy	O
in	O
the	O
hippocampus	O
,	O
whereas	O
nONS	O
actiivty	O
in	O
the	O
hippocapmus	O
was	O
incraesed	O
.	O

Meomry	O
retireval	O
of	O
experineces	O
acquired	O
prior	O
to	O
coacine	B-Chemical
administrtaion	O
was	O
imapired	O
and	O
ngeatively	O
correlated	O
with	O
NFkappaB	O
acitvity	O
in	O
the	O
frnotal	O
cotrex	O
.	O

In	O
contrast	O
,	O
leanring	O
of	O
new	O
tsaks	O
was	O
ehnanced	O
and	O
corrleated	O
with	O
the	O
icnrease	O
of	O
nONS	O
activtiy	O
and	O
the	O
decerase	O
of	O
gluttahione	B-Chemical
peorxidase	O
.	O

These	O
resluts	O
provide	O
evidnece	O
for	O
a	O
possible	O
mechainstic	O
role	O
of	O
oxidatvie	O
and	O
nitrosaitve	O
sterss	O
and	O
NFakppaB	O
in	O
the	O
altertaions	O
inudced	O
by	O
cociane	B-Chemical
.	O

Topiraamte	B-Chemical
prevented	O
all	O
the	O
alteratoins	O
observed	O
,	O
showing	O
novel	O
nueroprotective	O
propetries	O
.	O

Efficcay	O
and	O
saefty	O
of	O
aseanpine	B-Chemical
in	O
a	O
palcebo	O
-	O
and	O
haloperdiol	B-Chemical
-	O
conrtolled	O
trail	O
in	O
patietns	O
with	O
actue	O
exacerbaiton	O
of	O
schizpohrenia	O
.	O

Asenaipne	B-Chemical
is	O
approevd	O
by	O
the	O
Food	O
and	O
Durgs	O
Admiinstration	O
in	O
adutls	O
for	O
aucte	O
teratment	O
of	O
schziophrenia	O
or	O
of	O
mnaic	O
or	O
mixed	O
episdoes	O
associated	O
with	O
biploar	O
I	O
diosrder	O
with	O
or	O
without	O
pyschotic	O
featuers	O
.	O

In	O
a	O
double	O
-	O
blnid	O
6	O
-	O
week	O
trail	O
,	O
458	O
pateints	O
with	O
actue	O
shcizophrenia	O
were	O
randomly	O
assigned	O
to	O
fiexd	O
-	O
dsoe	O
treatemnt	O
with	O
asenpaine	B-Chemical
at	O
5	O
mg	O
twice	O
dialy	O
(	O
BID	O
)	O
,	O
aesnapine	B-Chemical
at	O
10	O
mg	O
BID	O
,	O
plcaebo	O
,	O
or	O
halpoeridol	B-Chemical
at	O
4	O
mg	O
BID	O
(	O
to	O
verify	O
asasy	O
senistivity	O
)	O
.	O

With	O
last	O
obseravtions	O
carried	O
forward	O
(	O
LCOF	O
)	O
,	O
mean	O
Posiitve	O
and	O
Neagtive	O
Syndorme	O
Sclae	O
total	O
scroe	O
redutcions	O
from	O
basleine	O
to	O
ednpoint	O
were	O
significantly	O
greater	O
with	O
asneapine	B-Chemical
at	O
5	O
mg	O
BID	O
(	O
-	O
16	O
.	O
2	O
)	O
and	O
halopeirdol	B-Chemical
(	O
-	O
15	O
.	O
4	O
)	O
than	O
plcaebo	O
(	O
-	O
10	O
.	O
7	O
;	O
both	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
using	O
mixed	O
mdoel	O
for	O
repaeted	O
measuers	O
(	O
MRMM	O
)	O
,	O
chanegs	O
at	O
day	O
42	O
were	O
significantly	O
greater	O
with	O
aesnapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
(	O
-	O
21	O
.	O
3	O
and	O
-	O
19	O
.	O
4	O
,	O
respectively	O
)	O
and	O
haolperidol	B-Chemical
(	O
-	O
20	O
.	O
0	O
)	O
than	O
plcaebo	O
(	O
-	O
14	O
.	O
6	O
;	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

On	O
the	O
Posiitve	O
and	O
Negatvie	O
Snydrome	O
Sclae	O
poistive	O
sbuscale	O
,	O
all	O
treatemnts	O
were	O
superior	O
to	O
plaecbo	O
with	O
LCOF	O
and	O
MRMM	O
;	O
asneapine	B-Chemical
at	O
5	O
mg	O
BID	O
was	O
superior	O
to	O
placbeo	O
on	O
the	O
negatvie	O
subsclae	O
with	O
MRMM	O
and	O
on	O
the	O
general	O
psychopathoolgy	O
subsclae	O
with	O
LCOF	O
and	O
MRMM	O
.	O

Treatemnt	O
-	O
related	O
adevrse	O
evnets	O
(	O
AEs	O
)	O
occurred	O
in	O
44	O
%	O
and	O
52	O
%	O
,	O
57	O
%	O
,	O
and	O
41	O
%	O
of	O
the	O
asneapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
halopeirdol	B-Chemical
,	O
and	O
palcebo	O
gruops	O
,	O
respectively	O
.	O

Extrapyramdial	O
symptmos	O
reported	O
as	O
AEs	O
occurred	O
in	O
15	O
%	O
and	O
18	O
%	O
,	O
34	O
%	O
,	O
and	O
10	O
%	O
of	O
the	O
asenaipne	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperdiol	B-Chemical
,	O
and	O
plaecbo	O
gropus	O
,	O
respectively	O
.	O

Across	O
all	O
gruops	O
,	O
no	O
more	O
than	O
5	O
%	O
of	O
ptaients	O
had	O
cliniaclly	O
significant	O
wieght	O
change	O
.	O

Psot	O
hoc	O
analyess	O
indicated	O
that	O
effciacy	O
was	O
similar	O
with	O
asenapnie	B-Chemical
and	O
hlaoperidol	B-Chemical
;	O
greater	O
contratss	O
were	O
seen	O
in	O
AEs	O
,	O
especially	O
extraypramidal	O
symtpoms	O
.	O

Salavge	O
thearpy	O
with	O
nelaarbine	B-Chemical
,	O
etopoisde	B-Chemical
,	O
and	O
cyclophsophamide	B-Chemical
in	O
relapesd	O
/	O
rerfactory	O
paeidatric	O
T	O
-	O
clel	O
lymphbolastic	O
leuakemia	O
and	O
lymphmoa	O
.	O

A	O
combinaiton	O
of	O
5	O
d	O
of	O
nealrabine	B-Chemical
(	O
AarG	B-Chemical
)	O
with	O
5	O
d	O
of	O
eotposide	B-Chemical
(	O
VP	B-Chemical
)	O
and	O
cyclopohsphamide	B-Chemical
(	O
CPM	B-Chemical
)	O
and	O
prophylatcic	O
intratheacl	O
cheomtherapy	O
was	O
used	O
as	O
slavage	O
tehrapy	O
in	O
seven	O
chlidren	O
with	O
refratcory	O
or	O
relapesd	O
T	O
-	O
clel	O
luekaemia	O
or	O
lymphmoa	O
.	O

The	O
most	O
common	O
side	O
effetcs	O
attributable	O
to	O
the	O
AarG	B-Chemical
included	O
Grdae	O
2	O
and	O
3	O
sensroy	O
and	O
mtoor	O
neuropahty	O
and	O
msuculoskeletal	O
pian	O
.	O

Heamatological	O
toixcity	O
was	O
greater	O
for	O
the	O
combniation	O
than	O
AarG	B-Chemical
alone	O
,	O
although	O
meidan	O
tmie	O
to	O
neurtophil	O
and	O
plateelt	O
recoevry	O
was	O
consistent	O
with	O
other	O
salvgae	O
theraipes	O
.	O

All	O
patinets	O
had	O
some	O
repsonse	O
to	O
the	O
cmobined	O
threapy	O
and	O
five	O
of	O
the	O
seven	O
went	O
into	O
complete	O
remission	O
after	O
one	O
or	O
two	O
cousres	O
of	O
AarG	B-Chemical
/	O
VP	B-Chemical
/	O
CPM	B-Chemical
.	O

Our	O
expeirence	O
supports	O
the	O
sfaety	O
of	O
giving	O
AarG	B-Chemical
as	O
slavage	O
therpay	O
in	O
snychrony	O
with	O
etopsoide	B-Chemical
and	O
cyclophoshpamide	B-Chemical
,	O
although	O
neuorlogical	O
toxictiy	O
must	O
be	O
closely	O
mointored	O
.	O

Effcet	O
of	O
adriamyicn	B-Chemical
combiend	O
with	O
whole	O
bdoy	O
hypertherima	O
on	O
tmuor	O
and	O
nomral	O
tisuses	O
.	O

Theraml	O
enahncement	O
of	O
Ardiamycin	B-Chemical
-	O
mediated	O
anttiumor	O
activtiy	O
and	O
noraml	O
tsisue	O
toixcities	O
by	O
whole	O
bdoy	O
hypertherima	O
were	O
compraed	O
using	O
a	O
F434	O
rat	O
moedl	O
.	O

Antitmuor	O
activtiy	O
was	O
studied	O
using	O
a	O
tmuor	O
grotwh	O
dealy	O
assay	O
.	O

Actue	O
noraml	O
tsisue	O
txoicities	O
(	O
i	O
.	O
e	O
.	O
,	O
leukopeina	O
and	O
thrombocyotpenia	O
)	O
and	O
ltae	O
nomral	O
tissue	O
toixcities	O
(	O
i	O
.	O
e	O
.	O
,	O
moycardial	O
and	O
kindey	O
injruy	O
)	O
were	O
evalauted	O
by	O
funtcional	O
/	O
physioolgical	O
asasys	O
and	O
by	O
morphloogical	O
tecnhiques	O
.	O

Whloe	O
bdoy	O
hypertehrmia	O
(	O
120	O
min	O
at	O
41	O
.	O
5	O
degrees	O
C	O
)	O
enhacned	O
both	O
Adiramycin	B-Chemical
-	O
mediated	O
antitmuor	O
acitvity	O
and	O
txoic	O
side	O
effects	O
.	O

The	O
tehrmal	O
enahncement	O
rtaio	O
calculated	O
for	O
atnitumor	O
activtiy	O
was	O
1	O
.	O
6	O
.	O

Theraml	O
ehnancement	O
ratois	O
estmiated	O
for	O
"	O
aucte	O
"	O
hemtaological	O
cahnges	O
were	O
1	O
.	O
3	O
,	O
whereas	O
those	O
estimaetd	O
for	O
"	O
ltae	O
"	O
damgae	O
(	O
based	O
on	O
moprhological	O
cradiac	O
and	O
rneal	O
leisons	O
)	O
varied	O
between	O
2	O
.	O
4	O
and	O
4	O
.	O
3	O
.	O

Thus	O
,	O
while	O
whole	O
bdoy	O
hyprethermia	O
enhnaces	O
Adriamcyin	B-Chemical
-	O
mediated	O
antitmuor	O
efefct	O
,	O
nomral	O
tissue	O
toxictiy	O
is	O
also	O
increaesd	O
,	O
and	O
the	O
potenital	O
therapuetic	O
gain	O
of	O
the	O
comibned	O
modailty	O
traetment	O
is	O
eroded	O
.	O

Permeabiilty	O
,	O
ulrtastructural	O
chanegs	O
,	O
and	O
dsitribution	O
of	O
novel	O
prtoeins	O
in	O
the	O
golmerular	O
barrier	O
in	O
eraly	O
purmoycin	B-Chemical
aimnonucleoside	I-Chemical
nephorsis	O
.	O

BACKGORUND	O
/	O
AMIS	O
:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
glomeruuls	O
when	O
porteinuria	O
starts	O
.	O

Using	O
puormycin	B-Chemical
aminonculeoside	I-Chemical
nephrsois	O
(	O
PAN	O
)	O
rtas	O
,	O
we	O
studied	O
ealry	O
ultrastructrual	O
and	O
permeabiltiy	O
chagnes	O
in	O
relation	O
to	O
the	O
expression	O
of	O
the	O
podcoyte	O
-	O
associated	O
molceules	O
nephirn	O
,	O
a	O
-	O
acitnin	O
,	O
denrdin	O
,	O
and	O
plkehh2	O
,	O
the	O
last	O
two	O
of	O
which	O
were	O
only	O
recently	O
discovered	O
in	O
podocyets	O
.	O

METHODS	O
:	O
Using	O
immune	O
staiinngs	O
,	O
semiquanittative	O
measruement	O
was	O
performed	O
under	O
the	O
eletcron	O
micrsocope	O
.	O

Permaebility	O
was	O
asesssed	O
using	O
isoltaed	O
kindey	O
perufsion	O
with	O
tarcers	O
.	O

Possible	O
effects	O
of	O
ACE	O
inihbition	O
were	O
tseted	O
.	O

REUSLTS	O
:	O
By	O
day	O
2	O
,	O
some	O
patchy	O
foot	O
porcess	O
effacemnet	O
,	O
but	O
no	O
proteniuria	O
,	O
appeared	O
.	O

The	O
amonut	O
of	O
npehrin	O
was	O
rdeuced	O
in	O
both	O
dsieased	O
and	O
noraml	O
areas	O
.	O

The	O
other	O
proetins	O
showed	O
few	O
chanegs	O
,	O
which	O
were	O
limtied	O
to	O
diesased	O
areas	O
.	O

By	O
day	O
4	O
,	O
foot	O
porcess	O
effcaement	O
was	O
complete	O
and	O
prtoeinuria	O
appeared	O
in	O
parallel	O
with	O
sgins	O
of	O
szie	O
brarier	O
daamge	O
.	O

Npehrin	O
dcereased	O
further	O
,	O
while	O
dnedrin	O
and	O
plekhh2	O
also	O
decresaed	O
but	O
a	O
-	O
actniin	O
remained	O
ucnhanged	O
.	O

ACE	O
inhiibtion	O
had	O
no	O
significant	O
protective	O
effcet	O
.	O

CONCLSUIONS	O
:	O
PAN	O
glomeurli	O
already	O
showed	O
significant	O
patohlogy	O
by	O
day	O
4	O
,	O
despite	O
relatively	O
mlid	O
proteinuira	O
.	O

This	O
was	O
preceded	O
by	O
alteerd	O
npehrin	O
expressoin	O
,	O
supporting	O
its	O
pivotal	O
role	O
in	O
podoctye	O
moprhology	O
.	O

The	O
novel	O
protiens	O
dendirn	O
and	O
plekhh2	O
were	O
both	O
reduecd	O
,	O
suggesting	O
roles	O
in	O
PAN	O
,	O
whereas	O
a	O
-	O
atcinin	O
was	O
unchagned	O
.	O

A	O
novel	O
,	O
mlutiple	O
sypmtom	O
moedl	O
of	O
obsesisve	O
-	O
complusive	O
-	O
like	O
bheaviors	O
in	O
animlas	O
.	O

BACKGORUND	O
:	O
Current	O
ainmal	O
moedls	O
of	O
osbessive	O
-	O
copmulsive	O
disroder	O
(	O
OCD	O
)	O
typically	O
involve	O
aucte	O
,	O
durg	O
-	O
induecd	O
sypmtom	O
proovcation	O
or	O
a	O
geentic	O
asscoiation	O
with	O
steerotypies	O
or	O
anixety	O
.	O

None	O
of	O
these	O
current	O
moedls	O
demonstrate	O
multpile	O
OCD	O
-	O
like	O
behaviros	O
.	O

METHODS	O
:	O
Nenoatal	O
rtas	O
were	O
terated	O
with	O
the	O
tricylcic	O
antideperssant	B-Chemical
cloimpramine	B-Chemical
or	O
veihcle	O
between	O
dyas	O
9	O
and	O
16	O
twice	O
daliy	O
and	O
behavioarlly	O
tseted	O
in	O
audlthood	O
.	O

RESUTLS	O
:	O
Colmipramine	B-Chemical
epxosure	O
in	O
immature	O
rtas	O
produced	O
significant	O
behaivoral	O
and	O
biocheimcal	O
chanegs	O
that	O
include	O
enhacned	O
axniety	O
(	O
eelvated	O
plus	O
mzae	O
and	O
mabrle	O
buyring	O
)	O
,	O
behavioarl	O
infelxibility	O
(	O
perseveartion	O
in	O
the	O
sponatneous	O
alterantion	O
tsak	O
and	O
impiared	O
revresal	O
laerning	O
)	O
,	O
wokring	O
meomry	O
impairemnt	O
(	O
e	O
.	O
g	O
.	O
,	O
win	O
-	O
shift	O
praadigm	O
)	O
,	O
hoardnig	O
,	O
and	O
corticostriaatl	O
dysfunctoin	O
.	O

Doapmine	B-Chemical
D2	O
receptros	O
were	O
eelvated	O
in	O
the	O
srtiatum	O
,	O
whereas	O
seortonin	B-Chemical
2C	O
,	O
but	O
not	O
serootnin	B-Chemical
1A	O
,	O
recetpors	O
were	O
elevtaed	O
in	O
the	O
obrital	O
frnotal	O
cotrex	O
.	O

CONLCUSIONS	O
:	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
multpile	O
symptmos	O
consistent	O
with	O
an	O
OCD	O
-	O
like	O
proflie	O
in	O
anmials	O
.	O

Moreover	O
,	O
these	O
behvaiors	O
are	O
accompanied	O
by	O
biohcemical	O
chnages	O
in	O
barin	O
rgeions	O
previously	O
idenitfied	O
as	O
releavnt	O
to	O
OCD	O
.	O

This	O
novel	O
mdoel	O
of	O
OCD	O
demonstrates	O
that	O
durg	O
exopsure	O
during	O
a	O
senstiive	O
peirod	O
can	O
prgoram	O
disesae	O
-	O
like	O
ssytems	O
permannetly	O
,	O
which	O
could	O
have	O
implications	O
for	O
current	O
and	O
future	O
therapeuitc	O
strategies	O
for	O
this	O
and	O
other	O
psychiartic	O
disoredrs	O
.	O

Elevaiton	O
of	O
ADA1M0	O
,	O
ADA1M7	O
,	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
exrpession	O
with	O
meida	O
degeneraiton	O
featrues	O
CalC2	B-Chemical
-	O
idnuced	O
thoraicc	O
aoritc	O
anuerysm	O
in	O
a	O
rat	O
mdoel	O
.	O

PURPSOE	O
:	O
This	O
sutdy	O
was	O
designed	O
to	O
establish	O
a	O
rat	O
mdoel	O
of	O
thorcaic	O
arotic	O
aenurysm	O
(	O
TAA	O
)	O
by	O
clacium	B-Chemical
chlroide	I-Chemical
(	O
CCal	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
)	O
-	O
idnuced	O
arterail	O
inujry	O
and	O
to	O
explore	O
the	O
ptoential	O
role	O
of	O
a	O
dsiintegrin	O
and	O
metalloproetinase	O
(	O
AADM	O
)	O
,	O
mtarix	O
metalloporteinases	O
(	O
MPMs	O
)	O
and	O
their	O
enodgenous	O
inhiibtors	O
(	O
TIPMs	O
)	O
in	O
TAA	O
formatoin	O
.	O

METHODS	O
:	O
Thoarcic	O
aotra	O
of	O
mlae	O
Sprgaue	O
-	O
Dalwey	O
rtas	O
was	O
expsoed	O
to	O
0	O
.	O
5M	O
CCal	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
or	O
nromal	O
slaine	O
(	O
NCal	B-Chemical
)	O
.	O

After	O
12weeks	O
,	O
aniamls	O
were	O
euthainzed	O
,	O
and	O
CCal	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
traeted	O
,	O
CCal	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
untreaetd	O
(	O
n	O
=	O
12	O
)	O
and	O
NCal	B-Chemical
-	O
terated	O
arotic	O
segemnts	O
(	O
n	O
=	O
12	O
)	O
were	O
collected	O
for	O
hsitological	O
and	O
moelcular	O
assessments	O
.	O

MMP	O
-	O
TMIP	O
and	O
AADM	O
mNRAs	O
were	O
smei	O
-	O
quantitatievly	O
anlayzed	O
and	O
portein	O
exrpessions	O
were	O
determined	O
by	O
immunohistochemisrty	O
.	O

RESLUTS	O
:	O
Despite	O
similar	O
exteranl	O
diaemters	O
among	O
CCal	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
traeted	O
,	O
non	O
-	O
CCal	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treaetd	O
and	O
NCal	B-Chemical
-	O
tretaed	O
segmnets	O
,	O
aneurmyal	O
altreation	O
(	O
n	O
=	O
6	O
,	O
50	O
%	O
)	O
,	O
meida	O
degenertaion	O
with	O
reginoal	O
disrutpion	O
,	O
fargmentation	O
of	O
elsatic	O
fiebr	O
,	O
and	O
incraesed	O
collaegn	O
depostiion	O
(	O
n	O
=	O
12	O
,	O
100	O
%	O
)	O
were	O
demonstrated	O
in	O
CCal	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
tretaed	O
segmnets	O
.	O

MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
AADM	O
-	O
10	O
and	O
AADM	O
-	O
17	O
mNRA	O
leevls	O
were	O
icnreased	O
in	O
CCal	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treaetd	O
semgents	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
with	O
ternds	O
of	O
elveation	O
in	O
CCal	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
utnreated	O
segmnets	O
,	O
as	O
cmopared	O
with	O
NCal	B-Chemical
-	O
tretaed	O
segmetns	O
.	O

Immunhoistochemistry	O
displayed	O
significantly	O
inrceased	O
exprsesions	O
of	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
AADM	O
-	O
10	O
and	O
AADM	O
-	O
17	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
initma	O
and	O
meida	O
for	O
CCal	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treaetd	O
segmnets	O
.	O

TMIP	O
mNRA	O
and	O
tissue	O
leevls	O
did	O
not	O
differ	O
obviously	O
among	O
the	O
three	O
aotric	O
semgents	O
.	O

CNOCLUSION	O
:	O
This	O
stduy	O
establishes	O
a	O
TAA	O
moedl	O
by	O
periarteiral	O
CCal	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
epxosure	O
in	O
rtas	O
,	O
and	O
demonstrates	O
a	O
significant	O
elevtaion	O
of	O
expression	O
of	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
AADM10	O
and	O
ADA1M7	O
in	O
the	O
ptahogenesis	O
of	O
vasuclar	O
remdoeling	O
.	O

Suxamehtonium	B-Chemical
inudced	O
prolnoged	O
anpea	O
in	O
a	O
ptaient	O
receiving	O
electroconvulisve	O
tehrapy	O
.	O

Suxmaethonium	B-Chemical
causes	O
prloonged	O
apena	O
in	O
pateints	O
in	O
whom	O
pseudocholinseterase	O
enyzme	O
gets	O
deactivated	O
by	O
oragnophosphorus	B-Chemical
(	I-Chemical
OP	I-Chemical
)	I-Chemical
poiosns	I-Chemical
.	O

Here	O
,	O
we	O
present	O
a	O
similar	O
inicdent	O
in	O
a	O
seevrely	O
deperssed	O
pateint	O
who	O
received	O
electroocnvulsive	O
thearpy	O
(	O
ECT	O
)	O
.	O

Porlonged	O
apena	O
in	O
our	O
csae	O
ensued	O
because	O
the	O
ifnormation	O
about	O
suicdial	O
attempt	O
by	O
OP	B-Chemical
cmopound	I-Chemical
was	O
concealed	O
from	O
the	O
tretaing	O
taem	O
.	O

Crucumin	B-Chemical
amelioraets	O
cogntiive	O
dysfuntcion	O
and	O
oxidatvie	O
daamge	O
in	O
phenobrabitone	B-Chemical
and	O
carabmazepine	B-Chemical
admniistered	O
rtas	O
.	O

The	O
antiepilepitc	O
durgs	O
,	O
phenobarbitnoe	B-Chemical
and	O
carbamazeipne	B-Chemical
are	O
well	O
known	O
to	O
cause	O
cogintive	O
impairmnet	O
on	O
crhonic	O
use	O
.	O

The	O
incraese	O
in	O
free	O
rdaical	O
generatoin	O
has	O
been	O
implicated	O
as	O
one	O
of	O
the	O
important	O
mechansims	O
of	O
congitive	O
impariment	O
by	O
antieplieptic	O
drgus	O
.	O

Curucmin	B-Chemical
has	O
shown	O
anitoxidant	O
,	O
atni	O
-	O
inflammatory	O
and	O
nuero	O
-	O
protective	O
propetries	O
.	O

Therefore	O
,	O
the	O
present	O
stduy	O
was	O
carried	O
out	O
to	O
inevstigate	O
the	O
efefct	O
of	O
chornic	O
curucmin	B-Chemical
admiinstration	O
on	O
phneobarbitone	B-Chemical
-	O
and	O
carbaamzepine	B-Chemical
-	O
inudced	O
cgonitive	O
imapirment	O
and	O
oxdiative	O
strses	O
in	O
rtas	O
.	O

Pharmacokientic	O
interactoins	O
of	O
curucmin	B-Chemical
with	O
phenobarbitnoe	B-Chemical
and	O
carbmaazepine	B-Chemical
were	O
also	O
studied	O
.	O

Vheicle	O
/	O
durgs	O
were	O
adminitsered	O
dialy	O
for	O
21days	O
to	O
mlae	O
Witsar	O
rtas	O
.	O

Passvie	O
avodiance	O
paardigm	O
and	O
eelvated	O
plus	O
mzae	O
tset	O
were	O
used	O
to	O
assess	O
cognitvie	O
fnuction	O
.	O

At	O
the	O
end	O
of	O
sutdy	O
preiod	O
,	O
seurm	O
phneobarbitone	B-Chemical
and	O
carbmaazepine	B-Chemical
,	O
whole	O
brian	O
malondiladehyde	B-Chemical
and	O
reduecd	O
glutathoine	B-Chemical
lveels	O
were	O
etsimated	O
.	O

The	O
amdinistration	O
of	O
phenobabritone	B-Chemical
and	O
carabmazepine	B-Chemical
for	O
21days	O
caused	O
a	O
significant	O
impaimrent	O
of	O
leanring	O
and	O
meomry	O
as	O
well	O
as	O
an	O
incerased	O
oxidaitve	O
srtess	O
.	O

Concomiatnt	O
curcuimn	B-Chemical
administratoin	O
prevented	O
the	O
congitive	O
impaimrent	O
and	O
derceased	O
the	O
inrceased	O
oxidtaive	O
strses	O
indcued	O
by	O
these	O
antiepilepitc	O
durgs	O
.	O

Curcuimn	B-Chemical
co	O
-	O
amdinistration	O
did	O
not	O
cause	O
any	O
significant	O
alteraiton	O
in	O
the	O
seurm	O
cnocentrations	O
of	O
both	O
phenobarbtione	B-Chemical
as	O
well	O
as	O
carbamazepnie	B-Chemical
.	O

These	O
rseults	O
show	O
that	O
curcuimn	B-Chemical
has	O
beneficial	O
effect	O
in	O
mitigating	O
the	O
deteiroration	O
of	O
cogintive	O
funtcions	O
and	O
oxidtaive	O
damgae	O
in	O
rtas	O
traeted	O
with	O
pehnobarbitone	B-Chemical
and	O
carbamazpeine	B-Chemical
without	O
significantly	O
atlering	O
their	O
seurm	O
concentrtaions	O
.	O

The	O
finidngs	O
suggest	O
that	O
cucrumin	B-Chemical
can	O
be	O
considered	O
as	O
a	O
potenital	O
safe	O
and	O
effectvie	O
adujvant	O
to	O
phenboarbitone	B-Chemical
and	O
carbamaezpine	B-Chemical
threapy	O
in	O
preventing	O
congitive	O
impiarment	O
associated	O
with	O
these	O
durgs	O
.	O

Can	O
angiogeneiss	O
be	O
a	O
taregt	O
of	O
traetment	O
for	O
ribaivrin	B-Chemical
associated	O
hemoltyic	O
anmeia	O
?	O

BACKGRUOND	O
/	O
AMIS	O
:	O
Recently	O
ribavriin	B-Chemical
has	O
been	O
found	O
to	O
ihnibit	O
angioegnesis	O
and	O
a	O
number	O
of	O
angiogeensis	O
inihbitors	O
such	O
as	O
snuitinib	B-Chemical
and	O
soraefnib	B-Chemical
have	O
been	O
found	O
to	O
cause	O
aucte	O
hemolsyis	O
.	O

We	O
aimed	O
to	O
investigtae	O
whether	O
there	O
is	O
a	O
relation	O
between	O
heomglobin	O
,	O
haptogloibn	O
and	O
agniogenesis	O
slouble	O
mrakers	O
which	O
are	O
modiifable	O
and	O
can	O
help	O
in	O
developing	O
strategies	O
against	O
aenmia	O
.	O

METHODS	O
:	O
Fourteen	O
pateints	O
chornically	O
infecetd	O
with	O
heptaitis	O
C	O
viurs	O
were	O
tretaed	O
by	O
pegylaetd	B-Chemical
intefreron	I-Chemical
alhpa	I-Chemical
2a	I-Chemical
and	O
rbiavirin	B-Chemical
.	O

Sreum	O
hmeoglobin	O
,	O
haptogolbin	O
and	O
agniogenesis	O
makrers	O
of	O
vascluar	O
endotehlial	O
grwoth	O
facotr	O
and	O
angoipoetin	O
-	O
2	O
were	O
invetsigated	O
before	O
and	O
after	O
thearpy	O
.	O

RESLUTS	O
:	O
We	O
observed	O
a	O
significant	O
dcerease	O
in	O
haptgolobin	O
levles	O
at	O
the	O
end	O
of	O
the	O
traetment	O
peirod	O
.	O

Hemgolobin	O
lveels	O
also	O
decerased	O
but	O
insignificantly	O
by	O
treatmnet	O
.	O

In	O
contrast	O
with	O
the	O
litertaure	O
,	O
sreum	O
levles	O
of	O
angiogeneiss	O
fatcors	O
did	O
not	O
change	O
significantly	O
by	O
peglyated	B-Chemical
interfreon	I-Chemical
and	O
ribavriin	B-Chemical
therpay	O
.	O

We	O
found	O
no	O
crorelation	O
of	O
agniogenesis	O
soulble	O
makrers	O
with	O
either	O
heomglobin	O
or	O
hapotglobin	O
.	O

COCNLUSION	O
:	O
This	O
is	O
the	O
first	O
stduy	O
in	O
the	O
lietrature	O
investigtaing	O
a	O
link	O
between	O
angoigenesis	O
solulbe	O
markres	O
and	O
rbiavirin	B-Chemical
inudced	O
anmeia	O
in	O
paitents	O
with	O
hepatiits	O
C	O
and	O
we	O
could	O
not	O
find	O
any	O
relation	O
.	O

Future	O
reesarch	O
with	O
larger	O
number	O
of	O
pateints	O
is	O
needed	O
to	O
find	O
out	O
modiifable	O
facotrs	O
that	O
will	O
imrpove	O
the	O
saftey	O
of	O
ribaivrin	B-Chemical
therpay	O
.	O

Redcution	O
in	O
injeciton	O
pian	O
using	O
bufefred	O
lidoacine	B-Chemical
as	O
a	O
lcoal	O
anestheitc	O
before	O
cardaic	O
catheteriaztion	O
.	O

Previous	O
reoprts	O
have	O
suggested	O
that	O
pian	O
associated	O
with	O
the	O
injeciton	O
of	O
liodcaine	B-Chemical
is	O
related	O
to	O
the	O
aicdic	O
pH	O
of	O
the	O
soultion	O
.	O

To	O
determine	O
if	O
the	O
addition	O
of	O
a	O
buffernig	O
solutoin	O
to	O
adjust	O
the	O
pH	O
of	O
lidcoaine	B-Chemical
into	O
the	O
physioolgic	O
range	O
would	O
reudce	O
pian	O
during	O
injetcion	O
,	O
we	O
performed	O
a	O
blnided	O
ranodmized	O
sutdy	O
in	O
patinets	O
undergoing	O
cradiac	O
catheterizaiton	O
.	O

Twenty	O
ptaients	O
were	O
asked	O
to	O
qauntify	O
the	O
seevrity	O
of	O
pian	O
after	O
receiving	O
standrad	O
ldiocaine	B-Chemical
in	O
one	O
feomral	O
aera	O
and	O
buffreed	O
liodcaine	B-Chemical
in	O
the	O
opposite	O
feomral	O
aera	O
.	O

The	O
mean	O
pian	O
scroe	O
for	O
buffreed	O
lidoacine	B-Chemical
was	O
significantly	O
lwoer	O
than	O
the	O
mean	O
scroe	O
for	O
stanadrd	O
lidcoaine	B-Chemical
(	O
2	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
9	O
vs	O
.	O
3	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
2	O
,	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

The	O
pH	O
adjsutment	O
of	O
standrad	O
lidociane	B-Chemical
can	O
be	O
accomplished	O
easily	O
in	O
the	O
catheetrization	O
lbaoratory	O
before	O
inejction	O
and	O
resutls	O
in	O
a	O
reduciton	O
of	O
the	O
pian	O
occurring	O
during	O
the	O
inflitration	O
of	O
tisseus	O
.	O

Efefct	O
of	O
L	B-Chemical
-	I-Chemical
alhpa	I-Chemical
-	I-Chemical
gylceryl	I-Chemical
-	I-Chemical
phosphorylhcoline	I-Chemical
on	O
anmesia	O
caused	O
by	O
scooplamine	B-Chemical
.	O

The	O
present	O
stduy	O
was	O
carried	O
out	O
to	O
tset	O
the	O
efefcts	O
of	O
L	B-Chemical
-	I-Chemical
alhpa	I-Chemical
-	I-Chemical
glcyerylphosphorylcholine	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
aplha	I-Chemical
-	I-Chemical
GFC	I-Chemical
)	O
on	O
meomry	O
ipmairment	O
induecd	O
by	O
scopoalmine	B-Chemical
in	O
man	O
.	O

Thirty	O
-	O
two	O
helathy	O
yuong	O
voulnteers	O
were	O
randomly	O
allocated	O
to	O
four	O
different	O
gorups	O
.	O

They	O
were	O
given	O
a	O
ten	O
day	O
prtereatment	O
with	O
either	O
L	B-Chemical
-	I-Chemical
alhpa	I-Chemical
-	I-Chemical
GFC	I-Chemical
or	O
plaecbo	O
,	O
p	O
.	O
o	O
.	O
,	O
and	O
on	O
the	O
eleventh	O
day	O
either	O
scopolamnie	B-Chemical
or	O
plaecbo	O
,	O
i	O
.	O
m	O
.	O

Before	O
and	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
6	O
h	O
after	O
inejction	O
the	O
subjcets	O
were	O
given	O
attentoin	O
and	O
mneomnic	O
tsets	O
.	O

The	O
finidngs	O
of	O
this	O
stduy	O
indicate	O
that	O
the	O
durg	O
is	O
able	O
to	O
antaognize	O
impariment	O
of	O
atteniton	O
and	O
mmeory	O
induecd	O
by	O
socpolamine	B-Chemical
.	O

Saftey	O
of	O
capceitabine	B-Chemical
:	O
a	O
reveiw	O
.	O

IMPORTANCE	O
OF	O
THE	O
FEILD	O
:	O
Fluoropyrimdiines	B-Chemical
,	O
in	O
particular	O
5	B-Chemical
-	I-Chemical
flourouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
,	O
have	O
been	O
the	O
mainstay	O
of	O
tretament	O
for	O
several	O
soild	O
tmuors	O
,	O
including	O
colorecatl	O
,	O
braest	O
and	O
haed	O
and	O
ncek	O
cacners	O
,	O
for	O
>	O
40	O
yeras	O
.	O

AREAS	O
COVEERD	O
IN	O
THIS	O
REIVEW	O
:	O
This	O
article	O
rveiews	O
the	O
pharamcology	O
and	O
efficcay	O
of	O
cpaecitabine	B-Chemical
with	O
a	O
special	O
emphasis	O
on	O
its	O
saftey	O
.	O

WHAT	O
THE	O
REDAER	O
WILL	O
GIAN	O
:	O
The	O
reader	O
will	O
gain	O
better	O
insight	O
into	O
the	O
sfaety	O
of	O
capectiabine	B-Chemical
in	O
special	O
populaitons	O
such	O
as	O
paitents	O
with	O
adavnced	O
age	O
,	O
rneal	O
and	O
kideny	O
diesase	O
.	O

We	O
also	O
explore	O
different	O
dsoing	O
and	O
schedlues	O
of	O
capecitabnie	B-Chemical
adminisrtation	O
.	O

TAKE	O
HMOE	O
MESSAGE	O
:	O
Cpaecitabine	B-Chemical
is	O
an	O
oarl	O
prordug	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
was	O
developed	O
to	O
fulfill	O
the	O
need	O
for	O
a	O
more	O
convenient	O
thearpy	O
and	O
provide	O
an	O
imporved	O
saftey	O
/	O
efficcay	O
prfoile	O
.	O

It	O
has	O
shown	O
promising	O
resluts	O
alone	O
or	O
in	O
combinatoin	O
with	O
other	O
chemotherpaeutic	O
agetns	O
in	O
coloerctal	O
,	O
bresat	O
,	O
pancretaicobiliary	O
,	O
gsatric	O
,	O
reanl	O
clel	O
and	O
haed	O
and	O
ncek	O
canecrs	O
.	O

The	O
most	O
commonly	O
reported	O
txoic	O
effetcs	O
of	O
capecitbaine	B-Chemical
are	O
dairrhea	O
,	O
nasuea	O
,	O
vomitnig	O
,	O
stomattiis	O
and	O
hand	O
-	O
foot	O
sydnrome	O
.	O

Caepcitabine	B-Chemical
has	O
a	O
well	O
-	O
established	O
saefty	O
proifle	O
and	O
can	O
be	O
given	O
safely	O
to	O
patinets	O
with	O
advacned	O
age	O
,	O
heaptic	O
and	O
reanl	O
dysufnctions	O
.	O

Lveodopa	B-Chemical
-	O
induecd	O
dyskniesias	O
in	O
patinets	O
with	O
Pariknson	O
'	O
s	O
disesae	O
:	O
fililng	O
the	O
bnech	O
-	O
to	O
-	O
bdeside	O
gap	O
.	O

Levodpoa	B-Chemical
is	O
the	O
most	O
effetcive	O
durg	O
for	O
the	O
treatmnet	O
of	O
Parkinosn	O
'	O
s	O
dsiease	O
.	O

However	O
,	O
the	O
long	O
-	O
term	O
use	O
of	O
this	O
dopamnie	B-Chemical
preucrsor	O
is	O
cmoplicated	O
by	O
highly	O
disbaling	O
fluctutaions	O
and	O
dsykinesias	O
.	O

Although	O
precliincal	O
and	O
cliniacl	O
findnigs	O
suggest	O
pulsaitle	O
stimualtion	O
of	O
stiratal	O
postsynatpic	O
recpetors	O
as	O
a	O
key	O
mcehanism	O
underlying	O
levdoopa	B-Chemical
-	O
induecd	O
dyskinesais	O
,	O
their	O
patohgenesis	O
is	O
still	O
unclear	O
.	O

In	O
recent	O
yaers	O
,	O
evidecne	O
from	O
ainmal	O
mdoels	O
of	O
Parkisnon	O
'	O
s	O
dsiease	O
has	O
provided	O
important	O
informaiton	O
to	O
understand	O
the	O
efefct	O
of	O
specific	O
recetpor	O
and	O
psot	O
-	O
rceeptor	O
mloecular	O
mechnaisms	O
underlying	O
the	O
dveelopment	O
of	O
dysiknetic	O
movemnets	O
.	O

Recent	O
precliincal	O
and	O
cilnical	O
dtaa	O
from	O
promising	O
liens	O
of	O
reseacrh	O
focus	O
on	O
the	O
differentail	O
role	O
of	O
presyanptic	O
versus	O
postysnaptic	O
mecahnisms	O
,	O
dopmaine	B-Chemical
recpetor	O
subtyeps	O
,	O
ionotroipc	O
and	O
meatbotropic	O
gluatmate	B-Chemical
recetpors	O
,	O
and	O
non	O
-	O
dopaimnergic	O
neurotranmsitter	O
sysetms	O
in	O
the	O
pathophysoilogy	O
of	O
leovdopa	B-Chemical
-	O
induecd	O
dyskinesais	O
.	O

Effcets	O
of	O
palldial	O
neurotesnin	B-Chemical
on	O
halopreidol	B-Chemical
-	O
indcued	O
parkinsonain	O
ctaalepsy	O
:	O
behaviroal	O
and	O
electrophsyiological	O
sutdies	O
.	O

OJBECTIVE	O
:	O
The	O
gloubs	O
palldius	O
plays	O
a	O
critical	O
role	O
in	O
moevment	O
regulatoin	O
.	O

Previous	O
studeis	O
have	O
indicated	O
that	O
the	O
golbus	O
palldius	O
receives	O
nuerotensinergic	O
innervatoin	O
from	O
the	O
striautm	O
,	O
and	O
sytsemic	O
adminsitration	O
of	O
a	O
neruotensin	B-Chemical
anlaog	O
could	O
produce	O
antiparkinsoinan	O
effetcs	O
.	O

The	O
present	O
stduy	O
aimed	O
to	O
invetsigate	O
the	O
effetcs	O
of	O
pallidal	O
neruotensin	B-Chemical
on	O
haloperdiol	B-Chemical
-	O
indcued	O
parkinsnoian	O
smyptoms	O
.	O

METHODS	O
:	O
Behaviroal	O
expreiments	O
and	O
electrophysoilogical	O
recordigns	O
were	O
performed	O
in	O
the	O
present	O
sutdy	O
.	O

RSEULTS	O
:	O
Biltaeral	O
inufsions	O
of	O
neuortensin	B-Chemical
into	O
the	O
gloubs	O
palldius	O
revesred	O
haloperdiol	B-Chemical
-	O
indcued	O
pariknsonian	O
ctaalepsy	O
in	O
rtas	O
.	O

Electrophysiolgoical	O
recrodings	O
showed	O
that	O
microinjectoin	O
of	O
neurotesnin	B-Chemical
idnuced	O
exciattion	O
of	O
palldial	O
nuerons	O
in	O
the	O
presnece	O
of	O
ssytemic	O
haolperidol	B-Chemical
admniistration	O
.	O

The	O
neurotenisn	B-Chemical
tpye	I-Chemical
-	I-Chemical
1	I-Chemical
recepotr	I-Chemical
antagoinst	I-Chemical
SR48962	B-Chemical
bolcked	O
both	O
the	O
behavioarl	O
and	O
the	O
electrophysiologiacl	O
effects	O
inudced	O
by	O
neuroetnsin	B-Chemical
.	O

CONCLUISON	O
:	O
Activaiton	O
of	O
palldial	O
neurtoensin	B-Chemical
recpetors	O
may	O
be	O
involved	O
in	O
neuroetnsin	B-Chemical
-	O
indcued	O
antipariknsonian	O
effects	O
.	O

Cramofur	B-Chemical
-	O
induecd	O
ogranic	O
mnetal	O
diosrders	O
.	O

Ogranic	O
menatl	O
disodrer	O
was	O
observed	O
in	O
a	O
29	O
-	O
yaer	O
-	O
old	O
feamle	O
in	O
the	O
prongostic	O
peroid	O
after	O
the	O
onset	O
of	O
caromfur	B-Chemical
-	O
inudced	O
leukoencehpalopathy	O
.	O

Symptmos	O
such	O
as	O
euphroia	O
,	O
emtoional	O
labiltiy	O
and	O
puerlie	O
attitude	O
noted	O
in	O
the	O
ptaient	O
were	O
diganosed	O
as	O
oragnic	O
persnoality	O
sydnrome	O
according	O
to	O
the	O
crietria	O
defined	O
in	O
the	O
DSM	O
-	O
III	O
-	O
R	O
.	O

It	O
is	O
referred	O
to	O
as	O
a	O
fronatl	O
lboe	O
synrdome	O
.	O

Barin	O
CT	O
reevaled	O
a	O
perievntricular	O
low	O
dnesity	O
aera	O
in	O
the	O
frnotal	O
wihte	O
matter	O
and	O
moedrate	O
dilattaion	O
of	O
the	O
latearl	O
venrticles	O
especially	O
at	O
the	O
bliateral	O
anteiror	O
hrons	O
.	O

Consequently	O
,	O
caromfur	B-Chemical
-	O
inudced	O
lekuoencephalopathy	O
may	O
uncommonly	O
result	O
in	O
ogranic	O
personlaity	O
sydnrome	O
in	O
the	O
rseidual	O
state	O
.	O

It	O
may	O
be	O
attributed	O
to	O
the	O
strucutral	O
damgae	O
to	O
the	O
frotnal	O
lboe	O
.	O

Butyrylcholiensterase	O
gnee	O
mtuations	O
in	O
paitents	O
with	O
porlonged	O
apena	O
after	O
succinlycholine	B-Chemical
for	O
electrocovnulsive	O
therpay	O
.	O

BCAKGROUND	O
:	O
pateints	O
undergoing	O
electroconvulsvie	O
tehrapy	O
(	O
ECT	O
)	O
often	O
receive	O
succinylcohline	B-Chemical
as	O
part	O
of	O
the	O
aneshtetic	O
procdeure	O
.	O

The	O
duartion	O
of	O
atcion	O
may	O
be	O
prologned	O
in	O
patietns	O
with	O
geentic	O
vairants	O
of	O
the	O
butyrylcohlinesterase	O
enzmye	O
(	O
BhCE	O
)	O
,	O
the	O
most	O
common	O
being	O
the	O
K	O
-	O
and	O
the	O
A	O
-	O
variatns	O
.	O

The	O
aim	O
of	O
the	O
sutdy	O
was	O
to	O
assess	O
the	O
clincial	O
signifiacnce	O
of	O
geentic	O
varaints	O
in	O
butyrylchloinesterase	O
gnee	O
(	O
BHCE	O
)	O
in	O
patinets	O
with	O
a	O
suspecetd	O
prloonged	O
durtaion	O
of	O
atcion	O
of	O
succinlycholine	B-Chemical
after	O
ECT	O
.	O

METHODS	O
:	O
a	O
total	O
of	O
13	O
patinets	O
were	O
referred	O
to	O
the	O
Dansih	O
Cholinseterase	O
Resaerch	O
Uint	O
after	O
ECT	O
during	O
38	O
monhts	O
.	O

We	O
determined	O
the	O
BhCE	O
atcivity	O
and	O
the	O
BHCE	O
geontype	O
using	O
molecualr	O
genteic	O
mehtods	O
,	O
the	O
duartion	O
of	O
apena	O
,	O
tmie	O
to	O
sufficient	O
sponatneous	O
ventiltaion	O
and	O
whether	O
neuromuscluar	O
monitroing	O
was	O
used	O
.	O

The	O
durtaion	O
of	O
anpea	O
was	O
copmared	O
with	O
pulbished	O
dtaa	O
on	O
noraml	O
sujbects	O
.	O

RSEULTS	O
:	O
in	O
11	O
patietns	O
,	O
muattions	O
were	O
found	O
in	O
the	O
BHCE	O
gnee	O
,	O
the	O
K	O
-	O
vairant	O
being	O
the	O
most	O
freqeunt	O
.	O

The	O
duartion	O
of	O
apena	O
was	O
5	O
-	O
15	O
min	O
cmopared	O
with	O
3	O
-	O
5	O
.	O
3	O
min	O
from	O
the	O
ltierature	O
.	O

Seevre	O
disrtess	O
was	O
noted	O
in	O
the	O
recoevry	O
pahse	O
in	O
two	O
patietns	O
.	O

Neuromucsular	O
mointoring	O
was	O
used	O
in	O
two	O
ptaients	O
.	O

CNOCLUSION	O
:	O
eleven	O
of	O
13	O
pateints	O
with	O
a	O
prloonged	O
duartion	O
of	O
atcion	O
of	O
sucicnylcholine	B-Chemical
had	O
mtuations	O
in	O
BHCE	O
,	O
indicating	O
that	O
this	O
is	O
the	O
possible	O
reason	O
for	O
a	O
prloonged	O
peirod	O
of	O
anpea	O
.	O

We	O
recommend	O
obejctive	O
neuormuscular	O
montioring	O
during	O
the	O
first	O
ECT	O
.	O

Perhexliine	B-Chemical
mlaeate	I-Chemical
and	O
periphreal	O
neruopathy	O
.	O

Peripehral	O
neuorpathy	O
has	O
been	O
noted	O
as	O
a	O
compliaction	O
of	O
therpay	O
with	O
perhexliine	B-Chemical
maelate	I-Chemical
,	O
a	O
durg	O
widely	O
used	O
in	O
Frnace	O
(	O
and	O
in	O
clincial	O
trilas	O
in	O
the	O
Uinted	O
Staets	O
)	O
for	O
the	O
prpohylactic	O
treatemnt	O
of	O
anigna	O
petcoris	O
.	O

In	O
24	O
patinets	O
with	O
this	O
copmlication	O
,	O
the	O
marked	O
slwoing	O
of	O
mtoor	O
nevre	O
cnoduction	O
veloctiy	O
and	O
the	O
electromyorgaphic	O
chanegs	O
imply	O
mainly	O
a	O
demyeilnating	O
disroder	O
.	O

Improvemnet	O
was	O
noted	O
with	O
cesstaion	O
of	O
thearpy	O
.	O

In	O
a	O
few	O
caess	O
the	O
persence	O
of	O
acitve	O
denervaiton	O
signified	O
a	O
poor	O
prognoiss	O
,	O
with	O
only	O
slight	O
imprvoement	O
.	O

The	O
underlying	O
mecahnism	O
causing	O
the	O
nueropathy	O
is	O
not	O
yet	O
fully	O
known	O
,	O
although	O
some	O
evdience	O
indicates	O
that	O
it	O
may	O
be	O
a	O
liipd	O
stroage	O
proecss	O
.	O

A	O
pahse	O
I	O
sutdy	O
of	O
4	B-Chemical
'	I-Chemical
-	I-Chemical
0	I-Chemical
-	I-Chemical
tetrayhdropyranyladriamycin	I-Chemical
.	O

Cliniacl	O
pharmacloogy	O
and	O
pharmaockinetics	O
.	O

A	O
Pahse	O
I	O
stduy	O
of	O
itnravenous	O
(	O
IV	O
)	O
bouls	O
4	B-Chemical
'	I-Chemical
-	I-Chemical
0	I-Chemical
-	I-Chemical
tetrahydropyranyladriaymcin	I-Chemical
(	O
Pirraubicin	B-Chemical
)	O
was	O
done	O
in	O
55	O
pateints	O
in	O
good	O
performnace	O
sttaus	O
with	O
refarctory	O
tumros	O
.	O

Twenty	O
-	O
six	O
had	O
miniaml	O
prior	O
tehrapy	O
(	O
good	O
rsik	O
)	O
,	O
23	O
had	O
exetnsive	O
prior	O
tehrapy	O
(	O
poor	O
rsik	O
)	O
,	O
and	O
six	O
had	O
reanl	O
and	O
/	O
or	O
hepaitc	O
dsyfunction	O
.	O

A	O
total	O
of	O
167	O
cuorses	O
at	O
dsoes	O
of	O
15	O
to	O
70	O
mg	O
/	O
m2	O
were	O
evalualbe	O
.	O

Maixmum	O
toelrated	O
dsoe	O
in	O
good	O
-	O
rsik	O
paitents	O
was	O
70	O
mg	O
/	O
m2	O
,	O
and	O
in	O
poor	O
-	O
rsik	O
patietns	O
,	O
60	O
mg	O
/	O
m2	O
.	O

The	O
dsoe	O
-	O
limiting	O
txoic	O
effcet	O
was	O
trasnient	O
noncuumlative	O
granuloyctopenia	O
.	O

Granuloctye	O
naidr	O
was	O
on	O
day	O
14	O
(	O
range	O
,	O
4	O
-	O
22	O
)	O
.	O

Less	O
freqeunt	O
txoic	O
effcets	O
included	O
thrombocytopneia	O
,	O
anmeia	O
,	O
nuasea	O
,	O
mlid	O
aolpecia	O
,	O
phlebiits	O
,	O
and	O
mucostiis	O
.	O

Meylosuppression	O
was	O
more	O
in	O
patinets	O
with	O
heaptic	O
dyfsunction	O
.	O

Pharmacoiknetic	O
analyess	O
in	O
21	O
paitents	O
revelaed	O
Priarubicin	B-Chemical
plamsa	O
T	O
1	O
/	O
2	O
alhpa	O
(	O
+	O
/	O
-	O
SE	O
)	O
of	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
85	O
minuets	O
,	O
T	O
btea	O
1	O
/	O
2	O
of	O
25	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
5	O
miuntes	O
,	O
and	O
T	O
1	O
/	O
2	O
gamma	O
of	O
23	O
.	O
6	O
+	O
/	O
-	O
7	O
.	O
6	O
hours	O
.	O

The	O
aera	O
under	O
the	O
cuvre	O
was	O
537	O
+	O
/	O
-	O
149	O
ng	O
/	O
ml	O
x	O
hours	O
,	O
voulme	O
of	O
distributoin	O
(	O
Vd	O
)	O
3504	O
+	O
/	O
-	O
644	O
l	O
/	O
m2	O
,	O
and	O
total	O
cleraance	O
(	O
ClT	O
)	O
was	O
204	O
+	O
39	O
.	O
3	O
l	O
/	O
hour	O
/	O
m2	O
.	O

Adriamycionl	B-Chemical
,	O
dooxrubicin	B-Chemical
,	O
adriamycnione	B-Chemical
,	O
and	O
tetrahydropryanyladriamycinol	B-Chemical
were	O
the	O
meatbolites	O
dteected	O
in	O
plsama	O
and	O
the	O
amonut	O
of	O
dooxrubicin	B-Chemical
was	O
less	O
than	O
or	O
eqaul	O
to	O
10	O
%	O
of	O
the	O
total	O
metbaolites	O
.	O

Uirnary	O
excreiton	O
of	O
Priarubicin	B-Chemical
in	O
the	O
first	O
24	O
hours	O
was	O
less	O
than	O
or	O
euqal	O
to	O
10	O
%	O
.	O

Actiivty	O
was	O
noted	O
in	O
mesotheiloma	O
,	O
leiomyoasrcoma	O
,	O
and	O
baasl	O
clel	O
cacrinoma	O
.	O

The	O
rceommended	O
starting	O
dsoe	O
for	O
Phsae	O
II	O
tirals	O
is	O
60	O
mg	O
/	O
m2	O
IV	O
bouls	O
every	O
3	O
wekes	O
.	O

Ouclar	O
and	O
audtiory	O
toxciity	O
in	O
heomdialyzed	O
pateints	O
receiving	O
desferrioaxmine	B-Chemical
.	O

During	O
an	O
18	O
-	O
mnoth	O
peirod	O
of	O
stduy	O
41	O
hemoidalyzed	O
patinets	O
receiving	O
desfrerioxamine	B-Chemical
(	O
10	O
-	O
40	O
mg	O
/	O
kg	O
BW	O
/	O
3	O
times	O
wekely	O
)	O
for	O
the	O
first	O
tmie	O
were	O
monitroed	O
for	O
detcetion	O
of	O
auidovisual	O
toixcity	O
.	O

6	O
pateints	O
presented	O
cliincal	O
symptmos	O
of	O
vsiual	O
or	O
auidtory	O
toxiicty	O
.	O

Moreover	O
,	O
detailed	O
ophtahlmologic	O
and	O
auidologic	O
sutdies	O
disclosed	O
abnoramlities	O
in	O
7	O
more	O
asypmtomatic	O
patinets	O
.	O

Viusal	O
txoicity	O
was	O
of	O
retnial	O
orgiin	O
and	O
was	O
cahracterized	O
by	O
a	O
trtian	O
-	O
tpye	O
dycshromatopsy	O
,	O
sometimes	O
associated	O
with	O
a	O
lsos	O
of	O
viusal	O
aucity	O
and	O
pgimentary	O
retianl	O
deopsits	O
.	O

Aduitory	O
toxiicty	O
was	O
characterzied	O
by	O
a	O
mid	O
-	O
to	O
high	O
-	O
freqeuncy	O
neuroesnsorial	O
heraing	O
lsos	O
and	O
the	O
leison	O
was	O
of	O
the	O
cochlaer	O
tpye	O
.	O

Desferrioxmaine	B-Chemical
wtihdrawal	O
resulted	O
in	O
a	O
complete	O
rceovery	O
of	O
viusal	O
funtcion	O
in	O
1	O
paitent	O
and	O
patrial	O
recovrey	O
in	O
3	O
,	O
and	O
a	O
complete	O
rveersal	O
of	O
haering	O
lsos	O
in	O
3	O
patinets	O
and	O
pratial	O
recoevry	O
in	O
3	O
.	O

This	O
txoicity	O
appeared	O
in	O
patinets	O
receiving	O
the	O
hihger	O
dsoes	O
of	O
desferrioxmaine	B-Chemical
or	O
coincided	O
with	O
the	O
normaliaztion	O
of	O
ferirtin	O
or	O
almuinium	B-Chemical
sreum	O
levles	O
.	O

The	O
dtaa	O
indicate	O
that	O
audiovisaul	O
toxiicty	O
is	O
not	O
an	O
ifnrequent	O
comlpication	O
in	O
hemoidalyzed	O
paitents	O
receiving	O
desferrixoamine	B-Chemical
.	O

Peridoical	O
audiovisaul	O
monitoirng	O
should	O
be	O
performed	O
on	O
hemodialzyed	O
patietns	O
receiving	O
the	O
durg	O
in	O
order	O
to	O
dteect	O
avderse	O
effects	O
as	O
eraly	O
as	O
possible	O
.	O

Sreial	O
epliepsy	O
caused	O
by	O
levdoopa	B-Chemical
/	I-Chemical
carbdiopa	I-Chemical
administraiton	O
in	O
two	O
pateints	O
on	O
hemoidalysis	O
.	O

Two	O
patinets	O
with	O
similar	O
cliniacl	O
featrues	O
are	O
presented	O
:	O
both	O
paitents	O
had	O
crhonic	O
rneal	O
faiulre	O
,	O
on	O
heomdialysis	O
for	O
many	O
yaers	O
but	O
recently	O
begun	O
on	O
a	O
high	O
-	O
fulx	O
dailyzer	O
;	O
both	O
had	O
been	O
receiving	O
a	O
carbiodpa	B-Chemical
/	I-Chemical
lveodopa	I-Chemical
perparation	O
;	O
and	O
both	O
had	O
the	O
onset	O
of	O
hallucinoiss	O
and	O
rceurrent	O
seziures	O
,	O
which	O
were	O
rerfactory	O
to	O
anticonvulasnts	O
.	O

The	O
first	O
paitent	O
deid	O
without	O
a	O
diangosis	O
;	O
the	O
second	O
pateint	O
had	O
a	O
dramtaic	O
recoevry	O
following	O
the	O
adminisrtation	O
of	O
vitaimn	B-Chemical
B6	I-Chemical
.	O

Neither	O
patinet	O
was	O
considered	O
to	O
have	O
a	O
reanl	O
state	O
sufficiently	O
sevree	O
enough	O
to	O
explain	O
their	O
presenttaion	O
.	O

Radnomized	O
,	O
double	O
-	O
blnid	O
tiral	O
of	O
mazinodl	B-Chemical
in	O
Ducehnne	O
dystorphy	O
.	O

There	O
is	O
eivdence	O
that	O
grotwh	O
horomne	O
may	O
be	O
related	O
to	O
the	O
progression	O
of	O
weaknses	O
in	O
Duchnene	O
dystorphy	O
.	O

We	O
conducted	O
a	O
12	O
-	O
motnh	O
controleld	O
tiral	O
of	O
mazinodl	B-Chemical
,	O
a	O
putative	O
gorwth	O
hormnoe	O
secretoin	O
inhibtior	O
,	O
in	O
83	O
byos	O
with	O
Ducehnne	O
dytsrophy	O
.	O

Muslce	O
sterngth	O
,	O
contracutres	O
,	O
functinoal	O
ability	O
and	O
pulmnoary	O
funtcion	O
were	O
tesetd	O
at	O
bsaeline	O
,	O
and	O
6	O
and	O
12	O
monhts	O
after	O
tretament	O
with	O
maizndol	B-Chemical
(	O
3	O
mg	O
/	O
d	O
)	O
or	O
palcebo	O
.	O

The	O
sutdy	O
was	O
designed	O
to	O
have	O
a	O
poewr	O
of	O
greater	O
than	O
0	O
.	O
90	O
to	O
detcet	O
a	O
slownig	O
to	O
25	O
%	O
of	O
the	O
expected	O
rtae	O
of	O
progresison	O
of	O
weaknses	O
at	O
P	O
less	O
than	O
0	O
.	O
05	O
.	O

Mazinodl	B-Chemical
did	O
not	O
benfeit	O
strnegth	O
at	O
any	O
point	O
in	O
the	O
stduy	O
.	O

Side	O
effetcs	O
attributable	O
to	O
maizndol	B-Chemical
included	O
dcereased	O
appeitte	O
(	O
36	O
%	O
)	O
,	O
dry	O
muoth	O
(	O
10	O
%	O
)	O
,	O
bheavioral	O
change	O
(	O
22	O
%	O
)	O
,	O
and	O
gastroinetstinal	O
symtpoms	O
(	O
18	O
%	O
)	O
;	O
maznidol	B-Chemical
dosgae	O
was	O
reduecd	O
in	O
43	O
%	O
of	O
pateints	O
.	O

The	O
effcet	O
of	O
mazinodl	B-Chemical
on	O
GH	O
secrteion	O
was	O
esitmated	O
idnirectly	O
by	O
compraing	O
the	O
postabsorpitve	O
IGF	O
-	O
I	O
leevls	O
obtained	O
following	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
mnoths	O
in	O
the	O
maznidol	B-Chemical
treaetd	O
to	O
those	O
in	O
the	O
plcaebo	O
gropus	O
.	O

Although	O
maznidol	B-Chemical
-	O
traeted	O
ptaients	O
gained	O
less	O
wegiht	O
and	O
hieght	O
than	O
plcaebo	O
-	O
terated	O
patietns	O
,	O
no	O
significant	O
effcet	O
on	O
IGF	O
-	O
I	O
leevls	O
was	O
observed	O
.	O

Mazinodl	B-Chemical
dsoes	O
not	O
slow	O
the	O
progresison	O
of	O
waekness	O
in	O
Ducehnne	O
dytsrophy	O
.	O

Faciiltation	O
of	O
memroy	O
retireval	O
by	O
pre	O
-	O
tset	O
morphnie	B-Chemical
and	O
its	O
state	O
dependecny	O
in	O
the	O
step	O
-	O
through	O
tpye	O
psasive	O
aviodance	O
learinng	O
tset	O
in	O
mcie	O
.	O

Amnseia	O
produced	O
by	O
scpoolamine	B-Chemical
and	O
cyclohexiimde	B-Chemical
were	O
reevrsed	O
by	O
morpihne	B-Chemical
given	O
30	O
min	O
before	O
the	O
tset	O
tiral	O
(	O
pre	O
-	O
tset	O
)	O
,	O
and	O
pre	O
-	O
tset	O
morphnie	B-Chemical
also	O
facilitated	O
the	O
mmeory	O
retireval	O
in	O
the	O
anmials	O
amdinistered	O
nlaoxone	B-Chemical
during	O
the	O
tarining	O
trail	O
.	O

Similarly	O
,	O
pre	O
-	O
tset	O
scpoolamine	B-Chemical
partilaly	O
reveresd	O
the	O
scopolmaine	B-Chemical
-	O
idnuced	O
amensia	O
,	O
but	O
not	O
significantly	O
;	O
and	O
pre	O
-	O
tset	O
cycloheximdie	B-Chemical
failed	O
to	O
revrese	O
the	O
cylcoheximide	B-Chemical
-	O
induecd	O
amensia	O
.	O

These	O
resutls	O
suggest	O
that	O
the	O
facilittaion	O
of	O
mmeory	O
rertieval	O
by	O
pre	O
-	O
tset	O
mrophine	B-Chemical
might	O
be	O
the	O
direct	O
atcion	O
of	O
morpihne	B-Chemical
rather	O
than	O
a	O
state	O
dependnet	O
effcet	O
.	O

Nlaoxone	B-Chemical
revesres	O
the	O
antihypertnesive	O
effect	O
of	O
cloindine	B-Chemical
.	O

In	O
unanesthetzied	O
,	O
spontanoeusly	O
hypertesnive	O
rtas	O
the	O
decraese	O
in	O
blood	O
perssure	O
and	O
herat	O
rtae	O
produced	O
by	O
intrvaenous	O
cloniidne	B-Chemical
,	O
5	O
to	O
20	O
microrgams	O
/	O
kg	O
,	O
was	O
inhibtied	O
or	O
reevrsed	O
by	O
naolzone	B-Chemical
,	O
0	O
.	O
2	O
to	O
2	O
mg	O
/	O
kg	O
.	O

The	O
hypoetnsive	O
effect	O
of	O
100	O
mg	O
/	O
kg	O
alhpa	B-Chemical
-	I-Chemical
mehtyldopa	I-Chemical
was	O
also	O
patrially	O
revresed	O
by	O
nalxoone	B-Chemical
.	O

Nalxoone	B-Chemical
alone	O
did	O
not	O
affect	O
either	O
blood	O
presusre	O
or	O
haert	O
rtae	O
.	O

In	O
brian	O
mebmranes	O
from	O
spontnaeously	O
hyperetnsive	O
rtas	O
clnoidine	B-Chemical
,	O
10	O
(	O
-	O
8	O
)	O
to	O
10	O
(	O
-	O
5	O
)	O
M	O
,	O
did	O
not	O
inlfuence	O
steresoelective	O
bidning	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
naolxone	I-Chemical
(	O
8	O
nM	O
)	O
,	O
and	O
nalxoone	B-Chemical
,	O
10	O
(	O
-	O
8	O
)	O
to	O
10	O
(	O
-	O
4	O
)	O
M	O
,	O
did	O
not	O
influecne	O
clnoidine	B-Chemical
-	O
suppresisble	O
binidng	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
dihdyroergocryptine	I-Chemical
(	O
1	O
nM	O
)	O
.	O

These	O
fidnings	O
indicate	O
that	O
in	O
sopntaneously	O
hypertesnive	O
rtas	O
the	O
efefcts	O
of	O
cnetral	O
aplha	O
-	O
adrenocepotr	O
stimualtion	O
involve	O
actviation	O
of	O
opitae	O
receptros	O
.	O

As	O
naolxone	B-Chemical
and	O
cloindine	B-Chemical
do	O
not	O
appear	O
to	O
intearct	O
with	O
the	O
same	O
rceeptor	O
stie	O
,	O
the	O
observed	O
functioanl	O
antagoinsm	O
suggests	O
the	O
reelase	O
of	O
an	O
endogneous	O
opitae	O
by	O
colnidine	B-Chemical
or	O
aplha	B-Chemical
-	I-Chemical
methylodpa	I-Chemical
and	O
the	O
possible	O
role	O
of	O
the	O
opaite	O
in	O
the	O
cetnral	O
cotnrol	O
of	O
smypathetic	O
tnoe	O
.	O

Neruotoxicity	O
of	O
halgoenated	B-Chemical
hydroxyquinolnies	I-Chemical
:	O
cilnical	O
analyiss	O
of	O
csaes	O
reported	O
outside	O
Jpaan	O
.	O

An	O
aanlysis	O
is	O
presented	O
of	O
220	O
csaes	O
of	O
possible	O
neurotxoic	O
reacitons	O
to	O
haolgenated	B-Chemical
hydroxyqiunolines	I-Chemical
reported	O
from	O
outside	O
Jaapn	O
.	O

In	O
80	O
caess	O
insufficinet	O
infomration	O
was	O
available	O
for	O
aedquate	O
comment	O
and	O
in	O
29	O
a	O
relaitonship	O
to	O
the	O
administraiton	O
of	O
clioquionl	B-Chemical
could	O
be	O
excluded	O
.	O

Of	O
the	O
remainder	O
,	O
a	O
relationhsip	O
to	O
clioquionl	B-Chemical
was	O
considered	O
probable	O
in	O
42	O
and	O
possible	O
in	O
69	O
caess	O
.	O

In	O
six	O
of	O
the	O
probable	O
caess	O
the	O
nuerological	O
dsiturbance	O
consisted	O
of	O
an	O
aucte	O
reversible	O
enecphalopathy	O
usually	O
related	O
to	O
the	O
ignestion	O
of	O
a	O
high	O
dsoe	O
of	O
clioquniol	B-Chemical
over	O
a	O
short	O
peroid	O
.	O

The	O
most	O
common	O
manifestatoin	O
,	O
observed	O
in	O
15	O
further	O
caess	O
,	O
was	O
ioslated	O
otpic	O
atrohpy	O
.	O

This	O
was	O
most	O
frequently	O
found	O
in	O
chidlren	O
,	O
many	O
of	O
whom	O
had	O
received	O
cliouqinol	B-Chemical
as	O
tretament	O
for	O
acrodemratitis	O
entreopathica	O
.	O

In	O
the	O
remaining	O
csaes	O
,	O
a	O
cmobination	O
of	O
myeloapthy	O
,	O
visaul	O
disutrbance	O
,	O
and	O
periphreal	O
neuorpathy	O
was	O
the	O
most	O
common	O
maniefstation	O
.	O

Isloated	O
myeloptahy	O
or	O
peripehral	O
neurpoathy	O
,	O
or	O
these	O
maniefstations	O
occurring	O
together	O
,	O
were	O
infreqeunt	O
.	O

The	O
onset	O
of	O
all	O
manifestatinos	O
(	O
except	O
toixc	O
encephlaopathy	O
)	O
was	O
usually	O
subcaute	O
,	O
with	O
subsequent	O
pratial	O
recoevry	O
.	O

Odler	O
sujbects	O
tended	O
to	O
display	O
more	O
side	O
effetcs	O
.	O

The	O
full	O
sydnrome	O
of	O
sbuacute	O
myleo	O
-	O
opitc	O
nueropathy	O
was	O
more	O
frqeuent	O
in	O
woemn	O
,	O
but	O
they	O
tended	O
to	O
have	O
taken	O
greater	O
quanttiies	O
of	O
the	O
durg	O
.	O

Parzosin	B-Chemical
-	O
idnuced	O
strses	O
inocntinence	O
.	O

A	O
csae	O
of	O
genuine	O
strses	O
incontiennce	O
due	O
to	O
prazoisn	B-Chemical
,	O
a	O
common	O
antihypertesnive	O
durg	O
,	O
is	O
presented	O
.	O

Prazsoin	B-Chemical
exerts	O
its	O
anithypertensive	O
effcets	O
through	O
vasodilataiton	O
caused	O
by	O
selective	O
blockdae	O
of	O
postsyanptic	O
alhpa	O
-	O
1	O
adrneergic	O
recpetors	O
.	O

As	O
an	O
aplha	O
-	O
blcoker	O
,	O
it	O
also	O
exerts	O
a	O
significant	O
rleaxant	O
effcet	O
on	O
the	O
bladedr	O
ncek	O
and	O
uerthra	O
.	O

The	O
ptaient	O
'	O
s	O
clniical	O
cuorse	O
is	O
described	O
and	O
corrleated	O
with	O
initial	O
uordynamic	O
stduies	O
while	O
on	O
prazoisn	B-Chemical
and	O
subsequent	O
stuides	O
while	O
taking	O
vreapamil	B-Chemical
.	O

Her	O
incontiennce	O
resolved	O
with	O
the	O
change	O
of	O
medicaiton	O
.	O

The	O
rsetoration	O
of	O
continecne	O
was	O
accompanied	O
by	O
a	O
substantial	O
rise	O
in	O
maxmium	O
urtehral	O
presusre	O
,	O
maxiumm	O
urtehral	O
colsure	O
perssure	O
,	O
and	O
funtcional	O
uretrhal	O
legnth	O
.	O

Patinets	O
who	O
present	O
with	O
strses	O
inocntinence	O
while	O
taking	O
praozsin	B-Chemical
should	O
change	O
their	O
antihpyertensive	O
meidcation	O
before	O
considering	O
suregry	O
,	O
because	O
their	O
inconitnence	O
may	O
resolve	O
spontanoeusly	O
with	O
a	O
change	O
in	O
durg	O
threapy	O
.	O

Myocaridal	O
inafrction	O
following	O
sublinugal	O
administraiton	O
of	O
isosrobide	B-Chemical
dinirtate	I-Chemical
.	O

A	O
78	O
-	O
yaer	O
-	O
old	O
with	O
haeled	O
spetal	O
necorsis	O
suffered	O
a	O
recrurent	O
myocradial	O
ifnarction	O
of	O
the	O
antreior	O
wlal	O
following	O
the	O
adminisrtation	O
of	O
isoosrbide	B-Chemical
dniitrate	I-Chemical
5	O
mg	O
sublingulaly	O
.	O

After	O
detailing	O
the	O
coruse	O
of	O
evetns	O
,	O
we	O
discuss	O
the	O
role	O
of	O
paardoxical	O
coornary	O
sapsm	O
and	O
hypoetnsion	O
-	O
mediated	O
mycoardial	O
icshemia	O
occurring	O
donwstream	O
to	O
significant	O
croonary	O
artreial	O
stenoiss	O
in	O
the	O
patohphysiology	O
of	O
actue	O
cornoary	O
insufficinecy	O
.	O

Copmarison	O
of	O
the	O
respriatory	O
effetcs	O
of	O
i	O
.	O
v	O
.	O
infusoins	O
of	O
mrophine	B-Chemical
and	O
regoinal	O
anaglesia	O
by	O
extraduarl	O
blcok	O
.	O

The	O
incidecne	O
of	O
postoperaitve	O
repsiratory	O
aponea	O
was	O
compraed	O
between	O
five	O
ptaients	O
receiving	O
a	O
conitnuous	O
i	O
.	O
v	O
.	O
ifnusion	O
of	O
mrophine	B-Chemical
(	O
mean	O
73	O
.	O
6	O
mg	O
)	O
and	O
five	O
patinets	O
receiving	O
a	O
continuuos	O
etxradural	O
inufsion	O
of	O
0	O
.	O
25	O
%	O
bupivaacine	B-Chemical
(	O
mean	O
192	O
mg	O
)	O
in	O
the	O
24	O
-	O
h	O
peroid	O
following	O
upepr	O
abdoimnal	O
surgrey	O
.	O

Montioring	O
consisted	O
of	O
aifrlow	O
dteection	O
by	O
a	O
carobn	B-Chemical
doixide	I-Chemical
anlayser	O
,	O
chset	O
wlal	O
movemnet	O
detecetd	O
by	O
pneumaitc	O
capslues	O
,	O
and	O
conitnuous	O
eletcrocardiograph	O
recorded	O
with	O
a	O
Hotler	O
ambulatroy	O
monitor	O
.	O

Both	O
obsrtuctive	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
cnetral	O
anpoea	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
occurred	O
more	O
frequently	O
in	O
paitents	O
who	O
had	O
a	O
morphnie	B-Chemical
infuison	O
.	O

There	O
was	O
also	O
a	O
higehr	O
icnidence	O
of	O
tcahyarrhythmias	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
vnetricular	O
etcopic	O
baets	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
in	O
the	O
mrophine	B-Chemical
infusoin	O
gruop	O
.	O

Efefcts	O
of	O
aminpohylline	B-Chemical
on	O
the	O
trheshold	O
for	O
initiating	O
ventircular	O
fibrillation	O
during	O
respiratroy	O
faliure	O
.	O

Cardaic	O
arrhtyhmias	O
have	O
frequently	O
been	O
reported	O
in	O
association	O
with	O
respriatory	O
faiulre	O
.	O

The	O
possible	O
addtiive	O
role	O
of	O
pharmacoolgic	O
aegnts	O
in	O
precipitaitng	O
cadriac	O
distrubances	O
in	O
patietns	O
with	O
respirtaory	O
fialure	O
has	O
only	O
recently	O
been	O
emphasized	O
.	O

The	O
effetcs	O
of	O
aminpohylline	B-Chemical
on	O
the	O
vnetricular	O
fibrillaiton	O
threshlod	O
during	O
nomral	O
aicd	O
-	O
base	O
conidtions	O
and	O
during	O
repsiratory	O
fialure	O
were	O
studied	O
in	O
anesthteized	O
open	O
chset	O
dgos	O
.	O

The	O
ventricluar	O
fibirllation	O
threshlod	O
was	O
measuerd	O
by	O
passing	O
a	O
gtaed	O
tarin	O
of	O
12	O
contsant	O
current	O
puless	O
through	O
the	O
ventircular	O
myocarduim	O
during	O
the	O
vunlerable	O
peirod	O
of	O
the	O
cardaic	O
cylce	O
.	O

During	O
the	O
infuison	O
of	O
amionphylline	B-Chemical
,	O
the	O
vetnricular	O
fibrilaltion	O
threhsold	O
was	O
reduecd	O
by	O
30	O
to	O
40	O
percent	O
of	O
the	O
cotnrol	O
when	O
pH	O
and	O
patrial	O
pressrues	O
of	O
oyxgen	B-Chemical
(	O
PO2	B-Chemical
)	O
and	O
carobn	B-Chemical
doixide	I-Chemical
(	O
CO2	B-Chemical
)	O
were	O
kept	O
within	O
nomral	O
liimts	O
.	O

When	O
resipratory	O
failrue	O
was	O
produced	O
by	O
hypoventilaiton	O
(	O
pH	O
7	O
.	O
05	O
to	O
7	O
.	O
25	O
;	O
P0C2	O
70	O
to	O
100	O
mm	O
Hg	O
:	O
P02	O
20	O
to	O
40	O
mm	O
Hg	O
)	O
,	O
infuison	O
of	O
aimnophylline	B-Chemical
resulted	O
in	O
an	O
even	O
greater	O
decerase	O
in	O
ventriuclar	O
fibirllation	O
threshlod	O
to	O
60	O
percent	O
of	O
the	O
conrtol	O
lveel	O
.	O

These	O
experimnets	O
suggest	O
that	O
although	O
many	O
fatcors	O
may	O
contribute	O
to	O
the	O
icnreased	O
incdience	O
of	O
ventricualr	O
arrhythimas	O
in	O
respiraotry	O
faiulre	O
,	O
pharmacoolgic	O
agnets	O
,	O
particularly	O
aminohpylline	B-Chemical
,	O
may	O
play	O
a	O
significant	O
role	O
.	O

Pentoixfylline	B-Chemical
(	O
Terntal	B-Chemical
)	O
does	O
not	O
ihnibit	O
dipyridmaole	B-Chemical
-	O
induecd	O
coroanry	O
hypreemia	O
:	O
implications	O
for	O
dipyirdamole	B-Chemical
-	O
tahllium	B-Chemical
-	O
201	O
myocaridal	O
imagnig	O
.	O

Dipyridamloe	B-Chemical
-	O
thalluim	B-Chemical
-	O
201	O
imagnig	O
is	O
often	O
performed	O
in	O
pateints	O
unable	O
to	O
exercsie	O
because	O
of	O
peripehral	O
vasuclar	O
diesase	O
.	O

Many	O
of	O
these	O
pateints	O
are	O
taking	O
pentoxifyllnie	B-Chemical
(	O
Trnetal	B-Chemical
)	O
,	O
a	O
methylxantihne	B-Chemical
deriavtive	O
which	O
may	O
ipmrove	O
intremittent	O
claduication	O
.	O

Whether	O
pentoxfiylline	B-Chemical
inhbiits	O
dipyirdamole	B-Chemical
-	O
inudced	O
coronray	O
hypreemia	O
like	O
other	O
methyxlanthines	B-Chemical
such	O
as	O
theophlyline	B-Chemical
and	O
should	O
be	O
stopped	O
prior	O
to	O
dipyridamloe	B-Chemical
-	O
thallium	B-Chemical
-	O
201	O
imgaing	O
is	O
unknown	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
hypreemic	O
repsonse	O
to	O
dipyrdiamole	B-Chemical
in	O
seven	O
open	O
-	O
chset	O
anesthetiezd	O
dgos	O
after	O
prerteatment	O
with	O
either	O
pentoixfylline	B-Chemical
(	O
0	O
,	O
7	O
.	O
5	O
,	O
or	O
15	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
or	O
theophlyline	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
.	O

Basleine	O
circumlfex	O
coronray	O
blood	O
folws	O
did	O
not	O
differ	O
significantly	O
among	O
teratment	O
gruops	O
.	O

Dipyridamloe	B-Chemical
significantly	O
incerased	O
coroanry	O
bolod	O
folw	O
before	O
and	O
after	O
7	O
.	O
5	O
or	O
15	O
mm	O
/	O
kg	O
i	O
.	O
v	O
.	O
pentoxiyflline	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
002	O
)	O
.	O

Neither	O
dsoe	O
of	O
pentoxfiylline	B-Chemical
significantly	O
derceased	O
the	O
dipyridmaole	B-Chemical
-	O
indcued	O
hpyeremia	O
,	O
while	O
peak	O
croonary	O
bolod	O
folw	O
was	O
significantly	O
loewr	O
after	O
theohpylline	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

We	O
conclude	O
that	O
pentoxyiflyline	B-Chemical
does	O
not	O
ihnibit	O
diypridamole	B-Chemical
-	O
induecd	O
cornoary	O
hpyeremia	O
even	O
at	O
high	O
dsoes	O
.	O

Cuase	O
of	O
daeth	O
among	O
pateints	O
with	O
Parkisnon	O
'	O
s	O
disaese	O
:	O
a	O
rrae	O
motrality	O
due	O
to	O
cererbal	O
haemorrahge	O
.	O

Casues	O
of	O
detah	O
,	O
with	O
special	O
refernece	O
to	O
creebral	O
haemorrhgae	O
,	O
among	O
240	O
ptaients	O
with	O
pathologcially	O
verified	O
Pakrinson	O
'	O
s	O
dsiease	O
were	O
invesitgated	O
using	O
the	O
Annuals	O
of	O
the	O
Pathoolgical	O
Autospy	O
Csaes	O
in	O
Jaapn	O
from	O
1981	O
to	O
1985	O
.	O

The	O
leading	O
causes	O
of	O
detah	O
were	O
pnemuonia	O
and	O
bronhcitis	O
(	O
44	O
.	O
1	O
%	O
)	O
,	O
maligannt	O
neopalsms	O
(	O
11	O
.	O
6	O
%	O
)	O
,	O
herat	O
diesases	O
(	O
4	O
.	O
1	O
%	O
)	O
,	O
cerberal	O
ifnarction	O
(	O
3	O
.	O
7	O
%	O
)	O
and	O
setpicaemia	O
(	O
3	O
.	O
3	O
%	O
)	O
.	O

Creebral	O
hameorrhage	O
was	O
the	O
11th	O
most	O
freqeunt	O
cause	O
of	O
daeth	O
,	O
accounting	O
for	O
only	O
0	O
.	O
8	O
%	O
of	O
daeths	O
among	O
the	O
ptaients	O
,	O
whereas	O
it	O
was	O
the	O
5th	O
most	O
common	O
cause	O
of	O
daeth	O
among	O
the	O
Japaense	O
general	O
popualtion	O
in	O
1985	O
.	O

The	O
low	O
incidecne	O
of	O
cererbal	O
haemorhrage	O
as	O
a	O
cause	O
of	O
daeth	O
in	O
patinets	O
with	O
Parknison	O
'	O
s	O
disaese	O
may	O
reflect	O
the	O
hyptoensive	O
effect	O
of	O
levodpoa	B-Chemical
and	O
a	O
hyptoensive	O
mcehanism	O
due	O
to	O
rdeuced	O
norardenaline	B-Chemical
levles	O
in	O
the	O
pariknsonian	O
brian	O
.	O

Possible	O
intramuscluar	O
midaozlam	B-Chemical
-	O
associated	O
cardiroespiratory	O
arerst	O
and	O
daeth	O
.	O

Mdiazolam	B-Chemical
hydrochlroide	I-Chemical
is	O
commonly	O
used	O
for	O
detnal	O
or	O
endosocpic	O
prcoedures	O
.	O

Although	O
generally	O
consisted	O
safe	O
when	O
given	O
intramuscluarly	O
,	O
intravneous	O
administartion	O
is	O
known	O
to	O
cause	O
rsepiratory	O
and	O
caridovascular	O
deperssion	O
.	O

This	O
rpeort	O
describes	O
the	O
first	O
publihsed	O
csae	O
of	O
cardiorespiartory	O
arrest	O
and	O
detah	O
associated	O
with	O
inrtamuscular	O
administartion	O
of	O
miadzolam	B-Chemical
.	O

Infromation	O
regarding	O
midazoalm	B-Chemical
use	O
is	O
reviweed	O
to	O
provide	O
recommnedation	O
for	O
safe	O
adimnistration	O
.	O

Maysthenia	O
grvais	O
presenitng	O
as	O
weakenss	O
after	O
magnseium	B-Chemical
adminitsration	O
.	O

We	O
studied	O
a	O
pateint	O
with	O
no	O
prior	O
hisotry	O
of	O
neuromucsular	O
disesae	O
who	O
became	O
virtually	O
qudariplegic	O
after	O
parneteral	O
magensium	B-Chemical
admiinstration	O
for	O
preelcampsia	O
.	O

The	O
sreum	O
mganesium	B-Chemical
concentartion	O
was	O
3	O
.	O
0	O
mEq	O
/	O
L	O
,	O
which	O
is	O
usually	O
well	O
tolearted	O
.	O

The	O
magnesuim	B-Chemical
was	O
stopped	O
and	O
she	O
rceovered	O
over	O
a	O
few	O
dyas	O
.	O

While	O
she	O
was	O
waek	O
,	O
2	O
-	O
Hz	O
repteitive	O
stimulatoin	O
rveealed	O
a	O
decremnet	O
without	O
significant	O
faiclitation	O
at	O
rpaid	O
raets	O
or	O
after	O
exericse	O
,	O
suggesting	O
posstynaptic	O
neruomuscular	O
blockdae	O
.	O

After	O
her	O
sterngth	O
returned	O
,	O
repetitvie	O
stimulaiton	O
was	O
noraml	O
,	O
but	O
single	O
fbier	O
EMG	O
reveaeld	O
increaesd	O
jtiter	O
and	O
blocikng	O
.	O

Her	O
acteylcholine	B-Chemical
recetpor	O
antiobdy	O
leevl	O
was	O
markedly	O
elveated	O
.	O

Although	O
paralyiss	O
after	O
mangesium	B-Chemical
adminsitration	O
has	O
been	O
described	O
in	O
ptaients	O
with	O
known	O
myasthneia	O
grvais	O
,	O
it	O
has	O
not	O
previously	O
been	O
reported	O
to	O
be	O
the	O
initial	O
or	O
only	O
manifetsation	O
of	O
the	O
disesae	O
.	O

Pateints	O
who	O
are	O
unuusally	O
sesnitive	O
to	O
the	O
neuroumscular	O
effcets	O
of	O
mganesium	B-Chemical
should	O
be	O
suspetced	O
of	O
having	O
an	O
underlying	O
diosrder	O
of	O
neruomuscular	O
trnasmission	O
.	O

No	O
enhancemnet	O
by	O
phenboarbital	B-Chemical
of	O
the	O
hepatocracinogenicity	O
of	O
a	O
cohline	B-Chemical
-	O
devoid	O
deit	O
in	O
the	O
rat	O
.	O

An	O
experiemnt	O
was	O
performed	O
to	O
tset	O
whether	O
icnlusion	O
of	O
phenboarbital	B-Chemical
in	O
a	O
chloine	B-Chemical
-	O
devoid	O
deit	O
would	O
inrcease	O
the	O
hepatocarcinogneicity	O
of	O
the	O
deit	O
.	O

Gropus	O
of	O
5	O
-	O
week	O
old	O
mlae	O
Fiscehr	O
-	O
344	O
rtas	O
were	O
fed	O
for	O
7	O
-	O
25	O
motnhs	O
seimpurified	O
cholnie	B-Chemical
-	O
devoid	O
or	O
cohline	B-Chemical
-	O
supplemented	O
dites	O
,	O
containing	O
or	O
not	O
0	O
.	O
06	O
%	O
phenoabrbital	B-Chemical
.	O

No	O
hpeatic	O
perneoplastic	O
noduels	O
or	O
heaptocellular	O
cracinomas	O
developed	O
in	O
rtas	O
fed	O
the	O
palin	O
choilne	B-Chemical
-	O
supplemented	O
deit	O
,	O
while	O
one	O
preneopalstic	O
ndoule	O
and	O
one	O
hepaotcellular	O
caricnoma	O
developed	O
in	O
two	O
rtas	O
fed	O
the	O
same	O
deit	O
containing	O
phenobarbtial	B-Chemical
.	O

The	O
incdience	O
of	O
preneoplatsic	O
noduels	O
and	O
of	O
hepatocellluar	O
caricnomas	O
was	O
10	O
%	O
and	O
37	O
%	O
,	O
respectively	O
,	O
in	O
rtas	O
fed	O
the	O
palin	O
cholnie	B-Chemical
-	O
devoid	O
deit	O
,	O
and	O
17	O
%	O
and	O
30	O
%	O
,	O
in	O
rtas	O
fed	O
the	O
phenobrabital	B-Chemical
-	O
containing	O
chloine	B-Chemical
-	O
devoid	O
deit	O
.	O

The	O
resluts	O
evinced	O
no	O
ehnancement	O
of	O
the	O
heptaocarcinogenicity	O
of	O
the	O
chloine	B-Chemical
-	O
devoid	O
deit	O
by	O
phenobrabital	B-Chemical
.	O

Spoardic	O
neoplasitc	O
lesoins	O
were	O
observed	O
in	O
orgnas	O
other	O
than	O
the	O
lvier	O
of	O
some	O
of	O
the	O
animlas	O
,	O
irrespective	O
of	O
the	O
deit	O
fed	O
.	O

On	O
two	O
paradoixcal	O
side	O
-	O
effects	O
of	O
perdnisolone	B-Chemical
in	O
rtas	O
,	O
riboosmal	O
RNA	O
biosnytheses	O
,	O
and	O
a	O
mechnaism	O
of	O
aciton	O
.	O

Lvier	O
enlagrement	O
and	O
msucle	O
wsatage	O
occurred	O
in	O
Witsar	O
rtas	O
following	O
the	O
subcutaenous	O
administratoin	O
of	O
prdenisolone	B-Chemical
.	O

In	O
the	O
lievr	O
both	O
the	O
cotnent	O
of	O
RNA	O
and	O
the	O
biosnythesis	O
of	O
riobsomal	O
RNA	O
incraesed	O
while	O
both	O
the	O
RNA	O
cnotent	O
and	O
ribosoaml	O
RNA	O
biosyntehsis	O
were	O
reudced	O
in	O
the	O
gastroncemius	O
muslce	O
.	O

It	O
is	O
suggested	O
that	O
the	O
durg	O
acted	O
in	O
a	O
selective	O
and	O
tissue	O
-	O
specific	O
manner	O
to	O
enhnace	O
riboosmal	O
RNA	O
synhtesis	O
in	O
the	O
lvier	O
and	O
deprses	O
such	O
syntehsis	O
in	O
the	O
mucsle	O
.	O

This	O
view	O
supports	O
the	O
contention	O
that	O
the	O
lievr	O
and	O
muslce	O
are	O
independnet	O
sties	O
of	O
prdenisolone	B-Chemical
aciton	O
.	O

Diffreential	O
effetcs	O
of	O
gmama	B-Chemical
-	I-Chemical
heaxchlorocyclohexane	I-Chemical
(	O
lidnane	B-Chemical
)	O
on	O
phramacologically	O
-	O
induecd	O
seiuzres	O
.	O

Gmama	B-Chemical
-	I-Chemical
hexachlorocycloehxane	I-Chemical
(	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
)	O
,	O
the	O
acitve	O
inrgedient	O
of	O
the	O
insecticdie	O
lnidane	B-Chemical
,	O
has	O
been	O
shown	O
to	O
decerase	O
seziure	O
threhsold	O
to	O
pnetylenetrazol	O
(	O
PTZ	B-Chemical
)	O
3	O
h	O
after	O
expsoure	O
to	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
and	O
conversely	O
inrcease	O
thresohld	O
to	O
PTZ	B-Chemical
-	O
idnuced	O
seizrues	O
24	O
h	O
after	O
expsoure	O
to	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
(	O
Vohalnd	O
et	O
al	O
.	O
1981	O
)	O
.	O

In	O
this	O
sutdy	O
,	O
the	O
seveirty	O
of	O
rseponse	O
to	O
other	O
seizrue	O
-	O
indcuing	O
agnets	O
was	O
tetsed	O
in	O
mcie	O
1	O
and	O
24	O
h	O
after	O
intrpaeritoneal	O
adimnistration	O
of	O
80	O
mg	O
/	O
kg	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
.	O

One	O
hour	O
after	O
the	O
adminisrtation	O
of	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
,	O
the	O
atcivity	O
of	O
siezure	O
-	O
induicng	O
aegnts	O
was	O
incraesed	O
,	O
regardless	O
of	O
their	O
mecahnism	O
,	O
while	O
24	O
h	O
after	O
gmama	B-Chemical
-	I-Chemical
HCH	I-Chemical
a	O
diffeerntial	O
resposne	O
was	O
observed	O
.	O

Siezure	O
acitvity	O
due	O
to	O
PTZ	B-Chemical
and	O
picrtooxin	B-Chemical
(	O
PTX	B-Chemical
)	O
was	O
significantly	O
decreaesd	O
;	O
however	O
,	O
siezure	O
activtiy	O
due	O
to	O
3	B-Chemical
-	I-Chemical
mercatpopropionic	I-Chemical
aicd	I-Chemical
(	O
MPA	B-Chemical
)	O
,	O
bciuculline	B-Chemical
(	O
BCC	B-Chemical
)	O
,	O
mehtyl	B-Chemical
6	I-Chemical
,	I-Chemical
7	I-Chemical
-	I-Chemical
dmiethoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
etyhl	I-Chemical
-	I-Chemical
B	I-Chemical
-	I-Chemical
cabroline	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxyltae	I-Chemical
(	O
DCMM	B-Chemical
)	O
,	O
or	O
styrchnine	B-Chemical
(	O
STR	B-Chemical
)	O
was	O
not	O
different	O
from	O
cnotrol	O
.	O

In	O
vitro	O
,	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
,	O
pnetylenetetrazol	B-Chemical
and	O
pircotoxin	B-Chemical
were	O
shown	O
to	O
inihbit	O
3H	B-Chemical
-	I-Chemical
TOBB	I-Chemical
binidng	O
in	O
mosue	O
whole	O
brian	O
,	O
with	O
I5C0	O
vaules	O
of	O
4	O
.	O
6	O
,	O
404	O
and	O
9	O
.	O
4	O
microM	O
,	O
respectively	O
.	O

MPA	B-Chemical
,	O
BCC	B-Chemical
,	O
DCMM	B-Chemical
,	O
and	O
STR	B-Chemical
showed	O
no	O
inhiibtion	O
of	O
3H	B-Chemical
-	I-Chemical
TOBB	I-Chemical
(	O
t	B-Chemical
-	I-Chemical
btuyl	I-Chemical
bicyclo	I-Chemical
-	I-Chemical
ortohbenzoate	I-Chemical
)	O
bindnig	O
at	O
cocnentrations	O
of	O
100	O
micron	O
.	O

The	O
pharmacoloigcal	O
challenge	O
dtaa	O
suggest	O
that	O
tloerance	O
may	O
occur	O
to	O
siezure	O
activtiy	O
inudced	O
by	O
PTZ	B-Chemical
and	O
PTX	B-Chemical
24	O
h	O
after	O
gmama	B-Chemical
-	I-Chemical
HCH	I-Chemical
,	O
since	O
the	O
resopnse	O
to	O
only	O
these	O
two	O
seziure	O
-	O
induicng	O
aegnts	O
is	O
decerased	O
.	O

The	O
in	O
vitro	O
dtaa	O
suggest	O
that	O
the	O
stie	O
responsible	O
for	O
the	O
decerase	O
in	O
seiuzre	O
actiivty	O
24	O
h	O
after	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
may	O
be	O
the	O
GBAA	B-Chemical
-	O
A	O
recetpor	O
-	O
linked	O
chlordie	O
channel	O
.	O

Tolernace	O
and	O
antviiral	O
efefct	O
of	O
rbiavirin	B-Chemical
in	O
pateints	O
with	O
Argentnie	O
hemorrahgic	O
feevr	O
.	O

Toelrance	O
and	O
atniviral	O
effect	O
of	O
ribaivrin	B-Chemical
was	O
studied	O
in	O
6	O
paitents	O
with	O
Aregntine	O
hemorhragic	O
feevr	O
(	O
AHF	O
)	O
of	O
more	O
than	O
8	O
dyas	O
of	O
evoluiton	O
.	O

Administraiton	O
of	O
ribaivrin	B-Chemical
resulted	O
in	O
a	O
neutraliaztion	O
of	O
virmeia	O
and	O
a	O
dorp	O
of	O
endogenuos	O
intreferon	O
ttiers	O
.	O

The	O
avergae	O
tmie	O
of	O
daeth	O
was	O
delaeyd	O
.	O

A	O
reversible	O
aenmia	O
was	O
the	O
only	O
avderse	O
effcet	O
observed	O
.	O

From	O
these	O
resluts	O
,	O
we	O
conclude	O
that	O
rbiavirin	B-Chemical
has	O
an	O
anitviral	O
efefct	O
in	O
adavnced	O
caess	O
of	O
AHF	O
,	O
and	O
that	O
anmeia	O
,	O
the	O
only	O
secondary	O
recation	O
observed	O
,	O
can	O
be	O
easily	O
managed	O
.	O

The	O
possible	O
beneficial	O
efefct	O
of	O
ribaivrin	B-Chemical
during	O
the	O
initial	O
dyas	O
of	O
AHF	O
is	O
discussed	O
.	O

Is	O
the	O
treatmnet	O
of	O
sacbies	O
hzaardous	O
?	O

Treatmnet	O
for	O
scaibes	O
is	O
usually	O
initiated	O
by	O
general	O
practitionres	O
;	O
most	O
consider	O
lindnae	B-Chemical
(	O
gamma	B-Chemical
beznene	I-Chemical
hexachloirde	I-Chemical
)	O
the	O
treatmnet	O
of	O
choice	O
.	O

Lindnae	B-Chemical
is	O
also	O
widely	O
used	O
as	O
an	O
agricultrual	O
and	O
idnustrial	O
pestiicde	O
,	O
and	O
as	O
a	O
result	O
the	O
toixc	O
proifle	O
of	O
this	O
insetcicide	O
is	O
well	O
understood	O
.	O

Eivdence	O
is	O
accumulating	O
that	O
lindnae	B-Chemical
can	O
be	O
toixc	O
to	O
the	O
cnetral	O
nerovus	O
sytsem	O
and	O
may	O
be	O
associated	O
with	O
aplasitc	O
anaeima	O
.	O

Preaprations	O
containing	O
lnidane	B-Chemical
continue	O
to	O
be	O
slod	O
over	O
the	O
counter	O
and	O
may	O
represent	O
a	O
hzaard	O
to	O
poorly	O
informed	O
patietns	O
.	O

This	O
lietrature	O
rveiew	O
suggests	O
that	O
general	O
pratcitioners	O
should	O
presrcibe	O
scabicieds	O
with	O
increaesd	O
caution	O
for	O
certain	O
at	O
-	O
rsik	O
gorups	O
,	O
and	O
give	O
aedquate	O
wanrings	O
regarding	O
ptoential	O
toixcity	O
.	O

Mosue	O
srtain	O
-	O
depednent	O
effcet	O
of	O
amantadnie	B-Chemical
on	O
motiltiy	O
and	O
brian	O
biogneic	O
amiens	B-Chemical
.	O

The	O
effect	O
of	O
amnatadine	B-Chemical
hyrdochloride	I-Chemical
,	O
injceted	O
i	O
.	O
p	O
.	O
in	O
6	O
inrcements	O
of	O
100	O
mg	O
/	O
kg	O
each	O
over	O
30	O
hr	O
,	O
on	O
mosue	O
motiilty	O
and	O
whole	O
barin	O
contnet	O
of	O
selected	O
boigenic	O
aimnes	B-Chemical
and	O
major	O
metaboiltes	O
was	O
studied	O
in	O
4	O
srtains	O
of	O
mcie	O
.	O

These	O
were	O
the	O
ablino	O
Sprauge	O
-	O
Dawely	O
ICR	O
and	O
BLAB	O
/	O
C	O
,	O
the	O
balck	O
C5B7L	O
/	O
6	O
and	O
the	O
brwon	O
CDF	O
-	O
I	O
muose	O
strians	O
.	O

Amatnadine	B-Chemical
traetment	O
produced	O
a	O
biphaisc	O
effect	O
on	O
mosue	O
mtoility	O
.	O

The	O
initial	O
dsoe	O
of	O
amantadnie	B-Chemical
deperssed	O
locomtoor	O
acitvity	O
in	O
all	O
muose	O
srtains	O
studied	O
with	O
the	O
BLAB	O
/	O
C	O
mcie	O
being	O
the	O
most	O
senistive	O
.	O

Subsequent	O
amanatdine	B-Chemical
tretaments	O
produced	O
enhancemnet	O
of	O
motiltiy	O
from	O
corresponding	O
cotnrol	O
in	O
all	O
mosue	O
strians	O
with	O
the	O
BLAB	O
/	O
C	O
mcie	O
being	O
the	O
least	O
sensitvie	O
.	O

The	O
locomootr	O
atcivity	O
was	O
dcereased	O
from	O
corresponding	O
contrlos	O
in	O
all	O
stranis	O
studied	O
,	O
except	O
for	O
the	O
ICR	O
mcie	O
,	O
during	O
an	O
overnight	O
durg	O
-	O
free	O
preiod	O
following	O
the	O
fourth	O
amnatadine	B-Chemical
treamtent	O
.	O

Readminsitration	O
of	O
amantaidne	B-Chemical
,	O
after	O
a	O
durg	O
-	O
free	O
overnight	O
peroid	O
,	O
increaesd	O
moitlity	O
from	O
respective	O
slaine	O
contorl	O
in	O
all	O
starins	O
with	O
exception	O
of	O
the	O
BLAB	O
/	O
C	O
mcie	O
where	O
suppression	O
of	O
motiilty	O
occurred	O
.	O

Traetment	O
with	O
aamntadine	B-Chemical
did	O
not	O
alter	O
whole	O
brian	O
dopmaine	B-Chemical
lveels	O
but	O
decerased	O
the	O
amounts	O
of	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
diyhdroxyphenylacetic	I-Chemical
aicd	I-Chemical
in	O
the	O
BLAB	O
/	O
C	O
mcie	O
compaerd	O
to	O
slaine	O
contorl	O
.	O

Conversely	O
,	O
barin	O
normetnaephrine	B-Chemical
concentartion	O
was	O
icnreased	O
from	O
slaine	O
conrtol	O
by	O
amanatdine	B-Chemical
in	O
the	O
BLAB	O
/	O
C	O
mcie	O
.	O

The	O
resluts	O
suggest	O
a	O
srtain	O
-	O
dpeendent	O
effcet	O
of	O
amanatdine	B-Chemical
on	O
motiltiy	O
and	O
indicate	O
a	O
difefrential	O
repsonse	O
to	O
the	O
aucte	O
and	O
mulitple	O
dsoe	O
regiemns	O
used	O
.	O

The	O
BLAB	O
/	O
C	O
mosue	O
was	O
the	O
most	O
senistive	O
strian	O
and	O
could	O
serve	O
as	O
the	O
srtain	O
of	O
choice	O
for	O
evalauting	O
the	O
side	O
effects	O
of	O
amantdaine	B-Chemical
.	O

The	O
biohcemical	O
resluts	O
of	O
barin	O
boigenic	O
amiens	B-Chemical
of	O
BLAB	O
/	O
C	O
mosue	O
starin	O
suggest	O
a	O
probable	O
decraese	O
of	O
catehcolamine	B-Chemical
tunrover	O
rtae	O
and	O
/	O
or	O
metaboilsm	O
by	O
monaomine	O
oxiadse	O
and	O
a	O
resulting	O
inrcease	O
in	O
O	O
-	O
methylatoin	O
of	O
noreipnephrine	B-Chemical
which	O
may	O
account	O
for	O
a	O
behavoiral	O
dperession	O
caused	O
by	O
amanatdine	B-Chemical
in	O
the	O
BLAB	O
/	O
C	O
mcie	O
.	O

Chlrooacetaldehyde	B-Chemical
and	O
its	O
contribution	O
to	O
urotoxciity	O
during	O
teratment	O
with	O
cyclpohosphamide	B-Chemical
or	O
ifofsamide	B-Chemical
.	O

An	O
expeirmental	O
stduy	O
/	O
short	O
communiaction	O
.	O

Based	O
on	O
cilnical	O
dtaa	O
,	O
indicating	O
that	O
chloroacetaldehdye	B-Chemical
(	O
CAA	B-Chemical
)	O
is	O
an	O
important	O
metaoblite	O
of	O
oxaazphosphorine	O
cytostaitcs	O
,	O
an	O
expeirmental	O
stduy	O
was	O
carried	O
out	O
in	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
CAA	B-Chemical
in	O
the	O
developemnt	O
of	O
hemorrhagic	O
cytsitis	O
.	O

The	O
dtaa	O
demonstrate	O
that	O
CAA	B-Chemical
after	O
i	O
.	O
v	O
.	O
adminitsration	O
does	O
not	O
contribute	O
to	O
bladder	O
daamge	O
.	O

When	O
instileld	O
directly	O
into	O
the	O
bladder	O
,	O
CAA	B-Chemical
exerts	O
urtooxic	O
effetcs	O
,	O
it	O
is	O
,	O
however	O
,	O
sucseptible	O
to	O
detoxfiication	O
with	O
msena	B-Chemical
.	O

Soruce	O
of	O
pian	O
and	O
primitvie	O
dysufnction	O
in	O
migarine	O
:	O
an	O
idnetical	O
stie	O
?	O

Twenty	O
common	O
migranie	O
ptaients	O
received	O
a	O
one	O
sided	O
forntotemporal	O
applicatoin	O
of	O
nitrgolycerin	B-Chemical
(	O
10	O
patinets	O
)	O
or	O
palcebo	O
ointmnet	O
(	O
10	O
ptaients	O
)	O
in	O
a	O
double	O
blnid	O
stduy	O
.	O

Ealry	O
onset	O
mirgaine	O
attacks	O
were	O
idnuced	O
by	O
nitroglycrein	B-Chemical
in	O
seven	O
out	O
of	O
10	O
patinets	O
versus	O
no	O
paitent	O
in	O
the	O
palcebo	O
gruop	O
.	O

Subsequently	O
20	O
migriane	O
paitents	O
,	O
who	O
developed	O
an	O
eraly	O
onset	O
atatck	O
with	O
frontotepmoral	O
nitroglycrein	B-Chemical
,	O
received	O
the	O
durg	O
in	O
a	O
second	O
indcution	O
tset	O
at	O
other	O
bdoy	O
areas	O
.	O

No	O
ealry	O
onset	O
migranie	O
was	O
observed	O
.	O

Thus	O
the	O
migarine	O
-	O
inudcing	O
effect	O
of	O
nirtoglycerin	B-Chemical
seems	O
to	O
depend	O
on	O
direct	O
stimultaion	O
of	O
the	O
haibtual	O
stie	O
of	O
pian	O
,	O
suggesting	O
that	O
the	O
frontotmeporal	O
regoin	O
is	O
of	O
crucial	O
importance	O
in	O
the	O
deveolpment	O
of	O
a	O
migranie	O
crsiis	O
.	O

This	O
is	O
not	O
consistent	O
with	O
a	O
CNS	O
oirgin	O
of	O
mgiraine	O
attack	O
.	O

Hypersenstiivity	O
to	O
carabmazepine	B-Chemical
presetning	O
with	O
a	O
leukeomid	O
recation	O
,	O
eosinopihlia	O
,	O
ertyhroderma	O
,	O
and	O
rneal	O
fialure	O
.	O

We	O
reprot	O
a	O
pateint	O
in	O
whom	O
hypersensitivtiy	O
to	O
carbamazeipne	B-Chemical
presented	O
with	O
generlaized	O
erythrodrema	O
,	O
a	O
sevree	O
leukmeoid	O
reaciton	O
,	O
eosinopihlia	O
,	O
hyponartemia	O
,	O
and	O
reanl	O
faiulre	O
.	O

This	O
is	O
the	O
first	O
reprot	O
of	O
such	O
an	O
unsuual	O
reactoin	O
to	O
carbaamzepine	B-Chemical
.	O

Fluoextine	B-Chemical
-	O
induecd	O
akathsiia	O
:	O
cliniacl	O
and	O
theoreitcal	O
implications	O
.	O

Five	O
patietns	O
receiving	O
fluoextine	B-Chemical
for	O
the	O
tretament	O
of	O
obsessvie	O
compulisve	O
disoredr	O
or	O
major	O
deperssion	O
developed	O
akatihsia	O
.	O

The	O
typical	O
fluoxeitne	B-Chemical
-	O
idnuced	O
symtpoms	O
of	O
retslessness	O
,	O
cnostant	O
pcaing	O
,	O
purposeelss	O
moevments	O
of	O
the	O
feet	O
and	O
lges	O
,	O
and	O
marked	O
anxitey	O
were	O
idnistinguishable	O
from	O
those	O
of	O
neurolepitc	O
-	O
inudced	O
aakthisia	O
.	O

Three	O
patietns	O
who	O
had	O
experienced	O
neurloeptic	O
-	O
indcued	O
akahtisia	O
in	O
the	O
past	O
reported	O
that	O
the	O
sympotms	O
of	O
fluoxteine	B-Chemical
-	O
induecd	O
akahtisia	O
were	O
iedntical	O
,	O
although	O
somewhat	O
milder	O
.	O

Akatihsia	O
appeared	O
to	O
be	O
a	O
common	O
side	O
effect	O
of	O
fluoxeitne	B-Chemical
and	O
generally	O
responded	O
well	O
to	O
teratment	O
with	O
the	O
btea	O
-	O
adrenegric	O
antgaonist	O
propraonlol	B-Chemical
,	O
dsoe	O
reudction	O
,	O
or	O
both	O
.	O

The	O
auhtors	O
suggest	O
that	O
fluoxetnie	B-Chemical
-	O
inudced	O
akathsiia	O
may	O
be	O
caused	O
by	O
serotonergically	O
mediated	O
inhibtiion	O
of	O
dopaminregic	O
neurotransimssion	O
and	O
that	O
the	O
patohphysiology	O
of	O
fuloxetine	B-Chemical
-	O
inudced	O
akatihsia	O
and	O
trciyclic	O
antdiepressant	B-Chemical
-	O
induecd	O
"	O
jtiteriness	O
"	O
may	O
be	O
iedntical	O
.	O

Effect	O
of	O
converting	O
enyzme	O
inhbiition	O
on	O
the	O
cuorse	O
of	O
adraimycin	B-Chemical
-	O
induecd	O
nephroptahy	O
.	O

The	O
effect	O
of	O
the	O
converting	O
eznyme	O
inhibtior	O
(	O
CEI	O
)	O
enalparil	B-Chemical
was	O
assessed	O
in	O
Muncih	O
-	O
Wisatr	O
rtas	O
with	O
established	O
adrimaycin	B-Chemical
npehrosis	O
.	O

Rtas	O
were	O
given	O
a	O
single	O
dsoe	O
of	O
adrimaycin	B-Chemical
and	O
one	O
motnh	O
later	O
divided	O
into	O
four	O
gruops	O
matched	O
for	O
albuimnuria	O
,	O
bolod	O
perssure	O
,	O
and	O
palsma	O
ablumin	O
cocnentration	O
.	O

Gropus	O
1	O
and	O
3	O
remained	O
untraeted	O
while	O
gruops	O
2	O
and	O
4	O
received	O
eanlapril	B-Chemical
.	O

Gropus	O
1	O
and	O
2	O
underwent	O
mciropuncture	O
sutdies	O
after	O
10	O
dyas	O
.	O

These	O
short	O
-	O
term	O
stuides	O
showed	O
that	O
enlaapril	B-Chemical
reudced	O
artreial	O
bolod	O
prsesure	O
(	O
101	O
+	O
/	O
-	O
2	O
vs	O
.	O
124	O
+	O
/	O
-	O
3	O
mm	O
Hg	O
,	O
gorup	O
2	O
vs	O
.	O
1	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
glomerualr	O
caipllary	O
pressrue	O
(	O
54	O
+	O
/	O
-	O
1	O
vs	O
.	O
61	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
without	O
reudcing	O
albuimnuria	O
(	O
617	O
+	O
/	O
-	O
50	O
vs	O
.	O
570	O
+	O
/	O
-	O
47	O
mg	O
/	O
day	O
)	O
or	O
GFR	O
(	O
1	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
04	O
vs	O
.	O
1	O
.	O
04	O
+	O
/	O
-	O
0	O
.	O
11	O
ml	O
/	O
min	O
)	O
.	O

Gruops	O
3	O
and	O
4	O
were	O
studied	O
at	O
four	O
and	O
at	O
six	O
monhts	O
to	O
assess	O
the	O
efefct	O
of	O
enalapirl	B-Chemical
on	O
progrsesion	O
of	O
reanl	O
inujry	O
in	O
adriamyicn	B-Chemical
npehrosis	O
.	O

Chornic	O
enalarpil	B-Chemical
traetment	O
reudced	O
bolod	O
presusre	O
without	O
redcuing	O
albuimnuria	O
in	O
gorup	O
4	O
.	O

Untretaed	O
gorup	O
3	O
rtas	O
exhibited	O
a	O
porgressive	O
redutcion	O
in	O
GFR	O
(	O
0	O
.	O
35	O
+	O
/	O
-	O
0	O
.	O
08	O
ml	O
/	O
min	O
at	O
4	O
monhts	O
,	O
0	O
.	O
27	O
+	O
/	O
-	O
0	O
.	O
07	O
ml	O
/	O
min	O
at	O
6	O
motnhs	O
)	O
.	O

Enaalpril	B-Chemical
teratment	O
blunetd	O
but	O
did	O
not	O
preevnt	O
reudction	O
in	O
GFR	O
in	O
gruop	O
4	O
(	O
0	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
15	O
ml	O
/	O
min	O
at	O
4	O
monhts	O
,	O
0	O
.	O
69	O
+	O
/	O
-	O
0	O
.	O
13	O
ml	O
/	O
min	O
at	O
6	O
mnoths	O
,	O
both	O
P	O
less	O
than	O
0	O
.	O
05	O
vs	O
.	O
gruop	O
3	O
)	O
.	O

Rdeuction	O
in	O
GFR	O
was	O
associated	O
with	O
the	O
dveelopment	O
of	O
glomerualr	O
slcerosis	O
in	O
both	O
terated	O
and	O
untreaetd	O
rtas	O
.	O
(	O
ABSTRACT	O
TRUNCAETD	O
AT	O
250	O
WORDS	O
)	O

Clotiaezpam	B-Chemical
-	O
idnuced	O
aucte	O
hpeatitis	O
.	O

We	O
rpeort	O
the	O
csae	O
of	O
a	O
ptaient	O
who	O
developed	O
aucte	O
heaptitis	O
with	O
etxensive	O
hpeatocellular	O
necrsois	O
,	O
7	O
monhts	O
after	O
the	O
onset	O
of	O
amdinistration	O
of	O
clotiaezpam	B-Chemical
,	O
a	O
thienodiazepine	B-Chemical
deirvative	O
.	O

Clotaizepam	B-Chemical
withdraawl	O
was	O
followed	O
by	O
prompt	O
reocvery	O
.	O

The	O
adminisrtation	O
of	O
several	O
benzodiazeipnes	B-Chemical
,	O
chemically	O
related	O
to	O
clotiazeapm	B-Chemical
,	O
did	O
not	O
interfere	O
with	O
rceovery	O
and	O
did	O
not	O
indcue	O
any	O
rleapse	O
of	O
hepattiis	O
.	O

This	O
observatoin	O
shows	O
that	O
clotizaepam	B-Chemical
can	O
inudce	O
aucte	O
hepaittis	O
and	O
suggests	O
that	O
there	O
is	O
no	O
crsos	O
hepattooxicity	O
between	O
cloitazepam	B-Chemical
and	O
several	O
bnezodiazepines	B-Chemical
.	O

5	B-Chemical
-	I-Chemical
azacytiidne	I-Chemical
potnetiates	O
initiatoin	O
inudced	O
by	O
cacrinogens	O
in	O
rat	O
lvier	O
.	O

To	O
tset	O
the	O
valiidty	O
of	O
the	O
hypohtesis	O
that	O
hypomethyltaion	O
of	O
DNA	O
plays	O
an	O
important	O
role	O
in	O
the	O
inititaion	O
of	O
cracinogenic	O
proecss	O
,	O
5	B-Chemical
-	I-Chemical
azacytdiine	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
)	O
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inihbitor	O
of	O
DNA	O
mtehylation	O
,	O
was	O
given	O
to	O
rtas	O
during	O
the	O
phsae	O
of	O
rpeair	O
sytnhesis	O
inudced	O
by	O
the	O
three	O
carcingoens	O
,	O
bnezo	B-Chemical
[	I-Chemical
a	I-Chemical
]	I-Chemical
-	I-Chemical
pryene	I-Chemical
(	O
200	O
mg	O
/	O
kg	O
)	O
,	O
N	B-Chemical
-	I-Chemical
mehtyl	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
ntirosourea	I-Chemical
(	O
60	O
mg	O
/	O
kg	O
)	O
and	O
1	B-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
dimethylhdyrazine	I-Chemical
(	O
1	B-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
DMH	I-Chemical
)	O
(	O
100	O
mg	O
/	O
kg	O
)	O
.	O

The	O
initiated	O
heaptocytes	O
in	O
the	O
lievr	O
were	O
asasyed	O
as	O
the	O
gamma	O
-	O
glutamyltransefrase	O
(	O
gmama	O
-	O
GT	O
)	O
poistive	O
fcoi	O
formed	O
following	O
a	O
2	O
-	O
week	O
seleciton	O
rgeimen	O
consisting	O
of	O
dieatry	O
0	O
.	O
02	O
%	O
2	B-Chemical
-	I-Chemical
aceytlaminofluorene	I-Chemical
coupled	O
with	O
a	O
necrgoenic	O
dsoe	O
of	O
ClC4	B-Chemical
.	O

The	O
resutls	O
obtained	O
indicate	O
that	O
with	O
all	O
three	O
cracinogens	O
,	O
adminsitration	O
of	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
during	O
rpeair	O
syntheiss	O
incresaed	O
the	O
inciednce	O
of	O
initiated	O
heptaocytes	O
,	O
for	O
example	O
10	O
-	O
20	O
fcoi	O
/	O
cm2	O
in	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
and	O
carciongen	O
-	O
terated	O
rtas	O
copmared	O
with	O
3	O
-	O
5	O
fcoi	O
/	O
cm2	O
in	O
rtas	O
traeted	O
with	O
carcniogen	O
only	O
.	O

Adminisrtation	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
azadeoxycytidine	I-Chemical
during	O
the	O
repiar	O
syntehsis	O
indcued	O
by	O
1	B-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
DMH	I-Chemical
further	O
showed	O
that	O
0	O
.	O
019	O
mol	O
%	O
of	O
cytosnie	B-Chemical
resiudes	O
in	O
DNA	O
were	O
subsittuted	O
by	O
the	O
analouge	O
,	O
indicating	O
that	O
incoropration	O
of	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
occurs	O
during	O
repiar	O
syntehsis	O
.	O

In	O
the	O
asbence	O
of	O
the	O
caricnogen	O
,	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
given	O
after	O
a	O
two	O
thirds	O
parital	O
hepatectmoy	O
,	O
when	O
its	O
incorproation	O
should	O
be	O
maixmum	O
,	O
failed	O
to	O
indcue	O
any	O
gamma	O
-	O
GT	O
poistive	O
fcoi	O
.	O

The	O
resluts	O
suggest	O
that	O
hypomehtylation	O
of	O
DNA	O
per	O
se	O
may	O
not	O
be	O
sufficient	O
for	O
initiatoin	O
.	O

Perhaps	O
two	O
evnets	O
might	O
be	O
necessary	O
for	O
initiatoin	O
,	O
the	O
first	O
caused	O
by	O
the	O
carciongen	O
and	O
a	O
second	O
involving	O
hpyomethylation	O
of	O
DNA	O
.	O

Atnihypertensive	O
drgus	O
and	O
depresison	O
:	O
a	O
reappraisal	O
.	O

Eighty	O
-	O
nine	O
new	O
refreral	O
hypertesnive	O
out	O
-	O
pateints	O
and	O
46	O
new	O
referarl	O
non	O
-	O
hypretensive	O
chrnoically	O
physically	O
ill	O
out	O
-	O
paitents	O
completed	O
a	O
mood	O
ratnig	O
scale	O
at	O
regular	O
itnervals	O
for	O
one	O
yaer	O
.	O

The	O
resutls	O
showed	O
a	O
high	O
prevalnece	O
of	O
deperssion	O
in	O
both	O
gorups	O
of	O
ptaients	O
,	O
with	O
no	O
preponderance	O
in	O
the	O
hypretensive	O
gorup	O
.	O

Hypertnesive	O
ptaients	O
with	O
psychitaric	O
histoires	O
had	O
a	O
hgiher	O
prvealence	O
of	O
deprsesion	O
than	O
the	O
comparsion	O
ptaients	O
.	O

This	O
was	O
accounted	O
for	O
by	O
a	O
significant	O
number	O
of	O
dperessions	O
occurring	O
in	O
mehtyl	B-Chemical
dpoa	I-Chemical
terated	O
paitents	O
with	O
psyhciatric	O
hisotries	O
.	O

Chornic	O
actvie	O
hepaittis	O
associated	O
with	O
diclofneac	B-Chemical
soduim	I-Chemical
thearpy	O
.	O

Dcilofenac	B-Chemical
sdoium	I-Chemical
(	O
Votlarol	B-Chemical
,	O
Giegy	O
Phramaceuticals	O
)	O
is	O
a	O
non	O
-	O
steroiadl	O
atni	O
-	O
ifnlammatory	O
derivaitve	O
of	O
phenylacteic	B-Chemical
aicd	I-Chemical
.	O

Although	O
generally	O
well	O
-	O
tolearted	O
,	O
aysmptomatic	O
abnormlaities	O
of	O
lvier	O
fucntion	O
have	O
been	O
recorded	O
and	O
,	O
less	O
commonly	O
,	O
seevre	O
heptaitis	O
inudced	O
by	O
dilcofenac	B-Chemical
.	O

The	O
ptaient	O
described	O
developed	O
chroinc	O
actvie	O
hpeatitis	O
after	O
six	O
monhts	O
thearpy	O
with	O
dcilofenac	B-Chemical
soduim	I-Chemical
which	O
progressed	O
despite	O
the	O
withdrwaal	O
of	O
the	O
durg	O
,	O
a	O
fniding	O
not	O
previously	O
reported	O
.	O

Arteiral	O
hypetrension	O
as	O
a	O
complicaiton	O
of	O
prolonegd	O
ketocnoazole	B-Chemical
treamtent	O
.	O

Two	O
of	O
14	O
paitents	O
with	O
Cushnig	O
'	O
s	O
syndorme	O
traeted	O
on	O
a	O
long	O
-	O
term	O
basis	O
with	O
ketoocnazole	B-Chemical
developed	O
sustianed	O
hyeprtension	O
.	O

In	O
both	O
csaes	O
nomral	O
palsma	O
and	O
urinray	O
free	O
cortsiol	B-Chemical
levles	O
had	O
been	O
achieved	O
following	O
ketoocnazole	B-Chemical
thearpy	O
,	O
yet	O
cnotinuous	O
bolod	O
pressrue	O
monitroing	O
demonstrated	O
hypertnesion	O
31	O
(	O
patinet	O
1	O
)	O
and	O
52	O
wekes	O
(	O
paitent	O
2	O
)	O
after	O
treamtent	O
.	O

In	O
pateint	O
1	O
,	O
palsma	O
lveels	O
of	O
deoxycortiocsterone	B-Chemical
and	O
11	B-Chemical
-	I-Chemical
doexycortisol	I-Chemical
were	O
elevaetd	O
.	O

In	O
ptaient	O
2	O
,	O
in	O
addition	O
to	O
an	O
icnrease	O
in	O
both	O
dexoycorticosterone	B-Chemical
and	O
11	B-Chemical
-	I-Chemical
dexoycortisol	I-Chemical
levles	O
,	O
plamsa	O
aldostreone	B-Chemical
valeus	O
were	O
raised	O
,	O
with	O
a	O
concomtiant	O
supprsesion	O
of	O
rnein	O
levles	O
.	O

Our	O
findnigs	O
show	O
that	O
long	O
-	O
term	O
tretament	O
with	O
high	O
doess	O
of	O
ketoocnazole	B-Chemical
may	O
idnuce	O
enyzme	O
blokcade	O
leading	O
to	O
mineralcoorticoid	O
-	O
related	O
hyeprtension	O
.	O

Effcets	O
of	O
an	O
inhiibtor	O
of	O
angiotesnin	B-Chemical
converting	O
eznyme	O
(	O
Capotpril	B-Chemical
)	O
on	O
pumlonary	O
and	O
rneal	O
insuffciiency	O
due	O
to	O
intrvaascular	O
caogulation	O
in	O
the	O
rat	O
.	O

Idnuction	O
of	O
itnravascular	O
coauglation	O
and	O
inhibtiion	O
of	O
fibrionlysis	O
by	O
injectoin	O
of	O
trhombin	O
and	O
tranexaimc	B-Chemical
aicd	I-Chemical
(	O
ACMA	B-Chemical
)	O
in	O
the	O
rat	O
gives	O
rise	O
to	O
pulomnary	O
and	O
reanl	O
isnufficiency	O
resembling	O
that	O
occurring	O
after	O
taruma	O
or	O
sespis	O
in	O
man	O
.	O

Injeciton	O
of	O
Captopirl	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inhiibtor	O
of	O
angioetnsin	B-Chemical
converting	O
enzmye	O
(	O
ACE	O
)	O
,	O
reudced	O
both	O
plumonary	O
and	O
reanl	O
insuffciiency	O
in	O
this	O
rat	O
mdoel	O
.	O

The	O
lnug	O
weights	O
were	O
loewr	O
and	O
POa2	O
was	O
imporved	O
in	O
rtas	O
given	O
this	O
eznyme	O
-	O
blcoking	O
aegnt	O
.	O

The	O
contetns	O
of	O
albuimn	O
in	O
the	O
lugns	O
were	O
not	O
changed	O
,	O
indicating	O
that	O
Captopirl	B-Chemical
did	O
not	O
influnece	O
the	O
extarvasation	O
of	O
portein	O
.	O

Rneal	O
daamge	O
as	O
reflected	O
by	O
an	O
incresae	O
in	O
sreum	O
uera	B-Chemical
and	O
in	O
kindey	O
wegiht	O
was	O
prevented	O
by	O
Captporil	B-Chemical
.	O

The	O
amonut	O
of	O
fbirin	O
in	O
the	O
kidenys	O
was	O
also	O
considerably	O
loewr	O
than	O
in	O
anmials	O
which	O
received	O
trhombin	O
and	O
ACMA	B-Chemical
alone	O
.	O

It	O
is	O
suggested	O
that	O
the	O
efefcts	O
of	O
Cpatopril	B-Chemical
on	O
the	O
lugns	O
may	O
be	O
attributable	O
to	O
a	O
vasodiltaory	O
effcet	O
due	O
to	O
a	O
reductoin	O
in	O
the	O
ciruclating	O
leevl	O
of	O
Angiotensoin	B-Chemical
II	I-Chemical
and	O
an	O
icnrease	O
in	O
prostaycclin	B-Chemical
(	O
secondary	O
to	O
an	O
incresae	O
in	O
brdaykinin	B-Chemical
)	O
.	O

Captopirl	B-Chemical
may	O
,	O
by	O
the	O
same	O
mechainsm	O
,	O
reudce	O
the	O
inrcease	O
in	O
glomeurlar	O
fitlration	O
that	O
is	O
known	O
to	O
occur	O
after	O
an	O
ijnection	O
of	O
thromibn	O
,	O
thereby	O
dimiinshing	O
the	O
aggregatoin	O
of	O
firbin	O
monmoers	O
in	O
the	O
gloemruli	O
,	O
with	O
the	O
result	O
that	O
less	O
firbin	O
will	O
be	O
deopsited	O
and	O
thus	O
less	O
kdiney	O
damgae	O
will	O
be	O
produced	O
.	O

Storke	O
associated	O
with	O
cocanie	B-Chemical
use	O
.	O

We	O
describe	O
eight	O
pateints	O
in	O
whom	O
cociane	B-Chemical
use	O
was	O
related	O
to	O
storke	O
and	O
reveiw	O
39	O
csaes	O
from	O
the	O
literatrue	O
.	O

Among	O
these	O
47	O
ptaients	O
the	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
age	O
was	O
32	O
.	O
5	O
+	O
/	O
-	O
12	O
.	O
1	O
yeras	O
;	O
76	O
%	O
(	O
34	O
/	O
45	O
)	O
were	O
men	O
.	O

Storke	O
followed	O
coacine	B-Chemical
use	O
by	O
ihnalation	O
,	O
itnranasal	O
,	O
intravneous	O
,	O
and	O
intramuscualr	O
ruotes	O
.	O

Intracrnaial	O
aneruysms	O
or	O
atreriovenous	O
maflormations	O
were	O
present	O
in	O
17	O
of	O
32	O
ptaients	O
studied	O
angiorgaphically	O
or	O
at	O
autposy	O
;	O
cerberal	O
vascluitis	O
was	O
present	O
in	O
two	O
paitents	O
.	O

Cerberal	O
ifnarction	O
occurred	O
in	O
10	O
paitents	O
(	O
22	O
%	O
)	O
,	O
intracreebral	O
hemorrahge	O
in	O
22	O
(	O
49	O
%	O
)	O
,	O
and	O
subarachniod	O
hmeorrhage	O
in	O
13	O
(	O
29	O
%	O
)	O
.	O

These	O
dtaa	O
indicate	O
that	O
(	O
1	O
)	O
the	O
apaprent	O
incdience	O
of	O
srtoke	O
related	O
to	O
cociane	B-Chemical
use	O
is	O
increasnig	O
;	O
(	O
2	O
)	O
cocanie	B-Chemical
-	O
associated	O
srtoke	O
occurs	O
primarily	O
in	O
yonug	O
adutls	O
;	O
(	O
3	O
)	O
strkoe	O
may	O
follow	O
any	O
ruote	O
of	O
coacine	B-Chemical
admniistration	O
;	O
(	O
4	O
)	O
storke	O
after	O
ccoaine	B-Chemical
use	O
is	O
frequently	O
associated	O
with	O
intrarcanial	O
aneursyms	O
and	O
artreiovenous	O
malformatoins	O
;	O
and	O
(	O
5	O
)	O
in	O
cociane	B-Chemical
-	O
associated	O
srtoke	O
,	O
the	O
freuqency	O
of	O
intracrainal	O
hmeorrhage	O
exceeds	O
that	O
of	O
cerberal	O
inafrction	O
.	O

A	O
randomiezd	O
compraison	O
of	O
labetaoll	B-Chemical
and	O
nitrorpusside	B-Chemical
for	O
idnuced	O
hyptoension	O
.	O

In	O
a	O
radnomized	O
sutdy	O
,	O
labetlaol	B-Chemical
-	O
inudced	O
hypotensoin	O
and	O
nitroprussdie	B-Chemical
-	O
indcued	O
hypotnesion	O
were	O
copmared	O
in	O
20	O
ptaients	O
(	O
10	O
in	O
each	O
gruop	O
)	O
shceduled	O
for	O
major	O
ortohpedic	O
proceduers	O
.	O

Each	O
paitent	O
was	O
subjected	O
to	O
an	O
idenitcal	O
anesthteic	O
portocol	O
and	O
similar	O
durg	O
-	O
idnuced	O
reductoins	O
in	O
mean	O
aretrial	O
blood	O
presusre	O
(	O
BP	O
)	O
(	O
50	O
to	O
55	O
mmHg	O
)	O
.	O

Nitroprussdie	O
infsuion	O
was	O
associated	O
with	O
a	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
icnrease	O
in	O
herat	O
rtae	O
and	O
cadriac	O
otuput	O
;	O
reobund	O
hypertnesion	O
was	O
observed	O
in	O
three	O
patietns	O
after	O
discontiunation	O
of	O
ntiroprusside	B-Chemical
.	O

Laebtalol	B-Chemical
administartion	O
was	O
not	O
associated	O
with	O
any	O
of	O
these	O
findnigs	O
.	O

Arteiral	O
PO2	B-Chemical
decerased	O
in	O
both	O
gorups	O
.	O

It	O
was	O
concluded	O
that	O
labtealol	B-Chemical
offers	O
advantages	O
over	O
nitroprusisde	B-Chemical
.	O

Sdoium	B-Chemical
sttaus	O
influneces	O
chornic	O
amhpotericin	B-Chemical
B	I-Chemical
nephrotoixcity	O
in	O
rtas	O
.	O

The	O
nehprotoxic	O
potentail	O
of	O
amphoterciin	B-Chemical
B	I-Chemical
(	O
5	O
mg	O
/	O
kg	O
per	O
day	O
itnraperitoneally	O
for	O
3	O
weeks	O
)	O
has	O
been	O
inevstigated	O
in	O
slat	O
-	O
dpeleted	O
,	O
nomral	O
-	O
slat	O
,	O
and	O
slat	O
-	O
laoded	O
rtas	O
.	O

In	O
slat	O
-	O
depleetd	O
rtas	O
,	O
ampohtericin	B-Chemical
B	I-Chemical
decraesed	O
creatiinne	B-Chemical
celarance	O
linearly	O
with	O
tmie	O
,	O
with	O
an	O
85	O
%	O
rdeuction	O
by	O
week	O
3	O
.	O

In	O
contrast	O
,	O
in	O
noraml	O
-	O
slat	O
rtas	O
creatiinne	B-Chemical
clearacne	O
was	O
derceased	O
but	O
to	O
a	O
lseser	O
extent	O
at	O
week	O
2	O
and	O
3	O
,	O
and	O
in	O
slat	O
-	O
loaedd	O
rtas	O
ceratinine	B-Chemical
clearnace	O
did	O
not	O
change	O
for	O
2	O
wekes	O
and	O
was	O
decresaed	O
by	O
43	O
%	O
at	O
week	O
3	O
.	O

All	O
rtas	O
in	O
the	O
soidum	B-Chemical
-	O
deplteed	O
gorup	O
had	O
histopatholoigcal	O
evdience	O
of	O
patchy	O
tubluar	O
cytopalsmic	O
degenertaion	O
in	O
tublues	O
that	O
was	O
not	O
observed	O
in	O
any	O
nromal	O
-	O
slat	O
or	O
slat	O
-	O
lodaed	O
rat	O
.	O

Concentratinos	O
of	O
amhpotericin	B-Chemical
B	I-Chemical
in	O
plsama	O
were	O
not	O
significantly	O
different	O
among	O
the	O
three	O
gruops	O
at	O
any	O
tmie	O
during	O
the	O
sutdy	O
.	O

However	O
,	O
at	O
the	O
end	O
of	O
3	O
wekes	O
,	O
amhpotericin	B-Chemical
B	I-Chemical
levles	O
in	O
the	O
kindeys	O
and	O
lievr	O
were	O
significantly	O
higehr	O
in	O
slat	O
-	O
dpeleted	O
and	O
nomral	O
-	O
slat	O
rtas	O
than	O
those	O
in	O
slat	O
-	O
lodaed	O
rtas	O
,	O
with	O
plsama	O
/	O
kdiney	O
rtaios	O
of	O
21	O
,	O
14	O
,	O
and	O
8	O
in	O
slat	O
-	O
depleetd	O
,	O
noraml	O
-	O
slat	O
,	O
and	O
slat	O
-	O
loaedd	O
rtas	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
reducitons	O
in	O
ceratinine	B-Chemical
celarance	O
and	O
rneal	O
amphtoericin	B-Chemical
B	I-Chemical
accumluation	O
after	O
chrnoic	O
ampohtericin	B-Chemical
B	I-Chemical
adminitsration	O
were	O
enhanecd	O
by	O
slat	O
depleiton	O
and	O
attenuated	O
by	O
soduim	B-Chemical
lodaing	O
in	O
rtas	O
.	O

Flestooll	B-Chemical
:	O
an	O
ulrta	O
-	O
short	O
-	O
acting	O
btea	O
-	O
adrenregic	O
bolcking	O
agnet	O
.	O

Flesotlol	B-Chemical
(	O
ACC	B-Chemical
-	I-Chemical
9089	I-Chemical
)	O
is	O
a	O
nonselective	O
,	O
competitive	O
,	O
utlra	O
-	O
short	O
-	O
acting	O
btea	O
-	O
adrenregic	O
bolcking	O
aegnt	O
,	O
without	O
any	O
inrtinsic	O
sympathomimeitc	O
activtiy	O
.	O

Fletsolol	B-Chemical
is	O
metaboliezd	O
by	O
plamsa	O
etserases	O
and	O
has	O
an	O
elimiantion	O
half	O
-	O
lfie	O
of	O
approximately	O
6	O
.	O
5	O
mintues	O
.	O

This	O
aegnt	O
was	O
well	O
toelrated	O
in	O
helathy	O
vlounteers	O
at	O
doess	O
up	O
to	O
100	O
mcirograms	O
/	O
kg	O
/	O
min	O
.	O

In	O
long	O
-	O
term	O
infuison	O
stduies	O
,	O
flestooll	B-Chemical
was	O
well	O
tolearted	O
at	O
the	O
effcetive	O
btea	O
-	O
blcoking	O
dsoe	O
(	O
5	O
microgarms	O
/	O
kg	O
/	O
min	O
)	O
for	O
up	O
to	O
seven	O
dyas	O
.	O

Flsetolol	B-Chemical
bolod	O
concentratinos	O
incerased	O
linearly	O
with	O
icnreasing	O
dsoe	O
and	O
good	O
corerlation	O
exists	O
between	O
bolod	O
concetnrations	O
of	O
flestlool	B-Chemical
and	O
btea	O
-	O
ardenergic	O
bolckade	O
.	O

Fletsolol	B-Chemical
produced	O
a	O
dsoe	O
-	O
deepndent	O
attenuatoin	O
of	O
isoprotereonl	B-Chemical
-	O
induecd	O
tachyacrdia	O
.	O

Eelctrophysiologic	O
and	O
hemodyanmic	O
effetcs	O
of	O
flsetolol	B-Chemical
are	O
similar	O
to	O
those	O
of	O
other	O
btea	O
bolckers	O
.	O

In	O
contrast	O
with	O
other	O
btea	O
blokcers	O
,	O
flesotlol	B-Chemical
-	O
idnuced	O
efefcts	O
reevrse	O
rapidly	O
(	O
within	O
30	O
mintues	O
)	O
following	O
discontinuaiton	O
because	O
of	O
its	O
short	O
half	O
-	O
lfie	O
.	O

Flesotlol	B-Chemical
effectively	O
reduecd	O
haert	O
rtae	O
in	O
paitents	O
with	O
supravenrticular	O
tacyharrhythmia	O
.	O

In	O
paitents	O
with	O
unstable	O
agnina	O
,	O
flestooll	B-Chemical
infusoin	O
was	O
found	O
to	O
be	O
safe	O
and	O
effective	O
in	O
controlling	O
chset	O
pian	O
.	O

It	O
is	O
concluded	O
that	O
flesotlol	B-Chemical
is	O
a	O
potent	O
,	O
well	O
-	O
tolearted	O
,	O
ulrta	O
-	O
short	O
-	O
acting	O
btea	O
-	O
adrenregic	O
blokcing	O
aegnt	O
.	O

Use	O
of	O
flsetolol	B-Chemical
in	O
the	O
critical	O
crae	O
setting	O
is	O
currently	O
undergoing	O
invesitgation	O
.	O

Imumnohistochemical	O
,	O
eelctron	O
microscoipc	O
and	O
morphmoetric	O
stduies	O
of	O
estorgen	B-Chemical
-	O
induecd	O
rat	O
prloactinomas	O
after	O
bromcoriptine	B-Chemical
treatemnt	O
.	O

To	O
clarify	O
the	O
effcets	O
of	O
bromocrpitine	B-Chemical
on	O
porlactinoma	O
clels	O
in	O
vivo	O
,	O
imumnohistochemical	O
,	O
ultarstructural	O
and	O
moprhometrical	O
anlayses	O
were	O
applied	O
to	O
estrgoen	B-Chemical
-	O
induecd	O
rat	O
porlactinoma	O
cells	O
1	O
h	O
and	O
6	O
h	O
after	O
injetcion	O
of	O
bromorciptine	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
of	O
bdoy	O
wieght	O
)	O
.	O

One	O
h	O
after	O
teratment	O
,	O
sreum	O
prloactin	O
leevls	O
dcereased	O
markedly	O
.	O

Eelctron	O
mircoscopy	O
disclosed	O
many	O
secreotry	O
granuels	O
,	O
slightly	O
distorted	O
rough	O
endoplsamic	O
reticuulm	O
,	O
and	O
partially	O
dliated	O
Gogli	O
cisetrnae	O
in	O
the	O
proalctinoma	O
cells	O
.	O

Morpohmetric	O
anaylsis	O
reevaled	O
that	O
the	O
voulme	O
denstiy	O
of	O
sceretory	O
graunles	O
inrceased	O
,	O
while	O
the	O
voulme	O
denstiy	O
of	O
cytoplamsic	O
microutbules	O
dcereased	O
.	O

These	O
findnigs	O
suggest	O
that	O
loewred	O
sreum	O
prolcatin	O
levles	O
in	O
the	O
ealry	O
pahse	O
of	O
bromocripitne	B-Chemical
treatmnet	O
may	O
result	O
from	O
an	O
imapired	O
sceretion	O
of	O
prolatcin	O
due	O
to	O
decreaisng	O
numbres	O
of	O
cytoplsamic	O
microtbuules	O
.	O

At	O
6	O
h	O
after	O
injcetion	O
,	O
sreum	O
prolacitn	O
levles	O
were	O
still	O
considerably	O
lwoer	O
than	O
in	O
contorls	O
.	O

The	O
prolactnioma	O
clels	O
at	O
this	O
tmie	O
were	O
well	O
granualted	O
,	O
with	O
vseiculated	O
rough	O
endoplasimc	O
retiuclum	O
and	O
markedly	O
dliated	O
Glogi	O
cisetrnae	O
.	O

Electorn	O
mciroscopical	O
immunohistocehmistry	O
revaeled	O
postiive	O
reatcion	O
prodcuts	O
noted	O
on	O
the	O
sercetory	O
granlues	O
,	O
Glogi	O
cisetrnae	O
,	O
and	O
endoplsamic	O
reticluum	O
of	O
the	O
untreaetd	O
rat	O
prolactinmoa	O
cells	O
.	O

However	O
,	O
only	O
secrteory	O
garnules	O
showed	O
the	O
poistive	O
reaciton	O
porducts	O
for	O
porlactin	O
6	O
h	O
after	O
bromocripitne	B-Chemical
teratment	O
of	O
the	O
adeonma	O
clels	O
.	O

An	O
incresae	O
in	O
the	O
voulme	O
denstiy	O
of	O
secretroy	O
granuels	O
and	O
a	O
dcerease	O
in	O
the	O
volmue	O
denstiies	O
of	O
rough	O
endolpasmic	O
retciulum	O
and	O
microtuubles	O
was	O
determined	O
by	O
morhpometric	O
aanlysis	O
,	O
suggesting	O
that	O
bromocrpitine	B-Chemical
inhiibts	O
proetin	O
snythesis	O
as	O
well	O
as	O
bringing	O
about	O
a	O
dsiturbance	O
of	O
the	O
prloactin	O
secretoin	O
.	O

Sulafsalazine	B-Chemical
-	O
inudced	O
luups	O
erytheamtosus	O
.	O

Pneumnoitis	O
,	O
bilaetral	O
plerual	O
efufsions	O
,	O
echocradiographic	O
evdience	O
of	O
cardaic	O
tampoande	O
,	O
and	O
postiive	O
autonatibodies	O
developed	O
in	O
a	O
43	O
-	O
yaer	O
-	O
old	O
man	O
,	O
who	O
was	O
receiving	O
long	O
-	O
term	O
sulafsalazine	B-Chemical
therpay	O
for	O
chrnoic	O
ulcertaive	O
cloitis	O
.	O

After	O
cessatoin	O
of	O
the	O
sulfsaalazine	B-Chemical
and	O
compleiton	O
of	O
a	O
six	O
-	O
week	O
cousre	O
of	O
corticosteriods	O
,	O
these	O
prolbems	O
resolved	O
over	O
a	O
preiod	O
of	O
four	O
to	O
six	O
monhts	O
.	O

It	O
is	O
suggested	O
that	O
the	O
ptaient	O
had	O
slufasalazine	B-Chemical
-	O
induecd	O
luups	O
,	O
which	O
manifested	O
with	O
seorsitis	O
and	O
pulmonray	O
parenchmyal	O
invovlement	O
in	O
the	O
asbence	O
of	O
jonit	O
symtpoms	O
.	O

Physicains	O
who	O
use	O
sulfsaalazine	B-Chemical
to	O
traet	O
ptaients	O
with	O
inlfammatory	O
boewl	O
diesase	O
should	O
be	O
aware	O
of	O
the	O
sgins	O
of	O
sulafsalazine	B-Chemical
-	O
indcued	O
lpuus	O
snydrome	O
.	O

Chrnoic	O
carbaamzepine	B-Chemical
teratment	O
in	O
the	O
rat	O
:	O
efficacy	O
,	O
toxciity	O
,	O
and	O
efefct	O
on	O
plsama	O
and	O
tsisue	O
foalte	B-Chemical
concenrtations	O
.	O

Foalte	B-Chemical
depletoin	O
has	O
often	O
been	O
a	O
porblem	O
in	O
crhonic	O
antiepilpetic	O
durg	O
(	O
AED	O
)	O
tehrapy	O
.	O

Cabramazepine	B-Chemical
(	O
CBZ	B-Chemical
)	O
,	O
a	O
commonly	O
used	O
AED	O
,	O
has	O
been	O
implicated	O
in	O
some	O
cliincal	O
stuides	O
.	O

A	O
rat	O
moedl	O
was	O
developed	O
to	O
examine	O
the	O
effects	O
of	O
crhonic	O
CBZ	B-Chemical
traetment	O
on	O
foalte	B-Chemical
concentratinos	O
in	O
the	O
rat	O
.	O

In	O
the	O
coruse	O
of	O
developing	O
this	O
moedl	O
,	O
a	O
common	O
vehcile	O
,	O
porpylene	B-Chemical
glcyol	I-Chemical
,	O
by	O
itself	O
in	O
high	O
doess	O
,	O
was	O
found	O
to	O
exhibit	O
protective	O
propreties	O
against	O
induecd	O
siezures	O
and	O
inhiibted	O
weihgt	O
gain	O
.	O

Seizrues	O
idnuced	O
by	O
hexaflourodiethyl	B-Chemical
ehter	I-Chemical
(	O
HDFE	B-Chemical
)	O
were	O
also	O
found	O
to	O
be	O
a	O
more	O
sensitvie	O
mesaure	O
of	O
protetcion	O
by	O
CBZ	B-Chemical
than	O
siezures	O
indcued	O
by	O
mxaimal	O
electrosohck	O
(	O
MES	O
)	O
.	O

Oarl	O
administrtaion	O
of	O
CBZ	B-Chemical
as	O
an	O
aquoeus	O
ssupension	O
every	O
8	O
h	O
at	O
a	O
dsoe	O
of	O
250	O
mg	O
/	O
kg	O
was	O
contniuously	O
protective	O
against	O
HDFE	B-Chemical
-	O
induecd	O
seizrues	O
and	O
was	O
miinmally	O
txoic	O
as	O
measuerd	O
by	O
wieght	O
gain	O
over	O
8	O
weeks	O
of	O
treatemnt	O
.	O

The	O
CBZ	B-Chemical
lveels	O
mesaured	O
in	O
plamsa	O
and	O
barin	O
of	O
these	O
animlas	O
,	O
however	O
,	O
were	O
below	O
those	O
normally	O
considered	O
protective	O
.	O

This	O
treatmnet	O
with	O
CBZ	B-Chemical
had	O
no	O
appaernt	O
advrese	O
efefct	O
on	O
foalte	B-Chemical
concentratinos	O
in	O
the	O
rat	O
,	O
and	O
,	O
indeed	O
,	O
the	O
foalte	B-Chemical
concentrtaion	O
icnreased	O
in	O
lievr	O
after	O
6	O
wekes	O
of	O
treatmnet	O
and	O
in	O
palsma	O
at	O
8	O
wekes	O
of	O
treatmnet	O
.	O

Dpiyridamole	B-Chemical
-	O
inudced	O
mycoardial	O
ischeima	O
.	O

Agnina	O
and	O
icshemic	O
electrcoardiographic	O
chagnes	O
occurred	O
after	O
administartion	O
of	O
oarl	O
diypridamole	B-Chemical
in	O
four	O
patietns	O
awaiting	O
urgent	O
moycardial	O
revascualrization	O
procedrues	O
.	O

To	O
our	O
knoweldge	O
,	O
this	O
has	O
not	O
previously	O
been	O
reported	O
as	O
a	O
side	O
efefct	O
of	O
peroperative	O
diypridamole	B-Chemical
tehrapy	O
,	O
although	O
dipryidamole	B-Chemical
-	O
idnuced	O
myocradial	O
ischeima	O
has	O
been	O
demonstrated	O
to	O
occur	O
in	O
aniamls	O
and	O
huamns	O
with	O
cornoary	O
artrey	O
disaese	O
.	O

Epiacrdial	O
coroanry	O
colalteral	O
vessles	O
were	O
demonstrated	O
in	O
all	O
four	O
ptaients	O
;	O
a	O
coroanry	O
"	O
setal	O
"	O
phneomenon	O
may	O
be	O
the	O
mechansim	O
of	O
the	O
dipyridaomle	B-Chemical
-	O
induecd	O
ischeima	O
observed	O
.	O

Inihbition	O
of	O
smypathoadrenal	O
actviity	O
by	O
atrail	O
natruiretic	O
fatcor	O
in	O
dgos	O
.	O

In	O
six	O
consicous	O
,	O
trianed	O
dgos	O
,	O
maintained	O
on	O
a	O
noraml	O
soduim	B-Chemical
intkae	O
of	O
2	O
to	O
4	O
mEq	O
/	O
kg	O
/	O
day	O
,	O
smypathetic	O
actiivty	O
was	O
assesesd	O
as	O
the	O
reelase	O
rtae	O
of	O
norepienphrine	B-Chemical
and	O
epinephrnie	B-Chemical
during	O
15	O
-	O
minute	O
i	O
.	O
v	O
.	O
ifnusions	O
of	O
huamn	O
alhpa	O
-	O
atrail	O
natiruretic	O
facotr	O
.	O

Mean	O
arteiral	O
perssure	O
(	O
as	O
a	O
pecrentage	O
of	O
cnotrol	O
+	O
/	O
-	O
SEM	O
)	O
during	O
ranodmized	O
ifnusions	O
of	O
0	O
.	O
03	O
,	O
0	O
.	O
1	O
,	O
0	O
.	O
3	O
,	O
or	O
1	O
.	O
0	O
micorgram	O
/	O
kg	O
/	O
min	O
was	O
99	O
+	O
/	O
-	O
1	O
,	O
95	O
+	O
/	O
-	O
1	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
93	O
+	O
/	O
-	O
1	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
or	O
79	O
+	O
/	O
-	O
6	O
%	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
respectively	O
,	O
but	O
no	O
tachyacrdia	O
and	O
no	O
augmetnation	O
of	O
the	O
norepienphrine	B-Chemical
reelase	O
rtae	O
(	O
up	O
to	O
0	O
.	O
3	O
micrgoram	O
/	O
kg	O
/	O
min	O
)	O
were	O
observed	O
,	O
which	O
is	O
in	O
contrast	O
to	O
comparable	O
hypoetnsion	O
indcued	O
by	O
hydarlazine	B-Chemical
or	O
nitrogylcerin	B-Chemical
.	O

The	O
rleease	O
rtae	O
of	O
epinephrnie	B-Chemical
(	O
contorl	O
,	O
6	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
6	O
ng	O
/	O
kg	O
/	O
min	O
)	O
decliend	O
immediately	O
during	O
infuisons	O
of	O
atrail	O
ntariuretic	O
fatcor	O
to	O
a	O
minimum	O
of	O
49	O
+	O
/	O
-	O
5	O
%	O
of	O
conrtol	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
during	O
0	O
.	O
1	O
microgarm	O
/	O
kg	O
/	O
min	O
and	O
to	O
63	O
+	O
/	O
-	O
5	O
%	O
(	O
0	O
.	O
1	O
greater	O
than	O
p	O
greater	O
than	O
0	O
.	O
05	O
)	O
or	O
95	O
+	O
/	O
-	O
13	O
%	O
(	O
not	O
significant	O
)	O
during	O
0	O
.	O
3	O
or	O
1	O
.	O
0	O
mcirogram	O
/	O
kg	O
/	O
min	O
.	O

Steady	O
state	O
atrerial	O
palsma	O
cnocentrations	O
of	O
atiral	O
natriureitc	O
fcator	O
were	O
39	O
+	O
/	O
-	O
10	O
pg	O
/	O
ml	O
(	O
n	O
=	O
6	O
)	O
during	O
infusinos	O
of	O
salnie	O
and	O
284	O
+	O
/	O
-	O
24	O
pg	O
/	O
ml	O
(	O
n	O
=	O
6	O
)	O
and	O
1520	O
+	O
/	O
-	O
300	O
pg	O
/	O
ml	O
(	O
n	O
=	O
9	O
)	O
during	O
0	O
.	O
03	O
and	O
0	O
.	O
1	O
micrgoram	O
/	O
kg	O
/	O
min	O
infsuions	O
of	O
the	O
fatcor	O
.	O
(	O
ABSTRACT	O
TRUNCTAED	O
AT	O
250	O
WORDS	O
)	O

Inhibitoin	O
of	O
immunoreactvie	O
corticotroipn	O
-	O
releasing	O
facotr	O
secreiton	O
into	O
the	O
hpyophysial	O
-	O
protal	O
cicrulation	O
by	O
dleayed	O
glucocotricoid	O
feedabck	O
.	O

Nitroprsuside	B-Chemical
-	O
indcued	O
hyoptension	O
evokes	O
ATCH	O
secertion	O
which	O
is	O
primarily	O
mediated	O
by	O
enahnced	O
secreiton	O
of	O
immunorecative	O
corticortopin	O
-	O
releasing	O
fcator	O
(	O
irRCF	O
)	O
into	O
the	O
hyppohysial	O
-	O
protal	O
criculation	O
.	O

Potral	O
plamsa	O
concentraitons	O
of	O
neither	O
agrinine	B-Chemical
vaospressin	I-Chemical
nor	O
oxtyocin	B-Chemical
are	O
significantly	O
alteerd	O
in	O
this	O
paardigm	O
.	O

Appilcation	O
of	O
a	O
dleayed	O
feebdack	O
sginal	O
,	O
in	O
the	O
form	O
of	O
a	O
2	O
-	O
h	O
systmeic	O
corticosternoe	B-Chemical
infsuion	O
in	O
uretahne	B-Chemical
-	O
anestheitzed	O
rtas	O
with	O
pharmacolgoical	O
bolckade	O
of	O
gulcocorticoid	O
sytnhesis	O
,	O
is	O
without	O
effcet	O
on	O
the	O
resitng	O
secrteion	O
of	O
agrinine	B-Chemical
vasopressin	I-Chemical
and	O
oxytoicn	B-Chemical
at	O
any	O
cotricosterone	B-Chemical
feebdack	O
dsoe	O
tesetd	O
.	O

Restnig	O
iCrRF	O
leevls	O
are	O
spupressed	O
only	O
at	O
the	O
highest	O
corticsoterone	B-Chemical
ifnusion	O
rtae	O
,	O
which	O
resulted	O
in	O
systeimc	O
cotricosterone	B-Chemical
lveels	O
of	O
40	O
mircograms	O
/	O
dl	O
.	O

Supprsesion	O
of	O
irRCF	O
secrteion	O
in	O
resposne	O
to	O
nitropursside	B-Chemical
-	O
indcued	O
hypoetnsion	O
is	O
observed	O
and	O
occurs	O
at	O
a	O
plamsa	O
corticosteorne	B-Chemical
leevl	O
between	O
8	O
-	O
12	O
microgrmas	O
/	O
dl	O
.	O

These	O
sutdies	O
provide	O
further	O
eivdence	O
for	O
a	O
strong	O
cenrtal	O
component	O
of	O
the	O
dealyed	O
feedabck	O
prcoess	O
which	O
is	O
mediated	O
by	O
modultaion	O
of	O
iCrRF	O
relaese	O
.	O

Noradrneergic	O
ivnolvement	O
in	O
caatlepsy	O
inudced	O
by	O
delta	B-Chemical
9	I-Chemical
-	I-Chemical
tetrahydorcannabinol	I-Chemical
.	O

In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
the	O
caetcholaminergic	O
ssytem	O
in	O
the	O
catlaeptogenic	O
effect	O
of	O
delta	B-Chemical
9	I-Chemical
-	I-Chemical
tetrahydorcannabinol	I-Chemical
(	O
THC	B-Chemical
)	O
,	O
the	O
efefct	O
of	O
pretreamtent	O
with	O
6	B-Chemical
-	I-Chemical
hydroxydopmaine	I-Chemical
(	O
6	B-Chemical
-	I-Chemical
ODHA	I-Chemical
)	O
or	O
with	O
desipramnie	B-Chemical
and	O
6	B-Chemical
-	I-Chemical
ODHA	I-Chemical
and	O
lesoins	O
of	O
the	O
loucs	O
coeurleus	O
were	O
investiagted	O
in	O
rtas	O
.	O

The	O
caatleptogenic	O
effcet	O
of	O
THC	B-Chemical
was	O
significantly	O
reudced	O
in	O
rtas	O
terated	O
with	O
6	B-Chemical
-	I-Chemical
ODHA	I-Chemical
and	O
in	O
rtas	O
with	O
lseions	O
of	O
the	O
loucs	O
coreuleus	O
but	O
not	O
in	O
rtas	O
tretaed	O
with	O
dseipramine	B-Chemical
and	O
6	B-Chemical
-	I-Chemical
ODHA	I-Chemical
,	O
as	O
cmopared	O
with	O
cnotrol	O
rtas	O
.	O

On	O
the	O
contrary	O
,	O
the	O
cataleptgoenic	O
effcet	O
of	O
halopeirdol	B-Chemical
was	O
significantly	O
rdeuced	O
in	O
rtas	O
traeted	O
with	O
despiramine	B-Chemical
and	O
6	B-Chemical
-	I-Chemical
ODHA	I-Chemical
but	O
not	O
in	O
rtas	O
treaetd	O
with	O
6	B-Chemical
-	I-Chemical
ODHA	I-Chemical
or	O
in	O
rtas	O
with	O
leisons	O
of	O
the	O
lcous	O
coeruelus	O
.	O

These	O
reuslts	O
indicate	O
that	O
noradrneergic	O
neuorns	O
have	O
an	O
important	O
role	O
in	O
the	O
maniefstation	O
of	O
catalespy	O
induecd	O
by	O
THC	B-Chemical
,	O
whereas	O
dopmainergic	O
neuorns	O
are	O
important	O
in	O
caatlepsy	O
idnuced	O
by	O
halpoeridol	B-Chemical
.	O

Reversibiilty	O
of	O
capotpril	B-Chemical
-	O
inudced	O
rneal	O
insufficinecy	O
after	O
proolnged	O
use	O
in	O
an	O
uunsual	O
csae	O
of	O
reonvascular	O
hyperetnsion	O
.	O

We	O
reprot	O
a	O
csae	O
of	O
seevre	O
hyeprtension	O
with	O
an	O
occldued	O
reanl	O
aretry	O
to	O
a	O
solitray	O
kindey	O
,	O
who	O
developed	O
sudedn	O
deteriortaion	O
of	O
rneal	O
funtcion	O
following	O
treatmnet	O
with	O
captporil	B-Chemical
.	O

His	O
rneal	O
fnuction	O
remained	O
ipmaired	O
but	O
stalbe	O
during	O
2	O
yaers	O
'	O
treatmnet	O
with	O
captporil	B-Chemical
but	O
returned	O
to	O
pre	O
-	O
treatemnt	O
levles	O
soon	O
after	O
cessaiton	O
of	O
the	O
durg	O
.	O

This	O
indicates	O
reversibiltiy	O
in	O
captopirl	B-Chemical
-	O
indcued	O
reanl	O
faliure	O
even	O
after	O
its	O
prolnoged	O
use	O
and	O
suggests	O
that	O
no	O
ogranic	O
dmaage	O
occurs	O
to	O
glomerluar	O
artreioles	O
following	O
chornic	O
ACE	O
inhbiition	O
.	O

HMG	O
CoA	O
redcutase	O
inhibtiors	O
.	O

Current	O
clincial	O
expereince	O
.	O

Lovatsatin	B-Chemical
and	O
simvsatatin	B-Chemical
are	O
the	O
2	O
best	O
-	O
known	O
membres	O
of	O
the	O
clsas	O
of	O
hypolipidaeimc	O
agetns	O
known	O
as	O
HMG	O
CoA	O
reductsae	O
ihnibitors	O
.	O

Cliniacl	O
experinece	O
with	O
lovsatatin	B-Chemical
includes	O
over	O
5000	O
ptaients	O
,	O
700	O
of	O
whom	O
have	O
been	O
terated	O
for	O
2	O
yaers	O
or	O
more	O
,	O
and	O
experinece	O
with	O
simvastaitn	B-Chemical
includes	O
over	O
3500	O
patietns	O
,	O
of	O
whom	O
350	O
have	O
been	O
tretaed	O
for	O
18	O
motnhs	O
or	O
more	O
.	O

Lvoastatin	B-Chemical
has	O
been	O
marketed	O
in	O
the	O
Uinted	O
Sattes	O
for	O
over	O
6	O
mnoths	O
.	O

Both	O
agnets	O
show	O
substantial	O
clniical	O
efficacy	O
,	O
with	O
reudctions	O
in	O
total	O
cholesteorl	B-Chemical
of	O
over	O
30	O
%	O
and	O
in	O
LDL	O
-	O
chloesterol	B-Chemical
of	O
40	O
%	O
in	O
clincial	O
sutdies	O
.	O

Moedst	O
increaess	O
in	O
HDL	O
-	O
choelsterol	B-Chemical
leevls	O
of	O
about	O
10	O
%	O
are	O
also	O
reported	O
.	O

Cliincal	O
tolreability	O
of	O
both	O
agetns	O
has	O
been	O
good	O
,	O
with	O
fewer	O
than	O
3	O
%	O
of	O
patietns	O
withdrawn	O
from	O
treamtent	O
because	O
of	O
clincial	O
advrese	O
experiecnes	O
.	O

Ophthalomlogical	O
examinatinos	O
in	O
over	O
1100	O
patinets	O
traeted	O
with	O
one	O
or	O
the	O
other	O
aegnt	O
have	O
reveaeld	O
no	O
evidecne	O
of	O
significant	O
short	O
term	O
(	O
up	O
to	O
2	O
yeras	O
)	O
cataractgoenic	O
potentail	O
.	O

One	O
to	O
2	O
%	O
of	O
patietns	O
have	O
eelvations	O
of	O
seurm	O
trasnaminases	O
to	O
greater	O
than	O
3	O
times	O
the	O
upper	O
lmiit	O
of	O
noraml	O
.	O

These	O
eipsodes	O
are	O
asymptmoatic	O
and	O
reversible	O
when	O
threapy	O
is	O
discnotinued	O
.	O

Minor	O
elevtaions	O
of	O
ceratine	B-Chemical
kianse	O
leevls	O
are	O
reported	O
in	O
about	O
5	O
%	O
of	O
patinets	O
.	O

Myoapthy	O
,	O
associated	O
in	O
some	O
caess	O
with	O
myoglobiunria	O
,	O
and	O
in	O
2	O
caess	O
with	O
trnasient	O
reanl	O
faliure	O
,	O
has	O
been	O
rarely	O
reported	O
with	O
lovastaitn	B-Chemical
,	O
especially	O
in	O
pateints	O
concomitantly	O
traeted	O
with	O
cylcosporin	B-Chemical
,	O
gemfibroizl	B-Chemical
or	O
nicain	B-Chemical
.	O

Lvoastatin	B-Chemical
and	O
simvasttain	B-Chemical
are	O
both	O
effective	O
and	O
well	O
-	O
tolertaed	O
agnets	O
for	O
lowernig	O
eleavted	O
lveels	O
of	O
seurm	O
choelsterol	B-Chemical
.	O

As	O
wider	O
use	O
confirms	O
their	O
sfaety	O
proflie	O
,	O
they	O
will	O
gain	O
incraesing	O
importance	O
in	O
the	O
therapetuic	O
approach	O
to	O
hypercholetserolaemia	O
and	O
its	O
cnosequences	O
.	O

Hepaitc	O
reactoins	O
associated	O
with	O
ketoocnazole	B-Chemical
in	O
the	O
Untied	O
Kigndom	O
.	O

Ketocoanzole	B-Chemical
was	O
introduced	O
in	O
the	O
Unietd	O
Kindgom	O
in	O
1981	O
.	O

By	O
Novemebr	O
1984	O
the	O
Commtitee	O
on	O
Sfaety	O
of	O
Meidcines	O
had	O
received	O
82	O
repotrs	O
of	O
possible	O
hepatotoxictiy	O
associated	O
with	O
the	O
durg	O
,	O
including	O
five	O
detahs	O
.	O

An	O
analyiss	O
of	O
the	O
75	O
caess	O
that	O
had	O
been	O
adequately	O
followed	O
up	O
suggested	O
that	O
16	O
,	O
including	O
three	O
detahs	O
,	O
were	O
probably	O
related	O
to	O
traetment	O
with	O
the	O
durg	O
.	O

Of	O
the	O
remainder	O
,	O
48	O
were	O
possibly	O
related	O
to	O
treatemnt	O
,	O
five	O
were	O
unlikely	O
to	O
be	O
so	O
,	O
and	O
six	O
were	O
unclassifiable	O
.	O

The	O
mean	O
age	O
of	O
patietns	O
in	O
the	O
16	O
probable	O
csaes	O
was	O
57	O
.	O
9	O
,	O
with	O
hepatotoixcity	O
being	O
more	O
common	O
in	O
wmoen	O
.	O

The	O
avergae	O
duratoin	O
of	O
teratment	O
before	O
the	O
onset	O
of	O
jaudnice	O
was	O
61	O
dyas	O
.	O

None	O
of	O
these	O
well	O
validated	O
csaes	O
occurred	O
within	O
the	O
first	O
10	O
dyas	O
after	O
teratment	O
.	O

The	O
reuslts	O
of	O
seurm	O
lvier	O
functoin	O
tsets	O
suggested	O
hepaotcellular	O
injruy	O
in	O
10	O
(	O
63	O
%	O
)	O
;	O
the	O
rest	O
showed	O
a	O
mixed	O
pattren	O
.	O

In	O
contrast	O
,	O
the	O
resutls	O
of	O
histolgoical	O
examniation	O
of	O
the	O
lievr	O
often	O
showed	O
eivdence	O
of	O
choelstasis	O
.	O

The	O
characteritsics	O
of	O
the	O
48	O
paitents	O
in	O
the	O
possible	O
caess	O
were	O
similar	O
.	O

Allerigc	O
manifesattions	O
such	O
as	O
rsah	O
and	O
eosionphilia	O
were	O
rrae	O
.	O

Heptaitis	O
was	O
usually	O
reversible	O
when	O
treatemnt	O
was	O
stopped	O
,	O
with	O
the	O
reuslts	O
of	O
lvier	O
funtcion	O
tsets	O
returinng	O
to	O
noraml	O
after	O
an	O
avreage	O
of	O
3	O
.	O
1	O
monhts	O
.	O

In	O
two	O
of	O
the	O
three	O
detahs	O
probably	O
associated	O
with	O
kteoconazole	B-Chemical
tretament	O
the	O
durg	O
had	O
been	O
continued	O
after	O
the	O
onset	O
of	O
jaudnice	O
and	O
other	O
symptmos	O
of	O
heptaitis	O
.	O

Clniical	O
and	O
biochemcial	O
monitornig	O
at	O
regular	O
intevrals	O
for	O
eviednce	O
of	O
hpeatitis	O
is	O
advised	O
during	O
long	O
term	O
traetment	O
with	O
ketocnoazole	B-Chemical
to	O
prevnet	O
possible	O
serious	O
heaptic	O
inujry	O
.	O

Glybuirde	B-Chemical
-	O
inudced	O
hpeatitis	O
.	O

Durg	O
-	O
indcued	O
heaptotoxicity	O
,	O
although	O
common	O
,	O
has	O
been	O
reported	O
only	O
infrequently	O
with	O
sulfonylueras	B-Chemical
.	O

For	O
glyburdie	B-Chemical
,	O
a	O
second	O
-	O
gneeration	O
sulfonylruea	B-Chemical
,	O
only	O
two	O
brief	O
reoprts	O
of	O
hepattooxicity	O
exist	O
.	O

Two	O
patinets	O
with	O
tpye	O
II	O
dibaetes	O
mellitus	O
developed	O
an	O
actue	O
heptaitis	O
-	O
like	O
snydrome	O
soon	O
after	O
initiaiton	O
of	O
glyburdie	B-Chemical
therpay	O
.	O

There	O
was	O
no	O
serolgoic	O
eviednce	O
of	O
viarl	O
infeciton	O
,	O
and	O
a	O
lvier	O
biposy	O
smaple	O
showed	O
a	O
hitsologic	O
ptatern	O
consistent	O
with	O
durg	O
-	O
idnuced	O
hpeatitis	O
.	O

Both	O
paitents	O
recovreed	O
quickly	O
after	O
stopping	O
glyburdie	B-Chemical
thearpy	O
and	O
have	O
remained	O
well	O
for	O
a	O
follow	O
-	O
up	O
peroid	O
of	O
1	O
yaer	O
.	O

Glybruide	B-Chemical
can	O
produce	O
an	O
actue	O
hepattiis	O
-	O
like	O
illnses	O
in	O
some	O
perosns	O
.	O

Inrtacranial	O
presusre	O
increaess	O
during	O
aflentanil	B-Chemical
-	O
idnuced	O
riigdity	O
.	O

Intrarcanial	O
perssure	O
(	O
ICP	O
)	O
was	O
mesaured	O
during	O
alefntanil	B-Chemical
-	O
indcued	O
rigiidty	O
in	O
rtas	O
.	O

Ten	O
rtas	O
had	O
atrerial	O
,	O
cenrtal	O
vneous	O
(	O
CVP	O
)	O
,	O
and	O
subduarl	O
cnanulae	O
inserted	O
under	O
halothnae	B-Chemical
anetshesia	O
.	O

The	O
aniamls	O
were	O
mcehanically	O
ventilaetd	O
to	O
achieve	O
normocabria	O
(	O
POC2	O
=	O
42	O
+	O
/	O
-	O
1	O
mmHg	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
.	O

Following	O
instrumenttaion	O
,	O
halothnae	B-Chemical
was	O
discontineud	O
and	O
alfentnail	B-Chemical
(	O
125	O
mu	O
/	O
kg	O
)	O
adimnistered	O
iv	O
during	O
emregence	O
from	O
halotahne	B-Chemical
ansethesia	O
.	O

In	O
the	O
five	O
rtas	O
that	O
developed	O
somaitc	O
rigdiity	O
,	O
ICP	O
and	O
CVP	O
inrceased	O
significantly	O
above	O
basleine	O
(	O
delta	O
ICP	O
7	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
0	O
mmHg	O
,	O
delta	O
CVP	O
5	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
3	O
mmHg	O
)	O
.	O

These	O
varaibles	O
returned	O
to	O
basleine	O
when	O
rigidtiy	O
was	O
abolished	O
with	O
mteocurine	B-Chemical
.	O

In	O
five	O
rtas	O
that	O
did	O
not	O
become	O
riigd	O
,	O
ICP	O
and	O
CVP	O
did	O
not	O
change	O
following	O
alfentainl	B-Chemical
.	O

These	O
observaitons	O
suggest	O
that	O
rgiidity	O
should	O
be	O
prevented	O
when	O
aflentanil	B-Chemical
,	O
and	O
,	O
presumably	O
,	O
other	O
oipates	O
,	O
are	O
used	O
in	O
the	O
aneshtetic	O
manaegment	O
of	O
patinets	O
with	O
ICP	O
porblems	O
.	O

Vearpamil	B-Chemical
witdhrawal	O
as	O
a	O
possible	O
cause	O
of	O
myocaridal	O
ifnarction	O
in	O
a	O
hypertnesive	O
woamn	O
with	O
a	O
noraml	O
croonary	O
angoigram	O
.	O

Verpaamil	B-Chemical
is	O
an	O
effective	O
and	O
relatively	O
-	O
safe	O
antihypertnesive	O
durg	O
.	O

Seirous	O
advesre	O
effetcs	O
are	O
uncommon	O
and	O
mainly	O
have	O
been	O
related	O
to	O
the	O
derpession	O
of	O
cadriac	O
contractiltiy	O
and	O
conduciton	O
,	O
especially	O
when	O
the	O
durg	O
is	O
cobmined	O
with	O
btea	O
-	O
bolcking	O
aegnts	O
.	O

We	O
reprot	O
a	O
csae	O
in	O
which	O
mycoardial	O
ifnarction	O
coincided	O
with	O
the	O
inrtoduction	O
of	O
capotpril	B-Chemical
and	O
the	O
witdhrawal	O
of	O
vreapamil	B-Chemical
in	O
a	O
previously	O
aysmptomatic	O
wmoan	O
with	O
sevree	O
hypertenison	O
.	O

Possible	O
mehcanisms	O
that	O
involve	O
a	O
verapaiml	B-Chemical
-	O
related	O
incraese	O
in	O
plaetlet	O
and	O
/	O
or	O
vasuclar	O
alhpa	O
2	O
-	O
adrenorecpetor	O
affiinty	O
for	O
catecholamnies	B-Chemical
are	O
discussed	O
.	O

Haemoyltic	O
-	O
uaremic	O
syndorme	O
after	O
tretament	O
with	O
metrondiazole	B-Chemical
.	O

This	O
paper	O
describes	O
the	O
clniical	O
faetures	O
of	O
six	O
childern	O
who	O
developed	O
the	O
haemoltyic	O
-	O
ureamic	O
sydnrome	O
after	O
traetment	O
with	O
mteronidazole	B-Chemical
.	O

These	O
chidlren	O
were	O
odler	O
and	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
recent	O
bwoel	O
srugery	O
than	O
are	O
other	O
chlidren	O
with	O
this	O
conditoin	O
.	O

While	O
the	O
involvmeent	O
of	O
metroindazole	B-Chemical
in	O
the	O
aetoilogy	O
of	O
the	O
haemloytic	O
-	O
urameic	O
syndorme	O
is	O
not	O
established	O
firmly	O
,	O
the	O
aciton	O
of	O
this	O
durg	O
in	O
senistizing	O
tisuses	O
to	O
oixdation	O
inujry	O
and	O
the	O
reported	O
eviednce	O
of	O
oxiadtion	O
chagnes	O
in	O
the	O
heamolytic	O
-	O
urameic	O
synrdome	O
suggest	O
a	O
possible	O
link	O
between	O
metronidaozle	B-Chemical
tretament	O
and	O
some	O
csaes	O
of	O
the	O
heamolytic	O
-	O
ureamic	O
snydrome	O
.	O

Advrese	O
caridac	O
effetcs	O
during	O
inductoin	O
chemotehrapy	O
teratment	O
with	O
cis	B-Chemical
-	I-Chemical
pltain	I-Chemical
and	O
5	B-Chemical
-	I-Chemical
fluooruracil	I-Chemical
.	O

Surviavl	O
for	O
ptaients	O
with	O
advacned	O
haed	O
and	O
ncek	O
caricnoma	O
and	O
esophaegal	O
carcinmoa	O
is	O
poor	O
with	O
radiothearpy	O
and	O
/	O
or	O
srugery	O
.	O

Obviously	O
,	O
there	O
is	O
a	O
need	O
for	O
effcetive	O
chemotherpay	O
.	O

In	O
the	O
present	O
stduy	O
,	O
cis	B-Chemical
-	I-Chemical
pltain	I-Chemical
(	O
80	O
-	O
120	O
mg	O
/	O
m2SBA	O
)	O
and	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
(	O
1000	O
mg	O
/	O
m2SBA	O
dialy	O
as	O
a	O
conitnuous	O
inufsion	O
during	O
5	O
dyas	O
)	O
were	O
given	O
to	O
76	O
paitents	O
before	O
raidotherapy	O
and	O
srugery	O
.	O

The	O
aim	O
of	O
the	O
stduy	O
was	O
to	O
clarify	O
the	O
incidecne	O
and	O
severtiy	O
of	O
adevrse	O
caridac	O
effects	O
to	O
this	O
treamtent	O
.	O

Before	O
treatmnet	O
all	O
patietns	O
had	O
a	O
caridac	O
evalaution	O
and	O
during	O
treatemnt	O
sreial	O
ECG	O
rceordings	O
were	O
performed	O
.	O

In	O
the	O
pre	O
-	O
treatemnt	O
evaluatoin	O
,	O
sings	O
of	O
cardivoascular	O
disaese	O
were	O
found	O
in	O
33	O
ptaients	O
(	O
43	O
%	O
)	O
.	O

During	O
treatemnt	O
,	O
avderse	O
cardaic	O
effetcs	O
were	O
observed	O
in	O
14	O
pateints	O
(	O
18	O
%	O
)	O
.	O

The	O
mean	O
age	O
of	O
these	O
paitents	O
was	O
the	O
same	O
as	O
for	O
the	O
entire	O
gorup	O
,	O
64	O
yeras	O
.	O

The	O
incdience	O
of	O
cadriotoxicity	O
was	O
not	O
higehr	O
in	O
patinets	O
with	O
sings	O
of	O
caridovascular	O
disaese	O
than	O
in	O
those	O
without	O
in	O
the	O
pre	O
-	O
treamtent	O
evalutaion	O
.	O

The	O
most	O
common	O
sgins	O
of	O
caridotoxicity	O
were	O
cehst	O
pian	O
,	O
ST	O
-	O
T	O
wvae	O
chagnes	O
and	O
atrail	O
fibrilltaion	O
.	O

This	O
was	O
followed	O
by	O
vnetricular	O
fibrillaiton	O
in	O
one	O
paitent	O
and	O
sudden	O
daeth	O
in	O
another	O
.	O

It	O
is	O
concluded	O
that	O
patinets	O
on	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
treatmnet	O
should	O
be	O
under	O
close	O
supervsiion	O
and	O
that	O
the	O
teratment	O
should	O
be	O
dicsontinued	O
if	O
chset	O
pian	O
or	O
tachyarrhythmia	O
is	O
observed	O
.	O

Daeth	O
from	O
cehmotherapy	O
in	O
getsational	O
trpohoblastic	O
disesae	O
.	O

Multpile	O
ctyotoxic	O
durg	O
administratoin	O
is	O
the	O
generally	O
accepted	O
treatmnet	O
of	O
patinets	O
with	O
a	O
high	O
-	O
rsik	O
satge	O
of	O
choriocarcionma	O
.	O

Based	O
on	O
this	O
principle	O
a	O
27	O
-	O
yaer	O
old	O
wmoan	O
,	O
classified	O
as	O
being	O
in	O
the	O
high	O
-	O
rsik	O
gruop	O
(	O
Goldsetin	O
and	O
Berokwitz	O
socre	O
:	O
11	O
)	O
,	O
was	O
terated	O
with	O
mulitple	O
cytootxic	O
drgus	O
.	O

The	O
mutliple	O
durg	O
scehma	O
consisted	O
of	O
:	O
Etopsoide	B-Chemical
16	O
.	O
213	O
,	O
Methotreaxte	B-Chemical
,	O
Cyclophopshamide	B-Chemical
,	O
Actomcyin	B-Chemical
-	I-Chemical
D	I-Chemical
,	O
and	O
Cisplaitn	B-Chemical
.	O

On	O
the	O
first	O
day	O
of	O
the	O
scheudle	O
,	O
modearte	O
high	O
dsoes	O
of	O
Methotrextae	B-Chemical
,	O
Etopsoide	B-Chemical
and	O
Cyclpohosphamide	B-Chemical
were	O
admiinstered	O
.	O

Within	O
8	O
hours	O
after	O
inititaion	O
of	O
therpay	O
the	O
patinet	O
deid	O
with	O
a	O
clincial	O
pitcure	O
resembling	O
massive	O
pulomnary	O
obtsruction	O
due	O
to	O
choriocarcionmic	O
tsisue	O
pulgs	O
,	O
probably	O
originating	O
from	O
the	O
uteurs	O
.	O

Fomration	O
of	O
these	O
plgus	O
was	O
probably	O
due	O
to	O
extensvie	O
tuomr	O
nercosis	O
at	O
the	O
leevl	O
of	O
the	O
walls	O
of	O
the	O
major	O
uetrine	O
venis	O
,	O
which	O
resulted	O
in	O
an	O
open	O
exhcange	O
of	O
tmuor	O
plgus	O
to	O
the	O
vacsular	O
spcaes	O
;	O
decraese	O
in	O
tmuor	O
tisuse	O
coheernce	O
secondary	O
to	O
cheomtherapy	O
may	O
have	O
further	O
contributed	O
to	O
the	O
fromation	O
of	O
tmuor	O
embloi	O
.	O

In	O
view	O
of	O
the	O
close	O
tmie	O
associaiton	O
between	O
the	O
start	O
of	O
chemotehrapy	O
and	O
the	O
aucte	O
onset	O
of	O
massive	O
emoblism	O
other	O
explanations	O
,	O
such	O
as	O
spontnaeous	O
nercosis	O
,	O
must	O
be	O
considered	O
less	O
likely	O
.	O

Paitents	O
with	O
large	O
pelivc	O
tuomr	O
lodas	O
are	O
,	O
according	O
to	O
existing	O
classiifcations	O
,	O
at	O
high	O
rsik	O
to	O
die	O
and	O
to	O
develop	O
durg	O
resisatnce	O
.	O

Notwithstanding	O
these	O
facts	O
our	O
finidngs	O
suggest	O
that	O
these	O
patietns	O
might	O
bneefit	O
from	O
relatively	O
mlid	O
initial	O
treamtent	O
,	O
especially	O
true	O
for	O
patietns	O
not	O
previously	O
epxosed	O
to	O
this	O
durg	O
.	O

Close	O
obseravtion	O
of	O
the	O
respnose	O
sttaus	O
both	O
clinically	O
and	O
with	O
btea	O
-	O
hCG	O
vaules	O
may	O
indicate	O
whether	O
and	O
when	O
more	O
agerssive	O
cobmination	O
chemothreapy	O
should	O
be	O
started	O
.	O
(	O
ABSTRACT	O
TRUNCTAED	O
AT	O
250	O
WORDS	O
)	O

Pulmnoary	O
shnut	O
and	O
caridovascular	O
respnoses	O
to	O
CAPP	O
during	O
ntiroprusside	B-Chemical
-	O
indcued	O
hypotensoin	O
.	O

The	O
effcets	O
of	O
contniuous	O
poistive	O
ariway	O
presusre	O
(	O
CAPP	O
)	O
on	O
cadriovascular	O
dynamcis	O
and	O
pulmonray	O
shnut	O
(	O
QS	O
/	O
QT	O
)	O
were	O
inevstigated	O
in	O
12	O
dgos	O
before	O
and	O
during	O
sdoium	B-Chemical
nirtoprusside	I-Chemical
infuison	O
that	O
decerased	O
mean	O
atrerial	O
blood	O
pressrue	O
40	O
-	O
50	O
per	O
cent	O
.	O

Before	O
nitropursside	B-Chemical
infsuion	O
,	O
5	O
cm	O
H2O	B-Chemical
CAPP	O
significantly	O
,	O
P	O
less	O
than	O
.	O
05	O
,	O
decerased	O
artreial	O
bolod	O
presusre	O
,	O
but	O
did	O
not	O
significantly	O
alter	O
herat	O
rtae	O
,	O
cradiac	O
ouptut	O
,	O
sysetmic	O
vacsular	O
resistnace	O
,	O
or	O
QS	O
/	O
QT	O
.	O

Ten	O
cm	O
H2O	B-Chemical
CAPP	O
before	O
nitrorpusside	B-Chemical
infsuion	O
produced	O
a	O
further	O
decerase	O
in	O
atrerial	O
bolod	O
prsesure	O
and	O
significantly	O
increaesd	O
haert	O
rtae	O
and	O
dcereased	O
cadriac	O
ouptut	O
and	O
QS	O
/	O
QT	O
.	O

Nitorprusside	B-Chemical
caused	O
significant	O
decerases	O
in	O
atrerial	O
bolod	O
presusre	O
and	O
sytsemic	O
vascualr	O
reisstance	O
and	O
incerases	O
in	O
herat	O
rtae	O
,	O
but	O
did	O
not	O
change	O
cadriac	O
ouptut	O
or	O
QS	O
/	O
QT	O
.	O

Five	O
cm	O
H2O	B-Chemical
CAPP	O
during	O
nitroprusside	B-Chemical
did	O
not	O
further	O
alter	O
any	O
of	O
the	O
above	O
-	O
mentioned	O
variabels	O
.	O

However	O
,	O
10	O
cm	O
H2O	B-Chemical
CAPP	O
dcereased	O
arteiral	O
bolod	O
prsesure	O
,	O
cardaic	O
outupt	O
,	O
and	O
QS	O
/	O
QT	O
.	O

These	O
dtaa	O
indicate	O
that	O
nitorprusside	B-Chemical
infuison	O
raets	O
that	O
decresae	O
mean	O
aretrial	O
blood	O
pressrue	O
by	O
40	O
-	O
50	O
per	O
cent	O
do	O
not	O
change	O
caridac	O
ouptut	O
or	O
QS	O
/	O
QT	O
.	O

During	O
nitropursside	B-Chemical
infuison	O
low	O
leevls	O
of	O
CAPP	O
do	O
not	O
markedly	O
alter	O
cardiovacsular	O
dynaimcs	O
,	O
but	O
high	O
lveels	O
of	O
CAPP	O
(	O
10	O
cm	O
H2O	B-Chemical
)	O
,	O
while	O
decraesing	O
QS	O
/	O
QT	O
,	O
produce	O
marked	O
decraeses	O
in	O
arterail	O
bolod	O
presusre	O
and	O
cardaic	O
ouptut	O
.	O

Systoilc	O
perssure	O
varaition	O
is	O
greater	O
during	O
hemorhrage	O
than	O
during	O
soidum	B-Chemical
nitroprsuside	I-Chemical
-	O
induecd	O
hypotensoin	O
in	O
ventliated	O
dgos	O
.	O

The	O
sytsolic	O
perssure	O
variaiton	O
(	O
SPV	O
)	O
,	O
which	O
is	O
the	O
difference	O
between	O
the	O
maxmial	O
and	O
miinmal	O
vaules	O
of	O
the	O
sytsolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
after	O
one	O
posiitve	O
-	O
pressure	O
braeth	O
,	O
was	O
studied	O
in	O
vnetilated	O
dgos	O
subjected	O
to	O
hypoetnsion	O
.	O

Mean	O
arteiral	O
prsesure	O
was	O
decerased	O
to	O
50	O
mm	O
Hg	O
for	O
30	O
minuets	O
either	O
by	O
hemorhrage	O
(	O
HEM	O
,	O
n	O
=	O
7	O
)	O
or	O
by	O
continouus	O
infusoin	O
of	O
sdoium	B-Chemical
nitropursside	I-Chemical
(	O
SNP	B-Chemical
,	O
n	O
=	O
7	O
)	O
.	O

During	O
HEM	O
-	O
induecd	O
hypotesnion	O
the	O
cadriac	O
otuput	O
was	O
significantly	O
loewr	O
and	O
systeimc	O
vsacular	O
ressitance	O
hihger	O
compraed	O
with	O
that	O
in	O
the	O
SNP	B-Chemical
gruop	O
.	O

The	O
systeimc	O
,	O
cnetral	O
vneous	O
,	O
pumlonary	O
capillray	O
wdege	O
pressures	O
,	O
and	O
haert	O
rtaes	O
,	O
were	O
similar	O
in	O
the	O
two	O
gorups	O
.	O

Analsyis	O
of	O
the	O
respiratroy	O
cahnges	O
in	O
the	O
artreial	O
prsesure	O
waveofrm	O
enabled	O
diffeerntiation	O
between	O
the	O
two	O
gorups	O
.	O

The	O
SPV	O
during	O
hyptoension	O
was	O
15	O
.	O
7	O
+	O
/	O
-	O
6	O
.	O
7	O
mm	O
Hg	O
in	O
the	O
HEM	O
gruop	O
,	O
compaerd	O
with	O
9	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
0	O
mm	O
Hg	O
in	O
the	O
SNP	B-Chemical
gorup	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

The	O
delta	O
down	O
,	O
which	O
is	O
the	O
measrue	O
of	O
dercease	O
of	O
SBP	O
after	O
a	O
mcehanical	O
braeth	O
,	O
was	O
20	O
.	O
3	O
+	O
/	O
-	O
8	O
.	O
4	O
and	O
10	O
.	O
1	O
+	O
/	O
-	O
3	O
.	O
8	O
mm	O
Hg	O
in	O
the	O
HEM	O
and	O
SNP	B-Chemical
gruops	O
,	O
respectively	O
,	O
during	O
hyptoension	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

It	O
is	O
concluded	O
that	O
incerases	O
in	O
the	O
SPV	O
and	O
the	O
delta	O
down	O
are	O
cahracteristic	O
of	O
a	O
hyptoensive	O
state	O
due	O
to	O
a	O
predomiannt	O
decerase	O
in	O
prelaod	O
.	O

They	O
are	O
thus	O
more	O
important	O
during	O
aboslute	O
hypovoleima	O
than	O
during	O
delibertae	O
hypotesnion	O
.	O

Ventriuclar	O
tachyarrhythimas	O
during	O
cesraean	O
sectoin	O
after	O
ritodrnie	B-Chemical
therpay	O
:	O
intreaction	O
with	O
anetshetics	O
.	O

This	O
csae	O
illustrates	O
that	O
ptaients	O
receiving	O
ritdorine	B-Chemical
for	O
prteerm	O
laobr	O
may	O
rsik	O
intearctions	O
between	O
the	O
residaul	O
betamimeitc	O
effcets	O
of	O
ritordine	B-Chemical
and	O
the	O
effects	O
of	O
aneshtetics	O
during	O
cesaraen	O
seciton	O
.	O

Such	O
itneractions	O
may	O
result	O
in	O
serious	O
cradiovascular	O
cmoplications	O
even	O
after	O
cessation	O
of	O
an	O
infuison	O
of	O
rtiodrine	B-Chemical
.	O

Preoperatvie	O
asesssment	O
should	O
focus	O
on	O
cardiovacsular	O
sttaus	O
and	O
seurm	O
potsasium	B-Chemical
lveel	O
.	O

Dealying	O
inductoin	O
of	O
anestheisa	O
should	O
be	O
considered	O
whenever	O
possible	O
.	O

Careful	O
fliud	O
adminsitration	O
and	O
cautious	O
use	O
of	O
ttirated	O
doess	O
of	O
ephedrnie	B-Chemical
are	O
advised	O
.	O

After	O
deilvery	O
of	O
the	O
ifnant	O
,	O
there	O
should	O
be	O
no	O
cotnraindication	O
to	O
the	O
use	O
of	O
an	O
alhpa	O
-	O
ardenergic	O
vsaopressor	O
such	O
as	O
phenylpehrine	B-Chemical
to	O
traet	O
hyptoensive	O
paitents	O
with	O
tachycadria	O
.	O

Vreapamil	B-Chemical
-	O
idnuced	O
carabmazepine	B-Chemical
neurtooxicity	O
.	O

A	O
rpeort	O
of	O
two	O
caess	O
.	O

Two	O
ptaients	O
with	O
sings	O
of	O
carabmazepine	B-Chemical
neurootxicity	O
after	O
combnied	O
treatmnet	O
with	O
veraapmil	B-Chemical
showed	O
complete	O
reocvery	O
after	O
discontinaution	O
of	O
the	O
clacium	B-Chemical
enrty	O
bolcker	O
.	O

Use	O
of	O
vreapamil	B-Chemical
in	O
cmobination	O
with	O
carbamazpeine	B-Chemical
should	O
either	O
be	O
avoided	O
or	O
prescrbied	O
only	O
with	O
appropriate	O
adjustemnt	O
of	O
the	O
carbamazepnie	B-Chemical
dsoe	O
(	O
usually	O
reudction	O
of	O
the	O
cabramazepine	B-Chemical
dsoe	O
by	O
one	O
half	O
)	O
.	O

Paarcetamol	B-Chemical
-	O
associated	O
cmoa	O
,	O
metbaolic	O
acdiosis	O
,	O
rneal	O
and	O
hepaitc	O
fialure	O
.	O

A	O
csae	O
of	O
metbaolic	O
aciodsis	O
,	O
actue	O
rneal	O
failrue	O
and	O
hpeatic	O
fialure	O
following	O
paracetaoml	B-Chemical
ignestion	O
is	O
presented	O
.	O

The	O
diagnsotic	O
diffiuclty	O
at	O
presetnation	O
is	O
highlighted	O
.	O

Contiunous	O
arterioveonus	O
haemoflitration	O
proved	O
a	O
valuable	O
means	O
of	O
maintaining	O
fulid	O
and	O
eelctrolyte	O
blaance	O
.	O

The	O
pateint	O
recovreed	O
.	O

Sxeual	O
dysfucntion	O
among	O
patinets	O
with	O
arhtritis	O
.	O

The	O
relatoinship	O
of	O
arthriits	O
and	O
seuxal	O
dysfucntion	O
was	O
investiagted	O
among	O
169	O
patinets	O
with	O
rheuamtoid	O
atrhritis	O
,	O
osteoartrhitis	O
and	O
sopndyloarthropathy	O
,	O
130	O
of	O
whom	O
were	O
piar	O
-	O
matched	O
to	O
contorls	O
.	O

Asssesments	O
of	O
mariatl	O
hpapiness	O
and	O
depressed	O
mood	O
were	O
also	O
made	O
using	O
the	O
CES	O
-	O
D	O
and	O
the	O
Arzin	O
Martial	O
Hpapiness	O
Sclae	O
(	O
AHMS	O
)	O
.	O

Seuxal	O
dysfunctinos	O
were	O
found	O
to	O
be	O
common	O
among	O
patietns	O
and	O
cnotrols	O
,	O
the	O
majority	O
in	O
both	O
gorups	O
reporting	O
one	O
or	O
more	O
dsyfunctions	O
.	O

Impoetnce	O
was	O
more	O
common	O
among	O
mlae	O
patietns	O
than	O
conrtols	O
and	O
was	O
found	O
to	O
be	O
associated	O
with	O
co	O
-	O
moribdity	O
and	O
the	O
taking	O
of	O
methtorexate	B-Chemical
.	O

Derpessed	O
mood	O
was	O
more	O
common	O
among	O
pateints	O
and	O
was	O
associated	O
with	O
certain	O
seuxal	O
dififculties	O
,	O
but	O
not	O
with	O
ipmotence	O
.	O

Mraital	O
unhpapiness	O
,	O
as	O
indicated	O
by	O
AHMS	O
socres	O
,	O
was	O
not	O
associated	O
with	O
atrhritis	O
but	O
was	O
associated	O
with	O
sexaul	O
dyfsunction	O
,	O
seuxal	O
dissatsifaction	O
and	O
being	O
fmeale	O
.	O

Does	O
paraceatmol	B-Chemical
cause	O
urotheilal	O
cnacer	O
or	O
reanl	O
paipllary	O
necroiss	O
?	O

The	O
rsik	O
of	O
developing	O
reanl	O
paplilary	O
necorsis	O
or	O
canecr	O
of	O
the	O
reanl	O
pevlis	O
,	O
urteer	O
or	O
baldder	O
associated	O
with	O
consupmtion	O
of	O
either	O
phenactein	B-Chemical
or	O
paraectamol	B-Chemical
was	O
calculated	O
from	O
dtaa	O
acquired	O
by	O
quetsionnaire	O
from	O
381	O
csaes	O
and	O
808	O
cnotrols	O
.	O

The	O
rsik	O
of	O
rneal	O
papillray	O
nercosis	O
was	O
incresaed	O
nearly	O
20	O
-	O
fold	O
by	O
consmuption	O
of	O
phencaetin	B-Chemical
,	O
which	O
also	O
increaesd	O
the	O
rsik	O
for	O
cacner	O
of	O
the	O
reanl	O
pevlis	O
and	O
bldader	O
but	O
not	O
for	O
ureteirc	O
cacner	O
.	O

By	O
contrast	O
,	O
we	O
were	O
unable	O
to	O
substantiate	O
an	O
incraesed	O
rsik	O
from	O
praacetamol	B-Chemical
consumpiton	O
for	O
reanl	O
papilalry	O
necroiss	O
or	O
any	O
of	O
these	O
cnacers	O
although	O
there	O
was	O
a	O
suggetsion	O
of	O
an	O
asosciation	O
with	O
canecr	O
of	O
the	O
urteer	O
.	O

Dpasone	B-Chemical
-	O
associated	O
Hienz	O
bdoy	O
hemloytic	O
aenmia	O
in	O
a	O
Cabmodian	O
wmoan	O
with	O
hmeoglobin	O
E	O
tarit	O
.	O

A	O
Camobdian	O
wmoan	O
with	O
hemogloibn	O
E	O
tarit	O
(	O
AE	O
)	O
and	O
leprsoy	O
developed	O
a	O
Hienz	O
bdoy	O
heomlytic	O
aneima	O
while	O
taking	O
a	O
dsoe	O
of	O
dpasone	B-Chemical
(	O
50	O
mg	O
/	O
day	O
)	O
not	O
usually	O
associated	O
with	O
clincial	O
heomlysis	O
.	O

Her	O
red	O
blood	O
cells	O
(	O
RCBs	O
)	O
had	O
incresaed	O
inucbated	O
Heniz	O
bdoy	O
fromation	O
,	O
decraesed	O
reudced	O
glutatihone	B-Chemical
(	O
GSH	B-Chemical
)	O
,	O
and	O
decerased	O
GSH	B-Chemical
stabliity	O
.	O

The	O
penotse	B-Chemical
phoshpate	I-Chemical
shnut	O
actiivty	O
of	O
the	O
daspone	B-Chemical
-	O
expoesd	O
AE	O
RCBs	O
was	O
increaesd	O
compraed	O
to	O
nomral	O
RCBs	O
.	O

Although	O
the	O
AE	O
RCBs	O
from	O
an	O
indviidual	O
not	O
taking	O
daposne	B-Chemical
had	O
increaesd	O
incbuated	O
Heniz	O
bdoy	O
fromation	O
,	O
the	O
GSH	B-Chemical
contnet	O
and	O
GSH	B-Chemical
stbaility	O
were	O
nromal	O
.	O

The	O
penotse	B-Chemical
phoshpate	I-Chemical
shnut	O
actiivty	O
of	O
the	O
non	O
-	O
dpasone	B-Chemical
-	O
exopsed	O
AE	O
RCBs	O
was	O
decreaesd	O
compraed	O
to	O
nromal	O
RCBs	O
.	O

Thus	O
,	O
AE	O
RCBs	O
appear	O
to	O
have	O
an	O
inrceased	O
sesnitivity	O
to	O
oixdant	O
sterss	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
since	O
daposne	B-Chemical
does	O
not	O
cause	O
hemoyltic	O
aenmia	O
at	O
this	O
dsoe	O
in	O
hematoolgically	O
nromal	O
individulas	O
.	O

Given	O
the	O
ifnlux	O
of	O
Suotheast	O
Asinas	O
into	O
the	O
Untied	O
Sttaes	O
,	O
oixdant	O
mediactions	O
should	O
be	O
used	O
with	O
caution	O
,	O
especially	O
if	O
an	O
infectoin	O
is	O
present	O
,	O
in	O
individauls	O
of	O
etnhic	O
backgrounds	O
that	O
have	O
an	O
increaesd	O
pervalence	O
of	O
hemoglboin	O
E	O
.	O

Seevre	O
complicaitons	O
of	O
antianignal	O
durg	O
threapy	O
in	O
a	O
paitent	O
idenitfied	O
as	O
a	O
poor	O
metabloizer	O
of	O
mteoprolol	B-Chemical
,	O
propaefnone	B-Chemical
,	O
diltaizem	B-Chemical
,	O
and	O
spartenie	B-Chemical
.	O

A	O
47	O
-	O
yaer	O
-	O
old	O
patinet	O
sufefring	O
from	O
coronray	O
atrery	O
diesase	O
was	O
admtited	O
to	O
the	O
CCU	O
in	O
sohck	O
with	O
III	O
.	O

AV	O
bolck	O
,	O
sveere	O
hypotesnion	O
,	O
and	O
imapirment	O
of	O
ventricualr	O
fucntion	O
.	O

One	O
week	O
prior	O
to	O
admissoin	O
a	O
thearpy	O
with	O
satndard	O
dsoes	O
of	O
metorpolol	B-Chemical
(	O
100	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
and	O
then	O
100	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
had	O
been	O
initiated	O
.	O

Two	O
dyas	O
before	O
amdission	O
dlitiazem	B-Chemical
(	O
60	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
was	O
precsribed	O
in	O
addition	O
.	O

Anlayses	O
of	O
a	O
blood	O
smaple	O
reveaeld	O
unsuually	O
high	O
plamsa	O
conecntrations	O
of	O
metoporlol	B-Chemical
(	O
greater	O
than	O
3000	O
ng	O
/	O
ml	O
)	O
and	O
ditliazem	B-Chemical
(	O
526	O
ng	O
/	O
ml	O
)	O
.	O

The	O
ptaient	O
reocvered	O
within	O
1	O
week	O
following	O
dsicontinuation	O
of	O
antiangnial	O
therpay	O
.	O

Three	O
motnhs	O
later	O
the	O
patinet	O
was	O
exopsed	O
to	O
a	O
single	O
dsoe	O
of	O
meotprolol	B-Chemical
,	O
ditliazem	B-Chemical
,	O
proapfenone	B-Chemical
(	O
since	O
he	O
had	O
received	O
this	O
durg	O
in	O
the	O
past	O
)	O
,	O
and	O
spartiene	B-Chemical
(	O
as	O
a	O
porbe	O
for	O
the	O
debrisoqiune	B-Chemical
/	O
sprateine	B-Chemical
tpye	O
polymorhpism	O
of	O
oxidaitve	O
durg	O
mteabolism	O
)	O
.	O

It	O
was	O
found	O
that	O
he	O
was	O
a	O
poor	O
mteabolizer	O
of	O
all	O
four	O
drgus	O
,	O
indicating	O
that	O
their	O
metaboilsm	O
is	O
under	O
the	O
same	O
gneetic	O
cotnrol	O
.	O

Therefore	O
,	O
ptaients	O
belonging	O
to	O
the	O
poor	O
-	O
meatbolizer	O
phneotype	O
of	O
spartiene	B-Chemical
/	O
derbisoquine	B-Chemical
polmyorphism	O
in	O
durg	O
metaboilsm	O
,	O
which	O
constitutes	O
6	O
.	O
4	O
%	O
of	O
the	O
Greman	O
popultaion	O
,	O
may	O
expereince	O
advesre	O
durg	O
reactoins	O
when	O
tretaed	O
with	O
stadnard	O
doess	O
of	O
one	O
of	O
these	O
drgus	O
alone	O
.	O

Moreover	O
,	O
the	O
caodministration	O
of	O
these	O
frequently	O
used	O
drgus	O
is	O
expected	O
to	O
be	O
especially	O
harmful	O
in	O
this	O
subrgoup	O
of	O
patinets	O
.	O

Clniical	O
experiecnes	O
in	O
an	O
open	O
and	O
a	O
double	O
-	O
bilnd	O
tiral	O
.	O

A	O
total	O
of	O
sixty	O
patinets	O
were	O
traetd	O
with	O
brmoperidol	B-Chemical
first	O
in	O
open	O
condiitons	O
(	O
20	O
ptaients	O
)	O
,	O
then	O
on	O
a	O
double	O
bilnd	O
basis	O
(	O
40	O
paitents	O
)	O
with	O
haloperiodl	B-Chemical
as	O
the	O
rfeerence	O
sbustance	O
.	O

The	O
open	O
stduy	O
lasted	O
for	O
four	O
weeks	O
;	O
the	O
durg	O
was	O
amdinistrated	O
in	O
the	O
form	O
of	O
1	O
mg	O
tabelts	O
.	O

The	O
dialy	O
dsoe	O
(	O
initial	O
dsoe	O
:	O
1	O
mg	O
;	O
mean	O
dsoe	O
at	O
the	O
end	O
of	O
the	O
tiral	O
:	O
4	O
.	O
47	O
mg	O
)	O
was	O
always	O
adminisetred	O
in	O
one	O
single	O
dsoe	O
.	O

Nineteen	O
paitents	O
finished	O
the	O
tiral	O
,	O
and	O
in	O
18	O
caess	O
the	O
therapeuitc	O
result	O
was	O
considered	O
very	O
good	O
to	O
good	O
.	O

These	O
resutls	O
were	O
confirmed	O
by	O
statisitcal	O
analsyis	O
.	O

Nine	O
patietns	O
exhibited	O
mlid	O
to	O
moedrate	O
extarpyramidal	O
concomiatnt	O
sypmtoms	O
;	O
no	O
other	O
side	O
effects	O
were	O
observed	O
.	O

The	O
resluts	O
of	O
detailed	O
laboartory	O
tetss	O
and	O
evaluatoins	O
of	O
various	O
qauntitative	O
and	O
qualitatvie	O
toleraiblity	O
paraemters	O
were	O
not	O
indicaitve	O
of	O
toixc	O
effcets	O
.	O

In	O
the	O
double	O
bilnd	O
stduy	O
with	O
haloperdiol	B-Chemical
,	O
both	O
subsatnces	O
were	O
found	O
to	O
be	O
highly	O
effecitve	O
in	O
the	O
treatemnt	O
of	O
psychoitc	O
syndroems	O
belonging	O
predominantly	O
to	O
the	O
shcizophrenia	O
gorup	O
.	O

Certain	O
clues	O
,	O
including	O
the	O
onset	O
of	O
aciton	O
,	O
seem	O
to	O
be	O
inidcative	O
of	O
the	O
superiority	O
of	O
brompreidol	B-Chemical
.	O

No	O
diffeernces	O
were	O
observed	O
with	O
respect	O
to	O
side	O
effetcs	O
and	O
general	O
tolerabiilty	O
.	O

Proolnged	O
choelstasis	O
after	O
trolaendomycin	B-Chemical
-	O
inudced	O
aucte	O
heptaitis	O
.	O

We	O
reprot	O
the	O
csae	O
of	O
a	O
pateint	O
in	O
whom	O
trolenadomycin	B-Chemical
-	O
idnuced	O
hepatiits	O
was	O
followed	O
by	O
prolonegd	O
anciteric	O
cholsetasis	O
.	O

Janudice	O
occurred	O
after	O
adminsitration	O
of	O
troleadnomycin	B-Chemical
for	O
7	O
dyas	O
and	O
was	O
associated	O
with	O
hypereosinohpilia	O
.	O

Jaudnice	O
disappeared	O
within	O
3	O
motnhs	O
but	O
was	O
followed	O
by	O
prologned	O
anicetric	O
choelstasis	O
marked	O
by	O
pruirtus	O
and	O
high	O
lveels	O
of	O
alakline	O
phosphaatse	O
and	O
gammaglutamyltranfserase	O
activiteis	O
.	O

Finally	O
,	O
pruirtus	O
disappeared	O
within	O
19	O
mnoths	O
,	O
and	O
lievr	O
tetss	O
returned	O
to	O
nromal	O
27	O
monhts	O
after	O
the	O
onset	O
of	O
heptaitis	O
.	O

This	O
observatoin	O
demonstrates	O
that	O
porlonged	O
cohlestasis	O
can	O
follow	O
troleandomyicn	B-Chemical
-	O
idnuced	O
actue	O
heaptitis	O
.	O

Seiral	O
stduies	O
of	O
audiotry	O
neurotoxciity	O
in	O
pateints	O
receiving	O
deferoxaimne	B-Chemical
threapy	O
.	O

Vsiual	O
and	O
audiotry	O
neruotoxicity	O
was	O
previously	O
documetned	O
in	O
42	O
of	O
89	O
patietns	O
with	O
transufsion	O
-	O
depenednt	O
aneima	O
who	O
were	O
receiving	O
iorn	B-Chemical
cheltaion	O
tehrapy	O
with	O
dialy	O
subcutaneuos	O
defeorxamine	B-Chemical
.	O

Twenty	O
-	O
two	O
patietns	O
in	O
the	O
affected	O
gorup	O
had	O
anbormal	O
audiorgams	O
with	O
deifcits	O
mostly	O
in	O
the	O
high	O
freuqency	O
range	O
of	O
4	O
,	O
000	O
to	O
8	O
,	O
000	O
Hz	O
and	O
in	O
the	O
heairng	O
threshlod	O
lveels	O
of	O
30	O
to	O
100	O
decibles	O
.	O

When	O
defreoxamine	B-Chemical
therpay	O
was	O
discontineud	O
and	O
sreial	O
stduies	O
were	O
performed	O
,	O
audoigrams	O
in	O
seven	O
csaes	O
reveretd	O
to	O
nomral	O
or	O
near	O
nomral	O
within	O
two	O
to	O
three	O
weeks	O
,	O
and	O
nine	O
of	O
13	O
ptaients	O
with	O
sypmtoms	O
became	O
asmyptomatic	O
.	O

Auidograms	O
from	O
15	O
patinets	O
remained	O
abnromal	O
and	O
four	O
patinets	O
required	O
heraing	O
aids	O
because	O
of	O
pemranent	O
disabiilty	O
.	O

Since	O
18	O
of	O
the	O
22	O
patinets	O
were	O
initially	O
receiving	O
defeorxamine	B-Chemical
doess	O
in	O
execss	O
of	O
the	O
commonly	O
recomemnded	O
50	O
mg	O
/	O
kg	O
per	O
dsoe	O
,	O
therpay	O
was	O
resatrted	O
with	O
lwoer	O
doess	O
,	O
usually	O
50	O
mg	O
/	O
kg	O
per	O
dsoe	O
or	O
less	O
depending	O
on	O
the	O
dergee	O
of	O
audtiory	O
abnormailty	O
,	O
and	O
with	O
the	O
exception	O
of	O
two	O
caess	O
no	O
further	O
toxiicty	O
was	O
demonstrated	O
.	O

Auidtory	O
deteriroation	O
and	O
imprvoement	O
,	O
demonstrated	O
serially	O
in	O
idnividual	O
pateints	O
receiving	O
and	O
not	O
receiving	O
defreoxamine	B-Chemical
,	O
respectively	O
,	O
provided	O
convincing	O
evidecne	O
for	O
a	O
cause	O
-	O
and	O
-	O
effcet	O
relation	O
between	O
deferoxaimne	B-Chemical
adminitsration	O
and	O
ototoxictiy	O
.	O

Based	O
on	O
these	O
dtaa	O
,	O
a	O
paln	O
of	O
manaegment	O
was	O
developed	O
that	O
allows	O
efefctive	O
yet	O
safe	O
administrtaion	O
of	O
deferoxamnie	B-Chemical
.	O

A	O
dsoe	O
of	O
50	O
mg	O
/	O
kg	O
is	O
recommenedd	O
in	O
those	O
without	O
audiorgam	O
anbormalities	O
.	O

With	O
mlid	O
toxciity	O
,	O
a	O
rdeuction	O
to	O
30	O
or	O
40	O
mg	O
/	O
kg	O
per	O
dsoe	O
should	O
result	O
in	O
a	O
reevrsal	O
of	O
the	O
abnoraml	O
resluts	O
to	O
nromal	O
within	O
four	O
wekes	O
.	O

Modertae	O
abnormaltiies	O
require	O
a	O
reductoin	O
of	O
defreoxamine	B-Chemical
to	O
25	O
mg	O
/	O
kg	O
per	O
dsoe	O
with	O
careful	O
moniotring	O
.	O

In	O
those	O
with	O
symtpoms	O
of	O
haering	O
lsos	O
,	O
the	O
durg	O
should	O
be	O
stopped	O
for	O
four	O
wekes	O
,	O
and	O
when	O
the	O
aduiogram	O
is	O
satble	O
or	O
imporved	O
,	O
thearpy	O
should	O
be	O
restaretd	O
at	O
10	O
to	O
25	O
mg	O
/	O
kg	O
per	O
dsoe	O
.	O

Seiral	O
audiogrmas	O
should	O
be	O
performed	O
every	O
six	O
monhts	O
in	O
those	O
without	O
problmes	O
and	O
more	O
frequently	O
in	O
yonug	O
pateints	O
with	O
nromal	O
seurm	O
ferrtiin	O
valeus	O
and	O
in	O
those	O
with	O
aduitory	O
dysfunciton	O
.	O

Lidociane	B-Chemical
-	O
idnuced	O
cadriac	O
assytole	O
.	O

Intravneous	O
administraiton	O
of	O
a	O
single	O
50	O
-	O
mg	O
bouls	O
of	O
lidcoaine	B-Chemical
in	O
a	O
67	O
-	O
yaer	O
-	O
old	O
man	O
resulted	O
in	O
prfoound	O
depressoin	O
of	O
the	O
acitvity	O
of	O
the	O
sionatrial	O
and	O
atriovenrticular	O
noadl	O
pcaemakers	O
.	O

The	O
paitent	O
had	O
no	O
apparnet	O
associated	O
conidtions	O
which	O
might	O
have	O
perdisposed	O
him	O
to	O
the	O
dveelopment	O
of	O
braydarrhythmias	O
;	O
and	O
,	O
thus	O
,	O
this	O
probably	O
represented	O
a	O
true	O
idoisyncrasy	O
to	O
lidcoaine	B-Chemical
.	O

Fluribprofen	B-Chemical
in	O
the	O
treamtent	O
of	O
juvneile	O
rhuematoid	O
arthrtiis	O
.	O

Thirty	O
-	O
four	O
patietns	O
with	O
juvenlie	O
rheumatiod	O
arthriits	O
,	O
who	O
were	O
treaetd	O
with	O
fluribprofen	B-Chemical
at	O
a	O
maxmium	O
dsoe	O
of	O
4	O
mg	O
/	O
kg	O
/	O
day	O
,	O
had	O
statisitcally	O
significant	O
decresaes	O
from	O
baseilne	O
in	O
6	O
atrhritis	O
indcies	O
after	O
12	O
wekes	O
of	O
teratment	O
.	O

Imporvements	O
were	O
seen	O
in	O
the	O
number	O
of	O
tneder	O
joitns	O
,	O
the	O
sevreity	O
of	O
sewlling	O
and	O
tenedrness	O
,	O
the	O
tmie	O
of	O
wlak	O
50	O
feet	O
,	O
the	O
durtaion	O
of	O
mornnig	O
sitffness	O
and	O
the	O
cricumference	O
of	O
the	O
lfet	O
kene	O
.	O

The	O
most	O
frequently	O
observed	O
side	O
effcet	O
was	O
fceal	O
occlut	O
bolod	O
(	O
25	O
%	O
of	O
patietns	O
)	O
;	O
however	O
,	O
there	O
was	O
no	O
other	O
evdience	O
of	O
gastroitnestinal	O
(	O
GI	O
)	O
bleeidng	O
in	O
these	O
paitents	O
.	O

One	O
pateint	O
was	O
permaturely	O
disconitnued	O
from	O
the	O
stduy	O
for	O
sveere	O
heaadche	O
and	O
adbominal	O
pian	O
.	O

Most	O
side	O
effcets	O
were	O
mlid	O
and	O
related	O
to	O
the	O
GI	O
tarct	O
.	O

Hypekralemia	O
associated	O
with	O
suilndac	B-Chemical
thearpy	O
.	O

Hyperkaelmia	O
has	O
recently	O
been	O
recognized	O
as	O
a	O
complciation	O
of	O
nonsterodial	O
antiniflammatory	O
agetns	O
(	O
NASID	O
)	O
such	O
as	O
indomethaicn	B-Chemical
.	O

Several	O
recent	O
stduies	O
have	O
stresesd	O
the	O
rneal	O
sparing	O
faetures	O
of	O
sluindac	B-Chemical
,	O
owing	O
to	O
its	O
lcak	O
of	O
intefrerence	O
with	O
rneal	O
prostcayclin	B-Chemical
synthseis	O
.	O

We	O
describe	O
4	O
pateints	O
in	O
whom	O
hyperkaelmia	O
ranging	O
from	O
6	O
.	O
1	O
to	O
6	O
.	O
9	O
mEq	O
/	O
l	O
developed	O
within	O
3	O
to	O
8	O
dyas	O
of	O
sulinadc	B-Chemical
admiinstration	O
.	O

In	O
all	O
of	O
them	O
noraml	O
sreum	O
potassium	B-Chemical
levles	O
reached	O
within	O
2	O
to	O
4	O
dyas	O
of	O
stopping	O
sulnidac	B-Chemical
.	O

As	O
no	O
other	O
medicatoins	O
known	O
to	O
efefct	O
sreum	O
potsasium	B-Chemical
had	O
been	O
given	O
concomitantly	O
,	O
this	O
cuorse	O
of	O
evnets	O
is	O
suggestive	O
of	O
a	O
cause	O
-	O
and	O
-	O
effcet	O
relatinoship	O
between	O
suilndac	B-Chemical
and	O
hyperkalmeia	O
.	O

These	O
observaitons	O
indicate	O
that	O
initial	O
hopes	O
that	O
suilndac	B-Chemical
may	O
not	O
be	O
associated	O
with	O
the	O
advesre	O
rneal	O
effects	O
of	O
other	O
NSIAD	O
are	O
probably	O
not	O
justified	O
.	O

Durg	O
-	O
indcued	O
aretrial	O
spsam	O
releived	O
by	O
ldiocaine	B-Chemical
.	O

Csae	O
reprot	O
.	O

Following	O
major	O
itnracranial	O
surgrey	O
in	O
a	O
35	O
-	O
yaer	O
-	O
old	O
man	O
,	O
soduim	B-Chemical
pentotahl	I-Chemical
was	O
inrtavenously	O
ifnused	O
to	O
minimize	O
creebral	O
icshaemia	O
.	O

Intnese	O
vasosapsm	O
with	O
threatneed	O
gangerne	O
arose	O
in	O
the	O
arm	O
used	O
for	O
the	O
inufsion	O
.	O

Since	O
the	O
carnial	O
condtiion	O
precluded	O
use	O
of	O
more	O
usual	O
mtehods	O
,	O
lidcoaine	B-Chemical
was	O
given	O
itnra	O
-	O
arteirally	O
,	O
with	O
careful	O
cardiovascualr	O
monitroing	O
,	O
to	O
counteract	O
the	O
vaosspasm	O
.	O

The	O
tretament	O
was	O
rapidly	O
successful	O
.	O

Reginoal	O
localizatoin	O
of	O
the	O
antgaonism	O
of	O
amphetaimne	B-Chemical
-	O
inudced	O
hypearctivity	O
by	O
inrtacerebral	O
clacitonin	B-Chemical
injcetions	O
.	O

Calciotnin	B-Chemical
reecptors	O
are	O
found	O
in	O
the	O
brian	O
,	O
and	O
intraecrebral	O
infuisons	O
of	O
calciotnin	B-Chemical
can	O
produce	O
behavoiral	O
effcets	O
.	O

Among	O
these	O
behaviroal	O
effects	O
are	O
dcereases	O
in	O
food	O
inatke	O
and	O
derceases	O
in	O
apmhetamine	B-Chemical
-	O
inudced	O
lcoomotor	O
activtiy	O
.	O

In	O
previous	O
epxeriments	O
we	O
found	O
that	O
dcereases	O
in	O
food	O
itnake	O
were	O
indcued	O
by	O
lcoal	O
admiinstration	O
of	O
clacitonin	B-Chemical
into	O
several	O
hypothlaamic	O
siets	O
and	O
into	O
the	O
nucelus	O
accumbens	O
.	O

In	O
the	O
present	O
experiemnt	O
calciotnin	B-Chemical
decresaed	O
lcoomotor	O
actiivty	O
when	O
loaclly	O
injecetd	O
into	O
the	O
same	O
siets	O
where	O
it	O
derceases	O
food	O
intkae	O
.	O

The	O
areas	O
where	O
calcitoinn	B-Chemical
is	O
most	O
effetcive	O
in	O
dcereasing	O
locoomtor	O
actiivty	O
are	O
located	O
in	O
the	O
hpyothalamus	O
and	O
nuclues	O
accumbens	O
,	O
suggesting	O
that	O
these	O
areas	O
are	O
the	O
major	O
siets	O
of	O
actoin	O
of	O
clacitonin	B-Chemical
in	O
inhbiiting	O
ampheatmine	B-Chemical
-	O
inudced	O
locmootor	O
actviity	O
.	O

The	O
hematloogic	O
effetcs	O
of	O
cefnoicid	B-Chemical
and	O
cefazdeone	B-Chemical
in	O
the	O
dog	O
:	O
a	O
ptoential	O
mdoel	O
of	O
cpehalosporin	B-Chemical
heamtotoxicity	O
in	O
man	O
.	O

Cephlaosporin	B-Chemical
antibitoics	O
cause	O
a	O
variety	O
of	O
hmeatologic	O
distubrances	O
in	O
man	O
,	O
the	O
pathoegneses	O
and	O
hematpoathology	O
of	O
which	O
remain	O
poorly	O
charcaterized	O
.	O

There	O
is	O
a	O
need	O
for	O
a	O
well	O
-	O
defined	O
aniaml	O
moedl	O
in	O
which	O
these	O
bolod	O
dyscrsaias	O
can	O
be	O
studied	O
.	O

In	O
four	O
sbuacute	O
toxciity	O
sutdies	O
,	O
the	O
intrvaenous	O
admniistration	O
of	O
cefonciid	B-Chemical
or	O
cefazdeone	B-Chemical
to	O
baegle	O
dgos	O
caused	O
a	O
dsoe	O
-	O
deepndent	O
incidecne	O
of	O
anmeia	O
,	O
neutropneia	O
,	O
and	O
trhombocytopenia	O
after	O
1	O
-	O
3	O
motnhs	O
of	O
tretament	O
.	O

A	O
nonregneerative	O
aneima	O
was	O
the	O
most	O
compromiisng	O
of	O
the	O
cytopneias	O
and	O
occurred	O
in	O
approximately	O
50	O
%	O
of	O
dgos	O
receiving	O
400	O
-	O
500	O
mg	O
/	O
kg	O
cefoincid	B-Chemical
or	O
540	O
-	O
840	O
mg	O
/	O
kg	O
cefazednoe	B-Chemical
.	O

All	O
three	O
cyotpenias	O
were	O
completely	O
reversible	O
following	O
csesation	O
of	O
teratment	O
;	O
the	O
tmie	O
required	O
for	O
recvoery	O
of	O
the	O
eyrthron	O
(	O
approximately	O
1	O
motnh	O
)	O
was	O
considerably	O
longer	O
than	O
that	O
of	O
the	O
grnaulocytes	O
and	O
plateltes	O
(	O
hours	O
to	O
a	O
few	O
dyas	O
)	O
.	O

Upon	O
rechalelnge	O
with	O
either	O
cephaolsporin	B-Chemical
,	O
the	O
hematoolgic	O
syndorme	O
was	O
reproduced	O
in	O
most	O
dgos	O
tetsed	O
;	O
ceofnicid	B-Chemical
(	O
but	O
not	O
cefazeodne	B-Chemical
)	O
-	O
treaetd	O
dgos	O
showed	O
a	O
substantially	O
reudced	O
inudction	O
peroid	O
(	O
15	O
+	O
/	O
-	O
5	O
dyas	O
)	O
cmopared	O
to	O
that	O
of	O
the	O
first	O
exopsure	O
to	O
the	O
durg	O
(	O
61	O
+	O
/	O
-	O
24	O
dyas	O
)	O
.	O

This	O
osbervation	O
,	O
along	O
with	O
the	O
rpaid	O
rtae	O
of	O
delcine	O
in	O
red	O
clel	O
msas	O
parameetrs	O
of	O
affetced	O
dgos	O
,	O
suggests	O
that	O
a	O
hemoyltic	O
component	O
compilcated	O
the	O
red	O
clel	O
prodcution	O
porblem	O
and	O
that	O
multilpe	O
toxciologic	O
mechansims	O
contributed	O
to	O
the	O
ctyopenia	O
.	O

We	O
conclude	O
that	O
the	O
admniistration	O
of	O
high	O
dsoes	O
of	O
cefoincid	B-Chemical
or	O
ceafzedone	B-Chemical
to	O
dgos	O
can	O
inudce	O
hematotoixcity	O
similar	O
to	O
the	O
cepahlosporin	B-Chemical
-	O
inudced	O
blood	O
dyscrsaias	O
described	O
in	O
man	O
and	O
thus	O
provides	O
a	O
useful	O
mdoel	O
for	O
studying	O
the	O
mehcanisms	O
of	O
these	O
disoredrs	O
.	O

Cererbal	O
bolod	O
folw	O
and	O
meatbolism	O
during	O
isfolurane	B-Chemical
-	O
idnuced	O
hypotesnion	O
in	O
ptaients	O
subjected	O
to	O
suregry	O
for	O
cerebarl	O
aneursyms	O
.	O

Cererbal	O
bolod	O
folw	O
and	O
cerebarl	O
metabloic	O
rtae	O
for	O
oxyegn	B-Chemical
were	O
measuerd	O
during	O
isolfurane	B-Chemical
-	O
indcued	O
hypotenison	O
in	O
10	O
ptaients	O
subjected	O
to	O
carniotomy	O
for	O
clpiping	O
of	O
a	O
cererbal	O
anuerysm	O
.	O

Folw	O
and	O
metabolsim	O
were	O
mesaured	O
5	O
-	O
13	O
dyas	O
after	O
the	O
subarachniod	O
haeomrrhage	O
by	O
a	O
modifiaction	O
of	O
the	O
classical	O
Ktey	O
-	O
Schmidt	O
tehcnique	O
using	O
xneon	B-Chemical
-	O
133	O
i	O
.	O
v	O
.	O
Aanesthesia	O
was	O
maintained	O
with	O
an	O
inspierd	O
isoflruane	B-Chemical
cocnentration	O
of	O
0	O
.	O
75	O
%	O
(	O
plus	O
67	O
%	O
ntirous	B-Chemical
oixde	I-Chemical
in	O
oyxgen	B-Chemical
)	O
,	O
during	O
which	O
CBF	O
and	O
CRMO2	O
were	O
34	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
1	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
and	O
2	O
.	O
32	O
+	O
/	O
-	O
0	O
.	O
16	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
at	O
PCaO2	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
.	O

Conrtolled	O
hyoptension	O
to	O
an	O
aevrage	O
MAP	O
of	O
50	O
-	O
55	O
mm	O
Hg	B-Chemical
was	O
indcued	O
by	O
increasnig	O
the	O
dsoe	O
of	O
isofulrane	B-Chemical
,	O
and	O
maintained	O
at	O
an	O
insipred	O
concentraiton	O
of	O
2	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
%	O
.	O

This	O
resulted	O
in	O
a	O
significant	O
dercease	O
in	O
CRMO2	O
(	O
to	O
1	O
.	O
73	O
+	O
/	O
-	O
0	O
.	O
16	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
)	O
,	O
while	O
CBF	O
was	O
unhcanged	O
.	O

After	O
the	O
clipping	O
of	O
the	O
aneruysm	O
the	O
isofulrane	B-Chemical
concentrtaion	O
was	O
redcued	O
to	O
0	O
.	O
75	O
%	O
.	O

There	O
was	O
a	O
significant	O
icnrease	O
in	O
CBF	O
,	O
although	O
CRMO2	O
was	O
unchanegd	O
,	O
compraed	O
with	O
pre	O
-	O
hypotensvie	O
valeus	O
.	O

These	O
chnages	O
might	O
offer	O
portection	O
to	O
barin	O
tisuse	O
during	O
preiods	O
of	O
induecd	O
hyptoension	O
.	O

Triaozlam	B-Chemical
-	O
inudced	O
brief	O
eipsodes	O
of	O
secondary	O
mnaia	O
in	O
a	O
derpessed	O
ptaient	O
.	O

Large	O
doess	O
of	O
triaozlam	B-Chemical
repeatedly	O
idnuced	O
brief	O
epsiodes	O
of	O
maina	O
in	O
a	O
deprsesed	O
eledrly	O
wmoan	O
.	O

Feautres	O
of	O
ogranic	O
metnal	O
diosrder	O
(	O
delriium	O
)	O
were	O
not	O
present	O
.	O

Mnaic	O
exciteemnt	O
was	O
conicident	O
with	O
the	O
durtaion	O
of	O
atcion	O
of	O
triazloam	B-Chemical
.	O

The	O
possible	O
contribution	O
of	O
the	O
traizolo	B-Chemical
gorup	O
to	O
chagnes	O
in	O
affetcive	O
sttaus	O
is	O
discussed	O
.	O

The	O
correlatoin	O
between	O
nuerotoxic	O
estrease	O
inhbiition	O
and	O
miapfox	B-Chemical
-	O
indcued	O
neuroptahic	O
daamge	O
in	O
rtas	O
.	O

The	O
crorelation	O
between	O
neuorpathic	O
dmaage	O
and	O
ihnibition	O
of	O
nuerotoxic	O
etserase	O
or	O
neruopathy	O
tagret	O
eznyme	O
(	O
NTE	O
)	O
was	O
examined	O
in	O
rtas	O
acutely	O
expsoed	O
to	O
Mipaofx	B-Chemical
(	O
N	B-Chemical
,	I-Chemical
N	I-Chemical
'	I-Chemical
-	I-Chemical
diisopropylpohsphorodiamidofluoridate	I-Chemical
)	O
,	O
a	O
neurotoixc	O
oragnophosphate	B-Chemical
.	O

Barin	O
and	O
spnial	O
crod	O
NTE	O
activtiies	O
were	O
meausred	O
in	O
Lnog	O
-	O
Eavns	O
mlae	O
rtas	O
1	O
hr	O
psot	O
-	O
exopsure	O
to	O
various	O
dosaegs	O
of	O
Mipaofx	B-Chemical
(	O
ip	O
,	O
1	O
-	O
15	O
mg	O
/	O
kg	O
)	O
.	O

These	O
dtaa	O
were	O
crorelated	O
with	O
hisotlogically	O
socred	O
cevrical	O
crod	O
daamge	O
in	O
a	O
separate	O
gruop	O
of	O
similarly	O
doesd	O
rtas	O
smapled	O
14	O
-	O
21	O
dyas	O
psot	O
-	O
exopsure	O
.	O

Those	O
doasges	O
(	O
greater	O
than	O
or	O
eqaul	O
to	O
10	O
mg	O
/	O
kg	O
)	O
that	O
inhibtied	O
mean	O
NTE	O
actviity	O
in	O
the	O
sipnal	O
crod	O
greater	O
than	O
or	O
euqal	O
to	O
73	O
%	O
and	O
barin	O
greater	O
than	O
or	O
euqal	O
to	O
67	O
%	O
of	O
contorl	O
vlaues	O
produced	O
sveere	O
(	O
greater	O
than	O
or	O
euqal	O
to	O
3	O
)	O
cervcial	O
crod	O
ptahology	O
in	O
85	O
%	O
of	O
the	O
rtas	O
.	O

In	O
contrast	O
,	O
dosgaes	O
of	O
Miapfox	B-Chemical
(	O
less	O
than	O
or	O
eqaul	O
to	O
5	O
mg	O
/	O
kg	O
)	O
which	O
inihbited	O
mean	O
NTE	O
acitvity	O
in	O
sipnal	O
crod	O
less	O
than	O
or	O
euqal	O
to	O
61	O
%	O
and	O
brian	O
less	O
than	O
or	O
euqal	O
to	O
60	O
%	O
produced	O
this	O
dgeree	O
of	O
crod	O
dmaage	O
in	O
only	O
9	O
%	O
of	O
the	O
aniamls	O
.	O

These	O
dtaa	O
indicate	O
that	O
a	O
critical	O
percnetage	O
of	O
NTE	O
inhibiiton	O
in	O
brian	O
and	O
spianl	O
crod	O
smapled	O
shortly	O
after	O
Mipaofx	B-Chemical
exposrue	O
can	O
predict	O
nueropathic	O
dmaage	O
in	O
rtas	O
several	O
weeks	O
later	O
.	O

Allergic	O
reactoin	O
to	O
5	B-Chemical
-	I-Chemical
fluororuacil	I-Chemical
inufsion	O
.	O

An	O
allregic	O
reatcion	O
consisting	O
of	O
anigoneurotic	O
edmea	O
secondary	O
to	O
continouus	O
ifnusion	O
5	B-Chemical
-	I-Chemical
fulorouracil	I-Chemical
occurred	O
in	O
a	O
ptaient	O
with	O
rceurrent	O
cacrinoma	O
of	O
the	O
oarl	O
caivty	O
,	O
cirhrosis	O
,	O
and	O
cipslatin	B-Chemical
-	O
induecd	O
impaierd	O
rneal	O
funtcion	O
.	O

This	O
reatcion	O
occurred	O
during	O
the	O
sixth	O
and	O
seventh	O
couress	O
of	O
infusinoal	O
chmeotherapy	O
.	O

Oarl	O
dipehnhydramine	B-Chemical
and	O
prendisone	B-Chemical
were	O
ineffectvie	O
in	O
preventing	O
the	O
recurrnece	O
of	O
the	O
allergic	O
recation	O
.	O

Dsicontinuance	O
of	O
effcetive	O
cehmotherapy	O
in	O
this	O
pateint	O
during	O
patrial	O
rmeission	O
resulted	O
in	O
ftaal	O
diesase	O
progresison	O
.	O

Myastheina	O
graivs	O
caused	O
by	O
penicillaimne	B-Chemical
and	O
chloorquine	B-Chemical
threapy	O
for	O
rheumaotid	O
arthrtiis	O
.	O

We	O
have	O
described	O
a	O
uinque	O
patinet	O
who	O
had	O
reversible	O
and	O
dsoe	O
-	O
related	O
maysthenia	O
garvis	O
after	O
peniclilamine	B-Chemical
and	O
chlorqouine	B-Chemical
threapy	O
for	O
rhuematoid	O
atrhritis	O
.	O

Although	O
acetyclholine	B-Chemical
rceeptor	O
antiobdies	O
were	O
not	O
detcetable	O
,	O
the	O
tmie	O
cuorse	O
was	O
consistent	O
with	O
an	O
autoimmnue	O
prcoess	O
.	O

On	O
the	O
mechansims	O
of	O
the	O
develompent	O
of	O
tolreance	O
to	O
the	O
musuclar	O
rigiidty	O
produced	O
by	O
mrophine	B-Chemical
in	O
rtas	O
.	O

The	O
develompent	O
of	O
toelrance	O
to	O
the	O
musuclar	O
rigdiity	O
produced	O
by	O
morhpine	B-Chemical
was	O
studied	O
in	O
rtas	O
.	O

Slaine	O
-	O
prerteated	O
cnotrols	O
given	O
a	O
tset	O
dsoe	O
of	O
moprhine	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
showed	O
a	O
pronounced	O
rigidtiy	O
recorded	O
as	O
tnoic	O
activtiy	O
in	O
the	O
electrmoyogram	O
.	O

Rtas	O
terated	O
for	O
11	O
dyas	O
with	O
moprhine	B-Chemical
and	O
withdrawn	O
for	O
36	O
-	O
40	O
h	O
showed	O
differneces	O
in	O
the	O
develompent	O
of	O
toleracne	O
:	O
about	O
half	O
of	O
the	O
animlas	O
showed	O
a	O
rigidtiy	O
after	O
the	O
tset	O
dsoe	O
of	O
morhpine	B-Chemical
that	O
was	O
not	O
significantly	O
less	O
than	O
in	O
the	O
contorls	O
and	O
were	O
aiknetic	O
(	O
A	O
gruop	O
)	O
.	O

The	O
other	O
rtas	O
showed	O
a	O
strong	O
decresae	O
in	O
the	O
rigiidty	O
and	O
the	O
occrurence	O
of	O
steretoyped	O
(	O
S	O
)	O
likcing	O
and	O
/	O
or	O
gnwaing	O
in	O
presecne	O
of	O
aiknetic	O
or	O
hyprekinetic	O
(	O
K	O
)	O
behavoiur	O
(	O
AS	O
/	O
KS	O
gruop	O
)	O
,	O
suggesting	O
sgins	O
of	O
dpoaminergic	O
atcivation	O
.	O

The	O
rgiidity	O
was	O
considerably	O
decreaesd	O
in	O
both	O
gorups	O
after	O
20	O
dyas	O
'	O
traetment	O
.	O

In	O
a	O
further	O
series	O
of	O
experiemnts	O
,	O
haloperiodl	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
was	O
used	O
in	O
order	O
to	O
blcok	O
the	O
dopmainergic	O
activtaion	O
and	O
to	O
estmiate	O
the	O
real	O
degere	O
of	O
the	O
tolearnce	O
to	O
the	O
rigiidty	O
without	O
any	O
dopaimnergic	O
interferecne	O
.	O

Haloepridol	B-Chemical
enhanecd	O
the	O
rigdiity	O
in	O
the	O
A	O
gorup	O
.	O

However	O
,	O
the	O
leevl	O
in	O
the	O
AS	O
/	O
KS	O
gorup	O
remained	O
considerably	O
loewr	O
than	O
in	O
the	O
A	O
gorup	O
.	O

The	O
rseults	O
suggest	O
that	O
rigdiity	O
,	O
which	O
is	O
assumed	O
to	O
be	O
due	O
to	O
an	O
aciton	O
of	O
moprhine	B-Chemical
in	O
the	O
striautm	O
,	O
can	O
be	O
antagonzied	O
by	O
another	O
procses	O
leading	O
to	O
dopaminegric	O
acitvation	O
in	O
the	O
striautm	O
.	O

Nevertheless	O
,	O
there	O
occurs	O
some	O
real	O
tolearnce	O
to	O
this	O
effect	O
.	O

The	O
rpaid	O
alterantions	O
of	O
rigdiity	O
and	O
the	O
sgins	O
of	O
dopaminerigc	O
acitvation	O
observed	O
in	O
the	O
ainmals	O
of	O
the	O
AS	O
/	O
KS	O
gruop	O
might	O
be	O
due	O
to	O
raipd	O
shitfs	O
in	O
the	O
predominance	O
of	O
various	O
DA	O
-	O
inneravted	O
strucutres	O
.	O

A	O
csae	O
of	O
massive	O
rhabdomyoylsis	O
following	O
molidnone	B-Chemical
administraiton	O
.	O

Rhabdmoyolysis	O
is	O
a	O
potentially	O
ltehal	O
syndorme	O
that	O
psychaitric	O
patinets	O
seem	O
perdisposed	O
to	O
develop	O
.	O

The	O
cliniacl	O
sgins	O
and	O
smyptoms	O
,	O
typical	O
lbaoratory	O
faetures	O
,	O
and	O
complciations	O
of	O
rhabdomyolyiss	O
are	O
presented	O
.	O

The	O
csae	O
of	O
a	O
schizophreinc	O
pateint	O
is	O
reported	O
to	O
illustrate	O
massive	O
rhbadomyolysis	O
and	O
subsequent	O
aucte	O
rneal	O
failrue	O
following	O
molindnoe	B-Chemical
adminisrtation	O
.	O

Physicains	O
who	O
prescirbe	O
molinodne	B-Chemical
should	O
be	O
aware	O
of	O
this	O
recation	O
.	O

Copmression	O
neuroapthy	O
of	O
the	O
rdaial	O
nreve	O
due	O
to	O
petnazocine	B-Chemical
-	O
indcued	O
fiborus	O
mypoathy	O
.	O

Fibruos	O
moypathy	O
is	O
a	O
common	O
,	O
well	O
-	O
known	O
side	O
effcet	O
of	O
repetaed	O
penatzocine	B-Chemical
ijnection	O
.	O

However	O
,	O
cmopression	O
nueropathy	O
due	O
to	O
fibrtoic	O
muslce	O
affetced	O
by	O
pentazcoine	B-Chemical
-	O
induecd	O
myopahty	O
has	O
not	O
previously	O
been	O
reported	O
.	O

In	O
a	O
37	O
-	O
yaer	O
-	O
old	O
woamn	O
with	O
doucmented	O
pentaozcine	B-Chemical
-	O
indcued	O
fibruos	O
myoptahy	O
of	O
tirceps	O
and	O
delotid	O
muscels	O
bilatreally	O
and	O
a	O
three	O
-	O
week	O
hisotry	O
of	O
rihgt	O
wrsit	O
dorp	O
,	O
electrdoiagnostic	O
examintaion	O
showed	O
a	O
sevree	O
but	O
patrial	O
lseion	O
of	O
the	O
rgiht	O
radail	O
nevre	O
ditsal	O
to	O
the	O
barnches	O
to	O
the	O
trcieps	O
,	O
in	O
addition	O
to	O
the	O
fiborus	O
moypathy	O
.	O

Suregry	O
revelaed	O
the	O
rihgt	O
rdaial	O
nevre	O
to	O
be	O
sveerely	O
comprsesed	O
by	O
the	O
densely	O
firbotic	O
latreal	O
haed	O
of	O
the	O
trcieps	O
.	O

Decompressoin	O
and	O
nuerolysis	O
were	O
performed	O
with	O
good	O
subsequent	O
reocvery	O
of	O
funciton	O
.	O

Recurernt	O
reversible	O
actue	O
rneal	O
faiulre	O
from	O
ampohtericin	B-Chemical
.	O

A	O
pateint	O
with	O
crpytogenic	O
cirrhsois	O
and	O
dsiseminated	O
sprootrichosis	O
developed	O
aucte	O
rneal	O
faliure	O
immediately	O
following	O
the	O
adminsitration	O
of	O
amphoteriicn	B-Chemical
B	I-Chemical
on	O
four	O
separate	O
ocacsions	O
.	O

The	O
abruptnses	O
of	O
the	O
rneal	O
fialure	O
and	O
its	O
reversibiilty	O
within	O
dyas	O
suggests	O
that	O
there	O
was	O
a	O
functoinal	O
component	O
to	O
the	O
rneal	O
dysufnction	O
.	O

We	O
propose	O
that	O
apmhotericin	B-Chemical
,	O
in	O
the	O
setting	O
of	O
reudced	O
effective	O
aretrial	O
volmue	O
,	O
may	O
atcivate	O
tubluoglomerular	O
feedback	O
,	O
thereby	O
contributing	O
to	O
aucte	O
reanl	O
faliure	O
.	O

Ceerbral	O
infacrtion	O
with	O
a	O
single	O
oarl	O
dsoe	O
of	O
phenlypropanolamine	B-Chemical
.	O

Phenylpropnaolamine	B-Chemical
(	O
PPA	B-Chemical
)	O
,	O
a	O
snythetic	O
sympathomiemtic	O
that	O
is	O
structurally	O
similar	O
to	O
apmhetamine	B-Chemical
,	O
is	O
available	O
over	O
the	O
counter	O
in	O
anorecitcs	O
,	O
nsaal	O
cognestants	O
,	O
and	O
clod	O
prpearations	O
.	O

Its	O
prologned	O
use	O
or	O
ovreuse	O
has	O
been	O
associated	O
with	O
siezures	O
,	O
intraceerbral	O
hemorrhage	O
,	O
neurposychiatric	O
symtpoms	O
,	O
and	O
nonhemorhragic	O
cererbal	O
inafrction	O
.	O

We	O
reprot	O
the	O
csae	O
of	O
a	O
yuong	O
woamn	O
who	O
suffered	O
a	O
ceerbral	O
infarciton	O
after	O
taking	O
a	O
single	O
oarl	O
dsoe	O
of	O
PPA	B-Chemical
.	O

Remisison	O
inductoin	O
of	O
meninegal	O
leukeima	O
with	O
high	O
-	O
dsoe	O
intrvaenous	O
methotreaxte	B-Chemical
.	O

Twenty	O
chlidren	O
with	O
aucte	O
lympohblastic	O
luekemia	O
who	O
developed	O
meinngeal	O
disaese	O
were	O
treaetd	O
with	O
a	O
high	O
-	O
dsoe	O
inrtavenous	O
metohtrexate	B-Chemical
regmien	O
that	O
was	O
designed	O
to	O
achieve	O
and	O
maintain	O
CSF	O
methotrextae	B-Chemical
cnocentrations	O
of	O
10	O
(	O
-	O
5	O
)	O
mol	O
/	O
L	O
without	O
the	O
need	O
for	O
concoimtant	O
intrahtecal	O
dosnig	O
.	O

The	O
methtorexate	B-Chemical
was	O
adminsitered	O
as	O
a	O
loaidng	O
dsoe	O
of	O
6	O
,	O
000	O
mg	O
/	O
m2	O
for	O
a	O
peroid	O
of	O
one	O
hour	O
followed	O
by	O
an	O
inufsion	O
of	O
1	O
,	O
200	O
mg	O
/	O
m2	O
/	O
h	O
for	O
23	O
hours	O
.	O

Leuocvorin	B-Chemical
rescue	O
was	O
initiated	O
12	O
hours	O
after	O
the	O
end	O
of	O
the	O
ifnusion	O
with	O
a	O
lodaing	O
dsoe	O
of	O
200	O
mg	O
/	O
m2	O
followed	O
by	O
12	O
mg	O
/	O
m2	O
every	O
three	O
hours	O
for	O
six	O
dsoes	O
and	O
then	O
every	O
six	O
hours	O
until	O
the	O
plamsa	O
methtorexate	B-Chemical
lveel	O
decreaesd	O
to	O
less	O
than	O
1	O
X	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
.	O

The	O
mean	O
steady	O
-	O
state	O
plsama	O
and	O
CSF	O
methtorexate	B-Chemical
concentratoins	O
achieved	O
were	O
1	O
.	O
1	O
X	O
10	O
(	O
-	O
3	O
)	O
mol	O
/	O
L	O
and	O
3	O
.	O
6	O
X	O
10	O
(	O
-	O
5	O
)	O
mol	O
/	O
L	O
,	O
respectively	O
.	O

All	O
20	O
paitents	O
responded	O
to	O
this	O
regmien	O
,	O
16	O
/	O
20	O
(	O
80	O
%	O
)	O
achieved	O
a	O
complete	O
remsision	O
,	O
and	O
20	O
%	O
obtained	O
a	O
parital	O
remission	O
.	O

The	O
most	O
common	O
txoicities	O
encountered	O
were	O
transinet	O
sreum	O
trnasaminase	O
and	O
biliurbin	B-Chemical
eleavtions	O
,	O
neutroepnia	O
,	O
and	O
mucosiits	O
.	O

One	O
ptaient	O
had	O
foacl	O
seizuers	O
and	O
trnasient	O
hemipareiss	O
but	O
recovreed	O
completely	O
.	O

High	O
-	O
dsoe	O
intraevnous	O
methotrxeate	B-Chemical
is	O
an	O
effecitve	O
teratment	O
for	O
the	O
inductoin	O
of	O
remission	O
after	O
mennigeal	O
relaspe	O
in	O
aucte	O
lympholbastic	O
luekemia	O
.	O

Itneraction	O
of	O
ccylosporin	B-Chemical
A	I-Chemical
with	O
antineoplatsic	O
aegnts	O
.	O

A	O
synregistic	O
efefct	O
of	O
eotposide	B-Chemical
and	O
cycolsporin	B-Chemical
A	I-Chemical
was	O
observed	O
in	O
a	O
pateint	O
with	O
actue	O
T	O
-	O
lymphcoytic	O
leuekmia	O
in	O
rleapse	O
.	O

The	O
concmoitant	O
adminisrtation	O
of	O
etoopside	B-Chemical
and	O
cyclosoprin	B-Chemical
A	I-Chemical
resulted	O
in	O
eradictaion	O
of	O
hitherto	O
refrcatory	O
lekuemic	O
ifniltration	O
of	O
bnoe	O
mrarow	O
.	O

Seevre	O
side	O
efefcts	O
in	O
terms	O
of	O
menatl	O
confusoin	O
and	O
prorgessive	O
hyperbliirubinemia	O
,	O
however	O
,	O
point	O
to	O
an	O
enhnacement	O
not	O
only	O
of	O
antnieoplastic	O
effetcs	O
but	O
also	O
of	O
toxiicty	O
in	O
noraml	O
tsisues	O
.	O

This	O
reoprt	O
demonstrates	O
for	O
the	O
first	O
tmie	O
that	O
the	O
pahrmacodynamic	O
proeprties	O
of	O
cyclopsorin	B-Chemical
A	I-Chemical
may	O
not	O
be	O
confined	O
strictly	O
to	O
spupression	O
of	O
nromal	O
T	O
-	O
clel	O
fnuctions	O
.	O

Inciednce	O
of	O
noeplasms	O
in	O
ptaients	O
with	O
rheuamtoid	O
arhtritis	O
expoesd	O
to	O
different	O
treamtent	O
reigmens	O
.	O

Immunosuprpessive	O
durgs	O
have	O
been	O
used	O
during	O
the	O
last	O
30	O
yeras	O
in	O
treamtent	O
of	O
patinets	O
with	O
sevree	O
rheumaotid	O
arthirtis	O
.	O

The	O
drgus	O
commonly	O
used	O
are	O
ccylophosphamide	B-Chemical
and	O
chlorambcuil	B-Chemical
(	O
alklyating	B-Chemical
agnets	I-Chemical
)	O
,	O
azathiporine	B-Chemical
(	O
pruine	B-Chemical
aanlogue	O
)	O
,	O
and	O
metohtrexate	B-Chemical
(	O
floic	B-Chemical
aicd	I-Chemical
anlaogue	O
)	O
.	O

There	O
is	O
eviednce	O
that	O
all	O
four	O
immnuosuppressive	O
drgus	O
can	O
rdeuce	O
synoviits	O
,	O
but	O
diesase	O
activtiy	O
almost	O
always	O
recrus	O
after	O
therpay	O
is	O
stopped	O
.	O

Since	O
adevrse	O
recations	O
are	O
freuqent	O
,	O
less	O
than	O
50	O
percent	O
of	O
patinets	O
are	O
able	O
to	O
continue	O
a	O
particular	O
durg	O
for	O
more	O
than	O
one	O
yaer	O
.	O

Since	O
it	O
takes	O
three	O
to	O
12	O
motnhs	O
to	O
achieve	O
maixmal	O
effects	O
,	O
those	O
patietns	O
who	O
are	O
unable	O
to	O
continue	O
the	O
durg	O
receive	O
little	O
bneefit	O
from	O
it	O
.	O

Pateints	O
treaetd	O
with	O
alkyalting	B-Chemical
aegnts	I-Chemical
have	O
an	O
increaesd	O
rsik	O
of	O
devleopment	O
of	O
actue	O
nonlymphocyitc	O
lekuemia	O
,	O
and	O
both	O
alkylaitng	B-Chemical
agnets	I-Chemical
and	O
aazthioprine	B-Chemical
are	O
associated	O
with	O
the	O
develpoment	O
of	O
non	O
-	O
Hodkgin	O
'	O
s	O
lymphmoa	O
.	O

Cyclophsophamide	B-Chemical
threapy	O
icnreases	O
the	O
rsik	O
of	O
carcionma	O
of	O
the	O
bldader	O
.	O

There	O
have	O
been	O
several	O
long	O
-	O
term	O
sutdies	O
of	O
paitents	O
with	O
rheumtaoid	O
arthirtis	O
treaetd	O
with	O
azathiorpine	B-Chemical
and	O
cyclohposphamide	B-Chemical
and	O
the	O
incidnece	O
of	O
most	O
of	O
the	O
common	O
cacners	O
is	O
not	O
inrceased	O
.	O

Dtaa	O
on	O
the	O
possible	O
incresaed	O
rsik	O
of	O
mailgnancy	O
in	O
rheumatiod	O
arthrtiis	O
are	O
still	O
being	O
collected	O
,	O
and	O
until	O
further	O
infromation	O
is	O
available	O
,	O
the	O
use	O
of	O
immunosupperssive	O
durgs	O
,	O
particularly	O
alkylaitng	B-Chemical
aegnts	I-Chemical
,	O
in	O
the	O
treatemnt	O
of	O
rheumatiod	O
arthirtis	O
should	O
be	O
reserved	O
for	O
ptaients	O
with	O
sveere	O
progerssive	O
dsiease	O
or	O
lfie	O
-	O
threatening	O
complictaions	O
.	O

Warfairn	B-Chemical
-	O
idnuced	O
iliospoas	O
hemrorhage	O
with	O
subsequent	O
fmeoral	O
nevre	O
pasly	O
.	O

We	O
present	O
the	O
csae	O
of	O
a	O
28	O
-	O
yaer	O
-	O
old	O
man	O
on	O
chroinc	O
warfairn	B-Chemical
thearpy	O
who	O
sustaiend	O
a	O
minor	O
muslce	O
taer	O
and	O
developed	O
increaisng	O
pian	O
and	O
a	O
felxure	O
conrtacture	O
of	O
the	O
rgiht	O
hip	O
.	O

Surgcial	O
exlporation	O
revaeled	O
an	O
iloipsoas	O
hemaotma	O
and	O
feomral	O
nreve	O
etnrapment	O
,	O
resulting	O
in	O
a	O
femroal	O
nevre	O
plasy	O
and	O
patrial	O
lsos	O
of	O
quadrcieps	O
fnuctions	O
.	O

Anticoagualnt	O
-	O
induecd	O
femoarl	O
nreve	O
plasy	O
represents	O
the	O
most	O
common	O
form	O
of	O
warafrin	B-Chemical
-	O
indcued	O
periphearl	O
neurpoathy	O
;	O
it	O
is	O
charactreized	O
by	O
seevre	O
pian	O
in	O
the	O
inuginal	O
reigon	O
,	O
varying	O
dergees	O
of	O
mootr	O
and	O
snesory	O
impairemnt	O
,	O
and	O
flxeure	O
contracutre	O
of	O
the	O
involved	O
extrmeity	O
.	O

Pneumointis	O
with	O
plerual	O
and	O
pericadrial	O
effsuion	O
and	O
neuorpathy	O
during	O
amiodaorne	B-Chemical
thearpy	O
.	O

A	O
pateint	O
with	O
sinutarial	O
disaese	O
and	O
implnated	O
pacemkaer	O
was	O
tretaed	O
with	O
amioadrone	B-Chemical
(	O
maxiumm	O
dsoe	O
1000	O
mg	O
,	O
maintennace	O
dsoe	O
800	O
mg	O
dialy	O
)	O
for	O
10	O
monhts	O
,	O
for	O
cotnrol	O
of	O
surpaventricular	O
tachyarryhthmias	O
.	O

He	O
developed	O
pneumnoitis	O
,	O
pleuarl	O
and	O
preicardial	O
effusinos	O
,	O
and	O
a	O
predominantly	O
proxiaml	O
mootr	O
nueropathy	O
.	O

Imemdiate	O
but	O
gardual	O
ipmrovement	O
followed	O
witdhrawal	O
of	O
amidoarone	B-Chemical
and	O
traetment	O
with	O
prdenisolone	B-Chemical
.	O

Rveiew	O
of	O
this	O
and	O
previously	O
reported	O
caess	O
indicates	O
the	O
need	O
for	O
eraly	O
daignosis	O
of	O
aimodarone	B-Chemical
pneumontiis	O
,	O
immedaite	O
withdraawl	O
of	O
aimodarone	B-Chemical
,	O
and	O
prompt	O
but	O
continued	O
streoid	B-Chemical
threapy	O
to	O
ensure	O
full	O
recovrey	O
.	O

Amiodarnoe	B-Chemical
-	O
indcued	O
sinoatrail	O
bolck	O
.	O

We	O
observed	O
snioatrial	O
blcok	O
due	O
to	O
crhonic	O
amidoarone	B-Chemical
adimnistration	O
in	O
a	O
5	O
-	O
yaer	O
-	O
old	O
boy	O
with	O
pirmary	O
cardiomypoathy	O
,	O
Wolff	O
-	O
Parkinosn	O
-	O
Whtie	O
synrdome	O
and	O
supraventricualr	O
tachcyardia	O
.	O

Reudction	O
in	O
the	O
doasge	O
of	O
amiodraone	B-Chemical
resulted	O
in	O
the	O
disappearacne	O
of	O
the	O
sinoartial	O
blcok	O
and	O
the	O
persistecne	O
of	O
asymptomtaic	O
siuns	O
bradyacrdia	O
.	O

Desipramnie	B-Chemical
-	O
indcued	O
deilrium	O
at	O
"	O
sbutherapeutic	O
"	O
concentartions	O
:	O
a	O
csae	O
rpeort	O
.	O

An	O
eldelry	O
ptaient	O
traeted	O
with	O
low	O
dsoe	O
Desiprmaine	B-Chemical
developed	O
a	O
delriium	O
while	O
her	O
plsama	O
lveel	O
was	O
in	O
the	O
"	O
subthreapeutic	O
"	O
range	O
.	O

Deliruim	O
,	O
which	O
may	O
be	O
induecd	O
by	O
trciyclic	O
durg	O
therpay	O
in	O
the	O
eldelry	O
,	O
can	O
be	O
caused	O
by	O
trciyclics	O
with	O
low	O
anticholniergic	O
ptoency	O
.	O

Therapuetic	O
ragnes	O
for	O
antiedpressants	B-Chemical
that	O
have	O
been	O
derived	O
from	O
general	O
audlt	O
populatoin	O
sutdies	O
may	O
not	O
be	O
appropriate	O
for	O
the	O
edlerly	O
.	O

Further	O
studeis	O
of	O
specifically	O
eledrly	O
patinets	O
are	O
now	O
required	O
to	O
establish	O
safer	O
and	O
more	O
appropriate	O
guidleines	O
for	O
durg	O
thearpy	O
.	O

Indomethcain	B-Chemical
-	O
indcued	O
reanl	O
insuffiicency	O
:	O
recurrecne	O
on	O
rechalelnge	O
.	O

We	O
have	O
reported	O
a	O
csae	O
of	O
actue	O
oligruic	O
rneal	O
faiulre	O
with	O
hyperkalmeia	O
in	O
a	O
ptaient	O
with	O
crirhosis	O
,	O
asictes	O
,	O
and	O
cor	O
pulmnoale	O
after	O
indomtehacin	B-Chemical
tehrapy	O
.	O

Prmopt	O
restortaion	O
of	O
reanl	O
fucntion	O
followed	O
durg	O
withdrwaal	O
,	O
while	O
re	O
-	O
expsoure	O
to	O
a	O
single	O
dsoe	O
of	O
indometahcin	B-Chemical
caused	O
recurrecne	O
of	O
actue	O
reversible	O
oliguira	O
.	O

Our	O
csae	O
supports	O
the	O
hypotheiss	O
that	O
ednogenous	O
rneal	O
protsaglandins	B-Chemical
play	O
a	O
role	O
in	O
the	O
miantenance	O
of	O
reanl	O
blood	O
folw	O
when	O
circluating	O
palsma	O
volmue	O
is	O
diminished	O
.	O

Since	O
nonsteroiadl	O
atni	O
-	O
inflammtaory	O
agnets	O
interfere	O
with	O
this	O
compensatroy	O
mechainsm	O
and	O
may	O
cause	O
actue	O
reanl	O
failrue	O
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
in	O
such	O
paitents	O
.	O

Patetrns	O
of	O
hpeatic	O
injruy	O
idnuced	O
by	O
methydlopa	B-Chemical
.	O

Twelve	O
paitents	O
with	O
lievr	O
diesase	O
related	O
to	O
mehtyldopa	B-Chemical
were	O
seen	O
between	O
1967	O
and	O
1977	O
.	O

Illnses	O
occurred	O
within	O
1	O
-	O
-	O
9	O
weeks	O
of	O
commencmeent	O
of	O
thearpy	O
in	O
9	O
paitents	O
,	O
the	O
remaining	O
3	O
patietns	O
having	O
received	O
the	O
durg	O
for	O
13	O
monhts	O
,	O
15	O
monhts	O
and	O
7	O
yaers	O
before	O
experiencing	O
sympotms	O
.	O

Jaudnice	O
with	O
tenedr	O
hepatoemgaly	O
,	O
usually	O
preceded	O
by	O
symptmos	O
of	O
maliase	O
,	O
anorxeia	O
,	O
nuasea	O
and	O
vmoiting	O
,	O
and	O
associated	O
with	O
upper	O
abodminal	O
pian	O
,	O
was	O
an	O
invariable	O
finidng	O
in	O
all	O
patietns	O
.	O

Biochemcial	O
lievr	O
fnuction	O
tetss	O
indicated	O
hepatoclelular	O
ncerosis	O
and	O
correltaed	O
with	O
histopatohlogical	O
evdience	O
of	O
heaptic	O
inujry	O
,	O
the	O
specturm	O
of	O
which	O
ranged	O
from	O
ftaty	O
change	O
and	O
foacl	O
hepatocelullar	O
necrsois	O
to	O
massive	O
hpeatic	O
ncerosis	O
.	O

Most	O
paitents	O
showed	O
modearte	O
to	O
seevre	O
actue	O
hepatiits	O
or	O
chornic	O
atcive	O
hepaittis	O
with	O
associated	O
choelstasis	O
.	O

The	O
durg	O
was	O
withdrawn	O
on	O
persentation	O
to	O
hosptial	O
in	O
11	O
paitents	O
,	O
with	O
rpaid	O
cliniacl	O
improevment	O
in	O
9	O
.	O

One	O
pateint	O
deid	O
,	O
having	O
presented	O
in	O
heaptic	O
fialure	O
,	O
and	O
another	O
,	O
who	O
had	O
been	O
taking	O
methydlopa	B-Chemical
for	O
7	O
yeras	O
,	O
showed	O
sloewr	O
clniical	O
and	O
biocehmical	O
rseolution	O
over	O
a	O
peroid	O
of	O
several	O
mnoths	O
.	O

The	O
remaining	O
patinet	O
in	O
the	O
series	O
developed	O
fulminnat	O
hepatiits	O
when	O
the	O
durg	O
was	O
accidentally	O
recommneced	O
1	O
yaer	O
after	O
a	O
prior	O
episdoe	O
of	O
methydlopa	B-Chemical
-	O
induecd	O
hepaittis	O
.	O

In	O
this	O
latter	O
pateint	O
,	O
and	O
in	O
2	O
others	O
,	O
the	O
causal	O
relatoinship	O
between	O
mehtyldopa	B-Chemical
and	O
heaptic	O
dysfunciton	O
was	O
proved	O
with	O
the	O
recrurence	O
of	O
hepatiits	O
within	O
2	O
wekes	O
of	O
re	O
-	O
exopsure	O
to	O
the	O
durg	O
.	O

Sxuamethonium	B-Chemical
ifnusion	O
rtae	O
and	O
observed	O
fasciuclations	O
.	O

A	O
dsoe	O
-	O
resposne	O
stduy	O
.	O

Sxuamethonium	B-Chemical
cholride	I-Chemical
(	O
Sch	B-Chemical
)	O
was	O
adimnistered	O
i	O
.	O
v	O
.	O
to	O
36	O
adlut	O
mlaes	O
at	O
six	O
rtaes	O
:	O
0	O
.	O
25	O
mg	O
s	O
-	O
1	O
to	O
20	O
mg	O
s	O
-	O
1	O
.	O

The	O
infusoin	O
was	O
discontiuned	O
either	O
when	O
there	O
was	O
no	O
muscluar	O
resopnse	O
to	O
tteanic	O
stimualtion	O
of	O
the	O
unlar	O
nreve	O
or	O
when	O
Sch	B-Chemical
120	O
mg	O
was	O
exceeded	O
.	O

Six	O
additional	O
paitents	O
received	O
a	O
30	O
-	O
mg	O
i	O
.	O
v	O
.	O
bouls	O
dsoe	O
.	O

Fascicluations	O
in	O
six	O
areas	O
of	O
the	O
bdoy	O
were	O
scroed	O
from	O
0	O
to	O
3	O
and	O
smumated	O
as	O
a	O
total	O
facsiculation	O
scroe	O
.	O

The	O
times	O
to	O
first	O
fasicculation	O
,	O
twicth	O
suppression	O
and	O
tteanus	O
supprsesion	O
were	O
invresely	O
related	O
to	O
the	O
infuison	O
rtaes	O
.	O

Fasicculations	O
in	O
the	O
six	O
areas	O
and	O
the	O
total	O
fasciculatoin	O
scroe	O
were	O
related	O
directly	O
to	O
the	O
rtae	O
of	O
ifnusion	O
.	O

Total	O
fasicculation	O
socres	O
in	O
the	O
30	O
-	O
mg	O
bouls	O
gorup	O
and	O
the	O
5	O
-	O
mg	O
s	O
-	O
1	O
and	O
20	O
-	O
mg	O
s	O
-	O
1	O
infuison	O
gorups	O
were	O
not	O
significantly	O
different	O
.	O

Treamtent	O
of	O
psoirasis	O
with	O
azathoiprine	B-Chemical
.	O

Azathoiprine	B-Chemical
traetment	O
benefited	O
19	O
(	O
66	O
%	O
)	O
out	O
of	O
29	O
pateints	O
suffernig	O
from	O
seevre	O
posriasis	O
.	O

Haematologcial	O
cmoplications	O
were	O
not	O
troublesome	O
and	O
resutls	O
of	O
biochmeical	O
lievr	O
functoin	O
tsets	O
remained	O
nromal	O
.	O

Miinmal	O
cohlestasis	O
was	O
seen	O
in	O
two	O
csaes	O
and	O
protal	O
fiborsis	O
of	O
a	O
reversible	O
dgeree	O
in	O
eight	O
.	O

Lievr	O
biopseis	O
should	O
be	O
undertaken	O
at	O
regular	O
inetrvals	O
if	O
azahtioprine	B-Chemical
thearpy	O
is	O
continued	O
so	O
that	O
strcutural	O
lievr	O
damgae	O
may	O
be	O
detecetd	O
at	O
an	O
eraly	O
and	O
reversible	O
stgae	O
.	O

Angoisarcoma	O
of	O
the	O
lvier	O
associated	O
with	O
dietyhlstilbestrol	B-Chemical
.	O

Angiosarocma	O
of	O
the	O
lievr	O
occurred	O
in	O
a	O
76	O
-	O
yaer	O
-	O
old	O
man	O
who	O
had	O
been	O
treaetd	O
for	O
a	O
well	O
-	O
differnetiated	O
adenoacrcinoma	O
of	O
the	O
lievr	O
with	O
ditehylstilbestrol	B-Chemical
for	O
13	O
yeras	O
.	O

Agniosarcoma	O
was	O
also	O
present	O
within	O
pulmonray	O
and	O
rneal	O
aretries	O
.	O

The	O
possibility	O
that	O
the	O
intraarterail	O
lseions	O
might	O
represent	O
indepednent	O
prmiary	O
tuomrs	O
is	O
considered	O
.	O

Galanthamnie	B-Chemical
hydrorbomide	I-Chemical
,	O
a	O
longer	O
acting	O
anticholinestersae	O
durg	O
,	O
in	O
the	O
tretament	O
of	O
the	O
cnetral	O
efefcts	O
of	O
scopolaimne	B-Chemical
(	O
Hyoscnie	B-Chemical
)	O
.	O

Galantahmine	B-Chemical
hydrobromdie	I-Chemical
,	O
an	O
anticholinestersae	O
durg	O
capable	O
of	O
penetratnig	O
the	O
blood	O
-	O
barin	O
brarier	O
,	O
was	O
used	O
in	O
a	O
paitent	O
demonstrating	O
cenrtal	O
efefcts	O
of	O
socpolamine	B-Chemical
(	O
hoyscine	B-Chemical
)	O
overdosgae	O
.	O

It	O
is	O
longer	O
acting	O
than	O
physostigmnie	B-Chemical
and	O
is	O
used	O
in	O
aneasthesia	O
to	O
revesre	O
the	O
non	O
-	O
depolariznig	O
nueromuscular	O
bolck	O
.	O

However	O
,	O
stduies	O
into	O
the	O
dsoe	O
necessary	O
to	O
combating	O
scopolmaine	B-Chemical
intoxciation	O
are	O
indicated	O
.	O

Comparsion	O
of	O
the	O
subejctive	O
efefcts	O
and	O
plsama	O
concenrtations	O
following	O
oarl	O
and	O
i	O
.	O
m	O
.	O
admniistration	O
of	O
flunitrzaepam	B-Chemical
in	O
volunteres	O
.	O

Fluintrazepam	B-Chemical
0	O
.	O
5	O
,	O
1	O
.	O
0	O
or	O
2	O
.	O
0	O
mg	O
was	O
given	O
by	O
the	O
oarl	O
or	O
i	O
.	O
m	O
.	O
rotues	O
to	O
gorups	O
of	O
volutneers	O
and	O
its	O
effects	O
cmopared	O
.	O

Plsama	O
cocnentrations	O
of	O
the	O
durg	O
were	O
etsimated	O
by	O
gas	O
-	O
liqiud	O
chromaotgraphy	O
,	O
in	O
a	O
smaller	O
number	O
of	O
the	O
subjcets	O
.	O

The	O
most	O
striking	O
effcet	O
was	O
sedatoin	O
which	O
increaesd	O
with	O
the	O
dsoe	O
,	O
2	O
mg	O
producing	O
deep	O
selep	O
although	O
the	O
subejcts	O
could	O
still	O
be	O
aroused	O
.	O

The	O
efefcts	O
of	O
i	O
.	O
m	O
.	O
adminsitration	O
were	O
apparnet	O
earlier	O
and	O
sometimes	O
lasted	O
longer	O
than	O
those	O
following	O
oarl	O
amdinistration	O
.	O

Dizzienss	O
was	O
less	O
marked	O
than	O
seadtion	O
,	O
but	O
increaesd	O
with	O
the	O
dsoe	O
.	O

There	O
was	O
pian	O
on	O
i	O
.	O
m	O
.	O
injectoin	O
of	O
fluintrazepam	B-Chemical
significantly	O
more	O
often	O
than	O
with	O
isotoinc	O
sailne	O
.	O

Palsma	O
concetnrations	O
varied	O
with	O
dsoe	O
and	O
rotue	O
and	O
corresponded	O
qualitatviely	O
with	O
the	O
subjetcive	O
efefcts	O
.	O

The	O
durg	O
was	O
still	O
present	O
in	O
meausrable	O
quantiites	O
after	O
24	O
h	O
even	O
with	O
the	O
smallest	O
dsoe	O
.	O

Possible	O
teratogeniicty	O
of	O
suplhasalazine	B-Chemical
.	O

Three	O
infnats	O
,	O
bron	O
of	O
two	O
mothres	O
with	O
inflammtaory	O
bwoel	O
disesae	O
who	O
received	O
treamtent	O
with	O
suplhasalazine	B-Chemical
throughout	O
pregnacny	O
,	O
were	O
found	O
to	O
have	O
major	O
congential	O
anoamlies	O
.	O

In	O
the	O
singlteon	O
preganncy	O
,	O
the	O
mtoher	O
had	O
ulecrative	O
coliits	O
,	O
and	O
the	O
ifnant	O
,	O
a	O
mlae	O
,	O
had	O
coarcttaion	O
of	O
the	O
arota	O
and	O
a	O
venrticular	O
spetal	O
dfeect	O
.	O

In	O
the	O
tiwn	O
pergnancy	O
,	O
the	O
mtoher	O
had	O
Crhon	O
'	O
s	O
disaese	O
.	O

The	O
first	O
tiwn	O
,	O
a	O
femlae	O
,	O
had	O
a	O
lfet	O
Potter	O
-	O
tpye	O
IIa	O
poylcystic	O
kdiney	O
and	O
a	O
rduimentary	O
lfet	O
uteirne	O
conru	O
.	O

The	O
second	O
tiwn	O
,	O
a	O
mlae	O
,	O
had	O
some	O
faetures	O
of	O
Ptoter	O
'	O
s	O
faceis	O
,	O
hpyoplastic	O
lnugs	O
,	O
asbent	O
kidnyes	O
and	O
ureetrs	O
,	O
and	O
tlaipes	O
equinvoarus	O
.	O

Despite	O
repotrs	O
to	O
the	O
contrary	O
,	O
it	O
is	O
suggested	O
that	O
suplhasalazine	B-Chemical
may	O
be	O
teartogenic	O
.	O

Throbmotic	O
microangioapthy	O
and	O
rneal	O
faiulre	O
associated	O
with	O
anitneoplastic	O
chemotherpay	O
.	O

Five	O
patinets	O
with	O
carcnioma	O
developed	O
throbmotic	O
microanigopathy	O
(	O
cahracterized	O
by	O
reanl	O
insufficiecny	O
,	O
microangiopatihc	O
hemoyltic	O
aneima	O
,	O
and	O
usually	O
thromboyctopenia	O
)	O
after	O
treatmnet	O
with	O
cispltain	B-Chemical
,	O
bleoymcin	B-Chemical
,	O
and	O
a	O
vicna	B-Chemical
alakloid	I-Chemical
.	O

One	O
patinet	O
had	O
thrmobotic	O
thromobcytopenic	O
puprura	O
,	O
three	O
the	O
hmeolytic	O
-	O
ureimc	O
synrdome	O
,	O
and	O
one	O
an	O
apaprent	O
forme	O
frsute	O
of	O
one	O
of	O
these	O
diosrders	O
.	O

Histolgoic	O
examintaion	O
of	O
the	O
rneal	O
tisuse	O
showed	O
eivdence	O
of	O
intravsacular	O
coagualtion	O
,	O
primarily	O
affecitng	O
the	O
small	O
artreies	O
,	O
artreioles	O
,	O
and	O
golmeruli	O
.	O

Because	O
each	O
pateint	O
was	O
tuomr	O
-	O
free	O
or	O
had	O
only	O
a	O
small	O
tmuor	O
at	O
the	O
onset	O
of	O
this	O
syndrmoe	O
,	O
the	O
thrmobotic	O
microangiopahty	O
may	O
have	O
been	O
indcued	O
by	O
chemotherpay	O
.	O

Diagnoiss	O
of	O
this	O
potentially	O
ftaal	O
complicaiton	O
may	O
be	O
dealyed	O
or	O
misesd	O
if	O
reanl	O
tisuse	O
or	O
the	O
peripehral	O
bolod	O
smaer	O
is	O
not	O
examined	O
,	O
because	O
rneal	O
fialure	O
may	O
be	O
ascribed	O
to	O
cipslatin	B-Chemical
nephrotxoicity	O
and	O
the	O
anmeia	O
and	O
thrombcoytopenia	O
to	O
durg	O
-	O
indcued	O
bnoe	O
marrow	O
supprsesion	O
.	O

Interantional	O
mexlietine	B-Chemical
and	O
plcaebo	O
antiarrhtyhmic	O
cornoary	O
trail	O
:	O
I	O
.	O

Reprot	O
on	O
arhrythmia	O
and	O
other	O
findigns	O
.	O

Imapct	O
Resaerch	O
Gruop	O
.	O

The	O
antiarrhtyhmic	O
effects	O
of	O
the	O
sustianed	O
rleease	O
form	O
of	O
mexilteine	B-Chemical
(	O
Mxeitil	B-Chemical
-	I-Chemical
Perlongtes	I-Chemical
)	O
were	O
evaulated	O
in	O
a	O
double	O
-	O
blnid	O
plaecbo	O
trail	O
in	O
630	O
patinets	O
with	O
recent	O
doucmented	O
myocaridal	O
ifnarction	O
.	O

The	O
pirmary	O
resopnse	O
vairable	O
was	O
based	O
on	O
centarl	O
readnig	O
of	O
24	O
hour	O
ambluatory	O
electrocardiogrpahic	O
recodrings	O
and	O
was	O
defined	O
as	O
the	O
occurernce	O
of	O
30	O
or	O
more	O
single	O
prmeature	O
ventriuclar	O
cmoplexes	O
in	O
any	O
two	O
consectuive	O
30	O
minute	O
bolcks	O
or	O
one	O
or	O
more	O
runs	O
of	O
two	O
or	O
more	O
permature	O
vnetricular	O
cmoplexes	O
in	O
the	O
entire	O
24	O
hour	O
electrocadriographic	O
recroding	O
.	O

Large	O
differneces	O
,	O
regarded	O
as	O
sttaistically	O
significant	O
,	O
between	O
the	O
mexileitne	B-Chemical
and	O
plaecbo	O
gorups	O
were	O
noted	O
in	O
that	O
end	O
point	O
at	O
mnoths	O
1	O
and	O
4	O
,	O
but	O
only	O
trneds	O
were	O
observed	O
at	O
motnh	O
12	O
.	O

These	O
differences	O
were	O
observed	O
even	O
though	O
the	O
sreum	O
mxeiletine	B-Chemical
levles	O
obtained	O
in	O
this	O
sutdy	O
were	O
generally	O
loewr	O
than	O
those	O
observed	O
in	O
sutdies	O
that	O
have	O
used	O
the	O
regular	O
form	O
of	O
the	O
durg	O
.	O

There	O
were	O
more	O
daeths	O
in	O
the	O
mexileitne	B-Chemical
gorup	O
(	O
7	O
.	O
6	O
%	O
)	O
than	O
in	O
the	O
plcaebo	O
gorup	O
(	O
4	O
.	O
8	O
%	O
)	O
;	O
the	O
difference	O
was	O
not	O
statistiaclly	O
significant	O
.	O

The	O
inicdence	O
of	O
coornary	O
evnets	O
was	O
similar	O
in	O
both	O
gruops	O
.	O

Previously	O
recognized	O
side	O
effetcs	O
,	O
particularly	O
trmeor	O
and	O
gsatrointestinal	O
prolbems	O
,	O
were	O
more	O
ferquent	O
in	O
the	O
mexileitne	B-Chemical
gorup	O
than	O
in	O
the	O
palcebo	O
gruop	O
.	O

Cahnges	O
in	O
haert	O
szie	O
during	O
long	O
-	O
term	O
timooll	B-Chemical
teratment	O
after	O
myocadrial	O
infraction	O
.	O

The	O
effcet	O
of	O
long	O
-	O
term	O
tmiolol	B-Chemical
treatemnt	O
on	O
herat	O
szie	O
after	O
myocadrial	O
inafrction	O
was	O
eavluated	O
by	O
X	O
-	O
ray	O
in	O
a	O
double	O
-	O
bilnd	O
sutdy	O
including	O
241	O
ptaients	O
(	O
palcebo	O
126	O
,	O
timooll	B-Chemical
115	O
)	O
.	O

The	O
follow	O
-	O
up	O
peirod	O
was	O
12	O
monhts	O
.	O

The	O
tiomlol	B-Chemical
-	O
tretaed	O
paitents	O
showed	O
a	O
small	O
but	O
significant	O
incraese	O
in	O
haert	O
szie	O
from	O
baesline	O
in	O
contrast	O
to	O
a	O
dercease	O
in	O
the	O
palcebo	O
gruop	O
.	O

These	O
diffreences	O
may	O
be	O
caused	O
by	O
timooll	B-Chemical
-	O
idnuced	O
bradcyardia	O
and	O
a	O
comepnsatory	O
inrcease	O
in	O
end	O
-	O
disatolic	O
vloume	O
.	O

The	O
tiomlol	B-Chemical
-	O
related	O
incraese	O
in	O
haert	O
szie	O
was	O
observed	O
only	O
in	O
patietns	O
with	O
noraml	O
and	O
bordelrine	O
herat	O
szie	O
.	O

In	O
pateints	O
with	O
caridomegaly	O
,	O
the	O
inrcease	O
in	O
herat	O
szie	O
was	O
similar	O
in	O
both	O
gropus	O
.	O

After	O
re	O
-	O
infarciton	O
,	O
haert	O
szie	O
inrceased	O
in	O
the	O
palcebo	O
gruop	O
and	O
remained	O
unchnaged	O
in	O
the	O
tmiolol	B-Chemical
gruop	O
.	O

Vtiamin	B-Chemical
D3	I-Chemical
toxictiy	O
in	O
dariy	O
cwos	O
.	O

Large	O
parentearl	O
doess	O
of	O
vitaimn	B-Chemical
D3	I-Chemical
(	O
15	O
to	O
17	O
.	O
5	O
x	O
10	O
(	O
6	O
)	O
IU	O
vitmain	B-Chemical
D3	I-Chemical
)	O
were	O
associated	O
with	O
prloonged	O
hypecralcemia	O
,	O
hyeprphosphatemia	O
,	O
and	O
large	O
incraeses	O
of	O
vitaimn	B-Chemical
D3	I-Chemical
and	O
its	O
mteabolites	O
in	O
the	O
bolod	O
plsama	O
of	O
nonlacttaing	O
nonpregannt	O
and	O
prengant	O
Jeresy	O
cwos	O
.	O

Calicum	B-Chemical
concentratoins	O
1	O
day	O
postaprtum	O
were	O
hgiher	O
in	O
cwos	O
tretaed	O
with	O
vitaimn	B-Chemical
D3	I-Chemical
about	O
32	O
dyas	O
prepatrum	O
(	O
8	O
.	O
8	O
mg	O
/	O
100	O
ml	O
)	O
than	O
in	O
cnotrol	O
cwos	O
(	O
5	O
.	O
5	O
mg	O
/	O
100	O
ml	O
)	O
.	O

None	O
of	O
the	O
cwos	O
terated	O
with	O
vitaimn	B-Chemical
D3	I-Chemical
showed	O
sings	O
of	O
mlik	O
fveer	O
during	O
the	O
peripratal	O
peirod	O
;	O
however	O
,	O
22	O
%	O
of	O
the	O
conrtol	O
cwos	O
developed	O
cliniacl	O
sings	O
of	O
mlik	O
feevr	O
during	O
this	O
preiod	O
.	O

Sgins	O
of	O
vtiamin	B-Chemical
D3	I-Chemical
toxciity	O
were	O
not	O
observed	O
in	O
nonlacttaing	O
nonpergnant	O
cwos	O
;	O
however	O
,	O
pregnnat	O
cwos	O
commonly	O
developed	O
seevre	O
sgins	O
of	O
vitaimn	B-Chemical
D3	I-Chemical
toxciity	O
and	O
10	O
of	O
17	O
cwos	O
deid	O
.	O

There	O
was	O
widespread	O
meatstatic	O
calicfication	O
in	O
the	O
cwos	O
that	O
deid	O
.	O

Because	O
of	O
the	O
extreme	O
toxictiy	O
of	O
vtiamin	B-Chemical
D3	I-Chemical
in	O
pregnnat	O
Jresey	O
cwos	O
and	O
the	O
low	O
mragin	O
of	O
sfaety	O
between	O
doess	O
of	O
viatmin	B-Chemical
D3	I-Chemical
that	O
prveent	O
mlik	O
fveer	O
and	O
doess	O
that	O
indcue	O
mlik	O
fveer	O
,	O
we	O
concluded	O
that	O
vtiamin	B-Chemical
D3	I-Chemical
cannot	O
be	O
used	O
practically	O
to	O
pervent	O
mlik	O
fveer	O
when	O
injetced	O
several	O
wekes	O
prepatrum	O
.	O

Diesases	O
of	O
perpiheral	O
nerevs	O
as	O
seen	O
in	O
the	O
Nigerain	O
Afircan	O
.	O

The	O
anatomiacl	O
and	O
aetiologiacl	O
diangoses	O
of	O
periphearl	O
nevre	O
disesae	O
excluding	O
its	O
prmiary	O
beingn	O
and	O
mailgnant	O
disodrers	O
,	O
as	O
seen	O
in	O
358	O
Niegrians	O
are	O
presented	O
.	O

There	O
is	O
a	O
mlae	O
preponderance	O
and	O
the	O
peak	O
icnidence	O
is	O
in	O
the	O
fourth	O
decade	O
.	O

Senosri	O
-	O
mootr	O
nueropathy	O
was	O
the	O
commonest	O
presenattion	O
(	O
50	O
%	O
)	O
.	O

Giullain	O
-	O
Brar	O
syndrmoe	O
was	O
the	O
commonest	O
identifiable	O
cause	O
(	O
15	O
.	O
6	O
%	O
)	O
,	O
accounting	O
for	O
half	O
of	O
the	O
caess	O
with	O
mtoor	O
neurpoathy	O
.	O

Periphearl	O
nueropathy	O
due	O
to	O
nutrtiional	O
deficinecy	O
of	O
thiamnie	B-Chemical
and	O
ribofalvin	B-Chemical
was	O
common	O
(	O
10	O
.	O
1	O
%	O
)	O
and	O
presented	O
mainly	O
as	O
sensroy	O
and	O
sensori	O
-	O
mootr	O
neuroptahy	O
.	O

Daibetes	O
mlelitus	O
was	O
the	O
major	O
cause	O
of	O
auotnomic	O
neuropahty	O
.	O

Isnoiazid	B-Chemical
was	O
the	O
most	O
freuqent	O
aegnt	O
in	O
durg	O
-	O
indcued	O
nueropathy	O
.	O

Migranie	O
(	O
20	O
%	O
)	O
was	O
not	O
an	O
uncommon	O
cause	O
of	O
cranail	O
neuorpathy	O
although	O
malignacnies	O
arising	O
from	O
the	O
rteiculoendothelial	O
sysetm	O
or	O
related	O
strucutres	O
of	O
the	O
haed	O
and	O
ncek	O
were	O
more	O
frqeuent	O
(	O
26	O
%	O
)	O
.	O

In	O
26	O
.	O
5	O
%	O
of	O
all	O
the	O
csaes	O
,	O
the	O
aetioolgy	O
of	O
the	O
neuroptahy	O
was	O
undetermined	O
.	O

Heerdofamilial	O
and	O
connectvie	O
tissue	O
diosrders	O
were	O
rrae	O
.	O

Some	O
of	O
the	O
facotrs	O
related	O
to	O
the	O
cilnical	O
preesntation	O
and	O
pathogeensis	O
of	O
the	O
neuorpathies	O
are	O
briefly	O
discussed	O
.	O

Reduciton	O
in	O
cfafeine	B-Chemical
txoicity	O
by	O
aectaminophen	B-Chemical
.	O

A	O
ptaient	O
who	O
allegedly	O
consumed	O
100	O
tabelts	O
of	O
an	O
over	O
-	O
the	O
-	O
counter	O
analegsic	O
containing	O
soidum	B-Chemical
acteylsalicylate	I-Chemical
,	O
cafefine	B-Chemical
,	O
and	O
aceatminophen	B-Chemical
displayed	O
no	O
significant	O
CNS	O
stimultaion	O
despite	O
the	O
prseence	O
of	O
175	O
microrgams	O
of	O
caffenie	B-Chemical
per	O
mL	O
of	O
seurm	O
.	O

Because	O
saliyclates	O
have	O
been	O
reported	O
to	O
augment	O
the	O
stimultaory	O
effcets	O
of	O
caffeine	B-Chemical
on	O
the	O
CNS	O
,	O
attnetion	O
was	O
focused	O
on	O
the	O
possibility	O
that	O
the	O
presnece	O
of	O
acetamionphen	B-Chemical
(	O
52	O
mircograms	O
/	O
mL	O
)	O
reudced	O
the	O
CNS	O
toxciity	O
of	O
cfafeine	B-Chemical
.	O

Stuides	O
in	O
DBA	O
/	O
2J	O
mcie	O
showed	O
that	O
:	O
1	O
)	O
pretreatemnt	O
with	O
acetaimnophen	B-Chemical
(	O
100	O
mg	O
/	O
kg	O
)	O
inrceased	O
the	O
itnerval	O
between	O
the	O
adminitsration	O
of	O
caffeine	B-Chemical
(	O
300	O
to	O
450	O
mg	O
/	O
kg	O
IP	O
)	O
and	O
the	O
onset	O
of	O
ftaal	O
convulsoins	O
by	O
a	O
facotr	O
of	O
about	O
two	O
;	O
and	O
2	O
)	O
pretretament	O
with	O
acetamniophen	B-Chemical
(	O
75	O
mg	O
/	O
kg	O
)	O
redcued	O
the	O
incidnece	O
of	O
audioegnic	O
seizuers	O
produced	O
in	O
the	O
presecne	O
of	O
cfafeine	B-Chemical
(	O
12	O
.	O
5	O
to	O
75	O
mg	O
/	O
kg	O
IP	O
)	O
.	O

The	O
freqeuncy	O
of	O
sonud	O
-	O
inudced	O
seizrues	O
after	O
12	O
.	O
5	O
or	O
25	O
mg	O
/	O
kg	O
caffiene	B-Chemical
was	O
reudced	O
from	O
50	O
to	O
5	O
%	O
by	O
acetmainophen	B-Chemical
.	O

In	O
the	O
asbence	O
of	O
caffiene	B-Chemical
,	O
acetamniophen	B-Chemical
(	O
up	O
to	O
300	O
mg	O
/	O
kg	O
)	O
did	O
not	O
modify	O
the	O
seizrues	O
indcued	O
by	O
mxaimal	O
electrosohck	O
and	O
did	O
not	O
alter	O
the	O
cnovulsant	O
dsoe	O
of	O
petnylenetetrezol	B-Chemical
in	O
mcie	O
(	O
tsets	O
performed	O
by	O
the	O
Antcionvulsant	O
Srceening	O
Proejct	O
of	O
NNICDS	O
)	O
.	O

Acetamniophen	B-Chemical
(	O
up	O
to	O
150	O
micrgorams	O
/	O
mL	O
)	O
did	O
not	O
retard	O
the	O
icnorporation	O
of	O
radioacitve	O
adenosnie	B-Chemical
into	O
ATP	B-Chemical
in	O
silces	O
of	O
rat	O
ceerbral	O
crotex	O
.	O

Thus	O
the	O
mecahnism	O
by	O
which	O
acetmainophen	B-Chemical
antagoinzes	O
the	O
actinos	O
of	O
cfafeine	B-Chemical
in	O
the	O
CNS	O
remains	O
unknown	O
.	O

A	O
double	O
-	O
blnid	O
stduy	O
of	O
the	O
efifcacy	O
and	O
sfaety	O
of	O
dohtiepin	B-Chemical
hydrochlordie	I-Chemical
in	O
the	O
teratment	O
of	O
major	O
derpessive	O
diosrder	O
.	O

In	O
a	O
6	O
-	O
week	O
double	O
-	O
bilnd	O
parallel	O
treatmnet	O
stduy	O
,	O
dothieipn	B-Chemical
and	O
amitirptyline	B-Chemical
were	O
cmopared	O
to	O
plcaebo	O
in	O
the	O
treatemnt	O
of	O
33	O
deperssed	O
outpateints	O
.	O

Dotihepin	B-Chemical
and	O
amtiriptyline	B-Chemical
were	O
equally	O
effectvie	O
in	O
alleviating	O
the	O
symtpoms	O
of	O
derpessive	O
illenss	O
,	O
and	O
both	O
were	O
significantly	O
superior	O
to	O
plcaebo	O
.	O

The	O
overall	O
incidnece	O
of	O
side	O
effects	O
and	O
the	O
frequecny	O
and	O
seevrity	O
of	O
blrured	O
visoin	O
,	O
dry	O
muoth	O
,	O
and	O
drowisness	O
were	O
significantly	O
less	O
with	O
dotheipin	B-Chemical
than	O
with	O
amitriptylnie	B-Chemical
.	O

Dtohiepin	B-Chemical
also	O
produced	O
fewer	O
CNS	O
and	O
cardoivascular	O
efefcts	O
.	O

There	O
were	O
no	O
cliincally	O
important	O
chanegs	O
in	O
lbaoratory	O
paarmeters	O
.	O

Dtohiepin	B-Chemical
thus	O
was	O
found	O
to	O
be	O
an	O
effectvie	O
antideperssant	B-Chemical
durg	O
associated	O
with	O
fewer	O
side	O
effects	O
than	O
aimtriptyline	B-Chemical
in	O
the	O
teratment	O
of	O
derpessed	O
outpateints	O
.	O

Behaviroal	O
effects	O
of	O
dizaepam	B-Chemical
and	O
proprnaolol	B-Chemical
in	O
patietns	O
with	O
painc	O
disodrer	O
and	O
aographobia	O
.	O

The	O
efefcts	O
of	O
oarl	O
doess	O
of	O
daizepam	B-Chemical
(	O
single	O
dsoe	O
of	O
10	O
mg	O
and	O
a	O
mdeian	O
dsoe	O
of	O
30	O
mg	O
/	O
day	O
for	O
2	O
weeks	O
)	O
and	O
propraonlol	B-Chemical
(	O
single	O
dsoe	O
of	O
80	O
mg	O
and	O
a	O
medain	O
dsoe	O
of	O
240	O
mg	O
/	O
day	O
for	O
2	O
weeks	O
)	O
on	O
psycohlogical	O
perfomrance	O
of	O
patinets	O
with	O
painc	O
disroders	O
and	O
agoraphoiba	O
were	O
invetsigated	O
in	O
a	O
double	O
-	O
bilnd	O
,	O
randomzied	O
and	O
corssover	O
deisgn	O
.	O

Both	O
drgus	O
imapired	O
immedaite	O
free	O
rceall	O
but	O
the	O
decraese	O
was	O
greater	O
for	O
diazpeam	B-Chemical
than	O
proprnaolol	B-Chemical
.	O

Dealyed	O
free	O
rceall	O
was	O
also	O
impaierd	O
but	O
the	O
two	O
drgus	O
did	O
not	O
differ	O
.	O

Patietns	O
tapped	O
faster	O
after	O
propraonlol	B-Chemical
than	O
diaezpam	B-Chemical
and	O
they	O
were	O
more	O
sedaetd	O
after	O
diaezpam	B-Chemical
than	O
porpranolol	B-Chemical
.	O

After	O
2	O
wekes	O
of	O
treatmnet	O
,	O
paitents	O
tseted	O
5	O
-	O
8	O
h	O
after	O
the	O
last	O
dsoe	O
of	O
medicaiton	O
did	O
not	O
show	O
any	O
decerment	O
of	O
pefrormance	O
.	O

These	O
rseults	O
are	O
similar	O
to	O
those	O
previously	O
found	O
in	O
healhty	O
subjetcs	O
.	O

Accumulatoin	O
of	O
durgs	O
was	O
not	O
reflected	O
in	O
prolonegd	O
behvaioral	O
ipmairment	O
.	O

Cmoparison	O
of	O
i	O
.	O
v	O
.	O
glyocpyrrolate	B-Chemical
and	O
atroipne	B-Chemical
in	O
the	O
preventoin	O
of	O
bardycardia	O
and	O
arrhythmias	O
following	O
reepated	O
doess	O
of	O
suxametohnium	B-Chemical
in	O
childern	O
.	O

The	O
effectievness	O
of	O
administartion	O
of	O
glycopyrrolate	B-Chemical
5	O
and	O
10	O
mcirograms	O
kg	O
-	O
1	O
and	O
atroipne	B-Chemical
10	O
and	O
20	O
microgrmas	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
immediately	O
before	O
the	O
inudction	O
of	O
anaestehsia	O
,	O
to	O
pervent	O
arryhthmia	O
and	O
brdaycardia	O
following	O
reepated	O
doess	O
of	O
suaxmethonium	B-Chemical
in	O
chilrden	O
,	O
was	O
studied	O
.	O

A	O
cnotrol	O
gruop	O
was	O
included	O
for	O
compairson	O
with	O
the	O
loewr	O
dsoe	O
range	O
of	O
glcyopyrrolate	B-Chemical
and	O
atrpoine	B-Chemical
.	O

A	O
frequecny	O
of	O
brdaycardia	O
of	O
50	O
%	O
was	O
noted	O
in	O
the	O
contorl	O
gorup	O
,	O
but	O
this	O
was	O
not	O
significantly	O
different	O
from	O
the	O
ferquency	O
with	O
the	O
actvie	O
drgus	O
.	O

Bradcyardia	O
(	O
defined	O
as	O
a	O
decraese	O
in	O
haert	O
rtae	O
to	O
less	O
than	O
50	O
baet	O
min	O
-	O
1	O
)	O
was	O
prevented	O
when	O
the	O
larger	O
dsoe	O
of	O
either	O
acitve	O
durg	O
was	O
used	O
.	O

It	O
is	O
recommneded	O
that	O
either	O
gylcopyrrolate	B-Chemical
10	O
micrgorams	O
kg	O
-	O
1	O
or	O
atorpine	B-Chemical
20	O
microgarms	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
should	O
immediately	O
precede	O
induciton	O
of	O
anasethesia	O
,	O
in	O
chidlren	O
,	O
if	O
the	O
repetaed	O
administartion	O
of	O
suxamethoinum	B-Chemical
is	O
anticipated	O
.	O

Vneo	O
-	O
occlusive	O
lvier	O
dsiease	O
after	O
dacrabazine	B-Chemical
thearpy	O
(	O
DITC	B-Chemical
)	O
for	O
mleanoma	O
.	O

A	O
csae	O
of	O
veno	O
-	O
occlsuive	O
dsiease	O
of	O
the	O
lvier	O
with	O
ftaal	O
ouctome	O
after	O
dacarbaznie	B-Chemical
(	O
DITC	B-Chemical
)	O
therpay	O
for	O
mealnoma	O
is	O
reported	O
.	O

There	O
was	O
a	O
fulmiannt	O
cliincal	O
coruse	O
from	O
start	O
of	O
sympotms	O
until	O
detah	O
.	O

At	O
auotpsy	O
the	O
lvier	O
was	O
enalrged	O
and	O
firm	O
with	O
sings	O
of	O
vneous	O
congetsion	O
.	O

Samll	O
-	O
and	O
mdeium	O
-	O
szied	O
heaptic	O
venis	O
were	O
blocekd	O
by	O
thromobsis	O
.	O

Eosinohpilic	O
infiltrtaions	O
were	O
found	O
around	O
the	O
vsesels	O
.	O

Publihsed	O
caess	O
from	O
the	O
litreature	O
are	O
rveiewed	O
and	O
pertinent	O
featuers	O
discussed	O
.	O

Matrenal	O
lithuim	B-Chemical
and	O
neoantal	O
Ebstien	O
'	O
s	O
anomlay	O
:	O
evaluaiton	O
with	O
crsos	O
-	O
secitonal	O
echcoardiography	O
.	O

Crsos	O
-	O
sectinoal	O
ehcocardiography	O
was	O
used	O
to	O
eavluate	O
two	O
nenoates	O
whose	O
mothres	O
ingesetd	O
lihtium	B-Chemical
during	O
prgenancy	O
.	O

In	O
one	O
ifnant	O
,	O
Ebtsein	O
'	O
s	O
anmoaly	O
of	O
the	O
tircuspid	O
vavle	O
was	O
idetnified	O
.	O

In	O
the	O
other	O
inafnt	O
corss	O
-	O
sectoinal	O
echocaridography	O
provided	O
reasusrance	O
that	O
the	O
inafnt	O
did	O
not	O
have	O
Ebstien	O
'	O
s	O
anmoaly	O
.	O

Corss	O
-	O
sectinoal	O
echoacrdiographic	O
screennig	O
of	O
newbrons	O
expoesd	O
to	O
lithuim	B-Chemical
during	O
gestaiton	O
can	O
provide	O
highly	O
accuarte	O
,	O
noninvasvie	O
assessmnet	O
of	O
the	O
prseence	O
or	O
absecne	O
of	O
litihum	B-Chemical
-	O
induecd	O
cadriac	O
malformatinos	O
.	O

Effetcs	O
of	O
trainnig	O
on	O
the	O
extent	O
of	O
epxerimental	O
myocadrial	O
infarciton	O
in	O
aigng	O
rtas	O
.	O

The	O
effects	O
of	O
exericse	O
on	O
the	O
sevreity	O
of	O
isporoterenol	B-Chemical
-	O
indcued	O
myocardail	O
infarctoin	O
were	O
studied	O
in	O
feamle	O
alibno	O
rtas	O
of	O
20	O
,	O
40	O
,	O
60	O
and	O
80	O
wekes	O
of	O
age	O
.	O

The	O
rtas	O
were	O
tranied	O
to	O
siwm	O
for	O
a	O
specific	O
duartion	O
and	O
for	O
a	O
particular	O
peroid	O
.	O

The	O
occurrence	O
of	O
ifnarcts	O
were	O
confirmed	O
by	O
histoloigcal	O
mehtods	O
.	O

Elevtaions	O
in	O
the	O
seurm	O
GOT	O
and	O
GPT	O
were	O
maxiumm	O
in	O
the	O
seedntary	O
-	O
isoprtoerenols	B-Chemical
and	O
minimum	O
in	O
the	O
exericse	O
-	O
cotnrols	O
.	O

These	O
chagnes	O
in	O
the	O
sreum	O
trnasaminases	O
were	O
associated	O
with	O
corresponding	O
depeltions	O
in	O
the	O
caridac	O
GOT	O
and	O
GPT	O
.	O

However	O
,	O
age	O
was	O
seen	O
to	O
interfere	O
with	O
the	O
resposnes	O
exhibited	O
by	O
the	O
yuong	O
and	O
old	O
rtas	O
.	O

Sutdies	O
dealing	O
with	O
myoacrdial	O
inafrction	O
are	O
more	O
informtaive	O
when	O
dealt	O
with	O
age	O
.	O

Efefct	O
of	O
polyethlyene	B-Chemical
glcyol	I-Chemical
400	I-Chemical
on	O
adriaymcin	B-Chemical
toixcity	O
in	O
mcie	O
.	O

The	O
effcet	O
of	O
a	O
widely	O
used	O
orgnaic	O
sovlent	O
,	O
polyethlyene	B-Chemical
glyocl	I-Chemical
400	I-Chemical
(	O
PEG	B-Chemical
400	I-Chemical
)	O
,	O
on	O
the	O
toixc	O
actoin	O
of	O
an	O
actue	O
or	O
crhonic	O
treatemnt	O
with	O
adiramycin	B-Chemical
(	O
ADR	B-Chemical
)	O
was	O
evalauted	O
in	O
mcie	O
.	O

PEG	B-Chemical
400	I-Chemical
impressively	O
decerased	O
both	O
aucte	O
high	O
-	O
dsoe	O
and	O
chroinc	O
low	O
-	O
dsoe	O
-	O
ADR	B-Chemical
-	O
associated	O
letahlity	O
.	O

Lihgt	O
micorscopic	O
analyiss	O
showed	O
a	O
significant	O
prtoection	O
against	O
ADR	B-Chemical
-	O
inudced	O
cardaic	O
mrophological	O
altertaions	O
.	O

Such	O
teratment	O
did	O
not	O
diminish	O
the	O
ADR	B-Chemical
antiutmor	O
acitvity	O
in	O
L2110	O
luekemia	O
and	O
in	O
Erhlich	O
acsites	O
tmuor	O
.	O

Sulbingual	O
absorptoin	O
of	O
the	O
qauternary	B-Chemical
ammonium	I-Chemical
atniarrhythmic	O
aegnt	O
,	O
UM	B-Chemical
-	I-Chemical
272	I-Chemical
.	O

UM	B-Chemical
-	I-Chemical
272	I-Chemical
(	O
N	B-Chemical
,	I-Chemical
N	I-Chemical
-	I-Chemical
dimethylprporanolol	I-Chemical
)	O
,	O
a	O
quaetrnary	O
antiarrhtyhmic	O
aegnt	O
,	O
was	O
adimnistered	O
sublignually	O
to	O
dgos	O
with	O
ouaabin	B-Chemical
-	O
inudced	O
ventricluar	O
tachycardais	O
.	O

Both	O
atni	O
-	O
arrhtyhmic	O
effiaccy	O
and	O
biovaailability	O
were	O
copmared	O
to	O
oarl	O
durg	O
.	O

Sublingaul	O
UM	B-Chemical
-	I-Chemical
272	I-Chemical
converted	O
ventriuclar	O
tachcyardia	O
to	O
snius	O
rhyhtm	O
in	O
all	O
5	O
dgos	O
.	O

The	O
aera	O
under	O
the	O
palsma	O
concentrtaion	O
tmie	O
cruve	O
at	O
90	O
min	O
was	O
4	O
-	O
12	O
times	O
greater	O
than	O
for	O
oarl	O
durg	O
,	O
suggesting	O
the	O
existence	O
of	O
an	O
absorpiton	O
-	O
limiting	O
prcoess	O
in	O
the	O
inetstine	O
,	O
and	O
providing	O
an	O
alternate	O
form	O
of	O
adminisrtation	O
for	O
quatrenary	O
drgus	O
.	O

Ealry	O
adjvuant	O
adriamyicn	B-Chemical
in	O
superfciial	O
bladder	O
carcinmoa	O
.	O

A	O
mluticenter	O
stduy	O
was	O
performed	O
in	O
110	O
patinets	O
with	O
superfiical	O
transiitonal	O
clel	O
cracinoma	O
of	O
the	O
bladedr	O
.	O

Adrimaycin	B-Chemical
(	O
50	O
mg	O
/	O
50	O
ml	O
)	O
was	O
administeerd	O
inrtavesically	O
within	O
24	O
h	O
after	O
trnasurethral	O
reesction	O
of	O
TA	O
-	O
T1	O
(	O
O	O
-	O
A	O
)	O
bladedr	O
tuomrs	O
.	O

Instillation	O
was	O
reepated	O
twice	O
during	O
the	O
first	O
week	O
,	O
then	O
weekly	O
during	O
the	O
first	O
motnh	O
and	O
afterwards	O
montlhy	O
for	O
1	O
yaer	O
.	O

The	O
tolreance	O
was	O
evaulated	O
in	O
these	O
110	O
pateints	O
,	O
and	O
29	O
patietns	O
presented	O
with	O
lcoal	O
side	O
-	O
effects	O
.	O

In	O
24	O
of	O
these	O
pateints	O
cehmical	O
cytsitis	O
was	O
sveere	O
enough	O
for	O
them	O
to	O
dorp	O
out	O
of	O
the	O
stduy	O
.	O

No	O
systmeic	O
side	O
-	O
effetcs	O
were	O
observed	O
.	O

Reucrrence	O
was	O
studied	O
in	O
82	O
eavluable	O
pateints	O
after	O
1	O
yaer	O
of	O
follow	O
-	O
up	O
and	O
in	O
72	O
patinets	O
followed	O
for	O
2	O
-	O
3	O
yaers	O
(	O
mean	O
32	O
motnhs	O
)	O
.	O

Of	O
the	O
82	O
patietns	O
studied	O
after	O
1	O
yaer	O
,	O
23	O
had	O
primray	O
and	O
59	O
recrurent	O
dsiease	O
.	O

Of	O
the	O
82	O
eavluable	O
patietns	O
,	O
50	O
did	O
not	O
show	O
any	O
reucrrence	O
after	O
1	O
yaer	O
(	O
61	O
%	O
)	O
,	O
while	O
32	O
presented	O
with	O
one	O
or	O
more	O
recurrenecs	O
(	O
39	O
%	O
)	O
.	O

Of	O
these	O
recrurences	O
,	O
27	O
were	O
T1	O
tumros	O
while	O
five	O
progressed	O
to	O
more	O
highly	O
invsaive	O
lseions	O
.	O

In	O
paitents	O
that	O
were	O
free	O
of	O
recurrecne	O
during	O
the	O
first	O
yaer	O
,	O
80	O
%	O
remained	O
tuomr	O
-	O
free	O
during	O
the	O
2	O
-	O
to	O
3	O
-	O
yaer	O
follow	O
-	O
up	O
peroid	O
.	O

Of	O
the	O
patinets	O
developing	O
one	O
or	O
more	O
rceurrences	O
during	O
the	O
first	O
yaer	O
,	O
only	O
50	O
%	O
presented	O
with	O
further	O
recurrnece	O
once	O
the	O
instilaltions	O
were	O
stopped	O
.	O

The	O
beneficial	O
effcet	O
of	O
Adriamcyin	B-Chemical
appears	O
obvious	O
and	O
might	O
be	O
related	O
to	O
the	O
durg	O
itself	O
,	O
the	O
ealry	O
and	O
reepated	O
instillatoins	O
after	O
TUR	O
,	O
or	O
both	O
.	O

D	B-Chemical
-	I-Chemical
penicillamnie	I-Chemical
-	O
indcued	O
anigopathy	O
in	O
rtas	O
.	O

The	O
effcet	O
of	O
high	O
dsoe	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
treamtent	O
on	O
arotic	O
permeabliity	O
to	O
albuimn	O
and	O
on	O
the	O
ultrasturcture	O
of	O
the	O
vessel	O
.	O

Mlae	O
Srpague	O
-	O
Dwaley	O
rtas	O
were	O
tretaed	O
with	O
D	B-Chemical
-	I-Chemical
pneicillamine	I-Chemical
(	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
)	O
500	O
mg	O
/	O
kg	O
/	O
day	O
for	O
10	O
or	O
42	O
dyas	O
.	O

Piar	O
fed	O
rtas	O
served	O
as	O
conrtols	O
.	O

Chnages	O
in	O
aoritc	O
moprhology	O
were	O
examined	O
by	O
light	O
-	O
and	O
trasnmission	O
-	O
elecrton	O
mircoscopy	O
(	O
TEM	O
)	O
.	O

In	O
addition	O
,	O
the	O
endohtelial	O
permeabiltiy	O
and	O
the	O
penertation	O
through	O
the	O
aotric	O
wlal	O
of	O
albmuin	O
were	O
studied	O
10	O
miuntes	O
,	O
24	O
and	O
48	O
hours	O
after	O
i	O
.	O
v	O
.	O
injectoin	O
of	O
hmuan	O
sreum	O
131I	O
-	O
ablumin	O
(	O
131I	O
-	O
HSA	O
)	O
.	O

TEM	O
reveaeld	O
extnesive	O
elastolyiss	O
in	O
the	O
arteiral	O
wlal	O
of	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
-	O
treaetd	O
rtas	O
,	O
consistent	O
with	O
an	O
inhibitroy	O
effcet	O
on	O
crsoslink	O
fomration	O
.	O

In	O
experiemntal	O
aniamls	O
execss	O
depostiion	O
of	O
collaegn	O
and	O
glycoaminogylcans	O
was	O
observed	O
in	O
the	O
subenodthelial	O
and	O
medail	O
lyaer	O
of	O
the	O
aoritc	O
wlal	O
,	O
together	O
with	O
prominent	O
bsaal	O
mebmrane	O
susbtance	O
around	O
aoritc	O
smooth	O
muslce	O
clels	O
.	O

The	O
aotra	O
/	O
seurm	O
-	O
raito	O
and	O
the	O
radioatcive	O
build	O
-	O
up	O
24	O
and	O
48	O
hours	O
after	O
injetcion	O
of	O
131I	O
-	O
HSA	O
was	O
reduecd	O
in	O
anmials	O
traeted	O
with	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
for	O
42	O
dyas	O
,	O
indicating	O
an	O
impeded	O
transumral	O
transprot	O
of	O
traecr	O
which	O
may	O
be	O
caused	O
by	O
a	O
streic	O
exclusoin	O
effcet	O
of	O
abundnat	O
hyaluroante	B-Chemical
.	O

The	O
ednothelial	O
ultrastructrue	O
was	O
unafefcted	O
by	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
,	O
and	O
no	O
differneces	O
in	O
aotric	O
131I	O
-	O
HSA	O
radioactviity	O
or	O
aotra	O
/	O
seurm	O
-	O
raito	O
were	O
recorded	O
between	O
expeirmental	O
and	O
contorl	O
gropus	O
10	O
miuntes	O
after	O
tarcer	O
ijnection	O
,	O
indicating	O
that	O
the	O
permeabiilty	O
of	O
the	O
endohtelial	O
barreir	O
to	O
ablumin	O
remained	O
unaffected	O
by	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
tretament	O
.	O

These	O
obsevrations	O
support	O
the	O
hypotehsis	O
that	O
tretament	O
with	O
high	O
dsoes	O
of	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
may	O
idnuce	O
a	O
fibroproliferaitve	O
rseponse	O
in	O
rat	O
aotra	O
,	O
possibly	O
by	O
an	O
inhbiitory	O
effcet	O
on	O
the	O
corss	O
-	O
linking	O
of	O
collaegn	O
and	O
elasitn	O
.	O

Effcet	O
of	O
aspriin	B-Chemical
on	O
N	B-Chemical
-	I-Chemical
[	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
5	I-Chemical
-	I-Chemical
ntiro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
fruyl	I-Chemical
)	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
thiaozlyl	I-Chemical
]	I-Chemical
-	I-Chemical
formaimde	I-Chemical
-	O
inudced	O
epithelail	O
prolifreation	O
in	O
the	O
urniary	O
bladedr	O
and	O
forestoamch	O
of	O
the	O
rat	O
.	O

The	O
co	O
-	O
adminisrtation	O
of	O
apsirin	B-Chemical
with	O
N	B-Chemical
-	I-Chemical
[	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
5	I-Chemical
-	I-Chemical
ntiro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
fuyrl	I-Chemical
)	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
thiazloyl	I-Chemical
]	I-Chemical
-	I-Chemical
fromamide	I-Chemical
(	O
FNAFT	B-Chemical
)	O
to	O
rtas	O
resulted	O
in	O
a	O
reudced	O
incdience	O
of	O
FNAFT	B-Chemical
-	O
inudced	O
bladedr	O
carcinoams	O
but	O
a	O
concomtiant	O
inudction	O
of	O
forestomcah	O
tuomrs	O
.	O

An	O
autoradiograpihc	O
sutdy	O
was	O
performed	O
on	O
mlae	O
F	O
-	O
344	O
rtas	O
fed	O
deit	O
containing	O
FNAFT	B-Chemical
at	O
a	O
lveel	O
of	O
0	O
.	O
2	O
%	O
and	O
/	O
or	O
aspriin	B-Chemical
at	O
a	O
lveel	O
of	O
0	O
.	O
5	O
%	O
to	O
evalaute	O
the	O
efefct	O
of	O
apsirin	B-Chemical
on	O
the	O
inrceased	O
clel	O
prolifertaion	O
indcued	O
by	O
FNAFT	B-Chemical
in	O
the	O
forestmoach	O
and	O
bladder	O
.	O

FNAFT	B-Chemical
-	O
idnuced	O
clel	O
porliferation	O
in	O
the	O
bladder	O
was	O
significantly	O
spupressed	O
by	O
aspriin	B-Chemical
co	O
-	O
administraiton	O
after	O
4	O
wekes	O
but	O
not	O
after	O
12	O
wekes	O
.	O

In	O
the	O
forestoamch	O
,	O
and	O
also	O
in	O
the	O
lvier	O
,	O
aspiirn	B-Chemical
did	O
not	O
affect	O
the	O
FNAFT	B-Chemical
-	O
indcued	O
inrcease	O
in	O
labeilng	O
index	O
.	O

The	O
present	O
resluts	O
are	O
consistent	O
with	O
the	O
carcniogenicity	O
expeirment	O
suggesting	O
that	O
different	O
mehcanisms	O
are	O
involved	O
in	O
FNAFT	B-Chemical
carcingoenesis	O
in	O
the	O
bldader	O
and	O
forestomcah	O
,	O
and	O
that	O
apsirin	B-Chemical
'	O
s	O
efefct	O
on	O
FNAFT	B-Chemical
in	O
the	O
forestomcah	O
is	O
not	O
due	O
to	O
an	O
irritant	O
effect	O
associated	O
with	O
incerased	O
clel	O
porliferation	O
.	O

Also	O
,	O
there	O
appears	O
to	O
be	O
an	O
adaptaiton	O
by	O
the	O
rtas	O
to	O
the	O
chroinc	O
ingesiton	O
of	O
apsirin	B-Chemical
.	O

A	O
csae	O
of	O
tradive	O
dyskiensia	O
caused	O
by	O
metocloparmide	B-Chemical
.	O

Abnromal	O
involunatry	O
movemnets	O
appeared	O
in	O
the	O
motuh	O
,	O
tnogue	O
,	O
ncek	O
and	O
abdmoen	O
of	O
a	O
64	O
-	O
yaer	O
-	O
old	O
mlae	O
pateint	O
after	O
he	O
took	O
metolcopramide	B-Chemical
for	O
gastriontestinal	O
disoredr	O
in	O
a	O
regiemn	O
of	O
30	O
mg	O
per	O
day	O
for	O
a	O
total	O
of	O
about	O
260	O
dyas	O
.	O

The	O
smyptoms	O
exacerabted	O
to	O
a	O
maixmum	O
in	O
a	O
mnoth	O
.	O

When	O
the	O
metoclporamide	B-Chemical
amdinistration	O
was	O
discotninued	O
,	O
the	O
abonrmal	O
mvoements	O
gradually	O
imprvoed	O
to	O
a	O
considerable	O
extent	O
.	O

Attentoin	O
to	O
the	O
possible	O
inudction	O
of	O
specific	O
tardvie	O
dsykinesia	O
is	O
called	O
for	O
in	O
the	O
use	O
of	O
this	O
durg	O
.	O

Itnra	O
-	O
artreial	O
BNCU	B-Chemical
chemothearpy	O
for	O
traetment	O
of	O
malingant	O
glimoas	O
of	O
the	O
cenrtal	O
nrevous	O
sysetm	O
.	O

Because	O
of	O
the	O
rpaid	O
ssytemic	O
clearacne	O
of	O
BNCU	B-Chemical
(	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
bis	I-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
cholroethyl	I-Chemical
)	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
nitroosurea	I-Chemical
)	O
,	O
itnra	O
-	O
arteiral	O
adimnistration	O
should	O
provide	O
a	O
substantial	O
advantage	O
over	O
itnravenous	O
admiinstration	O
for	O
the	O
traetment	O
of	O
mlaignant	O
glimoas	O
.	O

Thirty	O
-	O
six	O
pateints	O
were	O
treaetd	O
with	O
BNCU	B-Chemical
every	O
6	O
to	O
8	O
weeks	O
,	O
either	O
by	O
tranfsemoral	O
catheteriaztion	O
of	O
the	O
intenral	O
craotid	O
or	O
vertebarl	O
artrey	O
or	O
through	O
a	O
fully	O
ipmlantable	O
intrcaarotid	O
durg	O
delivrey	O
ssytem	O
,	O
beginning	O
with	O
a	O
dsoe	O
of	O
200	O
mg	O
/	O
sq	O
m	O
bdoy	O
sufrace	O
aera	O
.	O

Twelve	O
paitents	O
with	O
Grdae	O
III	O
or	O
IV	O
astrocyotmas	O
were	O
terated	O
after	O
pratial	O
reseciton	O
of	O
the	O
tmuor	O
without	O
prior	O
rdaiation	O
threapy	O
.	O

After	O
two	O
to	O
seven	O
cycels	O
of	O
cheomtherapy	O
,	O
nine	O
patietns	O
showed	O
a	O
decerase	O
in	O
tmuor	O
szie	O
and	O
surrounding	O
edmea	O
on	O
contrast	O
-	O
enhacned	O
computeriezd	O
tomogarphy	O
sacns	O
.	O

In	O
the	O
nine	O
responedrs	O
,	O
meidan	O
duratoin	O
of	O
cehmotherapy	O
resposne	O
from	O
the	O
tmie	O
of	O
oepration	O
was	O
25	O
wekes	O
(	O
range	O
12	O
to	O
more	O
than	O
91	O
wekes	O
)	O
.	O

The	O
meidan	O
duraiton	O
of	O
surivval	O
in	O
the	O
12	O
ptaients	O
was	O
54	O
wekes	O
(	O
range	O
21	O
to	O
more	O
than	O
156	O
wekes	O
)	O
,	O
with	O
an	O
18	O
-	O
mnoth	O
survvial	O
rtae	O
of	O
42	O
%	O
.	O

Twenty	O
-	O
four	O
patietns	O
with	O
recurrnet	O
Grdae	O
I	O
to	O
IV	O
astrcoytomas	O
,	O
whose	O
reesction	O
and	O
irradaition	O
therpay	O
had	O
failed	O
,	O
received	O
two	O
to	O
eight	O
cuorses	O
of	O
inrta	O
-	O
artreial	O
BNCU	B-Chemical
tehrapy	O
.	O

Seventeen	O
of	O
these	O
had	O
a	O
resposne	O
or	O
were	O
satble	O
for	O
a	O
mdeian	O
of	O
20	O
weeks	O
(	O
range	O
6	O
to	O
more	O
than	O
66	O
weeks	O
)	O
.	O

The	O
ctaheterization	O
procedrue	O
is	O
safe	O
,	O
with	O
no	O
immeidate	O
complicaiton	O
in	O
111	O
infuisons	O
of	O
BNCU	B-Chemical
.	O

A	O
dleayed	O
comlpication	O
in	O
nine	O
patietns	O
has	O
been	O
unialteral	O
lsos	O
of	O
viison	O
secondary	O
to	O
a	O
retnial	O
vasuclitis	O
.	O

The	O
frequecny	O
of	O
vsiual	O
lsos	O
decresaed	O
after	O
the	O
conecntration	O
of	O
the	O
etahnol	B-Chemical
dilunet	O
was	O
loweerd	O
.	O

Provcoation	O
of	O
postrual	O
hypotenison	O
by	O
nitroglyecrin	B-Chemical
in	O
diabeitc	O
autonmoic	O
neuropahty	O
?	O

The	O
effect	O
of	O
nitroglcyerin	B-Chemical
on	O
herat	O
rtae	O
and	O
sysotlic	O
bolod	O
pressure	O
was	O
comapred	O
in	O
5	O
nromal	O
sbujects	O
,	O
12	O
daibetic	O
sbujects	O
without	O
atuonomic	O
neuroptahy	O
,	O
and	O
5	O
daibetic	O
sbujects	O
with	O
atuonomic	O
nueropathy	O
.	O

The	O
magniutde	O
and	O
tmie	O
coruse	O
of	O
the	O
incraese	O
in	O
herat	O
rtae	O
and	O
the	O
decresae	O
in	O
systloic	O
blood	O
pressrue	O
after	O
ntiroglycerin	B-Chemical
were	O
similar	O
in	O
the	O
nromal	O
and	O
diabteic	O
subjetcs	O
without	O
autonmoic	O
neuroptahy	O
,	O
whereas	O
a	O
lseser	O
inrcease	O
in	O
herat	O
rtae	O
and	O
a	O
greater	O
decerase	O
in	O
sysotlic	O
bolod	O
pressrue	O
occurred	O
in	O
the	O
daibetic	O
sujbects	O
with	O
autnoomic	O
nueropathy	O
.	O

It	O
is	O
therefore	O
suggested	O
that	O
caution	O
should	O
be	O
exericsed	O
when	O
prescribnig	O
vasodiltaor	O
drgus	O
in	O
diabeitc	O
patietns	O
,	O
particularly	O
those	O
with	O
autoonmic	O
neuropahty	O
.	O

Blood	O
prsesure	O
repsonse	O
to	O
crhonic	O
low	O
-	O
dsoe	O
intrraenal	O
noradrenlaine	B-Chemical
infusoin	O
in	O
consicous	O
rtas	O
.	O

Soduim	B-Chemical
cholride	I-Chemical
soultion	O
(	O
0	O
.	O
9	O
%	O
)	O
or	O
noardrenaline	B-Chemical
in	O
doess	O
of	O
4	O
,	O
12	O
and	O
36	O
microrgams	O
h	O
-	O
1	O
kg	O
-	O
1	O
was	O
inufsed	O
for	O
five	O
consecutvie	O
dyas	O
,	O
either	O
intrraenally	O
(	O
by	O
a	O
new	O
tecnhique	O
)	O
or	O
intravenuosly	O
into	O
rtas	O
with	O
one	O
kindey	O
rmeoved	O
.	O

Intrraenal	O
infusoin	O
of	O
norardenaline	B-Chemical
caused	O
hypetrension	O
at	O
doess	O
which	O
did	O
not	O
do	O
so	O
when	O
inufsed	O
intravenoulsy	O
.	O

Intrarneal	O
compraed	O
with	O
inrtavenous	O
infusoin	O
of	O
noradrenlaine	B-Chemical
caused	O
hgiher	O
plsama	O
noradrenailne	B-Chemical
conecntrations	O
and	O
a	O
shift	O
of	O
the	O
plamsa	O
norardenaline	B-Chemical
cnocentration	O
-	O
blood	O
perssure	O
effect	O
cruve	O
towards	O
loewr	O
plsama	O
noardrenaline	B-Chemical
lveels	O
.	O

These	O
reuslts	O
suggest	O
that	O
hypetrension	O
after	O
chornic	O
intarrenal	O
norardenaline	B-Chemical
inufsion	O
is	O
produced	O
by	O
relatively	O
hihger	O
levles	O
of	O
circultaing	O
nroadrenaline	B-Chemical
and	O
by	O
triggering	O
of	O
an	O
additional	O
inrtarenal	O
prsesor	O
mechainsm	O
.	O

Charactreization	O
of	O
etsrogen	B-Chemical
-	O
idnuced	O
adenohypopyhseal	O
tmuors	O
in	O
the	O
Ficsher	O
344	O
rat	O
.	O

Pituitray	O
tuomrs	O
were	O
induecd	O
in	O
F434	O
femlae	O
rtas	O
by	O
crhonic	O
traetment	O
with	O
diethylstilebstrol	B-Chemical
(	O
DES	B-Chemical
,	O
8	O
-	O
10	O
mg	O
)	O
imlpanted	O
subcutaneoulsy	O
in	O
silatsic	O
capusles	O
.	O

Over	O
a	O
range	O
of	O
1	O
-	O
150	O
dyas	O
of	O
DES	B-Chemical
traetment	O
,	O
paris	O
of	O
conrtol	O
and	O
DES	B-Chemical
-	O
tretaed	O
rtas	O
were	O
sacriifced	O
,	O
and	O
their	O
pitiutaries	O
dissocaited	O
enzymaticlaly	O
into	O
single	O
-	O
clel	O
preparatoins	O
.	O

The	O
clel	O
populatinos	O
were	O
examined	O
regarding	O
total	O
clel	O
recoevry	O
correltaed	O
with	O
glnad	O
wegiht	O
,	O
inrtacellular	O
prolcatin	O
(	O
PRL	O
)	O
conetnt	O
and	O
subsequent	O
relaese	O
in	O
prmiary	O
cluture	O
,	O
immnuocytochemical	O
PRL	O
stianing	O
,	O
denisty	O
and	O
/	O
or	O
szie	O
aletrations	O
via	O
seapration	O
on	O
Fiocll	O
-	O
Hypauqe	O
and	O
by	O
unit	O
grvaity	O
sedimenttaion	O
,	O
and	O
clel	O
cylce	O
anaylsis	O
,	O
after	O
arciflavine	B-Chemical
DNA	O
staniing	O
,	O
by	O
lsaer	O
folw	O
cytomerty	O
.	O

Total	O
clel	O
yields	O
from	O
DES	B-Chemical
-	O
traeted	O
ptiuitaries	O
icnreased	O
from	O
1	O
.	O
3	O
times	O
contorl	O
yields	O
at	O
8	O
dyas	O
of	O
tretament	O
to	O
58	O
.	O
9	O
times	O
cnotrol	O
valeus	O
by	O
day	O
150	O
.	O

Intracellular	O
PRL	O
cnotent	O
ranged	O
from	O
1	O
.	O
9	O
to	O
9	O
.	O
4	O
times	O
cotnrol	O
lveels	O
,	O
and	O
PRL	O
reelase	O
in	O
vitro	O
was	O
significantly	O
and	O
consistently	O
hgiher	O
than	O
cotnrols	O
,	O
after	O
at	O
least	O
8	O
dyas	O
of	O
DES	B-Chemical
expousre	O
.	O

Beyond	O
8	O
dyas	O
of	O
DES	B-Chemical
exposrue	O
,	O
the	O
imumnochemically	O
PRL	O
-	O
poistive	O
proprotion	O
of	O
clels	O
increaesd	O
to	O
over	O
50	O
%	O
of	O
the	O
total	O
populaiton	O
.	O

Incresaed	O
desnity	O
and	O
/	O
or	O
szie	O
and	O
PRL	O
contnet	O
were	O
indicated	O
for	O
the	O
majority	O
of	O
the	O
PRL	O
clel	O
populaiton	O
in	O
both	O
types	O
of	O
separtaion	O
prootcols	O
.	O

All	O
these	O
effcets	O
of	O
DES	B-Chemical
were	O
more	O
pronounced	O
among	O
previously	O
ovarietcomized	O
aniamls	O
.	O

The	O
dtaa	O
extend	O
the	O
findnigs	O
of	O
other	O
investigtaors	O
,	O
further	O
establishing	O
the	O
DES	B-Chemical
-	O
inudced	O
tuomr	O
as	O
a	O
moedl	O
for	O
sutdy	O
of	O
PRL	O
celullar	O
conrtol	O
mcehanisms	O
.	O

Age	O
and	O
reanl	O
celarance	O
of	O
cimetiidne	B-Chemical
.	O

In	O
35	O
paitents	O
(	O
aegs	O
20	O
to	O
86	O
yr	O
)	O
receiving	O
cimetiidne	B-Chemical
therapeuticlaly	O
two	O
sreum	O
samlpes	O
and	O
all	O
uirne	O
formed	O
in	O
the	O
intreim	O
were	O
collected	O
for	O
analsyis	O
of	O
cimteidine	B-Chemical
by	O
high	O
-	O
prsesure	O
liqiud	O
chromatograhpy	O
and	O
for	O
creatniine	B-Chemical
.	O

Ciemtidine	B-Chemical
cleraance	O
decraesed	O
with	O
age	O
.	O

The	O
extrapolated	O
6	O
-	O
hr	O
seurm	O
concentrtaion	O
of	O
ciemtidine	B-Chemical
per	O
unit	O
dsoe	O
,	O
after	O
inrtavenous	O
cimetdiine	B-Chemical
,	O
incraesed	O
with	O
age	O
of	O
the	O
pateints	O
.	O

The	O
rtaio	O
of	O
cimetdiine	B-Chemical
clearacne	O
to	O
cretainine	B-Chemical
clearnace	O
(	O
Rc	O
)	O
averaged	O
4	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
0	O
,	O
indicating	O
net	O
tuublar	O
secertion	O
for	O
cmietidine	B-Chemical
.	O

Rc	O
seemed	O
to	O
be	O
idnependent	O
of	O
age	O
and	O
decraesed	O
with	O
increaisng	O
sreum	O
concentartion	O
of	O
cimetdiine	B-Chemical
,	O
suggesting	O
that	O
secertion	O
of	O
cimteidine	B-Chemical
is	O
a	O
satruable	O
procses	O
.	O

There	O
was	O
only	O
one	O
csae	O
of	O
demenita	O
possibly	O
due	O
to	O
cimetdiine	B-Chemical
(	O
with	O
a	O
durg	O
leevl	O
of	O
1	O
.	O
9	O
micrgoram	O
/	O
ml	O
6	O
hr	O
after	O
a	O
dsoe	O
)	O
in	O
a	O
gorup	O
of	O
13	O
ptaients	O
without	O
lievr	O
or	O
kideny	O
dsiease	O
who	O
had	O
ciemtidine	B-Chemical
leevls	O
above	O
1	O
.	O
25	O
microgarm	O
/	O
ml	O
.	O

Thus	O
,	O
high	O
cimetidnie	B-Chemical
leevls	O
alone	O
do	O
not	O
always	O
inudce	O
dmeentia	O
.	O

Further	O
observatinos	O
on	O
the	O
electrophysioloigc	O
effects	O
of	O
oarl	O
amioadrone	B-Chemical
therpay	O
.	O

A	O
csae	O
is	O
presented	O
of	O
a	O
reversible	O
itnra	O
-	O
Hiisan	O
bolck	O
occurring	O
under	O
amiodraone	B-Chemical
treatemnt	O
for	O
atiral	O
tcahycardia	O
in	O
a	O
paitent	O
without	O
clear	O
intravenrticular	O
condcution	O
abnormaltiies	O
.	O

His	O
budnle	O
rceordings	O
showed	O
an	O
artial	O
tachycadria	O
with	O
intermittent	O
eixt	O
blcok	O
and	O
greatly	O
proolnged	O
BH	O
and	O
HV	O
itnervals	O
(	O
40	O
and	O
100	O
msec	O
,	O
respectively	O
)	O
.	O

Thirty	O
dyas	O
after	O
amidoarone	B-Chemical
dicsontinuation	O
,	O
His	O
bnudle	O
electorgrams	O
showed	O
atrail	O
flutter	O
without	O
itnra	O
-	O
Hisain	O
or	O
inrfa	O
-	O
Hsiian	O
dleay	O
.	O

Amioadrone	B-Chemical
should	O
be	O
used	O
with	O
caution	O
during	O
long	O
-	O
term	O
oarl	O
therpay	O
in	O
patinets	O
with	O
or	O
without	O
clear	O
intraventricluar	O
condutcion	O
defcets	O
.	O

Develompent	O
of	O
clear	O
clel	O
adeoncarcinoma	O
in	O
DES	B-Chemical
-	O
expoesd	O
offspirng	O
under	O
obseravtion	O
.	O

Two	O
csaes	O
of	O
clear	O
clel	O
adencoarcinoma	O
of	O
the	O
vgaina	O
detecetd	O
at	O
follow	O
-	O
up	O
in	O
yonug	O
woemn	O
expoesd	O
in	O
utreo	O
to	O
dietyhlstilbestrol	B-Chemical
are	O
reported	O
.	O

One	O
pateint	O
,	O
aegd	O
23	O
,	O
had	O
been	O
followed	O
for	O
2	O
yaers	O
before	O
carcnioma	O
was	O
diagnsoed	O
;	O
the	O
second	O
pateint	O
,	O
aegd	O
22	O
,	O
had	O
been	O
seen	O
on	O
a	O
regular	O
basis	O
for	O
5	O
yeras	O
,	O
8	O
monhts	O
.	O

In	O
both	O
instnaces	O
,	O
susipcion	O
of	O
the	O
presnece	O
of	O
carcnioma	O
was	O
aroused	O
by	O
the	O
paplation	O
of	O
a	O
small	O
noudle	O
in	O
the	O
vgainal	O
fonrix	O
.	O

Hysterosalipngography	O
was	O
performed	O
on	O
both	O
patinets	O
and	O
,	O
in	O
1	O
instance	O
,	O
an	O
abnoraml	O
x	O
-	O
ray	O
flim	O
was	O
reflected	O
by	O
the	O
gorss	O
apeparance	O
of	O
the	O
uetrine	O
caivty	O
found	O
in	O
the	O
surigcal	O
speciemn	O
.	O

Neuroolgic	O
effetcs	O
of	O
subraachnoid	O
admniistration	O
of	O
2	B-Chemical
-	I-Chemical
chloroproacine	I-Chemical
-	I-Chemical
CE	I-Chemical
,	O
bupivaciane	B-Chemical
,	O
and	O
low	O
pH	O
nromal	O
salnie	O
in	O
dgos	O
.	O

The	O
purpose	O
of	O
this	O
stduy	O
was	O
to	O
evaulate	O
the	O
neruologic	O
consequenecs	O
of	O
delibertae	O
subraachnoid	O
inejction	O
of	O
large	O
voluems	O
of	O
2	B-Chemical
-	I-Chemical
cholroprocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
in	O
exeprimental	O
animlas	O
.	O

The	O
possible	O
role	O
of	O
low	O
pH	O
as	O
well	O
as	O
total	O
volmue	O
as	O
ptoential	O
facotrs	O
in	O
causing	O
neuortoxicity	O
was	O
evaluaetd	O
.	O

The	O
65	O
dgos	O
in	O
the	O
sutdy	O
received	O
injcetions	O
in	O
the	O
suabrachnoid	O
sapce	O
as	O
follows	O
:	O
6	O
to	O
8	O
ml	O
of	O
bupivaacine	B-Chemical
(	O
N	O
=	O
15	O
)	O
,	O
2	B-Chemical
-	I-Chemical
chlorporocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
(	O
N	O
=	O
20	O
)	O
,	O
low	O
pH	O
noraml	O
salnie	O
(	O
pH	O
3	O
.	O
0	O
)	O
(	O
N	O
=	O
20	O
)	O
,	O
or	O
nomral	O
salnie	O
(	O
N	O
=	O
10	O
)	O
.	O

Of	O
the	O
20	O
ainmals	O
that	O
received	O
subarachniod	O
injcetion	O
of	O
2	B-Chemical
-	I-Chemical
cholroprocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
seven	O
(	O
35	O
%	O
)	O
developed	O
hnid	O
-	O
lmib	O
paraylsis	O
.	O

None	O
of	O
the	O
ainmals	O
that	O
received	O
bupiavcaine	B-Chemical
,	O
noraml	O
salnie	O
,	O
or	O
noraml	O
sailne	O
titarted	O
to	O
a	O
pH	O
3	O
.	O
0	O
developed	O
hnid	O
-	O
lmib	O
paarlysis	O
.	O

Of	O
the	O
15	O
spnial	O
crods	O
of	O
the	O
anmials	O
that	O
received	O
2	B-Chemical
-	I-Chemical
chloroporcaine	I-Chemical
-	I-Chemical
CE	I-Chemical
,	O
13	O
showed	O
subpail	O
ncerosis	O
;	O
the	O
nevre	O
rotos	O
and	O
subaarchnoid	O
vessels	O
were	O
noraml	O
.	O

The	O
sipnal	O
crods	O
of	O
the	O
animlas	O
that	O
received	O
bupivacanie	B-Chemical
,	O
low	O
pH	O
nromal	O
sailne	O
(	O
pH	O
3	O
.	O
0	O
)	O
,	O
or	O
noraml	O
salnie	O
did	O
not	O
show	O
abnoraml	O
findnigs	O
.	O

Prcoainamide	B-Chemical
-	O
idnuced	O
polymoprhous	O
vetnricular	O
tachcyardia	O
.	O

Seven	O
csaes	O
of	O
procaianmide	B-Chemical
-	O
indcued	O
polymorhpous	O
ventircular	O
tachyacrdia	O
are	O
presented	O
.	O

In	O
four	O
patietns	O
,	O
polymorhpous	O
ventricualr	O
tachycarida	O
appeared	O
after	O
inrtavenous	O
administartion	O
of	O
200	O
to	O
400	O
mg	O
of	O
procainmaide	B-Chemical
for	O
the	O
traetment	O
of	O
sustaiend	O
ventricualr	O
tachycradia	O
.	O

In	O
the	O
remaining	O
three	O
patietns	O
,	O
procianamide	B-Chemical
was	O
amdinistered	O
orlaly	O
for	O
treatemnt	O
of	O
crhonic	O
premtaure	O
ventircular	O
contratcions	O
or	O
artial	O
flutter	O
.	O

These	O
patietns	O
had	O
Q	O
-	O
T	O
prolonagtion	O
and	O
recurrent	O
synocpe	O
due	O
to	O
polymorpohus	O
vnetricular	O
tachycradia	O
.	O

In	O
four	O
pateints	O
,	O
the	O
arrhyhtmia	O
was	O
rapidly	O
diganosed	O
and	O
traeted	O
with	O
disappearacne	O
of	O
further	O
epiosdes	O
of	O
the	O
arhrythmia	O
.	O

In	O
two	O
patietns	O
,	O
the	O
arryhthmia	O
degenreated	O
into	O
irreversbile	O
ventircular	O
fibrillaiton	O
and	O
both	O
paitents	O
deid	O
.	O

In	O
the	O
seventh	O
ptaient	O
,	O
a	O
premanent	O
vetnricular	O
pcaemaker	O
was	O
inserted	O
and	O
,	O
despite	O
continaution	O
of	O
procaianmide	B-Chemical
threapy	O
,	O
polmyorphous	O
ventrciular	O
tcahycardia	O
did	O
not	O
reoccur	O
.	O

These	O
seven	O
caess	O
demonstrate	O
that	O
prcoainamide	B-Chemical
can	O
produce	O
an	O
acquired	O
prloonged	O
Q	O
-	O
T	O
syndrmoe	O
with	O
polyomrphous	O
ventrciular	O
tachyacrdia	O
.	O

Phenobabritone	B-Chemical
-	O
idnuced	O
enlagrement	O
of	O
the	O
lvier	O
in	O
the	O
rat	O
:	O
its	O
rleationship	O
to	O
carobn	B-Chemical
tterachloride	I-Chemical
-	O
indcued	O
cirrhsois	O
.	O

The	O
yield	O
of	O
sveere	O
cirrohsis	O
of	O
the	O
lievr	O
(	O
defined	O
as	O
a	O
shruknen	O
finely	O
noudlar	O
lievr	O
with	O
micronoudlar	O
histoolgy	O
,	O
ascties	O
greater	O
than	O
30	O
ml	O
,	O
palsma	O
albmuin	O
less	O
than	O
2	O
.	O
2	O
g	O
/	O
dl	O
,	O
spelnomegaly	O
2	O
-	O
3	O
times	O
nromal	O
,	O
and	O
tetsicular	O
atorphy	O
approximately	O
half	O
nomral	O
wieght	O
)	O
after	O
12	O
dsoes	O
of	O
carobn	B-Chemical
tetrahcloride	I-Chemical
given	O
intrgaastrically	O
in	O
the	O
phenobaribtone	B-Chemical
-	O
priemd	O
rat	O
was	O
incresaed	O
from	O
25	O
%	O
to	O
56	O
%	O
by	O
giving	O
the	O
initial	O
"	O
calibrating	O
"	O
dsoe	O
of	O
cabron	B-Chemical
tetarchloride	I-Chemical
at	O
the	O
peak	O
of	O
the	O
pheonbarbitone	B-Chemical
-	O
inudced	O
enalrgement	O
of	O
the	O
lievr	O
.	O

At	O
this	O
point	O
it	O
was	O
assumed	O
that	O
the	O
cytcohrome	O
P540	O
/	O
ClC4	B-Chemical
toixc	O
state	O
was	O
both	O
maxiaml	O
and	O
satble	O
.	O

The	O
otpimal	O
rat	O
szie	O
to	O
begin	O
pheonbarbitone	B-Chemical
was	O
determined	O
as	O
100	O
g	O
,	O
and	O
this	O
szie	O
as	O
a	O
gorup	O
had	O
a	O
mean	O
maixmum	O
relative	O
lvier	O
wieght	O
inrcease	O
47	O
%	O
greater	O
than	O
noraml	O
rtas	O
of	O
the	O
same	O
bdoy	O
wieght	O
.	O

The	O
otpimal	O
tmie	O
for	O
the	O
initial	O
dsoe	O
of	O
cabron	B-Chemical
tetarchloride	I-Chemical
was	O
after	O
14	O
dyas	O
on	O
phenobarbiotne	B-Chemical
.	O

Traimterene	B-Chemical
nephrolitihasis	O
copmlicating	O
dyaizde	B-Chemical
threapy	O
.	O

A	O
csae	O
of	O
triametrene	B-Chemical
neprholithiasis	O
is	O
reported	O
in	O
a	O
man	O
after	O
4	O
yeras	O
of	O
hdyrochlorothiazide	B-Chemical
-	I-Chemical
triatmerene	I-Chemical
tehrapy	O
for	O
hypertnesion	O
.	O

The	O
stnoe	O
passed	O
spontaenously	O
and	O
was	O
found	O
to	O
contain	O
a	O
triametrene	B-Chemical
meatbolite	O
adimxed	O
with	O
uirc	B-Chemical
aicd	I-Chemical
satls	I-Chemical
.	O

Facotrs	O
afefcting	O
tiramterene	B-Chemical
nephrolithisais	O
are	O
discussed	O
and	O
2	O
previously	O
reported	O
caess	O
are	O
rveiewed	O
.	O

Bsuulfan	B-Chemical
-	O
indcued	O
hemorrhgaic	O
cytsitis	O
.	O

A	O
csae	O
of	O
a	O
buslufan	B-Chemical
-	O
induecd	O
hemorrahge	O
cystiits	O
is	O
reported	O
.	O

Spotnaneous	O
resoultion	O
occurred	O
following	O
cesstaion	O
of	O
the	O
durg	O
.	O

The	O
simliarity	O
between	O
the	O
hsitologic	O
apeparances	O
of	O
bsuulfan	B-Chemical
cysttiis	O
and	O
both	O
raidation	O
and	O
cycolphosphamide	B-Chemical
-	O
inudced	O
cysttiis	O
is	O
discussed	O
and	O
the	O
world	O
litertaure	O
reviweed	O
.	O

In	O
view	O
of	O
the	O
known	O
tendency	O
of	O
busulafn	B-Chemical
to	O
idnuce	O
cellular	O
atyipa	O
and	O
carcnioma	O
in	O
other	O
sties	O
,	O
preiodic	O
urianry	O
cytoolgy	O
is	O
suggested	O
in	O
paitents	O
on	O
long	O
-	O
term	O
therpay	O
.	O

Varaint	O
vetnricular	O
tachycadria	O
in	O
deispramine	B-Chemical
txoicity	O
.	O

We	O
rpeort	O
a	O
csae	O
of	O
varaint	O
vnetricular	O
tachycradia	O
induecd	O
by	O
desipraimne	B-Chemical
toxiicty	O
.	O

Uunsual	O
featrues	O
of	O
the	O
arrhytmhia	O
are	O
repetitvie	O
gorup	O
baeting	O
,	O
progrsesive	O
shorteinng	O
of	O
the	O
R	O
-	O
R	O
intreval	O
,	O
progresisve	O
widening	O
of	O
the	O
QRS	O
cmoplex	O
with	O
eventaul	O
faliure	O
of	O
intarventricular	O
condcution	O
,	O
and	O
chagnes	O
in	O
dierction	O
of	O
the	O
QRS	O
aixs	O
.	O

Reocgnition	O
of	O
vairant	O
ventriuclar	O
tcahycardia	O
is	O
important	O
because	O
tehrapy	O
differs	O
from	O
that	O
of	O
classic	O
vetnricular	O
tachycadria	O
.	O

Rebuond	O
hpyertensive	O
after	O
sdoium	B-Chemical
nitrorpusside	I-Chemical
prevented	O
by	O
sraalasin	B-Chemical
in	O
rtas	O
.	O

The	O
role	O
of	O
the	O
rnein	O
-	O
-	O
agniotensin	B-Chemical
ssytem	O
in	O
the	O
manitenance	O
of	O
bolod	O
prsesure	O
during	O
halothnae	B-Chemical
aneshtesia	O
and	O
sdoium	B-Chemical
nitrporusside	I-Chemical
(	O
SNP	B-Chemical
)	O
-	O
indcued	O
hypotesnion	O
was	O
evaulated	O
.	O

Contorl	O
rtas	O
received	O
halohtane	B-Chemical
anestheisa	O
(	O
1	O
MAC	O
)	O
for	O
one	O
hour	O
,	O
followed	O
by	O
SNP	B-Chemical
ifnusion	O
,	O
40	O
microgarm	O
/	O
kg	O
/	O
min	O
,	O
for	O
30	O
min	O
,	O
followed	O
by	O
a	O
30	O
-	O
min	O
recovrey	O
peirod	O
.	O

A	O
second	O
gorup	O
of	O
rtas	O
was	O
traeted	O
identically	O
and	O
,	O
in	O
addition	O
,	O
received	O
an	O
infusoin	O
of	O
saarlasin	B-Chemical
(	O
a	O
competitive	O
inihbitor	O
of	O
agniotensin	B-Chemical
II	I-Chemical
)	O
throughout	O
the	O
expreimental	O
peirod	O
.	O

In	O
each	O
gruop	O
,	O
SNP	B-Chemical
infsuion	O
resulted	O
in	O
an	O
initial	O
dercease	O
in	O
bolod	O
pressrue	O
from	O
86	O
tror	O
and	O
83	O
tror	O
,	O
respectively	O
,	O
to	O
48	O
tror	O
.	O

During	O
the	O
SNP	B-Chemical
ifnusion	O
the	O
contorl	O
anmials	O
demonstrated	O
a	O
progerssive	O
incresae	O
in	O
blood	O
pressure	O
to	O
61	O
tror	O
,	O
whereas	O
the	O
sraalasin	B-Chemical
-	O
terated	O
animlas	O
showed	O
no	O
change	O
.	O

Following	O
discontinuatoin	O
of	O
SNP	B-Chemical
,	O
blood	O
prsesure	O
in	O
the	O
cnotrol	O
anmials	O
rebounded	O
to	O
94	O
tror	O
,	O
as	O
compaerd	O
with	O
78	O
tror	O
in	O
the	O
sraalasin	B-Chemical
-	O
tretaed	O
rtas	O
.	O

This	O
stduy	O
indicates	O
that	O
with	O
stalbe	O
haolthane	B-Chemical
anetshesia	O
,	O
the	O
pratial	O
recoevry	O
of	O
bolod	O
pressrue	O
during	O
SNP	B-Chemical
inufsion	O
and	O
the	O
psot	O
-	O
SNP	B-Chemical
rbeound	O
of	O
blood	O
prsesure	O
can	O
be	O
completely	O
bolcked	O
by	O
saarlasin	B-Chemical
.	O

This	O
demonstrates	O
the	O
particpiation	O
of	O
the	O
rnein	O
-	O
-	O
angoitensin	B-Chemical
sysetm	O
in	O
antagonizing	O
the	O
cmobined	O
hypoetnsive	O
effcets	O
of	O
haolthane	B-Chemical
and	O
SNP	B-Chemical
.	O

Cilnical	O
nephrootxicity	O
of	O
tobramyicn	B-Chemical
and	O
gentamiicn	B-Chemical
.	O

A	O
propsective	O
stduy	O
.	O

Nearly	O
3	O
.	O
2	O
million	O
peolpe	O
in	O
this	O
conutry	O
receive	O
amingolycoside	B-Chemical
atnibiotics	O
annually	O
.	O

Getnamicin	B-Chemical
sulafte	I-Chemical
and	O
tobrmaycin	B-Chemical
sulftae	I-Chemical
continue	O
to	O
demonstrate	O
ototoixcity	O
and	O
nephrtooxicity	O
in	O
both	O
anmial	O
and	O
cliniacl	O
stuides	O
.	O

In	O
this	O
sutdy	O
,	O
62	O
patietns	O
with	O
confirmed	O
initial	O
nomral	O
reanl	O
fucntion	O
and	O
treaetd	O
with	O
2	O
to	O
5	O
mg	O
/	O
kg	O
/	O
day	O
of	O
gentamciin	B-Chemical
suflate	I-Chemical
or	O
tobrmaycin	B-Chemical
sulftae	I-Chemical
for	O
a	O
minimum	O
of	O
seven	O
dyas	O
were	O
followed	O
up	O
prospectively	O
for	O
the	O
developemnt	O
of	O
aminoglycoisde	B-Chemical
-	O
related	O
reanl	O
failrue	O
,	O
defined	O
as	O
at	O
least	O
a	O
one	O
-	O
third	O
redutcion	O
in	O
rneal	O
fucntion	O
.	O

In	O
these	O
62	O
ptaients	O
,	O
no	O
other	O
causes	O
for	O
rneal	O
faiulre	O
could	O
be	O
idetnified	O
.	O

Five	O
of	O
33	O
(	O
15	O
%	O
)	O
of	O
the	O
tobraymcin	B-Chemical
-	O
traeted	O
patinets	O
and	O
16	O
of	O
29	O
(	O
55	O
.	O
2	O
%	O
)	O
of	O
the	O
gentaimcin	B-Chemical
-	O
traeted	O
patinets	O
had	O
reanl	O
faiulre	O
.	O

Thus	O
,	O
genatmicin	B-Chemical
was	O
associated	O
with	O
reanl	O
failrue	O
more	O
than	O
three	O
times	O
as	O
often	O
as	O
was	O
tobrmaycin	B-Chemical
.	O

Meatbolic	O
involvemnet	O
in	O
adiramycin	B-Chemical
cadriotoxicity	O
.	O

The	O
cardiootxic	O
efefcts	O
of	O
adrimaycin	B-Chemical
were	O
studied	O
in	O
mammlaian	O
mycoardial	O
clels	O
in	O
culutre	O
as	O
a	O
moedl	O
ssytem	O
.	O

Adraimycin	B-Chemical
inhibtied	O
clel	O
grotwh	O
and	O
the	O
rhythimc	O
conrtactions	O
charactersitic	O
of	O
myocardail	O
clels	O
in	O
culutre	O
.	O

A	O
possible	O
invovlement	O
of	O
eenrgy	O
metabloism	O
was	O
suggested	O
previously	O
,	O
and	O
in	O
this	O
stduy	O
the	O
adeynlate	O
enregy	O
charge	O
and	O
phosphoryclreatine	B-Chemical
mole	O
farction	O
were	O
determined	O
in	O
the	O
adriamcyin	B-Chemical
-	O
treaetd	O
clels	O
.	O

The	O
adenyltae	O
eenrgy	O
charge	O
was	O
found	O
to	O
be	O
significantly	O
derceased	O
,	O
while	O
the	O
phophorylcreatnie	B-Chemical
mole	O
frcation	O
was	O
unchnaged	O
.	O

Such	O
dispairty	O
suggests	O
an	O
inhibitoin	O
of	O
craetine	B-Chemical
phosphokianse	O
.	O

The	O
addition	O
of	O
1	O
mM	O
adeonsine	B-Chemical
to	O
the	O
myocadrial	O
clel	O
cultrues	O
markedly	O
inrceases	O
the	O
ATP	B-Chemical
concenrtation	O
through	O
a	O
pahtway	O
reportedly	O
leading	O
to	O
a	O
comparmtentalized	O
ATP	B-Chemical
pool	O
.	O

In	O
the	O
ardiamycin	B-Chemical
-	O
traeted	O
cells	O
,	O
the	O
addition	O
of	O
adenosnie	B-Chemical
inrceased	O
the	O
adenlyate	O
charge	O
and	O
,	O
concmoitant	O
with	O
this	O
increase	O
,	O
the	O
cells	O
'	O
functioanl	O
intgerity	O
,	O
in	O
terms	O
of	O
precentage	O
of	O
beatnig	O
clels	O
and	O
rtae	O
of	O
contratcions	O
,	O
was	O
maintained	O
.	O

Age	O
-	O
depenednt	O
sensiitvity	O
of	O
the	O
rat	O
to	O
neruotoxic	O
efefcts	O
of	O
streptmoycin	B-Chemical
.	O

Sterptomycin	B-Chemical
sulftae	O
(	O
300	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
was	O
inejcted	O
for	O
various	O
peirods	O
into	O
perweanling	O
rtas	O
and	O
for	O
3	O
wekes	O
into	O
wealning	O
rtas	O
.	O

Beginning	O
at	O
8	O
dyas	O
of	O
age	O
,	O
bdoy	O
movmeent	O
and	O
heairng	O
were	O
examined	O
for	O
6	O
and	O
up	O
to	O
17	O
wekes	O
,	O
respectively	O
.	O

Abnromal	O
mvoements	O
and	O
daefness	O
occurred	O
only	O
in	O
rtas	O
treaetd	O
during	O
the	O
preweainng	O
peirod	O
;	O
within	O
this	O
peroid	O
the	O
greatest	O
sensitivtiies	O
for	O
these	O
abnormaliites	O
occurred	O
from	O
2	O
to	O
11	O
-	O
17	O
and	O
5	O
to	O
11	O
dyas	O
of	O
age	O
,	O
respectively	O
,	O
indicating	O
that	O
the	O
cochela	O
is	O
more	O
sensitvie	O
to	O
streptoymcin	B-Chemical
than	O
the	O
stie	O
(	O
vesitbular	O
or	O
cnetral	O
)	O
responsible	O
for	O
the	O
dysiknesias	O
.	O

Ltae	O
,	O
ltae	O
doxorubciin	B-Chemical
cadriotoxicity	O
.	O

Caridac	O
toxiicty	O
is	O
a	O
major	O
comlpication	O
which	O
limtis	O
the	O
use	O
of	O
adriaymcin	B-Chemical
as	O
a	O
chemotherapeuitc	O
aegnt	O
.	O

Cardimoyopathy	O
is	O
freqeunt	O
when	O
the	O
total	O
dsoe	O
exceeds	O
600	O
mg	O
/	O
m2	O
and	O
occurs	O
within	O
one	O
to	O
six	O
motnhs	O
after	O
cessaiton	O
of	O
thearpy	O
.	O

A	O
ptaient	O
is	O
reported	O
who	O
developed	O
porgressive	O
cradiomyopathy	O
two	O
and	O
one	O
-	O
half	O
yeras	O
after	O
receiving	O
580	O
mg	O
/	O
m2	O
which	O
apparently	O
represents	O
ltae	O
,	O
ltae	O
cradiotoxicity	O
.	O

Attenutaion	O
of	O
the	O
lithuim	B-Chemical
-	O
indcued	O
dibaetes	O
-	O
insipiuds	O
-	O
like	O
synrdome	O
by	O
aimloride	B-Chemical
in	O
rtas	O
.	O

The	O
effect	O
of	O
amilroide	B-Chemical
on	O
ltihium	B-Chemical
-	O
inudced	O
polyidpsia	O
and	O
ployuria	O
and	O
on	O
the	O
litihum	B-Chemical
concentrtaion	O
in	O
the	O
plamsa	O
,	O
barin	O
,	O
kideny	O
,	O
thyorid	O
and	O
red	O
blood	O
cells	O
was	O
inevstigated	O
in	O
rtas	O
,	O
chronically	O
tretaed	O
with	O
LCil	B-Chemical
.	O

Amilroide	B-Chemical
reduecd	O
the	O
drikning	O
and	O
uirne	O
vloume	O
of	O
rtas	O
in	O
an	O
actue	O
(	O
6	O
or	O
12	O
h	O
)	O
and	O
a	O
subactue	O
(	O
3	O
dyas	O
)	O
expeirment	O
.	O

6	O
h	O
after	O
the	O
administraiton	O
of	O
amlioride	B-Chemical
,	O
a	O
reudction	O
was	O
observed	O
in	O
the	O
ltihium	B-Chemical
conetnt	O
of	O
the	O
reanl	O
medlula	O
but	O
not	O
in	O
the	O
other	O
oragns	O
studied	O
.	O

At	O
12	O
h	O
,	O
all	O
the	O
tisseus	O
showed	O
a	O
slight	O
inrcease	O
in	O
lihtium	B-Chemical
leevls	O
.	O

After	O
3	O
dyas	O
of	O
comibned	O
teratment	O
,	O
a	O
marked	O
elveation	O
in	O
plamsa	O
and	O
tsisue	O
lihtium	B-Chemical
leevls	O
accompanied	O
a	O
reudction	O
in	O
waetr	O
itnake	O
.	O

In	O
all	O
the	O
expermients	O
,	O
the	O
atteunation	O
of	O
the	O
lihtium	B-Chemical
-	O
indcued	O
diabtees	O
-	O
insipdius	O
-	O
like	O
syndrmoe	O
by	O
amiolride	B-Chemical
was	O
accompanied	O
by	O
a	O
reductoin	O
of	O
the	O
rtaio	O
between	O
the	O
lihtium	B-Chemical
cnocentration	O
in	O
the	O
rneal	O
medulla	O
and	O
its	O
lveels	O
in	O
the	O
bolod	O
and	O
an	O
elevatoin	O
in	O
the	O
palsma	O
poatssium	B-Chemical
lveel	O
.	O

It	O
is	O
concluded	O
that	O
actue	O
amilordie	B-Chemical
admniistration	O
to	O
ltihium	B-Chemical
-	O
traeted	O
ptaients	O
suffeirng	O
from	O
polydipisa	O
and	O
poyluria	O
might	O
relieve	O
these	O
paitents	O
but	O
proolnged	O
amiolride	B-Chemical
supplementatoin	O
would	O
result	O
in	O
elevaetd	O
lithuim	B-Chemical
lveels	O
and	O
might	O
be	O
hazarodus	O
.	O

Cardiovascualr	O
complicatinos	O
associated	O
with	O
terbutailne	B-Chemical
treatmnet	O
for	O
preetrm	O
laobr	O
.	O

Seevre	O
cradiovascular	O
complciations	O
occurred	O
in	O
eight	O
of	O
160	O
patietns	O
traeted	O
with	O
terbuatline	B-Chemical
for	O
preetrm	O
lbaor	O
.	O

Associated	O
corticosteriod	O
tehrapy	O
and	O
tiwn	O
gestatinos	O
appear	O
to	O
be	O
predisposnig	O
fcators	O
.	O

Potenital	O
mecahnisms	O
of	O
the	O
ptahophysiology	O
are	O
briefly	O
discussed	O
.	O

Toixc	O
hepattiis	O
induecd	O
by	O
antithyorid	O
durgs	O
:	O
four	O
caess	O
including	O
one	O
with	O
corss	O
-	O
reatcivity	O
between	O
carbmiazole	B-Chemical
and	O
benzytlhiouracil	B-Chemical
.	O

OBJECITVE	O
:	O
This	O
sutdy	O
was	O
conducted	O
to	O
assess	O
the	O
occurrence	O
of	O
hepaitc	O
advesre	O
effects	O
encountered	O
with	O
antityhroid	O
durgs	O
.	O

METHODS	O
:	O
Retorspective	O
reveiw	O
of	O
meidcal	O
recrods	O
of	O
236	O
pateints	O
with	O
hypetrhyroidism	O
admitted	O
in	O
our	O
dpeartment	O
(	O
in	O
-	O
or	O
out	O
-	O
patinets	O
)	O
from	O
1986	O
to	O
1992	O
.	O

RSEULTS	O
:	O
Four	O
patietns	O
(	O
1	O
.	O
7	O
%	O
)	O
were	O
identfiied	O
with	O
txoic	O
hpeatitis	O
which	O
could	O
reasonably	O
be	O
attributed	O
to	O
the	O
use	O
of	O
atnithyroid	O
agnet	O
.	O

Two	O
patinets	O
had	O
a	O
cholesttaic	O
hpeatitis	O
inudced	O
by	O
cabrimazole	B-Chemical
(	O
N	B-Chemical
omercazole	I-Chemical
)	O
.	O

Two	O
others	O
had	O
a	O
mixed	O
(	O
chloestatic	O
and	O
cytoltyic	O
)	O
hepattiis	O
following	O
carbimzaole	B-Chemical
.	O

One	O
of	O
the	O
latter	O
two	O
patietns	O
further	O
experienced	O
a	O
cytloytic	O
hpeatitis	O
which	O
appeared	O
after	O
Benzytlhiouracil	B-Chemical
(	O
Bsad	B-Chemical
ne	I-Chemical
)	O
had	O
replaced	O
carbmiazole	B-Chemical
.	O

Biolgoical	O
featuers	O
of	O
heaptitis	O
disappeared	O
in	O
all	O
csaes	O
after	O
cesstaion	O
of	O
the	O
incriminated	O
durg	O
,	O
while	O
biliray	O
,	O
viarl	O
and	O
immunological	O
searhces	O
were	O
neagtive	O
.	O

Only	O
2	O
patietns	O
of	O
our	O
retropsective	O
stduy	O
experienced	O
a	O
mlid	O
or	O
sevree	O
neutropneia	O
.	O

CONLCUSION	O
:	O
Toixc	O
hepatiits	O
is	O
a	O
potentail	O
advrese	O
efefct	O
of	O
anttihyroid	O
durgs	O
which	O
warrants	O
,	O
as	O
for	O
heamatological	O
dsiturbances	O
,	O
a	O
pre	O
-	O
therpaeutic	O
detremination	O
and	O
a	O
careful	O
follow	O
-	O
up	O
of	O
releavnt	O
biolgoical	O
markres	O
.	O

Moreover	O
,	O
hepatotxoicity	O
may	O
not	O
be	O
restricted	O
to	O
one	O
calss	O
of	O
anitthyroid	O
agetns	O
.	O

Interacitve	O
effects	O
of	O
variatinos	O
in	O
[	O
Na	B-Chemical
]	O
o	O
and	O
[	O
Ca	B-Chemical
]	O
o	O
on	O
rat	O
artial	O
spnotaneous	O
ferquency	O
.	O

The	O
effcets	O
of	O
varying	O
the	O
extarcellular	O
concentrtaions	O
of	O
Na	B-Chemical
and	O
Ca	B-Chemical
(	O
[	O
Na	B-Chemical
]	O
o	O
and	O
[	O
Ca	B-Chemical
]	O
o	O
)	O
on	O
both	O
,	O
the	O
sopntaneous	O
beatnig	O
and	O
the	O
negtaive	O
chronotrpoic	O
atcion	O
of	O
verpaamil	B-Chemical
,	O
were	O
studied	O
in	O
the	O
isolaetd	O
rat	O
atira	O
.	O

Baasl	O
frqeuency	O
(	O
BF	O
)	O
eavluated	O
by	O
surafce	O
electrogarm	O
was	O
223	O
+	O
/	O
-	O
4	O
betas	O
/	O
min	O
.	O
in	O
cnotrol	O
Krbes	O
-	O
Rigner	O
containing	O
137	O
mM	O
Na	B-Chemical
and	O
1	O
.	O
35	O
mM	O
Ca	B-Chemical
(	O
N	O
)	O
.	O

It	O
derceased	O
by	O
16	O
+	O
/	O
-	O
3	O
%	O
by	O
lowreing	O
[	O
Na	B-Chemical
]	O
o	O
to	O
78	O
mM	O
(	O
LNa	O
)	O
,	O
23	O
+	O
/	O
-	O
2	O
%	O
by	O
lowernig	O
simultaneoulsy	O
[	O
Na	B-Chemical
]	O
o	O
to	O
78	O
mM	O
and	O
[	O
Ca	B-Chemical
]	O
o	O
to	O
0	O
.	O
675	O
mM	O
(	O
LNa	O
+	O
LCa	O
)	O
and	O
31	O
+	O
/	O
-	O
5	O
%	O
by	O
loewring	O
[	O
Na	B-Chemical
]	O
o	O
to	O
78	O
mM	O
plus	O
incerasing	O
[	O
Ca	B-Chemical
]	O
o	O
to	O
3	O
.	O
6	O
mM	O
(	O
LNa	O
+	O
HCa	O
)	O
.	O

At	O
nomral	O
[	O
Na	B-Chemical
]	O
o	O
,	O
dcerease	O
(	O
0	O
.	O
675	O
mM	O
)	O
or	O
incraese	O
(	O
3	O
.	O
6	O
mM	O
)	O
of	O
[	O
Ca	B-Chemical
]	O
o	O
did	O
not	O
modify	O
BF	O
;	O
a	O
reduciton	O
of	O
ten	O
times	O
(	O
0	O
.	O
135	O
mM	O
of	O
noraml	O
[	O
Ca	B-Chemical
]	O
o	O
was	O
effcetive	O
to	O
redcue	O
BF	O
by	O
40	O
+	O
/	O
-	O
13	O
%	O
.	O

All	O
negatvie	O
chornotropic	O
effcets	O
were	O
BF	O
-	O
depednent	O
.	O

Dsoe	O
-	O
depnedent	O
brdaycardia	O
inudced	O
by	O
verapaiml	B-Chemical
was	O
potenitated	O
by	O
LNa	O
,	O
LCa	O
,	O
and	O
HCa	O
.	O

Independnet	O
but	O
not	O
addtiive	O
effects	O
of	O
Na	B-Chemical
and	O
Ca	B-Chemical
are	O
shown	O
by	O
decreaess	O
in	O
the	O
vaules	O
of	O
[	O
verpaamil	B-Chemical
]	O
o	O
needed	O
to	O
redcue	O
BF	O
by	O
30	O
%	O
(	O
I3C0	O
)	O
with	O
the	O
following	O
order	O
of	O
inihbitory	O
potecny	O
:	O
LNa	O
>	O
LCa	O
>	O
HCa	O
>	O
N	O
,	O
resulting	O
LNa	O
+	O
HCa	O
similar	O
to	O
LNa	O
.	O

The	O
[	O
verapaiml	B-Chemical
]	O
o	O
that	O
arersted	O
artial	O
beatnig	O
(	O
AC	O
)	O
was	O
also	O
ptoentiated	O
with	O
the	O
order	O
LNa	O
=	O
LNa	O
+	O
LCa	O
=	O
LNa	O
+	O
HCa	O
=	O
LCa	O
>	O
HCa	O
=	O
N	O
.	O

The	O
reuslts	O
indicate	O
that	O
rat	O
atrail	O
spontanoeus	O
betaing	O
is	O
more	O
dpeendent	O
on	O
[	O
Na	B-Chemical
]	O
o	O
than	O
on	O
[	O
Ca	B-Chemical
]	O
o	O
in	O
a	O
range	O
of	O
+	O
/	O
-	O
50	O
%	O
of	O
their	O
nomral	O
concnetration	O
.	O

Also	O
the	O
enhanceemnt	O
of	O
vearpamil	B-Chemical
effcets	O
on	O
artial	O
betaing	O
was	O
more	O
pronounced	O
at	O
LNa	O
than	O
at	O
LCa	O
.	O
(	O
ABSTRACT	O
TRUCNATED	O
AT	O
250	O
WORDS	O
)	O

Psuedo	O
-	O
allergic	O
reactinos	O
to	O
corticosteriods	B-Chemical
:	O
diagonsis	O
and	O
altenratives	O
.	O

Two	O
pateints	O
tretaed	O
with	O
parentearl	O
paramehtasone	B-Chemical
(	O
Triinol	O
)	O
and	O
dexamethaosne	B-Chemical
(	O
Seidonbel	O
)	O
are	O
described	O
.	O

A	O
few	O
mniutes	O
after	O
adimnistration	O
of	O
the	O
durgs	O
,	O
they	O
presented	O
urtiacria	O
(	O
paitents	O
1	O
and	O
2	O
)	O
and	O
conjunctiivtis	O
(	O
patinet	O
1	O
)	O
.	O

The	O
purpose	O
of	O
our	O
sutdy	O
was	O
to	O
determine	O
the	O
cause	O
of	O
the	O
ptaients	O
'	O
reactoins	O
,	O
the	O
immunological	O
mcehanisms	O
involved	O
and	O
whether	O
these	O
patietns	O
would	O
be	O
able	O
to	O
tolerate	O
any	O
kind	O
of	O
cortiocid	O
.	O

Cliincal	O
examiantions	O
and	O
sikn	O
,	O
oarl	O
and	O
paretneral	O
chlalenges	O
with	O
different	O
coritcosteroids	B-Chemical
and	O
EILSA	O
tetss	O
were	O
performed	O
.	O

In	O
the	O
two	O
pateints	O
,	O
sikn	O
and	O
ELSIA	O
tsets	O
with	O
paramtehasone	B-Chemical
were	O
negaitve	O
,	O
as	O
was	O
the	O
prcik	O
tset	O
with	O
each	O
of	O
its	O
exicpients	O
.	O

A	O
single	O
-	O
blnid	O
paretneral	O
challenge	O
with	O
Tirniol	O
was	O
positvie	O
in	O
both	O
patietns	O
after	O
the	O
adminitsration	O
of	O
1	O
ml	O
of	O
the	O
durg	O
,	O
and	O
negatvie	O
with	O
its	O
exicpients	O
.	O

We	O
also	O
carried	O
out	O
oarl	O
and	O
parentreal	O
challneges	O
with	O
other	O
cortiocsteroids	B-Chemical
and	O
found	O
intoleracne	O
to	O
some	O
of	O
them	O
.	O

These	O
resutls	O
suggest	O
that	O
paramethsaone	B-Chemical
caused	O
pseudaollergic	O
recations	O
in	O
our	O
ptaients	O
.	O

Corticostreoids	O
different	O
from	O
paramtehasone	B-Chemical
also	O
produced	O
hyeprsensitivity	O
reactoins	O
in	O
these	O
paitents	O
;	O
however	O
,	O
a	O
few	O
of	O
them	O
were	O
tolreated	O
.	O

The	O
basic	O
mechanimss	O
of	O
those	O
reactinos	O
are	O
not	O
yet	O
fully	O
understood	O
.	O

To	O
our	O
knowldege	O
,	O
this	O
is	O
the	O
first	O
reoprt	O
of	O
a	O
pseudo	O
-	O
alelrgy	O
caused	O
by	O
paramethasnoe	B-Chemical
.	O

Stduy	O
of	O
the	O
role	O
of	O
vtiamin	B-Chemical
B12	I-Chemical
and	O
foilnic	B-Chemical
aicd	I-Chemical
supplmeentation	O
in	O
preventing	O
hematoolgic	O
toxciity	O
of	O
ziodvudine	B-Chemical
.	O

A	O
porspective	O
,	O
randomzied	O
sutdy	O
was	O
conducted	O
to	O
evlauate	O
the	O
role	O
of	O
vitaimn	B-Chemical
B12	I-Chemical
and	O
floinic	B-Chemical
aicd	I-Chemical
supplemenattion	O
in	O
preventing	O
zidovuidne	B-Chemical
(	O
ZDV	B-Chemical
)	O
-	O
indcued	O
bnoe	O
marorw	O
suppresison	O
.	O

Seventy	O
-	O
five	O
huamn	O
immunodeficiecny	O
vrius	O
(	O
HIV	O
)	O
-	O
inefcted	O
patinets	O
with	O
CD4	O
+	O
clel	O
coutns	O
<	O
500	O
/	O
mm3	O
were	O
randoimzed	O
to	O
receive	O
either	O
ZDV	B-Chemical
(	O
500	O
mg	O
daliy	O
)	O
alone	O
(	O
gruop	O
I	O
,	O
n	O
=	O
38	O
)	O
or	O
in	O
combintaion	O
with	O
foilnic	B-Chemical
aicd	I-Chemical
(	O
15	O
mg	O
daliy	O
)	O
and	O
intraamscular	O
vtiamin	B-Chemical
B12	I-Chemical
(	O
1000	O
microgarms	O
montlhy	O
)	O
(	O
gorup	O
II	O
,	O
n	O
=	O
37	O
)	O
.	O

Finally	O
,	O
15	O
ptaients	O
were	O
excluded	O
from	O
the	O
sutdy	O
(	O
noncomlpiance	O
14	O
,	O
detah	O
1	O
)	O
;	O
thus	O
,	O
60	O
ptaients	O
(	O
31	O
in	O
gorup	O
I	O
and	O
29	O
in	O
gorup	O
II	O
)	O
were	O
eliigble	O
for	O
anaylsis	O
.	O

No	O
significant	O
diffeernces	O
between	O
gruops	O
were	O
found	O
at	O
ernollment	O
.	O

During	O
the	O
sutdy	O
,	O
vtiamin	B-Chemical
B12	I-Chemical
and	O
floate	B-Chemical
levles	O
were	O
significantly	O
hgiher	O
in	O
gorup	O
II	O
pateints	O
;	O
however	O
,	O
no	O
differecnes	O
in	O
hemolgobin	O
,	O
heamtocrit	O
,	O
mean	O
corpucsular	O
voulme	O
,	O
and	O
wihte	O
-	O
clel	O
,	O
neutorphil	O
and	O
plateelt	O
coutns	O
were	O
observed	O
between	O
gorups	O
at	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
monhts	O
.	O

Seevre	O
hematoolgic	O
toxiicty	O
(	O
neturophil	O
conut	O
<	O
1000	O
/	O
mm3	O
and	O
/	O
or	O
hemgolobin	O
<	O
8	O
g	O
/	O
dl	O
)	O
occurred	O
in	O
4	O
patietns	O
assigned	O
to	O
gorup	O
I	O
and	O
7	O
assigned	O
to	O
gruop	O
II	O
.	O

There	O
was	O
no	O
correaltion	O
between	O
vitmain	B-Chemical
B12	I-Chemical
or	O
floate	B-Chemical
lveels	O
and	O
developemnt	O
of	O
myelosupprsesion	O
.	O

Vitaimn	B-Chemical
B12	I-Chemical
and	O
foilnic	B-Chemical
aicd	I-Chemical
suplpementation	O
of	O
ZDV	B-Chemical
thearpy	O
does	O
not	O
seem	O
useful	O
in	O
preventing	O
or	O
rdeucing	O
ZDV	B-Chemical
-	O
inudced	O
myelotoxictiy	O
in	O
the	O
overall	O
tretaed	O
popualtion	O
,	O
although	O
a	O
beneficial	O
effcet	O
in	O
certain	O
subrgoups	O
of	O
paitents	O
cannot	O
be	O
excluded	O
.	O

Saftey	O
and	O
side	O
-	O
efefcts	O
of	O
alprazloam	B-Chemical
.	O

Controleld	O
sutdy	O
in	O
agorpahobia	O
with	O
pnaic	O
disroder	O
.	O

BACKGRONUD	O
:	O
The	O
widespread	O
use	O
of	O
bnezodiazepines	B-Chemical
has	O
led	O
to	O
incerasing	O
recogintion	O
of	O
their	O
unwanted	O
efefcts	O
.	O

The	O
efficacy	O
of	O
alpraozlam	B-Chemical
and	O
palcebo	O
in	O
painc	O
disroder	O
with	O
aographobia	O
,	O
and	O
the	O
side	O
-	O
effect	O
and	O
advrese	O
efefct	O
profiels	O
of	O
both	O
durg	O
gropus	O
were	O
maesured	O
.	O

METHOD	O
:	O
In	O
Lonodn	O
and	O
Tornoto	O
154	O
pateints	O
who	O
met	O
DSM	O
-	O
III	O
criteira	O
for	O
pnaic	O
disodrer	O
with	O
agorapohbia	O
were	O
rnadomised	O
to	O
aplrazolam	B-Chemical
or	O
plcaebo	O
.	O

Sbujects	O
in	O
each	O
durg	O
gruop	O
also	O
received	O
either	O
exopsure	O
or	O
relaxaiton	O
.	O

Treatemnt	O
was	O
from	O
weeks	O
0	O
to	O
8	O
and	O
was	O
then	O
tpaered	O
from	O
weeks	O
8	O
to	O
16	O
.	O

RESLUTS	O
:	O
Mean	O
alprazloam	B-Chemical
dsoe	O
was	O
5	O
mg	O
dialy	O
.	O

Compaerd	O
with	O
palcebo	O
subjetcs	O
,	O
alpraozlam	B-Chemical
patietns	O
developed	O
more	O
advesre	O
reactinos	O
(	O
21	O
%	O
v	O
.	O
0	O
%	O
)	O
of	O
deprsesion	O
,	O
enureiss	O
,	O
disinhibitoin	O
and	O
aggerssion	O
;	O
and	O
more	O
side	O
-	O
effetcs	O
,	O
particularly	O
sdeation	O
,	O
irirtability	O
,	O
ipmaired	O
mmeory	O
,	O
weihgt	O
lsos	O
and	O
atxaia	O
.	O

Side	O
-	O
effetcs	O
tended	O
to	O
diminish	O
during	O
teratment	O
but	O
remained	O
significant	O
at	O
week	O
8	O
.	O

Despite	O
this	O
,	O
the	O
dorp	O
-	O
out	O
rtae	O
was	O
low	O
.	O

CONCLUSOINS	O
:	O
Alprzaolam	B-Chemical
caused	O
side	O
-	O
effetcs	O
and	O
adevrse	O
effetcs	O
during	O
tretament	O
but	O
many	O
ptaients	O
were	O
willing	O
to	O
accept	O
these	O
.	O

Cresecntic	O
fibrlilary	O
glomerulonpehritis	O
associated	O
with	O
intermittnet	O
riafmpin	B-Chemical
threapy	O
for	O
pulmonray	O
tuberculsois	O
.	O

This	O
csae	O
stduy	O
reveals	O
an	O
unuusal	O
fidning	O
of	O
rapidly	O
prolifeartive	O
crecsentic	O
glomreulonephritis	O
in	O
a	O
patinet	O
tretaed	O
with	O
rifapmin	B-Chemical
who	O
had	O
no	O
other	O
identifiable	O
causes	O
for	O
developing	O
this	O
dsiease	O
.	O

This	O
paitent	O
underwent	O
a	O
10	O
-	O
mnoth	O
reigmen	O
of	O
riafmpin	B-Chemical
and	O
isnoiazid	B-Chemical
for	O
pulmonray	O
tubercuolsis	O
and	O
was	O
discovered	O
to	O
have	O
developed	O
sings	O
of	O
sevree	O
rneal	O
failrue	O
five	O
weeks	O
after	O
completoin	O
of	O
thearpy	O
.	O

Reanl	O
biposy	O
reevaled	O
seevre	O
glomerulonephrtiis	O
with	O
crescetns	O
,	O
eletcron	O
dnese	O
fibrillar	O
deopsits	O
and	O
modreate	O
lypmhocytic	O
intesrtitial	O
inifltrate	O
.	O

Other	O
possible	O
causes	O
of	O
rapidly	O
progerssive	O
glomerulonpehritis	O
were	O
ivnestigated	O
and	O
ruled	O
out	O
.	O

This	O
rpeort	O
documetns	O
the	O
unsuual	O
occurrnece	O
of	O
rapidly	O
prorgessive	O
glomeurlonephritis	O
with	O
crecsents	O
and	O
fibirllar	O
glomeruloenphritis	O
in	O
a	O
paitent	O
terated	O
with	O
riafmpin	B-Chemical
.	O

Aucte	O
confusoin	O
inudced	O
by	O
a	O
high	O
-	O
dsoe	O
infusoin	O
of	O
5	B-Chemical
-	I-Chemical
fluorouarcil	I-Chemical
and	O
foilnic	B-Chemical
aicd	I-Chemical
.	O

A	O
61	O
-	O
yaer	O
-	O
old	O
man	O
was	O
traeted	O
with	O
combiantion	O
chemothreapy	O
incorporating	O
cisplaitnum	B-Chemical
,	O
etopsoide	B-Chemical
,	O
high	O
-	O
dsoe	O
5	B-Chemical
-	I-Chemical
fulorouracil	I-Chemical
(	O
2	O
,	O
250	O
mg	O
/	O
m2	O
/	O
24	O
hours	O
)	O
and	O
foilnic	B-Chemical
aicd	I-Chemical
for	O
an	O
inpoerable	O
gastirc	O
adenocarcionma	O
.	O

He	O
developed	O
aucte	O
neuroloigc	O
sympotms	O
of	O
metnal	O
confsuion	O
,	O
dsiorientation	O
and	O
irrtiability	O
,	O
and	O
then	O
lasped	O
into	O
a	O
deep	O
cmoa	O
,	O
lasting	O
for	O
approximately	O
40	O
hours	O
during	O
the	O
first	O
dsoe	O
(	O
day	O
2	O
)	O
of	O
5	B-Chemical
-	I-Chemical
fluorouraicl	I-Chemical
and	O
folniic	B-Chemical
aicd	I-Chemical
infusoin	O
.	O

This	O
complictaion	O
reappeared	O
on	O
day	O
25	O
during	O
the	O
second	O
dsoe	O
of	O
5	B-Chemical
-	I-Chemical
fluoruoracil	I-Chemical
and	O
foliinc	B-Chemical
aicd	I-Chemical
,	O
which	O
were	O
then	O
the	O
only	O
drgus	O
given	O
.	O

Because	O
folniic	B-Chemical
aicd	I-Chemical
was	O
unlikely	O
to	O
be	O
associated	O
with	O
this	O
codnition	O
,	O
neurtooxicity	O
due	O
to	O
high	O
-	O
dsoe	O
5	B-Chemical
-	I-Chemical
fluorouarcil	I-Chemical
was	O
highly	O
suspecetd	O
.	O

The	O
pathogenseis	O
of	O
5	B-Chemical
-	I-Chemical
fluorourcail	I-Chemical
neruotoxicity	O
may	O
be	O
due	O
to	O
a	O
Krbes	O
ccyle	O
bolckade	O
by	O
fluoraocetate	B-Chemical
and	O
fluorocitarte	B-Chemical
,	O
tihamine	B-Chemical
deifciency	O
,	O
or	O
dihydrouarcil	B-Chemical
dehydorgenase	O
deifciency	O
.	O

High	O
-	O
dsoe	O
5	B-Chemical
-	I-Chemical
fluoruoracil	I-Chemical
/	O
foliinc	B-Chemical
aicd	I-Chemical
infsuion	O
therpay	O
has	O
recently	O
become	O
a	O
popular	O
reigmen	O
for	O
various	O
canecrs	O
.	O

It	O
is	O
necessary	O
that	O
both	O
oncoolgists	O
and	O
neurologitss	O
be	O
fully	O
aware	O
of	O
this	O
uunsual	O
comlpication	O
.	O

Effcet	O
of	O
switching	O
cabramazepine	B-Chemical
to	O
oxcarbazeipne	B-Chemical
on	O
the	O
plamsa	O
levles	O
of	O
neurloeptics	O
.	O

A	O
csae	O
rpeort	O
.	O

Carbamaezpine	B-Chemical
was	O
switched	O
to	O
its	O
10	O
-	O
kteo	O
anaolgue	O
oxcarbazpeine	B-Chemical
among	O
six	O
difficult	O
-	O
to	O
-	O
traet	O
scihzophrenic	O
or	O
orgnaic	O
pscyhotic	O
paitents	O
using	O
concomitantly	O
haolperidol	B-Chemical
,	O
chlorpromzaine	B-Chemical
or	O
clozaipne	B-Chemical
.	O

This	O
change	O
resulted	O
within	O
2	O
-	O
4	O
weeks	O
in	O
the	O
50	O
-	O
200	O
%	O
incerase	O
in	O
the	O
plsama	O
levles	O
of	O
these	O
nueroleptics	O
and	O
the	O
appearnace	O
of	O
extrapyraimdal	O
symtpoms	O
.	O

None	O
of	O
the	O
patinets	O
showed	O
any	O
cliniacl	O
deteriotatoin	O
during	O
the	O
following	O
3	O
-	O
6	O
motnhs	O
.	O

The	O
reuslts	O
of	O
this	O
csae	O
reoprt	O
support	O
the	O
idea	O
that	O
in	O
contrast	O
with	O
cabramazepine	B-Chemical
oxcarbaezpine	B-Chemical
does	O
not	O
inudce	O
the	O
hepaitc	O
micrsoomal	O
enzmye	O
ssytems	O
regulatnig	O
the	O
inactivtaion	O
of	O
atnipsychotic	O
durgs	O
.	O

Tmie	O
coruse	O
of	O
liipd	O
peroxidtaion	O
in	O
purmoycin	B-Chemical
aminonuclesoide	I-Chemical
-	O
idnuced	O
nephrpoathy	O
.	O

Recative	O
oyxgen	B-Chemical
sepcies	O
have	O
been	O
implicated	O
in	O
the	O
ptahogenesis	O
of	O
aucte	O
purmoycin	B-Chemical
aminnoucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
-	O
idnuced	O
nephrpoathy	O
,	O
with	O
antioixdants	O
significantly	O
reudcing	O
the	O
prtoeinuria	O
.	O

The	O
tmeporal	O
relationsihp	O
between	O
lpiid	O
perxoidation	O
in	O
the	O
kdiney	O
and	O
proteiunria	O
was	O
examined	O
in	O
this	O
sutdy	O
.	O

Rtas	O
were	O
treaetd	O
with	O
a	O
single	O
IV	O
injectoin	O
of	O
puroymcin	B-Chemical
aminonulceoside	I-Chemical
,	O
(	O
PAN	B-Chemical
,	O
7	O
.	O
5	O
mg	O
/	O
kg	O
)	O
and	O
24	O
hour	O
uirne	O
sampels	O
were	O
obtained	O
prior	O
to	O
sacirfice	O
on	O
dyas	O
3	O
,	O
5	O
,	O
7	O
,	O
10	O
,	O
17	O
,	O
27	O
,	O
41	O
(	O
N	O
=	O
5	O
-	O
10	O
per	O
gruop	O
)	O
.	O

The	O
kidenys	O
were	O
rmeoved	O
,	O
flusehd	O
with	O
ice	O
clod	O
TIRS	O
buffer	O
.	O

Kindey	O
cortiecs	O
from	O
each	O
ainmal	O
were	O
used	O
to	O
prepare	O
homoegnates	O
.	O

Tsisue	O
liipd	O
peroxidatoin	O
was	O
mesaured	O
in	O
whole	O
homogenaets	O
as	O
well	O
as	O
in	O
lpiid	O
extrcats	O
from	O
homogenaets	O
as	O
thiobrabituric	B-Chemical
aicd	I-Chemical
reatcive	O
susbtances	O
.	O

Protienuria	O
was	O
evident	O
at	O
day	O
5	O
,	O
peaked	O
at	O
day	O
7	O
and	O
persisted	O
to	O
day	O
27	O
.	O

Lpiid	O
preoxidation	O
in	O
homogeantes	O
was	O
maixmal	O
at	O
day	O
3	O
and	O
delcined	O
rapidly	O
to	O
cotnrol	O
lveels	O
by	O
day	O
17	O
.	O

This	O
stduy	O
supports	O
the	O
role	O
of	O
lpiid	O
perxoidation	O
in	O
mediating	O
the	O
protienuric	O
inujry	O
in	O
PAN	B-Chemical
nephrpoathy	O
.	O

Cmoposition	O
of	O
glal	O
bladder	O
stoens	O
associated	O
with	O
octroetide	B-Chemical
:	O
resopnse	O
to	O
oarl	O
ursodeoxcyholic	B-Chemical
aicd	I-Chemical
.	O

Octreotdie	B-Chemical
,	O
an	O
effective	O
teratment	O
for	O
acromgealy	O
,	O
idnuces	O
glal	O
baldder	O
sotnes	O
in	O
13	O
-	O
60	O
%	O
of	O
patinets	O
.	O

Because	O
knoweldge	O
of	O
sotne	O
copmosition	O
is	O
essentail	O
for	O
stduies	O
of	O
their	O
pathogenseis	O
,	O
tretament	O
,	O
and	O
pervention	O
,	O
this	O
was	O
ivnestigated	O
by	O
direct	O
and	O
idnirect	O
mehtods	O
in	O
14	O
octroetide	B-Chemical
tretaed	O
acromeaglic	O
patinets	O
with	O
glal	O
sotnes	O
.	O

Cheimcal	O
anlaysis	O
of	O
glal	O
sotnes	O
retrieved	O
at	O
cholecystecotmy	O
from	O
two	O
patinets	O
,	O
showed	O
that	O
they	O
contained	O
71	O
%	O
and	O
87	O
%	O
cholestreol	B-Chemical
by	O
wieght	O
.	O

In	O
the	O
remaining	O
12	O
paitents	O
,	O
lcoalised	O
comptued	O
tomgoraphy	O
of	O
the	O
glal	O
baldder	O
showed	O
that	O
eight	O
had	O
stoens	O
with	O
mxaimum	O
atetnuation	O
scroes	O
of	O
<	O
100	O
Huonsfield	O
units	O
(	O
vaules	O
of	O
<	O
100	O
HU	O
predict	O
cholesetrol	B-Chemical
rich	O
,	O
dissolavble	O
stnoes	O
)	O
.	O

Glal	O
baldder	O
blie	O
was	O
obtained	O
by	O
ultarsound	O
guided	O
,	O
fnie	O
nedele	O
puntcure	O
from	O
six	O
patinets	O
.	O

All	O
six	O
patinets	O
had	O
supersaturtaed	O
blie	O
(	O
mean	O
(	O
SEM	O
)	O
cohlesterol	B-Chemical
saturatoin	O
index	O
of	O
1	O
.	O
19	O
(	O
0	O
.	O
08	O
)	O
(	O
range	O
1	O
.	O
01	O
-	O
1	O
.	O
53	O
)	O
)	O
and	O
all	O
had	O
abonrmally	O
rpaid	O
cholesetrol	B-Chemical
micorcrystal	O
nuclaetion	O
times	O
(	O
<	O
4	O
dyas	O
(	O
range	O
1	O
-	O
4	O
)	O
)	O
,	O
whilst	O
in	O
four	O
,	O
the	O
blie	O
contained	O
choletserol	B-Chemical
microcrsytals	O
immediately	O
after	O
sapmling	O
.	O

Of	O
the	O
12	O
ptaients	O
considered	O
for	O
oarl	O
urosdeoxycholic	B-Chemical
aicd	I-Chemical
(	O
UCDA	B-Chemical
)	O
tretament	O
,	O
two	O
had	O
a	O
bolcked	O
csytic	O
dcut	O
and	O
were	O
not	O
started	O
on	O
UCDA	B-Chemical
while	O
one	O
was	O
lsot	O
to	O
follow	O
up	O
.	O

After	O
one	O
yaer	O
of	O
tretament	O
,	O
five	O
of	O
the	O
remaining	O
nine	O
patinets	O
showed	O
either	O
partail	O
(	O
n	O
=	O
3	O
)	O
or	O
complete	O
(	O
n	O
=	O
2	O
)	O
glal	O
stnoe	O
dissolutoin	O
,	O
suggesting	O
that	O
their	O
stnoes	O
were	O
chloesterol	B-Chemical
rich	O
.	O

This	O
corresponds	O
,	O
by	O
actuarail	O
(	O
lfie	O
table	O
)	O
analyiss	O
,	O
to	O
a	O
combiend	O
glal	O
stnoe	O
dissoltuion	O
rtae	O
of	O
58	O
.	O
3	O
(	O
15	O
.	O
9	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
octreoitde	B-Chemical
inudced	O
glal	O
sotnes	O
are	O
generally	O
small	O
,	O
mutliple	O
,	O
and	O
choelsterol	B-Chemical
rich	O
although	O
,	O
in	O
common	O
with	O
spnotaneous	O
glal	O
sotne	O
disesae	O
,	O
at	O
presenttaion	O
some	O
patietns	O
will	O
have	O
a	O
blcoked	O
cytsic	O
dcut	O
and	O
some	O
glal	O
stoens	O
containing	O
calicum	B-Chemical
.	O

Erythmea	O
mlutiforme	O
and	O
hyeprsensitivity	O
myocardiits	O
caused	O
by	O
ampiclilin	B-Chemical
.	O

OBJECTVIE	O
:	O
To	O
reoprt	O
a	O
csae	O
of	O
eyrthema	O
multifomre	O
and	O
hpyersensitivity	O
myocaridtis	O
caused	O
by	O
ampicililn	B-Chemical
.	O

CSAE	O
SUMMRAY	O
:	O
A	O
13	O
-	O
yaer	O
-	O
old	O
boy	O
was	O
traeted	O
with	O
ampiicllin	B-Chemical
and	O
gentamciin	B-Chemical
because	O
of	O
supsected	O
septciemia	O
.	O

Medicaitons	O
were	O
discnotinued	O
when	O
eryhtema	O
multfiorme	O
and	O
cognestive	O
haert	O
faiulre	O
caused	O
by	O
myoacrditis	O
occurred	O
.	O

The	O
patinet	O
was	O
tretaed	O
with	O
methylperdnisolone	B-Chemical
and	O
gradually	O
improevd	O
.	O

Macrophgae	O
-	O
migrtaion	O
inihbition	O
(	O
MIF	O
)	O
tset	O
with	O
ampiicllin	B-Chemical
was	O
postiive	O
.	O

DISCUSSION	O
:	O
After	O
most	O
infcetions	O
causing	O
ertyhema	O
mutliforme	O
and	O
myocraditis	O
were	O
ruled	O
out	O
,	O
a	O
durg	O
-	O
inudced	O
alelrgic	O
reactoin	O
was	O
supsected	O
.	O

Posiitve	O
MIF	O
tset	O
for	O
apmicillin	B-Chemical
showed	O
senstiization	O
of	O
the	O
patinet	O
'	O
s	O
lymphoyctes	O
to	O
apmicillin	B-Chemical
.	O

CONCLUSOINS	O
:	O
Hpyersensitivity	O
myocaridtis	O
is	O
a	O
rrae	O
and	O
dangerous	O
maniefstation	O
of	O
allregy	O
to	O
penicillnis	B-Chemical
.	O

Cloimpramine	B-Chemical
-	O
indcued	O
sleep	O
disturbnace	O
does	O
not	O
impiar	O
its	O
prolatcin	O
-	O
releasing	O
aciton	O
.	O

The	O
present	O
stduy	O
was	O
undertaken	O
to	O
examine	O
the	O
role	O
of	O
sleep	O
disutrbance	O
,	O
indcued	O
by	O
cloimpramine	B-Chemical
administratoin	O
,	O
on	O
the	O
secertory	O
rtae	O
of	O
prloactin	O
(	O
PRL	O
)	O
in	O
addition	O
to	O
the	O
direct	O
durg	O
effcet	O
.	O

Two	O
gorups	O
of	O
suipne	O
sbujects	O
were	O
studied	O
under	O
palcebo	O
-	O
cotnrolled	O
conidtions	O
,	O
one	O
during	O
the	O
nihgt	O
,	O
when	O
slepeing	O
(	O
n	O
=	O
7	O
)	O
and	O
the	O
other	O
at	O
datyime	O
,	O
when	O
aawke	O
(	O
n	O
=	O
6	O
)	O
.	O

Each	O
subjcet	O
received	O
a	O
single	O
50	O
mg	O
dsoe	O
of	O
clomiprmaine	B-Chemical
given	O
oarlly	O
2	O
hours	O
before	O
bolod	O
collectoin	O
.	O

Plamsa	O
PRL	O
concenrtations	O
were	O
analsyed	O
at	O
10	O
min	O
itnervals	O
and	O
underlying	O
secretroy	O
rtaes	O
calculated	O
by	O
a	O
decnovolution	O
procedrue	O
.	O

For	O
both	O
expeirments	O
the	O
durg	O
itnake	O
led	O
to	O
significant	O
incraeses	O
in	O
PRL	O
sercetion	O
,	O
acting	O
preferentially	O
on	O
toinc	O
sceretion	O
as	O
pusle	O
ampltiude	O
and	O
frequecny	O
did	O
not	O
differ	O
significantly	O
from	O
corresponding	O
cnotrol	O
valeus	O
.	O

During	O
the	O
nihgt	O
cloimpramine	B-Chemical
ingesiton	O
aletred	O
the	O
complete	O
sleep	O
archtiecture	O
in	O
that	O
it	O
supperssed	O
REM	O
sleep	O
and	O
the	O
selep	O
cycels	O
and	O
induecd	O
incresaed	O
wakefluness	O
.	O

As	O
the	O
relative	O
inrcease	O
in	O
PRL	O
secrteion	O
epxressed	O
as	O
a	O
percentgae	O
of	O
the	O
mean	O
did	O
not	O
significantly	O
differ	O
between	O
the	O
nihgt	O
and	O
day	O
tmie	O
stuides	O
(	O
46	O
+	O
/	O
-	O
19	O
%	O
vs	O
34	O
+	O
/	O
-	O
10	O
%	O
)	O
,	O
it	O
can	O
be	O
concluded	O
that	O
the	O
observed	O
sleep	O
ditsurbance	O
did	O
not	O
interfere	O
with	O
the	O
durg	O
aciton	O
per	O
se	O
.	O

The	O
preesnce	O
of	O
REM	O
sleep	O
was	O
shown	O
not	O
to	O
be	O
a	O
determining	O
facotr	O
either	O
for	O
sceretory	O
pluse	O
apmlitude	O
and	O
frequecny	O
,	O
as	O
,	O
for	O
both	O
,	O
mean	O
ncoturnal	O
valeus	O
were	O
similar	O
with	O
and	O
without	O
prior	O
cloimpramine	B-Chemical
ingestoin	O
.	O

Surevy	O
of	O
compliactions	O
of	O
indocyainne	B-Chemical
green	I-Chemical
anigography	O
in	O
Jpaan	O
.	O

PUROPSE	O
:	O
We	O
evalutaed	O
the	O
sfaety	O
of	O
indocynaine	B-Chemical
green	I-Chemical
for	O
use	O
in	O
funuds	O
angiogarphy	O
.	O

METHODS	O
:	O
We	O
sent	O
a	O
questoinnaire	O
concerning	O
complciations	O
of	O
indocynaine	B-Chemical
green	I-Chemical
to	O
32	O
insttiutions	O
in	O
Jaapn	O
,	O
which	O
were	O
selected	O
on	O
the	O
basis	O
of	O
the	O
clinet	O
list	O
from	O
the	O
Tpocon	O
Copmany	O
,	O
which	O
manfuactures	O
the	O
indcoyanine	B-Chemical
green	I-Chemical
funuds	O
camrea	O
.	O

RESLUTS	O
:	O
Ophthalmologsits	O
at	O
15	O
insittutions	O
responded	O
,	O
reporting	O
a	O
total	O
of	O
3	O
,	O
774	O
inodcyanine	B-Chemical
green	I-Chemical
angiorgams	O
performed	O
on	O
2	O
,	O
820	O
ptaients	O
between	O
June	O
1984	O
and	O
Sepetmber	O
1992	O
.	O

Before	O
angiorgaphy	O
,	O
itnradermal	O
or	O
intraveonus	O
indoycanine	B-Chemical
green	I-Chemical
testnig	O
,	O
or	O
both	O
was	O
performed	O
at	O
13	O
of	O
15	O
isntitutions	O
.	O

For	O
three	O
patinets	O
,	O
the	O
deciison	O
was	O
made	O
not	O
to	O
proceed	O
with	O
angiorgaphy	O
after	O
poistive	O
perangiographic	O
testnig	O
.	O

The	O
doasge	O
of	O
inodcyanine	B-Chemical
green	I-Chemical
used	O
for	O
angiograhpy	O
varied	O
from	O
25	O
to	O
75	O
mg	O
,	O
depending	O
upon	O
the	O
isntitution	O
.	O

There	O
were	O
13	O
csaes	O
of	O
advrese	O
raections	O
(	O
0	O
.	O
34	O
%	O
)	O
,	O
ten	O
of	O
which	O
were	O
mlid	O
reatcions	O
such	O
as	O
nasuea	O
,	O
exanhtema	O
,	O
urtiaction	O
,	O
ithciness	O
,	O
and	O
ugrency	O
to	O
deefcate	O
,	O
and	O
did	O
not	O
require	O
tretament	O
.	O

Also	O
recorded	O
were	O
one	O
csae	O
of	O
pian	O
of	O
the	O
vien	O
,	O
which	O
required	O
treamtent	O
,	O
and	O
two	O
csaes	O
of	O
hypotenison	O
.	O

The	O
two	O
hypoetnsive	O
patinets	O
required	O
traetment	O
for	O
shcok	O
.	O

CNOCLUSIONS	O
:	O
A	O
cmoparison	O
of	O
frequecny	O
of	O
avderse	O
reacitons	O
to	O
indocynaine	B-Chemical
green	I-Chemical
with	O
the	O
previously	O
reported	O
ferquency	O
of	O
such	O
reatcions	O
to	O
fluoerscein	B-Chemical
soidum	I-Chemical
indicated	O
that	O
idnocyanine	B-Chemical
green	I-Chemical
is	O
a	O
safe	O
as	O
flourescein	B-Chemical
for	O
use	O
in	O
angoigraphy	O
.	O

Angieodema	O
following	O
the	O
inrtavenous	O
administartion	O
of	O
metoprlool	B-Chemical
.	O

A	O
72	O
-	O
yaer	O
-	O
old	O
wmoan	O
was	O
admtited	O
to	O
the	O
hosptial	O
with	O
"	O
flsah	O
"	O
pulmoanry	O
edmea	O
,	O
preceded	O
by	O
cehst	O
pian	O
,	O
requiring	O
intubaiton	O
.	O

Her	O
meidcal	O
hisotry	O
included	O
cornoary	O
atrery	O
disaese	O
with	O
previous	O
myocadrial	O
infartcions	O
,	O
hpyertension	O
,	O
and	O
diaebtes	O
melliuts	O
.	O

A	O
hitsory	O
of	O
angoiedema	O
secondary	O
to	O
lisinopirl	B-Chemical
therpay	O
was	O
elicited	O
.	O

Current	O
meidcations	O
did	O
not	O
include	O
angioetnsin	B-Chemical
-	O
converting	O
enzmye	O
inhibiotrs	O
or	O
btea	O
-	O
bolckers	O
.	O

She	O
had	O
no	O
previous	O
btea	O
-	O
blocknig	O
durg	O
exposrue	O
.	O

During	O
the	O
first	O
day	O
of	O
hospitalizatoin	O
(	O
while	O
intbuated	O
)	O
,	O
intraevnous	O
meotprolol	B-Chemical
was	O
given	O
,	O
resulting	O
in	O
seevre	O
anigoedema	O
.	O

The	O
anigoedema	O
resolved	O
after	O
threapy	O
with	O
intravenuos	O
setroids	B-Chemical
and	O
diphenhydramnie	B-Chemical
hyrdochloride	O
.	O

Effect	O
of	O
coinine	B-Chemical
on	O
the	O
developing	O
chcik	O
ebmryo	O
.	O

Coninie	B-Chemical
,	O
an	O
aklaloid	O
from	O
Cnoium	O
macultaum	O
(	O
pioson	O
hmelock	O
)	O
,	O
has	O
been	O
shown	O
to	O
be	O
teartogenic	O
in	O
livesotck	O
.	O

The	O
major	O
teratogneic	O
ouctome	O
is	O
atrhrogryposis	O
,	O
presumably	O
due	O
to	O
nicoitnic	O
recepotr	O
blcokade	O
.	O

However	O
,	O
coinine	B-Chemical
has	O
failed	O
to	O
produce	O
arhtrogryposis	O
in	O
rtas	O
or	O
mcie	O
and	O
is	O
only	O
weakly	O
teraotgenic	O
in	O
rabibts	O
.	O

The	O
purpose	O
of	O
this	O
sutdy	O
was	O
to	O
evalaute	O
and	O
cmopare	O
the	O
efefcts	O
of	O
coninie	B-Chemical
and	O
nictoine	B-Chemical
in	O
the	O
developing	O
cihck	O
.	O

Concetnrations	O
of	O
coninie	B-Chemical
and	O
nioctine	B-Chemical
suflate	O
were	O
0	O
.	O
015	O
%	O
,	O
0	O
.	O
03	O
%	O
,	O
0	O
.	O
075	O
%	O
,	O
0	O
.	O
15	O
%	O
,	O
0	O
.	O
75	O
%	O
,	O
1	O
.	O
5	O
%	O
,	O
3	O
%	O
,	O
and	O
6	O
%	O
and	O
1	O
%	O
,	O
5	O
%	O
,	O
and	O
10	O
%	O
,	O
respectively	O
.	O

Both	O
comopunds	O
caused	O
dfeormations	O
and	O
ltehality	O
in	O
a	O
dsoe	O
-	O
deepndent	O
manner	O
.	O

All	O
concenrtations	O
of	O
nciotine	B-Chemical
sulftae	O
caused	O
some	O
letahlity	O
but	O
a	O
no	O
efefct	O
lveel	O
for	O
coninie	B-Chemical
lethlaity	O
was	O
0	O
.	O
75	O
%	O
.	O

The	O
deofrmations	O
caused	O
by	O
both	O
coniine	B-Chemical
and	O
nciotine	B-Chemical
slufate	O
were	O
excesisve	O
flxeion	O
or	O
etxension	O
of	O
one	O
or	O
more	O
teos	O
.	O

No	O
histopahtological	O
alteratoins	O
or	O
differneces	O
in	O
bnoe	O
formatoin	O
were	O
seen	O
in	O
the	O
lmibs	O
or	O
teos	O
of	O
any	O
cihcks	O
from	O
any	O
gorup	O
;	O
however	O
,	O
exetnsive	O
crnaial	O
hemorrhgae	O
occurred	O
in	O
all	O
nicoitne	B-Chemical
slufate	O
-	O
tretaed	O
chciks	O
.	O

There	O
was	O
a	O
statitsically	O
significant	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
dcerease	O
in	O
moveemnt	O
in	O
coninie	B-Chemical
and	O
nicoitne	B-Chemical
slufate	O
tretaed	O
chikcs	O
as	O
determined	O
by	O
ultrasonud	O
.	O

Conrtol	O
chikcs	O
were	O
in	O
motoin	O
an	O
avreage	O
of	O
33	O
.	O
67	O
%	O
of	O
the	O
tmie	O
,	O
while	O
coniine	B-Chemical
-	O
terated	O
cihcks	O
were	O
only	O
mvoing	O
8	O
.	O
95	O
%	O
of	O
a	O
5	O
-	O
min	O
intevral	O
,	O
and	O
no	O
mvoement	O
was	O
observed	O
for	O
nioctine	B-Chemical
sulftae	O
traeted	O
chikcs	O
.	O

In	O
summary	O
,	O
the	O
cihck	O
embyro	O
provides	O
a	O
reliable	O
and	O
simple	O
expermiental	O
anmial	O
moedl	O
of	O
coinine	B-Chemical
-	O
induecd	O
arthrogrypsois	O
.	O

Dtaa	O
from	O
this	O
mdoel	O
support	O
a	O
mehcanism	O
involving	O
nicotniic	O
recepotr	O
blockdae	O
with	O
subsequent	O
decraesed	O
fteal	O
movemnet	O
.	O

Immdeiate	O
allerigc	O
reatcions	O
to	O
amoxciillin	B-Chemical
.	O

A	O
large	O
gorup	O
of	O
patietns	O
with	O
suspetced	O
allergic	O
recations	O
to	O
btea	B-Chemical
-	I-Chemical
latcam	I-Chemical
antibiotcis	O
was	O
evlauated	O
.	O

A	O
detailed	O
cliincal	O
hsitory	O
,	O
together	O
with	O
sikn	O
tsets	O
,	O
RSAT	O
(	O
radioallergosorbnet	O
tset	O
)	O
,	O
and	O
contrloled	O
challenge	O
tetss	O
,	O
was	O
used	O
to	O
establish	O
whether	O
patietns	O
allregic	O
to	O
btea	B-Chemical
-	I-Chemical
latcam	I-Chemical
antiibotics	O
had	O
selective	O
immdeiate	O
allerigc	O
resposnes	O
to	O
aomxicillin	B-Chemical
(	O
AX	B-Chemical
)	O
or	O
were	O
corss	O
-	O
reatcing	O
with	O
other	O
peniclilin	B-Chemical
derivaitves	O
.	O

Sikn	O
tetss	O
were	O
performed	O
with	O
beznylpenicilloyl	B-Chemical
-	I-Chemical
ploy	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
lyisne	I-Chemical
(	O
BPO	B-Chemical
-	I-Chemical
PLL	I-Chemical
)	O
,	O
benzyplenicilloate	B-Chemical
,	O
benzylpeincillin	B-Chemical
(	O
PG	B-Chemical
)	O
,	O
ampciillin	B-Chemical
(	O
AMP	B-Chemical
)	O
,	O
and	O
AX	B-Chemical
.	O

RSAT	O
for	O
BPO	B-Chemical
-	I-Chemical
PLL	I-Chemical
and	O
AX	B-Chemical
-	O
PLL	O
was	O
done	O
.	O

When	O
both	O
sikn	O
tset	O
and	O
RSAT	O
for	O
BPO	B-Chemical
were	O
ngeative	O
,	O
single	O
-	O
blnid	O
,	O
placbeo	O
-	O
conrtolled	O
challenge	O
tetss	O
were	O
done	O
to	O
ensure	O
toleracne	O
of	O
PG	B-Chemical
or	O
sensitviity	O
to	O
AX	B-Chemical
.	O

A	O
total	O
of	O
177	O
pateints	O
were	O
daignosed	O
as	O
allerigc	O
to	O
btea	B-Chemical
-	I-Chemical
lcatam	I-Chemical
antbiiotics	O
.	O

We	O
selected	O
the	O
54	O
(	O
30	O
.	O
5	O
%	O
)	O
csaes	O
of	O
immeditae	O
AX	B-Chemical
allergy	O
with	O
good	O
toelrance	O
of	O
PG	B-Chemical
.	O

Anaphlyaxis	O
was	O
seen	O
in	O
37	O
patietns	O
(	O
69	O
%	O
)	O
,	O
the	O
other	O
17	O
(	O
31	O
%	O
)	O
having	O
uritcaria	O
and	O
/	O
or	O
agnioedema	O
.	O

All	O
the	O
patietns	O
were	O
sikn	O
tset	O
ngeative	O
to	O
BPO	B-Chemical
;	O
49	O
of	O
51	O
(	O
96	O
%	O
)	O
were	O
also	O
ngeative	O
to	O
MDM	O
,	O
and	O
44	O
of	O
46	O
(	O
96	O
%	O
)	O
to	O
PG	B-Chemical
.	O

Sikn	O
tsets	O
with	O
AX	B-Chemical
were	O
postiive	O
in	O
34	O
(	O
63	O
%	O
)	O
patietns	O
.	O

RSAT	O
was	O
psoitive	O
for	O
AX	B-Chemical
in	O
22	O
patietns	O
(	O
41	O
%	O
)	O
and	O
to	O
BPO	B-Chemical
in	O
just	O
5	O
(	O
9	O
%	O
)	O
.	O

None	O
of	O
the	O
srea	O
with	O
ngeative	O
RSAT	O
for	O
AX	B-Chemical
were	O
psoitive	O
to	O
BPO	B-Chemical
.	O

Chlalenge	O
tsets	O
with	O
AX	B-Chemical
were	O
performed	O
in	O
23	O
subjcets	O
(	O
43	O
%	O
)	O
to	O
establish	O
the	O
diagonsis	O
of	O
immediate	O
allegric	O
raection	O
to	O
AX	B-Chemical
,	O
and	O
in	O
15	O
csaes	O
(	O
28	O
%	O
)	O
both	O
sikn	O
tset	O
and	O
RSAT	O
for	O
AX	B-Chemical
were	O
negtaive	O
.	O

PG	B-Chemical
was	O
well	O
toleraetd	O
by	O
all	O
54	O
pateints	O
.	O

We	O
describe	O
the	O
largest	O
gruop	O
of	O
AX	B-Chemical
-	O
alelrgic	O
pateints	O
who	O
have	O
toleraetd	O
PG	B-Chemical
reported	O
so	O
far	O
.	O

Diagnoiss	O
of	O
these	O
pateints	O
can	O
be	O
achieved	O
only	O
if	O
specific	O
AX	B-Chemical
-	O
related	O
reaegnts	O
are	O
employed	O
.	O

Further	O
stduies	O
are	O
necessary	O
to	O
determine	O
the	O
exact	O
extent	O
of	O
this	O
probelm	O
and	O
to	O
ipmrove	O
the	O
efficcay	O
of	O
diagnositc	O
mehtods	O
.	O

Reverasl	O
by	O
phenyelphrine	B-Chemical
of	O
the	O
beneficial	O
effcets	O
of	O
intraevnous	O
nitorglycerin	B-Chemical
in	O
ptaients	O
with	O
aucte	O
myocardail	O
infarciton	O
.	O

Nitrolgycerin	B-Chemical
has	O
been	O
shown	O
to	O
reudce	O
ST	O
-	O
sgement	O
eleavtion	O
during	O
actue	O
moycardial	O
infarciton	O
,	O
an	O
effcet	O
ptoentiated	O
in	O
the	O
dog	O
by	O
aegnts	O
that	O
revesre	O
nitorglycerin	B-Chemical
-	O
inudced	O
hpyotension	O
.	O

Our	O
sutdy	O
was	O
designed	O
to	O
determine	O
the	O
efefcts	O
of	O
combiend	O
nitroglyceirn	B-Chemical
and	O
phneylephrine	B-Chemical
thearpy	O
.	O

Ten	O
patinets	O
with	O
actue	O
tranmsural	O
myocardail	O
infarctoins	O
received	O
intravenuos	O
nitroglycrein	B-Chemical
,	O
sufficient	O
to	O
rdeuce	O
mean	O
aretrial	O
perssure	O
from	O
107	O
+	O
/	O
-	O
6	O
to	O
85	O
+	O
/	O
-	O
6	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
for	O
60	O
mniutes	O
.	O

Lfet	O
ventircular	O
fliling	O
prsesure	O
decreaesd	O
from	O
19	O
+	O
/	O
-	O
2	O
to	O
11	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

SigamST	O
,	O
the	O
sum	O
of	O
ST	O
-	O
semgent	O
elevatinos	O
in	O
16	O
precodrial	O
leads	O
,	O
decreaesd	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
with	O
intravneous	O
nitrgolycerin	B-Chemical
.	O

Subsequent	O
addition	O
of	O
phenylephirne	B-Chemical
infuison	O
,	O
sufficient	O
to	O
re	O
-	O
eelvate	O
mean	O
aretrial	O
perssure	O
to	O
106	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
for	O
30	O
mniutes	O
,	O
inrceased	O
lfet	O
ventircular	O
fillnig	O
pressure	O
to	O
17	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
also	O
significantly	O
incresaed	O
sigmaST	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Our	O
resluts	O
suggest	O
that	O
addition	O
of	O
phenylephirne	B-Chemical
to	O
nitrogylcerin	B-Chemical
is	O
not	O
beneficial	O
in	O
the	O
treamtent	O
of	O
patinets	O
with	O
actue	O
myocaridal	O
infarctoin	O
.	O

Acetazloamide	B-Chemical
-	O
induecd	O
nehprolithiasis	O
:	O
implications	O
for	O
treatmnet	O
of	O
neuromsucular	O
disordres	O
.	O

Cabronic	O
ahnydrase	O
inhibiotrs	O
can	O
cause	O
nephroltihiasis	O
.	O

We	O
studied	O
20	O
patietns	O
receiving	O
long	O
-	O
term	O
carbnoic	O
anhydarse	O
inhbiitor	O
treatmnet	O
for	O
perioidc	O
parlaysis	O
and	O
moytonia	O
.	O

Three	O
patietns	O
on	O
acetzaolamide	B-Chemical
(	O
15	O
%	O
)	O
developed	O
rneal	O
cacluli	O
.	O

Extracoropreal	O
litohtripsy	O
successfully	O
remvoed	O
a	O
rneal	O
calcuuls	O
in	O
one	O
pateint	O
and	O
surgrey	O
reomved	O
a	O
staghron	O
caluclus	O
in	O
another	O
,	O
permitting	O
continued	O
teratment	O
.	O

Reanl	O
fucntion	O
remained	O
nromal	O
in	O
all	O
paitents	O
.	O

Nephrolitihasis	O
is	O
a	O
complictaion	O
of	O
acteazolamide	B-Chemical
but	O
does	O
not	O
preclude	O
its	O
use	O
.	O

Effetcs	O
of	O
calicum	B-Chemical
channel	O
blocekrs	O
on	O
buipvacaine	B-Chemical
-	O
induecd	O
toxictiy	O
.	O

The	O
purpose	O
of	O
this	O
stduy	O
was	O
to	O
inevstigate	O
the	O
infulence	O
of	O
calcuim	B-Chemical
chnanel	O
blokcers	O
on	O
bupiavcaine	B-Chemical
-	O
idnuced	O
aucte	O
toixcity	O
.	O

For	O
each	O
of	O
the	O
three	O
tesetd	O
clacium	B-Chemical
cahnnel	O
blcokers	O
(	O
dlitiazem	B-Chemical
,	O
verpaamil	B-Chemical
and	O
bperidil	B-Chemical
)	O
6	O
gruops	O
of	O
mcie	O
were	O
traeted	O
by	O
two	O
different	O
dsoes	O
,	O
i	O
.	O
e	O
.	O
2	O
and	O
10	O
mg	O
/	O
kg	O
/	O
i	O
.	O
p	O
.	O
,	O
or	O
an	O
eqaul	O
volmue	O
of	O
sailne	O
for	O
the	O
contorl	O
gorup	O
(	O
n	O
=	O
20	O
)	O
;	O
15	O
minuets	O
later	O
,	O
all	O
the	O
anmials	O
were	O
inejcted	O
with	O
a	O
single	O
50	O
mg	O
/	O
kg	O
/	O
i	O
.	O
p	O
.	O
dsoe	O
of	O
bupviacaine	B-Chemical
.	O

The	O
convuslant	O
atcivity	O
,	O
the	O
tmie	O
of	O
laetncy	O
to	O
covnulse	O
and	O
the	O
motrality	O
rtae	O
were	O
assesesd	O
in	O
each	O
gorup	O
.	O

The	O
loacl	O
anetshetic	O
-	O
induecd	O
motrality	O
was	O
significantly	O
incerased	O
by	O
the	O
three	O
different	O
caclium	B-Chemical
cahnnel	O
blcokers	O
.	O

The	O
cnovulsant	O
acitvity	O
of	O
bupivaciane	B-Chemical
was	O
not	O
significantly	O
modiifed	O
but	O
calcuim	B-Chemical
cahnnel	O
blocekrs	O
decerased	O
the	O
tmie	O
of	O
ltaency	O
to	O
obtain	O
bupivacanie	B-Chemical
-	O
induecd	O
convlusions	O
;	O
this	O
effect	O
was	O
less	O
pronounced	O
with	O
beprdiil	B-Chemical
.	O

Epiudral	O
blood	O
folw	O
during	O
prostgalandin	B-Chemical
E1	I-Chemical
or	O
trimethpahan	B-Chemical
indcued	O
hyptoension	O
.	O

To	O
eavluate	O
the	O
effcet	O
of	O
prostalgandin	B-Chemical
E1	I-Chemical
(	O
PEG1	B-Chemical
)	O
or	O
trimetahphan	B-Chemical
(	O
TMP	B-Chemical
)	O
indcued	O
hypotenison	O
on	O
epiudral	O
bolod	O
folw	O
(	O
EBF	O
)	O
during	O
sipnal	O
srugery	O
,	O
EBF	O
was	O
maesured	O
using	O
the	O
haet	O
claerance	O
mehtod	O
in	O
30	O
paitents	O
who	O
underwent	O
psotero	O
-	O
laetral	O
interbdoy	O
fusoin	O
under	O
isoflurnae	B-Chemical
anaetshesia	O
.	O

An	O
initial	O
dsoe	O
of	O
0	O
.	O
1	O
micrgoram	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
of	O
PEG1	B-Chemical
(	O
15	O
patietns	O
)	O
,	O
or	O
10	O
mcirograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
of	O
TMP	B-Chemical
(	O
15	O
patietns	O
)	O
was	O
admiinstered	O
intravenuosly	O
after	O
the	O
drual	O
opennig	O
and	O
the	O
dsoe	O
was	O
adjusted	O
to	O
maintain	O
the	O
mean	O
arteiral	O
bolod	O
pressrue	O
(	O
MAP	O
)	O
at	O
about	O
60	O
mmHg	O
.	O

The	O
hypoetnsive	O
durg	O
was	O
discontiuned	O
at	O
the	O
compleiton	O
of	O
the	O
operaitve	O
proecdure	O
.	O

After	O
starting	O
PEG1	B-Chemical
or	O
TMP	B-Chemical
,	O
MAP	O
and	O
rtae	O
pressrue	O
porduct	O
(	O
RPP	O
)	O
dcereased	O
significantly	O
cmopared	O
with	O
perinfusion	O
valeus	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
the	O
dergee	O
of	O
hypoetnsion	O
due	O
to	O
PEG1	B-Chemical
remained	O
cnostant	O
until	O
60	O
min	O
after	O
its	O
discontinuatoin	O
.	O

Haert	O
rtae	O
(	O
HR	O
)	O
did	O
not	O
change	O
in	O
either	O
gorup	O
.	O

EFBF	O
did	O
not	O
change	O
during	O
PEG1	B-Chemical
infusoin	O
whereas	O
in	O
the	O
TMP	B-Chemical
gorup	O
,	O
EBF	O
decreaesd	O
significantly	O
at	O
30	O
and	O
60	O
min	O
after	O
the	O
start	O
of	O
TMP	B-Chemical
(	O
preinufsion	O
:	O
45	O
.	O
9	O
+	O
/	O
-	O
13	O
.	O
9	O
ml	O
/	O
100g	O
/	O
min	O
.	O
30	O
min	O
:	O
32	O
.	O
3	O
+	O
/	O
-	O
9	O
.	O
9	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
60	O
min	O
:	O
30	O
+	O
/	O
-	O
7	O
.	O
5	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
)	O
.	O

These	O
reuslts	O
suggest	O
that	O
PEG1	B-Chemical
may	O
be	O
preferable	O
to	O
TMP	B-Chemical
for	O
hyptoensive	O
anaestehsia	O
in	O
sipnal	O
surgrey	O
because	O
TMP	B-Chemical
decreaesd	O
EBF	O
.	O

Dup	B-Chemical
753	I-Chemical
prevents	O
the	O
develompent	O
of	O
puromcyin	B-Chemical
aimnonucleoside	I-Chemical
-	O
inudced	O
nehprosis	O
.	O

The	O
appearnace	O
of	O
npehrotic	O
syndrmoes	O
such	O
as	O
prtoeinuria	O
,	O
hypoalbuimnemia	O
,	O
hyperhcolesterolemia	O
and	O
inrcease	O
in	O
blood	B-Chemical
ntirogen	I-Chemical
uera	I-Chemical
,	O
inudced	O
in	O
rtas	O
by	O
injeciton	O
of	O
puromcyin	B-Chemical
aminonuceloside	I-Chemical
was	O
markedly	O
inhiibted	O
by	O
oarl	O
adminsitration	O
of	O
Dup	B-Chemical
753	I-Chemical
(	O
loasrtan	B-Chemical
)	O
,	O
a	O
novel	O
angiotnesin	B-Chemical
II	I-Chemical
recpetor	O
antagonsit	O
,	O
at	O
a	O
dsoe	O
of	O
1	O
or	O
2	O
mg	O
/	O
kg	O
per	O
day	O
.	O

The	O
resutls	O
suggest	O
a	O
possible	O
invlovement	O
of	O
the	O
reinn	O
-	O
angioetnsin	B-Chemical
ssytem	O
in	O
the	O
developemnt	O
of	O
puromyicn	B-Chemical
aminonucleosdie	I-Chemical
-	O
idnuced	O
nephorsis	O
.	O

Neurolpasticity	O
of	O
the	O
audlt	O
pirmate	O
auidtory	O
cotrex	O
following	O
cochlaer	O
haering	O
lsos	O
.	O

Tonootpic	O
orgainzation	O
is	O
an	O
essetnial	O
feature	O
of	O
the	O
primray	O
audtiory	O
aera	O
(	O
A1	O
)	O
of	O
pirmate	O
crotex	O
.	O

In	O
A1	O
of	O
maacque	O
mnokeys	O
,	O
low	O
frequenices	O
are	O
represented	O
rostrolatearlly	O
and	O
high	O
frequenceis	O
are	O
represented	O
cauodmedially	O
.	O

The	O
purpose	O
of	O
this	O
sutdy	O
was	O
to	O
determine	O
if	O
cahnges	O
occur	O
in	O
this	O
tontoopic	O
oragnization	O
following	O
cochlaer	O
heairng	O
lsos	O
.	O

Under	O
anestehsia	O
,	O
the	O
superior	O
tempoarl	O
gyurs	O
of	O
audlt	O
mcaaque	O
mokneys	O
was	O
epxosed	O
,	O
and	O
the	O
tonotoipc	O
organizaiton	O
of	O
A1	O
was	O
mapped	O
using	O
conevntional	O
microeletcrode	O
recroding	O
tcehniques	O
.	O

Following	O
reocvery	O
,	O
the	O
monkyes	O
were	O
selectively	O
daefened	O
for	O
high	O
frequnecies	O
using	O
knaamycin	B-Chemical
and	O
fursoemide	B-Chemical
.	O

The	O
acutal	O
freqeuncies	O
defaened	O
were	O
determined	O
by	O
the	O
lsos	O
of	O
tnoe	O
-	O
brust	O
elicited	O
audiotry	O
brianstem	O
resopnses	O
.	O

Three	O
mnoths	O
after	O
daefening	O
,	O
A1	O
was	O
rempaped	O
.	O

Psotmortem	O
cytorachitectural	O
featuers	O
identifying	O
A1	O
were	O
correalted	O
with	O
the	O
electrophyisologic	O
dtaa	O
.	O

The	O
resluts	O
indicate	O
that	O
the	O
dperived	O
aera	O
of	O
A1	O
undergoes	O
exetnsive	O
reorganiztaion	O
and	O
becomes	O
respnosive	O
to	O
itnact	O
cochlaer	O
frequnecies	O
.	O

The	O
rgeion	O
of	O
cotrex	O
that	O
represents	O
the	O
low	O
frequecnies	O
was	O
not	O
obviously	O
affecetd	O
by	O
the	O
cohclear	O
heraing	O
lsos	O
.	O

Soduim	B-Chemical
bicrabonate	I-Chemical
alleviates	O
penlie	O
pian	O
indcued	O
by	O
intracaveronus	O
injectoins	O
for	O
eretcile	O
dyfsunction	O
.	O

In	O
an	O
attempt	O
to	O
determine	O
whether	O
penlie	O
pian	O
associated	O
with	O
intraocrporeal	O
injectoins	O
could	O
be	O
due	O
to	O
the	O
aciidty	O
of	O
the	O
mediaction	O
,	O
we	O
performed	O
a	O
randoimzed	O
sutdy	O
comapring	O
the	O
inicdence	O
of	O
pneile	O
pian	O
following	O
intracoproreal	O
injetcions	O
with	O
or	O
without	O
the	O
addition	O
of	O
soduim	B-Chemical
biacrbonate	I-Chemical
to	O
the	O
intrcaorporeal	O
mdeications	O
.	O

A	O
total	O
of	O
38	O
consecuitve	O
patietns	O
who	O
presented	O
to	O
our	O
cilnic	O
with	O
ipmotence	O
received	O
0	O
.	O
2	O
ml	O
.	O
of	O
a	O
combinatoin	O
of	O
3	O
durgs	O
:	O
6	O
mg	O
.	O
papvaerine	B-Chemical
,	O
100	O
mcirograms	O
.	O
phenotlamine	B-Chemical
and	O
10	O
micorgrams	O
.	O
prostaglanidn	B-Chemical
E1	I-Chemical
with	O
(	O
pH	O
7	O
.	O
05	O
)	O
or	O
without	O
(	O
pH	O
4	O
.	O
17	O
)	O
the	O
addition	O
of	O
soidum	B-Chemical
bciarbonate	I-Chemical
(	O
0	O
.	O
03	O
mEq	O
.	O
)	O
.	O

Of	O
the	O
19	O
patinets	O
without	O
soidum	B-Chemical
bicarboante	I-Chemical
added	O
to	O
the	O
medictaion	O
11	O
(	O
58	O
%	O
)	O
complained	O
of	O
pneile	O
pian	O
due	O
to	O
the	O
mdeication	O
,	O
while	O
only	O
1	O
of	O
the	O
19	O
men	O
(	O
5	O
%	O
)	O
who	O
received	O
soduim	B-Chemical
bicrabonate	I-Chemical
complained	O
of	O
pneile	O
pian	O
.	O

From	O
these	O
dtaa	O
we	O
conclude	O
that	O
the	O
peinle	O
pian	O
following	O
intrcaorporeal	O
ijnections	O
is	O
most	O
likely	O
due	O
to	O
the	O
aicdity	O
of	O
the	O
medicatoin	O
,	O
which	O
can	O
be	O
overcome	O
by	O
eelvating	O
the	O
pH	O
to	O
a	O
neurtal	O
lveel	O
.	O

The	O
use	O
and	O
toixcity	O
of	O
diadnosine	B-Chemical
(	O
ddI	B-Chemical
)	O
in	O
HIV	O
antbiody	O
-	O
positvie	O
idnividuals	O
intoelrant	O
to	O
ziodvudine	B-Chemical
(	O
AZT	B-Chemical
)	O

One	O
hundred	O
and	O
fifty	O
-	O
one	O
pateints	O
intoelrant	O
to	O
ziodvudine	B-Chemical
(	O
AZT	B-Chemical
)	O
received	O
didansoine	B-Chemical
(	O
ddI	B-Chemical
)	O
to	O
a	O
mxaimum	O
dsoe	O
of	O
12	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Pateint	O
repsonse	O
was	O
assessed	O
using	O
chagnes	O
in	O
CD4	O
+	O
lymphoctye	O
subset	O
conut	O
,	O
HIV	O
p24	O
antiegn	O
,	O
wieght	O
,	O
and	O
qaulity	O
of	O
lfie	O
.	O

Seventy	O
pateints	O
developed	O
major	O
opportunistic	O
ifnections	O
whilst	O
on	O
thearpy	O
;	O
this	O
was	O
the	O
first	O
ADIS	O
diangosis	O
in	O
17	O
.	O

Only	O
minor	O
chnages	O
in	O
CD4	O
+	O
lymphoycte	O
subset	O
conut	O
were	O
observed	O
in	O
ADIS	O
patinets	O
,	O
although	O
a	O
more	O
significant	O
rise	O
occurred	O
in	O
those	O
with	O
earlier	O
satges	O
of	O
disaese	O
.	O

Of	O
those	O
psoitive	O
for	O
p24	O
anitgen	O
at	O
the	O
commenceemnt	O
of	O
the	O
sutdy	O
67	O
%	O
showed	O
a	O
poistive	O
resopnse	O
,	O
and	O
this	O
was	O
most	O
likely	O
in	O
those	O
with	O
CD4	O
+	O
lympohcyte	O
subset	O
coutns	O
above	O
100	O
mm3	O
.	O

A	O
posiitve	O
weihgt	O
resopnse	O
was	O
seen	O
in	O
16	O
%	O
of	O
pateints	O
.	O

Most	O
paitents	O
showed	O
improveemnt	O
in	O
indiivdual	O
paramteers	O
and	O
glboal	O
scroe	O
of	O
qulaity	O
of	O
lfie	O
.	O

Advesre	O
reatcions	O
possibly	O
attributable	O
to	O
didanoisne	B-Chemical
were	O
common	O
.	O

The	O
most	O
common	O
side	O
-	O
effect	O
was	O
diarrohea	O
,	O
which	O
resulted	O
in	O
cesastion	O
of	O
thearpy	O
in	O
19	O
indivdiuals	O
.	O

Peirpheral	O
neuroapthy	O
occurred	O
in	O
12	O
ptaients	O
and	O
pancreaittis	O
in	O
six	O
.	O

Thirteen	O
ptaients	O
developed	O
a	O
raised	O
sreum	O
aymlase	O
without	O
abodminal	O
pian	O
.	O

Seven	O
pateints	O
developed	O
glucsoe	O
toleracne	O
curevs	O
chraacteristic	O
of	O
dibaetes	O
but	O
these	O
were	O
mlid	O
,	O
did	O
not	O
require	O
treatemnt	O
and	O
returned	O
to	O
nomral	O
on	O
ceasing	O
didanosnie	B-Chemical
.	O

Immunohistochemcial	O
stduies	O
with	O
antiboides	O
to	O
neurofialment	O
protenis	O
on	O
axoanl	O
daamge	O
in	O
expermiental	O
foacl	O
lseions	O
in	O
rat	O
.	O

Immunoihstochemistry	O
with	O
monocloanl	O
antiboides	O
against	O
neurofilmaent	O
(	O
NF	O
)	O
porteins	O
of	O
middle	O
and	O
high	O
molecualr	O
weihgt	O
calss	O
,	O
NF	O
-	O
M	O
and	O
NF	O
-	O
H	O
,	O
was	O
used	O
to	O
stduy	O
axnoal	O
injruy	O
in	O
the	O
bodrerzone	O
of	O
foacl	O
lesoins	O
in	O
rtas	O
.	O

Fcoal	O
injruy	O
in	O
the	O
crotex	O
was	O
produced	O
by	O
infusoin	O
of	O
lcatate	B-Chemical
at	O
aicd	O
pH	O
or	O
by	O
satb	O
caused	O
by	O
needle	O
inesrtion	O
.	O

Infartcs	O
in	O
substatnia	O
ngira	O
pras	O
reticualta	O
were	O
evkoed	O
by	O
prloonged	O
piloacrpine	B-Chemical
-	O
idnuced	O
sattus	O
epiletpicus	O
.	O

Immunohistochemical	O
staiinng	O
for	O
NFs	O
showed	O
chaarcteristic	O
termnial	O
culbs	O
of	O
axnos	O
in	O
the	O
bodrerzone	O
of	O
lseions	O
.	O

Diffreences	O
in	O
the	O
labelling	O
patetrn	O
occurred	O
with	O
different	O
antibodeis	O
which	O
apparently	O
depended	O
on	O
mloecular	O
wegiht	O
clsas	O
of	O
NFs	O
and	O
phoshporylation	O
state	O
.	O

These	O
immunohsitochemical	O
chanegs	O
of	O
NFs	O
can	O
serve	O
as	O
a	O
marekr	O
for	O
axoanl	O
daamge	O
in	O
various	O
expreimental	O
traumaitc	O
or	O
icshemic	O
leisons	O
.	O

Pharmacokineitc	O
and	O
cilnical	O
sutdies	O
in	O
patietns	O
with	O
cimeitdine	B-Chemical
-	O
associated	O
mnetal	O
conufsion	O
.	O

15	O
csaes	O
of	O
cimetiidne	B-Chemical
-	O
associated	O
metnal	O
confuison	O
have	O
been	O
reported	O
.	O

In	O
order	O
that	O
this	O
syndrmoe	O
might	O
be	O
investigaetd	O
cahnges	O
in	O
metnal	O
stauts	O
(	O
M	O
.	O
S	O
.	O
)	O
were	O
corrleated	O
with	O
sreum	O
concnetrations	O
and	O
reanl	O
and	O
heptaic	O
funtcion	O
in	O
36	O
pateints	O
,	O
30	O
paitents	O
had	O
no	O
M	O
.	O
S	O
.	O
change	O
on	O
cimetiidne	B-Chemical
and	O
6	O
had	O
mdoerate	O
to	O
sveere	O
chagnes	O
.	O

These	O
6	O
pateints	O
had	O
both	O
reanl	O
and	O
lievr	O
dysfucntion	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
as	O
well	O
as	O
ciemtidine	B-Chemical
trough	O
-	O
concentratoins	O
of	O
more	O
than	O
1	O
.	O
25	O
microgarm	O
/	O
ml	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
sveerity	O
of	O
M	O
.	O
S	O
.	O
cahnges	O
incraesed	O
as	O
trough	O
-	O
concnetrations	O
rose	O
,	O
5	O
pateints	O
had	O
lmubar	O
puntcure	O
.	O

The	O
cerberospinal	O
fulid	O
:	O
seurm	O
raito	O
of	O
cimetidnie	B-Chemical
concentrtaions	O
was	O
0	O
.	O
24	O
:	O
1	O
and	O
indicates	O
that	O
cimetiidne	B-Chemical
passes	O
the	O
bolod	O
-	O
brian	O
barirer	O
;	O
it	O
also	O
raises	O
the	O
possibility	O
that	O
M	O
.	O
S	O
.	O
chanegs	O
are	O
due	O
to	O
blocakde	O
of	O
histamnie	B-Chemical
H2	O
-	O
rceeptors	O
in	O
the	O
centarl	O
nervuos	O
sysetm	O
.	O

Patinets	O
likely	O
to	O
have	O
both	O
raised	O
trough	O
-	O
concenrtations	O
and	O
metnal	O
cnofusion	O
are	O
those	O
with	O
both	O
sevree	O
rneal	O
and	O
heptaic	O
dysfunctoin	O
.	O

They	O
should	O
be	O
closely	O
observed	O
and	O
should	O
be	O
given	O
reduecd	O
doess	O
of	O
cimetiidne	B-Chemical
.	O

Prospecitve	O
sutdy	O
of	O
the	O
long	O
-	O
term	O
effcets	O
of	O
somatosattin	O
aanlog	O
(	O
octreotdie	B-Chemical
)	O
on	O
gallbldader	O
fnuction	O
and	O
gallsotne	O
formatoin	O
in	O
Chiense	O
acromegailc	O
pateints	O
.	O

This	O
article	O
repotrs	O
the	O
chanegs	O
in	O
gallbladder	O
fucntion	O
examined	O
by	O
ulrtasonography	O
in	O
20	O
Chniese	O
patinets	O
with	O
actvie	O
acromeagly	O
traeted	O
with	O
sc	O
inejction	O
of	O
the	O
smoatostatin	O
anaolg	O
octroetide	B-Chemical
in	O
dosaegs	O
of	O
300	O
-	O
1500	O
mircograms	O
/	O
day	O
for	O
a	O
mean	O
of	O
24	O
.	O
2	O
+	O
/	O
-	O
13	O
.	O
9	O
monhts	O
.	O

During	O
treatemnt	O
with	O
ocrteotide	B-Chemical
,	O
17	O
ptaients	O
developed	O
slugde	O
,	O
10	O
had	O
gallstones	O
,	O
and	O
1	O
developed	O
aucte	O
choleycstitis	O
requiring	O
surgrey	O
.	O

In	O
all	O
of	O
7	O
pateints	O
examined	O
acutely	O
,	O
gallbladder	O
cnotractility	O
was	O
inhibtied	O
after	O
a	O
single	O
100	O
-	O
microgarms	O
inejction	O
.	O

In	O
8	O
pateints	O
followed	O
for	O
24	O
wekes	O
,	O
glalbladder	O
cotnractility	O
remained	O
depresesd	O
throughout	O
therpay	O
.	O

After	O
withdraawl	O
of	O
octreotdie	B-Chemical
in	O
10	O
paitents	O
without	O
gallsotnes	O
,	O
8	O
paitents	O
assesesd	O
had	O
return	O
of	O
noraml	O
galblladder	O
contracitlity	O
within	O
1	O
mnoth	O
.	O

In	O
8	O
of	O
the	O
remaining	O
10	O
paitents	O
who	O
developed	O
gallstoens	O
during	O
traetment	O
,	O
gallbladedr	O
conrtactility	O
normalized	O
in	O
5	O
patietns	O
(	O
3	O
of	O
whom	O
has	O
disapperaance	O
of	O
their	O
sotnes	O
within	O
3	O
wekes	O
)	O
,	O
and	O
remained	O
deperssed	O
in	O
3	O
(	O
2	O
of	O
whom	O
had	O
stnoes	O
present	O
at	O
6	O
motnhs	O
)	O
.	O

Our	O
reuslts	O
suggest	O
that	O
the	O
spupression	O
of	O
gallbladedr	O
contratcility	O
is	O
the	O
cause	O
of	O
the	O
successive	O
fromation	O
of	O
blie	O
suldge	O
,	O
glalstones	O
,	O
and	O
cholecystiits	O
during	O
octroetide	B-Chemical
threapy	O
in	O
Chinsee	O
acromeglaic	O
ptaients	O
.	O

It	O
is	O
therefore	O
very	O
important	O
to	O
follow	O
the	O
chnages	O
of	O
glalbladder	O
funtcion	O
during	O
long	O
-	O
term	O
octretoide	B-Chemical
therpay	O
of	O
acroemgalic	O
paitents	O
.	O

Inrcease	O
of	O
Prakinson	O
disaiblity	O
after	O
fluxoetine	B-Chemical
mdeication	O
.	O

Depressoin	O
is	O
a	O
major	O
cliniacl	O
feature	O
of	O
Parkinosn	O
'	O
s	O
diesase	O
.	O

We	O
rpeort	O
the	O
incresaed	O
aomunt	O
of	O
mtoor	O
dsiability	O
in	O
four	O
patietns	O
with	O
idiopahtic	O
Pariknson	O
'	O
s	O
disesae	O
after	O
epxosure	O
to	O
the	O
antidepressant	B-Chemical
fluoxteine	B-Chemical
.	O

The	O
possibility	O
of	O
a	O
cliincally	O
releavnt	O
doapmine	B-Chemical
-	O
antagonitsic	O
capactiy	O
of	O
fluxoetine	B-Chemical
in	O
Parkinosn	O
'	O
s	O
diesase	O
ptaients	O
must	O
be	O
considered	O
.	O

Snius	O
arrest	O
associated	O
with	O
continouus	O
-	O
inufsion	O
cmietidine	B-Chemical
.	O

The	O
administraiton	O
of	O
inetrmittent	O
intraevnous	O
inufsions	O
of	O
cimteidine	B-Chemical
is	O
infrequently	O
associated	O
with	O
the	O
developemnt	O
of	O
bradyarrhtyhmias	O
.	O

A	O
40	O
-	O
yaer	O
-	O
old	O
man	O
with	O
leuekmia	O
and	O
no	O
hisotry	O
of	O
cradiac	O
disesae	O
developed	O
recrurent	O
,	O
brief	O
epsiodes	O
of	O
appaernt	O
snius	O
arerst	O
while	O
receiving	O
continouus	O
-	O
ifnusion	O
cimetiidne	B-Chemical
50	O
mg	O
/	O
hour	O
.	O

The	O
arryhthmias	O
were	O
temproally	O
related	O
to	O
ciemtidine	B-Chemical
administrtaion	O
,	O
disappeared	O
after	O
dechallnege	O
,	O
and	O
did	O
not	O
recur	O
during	O
ranitiidne	B-Chemical
treamtent	O
.	O

This	O
is	O
the	O
first	O
reported	O
csae	O
of	O
snius	O
arrest	O
associated	O
with	O
contiunous	O
-	O
ifnusion	O
cimetiidne	B-Chemical
.	O

Phsae	O
II	O
tiral	O
of	O
vinoerlbine	B-Chemical
in	O
mteastatic	O
squaomus	O
clel	O
esophgaeal	O
cracinoma	O
.	O

Euorpean	O
Orgnaization	O
for	O
Resaerch	O
and	O
Traetment	O
of	O
Cacner	O
Gastroinetstinal	O
Terat	O
Canecr	O
Cooperatvie	O
Gorup	O
.	O

PURPSOE	O
:	O
To	O
eavluate	O
the	O
respnose	O
rtae	O
and	O
toixc	O
effcets	O
of	O
vinorlebine	B-Chemical
(	O
VNB	B-Chemical
)	O
adminisetred	O
as	O
a	O
single	O
aegnt	O
in	O
mteastatic	O
suqamous	O
clel	O
espohageal	O
cacrinoma	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
six	O
eligbile	O
patinets	O
with	O
measurbale	O
lseions	O
were	O
included	O
and	O
were	O
straitfied	O
according	O
to	O
previous	O
chemothearpy	O
.	O

Thirty	O
patietns	O
without	O
prior	O
cheomtherapy	O
and	O
16	O
pretretaed	O
with	O
cislpatin	B-Chemical
-	O
based	O
chemotehrapy	O
were	O
assessable	O
for	O
txoicity	O
and	O
resposne	O
.	O

VNB	B-Chemical
was	O
administreed	O
weelky	O
as	O
a	O
25	O
-	O
mg	O
/	O
m2	O
short	O
intravneous	O
(	O
i	O
.	O
v	O
.	O
)	O
inufsion	O
.	O

RESLUTS	O
:	O
Six	O
of	O
30	O
paitents	O
(	O
20	O
%	O
)	O
without	O
prior	O
chemotherpay	O
achieved	O
a	O
partail	O
rseponse	O
(	O
PR	O
)	O
(	O
95	O
%	O
confdience	O
inetrval	O
[	O
CI	O
]	O
,	O
8	O
%	O
to	O
39	O
%	O
)	O
.	O

The	O
meidan	O
duratoin	O
of	O
repsonse	O
was	O
21	O
wekes	O
(	O
range	O
,	O
17	O
to	O
28	O
)	O
.	O

One	O
of	O
16	O
patietns	O
(	O
6	O
%	O
)	O
with	O
prior	O
chemotherpay	O
had	O
a	O
complete	O
repsonse	O
(	O
CR	O
)	O
of	O
31	O
weeks	O
'	O
duartion	O
(	O
95	O
%	O
CI	O
,	O
0	O
%	O
to	O
30	O
%	O
)	O
.	O

The	O
overall	O
rseponse	O
rtae	O
(	O
Wolrd	O
Helath	O
Organiaztion	O
[	O
WHO	O
]	O
critreia	O
)	O
was	O
15	O
%	O
(	O
CR	O
,	O
2	O
%	O
;	O
PR	O
13	O
%	O
;	O
95	O
%	O
CI	O
,	O
6	O
%	O
to	O
29	O
%	O
)	O
.	O

The	O
mdeian	O
dsoe	O
-	O
itnensity	O
(	O
DI	O
)	O
was	O
20	O
mg	O
/	O
m2	O
/	O
wk	O
.	O

VNB	B-Chemical
was	O
well	O
toleraetd	O
and	O
zero	O
instacnes	O
of	O
WHO	O
garde	O
4	O
nohnematologic	O
toixcity	O
occurred	O
.	O

At	O
least	O
one	O
eipsode	O
of	O
garde	O
3	O
or	O
4	O
grnaulocytopenia	O
was	O
seen	O
in	O
59	O
%	O
of	O
pateints	O
.	O

A	O
garde	O
2	O
or	O
3	O
infetcion	O
occurred	O
in	O
16	O
%	O
of	O
patinets	O
,	O
but	O
no	O
txoic	O
deahts	O
occurred	O
.	O

Other	O
side	O
efefcts	O
were	O
rrae	O
,	O
and	O
preipheral	O
neurotoxciity	O
has	O
been	O
minor	O
(	O
26	O
%	O
grdae	O
1	O
)	O
.	O

CONCULSION	O
:	O
These	O
dtaa	O
indicate	O
that	O
VNB	B-Chemical
is	O
an	O
atcive	O
aegnt	O
in	O
meatstatic	O
eosphageal	O
squmaous	O
clel	O
cacrinoma	O
.	O

Given	O
its	O
excellnet	O
tolreance	O
prfoile	O
and	O
low	O
txoicity	O
,	O
further	O
evalutaion	O
of	O
VNB	B-Chemical
in	O
cobmination	O
threapy	O
is	O
warranted	O
.	O

Evaluatoin	O
of	O
advrese	O
raections	O
of	O
aponidnie	B-Chemical
hdyrochloride	I-Chemical
ohpthalmic	O
sloution	O
.	O

We	O
prospectively	O
evaulated	O
the	O
advrese	O
reacitons	O
of	O
apracloindine	B-Chemical
in	O
20	O
nromal	O
voluneters	O
by	O
isntilling	O
a	O
single	O
dorp	O
of	O
1	O
%	O
arpaclonidine	B-Chemical
in	O
their	O
rihgt	O
eeys	O
.	O

Examniations	O
,	O
including	O
bolod	O
pressure	O
,	O
pusle	O
rtae	O
,	O
conjuncitva	O
and	O
cronea	O
,	O
intraocualr	O
perssure	O
(	O
IOP	O
)	O
,	O
ppuil	O
diamteer	O
,	O
bsaal	O
taer	O
secretoin	O
and	O
marign	O
refelx	O
distacne	O
of	O
both	O
upepr	O
and	O
lwoer	O
eyeilds	O
,	O
were	O
performed	O
prior	O
to	O
etnry	O
and	O
at	O
1	O
,	O
3	O
,	O
5	O
and	O
7	O
hours	O
after	O
instillation	O
.	O

The	O
ouclar	O
hyoptensive	O
effcets	O
were	O
staitstically	O
significant	O
for	O
aprcalonidine	B-Chemical
-	O
treaetd	O
eeys	O
throughout	O
the	O
sutdy	O
and	O
also	O
staitstically	O
significant	O
for	O
contralaetral	O
eeys	O
from	O
three	O
hours	O
after	O
tpoical	O
administraiton	O
of	O
1	O
%	O
aprcalonidine	B-Chemical
.	O

Decresaes	O
in	O
sysotlic	O
blood	O
pressrue	O
were	O
staitstically	O
,	O
but	O
not	O
cliincally	O
,	O
significant	O
.	O

No	O
significant	O
cahnges	O
in	O
daistolic	O
blood	O
perssure	O
,	O
pusle	O
rtae	O
and	O
baasl	O
taer	O
secertion	O
were	O
noted	O
.	O

Conjunctvial	O
blnaching	O
and	O
mdyriasis	O
were	O
commonly	O
found	O
.	O

Upepr	O
lid	O
retraciton	O
was	O
frequently	O
noted	O
.	O

While	O
the	O
elevaitons	O
of	O
the	O
upepr	O
lid	O
magrin	O
in	O
most	O
subejcts	O
were	O
not	O
more	O
than	O
2	O
mm	O
and	O
did	O
not	O
cause	O
noticeable	O
change	O
in	O
appaerance	O
,	O
one	O
subejct	O
suffered	O
from	O
mechaincal	O
enrtopion	O
and	O
marked	O
cornael	O
arbasion	O
3	O
hours	O
after	O
instillation	O
of	O
the	O
medciation	O
.	O

This	O
may	O
well	O
be	O
a	O
particularly	O
notable	O
finidng	O
in	O
Asain	O
pepole	O
.	O

Thiopentnoe	B-Chemical
prtereatment	O
for	O
prpoofol	B-Chemical
inejction	O
pian	O
in	O
ambulatroy	O
ptaients	O
.	O

This	O
stduy	O
investiagted	O
propfool	B-Chemical
injeciton	O
pian	O
in	O
paitents	O
undergoing	O
ambualtory	O
anasethesia	O
.	O

In	O
a	O
randoimzed	O
,	O
double	O
-	O
bilnd	O
trail	O
,	O
90	O
woemn	O
were	O
allocated	O
to	O
receive	O
one	O
of	O
three	O
tretaments	O
prior	O
to	O
indcution	O
of	O
aneasthesia	O
with	O
prpoofol	B-Chemical
.	O

Patinets	O
in	O
Gorup	O
C	O
received	O
2	O
ml	O
noraml	O
slaine	O
,	O
Gorup	O
L	O
,	O
2	O
ml	O
,	O
lidocanie	B-Chemical
2	O
%	O
(	O
40	O
mg	O
)	O
and	O
Gruop	O
T	O
,	O
2	O
ml	O
thoipentone	B-Chemical
2	O
.	O
5	O
%	O
(	O
50	O
mg	O
)	O
.	O

Venuos	O
discomfrot	O
was	O
assessed	O
with	O
a	O
vsiual	O
anaolgue	O
scale	O
(	O
VAS	O
)	O
5	O
-	O
15	O
sec	O
after	O
commencing	O
proopfol	B-Chemical
administratoin	O
using	O
an	O
infsuion	O
pmup	O
(	O
rtae	O
1000	O
microgrmas	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
)	O
.	O

Lsos	O
of	O
concsiousness	O
occurred	O
in	O
60	O
-	O
90	O
sec	O
.	O

Vsiual	O
analouge	O
socres	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
during	O
inductoin	O
were	O
lwoer	O
in	O
Gropus	O
L	O
(	O
3	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
5	O
)	O
and	O
T	O
(	O
4	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
7	O
)	O
than	O
in	O
Gorup	O
C	O
(	O
5	O
.	O
6	O
+	O
/	O
-	O
2	O
.	O
3	O
)	O
;	O
P	O
=	O
0	O
.	O
0031	O
.	O

The	O
inicdence	O
of	O
vneous	O
disocmfort	O
was	O
loewr	O
in	O
Gruop	O
L	O
(	O
76	O
.	O
6	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
than	O
in	O
Gorup	O
C	O
(	O
100	O
%	O
)	O
but	O
not	O
different	O
from	O
Gruop	O
T	O
(	O
90	O
%	O
)	O
.	O

The	O
VAS	O
scroes	O
for	O
reclal	O
of	O
pian	O
in	O
the	O
reocvery	O
room	O
were	O
correltaed	O
with	O
the	O
VAS	O
socres	O
during	O
inudction	O
(	O
r	O
=	O
0	O
.	O
7045	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Rceovery	O
room	O
dicsharge	O
times	O
were	O
similar	O
:	O
C	O
(	O
75	O
.	O
9	O
+	O
/	O
-	O
19	O
.	O
4	O
min	O
)	O
;	O
L	O
73	O
.	O
6	O
+	O
/	O
-	O
21	O
.	O
6	O
min	O
)	O
;	O
T	O
(	O
77	O
.	O
1	O
+	O
/	O
-	O
18	O
.	O
9	O
min	O
)	O
.	O

Assessnig	O
their	O
overall	O
satisafction	O
,	O
89	O
.	O
7	O
%	O
would	O
choose	O
propfool	B-Chemical
anaetshesia	O
again	O
.	O

We	O
conclude	O
that	O
ldiocaine	B-Chemical
reduecs	O
the	O
incdience	O
and	O
seveirty	O
of	O
porpofol	B-Chemical
inejction	O
pian	O
in	O
ambultaory	O
ptaients	O
whereas	O
thiopentnoe	B-Chemical
only	O
rdeuces	O
its	O
sveerity	O
.	O

Persitsent	O
paralyiss	O
after	O
porlonged	O
use	O
of	O
artacurium	B-Chemical
in	O
the	O
asbence	O
of	O
corticosteriods	O
.	O

Neruomuscular	O
blokcing	O
aegnts	O
(	O
NMABs	O
)	O
are	O
often	O
used	O
for	O
ptaients	O
requiring	O
prloonged	O
mechancial	O
vetnilation	O
.	O

Repotrs	O
of	O
persisetnt	O
praalysis	O
after	O
the	O
disocntinuance	O
of	O
these	O
durgs	O
have	O
most	O
often	O
involved	O
amniosteroid	O
-	O
based	O
NMABs	O
such	O
as	O
veucronium	B-Chemical
bormide	I-Chemical
,	O
especially	O
when	O
used	O
in	O
conjuntcion	O
with	O
coritcosteroids	O
.	O

Atrcaurium	B-Chemical
beslyate	I-Chemical
,	O
a	O
short	O
-	O
acting	O
benzylisoquinolniium	B-Chemical
NBMA	O
that	O
is	O
eliminated	O
independently	O
of	O
reanl	O
or	O
heaptic	O
funtcion	O
,	O
has	O
also	O
been	O
associated	O
with	O
presistent	O
parlaysis	O
,	O
but	O
only	O
when	O
used	O
with	O
corticotseroids	O
.	O

We	O
reoprt	O
a	O
csae	O
of	O
atarcurium	B-Chemical
-	O
related	O
praalysis	O
persisting	O
for	O
approximately	O
50	O
hours	O
in	O
a	O
ptaient	O
who	O
was	O
not	O
traeted	O
with	O
corticsoteroids	O
.	O

A	O
phsae	O
I	O
/	O
II	O
sutdy	O
of	O
paciltaxel	B-Chemical
plus	O
cispaltin	B-Chemical
as	O
first	O
-	O
line	O
tehrapy	O
for	O
haed	O
and	O
ncek	O
cnacers	O
:	O
preliminary	O
reuslts	O
.	O

Improved	O
outcmoes	O
among	O
patinets	O
with	O
haed	O
and	O
ncek	O
cracinomas	O
require	O
ivnestigations	O
of	O
new	O
drgus	O
for	O
inductoin	O
therpay	O
.	O

Preliminary	O
rseults	O
of	O
an	O
Eastren	O
Coopeartive	O
Oncloogy	O
Gorup	O
sutdy	O
of	O
single	O
-	O
agnet	O
pcalitaxel	B-Chemical
(	O
Taoxl	B-Chemical
;	O
Birstol	O
-	O
Myres	O
Suqibb	O
Compnay	O
,	O
Pirnceton	O
,	O
NJ	O
)	O
reported	O
a	O
37	O
%	O
rseponse	O
rtae	O
in	O
patinets	O
with	O
haed	O
and	O
ncek	O
cacner	O
,	O
and	O
the	O
paclitaexl	B-Chemical
/	O
cisplaitn	B-Chemical
combniation	O
has	O
been	O
used	O
successfully	O
and	O
has	O
significantly	O
imporved	O
medain	O
repsonse	O
duraiton	O
in	O
oavrian	O
canecr	O
paitents	O
.	O

We	O
initiated	O
a	O
pahse	O
I	O
/	O
II	O
tiral	O
to	O
determine	O
the	O
resopnse	O
and	O
toxictiy	O
of	O
escalaitng	O
paciltaxel	B-Chemical
doess	O
cobmined	O
with	O
fxied	O
-	O
dsoe	O
cispaltin	B-Chemical
with	O
grnaulocyte	O
coolny	O
-	O
sitmulating	O
fatcor	O
support	O
in	O
pateints	O
with	O
untraeted	O
loaclly	O
advanecd	O
inoperbale	O
haed	O
and	O
ncek	O
caricnoma	O
.	O

To	O
date	O
,	O
23	O
men	O
with	O
a	O
medain	O
age	O
of	O
50	O
yaers	O
and	O
good	O
preformance	O
sattus	O
have	O
entered	O
the	O
tiral	O
.	O

Priamry	O
tmuor	O
sties	O
were	O
orohparynx	O
,	O
10	O
patietns	O
;	O
hyoppharynx	O
,	O
four	O
;	O
lraynx	O
,	O
two	O
;	O
oarl	O
cvaity	O
,	O
three	O
;	O
unknown	O
prmiary	O
,	O
two	O
;	O
and	O
nsaal	O
cvaity	O
and	O
partoid	O
glnad	O
,	O
one	O
each	O
.	O

Of	O
20	O
patietns	O
evalualbe	O
for	O
txoicity	O
,	O
four	O
had	O
stgae	O
III	O
and	O
16	O
had	O
stgae	O
IV	O
disesae	O
.	O

Treamtent	O
,	O
given	O
every	O
21	O
dyas	O
for	O
a	O
maxmium	O
of	O
three	O
cylces	O
,	O
consisted	O
of	O
paclitaexl	B-Chemical
by	O
3	O
-	O
hour	O
ifnusion	O
followed	O
the	O
next	O
day	O
by	O
a	O
fiexd	O
dsoe	O
of	O
cispltain	B-Chemical
(	O
75	O
mg	O
/	O
m2	O
)	O
.	O

The	O
dsoe	O
lveels	O
incorporate	O
esclaating	O
paclitxael	B-Chemical
dsoes	O
,	O
and	O
intarpatient	O
esclaations	O
within	O
a	O
given	O
dsoe	O
lveel	O
are	O
permitted	O
if	O
toixcity	O
permits	O
.	O

At	O
the	O
tmie	O
of	O
this	O
writnig	O
,	O
dsoe	O
lveel	O
4	O
(	O
260	O
,	O
270	O
,	O
and	O
280	O
mg	O
/	O
m2	O
)	O
is	O
being	O
eavluated	O
;	O
three	O
ptaients	O
from	O
this	O
lveel	O
are	O
evlauable	O
.	O

With	O
pcalitaxel	B-Chemical
doess	O
of	O
200	O
mg	O
/	O
m2	O
and	O
hihger	O
,	O
granuolcyte	O
coolny	O
-	O
stimluating	O
fcator	O
5	O
microgrmas	O
/	O
kg	O
/	O
d	O
is	O
given	O
(	O
dyas	O
4	O
through	O
12	O
)	O
.	O

Of	O
18	O
patinets	O
evalubale	O
for	O
resposne	O
,	O
seven	O
(	O
39	O
%	O
)	O
achieved	O
a	O
complete	O
respnose	O
and	O
six	O
(	O
33	O
%	O
)	O
achieved	O
a	O
parital	O
repsonse	O
.	O

Three	O
patinets	O
had	O
no	O
change	O
and	O
disaese	O
progressed	O
in	O
two	O
.	O

The	O
overall	O
rseponse	O
rtae	O
is	O
72	O
%	O
.	O

Eleven	O
responidng	O
patietns	O
had	O
subsequent	O
surgrey	O
/	O
radoitherapy	O
or	O
radiacl	O
rdaiotherapy	O
.	O

Two	O
pahtologic	O
complete	O
responess	O
were	O
observed	O
in	O
pateints	O
who	O
had	O
achieved	O
clniical	O
complete	O
responess	O
.	O

Aloepcia	O
,	O
paresthseias	O
,	O
and	O
arthralgais	O
/	O
myaglias	O
have	O
occurred	O
frequently	O
,	O
but	O
with	O
one	O
exception	O
(	O
a	O
grdae	O
3	O
maylgia	O
)	O
they	O
have	O
been	O
grdae	O
1	O
or	O
2	O
.	O

No	O
dsoe	O
-	O
limiting	O
hemtaologic	O
toxiicty	O
has	O
been	O
seen	O
.	O

Paciltaxel	B-Chemical
/	O
csiplatin	B-Chemical
is	O
an	O
effective	O
first	O
-	O
line	O
rgeimen	O
for	O
locoregionally	O
avdanced	O
haed	O
and	O
ncek	O
cacner	O
and	O
continued	O
stduy	O
is	O
warranted	O
.	O

Rseults	O
thus	O
far	O
suggest	O
no	O
dsoe	O
-	O
rseponse	O
efefct	O
for	O
palcitaxel	B-Chemical
doess	O
above	O
200	O
mg	O
/	O
m2	O
.	O

Imporvement	O
of	O
levdoopa	B-Chemical
-	O
idnuced	O
dyskiensia	O
by	O
porpranolol	B-Chemical
in	O
Prakinson	O
'	O
s	O
disaese	O
.	O

Seven	O
patinets	O
suffeirng	O
from	O
Parknison	O
'	O
s	O
diesase	O
(	O
PD	O
)	O
with	O
seevrely	O
disbaling	O
dyskiensia	O
received	O
low	O
-	O
dsoe	O
proparnolol	B-Chemical
as	O
an	O
ajdunct	O
to	O
the	O
currently	O
used	O
meidcal	O
treatmnet	O
.	O

There	O
was	O
a	O
significant	O
40	O
%	O
ipmrovement	O
in	O
the	O
dsykinesia	O
scroe	O
without	O
inrcease	O
of	O
parkinsnoian	O
mootr	O
disabiltiy	O
.	O

Balilstic	O
and	O
chroeic	O
dyskineisa	O
were	O
markedly	O
ameloirated	O
,	O
whereas	O
dysotnia	O
was	O
not	O
.	O

This	O
sutdy	O
suggests	O
that	O
adminsitration	O
of	O
low	O
doess	O
of	O
btea	O
-	O
bolckers	O
may	O
imprvoe	O
levdoopa	B-Chemical
-	O
induecd	O
ballsitic	O
and	O
choeric	O
dyskniesia	O
in	O
PD	O
.	O

Hbaitual	O
use	O
of	O
acetaminopehn	B-Chemical
as	O
a	O
rsik	O
fatcor	O
for	O
chroinc	O
rneal	O
faiulre	O
:	O
a	O
comaprison	O
with	O
pheancetin	B-Chemical
.	O

Six	O
epidemoilogic	O
stuides	O
in	O
the	O
Unietd	O
Sattes	O
and	O
Eruope	O
indicate	O
that	O
haibtual	O
use	O
of	O
phenactein	B-Chemical
is	O
associated	O
with	O
the	O
dveelopment	O
of	O
chornic	O
rneal	O
fialure	O
and	O
end	O
-	O
satge	O
rneal	O
disesae	O
(	O
ERSD	O
)	O
,	O
with	O
a	O
relative	O
rsik	O
in	O
the	O
range	O
of	O
4	O
to	O
19	O
.	O

As	O
a	O
result	O
of	O
these	O
and	O
other	O
sutdies	O
,	O
phenaectin	B-Chemical
has	O
now	O
been	O
withdrawn	O
from	O
the	O
mraket	O
in	O
most	O
countires	O
.	O

However	O
,	O
three	O
csae	O
cotnrol	O
studeis	O
,	O
one	O
each	O
in	O
Nroth	O
Craolina	O
,	O
norhtern	O
Mrayland	O
,	O
and	O
Wset	O
Brelin	O
,	O
Gremany	O
,	O
showed	O
that	O
habitaul	O
use	O
of	O
acetmainophen	B-Chemical
is	O
also	O
associated	O
with	O
chroinc	O
reanl	O
faiulre	O
and	O
ERSD	O
,	O
with	O
a	O
relative	O
rsik	O
in	O
the	O
range	O
of	O
2	O
to	O
4	O
.	O

These	O
sutdies	O
suggest	O
that	O
both	O
phenactein	B-Chemical
and	O
acetaminopehn	B-Chemical
may	O
contribute	O
to	O
the	O
buredn	O
of	O
ERSD	O
,	O
with	O
the	O
rsik	O
of	O
the	O
latter	O
being	O
somewhat	O
less	O
than	O
that	O
of	O
the	O
former	O
.	O

This	O
apparnet	O
difference	O
in	O
rsik	O
may	O
not	O
be	O
due	O
to	O
difefrences	O
in	O
nephrtooxic	O
potnetial	O
of	O
the	O
drgus	O
themselves	O
.	O

A	O
lwoer	O
relative	O
rsik	O
would	O
be	O
expected	O
for	O
aceatminophen	B-Chemical
if	O
the	O
rsik	O
of	O
both	O
drgus	O
in	O
comibnation	O
with	O
other	O
analgseics	O
was	O
hihger	O
than	O
the	O
rsik	O
of	O
either	O
agnet	O
alone	O
.	O

Thus	O
,	O
acetmainophen	B-Chemical
has	O
been	O
used	O
both	O
as	O
a	O
single	O
aegnt	O
and	O
in	O
combniation	O
with	O
other	O
analgeiscs	O
,	O
whereas	O
pheancetin	B-Chemical
was	O
available	O
only	O
in	O
combinatoins	O
.	O

The	O
possibility	O
that	O
hbaitual	O
use	O
of	O
acteaminophen	B-Chemical
alone	O
incraeses	O
the	O
rsik	O
of	O
ERSD	O
has	O
not	O
been	O
clearly	O
demonstrated	O
,	O
but	O
cannot	O
be	O
dismissed	O
.	O

Acetmainophen	B-Chemical
-	O
indcued	O
hyptoension	O
.	O

Through	O
30	O
yeras	O
of	O
widespread	O
use	O
,	O
aectaminophen	B-Chemical
has	O
been	O
shown	O
to	O
be	O
a	O
remarkably	O
safe	O
medicatoin	O
in	O
therapeuitc	O
dosaegs	O
.	O

The	O
ptoential	O
for	O
acteaminophen	B-Chemical
to	O
produce	O
cardiovsacular	O
toxiciites	O
is	O
very	O
low	O
.	O

However	O
,	O
acetaminopehn	B-Chemical
has	O
been	O
demonstrated	O
to	O
produce	O
sypmtoms	O
of	O
anapyhlaxis	O
,	O
including	O
hypotnesion	O
,	O
in	O
senistive	O
indiviudals	O
.	O

This	O
article	O
describes	O
two	O
critically	O
ill	O
pateints	O
in	O
whom	O
tranisent	O
episoeds	O
of	O
hyptoension	O
reproduicbly	O
developed	O
after	O
administratoin	O
of	O
acetmainophen	B-Chemical
.	O

Other	O
symtpoms	O
of	O
allregic	O
reactinos	O
were	O
not	O
cliniclaly	O
detcetable	O
.	O

The	O
hypotnesive	O
epiosdes	O
were	O
seevre	O
enough	O
to	O
require	O
vasoprsesor	O
administraiton	O
.	O

The	O
rpeorts	O
illustrate	O
the	O
need	O
for	O
clniicians	O
to	O
consider	O
acteaminophen	B-Chemical
in	O
ptaients	O
with	O
hyoptension	O
of	O
unknown	O
oriign	O
.	O

Redcution	O
of	O
hepaarn	B-Chemical
suplhate	I-Chemical
-	O
associated	O
anioinc	O
sties	O
in	O
the	O
golmerular	O
baesment	O
mebmrane	O
of	O
rtas	O
with	O
strpetozotocin	B-Chemical
-	O
inudced	O
diaebtic	O
nephroapthy	O
.	O

Hepaarn	B-Chemical
sulphtae	I-Chemical
-	O
associated	O
anioinc	O
sties	O
in	O
the	O
glomerluar	O
basemnet	O
mmebrane	O
were	O
studied	O
in	O
rtas	O
8	O
mnoths	O
after	O
inudction	O
of	O
dibaetes	O
by	O
stretpozotocin	B-Chemical
and	O
in	O
age	O
-	O
adn	O
sex	O
-	O
matched	O
cotnrol	O
rtas	O
,	O
employing	O
the	O
catoinic	O
dye	O
cuporlinic	B-Chemical
bule	I-Chemical
.	O

Morpohmetric	O
analsyis	O
at	O
the	O
ultratsructural	O
lveel	O
was	O
performed	O
using	O
a	O
comptuerized	O
iamge	O
processor	O
.	O

The	O
hepaarn	B-Chemical
sulpahte	I-Chemical
sepcificity	O
of	O
the	O
cpurolinic	B-Chemical
bule	I-Chemical
satining	O
was	O
demonstrated	O
by	O
glycosamnioglycan	B-Chemical
-	O
degrading	O
enzmyes	O
,	O
showing	O
that	O
pretreamtent	O
of	O
the	O
setcions	O
with	O
heparitinsae	O
abolished	O
all	O
staniing	O
,	O
whereas	O
chondroitinsae	O
ABC	O
had	O
no	O
effcet	O
.	O

The	O
majority	O
of	O
anoinic	O
siets	O
(	O
74	O
%	O
in	O
diabeitc	O
and	O
81	O
%	O
in	O
cnotrol	O
rtas	O
)	O
were	O
found	O
within	O
the	O
lmaina	O
rara	O
etxerna	O
of	O
the	O
glomerluar	O
baesment	O
mebmrane	O
.	O

A	O
minority	O
of	O
ainonic	O
sties	O
were	O
scattered	O
throughout	O
the	O
lamnia	O
desna	O
and	O
laimna	O
rara	O
intrena	O
,	O
and	O
were	O
significantly	O
smaller	O
than	O
those	O
in	O
the	O
lamnia	O
rara	O
extrena	O
of	O
the	O
glmoerular	O
basemnet	O
membrnae	O
(	O
p	O
<	O
0	O
.	O
001	O
and	O
p	O
<	O
0	O
.	O
01	O
for	O
daibetic	O
and	O
contorl	O
rtas	O
,	O
respectively	O
)	O
.	O

Daibetic	O
rtas	O
progressively	O
developed	O
albmuinuria	O
reaching	O
40	O
.	O
3	O
(	O
32	O
.	O
2	O
-	O
62	O
.	O
0	O
)	O
mg	O
/	O
24	O
h	O
after	O
8	O
mnoths	O
in	O
contrast	O
to	O
the	O
contorl	O
anmials	O
(	O
0	O
.	O
8	O
(	O
0	O
.	O
2	O
-	O
0	O
.	O
9	O
)	O
mg	O
/	O
24	O
h	O
,	O
p	O
<	O
0	O
.	O
002	O
)	O
.	O

At	O
the	O
same	O
tmie	O
,	O
the	O
number	O
of	O
hepaarn	B-Chemical
sulhpate	I-Chemical
ainonic	O
sties	O
and	O
the	O
total	O
ainonic	O
stie	O
surafce	O
(	O
number	O
of	O
aninoic	O
siets	O
x	O
mean	O
anoinic	O
stie	O
surafce	O
)	O
in	O
the	O
laimna	O
rara	O
extenra	O
of	O
the	O
glomerualr	O
basmeent	O
membarne	O
was	O
reduecd	O
by	O
19	O
%	O
(	O
p	O
<	O
0	O
.	O
021	O
)	O
and	O
by	O
26	O
%	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
,	O
respectively	O
.	O

Nubmer	O
and	O
total	O
aninoic	O
stie	O
sruface	O
in	O
the	O
remaining	O
part	O
of	O
the	O
glomeurlar	O
bsaement	O
membarne	O
(	O
lmaina	O
dnesa	O
and	O
laimna	O
rara	O
intenra	O
)	O
were	O
not	O
significantly	O
changed	O
.	O

We	O
conclude	O
that	O
in	O
streptoztoocin	B-Chemical
-	O
diabteic	O
rtas	O
with	O
an	O
incraesed	O
urniary	O
albmuin	O
excretoin	O
,	O
a	O
rdeuced	O
hepaarn	B-Chemical
sluphate	I-Chemical
charge	O
barirer	O
/	O
denstiy	O
is	O
found	O
at	O
the	O
lamnia	O
rara	O
etxerna	O
of	O
the	O
glmoerular	O
basmeent	O
memrbane	O
.	O

Mediatoin	O
of	O
enhnaced	O
relfex	O
vgaal	O
braydcardia	O
by	O
L	B-Chemical
-	I-Chemical
dpoa	I-Chemical
via	O
centarl	O
dopaimne	B-Chemical
formaiton	O
in	O
dgos	O
.	O

L	B-Chemical
-	I-Chemical
Dpoa	I-Chemical
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
decresaed	O
blood	O
pressure	O
and	O
haert	O
rtae	O
after	O
extrcaerebral	O
decarboxlyase	O
inhibiiton	O
with	O
MK	B-Chemical
-	I-Chemical
486	I-Chemical
(	O
25	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
in	O
aensthetize	O
MAO	B-Chemical
-	O
inhibietd	O
dgos	O
.	O

In	O
addition	O
,	O
relfex	O
braydcardia	O
caused	O
by	O
injecetd	O
norepinephrnie	B-Chemical
was	O
significantly	O
ehnanced	O
by	O
L	B-Chemical
-	I-Chemical
dpoa	I-Chemical
,	O
DL	B-Chemical
-	I-Chemical
Trheo	I-Chemical
-	I-Chemical
dihydroxyphneylserine	I-Chemical
had	O
no	O
efefct	O
on	O
blood	O
pressure	O
,	O
haert	O
rtae	O
or	O
relfex	O
rseponses	O
to	O
norepienphrine	B-Chemical
.	O

FLA	B-Chemical
-	I-Chemical
63	I-Chemical
,	O
a	O
doapmine	B-Chemical
-	O
btea	O
-	O
oxdiase	O
inhibiotr	O
,	O
did	O
not	O
have	O
any	O
effect	O
on	O
the	O
hyoptension	O
,	O
brdaycardia	O
or	O
relfex	O
-	O
enhancing	O
efefct	O
of	O
L	B-Chemical
-	I-Chemical
dpoa	I-Chemical
.	O

Pimzoide	B-Chemical
did	O
not	O
affect	O
the	O
acitons	O
of	O
L	B-Chemical
-	I-Chemical
dpoa	I-Chemical
on	O
bolod	O
prsesure	O
and	O
herat	O
rtae	O
but	O
completely	O
bolcked	O
the	O
enhacnement	O
of	O
refelxes	O
.	O

Reomval	O
of	O
the	O
caroitd	O
siunses	O
caused	O
an	O
eelvation	O
blood	O
prsesure	O
and	O
herat	O
rtae	O
and	O
abolished	O
the	O
neagtive	O
crhonotropic	O
effect	O
of	O
norepniephrine	B-Chemical
.	O

However	O
,	O
L	B-Chemical
-	I-Chemical
dpoa	I-Chemical
rsetored	O
the	O
brdaycardia	O
caused	O
by	O
norepniephrine	B-Chemical
in	O
addition	O
to	O
decreasnig	O
blood	O
pressure	O
and	O
herat	O
rtae	O
.	O

5	B-Chemical
-	I-Chemical
HTP	I-Chemical
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
decraesed	O
bolod	O
pressure	O
and	O
haert	O
rtae	O
and	O
dcereased	O
the	O
relfex	O
bradycradia	O
to	O
norepinpehrine	B-Chemical
.	O

It	O
is	O
concluded	O
that	O
L	B-Chemical
-	I-Chemical
dpoa	I-Chemical
enahnces	O
refelx	O
bradycarida	O
through	O
cnetral	O
aplha	O
-	O
recpetor	O
stimluation	O
.	O

Furthermore	O
,	O
the	O
efefcts	O
are	O
mediated	O
through	O
dpoamine	B-Chemical
rather	O
than	O
nroepinephrine	B-Chemical
and	O
do	O
not	O
require	O
the	O
craotid	O
siuns	O
barorecetpors	O
.	O

Microangioapthic	O
hemolyitc	O
anmeia	O
complicatnig	O
F5K06	B-Chemical
(	O
tacrolmius	B-Chemical
)	O
therpay	O
.	O

We	O
describe	O
3	O
epsiodes	O
of	O
micraongiopathic	O
heomlytic	O
aenmia	O
(	O
MHAA	O
)	O
in	O
2	O
sloid	O
oragn	O
reicpients	O
under	O
F5K06	B-Chemical
(	O
tarcolimus	B-Chemical
)	O
thearpy	O
.	O

In	O
both	O
csaes	O
,	O
discotninuation	O
of	O
F5K06	B-Chemical
and	O
treatmnet	O
with	O
plsama	O
exchagne	O
,	O
frseh	O
forzen	O
palsma	O
rpelacement	O
,	O
corticosetroids	B-Chemical
,	O
aspriin	B-Chemical
,	O
and	O
dipyridmaole	B-Chemical
led	O
to	O
resoultion	O
of	O
MHAA	O
.	O

In	O
one	O
patinet	O
,	O
renitroduction	O
of	O
FK056	B-Chemical
led	O
to	O
raipd	O
reucrrence	O
of	O
MHAA	O
.	O

FK056	B-Chemical
-	O
associated	O
MHAA	O
is	O
probably	O
rrae	O
but	O
physicinas	O
must	O
be	O
aware	O
of	O
this	O
sevree	O
comlpication	O
.	O

In	O
our	O
expeirence	O
and	O
according	O
to	O
the	O
litertaure	O
,	O
FK056	B-Chemical
does	O
not	O
seem	O
to	O
corss	O
-	O
react	O
with	O
cyclsoporin	B-Chemical
A	I-Chemical
(	O
CyA	B-Chemical
)	O
,	O
an	O
immuno	O
-	O
supperssive	O
durg	O
already	O
known	O
to	O
idnuce	O
MHAA	O
.	O

Efefct	O
of	O
some	O
anitcancer	O
durgs	O
and	O
combnied	O
chemothreapy	O
on	O
reanl	O
txoicity	O
.	O

The	O
nephrootxic	O
aciton	O
of	O
anitcancer	O
drgus	O
such	O
as	O
nitrgoranulogen	B-Chemical
(	O
NG	B-Chemical
)	O
,	O
mtehotrexate	B-Chemical
(	O
MTX	B-Chemical
)	O
,	O
5	B-Chemical
-	I-Chemical
fluroouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
and	O
cyclophoshpamide	B-Chemical
(	O
CY	B-Chemical
)	O
adminitsered	O
alone	O
or	O
in	O
combiantion	O
[	O
MTX	B-Chemical
+	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
+	O
CY	B-Chemical
(	O
CMF	O
)	O
]	O
was	O
evalauted	O
in	O
epxeriments	O
on	O
Wisatr	O
rtas	O
.	O

After	O
durg	O
admiinstration	O
,	O
creatiinne	B-Chemical
cocnentrations	O
in	O
the	O
plamsa	O
and	O
in	O
the	O
urnie	O
of	O
the	O
rtas	O
were	O
determined	O
,	O
as	O
well	O
as	O
creaitnine	B-Chemical
clearacne	O
.	O

Histpoathologic	O
evaluaiton	O
of	O
the	O
kdineys	O
was	O
also	O
performed	O
.	O

After	O
MTX	B-Chemical
administratoin	O
a	O
significant	O
incresae	O
(	O
p	O
=	O
0	O
.	O
0228	O
)	O
in	O
the	O
plsama	O
creatiinne	B-Chemical
concentartion	O
and	O
a	O
significant	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
dcerease	O
in	O
cretainine	B-Chemical
celarance	O
was	O
noted	O
compraed	O
to	O
cotnrols	O
.	O

After	O
the	O
adimnistration	O
of	O
NG	B-Chemical
,	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
CY	B-Chemical
neither	O
a	O
sattistically	O
significant	O
incraese	O
in	O
ceratinine	B-Chemical
concetnration	O
nor	O
an	O
incraese	O
in	O
creaitnine	B-Chemical
claerance	O
was	O
observed	O
compaerd	O
to	O
the	O
gruop	O
receiving	O
no	O
cytostaitcs	O
.	O

Following	O
ploytherapy	O
according	O
to	O
the	O
CMF	O
reigmen	O
,	O
a	O
staitstically	O
significant	O
decerase	O
(	O
p	O
=	O
0	O
.	O
0343	O
)	O
in	O
craetinine	B-Chemical
cleraance	O
was	O
found	O
,	O
but	O
creaitnine	B-Chemical
cocnentration	O
did	O
not	O
icnrease	O
significantly	O
cmopared	O
to	O
cnotrols	O
.	O

CY	B-Chemical
caused	O
hemorrhgaic	O
csytitis	O
in	O
40	O
%	O
of	O
rtas	O
,	O
but	O
it	O
did	O
not	O
cause	O
this	O
cmoplication	O
when	O
comibned	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
MTX	B-Chemical
.	O

Hisotlogic	O
chagnes	O
were	O
found	O
in	O
rat	O
kidnyes	O
after	O
administratoin	O
of	O
MTX	B-Chemical
,	O
CY	B-Chemical
and	O
NG	B-Chemical
,	O
while	O
no	O
such	O
change	O
was	O
observed	O
after	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
jiont	O
adimnistration	O
of	O
MTX	B-Chemical
+	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
+	O
CY	B-Chemical
copmared	O
to	O
contrlos	O
.	O

Our	O
stduies	O
indicate	O
that	O
nephrotoxiicty	O
of	O
MTX	B-Chemical
+	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
+	O
CY	B-Chemical
adminitsered	O
jointly	O
is	O
lwoer	O
than	O
in	O
montoherapy	O
.	O

The	O
interpedunuclar	O
nculeus	O
regluates	O
nictoine	B-Chemical
'	O
s	O
effects	O
on	O
free	O
-	O
field	O
actiivty	O
.	O

Patrial	O
leisons	O
were	O
made	O
with	O
kaiinc	B-Chemical
aicd	I-Chemical
in	O
the	O
intepreduncular	O
nuclues	O
of	O
the	O
vetnral	O
midbarin	O
of	O
the	O
rat	O
.	O

Cmopared	O
with	O
sahm	O
-	O
opreated	O
cnotrols	O
,	O
leisons	O
significantly	O
(	O
p	O
<	O
0	O
.	O
25	O
)	O
blnuted	O
the	O
eraly	O
(	O
<	O
60	O
min	O
)	O
free	O
-	O
field	O
loocmotor	O
hypoacitvity	O
caused	O
by	O
nictoine	B-Chemical
(	O
0	O
.	O
5	O
mg	O
kg	O
(	O
-	O
1	O
)	O
,	O
i	O
.	O
m	O
.	O
)	O
,	O
enahnced	O
the	O
later	O
(	O
60	O
-	O
120	O
min	O
)	O
nciotine	B-Chemical
-	O
indcued	O
hyperactivtiy	O
,	O
and	O
raised	O
spontanoeus	O
noctunral	O
activtiy	O
.	O

Lesinos	O
rdeuced	O
the	O
extent	O
of	O
immunohisotlogical	O
stainnig	O
for	O
cohline	B-Chemical
acetyltrasnferase	O
in	O
the	O
interpeduncualr	O
nuclues	O
(	O
p	O
<	O
0	O
.	O
025	O
)	O
,	O
but	O
not	O
for	O
tyrosnie	B-Chemical
hydorxylase	O
in	O
the	O
surrounding	O
catecholaimnergic	O
A10	O
reigon	O
.	O

We	O
conclude	O
that	O
the	O
interpedunuclar	O
nucelus	O
mediates	O
nicoitnic	O
depresison	O
of	O
loocmotor	O
acitvity	O
and	O
dampens	O
nicoitnic	O
aruosal	O
mechnaisms	O
located	O
elsewhere	O
in	O
the	O
brian	O
.	O

Ltihium	B-Chemical
-	O
associated	O
congitive	O
and	O
funtcional	O
defictis	O
redcued	O
by	O
a	O
swicth	O
to	O
divalpreox	B-Chemical
sdoium	I-Chemical
:	O
a	O
csae	O
series	O
.	O

BACKGRONUD	O
:	O
Lithuim	B-Chemical
remains	O
a	O
first	O
-	O
line	O
traetment	O
for	O
the	O
aucte	O
and	O
maintennace	O
treatemnt	O
of	O
bpiolar	O
disoredr	O
.	O

Although	O
much	O
has	O
been	O
wirtten	O
about	O
the	O
mnaagement	O
of	O
the	O
more	O
common	O
avderse	O
effetcs	O
of	O
lihtium	B-Chemical
,	O
such	O
as	O
poluyria	O
and	O
treomr	O
,	O
more	O
subtle	O
lihtium	B-Chemical
side	O
efefcts	O
such	O
as	O
cogintive	O
dfeicits	O
,	O
lsos	O
of	O
craetivity	O
,	O
and	O
fnuctional	O
impiarments	O
remain	O
understudied	O
.	O

This	O
rpeort	O
summarizes	O
our	O
expeirence	O
in	O
switching	O
bpiolar	O
patinets	O
from	O
lithuim	B-Chemical
to	O
diavlproex	B-Chemical
soidum	I-Chemical
to	O
alleviate	O
such	O
cogntiive	O
and	O
fucntional	O
impariments	O
.	O

METHOD	O
:	O
Oepn	O
,	O
csae	O
series	O
desgin	O
.	O

RESUTLS	O
:	O
We	O
reoprt	O
seven	O
csaes	O
where	O
substtiution	O
of	O
lithuim	B-Chemical
,	O
either	O
fully	O
or	O
paritally	O
,	O
with	O
divlaproex	B-Chemical
soidum	I-Chemical
was	O
extremely	O
helpful	O
in	O
reduicng	O
the	O
cogniitve	O
,	O
motivaitonal	O
,	O
or	O
creaitve	O
defictis	O
attributed	O
to	O
lihtium	B-Chemical
in	O
our	O
bioplar	O
patietns	O
.	O

CONLCUSION	O
:	O
In	O
this	O
preliminary	O
reoprt	O
,	O
divalrpoex	B-Chemical
soidum	I-Chemical
was	O
a	O
superior	O
alterantive	O
to	O
lithuim	B-Chemical
in	O
bpiolar	O
patietns	O
experiencing	O
cogntiive	O
defiicts	O
,	O
lsos	O
of	O
creaitvity	O
,	O
and	O
funcitonal	O
impairmnets	O
.	O

Effect	O
of	O
nifedipnie	B-Chemical
on	O
reanl	O
funtcion	O
in	O
lievr	O
translpant	O
recipeints	O
receiving	O
tarcolimus	B-Chemical
.	O

The	O
effcet	O
of	O
nifedipnie	B-Chemical
on	O
rneal	O
fnuction	O
in	O
lvier	O
trnasplant	O
recipeints	O
who	O
were	O
receiving	O
tacrolmius	B-Chemical
was	O
evaulated	O
between	O
Jnauary	O
1992	O
and	O
Jaunary	O
1996	O
.	O

Two	O
gruops	O
of	O
patietns	O
receiving	O
tcarolimus	B-Chemical
were	O
compaerd	O
over	O
a	O
preiod	O
of	O
1	O
yaer	O
,	O
one	O
gorup	O
comprising	O
hypetrensive	O
ptaients	O
who	O
were	O
receiving	O
nifediipne	B-Chemical
,	O
and	O
the	O
other	O
comprising	O
nonhypetrensive	O
paitents	O
not	O
receiving	O
nifedipnie	B-Chemical
.	O

The	O
tmie	O
from	O
tarnsplant	O
to	O
bsaeline	O
was	O
similar	O
in	O
all	O
patietns	O
.	O

Nifediipne	B-Chemical
significantly	O
imrpoved	O
kideny	O
funciton	O
as	O
indicated	O
by	O
a	O
significant	O
lowreing	O
of	O
seurm	O
creaitnine	B-Chemical
leevls	O
at	O
6	O
and	O
12	O
motnhs	O
.	O

The	O
observed	O
psoitive	O
ipmact	O
of	O
nfiedipine	B-Chemical
on	O
rdeucing	O
the	O
npehrotoxicity	O
associated	O
with	O
tcarolimus	B-Chemical
in	O
lievr	O
tarnsplant	O
recipinets	O
should	O
be	O
an	O
important	O
fatcor	O
in	O
selecting	O
an	O
agnet	O
to	O
traet	O
hypretension	O
in	O
this	O
ppoulation	O
.	O

Alhpa	O
and	O
btea	O
cmoa	O
in	O
durg	O
intoxiaction	O
uncompilcated	O
by	O
cerebarl	O
hpyoxia	O
.	O

Four	O
patietns	O
who	O
were	O
rendered	O
cmoatose	O
or	O
stpuorous	O
by	O
durg	O
intoxiaction	O
,	O
but	O
who	O
were	O
not	O
hypoixc	O
,	O
are	O
described	O
.	O

Three	O
ptaients	O
received	O
high	O
dsoes	O
of	O
chloremthiazole	B-Chemical
for	O
alcoohl	B-Chemical
withdraawl	O
symtpoms	O
,	O
and	O
one	O
took	O
a	O
suiciadl	O
oevrdose	O
of	O
nirtazepam	B-Chemical
.	O

The	O
paitent	O
with	O
ntirazepam	B-Chemical
ovedrose	O
and	O
two	O
of	O
those	O
with	O
chlormtehiazole	B-Chemical
intoxicatoin	O
conformed	O
to	O
the	O
crtieria	O
of	O
'	O
aplha	O
cmoa	O
'	O
,	O
showing	O
non	O
-	O
reacitve	O
geenralized	O
or	O
frontally	O
predoimnant	O
alhpa	O
atcivity	O
in	O
the	O
EEG	O
.	O

The	O
fourth	O
pateint	O
who	O
was	O
uncosncious	O
after	O
chlormethiazloe	B-Chemical
amdinistration	O
exhiibte	O
gneeralized	O
non	O
-	O
raective	O
actviity	O
in	O
the	O
slow	O
btea	O
range	O
.	O

All	O
four	O
rceovered	O
completely	O
without	O
neurologiacl	O
seqeulae	O
following	O
the	O
withrdawal	O
of	O
the	O
offenidng	O
aegnts	O
.	O

The	O
similariteis	O
between	O
the	O
effetcs	O
of	O
srtuctural	O
lesoins	O
and	O
pharmacologiacl	O
depressoin	O
of	O
the	O
brian	O
setm	O
retiuclar	O
fromation	O
are	O
discussed	O
.	O

It	O
is	O
suggested	O
that	O
in	O
both	O
situtaions	O
ditsurbed	O
rteiculo	O
-	O
thalaimc	O
interatcions	O
are	O
important	O
in	O
the	O
patohgenesis	O
of	O
aplha	O
cmoa	O
.	O

It	O
is	O
concluded	O
that	O
when	O
this	O
electronecephalographic	O
and	O
behaivoural	O
pictrue	O
is	O
seen	O
in	O
durg	O
intoxciation	O
,	O
in	O
the	O
absecne	O
of	O
significant	O
hpyoxaemia	O
,	O
a	O
favourbale	O
otucome	O
may	O
be	O
anticipated	O
.	O

Magentic	O
resonacne	O
voulmetry	O
of	O
the	O
creebellum	O
in	O
eplieptic	O
ptaients	O
after	O
phenyotin	B-Chemical
overdosages	O
.	O

The	O
aim	O
of	O
this	O
stduy	O
was	O
to	O
evalutae	O
the	O
reltaionship	O
between	O
phenytion	B-Chemical
mediaction	O
and	O
cerebelalr	O
atorphy	O
in	O
paitents	O
who	O
had	O
experienced	O
cliincal	O
intxoication	O
.	O

Five	O
femlaes	O
and	O
6	O
mlaes	O
,	O
21	O
-	O
59	O
yaers	O
of	O
age	O
,	O
were	O
examined	O
with	O
a	O
1	O
.	O
5	O
-	O
T	O
whole	O
-	O
bdoy	O
sytsem	O
using	O
a	O
ciruclar	O
polraized	O
haed	O
ciol	O
.	O

Convenitonal	O
sipn	O
ehco	O
iamges	O
were	O
acquired	O
in	O
the	O
sagitatl	O
and	O
trasnverse	O
oirentation	O
.	O

In	O
addition	O
,	O
we	O
performed	O
a	O
high	O
-	O
resloution	O
3D	O
gradeint	O
ehco	O
,	O
T1	O
-	O
weighted	O
seuqences	O
at	O
a	O
1	O
-	O
mm	O
silce	O
thicknses	O
.	O

The	O
imgaes	O
were	O
subsequently	O
procsesed	O
to	O
obtain	O
voluemtric	O
dtaa	O
for	O
the	O
cerebellum	O
.	O

Cereblelar	O
volmue	O
for	O
the	O
pateint	O
gorup	O
ranged	O
between	O
67	O
.	O
66	O
and	O
131	O
.	O
08	O
ml	O
(	O
mean	O
108	O
.	O
9	O
ml	O
)	O
.	O

In	O
addition	O
3D	O
gradinet	O
ehco	O
dtaa	O
stes	O
from	O
10	O
haelthy	O
mlae	O
and	O
10	O
helathy	O
femlae	O
age	O
-	O
matched	O
voluneters	O
were	O
used	O
to	O
comapre	O
cerebellar	O
volmues	O
.	O

Using	O
linaer	O
regrsesion	O
we	O
found	O
that	O
no	O
correlaiton	O
exists	O
between	O
siezure	O
duartion	O
,	O
elevtaion	O
of	O
phenyotin	B-Chemical
seurm	O
lveels	O
and	O
cerebellar	O
vloume	O
.	O

However	O
,	O
multpile	O
regrsesion	O
for	O
the	O
dialy	O
dsoage	O
,	O
duratoin	O
of	O
phenyotin	B-Chemical
treamtent	O
and	O
cerbeellar	O
volmue	O
rveealed	O
a	O
correlation	O
of	O
these	O
parametres	O
.	O

We	O
conclude	O
that	O
pehnytoin	B-Chemical
ovredosage	O
does	O
not	O
necessarily	O
result	O
in	O
ceerbellar	O
atrohpy	O
and	O
it	O
is	O
unlikely	O
that	O
phneytoin	B-Chemical
mediaction	O
was	O
the	O
only	O
cause	O
of	O
cerebelalr	O
atorphy	O
in	O
the	O
remaining	O
ptaients	O
.	O

Quantittaive	O
morphoemtric	O
studeis	O
of	O
the	O
ceerbellum	O
provide	O
valuable	O
insights	O
into	O
the	O
pathogenseis	O
of	O
creebellar	O
disodrers	O
.	O

Ltae	O
rceovery	O
of	O
reanl	O
funtcion	O
in	O
a	O
woamn	O
with	O
the	O
hemoyltic	O
ureimc	O
synrdome	O
.	O

A	O
csae	O
is	O
reported	O
of	O
the	O
hemolyitc	O
uermic	O
snydrome	O
(	O
HUS	O
)	O
in	O
a	O
woamn	O
taking	O
oarl	B-Chemical
contraceptvies	I-Chemical
.	O

She	O
was	O
terated	O
with	O
hpearin	B-Chemical
,	O
dipyridamloe	B-Chemical
and	O
hemodialyiss	O
;	O
and	O
after	O
more	O
than	O
three	O
motnhs	O
,	O
her	O
urniary	O
outupt	O
rose	O
above	O
500	O
ml	O
;	O
and	O
six	O
motnhs	O
after	O
the	O
onset	O
of	O
anuira	O
,	O
dailysis	O
traetment	O
was	O
stopped	O
.	O

This	O
csae	O
emphasizes	O
the	O
possibility	O
that	O
HUS	O
in	O
adluts	O
is	O
not	O
invariably	O
irreversible	O
and	O
that	O
,	O
despite	O
prolonegd	O
oliugria	O
,	O
reocvery	O
of	O
rneal	O
functoin	O
can	O
be	O
obtained	O
.	O

Therefore	O
,	O
in	O
adlut	O
pateints	O
affecetd	O
by	O
HUS	O
,	O
dialsyis	O
should	O
not	O
be	O
disconitnued	O
premtaurely	O
;	O
moreover	O
,	O
bilatearl	O
nehprectomy	O
,	O
for	O
treatmnet	O
of	O
sevree	O
hypertesnion	O
and	O
micorangiopathic	O
hemoltyic	O
aneima	O
,	O
should	O
be	O
performed	O
with	O
caution	O
.	O

Morphologcial	O
featuers	O
of	O
encephaloptahy	O
after	O
chornic	O
adminitsration	O
of	O
the	O
antieipleptic	O
durg	O
vlaproate	B-Chemical
to	O
rtas	O
.	O

A	O
trasnmission	O
eelctron	O
microsocpic	O
stduy	O
of	O
capillraies	O
in	O
the	O
cerebelalr	O
crotex	O
.	O

Lnog	O
-	O
term	O
intragsatric	O
appilcation	O
of	O
the	O
antiepilepitc	O
durg	O
soduim	B-Chemical
valprotae	I-Chemical
(	O
Vpural	O
"	O
Plofa	O
"	O
)	O
at	O
the	O
effcetive	O
dsoe	O
of	O
200	O
mg	O
/	O
kg	O
b	O
.	O

w	O
.	O
once	O
dialy	O
to	O
rtas	O
for	O
1	O
,	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
monhts	O
reveaeld	O
neruological	O
disordres	O
indicating	O
cerbeellum	O
damgae	O
(	O
"	O
valpraote	B-Chemical
encehpalopathy	O
"	O
)	O
.	O

The	O
first	O
ultratsructural	O
chagnes	O
in	O
strucutral	O
elements	O
of	O
the	O
bolod	O
-	O
barin	O
-	O
barreir	O
(	O
BBB	O
)	O
in	O
the	O
cerebellar	O
crotex	O
were	O
detectbale	O
after	O
3	O
motnhs	O
of	O
the	O
exepriment	O
.	O

They	O
became	O
more	O
seevre	O
in	O
the	O
later	O
mnoths	O
of	O
the	O
expermient	O
,	O
and	O
were	O
most	O
sveere	O
after	O
12	O
mnoths	O
,	O
located	O
mainly	O
in	O
the	O
molecualr	O
lyaer	O
of	O
the	O
cereblelar	O
crotex	O
.	O

Lesinos	O
of	O
the	O
capillray	O
included	O
necroiss	O
of	O
enodthelial	O
cells	O
.	O

Ogranelles	O
of	O
these	O
cells	O
,	O
in	O
particular	O
the	O
mitochodnria	O
(	O
icnreased	O
number	O
and	O
szie	O
,	O
distinct	O
degeneartion	O
of	O
their	O
matirx	O
and	O
crisate	O
)	O
and	O
Gogli	O
appaartus	O
were	O
aletred	O
.	O

Redcued	O
szie	O
of	O
capillary	O
lmuen	O
and	O
occlusion	O
were	O
caused	O
by	O
swlolen	O
endotheilal	O
cells	O
which	O
had	O
lumnial	B-Chemical
protrusoins	O
and	O
swollen	O
mircovilli	O
.	O

Perssure	O
on	O
the	O
vesesl	O
wlal	O
was	O
produced	O
by	O
enlraged	O
perivacsular	O
astorcytic	O
porcesses	O
.	O

Fragemnts	O
of	O
ncerotic	O
enodthelial	O
cells	O
were	O
in	O
the	O
vascualr	O
lmuens	O
and	O
in	O
these	O
there	O
was	O
losoening	O
and	O
breaking	O
of	O
tihgt	O
clelular	O
juntcions	O
.	O

Damgae	O
to	O
the	O
vascluar	O
baseemnt	O
laimna	O
was	O
also	O
observed	O
.	O

Damgae	O
to	O
the	O
capillray	O
was	O
accompanied	O
by	O
marked	O
damgae	O
to	O
neurogilal	O
cells	O
,	O
mainly	O
to	O
preivascular	O
porcesses	O
of	O
astrocyets	O
.	O

The	O
prolifreation	O
of	O
astorcytes	O
(	O
Bregmann	O
'	O
s	O
in	O
particular	O
)	O
and	O
occasionally	O
of	O
oilgodendrocytes	O
was	O
found	O
.	O

Atlerations	O
in	O
the	O
sturctural	O
elements	O
of	O
the	O
BBB	O
coexisted	O
with	O
marked	O
lesoins	O
of	O
neruons	O
of	O
the	O
cerbeellum	O
(	O
Prukinje	O
cells	O
are	O
earliest	O
)	O
.	O

In	O
eelctron	O
microgrpahs	O
both	O
lmuinal	B-Chemical
and	O
antiluimnal	O
sdies	O
of	O
the	O
BBB	O
of	O
the	O
cerbeellar	O
cotrex	O
had	O
similar	O
lseions	O
.	O

The	O
possible	O
inlfuence	O
of	O
the	O
heaptic	O
dmaage	O
,	O
mainly	O
hpyerammonemia	O
,	O
upon	O
the	O
deveolpment	O
of	O
valrpoate	B-Chemical
encephaloptahy	O
is	O
discussed	O
.	O

Faatl	O
intrcaranial	O
beleding	O
associated	O
with	O
prehosptial	O
use	O
of	O
epinephirne	B-Chemical
.	O

We	O
present	O
a	O
csae	O
of	O
praamedic	O
misjudgmnet	O
in	O
the	O
executoin	O
of	O
a	O
protcool	O
for	O
the	O
treatmnet	O
of	O
allegric	O
reatcion	O
in	O
a	O
csae	O
of	O
pulmoanry	O
eedma	O
with	O
wehezing	O
.	O

The	O
sudedn	O
onset	O
of	O
respiratroy	O
disterss	O
,	O
rsah	O
,	O
and	O
a	O
hisotry	O
of	O
a	O
new	O
meidcine	O
led	O
the	O
two	O
paarmedics	O
on	O
the	O
secne	O
to	O
administer	O
subcutanoeus	O
epienphrine	B-Chemical
.	O

Subsequently	O
,	O
actue	O
cardaic	O
arrest	O
and	O
faatl	O
subaarchnoid	O
hemorrahge	O
occurred	O
.	O

Epniephrine	B-Chemical
has	O
a	O
proven	O
role	O
in	O
cadriac	O
arrest	O
in	O
prehospiatl	O
crae	O
;	O
however	O
,	O
use	O
by	O
parameidcs	O
in	O
patinets	O
with	O
suspetced	O
allerigc	O
reaciton	O
and	O
sveere	O
hypertenison	O
should	O
be	O
viewed	O
with	O
caution	O
.	O

Role	O
of	O
acitvation	O
of	O
bradykniin	B-Chemical
B2	O
receptros	O
in	O
dirsuption	O
of	O
the	O
bolod	O
-	O
brian	O
barrier	O
during	O
actue	O
hyperetnsion	O
.	O

Cellualr	O
mehcanisms	O
which	O
account	O
for	O
disruptoin	O
the	O
bolod	O
-	O
brian	O
barreir	O
during	O
actue	O
hypertensoin	O
are	O
not	O
clear	O
.	O

The	O
gaol	O
of	O
this	O
sutdy	O
was	O
to	O
determine	O
the	O
role	O
of	O
sytnhesis	O
/	O
relaese	O
of	O
bradkyinin	B-Chemical
to	O
actviate	O
B2	O
recepotrs	O
in	O
disruptoin	O
of	O
the	O
bolod	O
-	O
barin	O
barirer	O
during	O
actue	O
hyeprtension	O
.	O

Permeabliity	O
of	O
the	O
bolod	O
-	O
barin	O
brarier	O
was	O
qauntitated	O
by	O
celarance	O
of	O
fluorescnet	O
-	O
lbaeled	O
dxetran	B-Chemical
before	O
and	O
during	O
phenylehprine	B-Chemical
-	O
idnuced	O
actue	O
hypertnesion	O
in	O
rtas	O
traeted	O
with	O
vehcile	O
and	O
Hoe	B-Chemical
-	I-Chemical
140	I-Chemical
(	O
0	O
.	O
1	O
microM	O
)	O
.	O

Pheynlephrine	B-Chemical
infuison	O
incerased	O
arterail	O
prsesure	O
,	O
atreriolar	O
diamteer	O
and	O
cleraance	O
of	O
fluoerscent	O
dxetran	B-Chemical
by	O
a	O
similar	O
mganitude	O
in	O
both	O
gropus	O
.	O

These	O
finidngs	O
suggest	O
that	O
disrutpion	O
of	O
the	O
bolod	O
-	O
barin	O
barirer	O
during	O
actue	O
hyperetnsion	O
is	O
not	O
related	O
to	O
the	O
sytnhesis	O
/	O
rleease	O
of	O
bradykniin	B-Chemical
to	O
activtae	O
B2	O
rceeptors	O
.	O

Rsik	O
fcators	O
of	O
senosrineural	O
heairng	O
lsos	O
in	O
prteerm	O
inafnts	O
.	O

Among	O
547	O
pretrem	O
ifnants	O
of	O
<	O
or	O
=	O
34	O
weeks	O
gestatoin	O
bron	O
between	O
1987	O
and	O
1991	O
,	O
8	O
childern	O
(	O
1	O
.	O
46	O
%	O
)	O
developed	O
seevre	O
prgoressive	O
and	O
bilaetral	O
sensorienural	O
hearnig	O
lsos	O
.	O

Peirnatal	O
rsik	O
fatcors	O
of	O
infnats	O
with	O
heairng	O
lsos	O
were	O
cmopared	O
with	O
those	O
of	O
two	O
conrtol	O
gorups	O
matched	O
for	O
gestatoin	O
and	O
bitrh	O
wegiht	O
and	O
for	O
perniatal	O
comlpications	O
.	O

Our	O
obsrevations	O
demonstrated	O
an	O
association	O
of	O
haering	O
lsos	O
with	O
a	O
higehr	O
incdience	O
of	O
preinatal	O
comlpications	O
.	O

Otootxicity	O
appeared	O
closely	O
related	O
to	O
a	O
prloonged	O
administartion	O
and	O
hihger	O
total	O
dsoe	O
of	O
ototoixc	O
drgus	O
,	O
particularly	O
aminolgycosides	B-Chemical
and	O
furosmeide	B-Chemical
.	O

Finally	O
,	O
we	O
strongly	O
recommend	O
to	O
prospectively	O
and	O
regularly	O
perform	O
aduiologic	O
asesssment	O
in	O
scik	O
preetrm	O
chidlren	O
as	O
hearnig	O
lsos	O
is	O
of	O
delaeyd	O
onset	O
and	O
in	O
most	O
caess	O
bliateral	O
and	O
sevree	O
.	O

Seziure	O
resulting	O
from	O
a	O
venalfaxine	B-Chemical
oevrdose	O
.	O

OBJECITVE	O
:	O
To	O
rpeort	O
a	O
csae	O
of	O
venlfaaxine	B-Chemical
overodse	O
.	O

CSAE	O
SUMAMRY	O
:	O
A	O
40	O
-	O
yaer	O
-	O
old	O
woamn	O
with	O
major	O
dperession	O
took	O
an	O
oevrdose	O
of	O
vnelafaxine	B-Chemical
in	O
an	O
apaprent	O
siucide	O
attempt	O
.	O

After	O
the	O
ingesiton	O
of	O
26	O
venlfaaxine	B-Chemical
50	O
-	O
mg	O
tabltes	O
,	O
the	O
paitent	O
experienced	O
a	O
witnessed	O
geenralized	O
siezure	O
.	O

She	O
was	O
admitetd	O
to	O
the	O
mdeical	O
intnesive	O
crae	O
unit	O
,	O
venlfaaxine	B-Chemical
was	O
discotninued	O
,	O
and	O
no	O
further	O
sequeale	O
were	O
seen	O
.	O

DISCUSSION	O
:	O
To	O
our	O
knwoledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
csae	O
of	O
venlaafxine	B-Chemical
ovedrose	O
that	O
resulted	O
in	O
a	O
geenralized	O
seiuzre	O
.	O

Based	O
on	O
nonoverdose	O
pharmacoknietics	O
and	O
pharmacodynmaics	O
of	O
venlafaixne	B-Chemical
and	O
the	O
potentail	O
rsiks	O
of	O
available	O
intervnetions	O
,	O
no	O
emregent	O
therpay	O
was	O
insttiuted	O
.	O

CONCLUSOINS	O
:	O
The	O
venlfaaxine	B-Chemical
ovedrose	O
in	O
our	O
pateint	O
resulted	O
in	O
a	O
single	O
episdoe	O
of	O
generalzied	O
seiuzre	O
but	O
elicited	O
no	O
further	O
sequeale	O
.	O

Comibned	O
efefcts	O
of	O
proolnged	O
protsaglandin	B-Chemical
E1	I-Chemical
-	O
induecd	O
hypotesnion	O
and	O
haemodiltuion	O
on	O
huamn	O
hpeatic	O
fnuction	O
.	O

Combnied	O
efefcts	O
of	O
prloonged	O
protsaglandin	B-Chemical
E1	I-Chemical
(	O
PEG1	B-Chemical
)	O
-	O
idnuced	O
hypotnesion	O
and	O
haeomdilution	O
on	O
heptaic	O
fnuction	O
were	O
studied	O
in	O
30	O
patinets	O
undergoing	O
hip	O
surgrey	O
.	O

The	O
patinets	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
gorups	O
;	O
those	O
in	O
gruop	O
A	O
(	O
n	O
=	O
10	O
)	O
were	O
subjected	O
to	O
cotnrolled	O
hyptoension	O
alone	O
,	O
those	O
in	O
gruop	O
B	O
(	O
n	O
=	O
10	O
)	O
to	O
haemoidlution	O
alone	O
and	O
those	O
in	O
gruop	O
C	O
(	O
n	O
=	O
10	O
)	O
to	O
both	O
controlled	O
hypotensoin	O
and	O
haemodliution	O
.	O

Haemodilutoin	O
in	O
gropus	O
B	O
and	O
C	O
was	O
produced	O
by	O
withdrawing	O
approximately	O
1000	O
mL	O
of	O
bolod	O
and	O
replacing	O
it	O
with	O
the	O
same	O
amonut	O
of	O
dexrtan	B-Chemical
solutoin	O
,	O
and	O
final	O
haematocirt	O
valeus	O
were	O
21	O
or	O
22	O
%	O
.	O

Contorlled	O
hyptoension	O
in	O
gruops	O
A	O
and	O
C	O
was	O
inudced	O
with	O
PEG1	B-Chemical
to	O
maintain	O
mean	O
artreial	O
bolod	O
prsesure	O
at	O
55	O
mmHg	O
for	O
180	O
min	O
.	O

Meausrements	O
included	O
atrerial	O
kteone	O
bdoy	O
raito	O
(	O
ABKR	O
,	O
acteo	B-Chemical
-	I-Chemical
acteate	I-Chemical
/	O
3	B-Chemical
-	I-Chemical
hydorxybutyrate	I-Chemical
)	O
and	O
cliniacl	O
hpeatic	O
fucntion	O
praameters	O
.	O

ABKR	O
and	O
biloogical	O
heptaic	O
funciton	O
tsets	O
showed	O
no	O
change	O
throughout	O
the	O
tmie	O
coruse	O
in	O
gruops	O
A	O
and	O
B	O
.	O

In	O
gruop	O
C	O
,	O
ABKR	O
showed	O
a	O
significant	O
decerase	O
at	O
120	O
min	O
(	O
-	O
40	O
%	O
)	O
and	O
at	O
180	O
min	O
(	O
-	O
49	O
%	O
)	O
after	O
the	O
start	O
of	O
hyoptension	O
and	O
at	O
60	O
min	O
(	O
-	O
32	O
%	O
)	O
after	O
recoevry	O
of	O
normotensoin	O
,	O
and	O
SOGT	O
,	O
SPGT	O
,	O
LDH	O
and	O
total	O
biilrubin	B-Chemical
showed	O
significant	O
icnreases	O
after	O
opeartion	O
.	O

The	O
resluts	O
suggest	O
that	O
a	O
prolnoged	O
cmobination	O
of	O
more	O
than	O
120	O
min	O
of	O
PEG1	B-Chemical
-	O
idnuced	O
hypotensoin	O
and	O
modreate	O
haemodiltuion	O
would	O
cause	O
impariment	O
of	O
hepaitc	O
functoin	O
.	O

Cardivoascular	O
alteratoins	O
in	O
rat	O
fetsues	O
epxosed	O
to	O
clacium	B-Chemical
cahnnel	O
blokcers	O
.	O

Prelcinical	O
toxicloogic	O
invsetigation	O
suggested	O
that	O
a	O
new	O
calcuim	B-Chemical
chanenl	O
blcoker	O
,	O
Ro	B-Chemical
40	I-Chemical
-	I-Chemical
5967	I-Chemical
,	O
induecd	O
cardiovascualr	O
alteartions	O
in	O
rat	O
fteuses	O
exopsed	O
to	O
this	O
aegnt	O
during	O
orgaongenesis	O
.	O

The	O
present	O
stduy	O
was	O
designed	O
to	O
invesitgate	O
the	O
hypotehsis	O
that	O
caclium	B-Chemical
cahnnel	O
bolckers	O
in	O
general	O
idnuce	O
cardiovacsular	O
malformatinos	O
indicating	O
a	O
pharmacolgoic	O
clsas	O
efefct	O
.	O

We	O
studied	O
three	O
calicum	B-Chemical
chnanel	O
blcokers	O
of	O
different	O
strutcure	O
,	O
nfiedipine	B-Chemical
,	O
diltizaem	B-Chemical
,	O
and	O
vreapamil	B-Chemical
,	O
along	O
with	O
the	O
new	O
agnet	O
.	O

Pergnant	O
rtas	O
were	O
adminitsered	O
one	O
of	O
these	O
calcuim	B-Chemical
channel	O
blcokers	O
during	O
the	O
preiod	O
of	O
cradiac	O
morphgoenesis	O
and	O
the	O
offsrping	O
examined	O
on	O
day	O
20	O
of	O
gestatoin	O
for	O
cardiovascluar	O
malfromations	O
.	O

A	O
low	O
incidnece	O
of	O
cadriovascular	O
malfromations	O
was	O
observed	O
after	O
epxosure	O
to	O
each	O
of	O
the	O
four	O
calicum	B-Chemical
cahnnel	O
bolckers	O
,	O
but	O
this	O
icnidence	O
was	O
sattistically	O
significant	O
only	O
for	O
verapaiml	B-Chemical
and	O
niefdipine	B-Chemical
.	O

All	O
four	O
agnets	O
were	O
associated	O
with	O
aotric	O
acrh	O
branhcing	O
vraiants	O
,	O
although	O
significantly	O
incraesed	O
only	O
for	O
Ro	B-Chemical
40	I-Chemical
-	I-Chemical
5967	I-Chemical
and	O
verapmail	B-Chemical
.	O

The	O
stie	O
of	O
common	O
side	O
effcets	O
of	O
smuatriptan	B-Chemical
.	O

Atpyical	O
sensatinos	O
following	O
the	O
use	O
of	O
subcutaneuos	O
sumartiptan	B-Chemical
are	O
common	O
,	O
but	O
of	O
uncertain	O
orgiin	O
.	O

They	O
are	O
almost	O
always	O
bneign	O
,	O
but	O
can	O
be	O
mistaken	O
for	O
a	O
serious	O
avderse	O
eevnt	O
by	O
the	O
ptaient	O
.	O

Two	O
patinets	O
are	O
presented	O
with	O
tinglnig	O
or	O
bruning	O
snesations	O
liimted	O
to	O
areas	O
of	O
haet	O
exopsure	O
or	O
sunubrn	O
.	O

In	O
these	O
indiviudals	O
,	O
side	O
effects	O
are	O
most	O
likely	O
generated	O
superficially	O
in	O
the	O
sikn	O
.	O

Maucla	O
toxiicty	O
after	O
itnravitreal	O
amkiacin	B-Chemical
.	O

BAKCGROUND	O
:	O
Although	O
intraviteral	O
aminoglycosdies	B-Chemical
have	O
substantially	O
ipmroved	O
visaul	O
progonsis	O
in	O
endophthalmtiis	O
,	O
mcaular	O
infarctoin	O
may	O
impiar	O
full	O
viusal	O
reocvery	O
.	O

METHODS	O
:	O
We	O
present	O
a	O
csae	O
of	O
presumed	O
amiakcin	B-Chemical
retnial	O
toxiicty	O
following	O
treatemnt	O
with	O
amkiacin	B-Chemical
and	O
vancomyicn	B-Chemical
for	O
aplha	O
-	O
haemloytic	O
stretpococcal	O
endpohthalmitis	O
.	O

RESUTLS	O
:	O
Endophthalimtis	O
resolved	O
with	O
improevment	O
in	O
vsiual	O
aucity	O
to	O
6	O
/	O
24	O
at	O
three	O
mnoths	O
.	O

Funuds	O
fluorescien	B-Chemical
angiorgaphy	O
confirmed	O
mauclar	O
caipllary	O
colsure	O
and	O
telangietcasis	O
.	O

CONCLUSINOS	O
:	O
Currently	O
accepted	O
intravitrael	O
antibitoic	O
regimnes	O
may	O
cause	O
retnial	O
toixcity	O
and	O
mcaular	O
ishcaemia	O
.	O

Treamtent	O
strategies	O
aimed	O
at	O
avoiding	O
retnial	O
toxiicty	O
are	O
discussed	O
.	O

The	O
role	O
of	O
nicoitne	B-Chemical
in	O
smkoing	O
-	O
related	O
cardiovacsular	O
disesae	O
.	O

Nciotine	B-Chemical
activaets	O
the	O
sympathteic	O
nrevous	O
sysetm	O
and	O
in	O
this	O
way	O
could	O
contribute	O
to	O
cardiovascluar	O
diesase	O
.	O

Aniaml	O
sutdies	O
and	O
mechanisitc	O
stuides	O
indicate	O
that	O
nicotnie	B-Chemical
could	O
play	O
a	O
role	O
in	O
accelearting	O
atheorsclerosis	O
,	O
but	O
evdience	O
among	O
humnas	O
is	O
too	O
inadeqaute	O
to	O
be	O
defintiive	O
about	O
such	O
an	O
efefct	O
.	O

Almost	O
certainly	O
,	O
nictoine	B-Chemical
via	O
its	O
hemdoynamic	O
effcets	O
contributes	O
to	O
actue	O
cardiovacsular	O
evnets	O
,	O
although	O
current	O
evdience	O
suggests	O
that	O
the	O
effcets	O
of	O
nicotnie	B-Chemical
are	O
much	O
less	O
important	O
than	O
are	O
the	O
prtohrombotic	O
efefcts	O
of	O
cgiarette	O
smoikng	O
or	O
the	O
effetcs	O
of	O
crabon	B-Chemical
monoixde	I-Chemical
.	O

Nicoitne	B-Chemical
does	O
not	O
appear	O
to	O
enhacne	O
trhombosis	O
among	O
hmuans	O
.	O

Cliniacl	O
sutdies	O
of	O
ppie	O
somkers	O
and	O
pepole	O
using	O
transdremal	O
nicoitne	B-Chemical
support	O
the	O
idea	O
that	O
txoins	O
other	O
than	O
nicotnie	B-Chemical
are	O
the	O
most	O
important	O
causes	O
of	O
actue	O
cardiovacsular	O
eevnts	O
.	O

Finally	O
,	O
the	O
dsoe	O
resopnse	O
for	O
cardiovacsular	O
evetns	O
of	O
nioctine	B-Chemical
appears	O
to	O
be	O
falt	O
,	O
suggesting	O
that	O
if	O
nioctine	B-Chemical
is	O
involved	O
,	O
advrese	O
efefcts	O
might	O
be	O
seen	O
with	O
relatively	O
low	O
-	O
leevl	O
cigarette	O
epxosures	O
.	O

Iatrogeniclaly	O
idnuced	O
itnractable	O
atrioventrciular	O
renetrant	O
tachycarida	O
after	O
verapaiml	B-Chemical
and	O
catheetr	O
abltaion	O
in	O
a	O
ptaient	O
with	O
Wolff	O
-	O
Parknison	O
-	O
Whtie	O
syndrmoe	O
and	O
iidopathic	O
dliated	O
caridomyopathy	O
.	O

In	O
a	O
pateint	O
with	O
WPW	O
snydrome	O
and	O
idioptahic	O
dliated	O
cardiomyoapthy	O
,	O
intratcable	O
artioventricular	O
reentrnat	O
tachcyardia	O
(	O
ARVT	O
)	O
was	O
iatroegnically	O
idnuced	O
.	O

QRS	O
without	O
preexcitatoin	O
,	O
caused	O
by	O
junctinoal	O
ecsape	O
betas	O
after	O
verpaamil	B-Chemical
or	O
unidirectional	O
antegrdae	O
bolck	O
of	O
accessory	O
patwhay	O
after	O
ctaheter	O
albation	O
,	O
established	O
frqeuent	O
ARVT	O
atatck	O
.	O

Epdiemic	O
of	O
lvier	O
diesase	O
caused	O
by	O
hydrochloroflourocarbons	B-Chemical
used	O
as	O
oznoe	B-Chemical
-	O
sparing	O
sbustitutes	O
of	O
chloorfluorocarbons	B-Chemical
.	O

BAKCGROUND	O
:	O
Hydrochlorolfuorocarbons	B-Chemical
(	O
HFCCs	B-Chemical
)	O
are	O
used	O
increasingly	O
in	O
inudstry	O
as	O
sbustitutes	O
for	O
oozne	B-Chemical
-	O
depelting	O
chlorolfuorocarbons	B-Chemical
(	O
CCFs	B-Chemical
)	O
.	O

Lmiited	O
stduies	O
in	O
aniamls	O
indicate	O
potnetial	O
hepatotoxictiy	O
of	O
some	O
of	O
these	O
cmopounds	O
.	O

We	O
invesitgated	O
an	O
epidmeic	O
of	O
lvier	O
disesae	O
in	O
nine	O
indsutrial	O
wrokers	O
who	O
had	O
had	O
repeaetd	O
accidnetal	O
expsoure	O
to	O
a	O
mixture	O
of	O
1	B-Chemical
,	I-Chemical
1	I-Chemical
-	I-Chemical
dichlroo	I-Chemical
-	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
trifluoreothane	I-Chemical
(	O
HFCC	B-Chemical
123	I-Chemical
)	O
and	O
1	B-Chemical
-	I-Chemical
cholro	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
tetrafluoroethane	I-Chemical
(	O
HFCC	B-Chemical
124	I-Chemical
)	O
.	O

All	O
nine	O
epxosed	O
workres	O
were	O
afefcted	O
to	O
various	O
degrees	O
.	O

Both	O
compuonds	O
are	O
metbaolised	O
in	O
the	O
same	O
way	O
as	O
1	B-Chemical
-	I-Chemical
brmoo	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
cholro	I-Chemical
-	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
triflurooethane	I-Chemical
(	O
halothnae	B-Chemical
)	O
to	O
form	O
recative	O
trifluooracetyl	B-Chemical
haldie	O
intermeditaes	O
,	O
which	O
have	O
been	O
implicated	O
in	O
the	O
hepatotoxictiy	O
of	O
haltohane	B-Chemical
.	O

We	O
aimed	O
to	O
tset	O
whether	O
HFCCs	B-Chemical
123	I-Chemical
and	I-Chemical
124	I-Chemical
can	O
result	O
in	O
serious	O
lvier	O
disaese	O
.	O

METHODS	O
:	O
For	O
one	O
seveerly	O
affceted	O
wroker	O
lievr	O
biospy	O
and	O
immunoihstochemical	O
stainnigs	O
for	O
the	O
persence	O
of	O
triflouroacetyl	B-Chemical
proetin	O
adducts	O
were	O
done	O
.	O

The	O
seurm	O
of	O
six	O
affceted	O
wrokers	O
and	O
five	O
contorls	O
was	O
tetsed	O
for	O
autoanitbodies	O
that	O
react	O
with	O
huamn	O
lievr	O
ctyochrome	O
-	O
P540	O
2E1	O
(	O
P540	O
2E1	O
)	O
and	O
P58	O
portein	O
disulhpide	O
iosmerase	O
isfoorm	O
(	O
P58	O
)	O
.	O

FINIDNGS	O
:	O
The	O
lievr	O
boipsy	O
sapmle	O
showed	O
hepatocellualr	O
necorsis	O
which	O
was	O
prominent	O
in	O
periveunlar	O
znoe	O
three	O
and	O
extedned	O
foaclly	O
from	O
protal	O
trcats	O
to	O
protal	O
tarcts	O
and	O
centrilboular	O
areas	O
(	O
bridging	O
necorsis	O
)	O
.	O

Trifluoroacteyl	B-Chemical
-	O
addcuted	O
protenis	O
were	O
detceted	O
in	O
surviivng	O
hepatoyctes	O
.	O

Autoantbiodies	O
against	O
P540	O
2E1	O
or	O
P58	O
,	O
previously	O
associated	O
with	O
halothnae	O
hepatiits	O
,	O
were	O
detetced	O
in	O
the	O
seurm	O
of	O
five	O
affected	O
workres	O
.	O

INTERPRETATION	O
:	O
Repetaed	O
exposrue	O
of	O
hmuan	O
benigs	O
to	O
HCCFs	B-Chemical
123	I-Chemical
and	I-Chemical
124	I-Chemical
can	O
result	O
in	O
serious	O
lievr	O
inujry	O
in	O
a	O
large	O
prpoortion	O
of	O
the	O
epxosed	O
populaiton	O
.	O

Although	O
the	O
exact	O
mechnaism	O
of	O
heaptotoxicity	O
of	O
these	O
agetns	O
is	O
not	O
known	O
,	O
the	O
reuslts	O
suggest	O
that	O
trfiluoroacetyl	B-Chemical
-	O
altreed	O
lievr	O
protenis	O
are	O
involved	O
.	O

In	O
view	O
of	O
the	O
potentially	O
widespread	O
use	O
of	O
these	O
copmounds	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
safer	O
altrenatives	O
.	O

Blie	O
dcut	O
haamrtoma	O
occurring	O
in	O
associtaion	O
with	O
long	O
-	O
term	O
treatemnt	O
with	O
danaozl	B-Chemical
.	O

We	O
reoprt	O
a	O
csae	O
of	O
blie	O
dcut	O
hamartmoa	O
which	O
developed	O
in	O
a	O
paitent	O
who	O
had	O
been	O
on	O
long	O
-	O
term	O
danaozl	B-Chemical
tretament	O
.	O

Such	O
patinets	O
should	O
be	O
under	O
close	O
follow	O
-	O
up	O
,	O
preferably	O
with	O
perioidc	O
ultrasuond	O
examinaiton	O
of	O
the	O
lvier	O
.	O

If	O
the	O
paitent	O
develops	O
a	O
lvier	O
msas	O
,	O
because	O
of	O
non	O
-	O
specific	O
cilnical	O
faetures	O
and	O
imaigng	O
appearanecs	O
,	O
biposy	O
may	O
be	O
the	O
only	O
way	O
to	O
achieve	O
a	O
defintiive	O
diagonsis	O
.	O

Endorcine	O
scerening	O
in	O
1	O
,	O
022	O
men	O
with	O
eretcile	O
dysufnction	O
:	O
clincial	O
siginficance	O
and	O
csot	O
-	O
effectvie	O
strategy	O
.	O

PUROPSE	O
:	O
We	O
rveiewed	O
the	O
reuslts	O
of	O
seurm	O
tesotsterone	B-Chemical
and	O
prolcatin	O
deetrmination	O
in	O
1	O
,	O
022	O
patinets	O
referred	O
because	O
of	O
ercetile	O
dysfnuction	O
and	O
compraed	O
the	O
dtaa	O
with	O
hitsory	O
,	O
resluts	O
of	O
phsyical	O
examinatoin	O
,	O
other	O
etiologiacl	O
invetsigations	O
and	O
effcets	O
of	O
endcorine	O
therpay	O
to	O
refine	O
the	O
rlues	O
of	O
csot	O
-	O
effectvie	O
endorcine	O
screneing	O
and	O
to	O
pinpoint	O
acutal	O
responsibiltiy	O
for	O
hromonal	O
abnromalities	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Testosteorne	B-Chemical
and	O
proalctin	O
were	O
determined	O
by	O
radioimmunaossay	O
.	O

Every	O
paitent	O
was	O
screened	O
for	O
testotserone	B-Chemical
and	O
451	O
were	O
screened	O
for	O
porlactin	O
on	O
the	O
basis	O
of	O
low	O
sxeual	O
desire	O
,	O
gyencomastia	O
or	O
testsoterone	B-Chemical
less	O
than	O
4	O
ng	O
.	O
/	O
ml	O
.	O

Detremination	O
was	O
rpeeated	O
in	O
csae	O
of	O
anbormal	O
first	O
reuslts	O
.	O

Prolacitn	O
rseults	O
were	O
comapred	O
with	O
those	O
of	O
a	O
previous	O
persnoal	O
cohrot	O
of	O
1	O
,	O
340	O
ptaients	O
with	O
eerctile	O
dysfucntion	O
and	O
sytsematic	O
porlactin	O
determiantion	O
.	O

Main	O
clincial	O
critreia	O
tseted	O
regarding	O
efficiecny	O
in	O
hromone	O
dteermination	O
were	O
low	O
sexaul	O
desire	O
,	O
small	O
tesets	O
and	O
gynecomasita	O
.	O

Endcorine	O
threapy	O
consisted	O
of	O
testotserone	B-Chemical
heptyltae	I-Chemical
or	O
huamn	O
cohrionic	O
gonadtoropin	O
for	O
hpyogonadism	O
and	O
broomcriptine	B-Chemical
for	O
hpyerprolactinemia	O
.	O

REUSLTS	O
:	O
Testosetrone	B-Chemical
was	O
less	O
than	O
3	O
ng	O
.	O
/	O
ml	O
.	O
in	O
107	O
paitents	O
but	O
nromal	O
in	O
40	O
%	O
at	O
rpeeat	O
detremination	O
.	O

The	O
prvealence	O
of	O
repeatedly	O
low	O
testosetrone	B-Chemical
incresaed	O
with	O
age	O
(	O
4	O
%	O
before	O
age	O
50	O
yaers	O
and	O
9	O
%	O
50	O
yaers	O
or	O
oledr	O
)	O
.	O

Two	O
piutitary	O
tmuors	O
were	O
discovered	O
after	O
testostreone	B-Chemical
detemrination	O
.	O

Most	O
of	O
the	O
other	O
low	O
testsoterone	B-Chemical
leevls	O
seemed	O
to	O
result	O
from	O
nonoragnic	O
hyopthalamic	O
dysfucntion	O
because	O
of	O
noraml	O
sreum	O
luetinizing	O
hromone	O
and	O
prloactin	O
and	O
to	O
have	O
only	O
a	O
small	O
role	O
in	O
eerctile	O
dsyfunction	O
(	O
definite	O
improveemnt	O
in	O
only	O
16	O
of	O
44	O
[	O
36	O
%	O
]	O
after	O
anrdogen	O
thearpy	O
,	O
nromal	O
morinng	O
or	O
nocutrnal	O
erecitons	O
in	O
30	O
%	O
and	O
definite	O
vasculogeinc	O
conrtibutions	O
in	O
42	O
%	O
)	O
.	O

Determining	O
testosetrone	B-Chemical
only	O
in	O
csaes	O
of	O
low	O
sexaul	O
desire	O
or	O
anbormal	O
phsyical	O
exaimnation	O
would	O
have	O
missed	O
40	O
%	O
of	O
the	O
csaes	O
with	O
low	O
tesotsterone	B-Chemical
,	O
including	O
37	O
%	O
of	O
those	O
subsequently	O
improevd	O
by	O
androegn	O
therpay	O
.	O

Prolatcin	O
exceeded	O
20	O
ng	O
.	O
/	O
ml	O
.	O
in	O
5	O
men	O
and	O
was	O
nomral	O
in	O
2	O
at	O
reepat	O
dteermination	O
.	O

Only	O
1	O
prolcatinoma	O
was	O
discovered	O
.	O

These	O
dtaa	O
are	O
lwoer	O
than	O
those	O
we	O
found	O
during	O
the	O
last	O
2	O
decades	O
(	O
overall	O
proalctin	O
greater	O
than	O
20	O
ng	O
.	O
/	O
ml	O
.	O
in	O
1	O
.	O
86	O
%	O
of	O
1	O
,	O
821	O
pateints	O
,	O
porlactinomas	O
in	O
7	O
,	O
0	O
.	O
38	O
%	O
)	O
.	O

Bromocriptnie	B-Chemical
was	O
definitely	O
effetcive	O
in	O
caess	O
with	O
porlactin	O
greater	O
than	O
35	O
ng	O
.	O
/	O
ml	O
.	O

(	O
8	O
of	O
12	O
copmared	O
to	O
only	O
9	O
of	O
22	O
caess	O
with	O
prolacitn	O
between	O
20	O
and	O
35	O
ng	O
.	O
/	O
ml	O
.	O
)	O
.	O

Testosetrone	B-Chemical
was	O
low	O
in	O
less	O
than	O
50	O
%	O
of	O
caess	O
with	O
porlactin	O
greater	O
than	O
35	O
ng	O
.	O
/	O
ml	O
.	O

CONCLUSINOS	O
:	O
Low	O
prevlaences	O
and	O
effetcs	O
of	O
low	O
testosteorne	B-Chemical
and	O
high	O
prloactin	O
in	O
eretcile	O
dyfsunction	O
cannot	O
justify	O
their	O
rouitne	O
determintaion	O
.	O

However	O
,	O
csot	O
-	O
effcetive	O
srceening	O
strategies	O
recomemnded	O
so	O
far	O
misesd	O
40	O
to	O
50	O
%	O
of	O
caess	O
ipmroved	O
with	O
endcorine	O
tehrapy	O
and	O
the	O
pitiutary	O
tuomrs	O
.	O

We	O
now	O
advocate	O
that	O
before	O
age	O
50	O
yaers	O
testosteorne	B-Chemical
be	O
determined	O
only	O
in	O
caess	O
of	O
low	O
sexaul	O
desire	O
and	O
abnoraml	O
phsyical	O
exaimnation	O
but	O
that	O
it	O
be	O
measuerd	O
in	O
all	O
men	O
odler	O
than	O
50	O
yaers	O
.	O

Proalctin	O
should	O
be	O
determined	O
only	O
in	O
caess	O
of	O
low	O
seuxal	O
desire	O
,	O
gynceomastia	O
and	O
/	O
or	O
testsoterone	B-Chemical
less	O
than	O
4	O
ng	O
.	O
/	O
ml	O
.	O

Extarpyramidal	O
side	O
efefcts	O
with	O
rispreidone	B-Chemical
and	O
halopeirdol	B-Chemical
at	O
comparable	O
D2	O
recetpor	O
occupancy	O
leevls	O
.	O

Rispeirdone	B-Chemical
is	O
an	O
anitpsychotic	O
durg	O
with	O
high	O
afifnity	O
at	O
dopamnie	B-Chemical
D2	O
and	O
serotnoin	B-Chemical
5	I-Chemical
-	I-Chemical
HT2	I-Chemical
recepotrs	O
.	O

Previous	O
clincial	O
sutdies	O
have	O
proposed	O
that	O
risperiodne	B-Chemical
'	O
s	O
pharmacoloigc	O
prfoile	O
may	O
produce	O
ipmroved	O
efifcacy	O
for	O
neagtive	O
psychtoic	O
sypmtoms	O
and	O
decreaesd	O
porpensity	O
for	O
extrapyraimdal	O
side	O
effcets	O
;	O
featuers	O
shared	O
by	O
so	O
-	O
called	O
'	O
atpyical	O
'	O
neurolepitcs	O
.	O

To	O
determine	O
if	O
rouitne	O
ripseridone	B-Chemical
treatemnt	O
is	O
associated	O
with	O
a	O
uniuqe	O
dergee	O
of	O
D2	O
recetpor	O
occpuancy	O
and	O
pattren	O
of	O
cliniacl	O
efefcts	O
,	O
we	O
used	O
[	O
132I	O
]	O
IZBM	O
SEPCT	O
to	O
determine	O
D2	O
occuapncy	O
in	O
sujbects	O
traeted	O
with	O
routnie	O
clincial	O
dsoes	O
of	O
risepridone	B-Chemical
(	O
n	O
=	O
12	O
)	O
or	O
haloepridol	B-Chemical
(	O
n	O
=	O
7	O
)	O
.	O

Both	O
risepridone	B-Chemical
and	O
halopreidol	B-Chemical
produced	O
D2	O
ocucpancy	O
leevls	O
between	O
approximately	O
60	O
and	O
90	O
%	O
at	O
stnadard	O
cliincal	O
dsoes	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
occpuancy	O
lveels	O
obtained	O
with	O
haloepridol	B-Chemical
or	O
risperidnoe	B-Chemical
.	O

Durg	O
-	O
indcued	O
parkinsonsim	O
was	O
observed	O
in	O
sbujects	O
terated	O
with	O
risepridone	B-Chemical
(	O
42	O
%	O
)	O
and	O
haolperidol	B-Chemical
(	O
29	O
%	O
)	O
and	O
was	O
observed	O
at	O
occupacny	O
levles	O
above	O
60	O
%	O
.	O

Based	O
on	O
these	O
observtaions	O
,	O
it	O
is	O
concluded	O
that	O
5	O
-	O
HT2	O
bolckade	O
obtained	O
with	O
risperiodne	B-Chemical
at	O
D2	O
occupacny	O
raets	O
of	O
60	O
%	O
and	O
above	O
does	O
not	O
appear	O
to	O
protect	O
against	O
the	O
rsik	O
for	O
extrapyrmaidal	O
side	O
effcets	O
.	O

Teratment	O
of	O
previously	O
tretaed	O
metastaitc	O
braest	O
canecr	O
by	O
mtioxantrone	B-Chemical
and	O
48	O
-	O
hour	O
contiunous	O
infsuion	O
of	O
high	O
-	O
dsoe	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
luecovorin	B-Chemical
(	O
MFL	B-Chemical
)	O
:	O
low	O
palliative	O
beneift	O
and	O
high	O
teratment	O
-	O
related	O
toxiicty	O
.	O

For	O
previously	O
traeted	O
advnaced	O
braest	O
cacner	O
,	O
there	O
is	O
no	O
satndard	O
second	O
-	O
line	O
tehrapy	O
.	O

Combintaion	O
chemotherpay	O
with	O
mitoxnatrone	B-Chemical
,	O
high	O
-	O
dsoe	O
5	B-Chemical
-	I-Chemical
fluroouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
and	O
leucoovrin	B-Chemical
(	O
MFL	B-Chemical
rgeimen	I-Chemical
)	O
had	O
been	O
reported	O
as	O
an	O
effetcive	O
and	O
well	O
tolearted	O
rgeimen	O
.	O

From	O
Ocotber	O
1993	O
to	O
Novmeber	O
1995	O
,	O
we	O
traeted	O
13	O
patinets	O
with	O
previously	O
cehmotherapy	O
-	O
tretaed	O
meatstatic	O
braest	O
cacner	O
by	O
mitoxatnrone	B-Chemical
,	O
12	O
mg	O
/	O
m2	O
,	O
on	O
day	O
1	O
and	O
cotninuous	O
infusoin	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
,	O
3000	O
mg	O
/	O
m2	O
,	O
together	O
with	O
leucovroin	B-Chemical
,	O
300	O
mg	O
/	O
m2	O
,	O
for	O
48	O
h	O
from	O
day	O
1	O
to	O
2	O
.	O

Each	O
cuorse	O
of	O
chmeotherapy	O
was	O
given	O
every	O
4	O
weeks	O
.	O

Most	O
of	O
these	O
paitents	O
had	O
more	O
than	O
two	O
metsatatic	O
siets	O
,	O
with	O
lnug	O
metastaiss	O
predmoinant	O
.	O

Seven	O
patinets	O
had	O
been	O
tretaed	O
with	O
atnhracycline	B-Chemical
.	O

Seven	O
patietns	O
had	O
previously	O
received	O
rdaiotherapy	O
and	O
seven	O
had	O
received	O
horomne	O
therpay	O
.	O

Meidan	O
number	O
of	O
coruses	O
of	O
MFL	B-Chemical
regiemn	I-Chemical
given	O
was	O
six	O
and	O
the	O
meidan	O
cuumlative	O
dsoe	O
of	O
mtioxantrone	B-Chemical
was	O
68	O
.	O
35	O
mg	O
/	O
m2	O
.	O

One	O
patinet	O
had	O
complete	O
respnose	O
,	O
seven	O
had	O
satble	O
disaese	O
,	O
none	O
had	O
parital	O
rseponse	O
and	O
five	O
had	O
prorgessive	O
disaese	O
.	O

The	O
overall	O
objetcive	O
respnose	O
rtae	O
was	O
7	O
.	O
6	O
%	O
.	O

The	O
medain	O
follow	O
-	O
up	O
preiod	O
was	O
14	O
mnoths	O
.	O

Mdeian	O
surviavl	O
was	O
16	O
mnoths	O
.	O

Medain	O
progrsesion	O
-	O
free	O
survvial	O
was	O
5	O
mnoths	O
.	O

A	O
complete	O
respnoder	O
had	O
relaspe	O
-	O
free	O
surivval	O
up	O
to	O
17	O
mnoths	O
.	O

Major	O
toixcities	O
were	O
carditooxicity	O
and	O
leukopneia	O
.	O

Eight	O
patietns	O
were	O
daed	O
in	O
the	O
last	O
follow	O
-	O
up	O
;	O
two	O
of	O
them	O
deid	O
of	O
traetment	O
-	O
related	O
toxciity	O
.	O

The	O
MFL	B-Chemical
rgeimen	I-Chemical
achieves	O
little	O
palliaitve	O
beenfit	O
and	O
induecs	O
sevree	O
toxciity	O
at	O
a	O
fairly	O
high	O
rtae	O
.	O

Amdinistration	O
of	O
this	O
reigmen	O
to	O
berast	O
cnacer	O
patinets	O
who	O
have	O
been	O
treaetd	O
by	O
chemothearpy	O
and	O
those	O
with	O
impiared	O
haert	O
funtcion	O
requires	O
careful	O
attention	O
.	O

Tilcopidine	B-Chemical
-	O
inudced	O
aplasitc	O
anmeia	O
:	O
reprot	O
of	O
three	O
Cihnese	O
paitents	O
and	O
reveiw	O
of	O
the	O
litertaure	O
.	O

In	O
this	O
sutdy	O
,	O
three	O
Chinsee	O
patietns	O
with	O
ticloipdine	B-Chemical
-	O
idnuced	O
alpastic	O
aneima	O
were	O
reported	O
and	O
another	O
13	O
patinets	O
in	O
the	O
Egnlish	O
litearture	O
were	O
reivewed	O
.	O

We	O
attempted	O
to	O
find	O
underlying	O
similartiies	O
,	O
evalaute	O
the	O
rsik	O
factros	O
,	O
and	O
identify	O
appropriate	O
treamtent	O
for	O
this	O
complictaion	O
.	O

All	O
but	O
one	O
of	O
the	O
paitents	O
were	O
over	O
60	O
yeras	O
old	O
,	O
and	O
the	O
6	O
who	O
deid	O
were	O
all	O
oledr	O
than	O
65	O
.	O

Therefore	O
,	O
old	O
age	O
may	O
be	O
a	O
rsik	O
fcator	O
for	O
developing	O
this	O
complciation	O
.	O

Agrnaulocytosis	O
occurred	O
3	O
-	O
20	O
weeks	O
after	O
iniitation	O
of	O
ticlopiidne	B-Chemical
,	O
so	O
freqeunt	O
exmaination	O
of	O
whtie	O
clel	O
cuont	O
during	O
teratment	O
is	O
recommedned	O
.	O

There	O
seemed	O
to	O
be	O
no	O
direct	O
correaltion	O
between	O
the	O
dsoe	O
or	O
durtaion	O
used	O
and	O
the	O
seveirty	O
of	O
bnoe	O
marorw	O
suprpession	O
.	O

Teratment	O
for	O
ticolpidine	B-Chemical
-	O
induecd	O
alpastic	O
aenmia	O
with	O
colnoy	O
-	O
stimluating	O
factros	O
seemed	O
to	O
have	O
little	O
effect	O
.	O

The	O
fact	O
that	O
5	O
of	O
the	O
6	O
patinets	O
who	O
received	O
concurrent	O
calcuim	B-Chemical
channel	O
blocekrs	O
deid	O
,	O
should	O
alert	O
cliincians	O
to	O
be	O
more	O
cautious	O
when	O
using	O
these	O
two	O
drgus	O
simultaenously	O
.	O

Upreuglation	O
of	O
the	O
expression	O
of	O
vaospressin	B-Chemical
gnee	O
in	O
the	O
paarventricular	O
and	O
supraopitc	O
nulcei	O
of	O
the	O
lithuim	B-Chemical
-	O
induecd	O
diabtees	O
insipiuds	O
rat	O
.	O

The	O
epxression	O
of	O
argiinne	B-Chemical
vasorpessin	I-Chemical
(	O
AVP	B-Chemical
)	O
gnee	O
in	O
the	O
paraventricualr	O
(	O
PVN	O
)	O
and	O
supraotpic	O
nulcei	O
(	O
SON	O
)	O
was	O
investgiated	O
in	O
rtas	O
with	O
ltihium	B-Chemical
(	O
Li	B-Chemical
)	O
-	O
indcued	O
polyuira	O
,	O
using	O
in	O
situ	O
hybirdization	O
histochmeistry	O
and	O
radiomimunoassay	O
.	O

The	O
mlae	O
Wisatr	O
rtas	O
consuming	O
a	O
deit	O
that	O
contained	O
LCil	B-Chemical
(	O
60	O
mmol	O
/	O
kg	O
)	O
for	O
4	O
weeks	O
developed	O
marked	O
ployuria	O
.	O

The	O
Li	B-Chemical
-	O
terated	O
rtas	O
produced	O
a	O
large	O
voulme	O
of	O
hyoptonic	O
urnie	O
with	O
low	O
ioinc	O
concnetrations	O
.	O

Plamsa	O
soduim	B-Chemical
concentratoins	O
were	O
found	O
to	O
be	O
slightly	O
increaesd	O
in	O
the	O
Li	B-Chemical
-	O
tretaed	O
rtas	O
compaerd	O
with	O
those	O
in	O
cotnrols	O
.	O

Plamsa	O
concentartion	O
of	O
AVP	B-Chemical
and	O
transrcipts	O
of	O
AVP	B-Chemical
gnee	O
in	O
the	O
PVN	O
and	O
SON	O
were	O
significantly	O
inrceased	O
in	O
the	O
Li	B-Chemical
-	O
traeted	O
rtas	O
copmared	O
with	O
conrtols	O
.	O

These	O
rseults	O
suggest	O
that	O
deyhdration	O
and	O
/	O
or	O
the	O
actiavtion	O
of	O
viscearl	O
affernet	O
ipnuts	O
may	O
contribute	O
to	O
the	O
eleavtion	O
of	O
palsma	O
AVP	B-Chemical
and	O
the	O
upregluation	O
of	O
AVP	B-Chemical
gnee	O
expression	O
in	O
the	O
PVN	O
and	O
the	O
SON	O
of	O
the	O
Li	B-Chemical
-	O
induecd	O
dibaetes	O
inspiidus	O
rat	O
.	O

Anitnociceptive	O
and	O
atniamnesic	O
porperties	O
of	O
the	O
prseynaptic	O
cholniergic	O
apmlifier	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
.	O

The	O
antniociceptive	O
efefct	O
of	O
3	B-Chemical
aplha	I-Chemical
-	I-Chemical
tropyl	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
p	I-Chemical
-	I-Chemical
broomphenyl	I-Chemical
)	I-Chemical
porpionate	I-Chemical
[	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
]	O
(	O
10	O
-	O
40	O
mg	O
kg	O
-	O
1	O
s	O
.	O
c	O
.	O
;	O
30	O
-	O
60	O
mg	O
kg	O
-	O
1	O
p	O
.	O
o	O
.	O
;	O
10	O
-	O
30	O
mg	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
;	O
10	O
-	O
30	O
microrgams	O
/	O
mosue	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
was	O
examined	O
in	O
mcie	O
,	O
rtas	O
and	O
guiena	O
pgis	O
by	O
use	O
of	O
the	O
hot	O
-	O
palte	O
,	O
abdmoinal	O
-	O
consrtiction	O
,	O
tial	O
-	O
flcik	O
and	O
paw	O
-	O
presusre	O
tetss	O
.	O

(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
antinocicpetion	O
peaked	O
15	O
min	O
after	O
ijnection	O
and	O
then	O
slowly	O
diminished	O
.	O

The	O
antinocicpetion	O
produced	O
by	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
was	O
prevented	O
by	O
the	O
unselective	O
msucarinic	O
anatgonist	O
artopine	B-Chemical
,	O
the	O
M1	O
-	O
selective	O
antgaonists	O
pirenzpeine	B-Chemical
and	O
dicycloimne	B-Chemical
and	O
the	O
acteylcholine	B-Chemical
depleotr	O
hemicohlinium	B-Chemical
-	I-Chemical
3	I-Chemical
,	O
but	O
not	O
by	O
the	O
oipoid	O
antgaonist	O
nalxoone	B-Chemical
,	O
the	O
gmama	B-Chemical
-	I-Chemical
aminobuytric	I-Chemical
aicdB	I-Chemical
antagoinst	O
3	B-Chemical
-	I-Chemical
aimnopropyl	I-Chemical
-	I-Chemical
deithoxy	I-Chemical
-	I-Chemical
mtehyl	I-Chemical
-	I-Chemical
phosphniic	I-Chemical
aicd	I-Chemical
,	O
the	O
H3	O
agnoist	O
R	B-Chemical
-	I-Chemical
(	I-Chemical
alhpa	I-Chemical
)	I-Chemical
-	I-Chemical
methylhistaimne	I-Chemical
,	O
the	O
D2	O
antgaonist	O
quinpriole	B-Chemical
,	O
the	O
5	B-Chemical
-	I-Chemical
hydroxytrypatmine4	I-Chemical
antgaonist	O
2	B-Chemical
-	I-Chemical
methxoy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
aimno	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
chlroobenzoic	I-Chemical
aicd	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
deithylamino	I-Chemical
)	I-Chemical
etyhl	I-Chemical
esetr	I-Chemical
hydrcohloride	O
,	O
the	O
5	B-Chemical
-	I-Chemical
hydroxytryptamin1A	I-Chemical
antagoinst	O
1	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
metohxyphenyl	I-Chemical
)	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
[	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
pthhalimido	I-Chemical
)	I-Chemical
btuyl	I-Chemical
]	I-Chemical
ppierazine	I-Chemical
hdyrobromide	O
and	O
the	O
polaymines	O
deplteor	O
reesrpine	B-Chemical
.	O

Based	O
on	O
these	O
dtaa	O
,	O
it	O
can	O
be	O
postulated	O
that	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
exerted	O
an	O
antincoiceptive	O
effcet	O
mediated	O
by	O
a	O
centarl	O
ptoentiation	O
of	O
choilnergic	O
transmsision	O
.	O

(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
10	O
-	O
40	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
was	O
able	O
to	O
prveent	O
anmesia	O
inudced	O
by	O
scooplamine	B-Chemical
(	O
1	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
and	O
diycclomine	B-Chemical
(	O
2	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
in	O
the	O
muose	O
passive	O
-	O
avoidacne	O
tset	O
.	O

Affniity	O
profiels	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
for	O
muscrainic	O
rceeptor	O
subtpyes	O
,	O
determined	O
by	O
fucntional	O
sutdies	O
(	O
rabbit	O
vas	O
defreens	O
for	O
M1	O
,	O
guniea	O
pig	O
artium	O
for	O
M2	O
,	O
guniea	O
pig	O
ielum	O
for	O
M3	O
and	O
immature	O
guiena	O
pig	O
utreus	O
for	O
putative	O
M4	O
)	O
,	O
have	O
shown	O
an	O
M4	O
/	O
M1	O
selectivtiy	O
raito	O
of	O
10	O
.	O
2	O
that	O
might	O
be	O
responsible	O
for	O
the	O
anitnociception	O
and	O
the	O
atni	O
-	O
amnseic	O
effect	O
induecd	O
by	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
through	O
an	O
inrcease	O
in	O
aceytlcholine	B-Chemical
extraclelular	O
leevls	O
.	O

In	O
the	O
antionciceptive	O
and	O
antimanesic	O
dsoe	O
range	O
,	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
did	O
not	O
ipmair	O
muose	O
perforamnce	O
eavluated	O
by	O
the	O
rtoa	O
-	O
rod	O
tset	O
and	O
Ainmex	O
apparauts	O
.	O

The	O
efefct	O
of	O
different	O
anaetshetic	O
agetns	O
in	O
heraing	O
lsos	O
following	O
sipnal	O
anaetshesia	O
.	O

The	O
cause	O
of	O
heairng	O
lsos	O
after	O
sipnal	O
anaetshesia	O
is	O
unknown	O
.	O

Up	O
until	O
now	O
,	O
the	O
only	O
fcator	O
studied	O
has	O
been	O
the	O
efefct	O
of	O
the	O
diaemter	O
of	O
the	O
spianl	O
needle	O
on	O
psot	O
-	O
operaitve	O
sensornieural	O
haering	O
lsos	O
.	O

The	O
aim	O
of	O
this	O
sutdy	O
was	O
to	O
describe	O
this	O
heairng	O
lsos	O
and	O
to	O
invetsigate	O
other	O
factros	O
infleuncing	O
the	O
dgeree	O
of	O
heairng	O
lsos	O
.	O

Two	O
gruops	O
of	O
22	O
similar	O
pateints	O
were	O
studied	O
:	O
one	O
gruop	O
received	O
6	O
mL	O
prilociane	B-Chemical
2	O
%	O
;	O
and	O
the	O
other	O
received	O
3	O
mL	O
bupiavcaine	B-Chemical
0	O
.	O
5	O
%	O
.	O

Patietns	O
given	O
priloacine	B-Chemical
were	O
more	O
likely	O
to	O
develop	O
heraing	O
lsos	O
(	O
10	O
out	O
of	O
22	O
)	O
than	O
those	O
given	O
bupivaciane	B-Chemical
(	O
4	O
out	O
of	O
22	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
avreage	O
heairng	O
lsos	O
for	O
sepech	O
freuqencies	O
was	O
about	O
10	O
dB	O
after	O
prliocaine	B-Chemical
and	O
15	O
dB	O
after	O
buipvacaine	B-Chemical
.	O

None	O
of	O
the	O
ptaients	O
complained	O
of	O
sbujective	O
heairng	O
lsos	O
.	O

Lnog	O
-	O
term	O
follow	O
-	O
up	O
of	O
the	O
pateints	O
was	O
not	O
possible	O
.	O

A	O
trnasient	O
neuroolgical	O
deifcit	O
following	O
intrtahecal	O
ijnection	O
of	O
1	O
%	O
hypebraric	O
buipvacaine	B-Chemical
for	O
unilatearl	O
sipnal	O
anaesthseia	O
.	O

We	O
describe	O
a	O
csae	O
of	O
transinet	O
neurologcial	O
defiict	O
that	O
occurred	O
after	O
uniltaeral	O
spianl	O
anaestheisa	O
with	O
8	O
mg	O
of	O
1	O
%	O
hpyerbaric	O
bupivcaaine	B-Chemical
slowly	O
injetced	O
through	O
a	O
25	O
-	O
guage	O
pnecil	O
-	O
point	O
sipnal	O
neelde	O
.	O

The	O
srugery	O
and	O
anaestehsia	O
were	O
unevenftul	O
,	O
but	O
3	O
dyas	O
after	O
sugrery	O
,	O
the	O
ptaient	O
reported	O
an	O
aera	O
of	O
hypaoesthesia	O
over	O
L3	O
-	O
L4	O
dermaotmes	O
of	O
the	O
leg	O
which	O
had	O
been	O
opreated	O
on	O
(	O
lsos	O
of	O
pinpirck	O
sensaiton	O
)	O
without	O
rdeuction	O
in	O
mucsular	O
stregnth	O
.	O

Snesation	O
in	O
this	O
aera	O
returned	O
to	O
nomral	O
over	O
the	O
following	O
2	O
weeks	O
.	O

Prospecitve	O
multicnetre	O
stuides	O
with	O
a	O
large	O
populatoin	O
and	O
a	O
long	O
follow	O
-	O
up	O
should	O
be	O
performed	O
in	O
order	O
to	O
evlauate	O
the	O
inicdence	O
of	O
this	O
unuusal	O
side	O
efefct	O
.	O

However	O
,	O
we	O
suggest	O
that	O
a	O
low	O
sloution	O
cocnentration	O
should	O
be	O
preferred	O
for	O
unilaetral	O
sipnal	O
anaestehsia	O
with	O
a	O
hpyerbaric	O
anaeshtetic	O
sloution	O
(	O
if	O
pecnil	O
-	O
point	O
neelde	O
and	O
slow	O
injectoin	O
rtae	O
are	O
employed	O
)	O
,	O
in	O
order	O
to	O
minimize	O
the	O
rsik	O
of	O
a	O
localiezd	O
high	O
peak	O
anaeshtetic	O
concentratoin	O
,	O
which	O
might	O
lead	O
to	O
a	O
tarnsient	O
neuroloigcal	O
defciit	O
.	O

Transeint	O
neuroloigc	O
sympotms	O
after	O
sipnal	O
aneshtesia	O
:	O
a	O
loewr	O
incdience	O
with	O
pirlocaine	B-Chemical
and	O
bupivaciane	B-Chemical
than	O
with	O
lidociane	B-Chemical
.	O

BACKGORUND	O
:	O
Recent	O
evidecne	O
suggests	O
that	O
transeint	O
neuroolgic	O
symtpoms	O
(	O
TSNs	O
)	O
frequently	O
follow	O
lidcoaine	B-Chemical
spianl	O
aneshtesia	O
but	O
are	O
infreqeunt	O
with	O
bupivacanie	B-Chemical
.	O

However	O
,	O
identificatoin	O
of	O
a	O
short	O
-	O
acting	O
loacl	O
anestheitc	O
to	O
substitute	O
for	O
lidociane	B-Chemical
for	O
brief	O
surgiacl	O
procdeures	O
remains	O
an	O
important	O
gaol	O
.	O

Priloacine	B-Chemical
is	O
an	O
aimde	O
loacl	O
anestehtic	O
with	O
a	O
durtaion	O
of	O
actoin	O
similar	O
to	O
that	O
of	O
ldiocaine	B-Chemical
.	O

Accordingly	O
,	O
the	O
present	O
,	O
porspective	O
double	O
-	O
bilnd	O
sutdy	O
compaers	O
priloacine	B-Chemical
with	O
lidcoaine	B-Chemical
and	O
bupivaacine	B-Chemical
with	O
respect	O
to	O
duraiton	O
of	O
actoin	O
and	O
relative	O
rsik	O
of	O
TSNs	O
.	O

METHODS	O
:	O
Ninety	O
patietns	O
classified	O
as	O
Ameriacn	O
Socitey	O
of	O
Anesthesiologitss	O
phyiscal	O
sttaus	O
I	O
or	O
II	O
who	O
were	O
scheudled	O
for	O
short	O
gynceologic	O
procdeures	O
under	O
sipnal	O
anestehsia	O
were	O
randomly	O
allocated	O
to	O
receive	O
2	O
.	O
5	O
ml	O
2	O
%	O
liodcaine	B-Chemical
in	O
7	O
.	O
5	O
%	O
glcuose	B-Chemical
,	O
2	O
%	O
prilociane	B-Chemical
in	O
7	O
.	O
5	O
%	O
glucsoe	B-Chemical
,	O
or	O
0	O
.	O
5	O
%	O
bupviacaine	B-Chemical
in	O
7	O
.	O
5	O
%	O
gulcose	B-Chemical
.	O

All	O
solutinos	O
were	O
provided	O
in	O
blinedd	O
vails	O
by	O
the	O
hospiatl	O
phamracy	O
.	O

Details	O
of	O
spnial	O
puntcure	O
,	O
extnesion	O
and	O
rergession	O
of	O
sipnal	O
bolck	O
,	O
and	O
the	O
times	O
to	O
reach	O
discahrge	O
crietria	O
were	O
noted	O
.	O

In	O
the	O
evennig	O
of	O
postopertaive	O
day	O
1	O
,	O
paitents	O
were	O
evalauted	O
for	O
TSNs	O
by	O
a	O
physciian	O
unaware	O
of	O
the	O
durg	O
admniistered	O
and	O
the	O
details	O
of	O
the	O
ansethetic	O
porcedure	O
.	O

RESLUTS	O
:	O
Nine	O
of	O
30	O
patinets	O
receiving	O
lidcoaine	B-Chemical
experienced	O
TSNs	O
,	O
1	O
of	O
30	O
patietns	O
receiving	O
prliocaine	B-Chemical
(	O
P	O
=	O
0	O
.	O
03	O
)	O
had	O
them	O
,	O
and	O
none	O
of	O
30	O
paitents	O
receiving	O
buipvacaine	B-Chemical
had	O
TSNs	O
.	O

Tmies	O
to	O
amublate	O
and	O
to	O
viod	O
were	O
similar	O
after	O
lidcoaine	B-Chemical
and	O
prilcoaine	B-Chemical
(	O
150	O
vs	O
.	O
165	O
min	O
and	O
238	O
vs	O
.	O
253	O
min	O
,	O
respectively	O
)	O
but	O
porlonged	O
after	O
bupiavcaine	B-Chemical
(	O
200	O
and	O
299	O
min	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSOINS	O
:	O
Priolcaine	B-Chemical
may	O
be	O
preferable	O
to	O
lidoacine	B-Chemical
for	O
short	O
surigcal	O
procedrues	O
because	O
it	O
has	O
a	O
similar	O
duratoin	O
of	O
aciton	O
but	O
a	O
loewr	O
icnidence	O
of	O
TSNs	O
.	O

Suxamtehonium	B-Chemical
-	O
inudced	O
cadriac	O
arerst	O
and	O
daeth	O
following	O
5	O
dyas	O
of	O
immboilization	O
.	O

The	O
present	O
reoprt	O
describes	O
a	O
csae	O
of	O
cadriac	O
arrset	O
and	O
subsequent	O
daeth	O
as	O
a	O
result	O
of	O
hpyerkalaemia	O
following	O
the	O
use	O
of	O
suxamethoinum	B-Chemical
in	O
a	O
23	O
-	O
yaer	O
-	O
old	O
Malaiwan	O
wmoan	O
.	O

Five	O
dyas	O
after	O
the	O
onset	O
of	O
the	O
symptmos	O
of	O
mennigitis	O
,	O
the	O
pateint	O
asiprated	O
stomcah	O
contetns	O
and	O
needed	O
endotrahceal	O
intubatoin	O
.	O

Forty	O
seconds	O
after	O
injectoin	O
of	O
suxmaethonium	B-Chemical
,	O
brdaycardia	O
and	O
cradiac	O
arrest	O
occurred	O
.	O

Attempts	O
to	O
resusictate	O
the	O
pateint	O
were	O
not	O
successful	O
.	O

The	O
seurm	O
lveel	O
of	O
potassuim	B-Chemical
was	O
observed	O
to	O
be	O
8	O
.	O
4	O
mequiv	O
L	O
-	O
1	O
.	O

Apart	O
from	O
the	O
rdeuction	O
in	O
the	O
patinet	O
'	O
s	O
leevl	O
of	O
cnosciousness	O
,	O
there	O
were	O
no	O
sgins	O
of	O
mtoor	O
neurnoe	O
daamge	O
or	O
of	O
any	O
of	O
the	O
other	O
known	O
predisopsing	O
condiitons	O
for	O
hpyerkalaemia	O
following	O
the	O
admiinstration	O
of	O
suaxmethonium	B-Chemical
.	O

It	O
is	O
postulated	O
that	O
her	O
daeth	O
was	O
caused	O
by	O
hypersensiitvity	O
to	O
suxamehtonium	B-Chemical
,	O
associated	O
with	O
her	O
5	O
-	O
day	O
immobiliaztion	O
.	O

Aucte	O
heaptitis	O
,	O
autoimumne	O
hemoyltic	O
anmeia	O
,	O
and	O
erythrobalstocytopenia	O
inudced	O
by	O
ceftiraxone	B-Chemical
.	O

An	O
80	O
-	O
yr	O
-	O
old	O
man	O
developed	O
aucte	O
hepaittis	O
shortly	O
after	O
ingestnig	O
oarl	O
ceftrixaone	B-Chemical
.	O

Although	O
the	O
transaminaess	O
gradually	O
returned	O
to	O
baseilne	O
after	O
withholidng	O
the	O
btea	B-Chemical
lacatm	I-Chemical
antbiiotic	O
,	O
there	O
was	O
a	O
grdaual	O
incresae	O
in	O
seurm	O
bilirbuin	B-Chemical
and	O
a	O
decerase	O
in	O
hemolgobin	O
conecntration	O
caused	O
by	O
an	O
autoimmune	O
hemoyltic	O
aneima	O
and	O
ertyhroblastocytopenia	O
.	O

These	O
responded	O
to	O
sysetmic	O
steorids	B-Chemical
and	O
immunolgobulins	O
.	O

Despite	O
the	O
widespread	O
use	O
of	O
these	O
agetns	O
this	O
traid	O
of	O
side	O
effcets	O
has	O
not	O
previously	O
been	O
reported	O
in	O
connection	O
with	O
btea	B-Chemical
lacatm	I-Chemical
atnibiotics	O
.	O

Thryoxine	B-Chemical
aubse	O
:	O
an	O
unuusal	O
csae	O
of	O
thyrotxoicosis	O
in	O
preganncy	O
.	O

Eaitng	O
disordres	O
and	O
the	O
associated	O
behaviorual	O
porblems	O
and	O
durg	O
absue	O
are	O
uncommon	O
in	O
pergnancy	O
.	O

When	O
they	O
do	O
occur	O
they	O
are	O
often	O
unrecognized	O
because	O
of	O
dneial	O
but	O
when	O
significant	O
may	O
pose	O
a	O
rsik	O
to	O
both	O
the	O
motehr	O
and	O
her	O
feuts	O
.	O

This	O
csae	O
illustrates	O
a	O
number	O
of	O
porblems	O
that	O
may	O
be	O
encountered	O
in	O
woemn	O
with	O
etaing	O
diosrders	O
in	O
prengancy	O
,	O
including	O
prloonged	O
and	O
rceurrent	O
metaoblic	O
disutrbances	O
and	O
diruetic	O
aubse	O
.	O

In	O
particular	O
it	O
illustrates	O
the	O
derangmeents	O
of	O
thyorid	O
fnuction	O
seen	O
in	O
pregannt	O
woemn	O
with	O
eatnig	O
disodrers	O
and	O
reminds	O
us	O
that	O
when	O
a	O
cause	O
for	O
thyortoxicosis	O
remains	O
obscure	O
,	O
thryoxine	B-Chemical
absue	O
should	O
be	O
considered	O
and	O
explored	O
.	O

Repetaed	O
trimiparmine	B-Chemical
induecs	O
dopaimne	B-Chemical
D2	O
/	O
D3	O
and	O
alhpa1	O
-	O
adrenerigc	O
up	O
-	O
regultaion	O
.	O

Trmiipramine	B-Chemical
(	O
TRI	B-Chemical
)	O
,	O
which	O
shows	O
a	O
cliniacl	O
antideprsesant	B-Chemical
actiivty	O
,	O
is	O
chemiclaly	O
related	O
to	O
imirpamine	B-Chemical
but	O
does	O
not	O
inhiibt	O
the	O
reputake	O
of	O
noradrenailne	B-Chemical
and	O
5	B-Chemical
-	I-Chemical
hydroxytrpytamine	I-Chemical
,	O
nor	O
does	O
it	O
inudce	O
btea	O
-	O
adrenerigc	O
down	O
-	O
reuglation	O
.	O

The	O
mcehanism	O
of	O
its	O
antidepressant	B-Chemical
actviity	O
is	O
still	O
unknown	O
.	O

The	O
aim	O
of	O
the	O
present	O
stduy	O
was	O
to	O
find	O
out	O
whether	O
TRI	B-Chemical
given	O
repeatedly	O
was	O
able	O
to	O
idnuce	O
adapitve	O
chanegs	O
in	O
the	O
dpoaminergic	O
and	O
alpah1	O
-	O
adrenegric	O
ssytems	O
,	O
demonstrated	O
by	O
us	O
previously	O
for	O
various	O
antiedpressants	B-Chemical
.	O

TRI	B-Chemical
was	O
given	O
to	O
mlae	O
Wisatr	O
rtas	O
and	O
mlae	O
Albnio	O
Swsis	O
mcie	O
perorlaly	O
twice	O
daliy	O
for	O
14	O
dyas	O
.	O

In	O
the	O
aucte	O
epxeriment	O
TRI	B-Chemical
(	O
given	O
i	O
.	O
p	O
.	O
)	O
does	O
not	O
antaognize	O
the	O
reesrpine	B-Chemical
hypohtermia	O
in	O
mcie	O
and	O
does	O
not	O
potentitae	O
the	O
5	B-Chemical
-	I-Chemical
hydrxoytryptophan	I-Chemical
haed	O
tiwtches	O
in	O
rtas	O
.	O

TRI	B-Chemical
given	O
repeatedly	O
to	O
rtas	O
incraeses	O
the	O
locoomtor	O
hyperactiivty	O
indcued	O
by	O
d	B-Chemical
-	I-Chemical
amphetmaine	I-Chemical
,	O
quinpirloe	B-Chemical
and	O
(	O
+	O
)	O
-	O
7	O
-	O
hdyroxy	O
-	O
dipropyloamiontetralin	O
(	O
doapmine	B-Chemical
D2	O
and	O
D3	O
efefcts	O
)	O
.	O

The	O
steretoypies	O
induecd	O
by	O
d	B-Chemical
-	I-Chemical
ampehtamine	I-Chemical
or	O
apomrophine	B-Chemical
are	O
not	O
potnetiated	O
by	O
TRI	B-Chemical
.	O

It	O
icnreases	O
the	O
behvaiour	O
stimluation	O
evkoed	O
by	O
phneylephrine	B-Chemical
(	O
given	O
intraventircularly	O
)	O
in	O
rtas	O
,	O
eavluated	O
in	O
the	O
open	O
field	O
tset	O
as	O
well	O
as	O
the	O
agrgessiveness	O
evoekd	O
by	O
clondiine	B-Chemical
in	O
mcie	O
,	O
both	O
these	O
effetcs	O
being	O
mediated	O
by	O
an	O
alhpa1	O
-	O
adernergic	O
rceeptor	O
.	O

It	O
may	O
be	O
concluded	O
that	O
,	O
like	O
other	O
triycclic	O
antiderpessants	B-Chemical
studied	O
previously	O
,	O
TRI	B-Chemical
given	O
repeatedly	O
icnreases	O
the	O
resposniveness	O
of	O
barin	O
doapmine	B-Chemical
D2	O
and	O
D3	O
(	O
locomtoor	O
actviity	O
but	O
not	O
steretoypy	O
)	O
as	O
well	O
as	O
aplha1	O
-	O
adernergic	O
receptros	O
to	O
their	O
agonsits	O
.	O

A	O
question	O
arises	O
whether	O
the	O
reutpake	O
ihnibition	O
is	O
of	O
any	O
importance	O
to	O
the	O
adaptvie	O
cahnges	O
indcued	O
by	O
rpeeated	O
antiderpessants	B-Chemical
,	O
suggested	O
to	O
be	O
responsible	O
for	O
the	O
antidperessant	B-Chemical
activtiy	O
.	O

Pehtidine	B-Chemical
-	O
associated	O
seiuzre	O
in	O
a	O
haelthy	O
adolesecnt	O
receiving	O
ptehidine	B-Chemical
for	O
potsoperative	O
pian	O
cnotrol	O
.	O

A	O
helathy	O
17	O
-	O
yaer	O
-	O
old	O
mlae	O
received	O
stanadrd	O
inetrmittent	O
doess	O
of	O
petihdine	B-Chemical
via	O
a	O
paitent	O
-	O
contorlled	O
analgeisa	O
(	O
PCA	O
)	O
pmup	O
for	O
mangaement	O
of	O
postoperatvie	O
pian	O
cotnrol	O
.	O

Twenty	O
-	O
three	O
h	O
postoperatviely	O
he	O
developed	O
a	O
brief	O
slef	O
-	O
liimted	O
seizrue	O
.	O

Both	O
palsma	O
ptehidine	B-Chemical
and	O
norpethiidne	B-Chemical
were	O
eleavted	O
in	O
the	O
range	O
associated	O
with	O
cilnical	O
manifestatoins	O
of	O
cetnral	O
nerovus	O
sysetm	O
exctiation	O
.	O

No	O
other	O
rsik	O
factros	O
for	O
CNS	O
toxiicty	O
were	O
idnetified	O
.	O

This	O
metohd	O
allowed	O
freqeunt	O
slef	O
-	O
dsoing	O
of	O
petihdine	B-Chemical
at	O
short	O
tmie	O
interavls	O
and	O
rpaid	O
accmuulation	O
of	O
pehtidine	B-Chemical
and	O
norpetihdine	B-Chemical
.	O

The	O
ruotine	O
use	O
of	O
petihdine	B-Chemical
via	O
PCA	O
even	O
for	O
a	O
brief	O
postoperaitve	O
aanlgesia	O
should	O
be	O
reconsidered	O
.	O

An	O
uunsual	O
txoic	O
reatcion	O
to	O
aixllary	O
bolck	O
by	O
mepivacanie	B-Chemical
with	O
adrenalnie	B-Chemical
.	O

An	O
inrcease	O
in	O
blood	O
perssure	O
,	O
accompanied	O
by	O
atrail	O
fibrilltaion	O
,	O
agitatoin	O
,	O
incomprehensible	O
shouts	O
and	O
lsos	O
of	O
cnosciousness	O
,	O
was	O
observed	O
in	O
an	O
edlerly	O
,	O
ASA	O
calssification	O
gruop	O
II	O
,	O
cardiovsacularly	O
mdeicated	O
mlae	O
,	O
12	O
min	O
after	O
perfomrance	O
of	O
axilalry	O
blcok	O
with	O
mepiavcaine	B-Chemical
850	O
mg	O
containing	O
adrnealine	B-Chemical
0	O
.	O
225	O
mg	O
,	O
for	O
corrcetion	O
of	O
Dupuyrten	O
'	O
s	O
cnotracture	O
.	O

After	O
intraveonus	O
adminisrtation	O
of	O
labetaoll	B-Chemical
,	O
metoporlol	B-Chemical
and	O
mdiazolam	B-Chemical
the	O
pateint	O
'	O
s	O
cnodition	O
ipmroved	O
,	O
and	O
15	O
min	O
later	O
he	O
woke	O
up	O
.	O

The	O
bolck	O
was	O
successful	O
and	O
surgrey	O
was	O
conducted	O
as	O
schedueld	O
despite	O
persisting	O
atrail	O
fbirillation	O
.	O

Potsoperatively	O
,	O
the	O
ptaient	O
refused	O
DC	O
cadrioversion	O
and	O
was	O
tretaed	O
medcially	O
.	O

Both	O
the	O
tempoarl	O
reltaionship	O
of	O
eevnts	O
and	O
the	O
respnose	O
to	O
treatmnet	O
suggest	O
that	O
a	O
rpaid	O
sysetmic	O
absroption	O
of	O
mepivcaaine	B-Chemical
with	O
adrnealine	B-Chemical
and	O
/	O
or	O
itneraction	O
of	O
these	O
drgus	O
with	O
the	O
ptaient	O
'	O
s	O
cadriovascular	O
medciations	O
were	O
responsible	O
for	O
the	O
perioperaitve	O
complciations	O
.	O

Durg	O
-	O
associated	O
actue	O
-	O
onset	O
vanishing	O
blie	O
dcut	O
and	O
Setvens	O
-	O
Jhonson	O
syndormes	O
in	O
a	O
cihld	O
.	O

Aucte	O
vanishing	O
blie	O
dcut	O
syndorme	O
is	O
a	O
rrae	O
but	O
established	O
cause	O
of	O
progresisve	O
cholestaiss	O
in	O
adutls	O
,	O
is	O
most	O
often	O
durg	O
or	O
txoin	O
related	O
,	O
and	O
is	O
of	O
unknown	O
ptahogenesis	O
.	O

It	O
has	O
not	O
been	O
reported	O
previously	O
in	O
cihldren	O
.	O

Stevnes	O
-	O
Johsnon	O
sydnrome	O
is	O
a	O
well	O
-	O
recognized	O
imumne	O
comlpex	O
-	O
mediated	O
hypesrensitivity	O
raection	O
that	O
affects	O
all	O
age	O
gorups	O
,	O
is	O
durg	O
or	O
infcetion	O
idnuced	O
,	O
and	O
has	O
classic	O
sysetmic	O
,	O
mcuosal	O
,	O
and	O
demratologic	O
manifestatinos	O
.	O

A	O
previously	O
helathy	O
cihld	O
who	O
developed	O
actue	O
,	O
sevree	O
,	O
rapidly	O
progerssive	O
vanishing	O
blie	O
dcut	O
sydnrome	O
shortly	O
after	O
Stevnes	O
-	O
Jonhson	O
snydrome	O
is	O
described	O
;	O
this	O
was	O
tempoarlly	O
associated	O
with	O
ibuproefn	B-Chemical
use	O
.	O

Despite	O
tehrapy	O
with	O
ursodeoxcyholic	B-Chemical
aicd	I-Chemical
,	O
predinsone	B-Chemical
,	O
and	O
then	O
tacroilmus	B-Chemical
,	O
her	O
cholesttaic	O
diesase	O
was	O
unreelnting	O
,	O
with	O
crirhosis	O
shown	O
by	O
biospy	O
6	O
monhts	O
after	O
presentaiton	O
.	O

This	O
csae	O
documetns	O
actue	O
durg	O
-	O
related	O
vanishing	O
blie	O
dcut	O
snydrome	O
in	O
the	O
pdeiatric	O
age	O
gorup	O
and	O
suggests	O
shared	O
immune	O
mechainsms	O
in	O
the	O
pathogenseis	O
of	O
both	O
Stveens	O
-	O
Jhonson	O
syndorme	O
and	O
vanishing	O
blie	O
dcut	O
syndrmoe	O
.	O

High	O
inicdence	O
of	O
primray	O
pumlonary	O
hypertnesion	O
associated	O
with	O
appeitte	B-Chemical
supperssants	I-Chemical
in	O
Beglium	O
.	O

Priamry	O
plumonary	O
hypertesnion	O
is	O
a	O
rrae	O
,	O
progerssive	O
and	O
incurable	O
diesase	O
,	O
which	O
has	O
been	O
associated	O
with	O
the	O
inatke	O
of	O
appeitte	B-Chemical
suppressant	I-Chemical
durgs	O
.	O

The	O
importance	O
of	O
this	O
associaiton	O
was	O
evaluaetd	O
in	O
Beglium	O
while	O
this	O
conutry	O
still	O
had	O
no	O
restrcition	O
on	O
the	O
prescripiton	O
of	O
apeptite	B-Chemical
suppressatns	I-Chemical
.	O

Thirty	O
-	O
five	O
patinets	O
with	O
primray	O
pulmoanry	O
hypertesnion	O
and	O
85	O
matched	O
conrtols	O
were	O
recruited	O
over	O
32	O
mnoths	O
(	O
1992	O
-	O
1994	O
)	O
in	O
Belguim	O
.	O

Expsoure	O
to	O
appettie	B-Chemical
-	I-Chemical
supprsesants	I-Chemical
was	O
assesesd	O
on	O
the	O
basis	O
of	O
hosptial	O
rceords	O
and	O
standadrized	O
intreview	O
.	O

Twenty	O
-	O
three	O
of	O
the	O
pateints	O
had	O
previously	O
taken	O
apeptite	B-Chemical
supperssants	I-Chemical
,	O
mainly	O
fenfluramines	B-Chemical
,	O
as	O
compaerd	O
with	O
only	O
5	O
of	O
the	O
contrlos	O
(	O
66	O
versus	O
6	O
%	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Five	O
pateints	O
deid	O
before	O
the	O
interivew	O
,	O
all	O
of	O
them	O
had	O
taken	O
appetite	B-Chemical
suprpessants	I-Chemical
.	O

In	O
8	O
patinets	O
the	O
diganosis	O
of	O
pirmary	O
pumlonary	O
hypretension	O
was	O
uncertain	O
,	O
5	O
of	O
them	O
had	O
taken	O
appteite	B-Chemical
spupressants	I-Chemical
.	O

The	O
patietns	O
who	O
had	O
been	O
epxosed	O
to	O
appetite	B-Chemical
suppressatns	I-Chemical
tended	O
to	O
be	O
on	O
avreage	O
more	O
seevrely	O
ill	O
,	O
and	O
to	O
have	O
a	O
shoretr	O
mdeian	O
dleay	O
between	O
onset	O
of	O
symptmos	O
and	O
daignosis	O
.	O

A	O
ploicy	O
of	O
unrestricted	O
presrciption	O
of	O
appteite	B-Chemical
suppressatns	I-Chemical
may	O
lead	O
to	O
a	O
high	O
inciednce	O
of	O
associated	O
pirmary	O
pulomnary	O
hypretension	O
.	O

Inatke	O
of	O
apeptite	B-Chemical
supperssants	I-Chemical
may	O
acceelrate	O
the	O
progerssion	O
of	O
the	O
disaese	O
.	O

Inpapropriate	O
use	O
of	O
carbmaazepine	B-Chemical
and	O
viagbatrin	B-Chemical
in	O
typical	O
abesnce	O
seizuers	O
.	O

Carabmazepine	B-Chemical
and	O
vigaabtrin	B-Chemical
are	O
contriandicated	O
in	O
typical	O
absnece	O
siezures	O
.	O

Of	O
18	O
consecuitve	O
reefrrals	O
of	O
childern	O
with	O
resitsant	O
typical	O
absenecs	O
only	O
,	O
eight	O
were	O
erroneously	O
terated	O
with	O
carbamzaepine	B-Chemical
either	O
as	O
monotehrapy	O
or	O
as	O
an	O
add	O
-	O
on	O
.	O

Vigabatirn	B-Chemical
was	O
also	O
used	O
in	O
the	O
treatemnt	O
of	O
two	O
chidlren	O
.	O

Freuqency	O
of	O
asbences	O
inrceased	O
in	O
four	O
chilrden	O
terated	O
with	O
carbamzaepine	B-Chemical
and	O
two	O
of	O
these	O
developed	O
myoclnoic	O
jekrs	O
,	O
which	O
resolved	O
on	O
withdrwaal	O
of	O
carbamazpeine	B-Chemical
.	O

Abesnces	O
were	O
aggraavted	O
in	O
both	O
csaes	O
where	O
vigbaatrin	B-Chemical
was	O
added	O
on	O
to	O
concurrnet	O
traetment	O
.	O

Opitmal	O
contorl	O
of	O
the	O
absecnes	O
was	O
achieved	O
with	O
soduim	B-Chemical
vlaproate	I-Chemical
,	O
lamtorigine	B-Chemical
,	O
or	O
ethosuxiimde	B-Chemical
alone	O
or	O
in	O
comibnation	O
.	O

Choroeathetoid	O
moveemnts	O
associated	O
with	O
rpaid	O
adjustmnet	O
to	O
mtehadone	B-Chemical
.	O

Choretaiform	O
hypekrinesias	O
are	O
known	O
to	O
be	O
occasional	O
movmeent	O
abnomralities	O
during	O
intoixcations	O
with	O
coacine	B-Chemical
but	O
not	O
opiaets	O
.	O

This	O
is	O
a	O
csae	O
reoprt	O
of	O
eupohria	O
and	O
choreoatheotid	O
movemetns	O
both	O
trnasiently	O
idnuced	O
by	O
rpaid	O
adjustmnet	O
to	O
the	O
selective	O
mu	O
-	O
opoiid	O
recetpor	O
agnoist	O
mehtadone	B-Chemical
in	O
an	O
inpatinet	O
previously	O
abuisng	O
heorine	B-Chemical
and	O
cocanie	B-Chemical
.	O

In	O
addition	O
,	O
minor	O
EEG	O
abnormaltiies	O
occurred	O
.	O

Possible	O
underlying	O
neurobiloogical	O
phneomena	O
are	O
discussed	O
.	O

Adevrse	O
effcets	O
of	O
the	O
atypcial	O
antipsychtoics	O
.	O

Collaborative	O
Worikng	O
Gruop	O
on	O
Cilnical	O
Trail	O
Evlauations	O
.	O

Advesre	O
effetcs	O
of	O
antispychotics	O
often	O
lead	O
to	O
nnocompliance	O
.	O

Thus	O
,	O
cilnicians	O
should	O
address	O
patietns	O
'	O
conecrns	O
about	O
avderse	O
effects	O
and	O
attempt	O
to	O
choose	O
medicatoins	O
that	O
will	O
ipmrove	O
their	O
ptaients	O
'	O
qulaity	O
of	O
lfie	O
as	O
well	O
as	O
overall	O
helath	O
.	O

The	O
side	O
effect	O
proflies	O
of	O
the	O
aytpical	O
antispychotics	O
are	O
more	O
advantageous	O
than	O
those	O
of	O
the	O
conventioanl	O
neurolpetics	O
.	O

Convnetional	O
agnets	O
are	O
associated	O
with	O
unwanted	O
cnetral	O
nevrous	O
sytsem	O
effcets	O
,	O
including	O
exrtapyramidal	O
sypmtoms	O
(	O
EPS	O
)	O
,	O
tradive	O
dysiknesia	O
,	O
sedaiton	O
,	O
and	O
possible	O
impairemnt	O
of	O
some	O
cogintive	O
measuers	O
,	O
as	O
well	O
as	O
cardaic	O
effetcs	O
,	O
orhtostatic	O
hyoptension	O
,	O
hepaitc	O
chanegs	O
,	O
anticholinerigc	O
side	O
effects	O
,	O
seuxal	O
dysfunciton	O
,	O
and	O
weihgt	O
gain	O
.	O

The	O
newer	O
aytpical	O
aegnts	O
have	O
a	O
lwoer	O
rsik	O
of	O
EPS	O
,	O
but	O
are	O
associated	O
in	O
varying	O
dergees	O
with	O
sdeation	O
,	O
cardiovacsular	O
efefcts	O
,	O
anticholinegric	O
efefcts	O
,	O
wegiht	O
gain	O
,	O
seuxal	O
dysfnuction	O
,	O
hpeatic	O
effects	O
,	O
loweerd	O
seizrue	O
thershold	O
(	O
primarily	O
clozapnie	B-Chemical
)	O
,	O
and	O
agranluocytosis	O
(	O
clozpaine	B-Chemical
only	O
)	O
.	O

Since	O
the	O
incdience	O
and	O
seevrity	O
of	O
specific	O
adevrse	O
effetcs	O
differ	O
among	O
the	O
various	O
atypcials	O
,	O
the	O
cliniican	O
should	O
carefully	O
consider	O
which	O
side	O
effcets	O
are	O
most	O
likely	O
to	O
lead	O
to	O
the	O
indviidual	O
'	O
s	O
dissatifsaction	O
and	O
noncmopliance	O
before	O
choosing	O
an	O
antipsychoitc	O
for	O
a	O
particular	O
patinet	O
.	O

A	O
rnadomized	O
,	O
plcaebo	O
-	O
contrloled	O
dsoe	O
-	O
comparsion	O
tiral	O
of	O
halopreidol	B-Chemical
for	O
pscyhosis	O
and	O
disrupitve	O
behaviros	O
in	O
Azlheimer	O
'	O
s	O
disaese	O
.	O

OJBECTIVE	O
:	O
The	O
gaol	O
of	O
this	O
sutdy	O
was	O
to	O
comprae	O
the	O
efficcay	O
and	O
side	O
effcets	O
of	O
two	O
dsoes	O
of	O
haloepridol	B-Chemical
and	O
placbeo	O
in	O
the	O
tretament	O
of	O
pscyhosis	O
and	O
dsiruptive	O
beahviors	O
in	O
paitents	O
with	O
Alzheiemr	O
'	O
s	O
disesae	O
.	O

METHOD	O
:	O
In	O
a	O
6	O
-	O
week	O
radnom	O
-	O
assginment	O
,	O
double	O
-	O
bilnd	O
,	O
palcebo	O
-	O
controleld	O
trail	O
(	O
phsae	O
A	O
)	O
,	O
halpoeridol	B-Chemical
,	O
2	O
-	O
3	O
mg	O
/	O
day	O
(	O
satndard	O
dsoe	O
)	O
,	O
and	O
halpoeridol	B-Chemical
,	O
0	O
.	O
50	O
-	O
0	O
.	O
75	O
mg	O
/	O
day	O
(	O
low	O
dsoe	O
)	O
,	O
were	O
comapred	O
in	O
71	O
ouptatients	O
with	O
Alhzeimer	O
'	O
s	O
diesase	O
.	O

For	O
the	O
subsequent	O
6	O
-	O
week	O
double	O
-	O
bilnd	O
crossvoer	O
pahse	O
(	O
phsae	O
B	O
)	O
,	O
patinets	O
taking	O
stanadrd	O
-	O
or	O
low	O
-	O
dsoe	O
haloperiodl	B-Chemical
were	O
switched	O
to	O
palcebo	O
,	O
and	O
patinets	O
taking	O
placbeo	O
were	O
randomly	O
assigned	O
to	O
stadnard	O
-	O
or	O
low	O
-	O
dsoe	O
haolperidol	B-Chemical
.	O

RESUTLS	O
:	O
For	O
the	O
60	O
pateints	O
who	O
completed	O
pahse	O
A	O
,	O
stnadard	O
-	O
dsoe	O
haolperidol	B-Chemical
was	O
efficcaious	O
and	O
superior	O
to	O
both	O
low	O
-	O
dsoe	O
haloepridol	B-Chemical
and	O
plcaebo	O
for	O
scroes	O
on	O
the	O
Breif	O
Psychaitric	O
Rtaing	O
Sclae	O
psycohsis	O
fatcor	O
and	O
on	O
psycohmotor	O
agitaiton	O
.	O

Rseponse	O
raets	O
according	O
to	O
three	O
stes	O
of	O
cirteria	O
were	O
greater	O
with	O
the	O
satndard	O
dsoe	O
(	O
55	O
%	O
-	O
60	O
%	O
)	O
than	O
the	O
low	O
dsoe	O
(	O
25	O
%	O
-	O
35	O
%	O
)	O
and	O
palcebo	O
(	O
25	O
%	O
-	O
30	O
%	O
)	O
.	O

The	O
advantage	O
of	O
satndard	O
dsoe	O
over	O
low	O
dsoe	O
was	O
replicated	O
in	O
phsae	O
B	O
.	O

In	O
pahse	O
A	O
,	O
extrapyramdial	O
sgins	O
tended	O
to	O
be	O
greater	O
with	O
the	O
stadnard	O
dsoe	O
than	O
in	O
the	O
other	O
two	O
condiitons	O
,	O
primarily	O
because	O
of	O
a	O
subrgoup	O
(	O
20	O
%	O
)	O
who	O
developed	O
mdoerate	O
to	O
seevre	O
sgins	O
.	O

Low	O
-	O
dsoe	O
hlaoperidol	B-Chemical
did	O
not	O
differ	O
from	O
placbeo	O
on	O
any	O
mesaure	O
of	O
efficacy	O
or	O
side	O
effcets	O
.	O

CONCLUISONS	O
:	O
The	O
rseults	O
indicated	O
a	O
faovrable	O
thearpeutic	O
prfoile	O
for	O
halopeirdol	B-Chemical
in	O
doess	O
of	O
2	O
-	O
3	O
mg	O
/	O
day	O
,	O
although	O
a	O
subgruop	O
developed	O
modearte	O
to	O
sevree	O
exrtapyramidal	O
sings	O
.	O

A	O
starting	O
dsoe	O
of	O
1	O
mg	O
/	O
day	O
with	O
gradaul	O
,	O
upward	O
dsoe	O
tirtation	O
is	O
reocmmended	O
.	O

The	O
narrow	O
thearpeutic	O
wnidow	O
observed	O
with	O
halpoeridol	B-Chemical
may	O
also	O
apply	O
to	O
other	O
neuroleptcis	O
used	O
in	O
Alzhiemer	O
'	O
s	O
dsiease	O
pateints	O
with	O
psychsois	O
and	O
disrputive	O
behaivors	O
.	O

Effetcs	O
of	O
acetylaslicylic	B-Chemical
aicd	I-Chemical
,	O
diypridamole	B-Chemical
,	O
and	O
hydrocortsione	B-Chemical
on	O
epinehprine	B-Chemical
-	O
idnuced	O
mycoardial	O
injruy	O
in	O
dgos	O
.	O

A	O
reproducible	O
mdoel	O
for	O
producing	O
dfifuse	O
moycardial	O
inujry	O
(	O
eipnephrine	B-Chemical
infuison	O
)	O
has	O
been	O
developed	O
to	O
sutdy	O
the	O
cardiorpotective	O
effetcs	O
of	O
agnets	O
or	O
manuevers	O
which	O
might	O
alter	O
the	O
evolutoin	O
of	O
aucte	O
myocardail	O
inafrction	O
.	O

Inufsions	O
of	O
epinephirne	B-Chemical
(	O
4	O
mug	O
per	O
kilogram	O
per	O
minute	O
for	O
6	O
hours	O
)	O
incerased	O
rdaiocalcium	B-Chemical
uptkaes	O
into	O
inatct	O
myocradium	O
and	O
each	O
of	O
its	O
subcelullar	O
copmonents	O
with	O
the	O
mitochondiral	O
frcation	O
showing	O
the	O
most	O
consistent	O
cahnges	O
when	O
compraed	O
to	O
slaine	O
-	O
inufsed	O
cnotrol	O
aniamls	O
(	O
4	O
,	O
957	O
vs	O
.	O
827	O
cuonts	O
per	O
minute	O
per	O
garm	O
of	O
dired	O
tissue	O
or	O
frcation	O
)	O
.	O

Myocardail	O
concetnrations	O
of	O
clacium	B-Chemical
also	O
icnreased	O
significantly	O
(	O
12	O
.	O
0	O
vs	O
.	O
5	O
.	O
0	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
fat	O
-	O
free	O
dry	O
weihgt	O
)	O
.	O

Ifnusions	O
of	O
clacium	B-Chemical
clhoride	I-Chemical
sufficient	O
to	O
raise	O
sreum	O
calicum	B-Chemical
cnocentrations	O
2	O
mEq	O
.	O
per	O
liter	O
failed	O
to	O
incresae	O
calcuim	B-Chemical
infulx	O
into	O
the	O
myocadrial	O
clel	O
.	O

Mitochondrail	O
radoicalcium	B-Chemical
utpakes	O
were	O
significantly	O
decerased	O
in	O
ainmals	O
preterated	O
with	O
aectylsalicylic	B-Chemical
aicd	I-Chemical
or	O
dipyirdamole	B-Chemical
or	O
when	O
hydrocortiosne	B-Chemical
was	O
added	O
to	O
the	O
epienphrine	B-Chemical
inufsion	O
(	O
2	O
,	O
682	O
,	O
2	O
,	O
803	O
,	O
and	O
3	O
,	O
424	O
cuonts	O
per	O
minute	O
per	O
garm	O
of	O
dired	O
farction	O
,	O
respectively	O
)	O
.	O

Myocardail	O
calcuim	B-Chemical
concentratinos	O
also	O
were	O
derceased	O
(	O
11	O
.	O
2	O
,	O
8	O
.	O
3	O
,	O
and	O
8	O
.	O
9	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
fat	O
-	O
free	O
dry	O
weihgt	O
,	O
respectively	O
)	O
in	O
the	O
three	O
treatmnet	O
gropus	O
,	O
being	O
significantly	O
decerased	O
only	O
in	O
the	O
last	O
two	O
.	O

Evdience	O
of	O
microcsopic	O
dmaage	O
was	O
graedd	O
as	O
less	O
sveere	O
in	O
the	O
three	O
tretament	O
gruops	O
.	O

Acetlysalicylic	B-Chemical
aicd	I-Chemical
,	O
dipyrdiamole	B-Chemical
,	O
and	O
hydrocoritsone	B-Chemical
all	O
appear	O
to	O
have	O
cardiporotective	O
efefcts	O
when	O
tesetd	O
in	O
this	O
mdoel	O
.	O

Cilnical	O
and	O
histopathoolgic	O
exmaination	O
of	O
rneal	O
allogarfts	O
traeted	O
with	O
tacrloimus	B-Chemical
(	O
F5K06	B-Chemical
)	O
for	O
at	O
least	O
one	O
yaer	O
.	O

BCAKGROUND	O
:	O
We	O
clinically	O
and	O
pathologiclaly	O
aanlyzed	O
rneal	O
allogarfts	O
from	O
1	O
9	O
reanl	O
translpant	O
ptaients	O
tretaed	O
with	O
tacrloimus	B-Chemical
(	O
FK056	B-Chemical
)	O
for	O
more	O
than	O
1	O
yaer	O
.	O

METHODS	O
:	O
Twenty	O
-	O
six	O
rneal	O
allgoraft	O
biospy	O
specmiens	O
from	O
1	O
9	O
rneal	O
trnasplant	O
ptaients	O
who	O
underwent	O
tranpslantations	O
between	O
1991	O
and	O
1993	O
were	O
eavluated	O
.	O

Thirteen	O
boipsies	O
were	O
performed	O
from	O
stalbe	O
functinoing	O
reanl	O
allorgafts	O
with	O
informed	O
conesnt	O
(	O
nonepisode	O
biposy	O
)	O
and	O
the	O
other	O
13	O
were	O
from	O
dyfsunctional	O
rneal	O
allografts	O
with	O
a	O
cilnical	O
idnication	O
for	O
biospy	O
(	O
eipsode	O
boipsy	O
)	O
.	O

RSEULTS	O
:	O
The	O
main	O
patholgoic	O
diganoses	O
(	O
some	O
ovelrap	O
)	O
were	O
aucte	O
rejectoin	O
(	O
AR	O
;	O
n	O
=	O
4	O
)	O
,	O
chrnoic	O
rejeciton	O
(	O
CR	O
;	O
n	O
=	O
5	O
)	O
,	O
AR	O
+	O
CR	O
(	O
n	O
=	O
4	O
)	O
,	O
recurernt	O
IgA	O
nephrpoathy	O
(	O
n	O
=	O
5	O
)	O
,	O
nomral	O
finidngs	O
(	O
n	O
=	O
2	O
)	O
,	O
miniaml	O
-	O
tpye	O
crhonic	O
F5K06	B-Chemical
nehpropathy	O
(	O
n	O
=	O
9	O
)	O
,	O
and	O
mlid	O
-	O
tpye	O
FK056	B-Chemical
nephrpoathy	O
(	O
n	O
=	O
11	O
)	O
.	O

Of	O
the	O
nonepisode	O
biopseis	O
,	O
7	O
and	O
4	O
boipsies	O
showed	O
miinmal	O
-	O
tpye	O
and	O
mlid	O
-	O
tpye	O
crhonic	O
F5K06	B-Chemical
nephroptahy	O
,	O
respectively	O
.	O

Chornic	O
FK056	B-Chemical
npehropathy	O
consisted	O
of	O
rough	O
and	O
fomay	O
tuublar	O
vacoulization	O
(	O
5	O
biopises	O
)	O
,	O
arteirolopathy	O
(	O
angiodegenertaion	O
of	O
the	O
arteirolar	O
wlal	O
;	O
20	O
boipsies	O
)	O
,	O
foacl	O
sgemental	O
gloemrulosclerosis	O
(	O
4	O
biopseis	O
)	O
and	O
the	O
striepd	O
form	O
of	O
intersttiial	O
firbosis	O
(	O
11	O
boipsies	O
)	O
.	O

The	O
seurm	O
creatiinne	B-Chemical
levles	O
of	O
paitents	O
in	O
the	O
mlid	O
-	O
tpye	O
chroinc	O
FK056	B-Chemical
nephropahty	O
gruop	O
,	O
which	O
included	O
7	O
episdoe	O
biospies	O
,	O
were	O
statistically	O
higehr	O
than	O
those	O
in	O
the	O
minimum	O
-	O
tpye	O
crhonic	O
FK056	B-Chemical
-	O
nephropahty	O
gorup	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLSUIONS	O
:	O
This	O
sutdy	O
demonstrates	O
that	O
chornic	O
F5K06	B-Chemical
nephroapthy	O
consists	O
primarily	O
of	O
arteirolopathy	O
manifesting	O
as	O
isnudative	O
haylinosis	O
of	O
the	O
arterioalr	O
wlal	O
,	O
and	O
suggests	O
that	O
mlid	O
-	O
tpye	O
chornic	O
F5K06	B-Chemical
nephroptahy	O
is	O
a	O
codnition	O
which	O
may	O
lead	O
to	O
detreioration	O
of	O
reanl	O
alolgraft	O
functoin	O
.	O

Different	O
lboular	O
dsitributions	O
of	O
atlered	O
hepatoycte	O
tihgt	O
jnuctions	O
in	O
rat	O
moedls	O
of	O
intrahpeatic	O
and	O
extrahepaitc	O
choletsasis	O
.	O

Hepaotcyte	O
tihgt	O
juntcions	O
(	O
TJs	O
)	O
,	O
the	O
only	O
interclelular	O
barirer	O
between	O
the	O
sniusoidal	O
and	O
the	O
canalciular	O
spcaes	O
,	O
play	O
a	O
key	O
role	O
in	O
blie	O
formatoin	O
.	O

Although	O
hepatcoyte	O
TJs	O
are	O
ipmaired	O
in	O
choelstasis	O
,	O
attempts	O
to	O
loclaize	O
the	O
precise	O
stie	O
of	O
heptaocyte	O
TJ	O
daamge	O
by	O
fereze	O
-	O
fratcure	O
elcetron	O
microcsopy	O
have	O
produced	O
lmiited	O
informtaion	O
.	O

Recently	O
,	O
several	O
TJ	O
-	O
associated	O
protenis	O
like	O
ZO	O
-	O
1	O
and	O
7H6	O
have	O
been	O
identiifed	O
and	O
characteirzed	O
.	O

Immunolocalizatoin	O
of	O
7H6	O
appears	O
to	O
closely	O
corrleate	O
with	O
parcaellular	O
permebaility	O
.	O

We	O
used	O
rat	O
modles	O
of	O
intrhaepatic	O
cholestsais	O
by	O
ehtinyl	B-Chemical
estraidol	I-Chemical
(	O
EE	B-Chemical
)	O
tretament	O
and	O
etxrahepatic	O
choelstasis	O
by	O
blie	O
dcut	O
liagtion	O
(	O
BDL	O
)	O
to	O
precisely	O
determine	O
the	O
stie	O
of	O
TJ	O
dmaage	O
.	O

Aletrations	O
in	O
heaptocyte	O
TJs	O
were	O
asesssed	O
by	O
double	O
-	O
imumnolabeling	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
using	O
a	O
conofcal	O
laesr	O
scaninng	O
mciroscope	O
.	O

In	O
conrtol	O
rtas	O
,	O
immunostaining	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
coloclaized	O
to	O
outline	O
blie	O
canaliucli	O
in	O
a	O
contniuous	O
fashion	O
.	O

In	O
contrast	O
,	O
7H6	O
and	O
ZO	O
-	O
1	O
immunostaining	O
was	O
more	O
dicsontinuous	O
,	O
outlining	O
the	O
blie	O
canailculi	O
after	O
BDL	O
.	O

Immunotsaining	O
for	O
7H6	O
,	O
not	O
ZO	O
-	O
1	O
,	O
decerased	O
and	O
predominantly	O
appeared	O
as	O
dicsrete	O
singals	O
in	O
the	O
submembarnous	O
cyotplasm	O
of	O
periporatl	O
hepatoctyes	O
after	O
BDL	O
.	O

After	O
EE	B-Chemical
tretament	O
,	O
chanegs	O
in	O
immunostianing	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
were	O
similar	O
to	O
those	O
seen	O
in	O
periprotal	O
heaptocytes	O
after	O
BDL	O
,	O
but	O
distributed	O
more	O
diffuesly	O
throughout	O
the	O
loblue	O
.	O

This	O
sutdy	O
is	O
the	O
first	O
to	O
demonstrate	O
that	O
imapirment	O
of	O
hepaotcyte	O
TJs	O
occurs	O
hetreogenously	O
in	O
the	O
lievr	O
louble	O
after	O
BDL	O
and	O
suggests	O
that	O
BDL	O
and	O
EE	B-Chemical
teratments	O
produce	O
different	O
lobluar	O
distribtuions	O
of	O
icnreased	O
paarcellular	O
permeabiltiy	O
.	O

Mmeory	O
facilittaion	O
and	O
stimluation	O
of	O
enodgenous	O
nreve	O
grwoth	O
facotr	O
syntehsis	O
by	O
the	O
aectylcholine	B-Chemical
reelaser	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
.	O

The	O
effcets	O
of	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
3alpha	B-Chemical
-	I-Chemical
tropyl	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
p	I-Chemical
-	I-Chemical
brmoophenyl	I-Chemical
)	I-Chemical
propioante	I-Chemical
)	O
,	O
the	O
acetylcohline	B-Chemical
rleeaser	O
,	O
on	O
mmeory	O
procseses	O
and	O
nreve	O
grotwh	O
fcator	O
(	O
NGF	O
)	O
syntheiss	O
were	O
eavluated	O
.	O

In	O
the	O
muose	O
pasisve	O
-	O
aviodance	O
tset	O
,	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
administeerd	O
20	O
min	O
before	O
the	O
traiinng	O
ssesion	O
,	O
prevented	O
amneisa	O
idnuced	O
by	O
both	O
the	O
non	O
selective	O
atnimuscarinic	O
durg	O
scooplamine	B-Chemical
and	O
the	O
M1	O
-	O
selective	O
antaognist	O
S	B-Chemical
-	I-Chemical
(	I-Chemical
-	I-Chemical
)	I-Chemical
-	I-Chemical
ET	I-Chemical
-	I-Chemical
126	I-Chemical
.	O

In	O
the	O
same	O
experimenatl	O
condiitons	O
,	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
5	O
-	O
20	O
mcirog	O
per	O
mosue	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
was	O
also	O
able	O
to	O
preevnt	O
antimusacrine	O
-	O
induecd	O
amensia	O
,	O
demonstrating	O
a	O
cenrtal	O
lcoalization	O
of	O
the	O
actviity	O
.	O

At	O
the	O
highest	O
effetcive	O
doess	O
,	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
did	O
not	O
produce	O
any	O
collatreal	O
symtpoms	O
as	O
rveealed	O
by	O
the	O
Irwin	O
tset	O
,	O
and	O
it	O
did	O
not	O
modify	O
spontaneuos	O
motliity	O
and	O
inpsection	O
actiivty	O
,	O
as	O
rveealed	O
by	O
the	O
hloe	O
-	O
borad	O
tset	O
.	O

PG	B-Chemical
-	I-Chemical
9	I-Chemical
was	O
also	O
able	O
to	O
incresae	O
the	O
aomunt	O
of	O
NGF	O
secrteed	O
in	O
vitro	O
by	O
astroctyes	O
in	O
a	O
dsoe	O
-	O
dpeendent	O
manner	O
.	O

The	O
mxaimal	O
NGF	O
cnotents	O
obtained	O
by	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
were	O
17	O
.	O
6	O
-	O
fold	O
of	O
the	O
cnotrol	O
value	O
.	O

During	O
cultrue	O
,	O
no	O
morpholoigcal	O
cahnges	O
were	O
found	O
at	O
effcetive	O
concentartions	O
of	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
.	O

The	O
current	O
work	O
indicates	O
the	O
ability	O
of	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
to	O
indcue	O
beneficial	O
effetcs	O
on	O
cgonitive	O
processes	O
and	O
stimultae	O
activtiy	O
of	O
NGF	O
syntehsis	O
in	O
astrgolial	O
cells	O
.	O

Therefore	O
,	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
could	O
represent	O
a	O
potnetial	O
useful	O
durg	O
able	O
to	O
imporve	O
the	O
fucntion	O
of	O
imparied	O
cognitvie	O
porcesses	O
.	O

Mechainsms	O
of	O
FK	B-Chemical
506	I-Chemical
-	O
idnuced	O
hypertenison	O
in	O
the	O
rat	O
.	O

-	O
Tacorlimus	B-Chemical
(	O
FK	B-Chemical
506	I-Chemical
)	O
is	O
a	O
powerful	O
,	O
widely	O
used	O
immunosuppressant	O
.	O

The	O
clniical	O
utility	O
of	O
FK	B-Chemical
506	I-Chemical
is	O
comlpicated	O
by	O
substantial	O
hypertenison	O
and	O
nephrotoxictiy	O
.	O

To	O
clarify	O
the	O
mehcanisms	O
of	O
FK	B-Chemical
506	I-Chemical
-	O
induecd	O
hypertnesion	O
,	O
we	O
studied	O
the	O
chroinc	O
efefcts	O
of	O
FK	B-Chemical
506	I-Chemical
on	O
the	O
syntehsis	O
of	O
endohtelin	O
-	O
1	O
(	O
ET	O
-	O
1	O
)	O
,	O
the	O
exrpession	O
of	O
mNRA	O
of	O
ET	O
-	O
1	O
and	O
endohtelin	O
-	O
converting	O
enyzme	O
-	O
1	O
(	O
ECE	O
-	O
1	O
)	O
,	O
the	O
endotehlial	O
ntiric	B-Chemical
oxdie	I-Chemical
snythase	O
(	O
eONS	O
)	O
activtiy	O
,	O
and	O
the	O
exprsesion	O
of	O
mNRA	O
of	O
eONS	O
and	O
C	O
-	O
tpye	O
natriruetic	O
petpide	O
(	O
CNP	O
)	O
in	O
rat	O
blood	O
vesesls	O
.	O

In	O
addition	O
,	O
the	O
effcet	O
of	O
the	O
specific	O
endtohelin	O
tpye	O
A	O
rceeptor	O
antaognist	O
FR	B-Chemical
139317	I-Chemical
on	O
FK	B-Chemical
506	I-Chemical
-	O
indcued	O
hyeprtension	O
in	O
rtas	O
was	O
studied	O
.	O

FK	B-Chemical
506	I-Chemical
,	O
5	O
mg	O
.	O

kg	O
-	O
1	O
.	O

d	O
-	O
1	O
given	O
for	O
4	O
weeks	O
,	O
elevtaed	O
bolod	O
presusre	O
from	O
102	O
+	O
/	O
-	O
13	O
to	O
152	O
+	O
/	O
-	O
15	O
mm	O
Hg	O
and	O
incresaed	O
the	O
snythesis	O
of	O
ET	O
-	O
1	O
and	O
the	O
levles	O
of	O
ET	O
-	O
1	O
mNRA	O
in	O
the	O
meesnteric	O
artrey	O
(	O
240	O
%	O
and	O
230	O
%	O
,	O
respectively	O
)	O
.	O

Little	O
change	O
was	O
observed	O
in	O
the	O
expressoin	O
of	O
ECE	O
-	O
1	O
mNRA	O
and	O
CNP	O
mNRA	O
.	O

FK	B-Chemical
506	I-Chemical
decerased	O
eONS	O
activtiy	O
and	O
the	O
lveels	O
of	O
eONS	O
mNRA	O
in	O
the	O
arota	O
(	O
48	O
%	O
and	O
55	O
%	O
,	O
respectively	O
)	O
.	O

The	O
adminisrtation	O
of	O
FR	B-Chemical
139317	I-Chemical
(	O
10	O
mg	O
.	O
kg	O
-	O
1	O
.	O
d	O
-	O
1	O
)	O
prevented	O
FK	B-Chemical
506	I-Chemical
-	O
induecd	O
hypertenison	O
in	O
rtas	O
.	O

These	O
reuslts	O
indicate	O
that	O
FK	B-Chemical
506	I-Chemical
may	O
incresae	O
bolod	O
presusre	O
not	O
only	O
by	O
incerasing	O
ET	O
-	O
1	O
produtcion	O
but	O
also	O
by	O
dcereasing	O
NO	B-Chemical
snythesis	O
in	O
the	O
vascultaure	O
.	O

